Document

Large accelerated filer o

Accelerated filer o

Non-accelerated filer x

Smaller reporting company o

Emerging growth company x

0001682852-19-000023.txt : 20190509 0001682852-19-000023.hdr.sgml : 20190509 20190509163359 ACCESSION NUMBER: 0001682852-19-000023 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 87 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190509 DATE AS OF CHANGE: 20190509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 19811117 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 10-Q 1 moderna10-q3312019.htm 10-Q Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _ to _

Commission File Number: 001-38753

Moderna, Inc.

(Exact Name of Registrant as Specified in Its Charter)



Delaware		81-3467528
(State or Other Jurisdiction of Incorporation or Organization)		(IRS Employer Identification No.)

200 Technology Square Cambridge, Massachusetts		02139
(Address of Principal Executive Offices)		(Zip Code)

(617) 714-6500

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No x

Securities registered pursuant to Section 12(b) of the Act:



Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	MRNA	The NASDAQ Stock Market LLC

As of April 29, 2019, there were 329,003,270 shares of the registrant’s common stock, par value $0.0001 per share, outstanding.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q ("Form 10-Q"), including the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains express or implied forward-looking statements that are based on our management’s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Form 10-Q include, but are not limited to, statements about:


•	the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;


•	our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop development candidates and investigational medicines, including by applying learnings from one program to our other programs and from one modality to our other modalities;


•	our ability and the potential to successfully manufacture our drug substances, delivery vehicles, development candidates, and investigational medicines for preclinical use, for clinical trials and on a larger scale for commercial use, if approved;


•	the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and investigational medicines;


•	our ability to obtain funding for our operations necessary to complete further development and commercialization of our investigational medicines;


•	our ability to obtain and maintain regulatory approval of our investigational medicines;


•	our ability to commercialize our products, if approved;


•	the pricing and reimbursement of our investigational medicines, if approved;


•	the implementation of our business model, and strategic plans for our business, investigational medicines, and technology;


•	the scope of protection we are able to establish and maintain for intellectual property rights covering our investigational medicines and technology;


•	estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;


•	the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or arrangements, and our ability to attract collaborators with development, regulatory, and commercialization expertise;


•	future agreements with third parties in connection with the commercialization of our investigational medicines, if approved;


•	the size and growth potential of the markets for our investigational medicines, and our ability to serve those markets;


•	our financial performance;


•	the rate and degree of market acceptance of our investigational medicines;


•	regulatory developments in the United States and foreign countries;


•	our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;


•	our ability to produce our products or investigational medicines with advantages in turnaround times or manufacturing cost;


•	the success of competing therapies that are or may become available;


•	our ability to attract and retain key scientific or management personnel;


•	the impact of laws and regulations;


•	developments relating to our competitors and our industry; and


•	other risks and uncertainties, including those discussed in Part II, Item 1A - Risk Factors in this Form 10-Q.

In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section entitled “Risk Factors” and elsewhere in this Form 10-Q. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those expressed or implied by the forward-looking statements. No forward-looking statement is a guarantee of future performance.

The forward-looking statements in this Form 10-Q represent our views as of the date of this Form 10-Q. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Form 10-Q.

This Form 10-Q includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We have not independently verified the information contained in such sources.

NOTE REGARDING COMPANY REFERENCES

Unless the context otherwise requires, the terms “Moderna,” “the Company,” “we,” “us,” and “our” in this Form 10-Q refer to Moderna, Inc. and its consolidated subsidiaries.

Table of Contents



PART I.		Page
Item 1.	Financial Statements (Unaudited)	5
	Condensed Consolidated Balance Sheets as of March 31, 2019 and December 31, 2018	5
	Condensed Consolidated Statements of Operations for the three months ended March 31, 2019 and 2018	6
	Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2019 and 2018	7
	Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the three months ended March 31, 2019 and 2018	8
	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and 2018	9
	Notes to Condensed Consolidated Financial Statements	10
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	39
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	59
Item 4.	Controls and Procedures	59
PART II.
Item 1.	Legal Proceedings	60
Item 1A.	Risk Factors	60
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	60
Item 6.	Exhibits	60
SIGNATURES

Table of Contents

Item 1. Financial Statements

MODERNA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, in thousands, except share and per share data)



	March 31,			December 31,
	2019			2018
Assets
Current assets:
Cash and cash equivalents	$	502,934		$	658,364
Investments	605,990			863,063
Accounts receivable	5,646			11,686
Accounts receivable from related party	965			899
Prepaid expenses and other current assets	25,292			28,399
Restricted cash	—			595
Total current assets	1,140,827			1,563,006
Investments, non-current	437,659			172,990
Property and equipment, net	213,460			211,977
Restricted cash, non-current	11,823			11,532
Other non-current assets	2,438			2,644
Total assets	$	1,806,207		$	1,962,149
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	38,509		$	31,210
Accrued liabilities	42,183			79,073
Deferred revenue	73,958			109,056
Other current liabilities	4,509			3,464
Total current liabilities	159,159			222,803
Deferred revenue, non-current	156,862			165,352
Deferred lease obligation, non-current	10,556			10,006
Lease financing obligation	33,384			33,489
Other non-current liabilities	213			258
Total liabilities	360,174			431,908
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, par value $0.0001; 162,000,000 shares authorized as of March 31, 2019 and December 31, 2018; no shares issued or outstanding at March 31, 2019 and December 31, 2018	—			—
Common stock, par value $0.0001; 1,600,000,000 shares authorized as of March 31, 2019 and December 31, 2018; 328,853,340 and 328,798,904 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively	33			33
Additional paid-in capital	2,556,709			2,538,155
Accumulated other comprehensive income (loss)	591			(1,320		)
Accumulated deficit	(1,111,300		)	(1,006,627		)
Total stockholders’ equity	1,446,033			1,530,241
Total liabilities and stockholders’ equity	$	1,806,207		$	1,962,149

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

MODERNA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, in thousands, except share and per share data)



	Three Months Ended March 31,
	2019			2018
Revenue:
Collaboration revenue	$	13,301		$	20,110
Collaboration revenue from related party	814			7,350
Grant revenue	1,910			1,579
Total revenue	16,025			29,039
Operating expenses:
Research and development	130,575			90,124
General and administrative	27,283			16,317
Total operating expenses	157,858			106,441
Loss from operations	(141,833		)	(77,402		)
Interest income	10,972			5,209
Other expense, net	(1,820		)	(183		)
Loss before benefit from income taxes	(132,681		)	(72,376		)
Benefit from income taxes	(24		)	—
Net loss	$	(132,657	)	$	(72,376	)
Net loss attributable to common stockholders (Note 11)	$	(132,657	)	$	(75,857	)
Net loss per share attributable to common stockholders, basic and diluted	$	(0.40	)	$	(1.16	)
Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted	328,809,986			65,430,835

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

MODERNA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited, in thousands)



	Three Months Ended March 31,
	2019			2018
Net loss	$	(132,657	)	$	(72,376	)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale debt securities, net of tax, $540 and $0	1,908			(1,999		)
Less: Amounts recognized for net realized loss included in net loss	3			6
Total other comprehensive income (loss)	1,911			(1,993		)
Comprehensive loss	$	(130,746	)	$	(74,369	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

MODERNA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)

(Unaudited, in thousands)



	Redeemable Convertible Preferred Stock			Common Stock			Additional Paid-In Capital		Accumulated Other Comprehensive (Loss) Income			Accumulated Deficit			Total Stockholders’ Equity
	Shares	Amount		Shares	Amount		Additional Paid-In Capital		Accumulated Other Comprehensive (Loss) Income			Accumulated Deficit			Total Stockholders’ Equity

Balance at December 31, 2018	—	$	—	328,798,904	$	33	$	2,538,155	$	(1,320	)	$	(1,006,627	)	$	1,530,241
Transition adjustment from adoption of ASU Topic 606 (Note 2)				—	—		—		—			27,984			27,984
Vesting of restricted common stock	—	—		48,911	—		—		—			—			—
Exercise of options to purchase common stock, net	—	—		5,525	—		57		—			—			57
Stock-based compensation	—	—		—	—		18,497		—			—			18,497
Unrealized gain on marketable securities	—	—		—	—		—		1,911			—			1,911
Net loss	—	—		—	—		—		—			(132,657		)	(132,657		)
Balance at March 31, 2019	—	$	—	328,853,340	$	33	$	2,556,709	$	591		$	(1,111,300	)	$	1,446,033



	Redeemable Convertible Preferred Stock			Common Stock			Additional Paid-In Capital		Accumulated Other Comprehensive Loss			Accumulated Deficit			Total Stockholders’ Deficit
	Shares	Amount		Shares	Amount		Additional Paid-In Capital		Accumulated Other Comprehensive Loss			Accumulated Deficit			Total Stockholders’ Deficit

Balance at December 31, 2017	448,686,791	$	1,176,661	65,206,999	$	6	$	71,679	$	(1,157	)	$	(621,893	)	$	(551,365	)
Vesting of restricted common stock	—	—		335,053	—		—		—			—			—
Issuance of Series G redeemable convertible preferred stock, net of issuance costs of $10,517	55,666,004	549,413		—	—		152		—			—			152
Exercise of options to purchase common stock, net	—	—		1,789	—		22		—			—			22
Stock-based compensation	—	—		—	—		11,851		—			—			11,851
Unrealized loss on marketable securities	—	—		—	—		—		(1,993		)	—			(1,993		)
Net loss	—	—		—	—		—		—			(72,376		)	(72,376		)
Balance at March 31, 2018	504,352.795	$	1,726,074	65,543,841	$	6	$	83,704	$	(3,150	)	$	(694,269	)	$	(613,709	)

Table of Contents

MODERNA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)



	Three Months Ended March 31,
	2019			2018
Operating activities
Net loss	$	(132,657	)	$	(72,376	)
Adjustments to reconcile net loss to net cash (used in) operating activities:
Stock-based compensation	18,497			11,851
Depreciation and amortization	7,328			5,153
Amortization of investment premiums	(1,005		)	(83		)
Loss on disposal of property and equipment	19			—
Changes in assets and liabilities:
Accounts receivable	6,040			3,876
Accounts receivable from related party	(66		)	(28,529		)
Prepaid expenses and other assets	3,313			(2,241		)
Accounts payable	1,731			1,467
Accrued liabilities	(32,557		)	(37,031		)
Deferred revenue	(15,604		)	6,193
Deferred lease obligation	550			152
Other liabilities	484			183
Net cash used in operating activities	(143,927		)	(111,385		)
Investing activities
Purchases of marketable securities	(429,517		)	(660,239		)
Proceeds from maturities of marketable securities	403,940			189,814
Proceeds from sales of marketable securities	21,413			18,630
Purchases of property and equipment	(7,595		)	(31,909		)
Net cash used in investing activities	(11,759		)	(483,704		)
Financing activities
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs	—			549,531
Proceeds from issuance of common stock through equity plans	57			22
Reimbursement of assets under lease financing obligation	—			1,727
Payments on financing lease obligation	(105		)	(1,285		)
Net cash (used in) provided by financing activities	(48		)	549,995
Net decrease in cash, cash equivalents and restricted cash	(155,734		)	(45,094		)
Cash, cash equivalents and restricted cash, beginning of year	670,491			147,608
Cash, cash equivalents and restricted cash, end of period	$	514,757		$	102,514
Non-cash investing and financing activities
Issuance costs included in accounts payable and accrued liabilities	$	796		$	—
Purchases of property and equipment included in accounts payable and accrued liabilities	$	14,127		$	28,527
Leasehold improvements included in prepaid and other current assets	$	10,089		$	9,889
Lease financing obligation	$	10,089		$	9,889

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

MODERNA, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Description of the Business

Moderna, Inc. is a Delaware Corporation, incorporated under the laws of the State of Delaware on July 22, 2016 (collectively, with its consolidated subsidiaries, any of Moderna, Company, we, us or our). In August 2018, we changed our name from Moderna Therapeutics, Inc. to Moderna, Inc. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. We are creating a new generation of potentially transformative medicines based on messenger RNA (mRNA), to improve the lives of patients. Since inception, we have incurred significant net losses. We expect to continue to incur significant expenses and operating losses for the foreseeable future. In addition, we anticipate that our expenses will increase significantly in connection with our ongoing activities to support our platform research, drug discovery and clinical development, infrastructure and Research Engine and Early Development engine, digital infrastructure, creation of a portfolio of intellectual property, and administrative support.

We do not expect to generate significant revenue from sales of potential mRNA medicines unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our investigational medicines. If we seek to obtain regulatory approval for any of our investigational medicines, we expect to incur significant commercialization expenses.

As a result, we will need substantial additional funding to support our continued operations and pursue our growth strategy. Until we can generate significant revenue from potential mRNA medicines, if ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings, government funding arrangements, strategic alliances and marketing, distribution and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our programs. We believe that our cash, cash equivalents, and investments as of March 31, 2019 will be sufficient to enable us to fund our projected operations through at least the next 12 months from the issuance of these financial statements.

Because of the numerous risks and uncertainties associated with pharmaceutical development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenues from the sale of our medicines, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.

2. Summary of Basis of Presentation and Recent Accounting Standards

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in conformity with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2018 (2018 Form 10-K), except for changes associated with recent accounting standards for revenue recognition as detailed in "Note 2 - Recent Accounting Standards and Accounting Policies." This report should be read in conjunction with the consolidated financial statements in our 2018 Form 10-K.

We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, income tax provisions, stock-based compensation, and useful lives of long-lived assets. We base our estimates on historical experience and on various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results that we experience may differ materially from our estimates. The condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, but are not necessarily indicative of the results of operations to be anticipated for the full year ending December 31, 2019.

Table of Contents

Recent Accounting Standards and Accounting Policies

Revenue Recognition

On January 1, 2019, we adopted Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606), using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. We recognized the cumulative effect of the adoption as an adjustment to the opening balance of accumulated deficit in the current period condensed consolidated balance sheet. Results for reporting periods beginning after January 1, 2019 are presented under ASC 606, while prior period amounts have not been adjusted and continue to be reported in accordance with our historic accounting under ASC Topic 605, Revenue Recognition (ASC 605). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.

Our revenue is primarily generated through collaboration arrangements and grants from government-sponsored and private organizations. Our collaboration arrangements typically contain multiple promises, including licenses to our intellectual property, options to obtain development and commercialization rights, research and development services, and obligations to develop and manufacture preclinical and clinical material. Such arrangements provide for various types of payments to us, including upfront payments, funding of research and development activities, funding for the purchase of preclinical and clinical material, development, regulatory and commercial milestone payments, licensing fees, option exercise payments, and royalties based on product sales. We have received grants from various government-sponsored and private organizations for research and related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin.

We analyze our collaboration arrangements to assess whether they are within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and our collaboration partner are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606. If we conclude that some or all aspects of the arrangement are within the scope of ASC 808 and do not represent a transaction with a customer, we recognize our allocation of the shared costs incurred with respect to the jointly conducted activities as a component of the related expense in the period incurred. Pursuant to ASC 606, a customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. If we conclude a counter-party to a transaction is not a customer or otherwise not within the scope of ASC 606 or ASC 808, we consider the guidance in other accounting literature as applicable or by analogy to account for such transaction. We also consider the guidance in ASC 606 with respect to principal versus agent considerations, in determining the appropriate treatment for the transactions between us and the strategic collaborator and the transactions between us and other third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, are accounted for as gross revenue.

We receive payments from our customers based on billing schedules established in each contract. Upfront payments and fees are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period when we perform our obligations under the arrangement. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current liabilities on our condensed consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities on our condensed consolidated balance sheets. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. As of March 31, 2019, we had not capitalized any costs to obtain any of our contracts.

Collaboration Revenue

To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following steps: (i) identify the contract(s) with the customer; (ii) identify the performance obligations in the

Table of Contents

contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) each performance obligation is satisfied.

We account for a contract with a customer that is within the scope of ASC 606 when all of the following criteria are met: (i) the arrangement has been approved by the parties and the parties are committed to perform their respective obligations; (ii) each party’s rights regarding the goods and/or services to be transferred can be identified; (iii) the payment terms for the goods and/or services to be transferred can be identified; (iv) the arrangement has commercial substance; and (v) collection of substantially all of the consideration to which we will be entitled in exchange for the goods and/or services that will be transferred to the customer is probable. We also determine the term of the contract based on the period in which we and our customer have present and enforceable rights and obligations for purposes of identifying the performance obligations and determining the transaction price.

We evaluate contracts that contain multiple promises to determine which promises are distinct. Promises are considered to be distinct and therefore, accounted for as separate performance obligations, provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. In assessing whether a promise is distinct, we consider factors such as whether: (i) we provide a significant service of integrating goods and/or services with other goods and/or services promised in the contract; (ii) one or more of the goods and/or services significantly modifies or customizes, or are significantly modified or customized by one or more of the other goods and/or services promised in the contract; and (iii) the goods and/or services are highly interdependent or highly interrelated. Individual goods or services (or bundles of goods and/or services) that meet both criteria for being distinct are accounted for as separate performance obligations. Promises that are not distinct at contract inception are combined and accounted for as a single performance obligation. Options to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer’s election.

The transaction price is generally comprised of an upfront payment due at contract inception and variable consideration in the form of payments for our services and materials and milestone payments due upon the achievement of specified events. Other payments the Company could be entitled to include tiered royalties earned when customers recognize net sales of licensed products. We consider the existence of any significant financing component within our arrangements and have determined that a significant financing component does not exist in our arrangements as substantive business purposes exist to support the payment structure other than to provide a significant benefit of financing. We measure the transaction price based on the amount of consideration we expect to be entitled in exchange for transferring the promised goods and/or services to the customer. We utilize either the expected value method or the most likely amount method to estimate the amount of variable consideration, depending on which method is expected to better predict the amount of consideration to which we will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. With respect to arrangements that include payments for a development or regulatory milestone payment, we evaluate whether the associated event is considered probable of achievement and estimate the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within our control or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, we re-evaluate the probability of achievement of each milestone and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, wherein the license is deemed to be the sole or predominant item to which the payments relate, we recognize revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.

We generally allocate the transaction price to each performance obligation based on a relative standalone selling price basis. We develop assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated research and development costs. However, in certain instances, we allocate variable consideration entirely to one or more performance obligation if the terms of the variable consideration relate to the satisfaction of the respective performance obligation and the amount allocated is consistent with the amount we would expect to receive for the satisfaction of the respective performance obligation.

Table of Contents

We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. For performance obligations that are satisfied at a point in time, we recognize revenue when control of the goods and/or services is transferred to the customer. For performance obligations that are satisfied over time, we recognize revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. We generally use input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. With respect to arrangements containing a license to our intellectual property that is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from amounts allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which we are expected to complete our performance obligations under an arrangement. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.

Grant Revenue

We have contracts with the U.S. government’s Defense Advanced Research Projects Agency (DARPA), Biomedical Advanced Research (BARDA), and the Bill & Melinda Gates Foundation (Gates Foundation). We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Revenues and related expenses are presented gross in the condensed consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.

Comprehensive Loss

Comprehensive loss includes net loss and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments. Total comprehensive loss for all periods presented has been disclosed in the condensed consolidated statements of comprehensive loss.

The components of accumulated other comprehensive loss for the three months ended March 31, 2019 are as follows (in thousands):



	Unrealized Gain on Available-for-Sale Debt Securities
Accumulated other comprehensive loss, balance at December 31, 2018	$	(1,320	)
Other comprehensive income	1,911
Accumulated other comprehensive loss, balance at March 31, 2019	$	591

Emerging Growth Company Status

We are an “emerging growth company,” (EGC) as defined in the Jumpstart Our Business Startups Act, (JOBS Act), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. We may take advantage of these exemptions until we are no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. We have elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, our condensed consolidated financial statements may not be comparable to companies that comply with public company FASB standards’ effective dates. We may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of our initial public offering (IPO) or such earlier time that we are no longer an EGC.

Table of Contents

Recently Adopted Accounting Standards

ASU No. 2014-09, Revenue from Contracts with Customers

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements in ASC 605 and most industry specific guidance. ASC 606 provides a single comprehensive model for use in accounting for revenue arising from contracts with customers. We adopted the new revenue standard on January 1, 2019 using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. We recognized the cumulative effect of the adoption as an adjustment to the opening balance of accumulated deficit in the first quarter of 2019. We have elected to use the practical expedient to aggregate the impact of all contract modifications that occurred prior to the ASC 606 adoption with respect to (i) identification of the satisfied and unsatisfied performance obligations, (ii) determination of the transaction price and (iii) allocation of the transaction price to the satisfied and unsatisfied performance obligations.

ASC 606 requires significant judgment and estimates and results in changes to, but not limited to: (i) the determination of the transaction price, including estimates of variable consideration, (ii) the allocation of the transaction price, including the determination of estimated selling price, and (iii) the pattern of recognition, including the application of proportional performance as a measure of progress on service-related promises and application of point-in-time recognition for supply-related promises. We recorded the cumulative-effect adjustment of $28.0 million to the opening balance of accumulated deficit as of January 1, 2019 with a corresponding decrease to deferred revenue. The effect of the adoption of ASC 606 on our condensed consolidated balance sheet is as follows (in thousands):



Condensed Consolidated Balance Sheet	Balance at December 31, 2018			Adjustments			Balance at January 1, 2019
Deferred revenue, current	$	109,056		$	(27,281	)	$	81,775
Deferred revenue, non-current	165,352			(3,441		)	161,911
Accounts receivable	11,686			(2,738		)	8,948
Accumulated deficit	(1,006,627		)	27,984			(978,643		)

The cumulative-effect adjustment is primarily due to the application of ASC 606 to our strategic collaboration agreements, particularly our Combined 2018 AZ Agreements, 2016 VEGF Exercise and Merck PCV/SAV Agreement (see Note 3). In addition, as a result of the cumulative decrease in deferred revenue, our corresponding deferred tax asset was decreased by $8.4 million, which was offset by a corresponding decrease to our valuation allowance.

A substantial portion of the $28.0 million cumulative-effect adjustment is the result of the application of ASC 606 regarding the allocation of the transaction price and the measurement of progress in satisfying performance obligations. In particular, for the Combined 2018 AZ Agreements, the adoption of ASC 606 resulted in the decrease of previously deferred revenue of $39.9 million. For the Merck PCV/SAV Agreement, the adoption of ASC 606 resulted in a reversal of previously recognized revenue and an increase in deferred revenue of $13.9 million. These adjustments are due to the change in the way we allocate the transaction price to each performance obligation and measure our performance under each agreement from a straight-line method to a proportional performance model. In addition, the adoption of ASC 606 resulted in the decrease of $4.3 million of previously deferred revenue relating to the 2016 VEGF Exercise. Under ASC 605, the product option fee and the clinical milestone payment we received pursuant to the VEGF Exercise were deferred until the consideration pertaining to the clinical supply of mRNA can be reasonably estimated. Under ASC 606, we are required to estimate the total variable consideration to determine the total consideration and recognize the revenue as clinical supply is shipped to the customer based on the proportionate amount of the transaction price. As a result, the balance of remaining deferred revenues at January 1, 2019 was $75.7 million, $37.1 million and $125.2 million related to the Combined 2018 AZ Agreements, 2016 VEGF Exercise and the Merck PCV/SAV Agreement, respectively.

Table of Contents

The following tables summarize the effects of adopting ASC 606 on our condensed consolidated financial statements at March 31, 2019, and for the three months ended March 31, 2019 (in thousands, except per share data):



	March 31, 2019
Condensed Consolidated Balance Sheet	As reported under ASC 606			Adjustments			Balance without adoption of ASC 606
Deferred revenue, current	$	73,958		$	36,452		$	110,410
Deferred revenue, non-current	156,862			(29,840		)	127,022
Accumulated deficit	(1,111,300		)	(6,077		)	(1,117,377		)



	Three Months Ended March 31, 2019
Condensed Consolidated Statement of Operations	As reported under ASC 606			Adjustments			Amount without adoption of ASC 606
Revenue:
Collaboration revenue	$	13,301		$	(1,786	)	$	11,515
Collaboration revenue from related party	814			24,377			25,191
Total revenue	16,025			21,907			37,932
Loss from operations	(141,833		)	21,907			(119,926		)
Loss before benefit from income taxes	(132,681		)	21,907			(110,774		)
Net (loss) income	(132,657		)	21,907			(110,750		)
Net loss per share - basic and diluted	(0.40		)	0.06			(0.34		)

ASU No. 2016-18, Statement of Cash Flows: Restricted Cash

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires the statement of cash flows to explain the change during the period in the total of cash, cash equivalents and restricted cash. When cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new standard requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet. This reconciliation can be presented either on the face of the statement of cash flows or in the notes to the financial statements. The new standard became effective for us on January 1, 2019. As a result of adopting this new standard using a retrospective transition method for each period presented, we include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed statements of cash flows.

The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows (in thousands):



	As of March 31,
	2019		2018
Cash and cash equivalents	$	502,934	$	90,479
Restricted cash	—		237
Restricted cash, non-current	11,823		11,798
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows	$	514,757	$	102,514

Table of Contents

ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting

In June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance generally consistent with the accounting for employee share-based compensation. The new standard will be effective for us on January 1, 2020, with early adoption permitted. We early adopted this standard in the first quarter of 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and disclosure.

ASU No. 2018-18, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606

In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which clarifies the interaction between Topic 808 and Topic 606, Revenue from Contracts with Customers. Currently, Topic 808 does not provide comprehensive recognition or measurement guidance for collaborative arrangements, and the accounting for those arrangements is often based on an analogy to other accounting literature or an accounting policy election. Similarly, aspects of Topic 606 have resulted in diversity in practice on the effect of the revenue standard on the accounting for collaborative arrangements. The standard will become effective for us beginning on January 1, 2021, with early adoption permitted. We early adopted this standard in connection with the adoption of ASC 606 in the first quarter of 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and disclosure.

Recently Issued Accounting Standards

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our condensed consolidated financial statements and disclosures.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes all existing lease guidance. This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. The new standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments. Lessees are required to classify leases as either finance or operating leases. If the lease is effectively a financed-purchase by the lessee, it is classified as a financing lease, otherwise it is classified as an operating lease. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. ASC 842 provides accounting guidance for transactions that meet specific criteria for a leaseback transaction. If the criteria are not met, the transaction is considered a “failed sale” and the transaction must be accounted for as a financing arrangement. The new standard will be effective for us on January 1, 2020, assuming we continue to qualify as an EGC.. Upon adoption, the new standard, as amended, allows lessees to apply the transition requirements either (1) retrospectively to each prior reporting period presented in the financial statements with the cumulative effect of applying the new rules recognized at the beginning of the earliest comparative period presented, or (2) retrospectively at the beginning of the period of adoption with the cumulative effect of applying the new rules recognized then. We are currently evaluating the potential impact ASU 2016-02 may have on our financial position and results of operations. Our assessment will include, but is not limited to, evaluating the impact this standard has on the lease of our corporate headquarters at 200 Technology Square in Cambridge, MA, the lease of our office and laboratory space at 500 Technology Square, Cambridge, MA and our manufacturing and additional facilities in Norwood, MA, (see Note 7), and the identification of any embedded leases.

In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (ASU 2016-13). ASU 2016-13 will change how companies account for credit losses for most financial assets and certain other instruments. For trade receivables, loans and held-to-maturity debt securities, companies will be required to recognize an allowance for credit losses rather than reducing the carrying value of the asset. Assuming we continue to qualify as an EGC, ASU 2016-13 will be effective for us for fiscal years beginning after December 15, 2020, , including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 will have on the Company’s financial position and results of operations.

In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Topic 350): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This standard requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This standard should be applied either retrospectively or prospectively, and will be effective for us in January 2021, assuming we continue to qualify as an EGC, with early adoption permitted. We are currently evaluating the potential impact this standard may have on our condensed consolidated financial statements and results of operations upon adoption.

Table of Contents

3. Collaboration Agreements

The following table summarizes our total consolidated net revenues from our strategic collaborators for the periods presented (in thousands):



	Three Months Ended
Collaboration Revenue by Strategic Collaborator:	March 31, 2019 as reported (under ASU 606)		March 31, 2019 without adoption of 606 (under ASC 605)		March 31, 2018 as reported (under ASC 605)
Merck	$	10,687	$	11,515	$	15,967
AstraZeneca	814		25,191		7,350
Vertex	2,614		—		4,143
Total collaborative revenue	$	14,115	$	36,706	$	27,460

The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the three months ended March 31, 2019 (in thousands):



	January 1, 2019		Additions		Deductions			March 31, 2019
Contract Assets:
Accounts receivable	$	4,612	$	2,735	$	(3,747	)	$	3,600
Contract Liabilities:
Deferred revenue	$	240,924	$	1,137	$	(13,582	)	$	228,479

During the three months ended March 31, 2019, we recognized the following revenues as a result of the change in the contract liability balances related to our collaboration agreements (in thousands):



Revenue recognized in the period from:	Three Months Ended March 31, 2019
Amounts included in contract liabilities at the beginning of the period ⁽¹⁾	$	13,582

⁽¹⁾ We first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period first applies to the beginning contract liability.

As of March 31, 2019, the aggregated amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied was $279.5 million.

Table of Contents

AstraZeneca – Strategic Alliances in Cardiovascular and Oncology

2013 Option Agreement and Services and Collaboration Agreement

In March 2013, we entered into an Option Agreement, the AZ Option Agreement, and a related Services and Collaboration Agreement, the AZ Services Agreement, with AstraZeneca, which were amended and restated in June 2018. We refer to these agreements in the forms that existed prior to the 2018 amendment and restatement as the 2013 AZ Agreements. Under the 2013 AZ Agreements, we granted AstraZeneca certain exclusive rights and licenses, and options to obtain exclusive rights to develop and commercialize potential therapeutic mRNA medicines directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services to AstraZeneca. Pursuant to the 2013 AZ Agreements, AstraZeneca was responsible for all research, development and commercialization activities, while we provided specified research and manufacturing services during a research and evaluation period, as described below, to further AstraZeneca’s activities pursuant to an agreed upon services plan. Under the 2013 AZ Agreements, AstraZeneca could have requested we provide additional services, at AstraZeneca’s expense. Subject to customary “back-up” supply rights granted to AstraZeneca, we exclusively manufactured (or had manufactured) mRNA for all research, development and commercialization purposes under the 2013 AZ Agreements until, on a product-by-product basis, the expiration of the time period for which we are entitled to receive earn-out payments with respect to such product pursuant to the 2013 AZ Agreements.

As of the effective date of the 2013 AZ Agreements, AstraZeneca acquired forty options that it may exercise to obtain exclusive rights to clinically develop and commercialize identified development candidates (and related back-up candidates) directed to specified targets that arise during the research and evaluation period. During the research and evaluation period for research candidates under the 2013 AZ Agreements, AstraZeneca could have elected to designate a limited number of research candidates as development candidates in order to continue preclinical development on such development candidates (and related back-up candidates). From such pool of development candidates designated by AstraZeneca, during a specified option exercise period, AstraZeneca could have then exercised one of its options to obtain exclusive rights to clinically develop and commercialize an identified development candidate (and related back-up candidates). If AstraZeneca did not exercise one of its options to acquire exclusive rights to clinically develop and commercialize a particular development candidate during the defined option exercise period for such development candidate, AstraZeneca’s rights to exercise an option and other rights granted under the 2013 AZ Agreements with respect to such development candidate (and related back-up candidates) would terminate, all rights to exploit such development candidate (and related back-up candidates) would be returned to us and all data and results generated by AstraZeneca with respect to such development candidate (and related back-up candidates) would be either assigned or licensed to us. Upon the earlier of termination of the 2013 AZ Agreements for any reason and a specified anniversary of the effective date of the 2013 AZ Agreements, all unexercised options, and the right to exercise any and all options if not previously exercised by AstraZeneca, would automatically terminate. On a target-by-target basis, we and AstraZeneca agreed to certain defined exclusivity obligations under the 2013 AZ Agreements with respect to the research, development and commercialization of mRNA medicines for such target.

As of the effective date of the 2013 AZ Agreements, AstraZeneca made upfront cash payments to us totaling $240.0 million. Under the 2013 AZ Agreements, we were entitled to receive payments that are not related to any specific program of up to $180.0 million in the aggregate for the achievement of three technical milestones relating to toxicity, delivery, and competition criteria. We achieved the toxicity and competition milestones in the year ended December 31, 2015. The delivery milestone has expired. Under the 2013 AZ Agreements, AstraZeneca was obligated to pay us a $10.0 million option exercise fee with respect to each development candidate (and related back-up candidates) for which it exercised an option. In addition, upon AstraZeneca’s exercise of each option, we were eligible to receive certain payments contingent upon the achievement of specified clinical, regulatory, and commercial events. For any product candidate optioned by AstraZeneca, we were eligible to receive, per product candidate, up to $100.0 million in payments for achievement of development milestones, up to $100.0 million payments for achievement of regulatory milestones, and up to $200.0 million payments for achievement of commercial milestones. Additionally, under the 2013 AZ Agreements, we were entitled to receive, on a product-by-product basis, earn-out payments on worldwide net sales of products ranging from a high-single digit percentage to 12%, subject to certain reductions, with an aggregate minimum floor.

We received from AstraZeneca under the 2013 AZ Agreements an option exercise payment of $10.0 million in the year ended December 31, 2016, and a clinical milestone payment of $30.0 million with respect to AstraZeneca’s VEGF-A product (AZD8601) during the year ended December 31, 2018, that is currently being developed in a Phase 2 clinical trial in certain fields.

Unless earlier terminated, the 2013 AZ Agreements would have continued until the expiration of AstraZeneca’s earn-out and contingent option exercise payment obligations for optioned product candidates. Either party had the right to terminate the 2013 AZ Agreements upon the other party’s material breach, either in its entirety or in certain circumstances, with respect to relevant candidates, subject to a defined materiality threshold and specified notice and cure provisions. If AstraZeneca had the right to terminate the 2013 AZ Agreements for our material breach, then AstraZeneca could have elected, in lieu of terminating the 2013 AZ

Table of Contents

Agreements, in their entirety or with respect to such candidates, to have the 2013 AZ Agreements remain in effect, subject to reductions in certain payments we were eligible to receive and certain adjustments to AstraZeneca’s obligations under the 2013 AZ Agreements. AstraZeneca had the right to terminate the 2013 AZ Agreements in full, without cause, upon 90-days’ prior notice to us.

2016 Strategic Alliance with AstraZeneca – IL12

In January 2016, we entered into a new Strategic Drug Development Collaboration and License Agreement, which we refer to as the 2016 AZ Agreement, with AstraZeneca to discover, develop and commercialize potential mRNA medicines for the treatment of a range of cancers.

Under the terms of the 2016 AZ Agreement, we and AstraZeneca have agreed to work together on an immuno-oncology program focused on the intratumoral delivery of a potential mRNA medicine to make the IL12 protein. The 2016 AZ Agreement initially included research activities with respect to a second discovery program. During a limited period of time, each party had an opportunity to propose additional discovery programs to be conducted under the 2016 AZ Agreement. We are responsible for conducting and funding all discovery and preclinical development activities under the 2016 AZ Agreement in accordance with an agreed upon discovery program plan for the IL12 program and any other discovery program the parties agree to conduct under the 2016 AZ Agreement. For the IL12 program and any other discovery program the parties agree to conduct under the 2016 AZ Agreement, during a defined election period that commenced as of the effective date of the 2016 AZ Agreement (for the IL12 program) and otherwise will commence on initiation of any such new discovery program, AstraZeneca may elect to participate in the clinical development of a development candidate arising under the 2016 AZ Agreement from such program. If AstraZeneca so elects (as it has for the IL12 program), AstraZeneca will lead clinical development activities worldwide and we will be responsible for certain activities, including being solely responsible for manufacturing activities, all in accordance with an agreed upon development plan. AstraZeneca will be responsible for funding all Phase 1 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan), and Phase 2 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan) up to a defined dollar threshold. We and AstraZeneca will equally share the costs of Phase 2 clinical development activities in excess of such dollar threshold, all Phase 3 clinical development activities and certain other costs of late-stage clinical development activities, unless we elect not to participate in further development and commercialization activities and instead receive tiered royalties, as described below.

We and AstraZeneca will co-commercialize products in the U.S. in accordance with an agreed upon commercialization plan and budget, and on a product-by-product basis will equally share the U.S. profits or losses arising from such commercialization. Notwithstanding, on a product-by-product basis, prior to a specified stage of development of a given product, we have the right to elect not to participate in the further development and commercialization activities for such product. If we make such election, instead of participating in the U.S. profits and losses share with respect to such product, we are obligated to discuss future financial terms with AstraZeneca. If we are unable to agree on future financial terms within a short, defined period of time, we are entitled to receive tiered royalties at default rates set forth in the 2016 AZ Agreement, ranging from percentages in the mid-single digits to 20% on worldwide net sales of products, subject to certain reductions with an aggregate minimum floor. AstraZeneca has sole and exclusive responsibility for all ex-U.S. commercialization efforts. Unless we have elected to not to participate in further development (in which case royalties on ex-U.S. net sales will be at the default rates as described above, unless otherwise agreed by the parties), we are entitled to tiered royalties at rates ranging from 10% to 30% on ex-U.S. net sales of the products, subject to certain reductions with an aggregate minimum floor. Subject to customary “back-up” supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) products for all development and commercialization purposes. We and AstraZeneca have agreed to certain defined exclusivity obligations with each other under the 2016 AZ Agreement with respect to the development and commercialization of mRNA medicines for IL12.

Unless earlier terminated, our strategic alliance under the 2016 AZ Agreement will continue on a product-by-product basis (i) until both parties cease developing and commercializing such product without the intention to resume, if we have not elected our right not to participate in further development and commercialization of such product or (ii) on a country-by-country basis, until the end of the applicable royalty term for such product in such country, if we have elected our right not to participate in further development and commercialization of such product.

Either party may terminate the 2016 AZ Agreement upon the other party’s material breach, subject to specified notice and cure provisions. Each party may also terminate the 2016 AZ Agreement in the event the other party challenges such party’s patent rights, subject to certain defined exceptions. AstraZeneca has the right to terminate the 2016 AZ Agreement in full or with respect to any program for scientific, technical, regulatory or commercial reasons at any time upon 90 days’ prior written notice to us. On a product-by-product basis, we have the right to terminate the 2016 AZ Agreement in certain cases if AstraZeneca has suspended or is no longer proceeding with the development or commercialization of such product for a period of twelve consecutive months, subject to specified

Table of Contents

exceptions, including tolling for events outside of AstraZeneca’s control. On a product-by-product basis, if the 2016 AZ Agreement is terminated with respect to a given product, AstraZeneca’s rights in such product will terminate and, to the extent we terminated for AstraZeneca’s breach, patent challenge or cessation of development or AstraZeneca terminated in its discretion, AstraZeneca will grant us reversion licenses and take certain other actions so as to enable us to continue developing and commercializing such product in the oncology field.

If we continue developing and commercializing a given product following termination of the 2016 AZ Agreement by AstraZeneca in its discretion with respect to such product, AstraZeneca is entitled to receive a mid-single digit royalty on our worldwide net sales of such product and a high-single digit percentage of the amounts received by us from a third party in consideration of a license to such third party to exploit such product, in each case, until AstraZeneca recovers an amount equal to specified development costs incurred by AstraZeneca under the 2016 AZ Agreement with respect to such product prior to such termination. Such percentages increase by a low to mid-single digit amount to the extent such termination occurs after such product achieves a specified stage of development.

2017 Strategic Alliance with AstraZeneca – Relaxin

In October 2017, we entered a new Collaboration and License Agreement, which we refer to as the 2017 AZ Agreement, under which AstraZeneca may clinically develop and commercialize a development candidate, now known as AZD7970, which is comprised of an mRNA construct for the relaxin protein designed by us and encapsulated in one of our proprietary lipid nanoparticles ("LNP"). We discovered and performed preclinical development activities for AZD7970 prior to the initiation of the strategic alliance with AstraZeneca under the 2017 AZ Agreement.

Under the terms of the 2017 AZ Agreement, we will fund and be responsible for conducting preclinical development activities for AZD7970 through completion of IND-enabling GLP toxicology studies and AstraZeneca will lead pharmacological studies, each in accordance with an agreed upon discovery program plan. During a defined election period that commences as of the effective date of the 2017 AZ Agreement, AstraZeneca may elect to participate in further development and commercialization of AZD7970. Upon such election, AstraZeneca will lead clinical development activities for AZD7970 worldwide and we will be responsible for manufacturing AZD7970, certain regulatory matters and any other development activities that we agree to perform and that are set forth in an agreed upon development plan. AstraZeneca will be responsible for funding Phase 1 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan, up to a cap above which such costs are shared), and Phase 2 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan, up to a cap above which such costs are shared) up to a defined dollar threshold. Thereafter, we and AstraZeneca will equally share the costs of Phase 2 clinical development activities in excess of such defined dollar threshold, all Phase 3 clinical development activities and certain other costs of late-stage clinical development activities, unless we elect not to participate in further development and co-commercialization activities and instead receive tiered royalties as described below. If the development candidate is determined to be IND-ready, and AstraZeneca does not timely elect to participate in the clinical development of AZD7970, AstraZeneca is obligated to reimburse us for certain costs we incurred in the manufacture and development of AZD7970, since execution of the 2017 AZ Agreement.

We and AstraZeneca will co-commercialize AZD7970 in the United States in accordance with an agreed upon commercialization plan and budget, and will equally share U.S. profits or losses arising from such commercialization. Notwithstanding, prior to a specified stage of development of AZD7970, we have the right to elect not to participate in the further development and commercialization activities for AZD7970. If we make such election, instead of participating in the U.S. profits and losses share with respect to AZD7970, we are obligated to discuss future financial terms with AstraZeneca. If we are unable to agree on future financial terms within a short, defined period of time, we are entitled to receive tiered royalties at default rates set forth in the 2017 AZ Agreement, ranging from percentages in the mid-single digits to the low 20s on worldwide net sales by AstraZeneca of AZD7970, subject to certain reductions, with an aggregate minimum floor. AstraZeneca has sole and exclusive responsibility for all ex-U.S. commercialization efforts. Unless we have elected not to participate in further development (in which case royalties on ex-U.S. net sales will be at the default rates as described above, unless otherwise agreed by the parties), we are entitled to receive tiered royalties at rates ranging from 10% to 30% on annual ex-U.S. net sales of AZD7970, subject to certain reductions with an aggregate minimum floor. Subject to customary “back-up” supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) products for all development and commercialization purposes. Additionally, we and AstraZeneca have agreed to certain defined exclusivity obligations under the 2017 AZ Agreement with respect to the development and commercialization of mRNA medicines for Relaxin.

Unless earlier terminated, our strategic alliance under the 2017 AZ Agreement will continue (i) until the expiration of AstraZeneca’s election period, if it does not elect to participate in the clinical development of AZD7970, (ii) until both parties cease developing and commercializing AZD7970 without the intention to resume, if we have not elected our right not to participate in further development

Table of Contents

and commercialization of AZD7970, (iii) on a country-by-country basis, until the end of the applicable royalty term for AZD7970 in such country, if we have elected our right not to participate in further development and commercialization of AZD7970 or (iv) following completion of IND-enabling studies with respect to AZD7970, if we provide AstraZeneca with written notice that we do not reasonably believe that the product is IND-ready.

Either party may terminate the 2017 AZ Agreement upon the other party’s material breach, subject to specified notice and cure provisions. Each party may also terminate the 2017 AZ Agreement in the event the other party challenges the validity or enforceability of such party’s patent rights, subject to certain defined exceptions. AstraZeneca has the right to terminate the 2017 AZ Agreement in full for scientific, technical, regulatory or commercial reasons at any time upon 90 days’ prior written notice to us. We have the right to terminate the 2017 AZ Agreement in certain cases if AstraZeneca has suspended or is no longer proceeding with the development or commercialization of AZD7970 for a period of twelve consecutive months, subject to specified exceptions, including tolling for events outside of AstraZeneca’s control. If AstraZeneca does not timely elect to participate in clinical development of AZD7970, or the Agreement is terminated, AstraZeneca’s rights in AZD7970 will terminate and, to the extent we terminated for AstraZeneca’s breach, patent challenge or cessation of development or AstraZeneca terminated in its discretion, AstraZeneca will grant us reversion licenses and take certain other actions so as to enable us to continue developing and commercializing AZD7970 in the cardiovascular and cardiometabolic fields.

If we continue developing and commercializing AZD7970 following a termination of the 2017 AZ Agreement by AstraZeneca in its discretion, AstraZeneca is entitled to receive a mid-single digit royalty on our worldwide net sales of AZD7970 and a high-single digit percentage of the amounts received by us from a third party in consideration for a license to such third party to exploit AZD7970, in each case until AstraZeneca recovers an amount equal to specified development costs incurred by AstraZeneca under the 2017 AZ Agreement with respect to AZD7970 prior to such termination. Such percentages increase by a low to mid-single digit amount to the extent such termination occurs after such product achieves a specified stage of development.

2013 Agreements with AstraZeneca, amended and restated in 2018

In June 2018, we entered into an Amended and Restated Option Agreement and a related Amended and Restated Services and Collaboration Agreement with AstraZeneca, or the 2018 A&R Agreements, which amended and restated the 2013 AZ Agreements. Under the 2018 A&R Agreements, we granted AstraZeneca certain exclusive rights and licenses to research, develop and commercialize potential therapeutic mRNA medicines directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services to AstraZeneca. The activities to be performed by the parties under the 2018 A&R Agreements are limited to defined biological targets in the cardiovascular and cardiometabolic fields and one defined target in the cancer field.

Pursuant to the 2018 A&R Agreements, AstraZeneca is responsible for all research, development and commercialization activities and associated costs, while we provide specified research and manufacturing services during a research and evaluation period, as described below, to further AstraZeneca’s activities conducted pursuant to an agreed upon services plan. During this research and evaluation period, these research services, and manufacturing services in excess of a specified threshold, are provided at AstraZeneca’s expense, and manufacturing services below the specified threshold are provided at no additional expense to AstraZeneca. AstraZeneca may request we provide additional research and manufacturing services, at AstraZeneca’s expense, following the end of the research and evaluation period. Subject to customary “back-up” supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) mRNA for all research, development and commercialization purposes under the 2018 A&R Agreements until, on a product-by-product basis, the expiration of the time period for which we are entitled to receive earn-out payments with respect to such product pursuant to the 2018 A&R Agreements.

As of the effective date of the 2013 AZ Agreements, and as further reflected in the 2018 A&R Agreements, AstraZeneca acquired forty options that it may exercise to obtain exclusive rights to clinically develop and commercialize identified development candidates (and related back-up candidates) directed to specified targets that arise during the research and evaluation period. During the research and evaluation period for research candidates, AstraZeneca may elect to designate a limited number of research candidates as development candidates in order to continue preclinical development on such development candidates (and related back-up candidates). From such pool of development candidates designated by AstraZeneca, during a specified option exercise period, AstraZeneca may then exercise one of its options to obtain exclusive rights to clinically develop and commercialize an identified development candidate (and related back-up candidates) in certain fields. If AstraZeneca does not exercise one of its options to acquire exclusive rights to clinically develop and commercialize a particular development candidate during the defined option exercise period for such development candidate, AstraZeneca’s rights to exercise an option and other rights granted under the 2018 A&R Agreements with respect to such development candidate (and related back-up candidates) will terminate, all rights to exploit such development candidate (and related back-up candidates) will be returned to us and all data and results generated by AstraZeneca with respect to such development

Table of Contents

candidate (and related back-up candidates) will be either assigned or licensed to us. Upon the earlier of termination of the 2018 A&R Agreements for any reason and a specified anniversary of the effective date of the 2013 AZ Agreements, all unexercised options, and the right to exercise any and all options if not previously exercised by AstraZeneca, will automatically terminate.

On a target-by-target basis, we and AstraZeneca have agreed to certain defined exclusivity obligations under the 2018 A&R Agreements with respect to the research, development and commercialization of mRNA medicines for such target in certain fields. In addition, we and AstraZeneca have agreed to certain defined exclusivity obligations with respect to the research, development and commercialization of mRNA medicines coding for the same polypeptide as any development candidate being developed under the 2018 A&R Agreements.

Unless earlier terminated, the 2018 A&R Agreements will continue until the expiration of AstraZeneca’s earn-out and contingent option exercise payment obligations for optioned product candidates. Either party may terminate the 2018 A&R Agreements upon the other party’s material breach, either in its entirety or in certain circumstances, with respect to relevant candidates, subject to a defined materiality threshold and specified notice and cure provisions. If AstraZeneca has the right to terminate the 2018 A&R Agreements for our material breach, then AstraZeneca may elect, in lieu of terminating the 2018 A&R Agreements, in their entirety or with respect to such candidates, to have the 2018 A&R Agreements remain in effect, subject to reductions in certain payments we are eligible to receive and certain adjustments to AstraZeneca’s obligations under the 2018 A&R Agreements. AstraZeneca may terminate the 2018 A&R Agreements in full, without cause, upon 90 days’ prior notice to us.

Accounting Treatment

For periods prior to January 1, 2019, we applied the provisions of ASC 605 in accounting for these arrangements, except for the 2017 AZ Agreement which was accounted for under ASC 808. In August 2016, AstraZeneca exercised a product option available pursuant to the 2013 AZ Agreements to obtain exclusive rights to clinically develop and commercialize the VEGF-A product (AZD8601). This option exercise is referred to as the 2016 VEGF Exercise. Consistent with our conclusions under ASC 605 and pursuant to ASC 606, we determined that the 2016 VEGF Exercise and the 2017 AZ Agreement should be accounted for as separate transactions as the agreements are not interrelated or interdependent. Conversely, the 2013 Agreements, as amended by the 2018 A&R Agreements, and the 2016 AZ Agreement, were combined for accounting purposes and treated as a single agreement, as these agreements were negotiated in contemplation of each other. As of the date of our initial application of ASC 606, we applied the practical expedient to include the aggregate effect of all modifications to the arrangement that occurred before January 1, 2019 with respect to (i) identification of the satisfied and unsatisfied performance obligations, (ii) determination of the transaction price and (iii) allocation of the transaction price to the satisfied and unsatisfied performance obligations. Therefore, we aggregated effects of all the modifications prior to January 1, 2019 to the 2013 Agreements, including the effects of the 2018 A&R Agreements, and the 2016 AZ Agreement were combined into one transaction for accounting purposes. We will refer to this combined transaction as the Combined 2018 AZ Agreements. We determined that all aspects of Combined 2018 AZ Agreements and the 2016 VEGF Exercise represent a transaction with a customer and therefore is accounted for in accordance with ASC 606 as of the date of the initial application.

Combined 2018 AZ Agreements

We identified the following performance obligations in the Combined 2018 AZ Agreements: (i) a combined performance obligation that includes a research license, research and development pool services, and manufacturing obligations related to the 2013 AZ Agreements, as amended by the 2018 A&R Agreements, collectively referred to as the Combined 2018 AZ Agreement Performance Obligation, (ii) preclinical development services for IL12, (iii) preclinical development services for an oncology development target, (iv) a combined performance obligation for a development and commercialization license and manufacturing obligations for IL12, and (v) a material right to receive development and commercialization rights and manufacturing services for an oncology development target.

We concluded that the research license is not distinct from the research and development pool services or the manufacturing obligations related to the 2018 A&R Agreements, as AstraZeneca cannot fully exploit the value of the research license without receipt of such services and supply. Our services and supply involve specialized expertise, particularly as it relates to mRNA technology that is not available in the marketplace. Any supply requested by AstraZeneca in excess of the minimum quantities specified in the agreement are considered customer options and treated as separate contracts for accounting purposes. Further, we concluded that AstraZeneca cannot exploit the value of the development and commercialization license for IL12 without receipt of supply as the development and commercialization license does not convey to AstraZeneca the right to manufacture and therefore combined the development and commercialization license and the manufacturing obligations for IL12 into one performance obligation.

Table of Contents

As of January 1, 2019, the date of initial adoption of ASC 606, the total transaction price was determined to be $400.0 million comprised of the $240.0 million in upfront payments pertaining to the 2013 AZ Agreements and $160.0 million of variable consideration comprised of $40.0 million of estimated reimbursement for IL12 manufacturing obligations and $120.0 million of milestone payments ($60.0 million toxicity milestone and $60.0 million competition milestone), received prior to the adoption date of ASC 606. We utilize the most likely amount method to determine the amount of reimbursement for IL12 manufacturing obligations to be received. We determined that any sales-based royalties related to IL12 will be recognized when the related sales occur as they were determined to relate predominately to the license granted and therefore have been excluded from the transaction price. In addition, we are eligible to receive future milestones and royalties on future commercial sales for optioned product candidates under the 2018 A&R Agreements and future royalties under the 2016 Agreement; however, these amounts are not considered variable consideration under the Combined 2018 Agreements as we are only eligible to receive such amounts if AstraZeneca exercises its options (including certain options that are deemed to be material rights). We have concluded that the exercise of an optioned product candidate represents a separate transaction under ASC 606. We will re-evaluate the transaction price at the end of each reporting period. There was a $0.3 million increase to the transaction price resulting from a change in estimate of the variable consideration during the three months ended March 31, 2019.

The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. We developed the estimated standalone selling price for the licenses included in the Combined 2018 AZ Agreement Performance Obligation and the combined performance obligation for a development and commercialization license and manufacturing obligations for IL12 primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success and the time needed to commercialize a product candidate pursuant to the associated license. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the performance obligation, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated costs, adjusted for a reasonable profit margin that would be expected to be realized under similar contracts. The estimated standalone selling price of the material right to receive development and commercialization rights and manufacturing services for an oncology development target was developed by estimating the amount of discount that AstraZeneca would receive when exercising the option and adjusting such amount by the likelihood that the option will be exercised.

The transaction price allocated to each performance obligation was as follows: (i) $292.4 million to the Combined 2018 AZ Agreement Performance Obligation, (ii) $8.1 million to the preclinical development services for IL12 performance obligation, (iii) $8.1 million to the preclinical development services for an oncology development target performance obligation, (iv) $89.8 million to the combined performance obligation for a development and commercialization license and manufacturing obligations for IL12, and (v) $1.6 million to the material right to receive development and commercialization rights and manufacturing services for an oncology development target. As part of the allocation of the transaction price to each of the performance obligations, we concluded that the $60.0 million toxicology milestone and the estimated reimbursement for IL12 manufacturing costs can be allocated entirely to specific performance obligations because the variable payment relates specifically to our effort to satisfy the performance obligation and such allocation is consistent with the allocation objectives of ASC 606.

We measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for the Combined 2018 AZ Agreement Performance Obligation and the preclinical development services for IL12 and the other oncology target performance obligations. We recognize revenue related to the amounts allocated to the combined performance obligation for a development and commercialization license and manufacturing obligations for IL12 based on the point in time upon which control of supply is transferred to AstraZeneca for each delivery of the associated supply.

We recognize revenue for the Combined 2018 AZ Agreement Performance Obligation, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend. This ratio is applied to the transaction price allocated to this combined performance obligation. We also estimate the development plan, including expected demand from AstraZeneca, and the associated costs for this combined performance obligation, as we will satisfy this combined performance obligation as the manufacturing services are performed. Management has applied significant judgment in the process of developing our budget estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up.

For the three months ended March 31, 2019 and 2018, we recognized collaboration revenue of $0.8 million and $7.4 million, respectively, from the Combined 2018 AZ Agreements. The revenue recognized for the three months ended March 31, 2019 includes the amortization of deferred revenue due to the satisfaction of our performance obligation during the period. As of March 31, 2019, the aggregate amount of the transaction price allocated to the remaining performance obligations that are unsatisfied is $112.5 million. $102.8 million is expected to be recognized as revenue through December 31, 2027 and $9.7 million is expected to be recognized as

Table of Contents

revenue at the earlier of expiration or modification of the Combined 2018 AZ Agreement. We had deferred revenue of $75.5 million and $115.6 million as of March 31, 2019 and December 31, 2018, respectively, from the Combined 2018 AZ Agreements, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the services are expected to be performed or control of the supply is expected to be transferred.

2016 VEGF Exercise

We concluded that the 2016 VEGF Exercise should be treated as a separate transaction for accounting purposes. We identified one performance obligation in this arrangement which is comprised of the exclusive license to develop and commercialize VEGF and the manufacturing of clinical supply. We concluded that the VEGF license is not distinct from the manufacturing obligations because AstraZeneca cannot fully exploit the value of the license without receipt of such supply. This is due to limitations inherent in the licenses conveyed wherein AstraZeneca does not have the contractual right to manufacture during the term of the agreement.

As of January 1, 2019, the date of initial adoption of ASC 606, the total transaction price was determined to be $55.1 million comprised of the $40.0 million in fixed payments pertaining to a $10.0 million option exercise fee and a $30.0 million milestone achieved prior to the adoption of ASC 606 and $15.1 million of variable consideration related to the estimated reimbursement for clinical supply. We are eligible to receive future milestones and royalties on future commercial sales under this arrangement. We utilize the most likely amount method to estimate any development and regulatory milestone payments to be received and the amount of estimated reimbursement for clinical supply. As of January 1, 2019, there were no milestones that had not been achieved included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or AstraZeneca’s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. We will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. When a milestone payment is included in the transaction price in the future, it will be recognized as revenue based on the relative completion of the underlying performance obligation. There were no changes to the transaction price during the three months ended March 31, 2019.

We recognize revenue related to the amount of the transaction price allocated to the VEGF Exercise performance obligation based on the point in time upon which control of supply is transferred to AstraZeneca for each delivery of the associated supply.

For the three months ended March 31, 2019 and 2018, we did not recognize any collaboration revenue from the 2016 VEGF Exercise. As of March 31, 2019, the aggregate amount of the transaction price allocated to the remaining performance obligation that is unsatisfied is $51.0 million, which is expected to be recognized as revenue through December 31, 2023. We had deferred revenue of $37.1 million and $41.2 million as of March 31, 2019 and December 31, 2018, respectively, from the 2016 VEGF Exercise, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the control of the supply is expected to be transferred.

2017 AZ Agreement

We concluded the 2017 AZ Agreement is under the scope of ASC 808 as we and AstraZeneca are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on commercial success of the activities of the arrangement. Additionally, we determined the development, manufacturing and commercialization activities are not deliverables under ASC 606. As a result, the activities conducted pursuant to the development, manufacturing and commercialization activities are accounted for as a component of the related expense in the period incurred. We considered the guidance in ASC 606 by analogy in determining the appropriate treatment for the transactions between us and AstraZeneca and concluded that reimbursement for transactions in which we are considered to be principal because we control a promised good or service before transferring that good or service to the customer, are accounted for as gross revenue.

We did not recognize any revenue from the 2017 AZ Agreement for the three months ended March 31, 2019 and 2018, respectively.

Table of Contents

Merck – Strategic Alliances in Infectious Diseases and Cancer Vaccines

2015 Strategic Alliance with Merck – Infectious Disease

In January 2015, we entered into a Master Collaboration and License Agreement with Merck, which was amended in January 2016, June 2016, and May 2019, and which we refer to, as amended, as the 2015 Merck Agreement. Pursuant to the 2015 Merck Agreement, we and Merck have agreed to research, develop, and commercialize potential mRNA medicines for the prevention of infections by RSV. Pursuant to the 2015 Merck Agreement, Merck is primarily responsible for research, development, and commercialization activities and associated costs of such research and commercialization. We are responsible for designing and manufacturing all mRNA constructs for preclinical and Phase 1 and Phase 2 clinical development purposes, and Merck pays us for such manufacture, and we are responsible for certain costs associated with the conduct of a Phase 1 clinical trial for a RSV vaccine product candidate (mRNA-1172). Responsibility for manufacturing mRNA constructs for late stage clinical development and commercialization purposes is to be determined.

The 2015 Merck Agreement includes a three-year period, expected to end on January 12, 2022, during which Merck may continue to preclinically and clinically develop RSV vaccine product candidates that arose during an initial four-year research period which terminated in January 2019. Merck may, prior to the end of this three-year period, elect to exclusively develop and commercialize up to five RSV vaccine product candidates.

We and Merck have agreed to certain defined exclusivity obligations during the term of the 2015 Merck Agreement with respect to potential mRNA medicines against RSV infection. As part of the May 2019 amendment of the 2015 Merck Agreement, these exclusivity obligations do not restrict Moderna from researching, developing, and commercializing a potential mRNA medicine for the prevention of a specific set of respiratory infections, including RSV, for the pediatric population.

Under the terms of the 2015 Merck Agreement, we received a $50.0 million upfront payment. We are eligible to receive, on a product-by-product basis, up to $300.0 million in aggregate milestone payments upon the achievement of certain development, regulatory, and commercial milestone events. To date, we have received from Merck a clinical milestone payment of $5.0 million with respect to the initiation of a Phase 1 clinical trial for a Merck RSV vaccine product candidate. In addition, under the terms of the 2015 Merck Agreement, we are eligible to receive an additional milestone payment unless Merck elects not to continue with further clinical development of mRNA-1172. On a product-by-product basis, we are also entitled to receive royalties on Merck’s net sales of products at rates ranging from the mid-single digits to low teens, subject to certain reductions, with an aggregate minimum floor. Additionally, concurrent with entering into the 2015 Merck Agreement in 2015, Merck made a $50.0 million equity investment in us, and concurrent with amending the 2015 Merck Agreement in January 2016, we received an upfront payment of $10.0 million from Merck.

Unless earlier terminated, the 2015 Merck Agreement will continue on a product-by-product and country-by-country basis for so long as royalties are payable by Merck on a given product in a given country. Either party may terminate the 2015 Merck Agreement upon the other party’s material breach, either in its entirety or with respect to a particular program, product candidate, product or country, subject to specified notice and cure provisions. Merck may terminate the 2015 Merck Agreement in full or with respect to a particular product candidate or product upon certain advance notice to us for any reason, or earlier if Merck determines the alliance or product is no longer commercially practicable. If Merck has the right to terminate the 2015 Merck Agreement, in its entirety or with respect to a program, product candidate or product, for our material breach, then Merck may elect, in lieu of terminating the 2015 Merck Agreement, to have the 2015 Merck Agreement remain in effect, subject to reductions in certain payments we are eligible to receive with respect to the terminable rights. Upon a termination of the 2015 Merck Agreement with respect to a program, all licenses and other rights granted to Merck with respect to such program will terminate and the continued development and commercialization of product candidates and products will revert to us. If the 2015 Merck Agreement is terminated with respect to a given product candidate or product, all licenses and other rights granted to Merck with respect to such product candidate or product will terminate and, to the extent we terminated for Merck’s breach, Merck will grant us licenses under select Merck technology for our continued development and commercialization of such product candidate or product. As a part of the May 2019 amendment of the 2015 Merck Agreement, we and Merck agreed to and conclude the collaboration as it relates to development of potential mRNA medicines for other viruses, including mRNA-1278 for the prevention of VZV infection.

Accounting Treatment

Table of Contents

performance obligations. Additionally, we determined that all aspects of amended 2015 Merck Agreement represent a transaction with a customer and therefore the amended 2015 Merck Agreement is accounted for in accordance with ASC 606 as of the date of the initial application. As of the date of initial adoption of ASC 606, the four-year research period was substantially complete and we concluded there were no unsatisfied performance obligations pertaining to the amended 2015 Merck Agreement. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) research services during the three-year period following the initial four-year research period during which Merck may continue to preclinically and clinically develop product candidates and (ii) clinical mRNA supply for Phase 1 and Phase 2 and/or non-cGMP mRNA supply beyond the initial four-year research period. Therefore, such options will be accounted for as a separate contract upon the customer’s election. After completion of the initial four-year research period and as a part of the May 2019 amendment of the 2015 Merck Agreement, Merck elected to establish a new RSV vaccine product candidate and to conduct a Phase 1 clinical trial. We and Merck agreed to focus the collaboration activities on RSV and discontinue the collaboration as it relates to the development of development candidates for other viruses.

As of the date of initial application of ASC 606, the total transaction price of $65.0 million comprised of the $60.0 million in aggregate upfront payments, including $50.0 million related to research and development funding plus a $10.0 million funding from the 2016 amendment of the 2015 Merck Agreement, and a $5.0 million payment pertaining to achievement of a development milestone during the year ended December 31, 2017, which had been allocated entirely to the satisfied performance obligation and recognized in full. We utilize the most likely amount method to estimate any development and regulatory milestone payments to be received. As of January 1, 2019, there were no milestones that had not been achieved included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or Merck’s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. We will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. When a milestone payment is included in the transaction price in the future, it will be recognized as revenue based on the relative completion of the underlying performance obligation. There were no changes to the transaction price during the three months ended March 31, 2019.

We had no deferred revenue as of March 31, 2019 or December 31, 2018 from the amended Merck 2015 Agreement as all performance obligations under the amended 2015 Merck Agreement were completed. For the three months ended March 31, 2018, we recognized collaboration revenue of $2.0 million from the amended 2015 Merck Agreement.

Additionally, we recognized collaboration revenue of $0.5 million for the three months ended March 31, 2019, pursuant to separate agreements with Merck related to the exercise of customer options to purchase clinical mRNA supply to further develop a product candidate after the initial four-year research period. Clinical mRNA supply is recognized as collaboration revenue at a point in time upon which control of supply is transferred to Merck for each delivery of the associated supply.

We are currently evaluating the accounting related to the May 2019 amendment of the 2015 Merck Agreement.

2016 Cancer Vaccine Strategic Alliance—Personalized mRNA Cancer Vaccines

In June 2016, we entered into a personalized mRNA cancer vaccines (PCV) Collaboration and License Agreement with Merck Sharp & Dohme Corp., or Merck, which we refer to as the PCV Agreement, to develop and commercialize PCVs for individual patients using our mRNA vaccine and formulation technology. Under the strategic alliance, we identify genetic mutations present in a particular patient’s tumor cells, synthesize mRNA for these mutations, encapsulate the mRNA in one of our proprietary LNPs and administer to each patient a unique mRNA cancer vaccine designed to specifically activate the patient’s immune system against her or his own cancer cells.

Pursuant to the PCV Agreement, we are responsible for designing and researching PCVs, providing manufacturing capacity and manufacturing PCVs, and conducting Phase 1 and Phase 2 clinical trials for PCVs, alone and in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget and under the oversight of a committee comprised of equal representatives of each party. The parties have entered into a clinical quality agreement with respect to Moderna’s manufacture and supply activities. We received an upfront payment of $200.0 million from Merck. In November 2017, we and Merck announced the achievement of a key milestone for the first-in-human dosing of a PCV (mRNA-4157) as a part of the alliance. The Phase 1 open-label, dose escalation, multicenter clinical trial in the United States (KEYNOTE-603) is

Table of Contents

designed to assess the safety, tolerability and immunogenicity of mRNA-4157 alone in subjects with resected solid tumors and in combination with KEYTRUDA, in subjects with unresectable solid tumors.

Until the expiration of a defined period of time following our completion of Phase 1 and Phase 2 clinical trials for PCVs under the PCV Agreement and delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of PCVs by making a $250.0 million participation payment to us. If Merck exercises its election and pays the participation payment, then the parties will equally co-fund subsequent clinical development of PCVs, with Merck primarily responsible for conducting clinical development activities under a jointly agreed development plan and budget. Each party may also conduct additional clinical trials for PCVs that are not included in the jointly agreed development plan and budget, in which case the non-conducting party will reimburse the conducting party for half of the total costs for such trials, plus interest, from its share of future profits resulting from sales of such PCVs, if any. Merck will lead worldwide commercialization of PCVs, subject to Moderna’s option to co-promote PCVs in the United States, and the parties will equally share the profits or losses arising from worldwide commercialization. Until a PCV becomes profitable, we may elect to defer payment of our share of the commercialization and related manufacturing costs and instead reimburse Merck for such costs, plus interest, from our share of future profits resulting from sales of such PCV, if any. Subject to customary “back-up” supply rights granted to Merck, we will manufacture (or have manufactured) PCVs for preclinical and clinical purposes. Manufacture of PCVs for commercial purposes will be determined by the parties in accordance with the terms of the PCV Agreement. Under the PCV Agreement, we grant certain licenses to Merck to perform its collaboration activities.

If Merck does not exercise its right to participate in future development and commercialization of PCVs, then Moderna will retain the exclusive right to develop and commercialize PCVs developed during the strategic alliance, subject to Merck’s rights to receive a percentage in the high teens to the low 20s, subject to reductions of our net profits on sales of such PCVs. During a limited period following such non-exercise, Merck has the right to perform clinical studies of such PCVs in combination with KEYTRUDA, for which we agree to use reasonable efforts to supply such PCVs. During such limited period, we also have the right to perform clinical studies of PCVs in combination with KEYTRUDA, for which Merck agrees to use reasonable efforts to supply KEYTRUDA. In addition, following its non-exercise, Merck is also entitled to receive a percentage in the high teens to the low 20s, subject to reductions, of our net profits on sales of certain PCVs first developed by us following such non-exercise and reaching a specified development stage within a defined period of time.

We and Merck have agreed to certain defined, limited exclusivity obligations with respect to the development and commercialization of PCVs.

2018 Expansion of the Cancer Vaccine Strategic Alliance—Shared Neoepitope Cancer Vaccines

In April 2018, we and Merck agreed to expand our cancer vaccine strategic alliance to include the development and commercialization of our KRAS vaccine development candidate, mRNA-5671, and potentially other shared neoantigen mRNA cancer vaccines (SAVs). We preclinically developed mRNA-5671 prior to its inclusion in the cancer vaccine strategic alliance and it is comprised of a novel mRNA construct designed by us and encapsulated in one of our proprietary LNPs. The PCV Agreement was amended and restated to include the new SAV strategic alliance (PCV/SAV Agreement).

We have granted Merck certain licenses and we and Merck have agreed to certain exclusivity obligations with respect to SAVs and particular SAV programs, which obligations are subject to termination or expiration upon certain triggering events.

Under the PCV/SAV Agreement, Merck will be responsible for conducting Phase 1 and Phase 2 clinical trials for mRNA-5671 and for all costs associated with such activities, in accordance with a jointly agreed development plan and budget, and we will be responsible for manufacturing and supplying all mRNA-5671 required to conduct such trials and for all costs and expenses associated with such manufacture and supply. Under the PCV/SAV Agreement, our budgeted commitment for PCVs increased to $243.0 million. Until the expiration of a defined period of time following the completion of Phase 1 and Phase 2 clinical trials for mRNA-5671 under the PCV/SAV Agreement and our delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of mRNA-5671 by making a participation payment to us. If Merck exercises its participation rights, then the parties will equally co-fund subsequent clinical development of mRNA-5671, with Merck primarily responsible for conducting clinical development activities under a jointly agreed development plan and budget. If Merck declines to participate in future development and commercialization activities following the initial Phase 1 and Phase 2 clinical trials for mRNA-5671, then we will retain the rights to develop and commercialize mRNA-5671. If Merck elects to participate in future development and commercialization of mRNA-5671, Merck may also conduct additional clinical trials for mRNA-5671 that are not included in the jointly agreed development plan and budget, in which case we will reimburse Merck for half of the total development costs for such clinical trials, plus interest, from our share of future profits resulting from sales of mRNA-5671, if any. If Merck does conduct additional clinical trials for mRNA-5671, we will be responsible for manufacturing and supplying all mRNA-5671 required to conduct

Table of Contents

such trials. Merck will lead worldwide commercialization of mRNA-5671, subject to our option to co-promote mRNA-5671 in the United States, and the parties will equally share the operating profits or losses arising from worldwide commercialization. Until mRNA-5671 becomes profitable, we may elect to defer payment of our share of the commercialization and related manufacturing costs and instead reimburse Merck for such costs, plus interest, from our share of future profits resulting from sales of mRNA-5671, if any. Subject to “back-up” supply rights granted to Merck, we will manufacture (or have manufactured) mRNA-5671 and other SAVs for preclinical and clinical purposes. After Merck exercises its right to participate in future development and commercialization of mRNA-5671 and other SAVs, we will grant the applicable development and commercialization licenses and the parties are obligated to discuss responsibility for future manufacturing, giving consideration to applicable criteria.

Pursuant to the PCV/SAV Agreement, for a defined period of time, either party may propose that the parties conduct additional programs for the research and development of SAVs directed to different shared neoantigens. If the parties agree to conduct any such programs, then we will be responsible for conducting and funding preclinical discovery and research activities for such SAVs, and otherwise the programs would be conducted on substantially the same terms as mRNA-5671 program. If we or Merck propose a new SAV program and the other party does not agree to conduct such program, then the PCV/SAV Agreement includes provisions allowing the proposing party to proceed with such development, at the proposing party’s expense. If Merck is the proposing party, we will be responsible for manufacturing and supplying material for such program at Merck’s expense. In such case, the non-proposing party will have the right to opt-in to such SAV program any time before the proposing party commits to performing Good Laboratory Practice (GLP)-toxicity studies. Until the expiration of a defined period of time following our completion of Phase 1 and Phase 2 clinical trials for any SAV program mutually agreed by the parties under the PCV/SAV Agreement and our delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of such SAV by making a participation payment to us.

Unless earlier terminated, the PCV/SAV Agreement will continue on a program-by-program basis until Merck terminates its participation in such program. Following any such termination, we will retain the exclusive right to develop and commercialize PCVs or SAVs developed as a part of such program, subject to restrictions and certain limited rights retained by Merck.

In connection with the amendment of the PCV Agreement to include the development and commercialization of mRNA-5671 and potentially other SAVs, Merck made a contemporaneous equity investment in our Series H redeemable convertible preferred stock, resulting in gross proceeds of $125.0 million, of which $13.0 million is determined to be a premium and recorded to deferred revenue.

Accounting Treatment

We determined that the PCV/SAV Agreement should be accounted for separately from the amended 2015 Merck Agreement, as the agreements were not negotiated in contemplation of one another and the elements within each of the agreements are not closely interrelated or interdependent on each other.

For periods prior to January 1, 2019, we applied the provisions of ASC 605 in accounting for this arrangement. As of the date of our initial application of ASC 606, we applied the practical expedient to include the aggregate effect of all modifications to the arrangement that occurred before January 1, 2019 with respect to: (i) identification of the satisfied and unsatisfied performance obligations, (ii) determination of the transaction price and (iii) allocation of the transaction price to the satisfied and unsatisfied performance obligations. Additionally, we determined that all aspects of the PCV/SAV Agreement represent a transaction with a customer and therefore the PCV/SAV Agreement is accounted for in accordance with ASC 606 as of the date of the initial application. Further, the equity investment in our Series H redeemable convertible preferred stock was considered together with the PCV/SAV Agreement as the transactions were executed contemporaneously in contemplation of one another. Further, the purchase price paid by Merck with respect to the investment in the Series H redeemable convertible preferred stock was not representative of fair value on the date of such purchase. As such, the incremental proceeds received in excess of the fair value of the underlying stock related to the equity investment were included in the transaction price related to the PCV/SAV Agreement and the shares of Series H redeemable convertible preferred stock purchased by Merck were recorded at their respective fair value on the date of issuance.

We identified the following performance obligations in the PCV/SAV Agreement: (i) a research license and research and development services, including manufacturing and supply of PCVs, during the proof of concept (POC) term for the PCV program, referred to as the PCV Performance Obligation, and (ii) research license and manufacturing and supply of mRNA-5671 during the POC term for the KRAS program, referred to as the KRAS Performance Obligation. We concluded that the research license is not distinct from the research and development services, including manufacturing and supply of PCVs, during the POC term for the PCV program, as Merck cannot fully exploit the value of the license without receipt of such services and supply. Our services and supply involve specialized expertise, particularly as it relates to mRNA technology that is not available in the marketplace. Therefore, the research license has been combined with the research and development services, including manufacturing and supply

Table of Contents

of PCVs, during the POC term for the PCV program, into a single performance obligation. Similarly, we concluded that the research license is not distinct from the manufacturing and supply of mRNA-5671 during the POC term for the KRAS program, as Merck cannot fully exploit the value of the license without receipt of such supply which must be provided by us. This is due to limitations inherent in the licenses conveyed wherein Merck does not have the contractual right to manufacture during the POC term. Therefore, the research license has been combined with the manufacturing and supply of mRNA-5671, during the POC term for the KRAS program, into a single performance obligation. Conversely, we concluded that the PCV Performance Obligation and the KRAS Performance Obligation are distinct from each other because Merck can fully exploit the value of each program for its intended purpose without the promises associated with the other program. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) Merck participation election license related to future joint development and commercialization on a program-by-program basis, (ii) manufacturing and supply in support of certain SAV programs and/or the PCV program upon Merck election to not participate in future development and commercialization of that program and (iii) research and development services associated with certain SAV programs. Therefore, such options will be accounted for as a separate contract upon the customer’s election.

As of January 1, 2019, the date of initial application of ASC 606, the total transaction price was determined to be $213.0 million comprised of the $200.0 million upfront payment pertaining to the PCV Agreement and the premium associated with the contemporaneous sale of Series H redeemable convertible preferred stock of $13.0 million. We determined there are no components of variable consideration that should be included in the transaction price as of the date of initial application, as additional consideration to which we could be entitled is subject to Merck’s election to exercise a customer option that was deemed to be a marketing offer. We will re-evaluate the transaction price at the end of each reporting period. There were no changes to the transaction price during the three months ended March 31, 2019.

The transaction price was allocated to the performance obligations based on the relative estimated standalone selling price of each performance obligation. We developed the estimated standalone selling price for the license included in each of the PCV Performance Obligation and the KRAS Performance Obligation primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success and the time needed to commercialize a product candidate pursuant to the associated license. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the PCV Performance Obligation and the KRAS Performance Obligation, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated cost, adjusted for a reasonable profit margin that would be expected to be realized under similar contracts.

The transaction price allocated to each performance obligation was as follows: (i) $206.3 million to the PCV Performance Obligation and (ii) $6.7 million allocated to the KRAS Performance Obligation. We will recognize revenue related to amounts allocated to the PCV Performance Obligation over time as the underlying services are performed using a proportional performance model. We measure proportional performance using an input method based on the costs incurred relative to the total estimated costs of research and development efforts. We recognize revenue related to the amounts allocated to the KRAS Performance Obligation based on the point in time upon which control of supply is transferred to Merck for each delivery of the associated supply.

For the three months ended March 31, 2019 and 2018, we recognized collaboration revenue of $10.2 million and $14.0 million, respectively, in the condensed consolidated statements of operations, from the Merck PCV/SAV Agreement. The revenue recognized during the three months ended March 31, 2019 includes $10.2 million related to the amortization of deferred revenue due to the satisfaction of our performance during the period. As of March 31, 2019, the aggregate amount of the transaction price allocated to the remaining performance obligations that are unsatisfied is $115.0 million, which is expected to be recognized as revenue through December 31, 2021. We had deferred revenue of $115.0 million and $111.3 million, as of March 31, 2019 and December 31, 2018, respectively, from the Merck PCV/SAV Agreement, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the services are expected to be performed or control of the supply is expected to be transferred.

Vertex – 2016 Strategic Alliance in Cystic Fibrosis

In July 2016, we entered into a Strategic Collaboration and License Agreement, with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited, together, Vertex, which we refer to as the Vertex Agreement. The Vertex Agreement is aimed at the discovery and development of potential mRNA medicines for the treatment of cystic fibrosis (CF) by enabling cells in the lungs of people with CF to produce functional CFTR proteins.

Table of Contents

Pursuant to the Vertex Agreement, we lead discovery efforts during a three-year research period, leveraging our Platform technology and mRNA delivery expertise along with Vertex’s scientific experience in CF biology and the functional understanding of CFTR. Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Subject to customary “back-up” supply rights granted to Vertex, we exclusively manufacture (or have manufactured) mRNA for preclinical, clinical and commercialization purposes. The parties established a joint steering committee to oversee and coordinate activities under the Vertex Agreement. We and Vertex have granted each other certain licenses under the Vertex Agreement.

Under the terms of the Vertex Agreement, we received a $20.0 million upfront payment from Vertex. Vertex has the right to extend the initial three-year research period by one additional year by making an additional payment to us. We are eligible to receive up to $55.0 million in payments for achievement of development milestones, up to $220.0 million in payments for achievement of regulatory milestones and potentially could receive an additional $3.0 million milestone payment for achievement of a regulatory milestone for second and each subsequent product under the Vertex Agreement. Vertex will also pay us tiered royalties at rates ranging from the low- to high-teens on worldwide net sales of products arising from the strategic alliance, subject to certain reductions, with an aggregate minimum floor. In connection with the strategic alliance, Vertex also made a $20.0 million equity investment in our Series F redeemable convertible preferred stock. During the term of the Vertex Agreement, we and Vertex have agreed to certain defined exclusivity obligations under the Vertex Agreement with respect to the development and commercialization of certain mRNA medicines.

Unless earlier terminated, the Vertex Agreement will continue until the expiration of all royalty terms. Vertex may terminate the Vertex Agreement for convenience upon 90 days’ prior written notice, except if termination relates to a product in a country where Vertex has received marketing approval, which, in such case, Vertex must provide 180 days’ prior written notice. Either party may terminate the Vertex Agreement upon the other party’s material breach, subject to specified notice and cure provisions. Each party may also terminate the Vertex Agreement in the event that the other party challenges the validity or enforceability of such party’s patent rights, subject to certain exceptions, or if the other party becomes insolvent.

Accounting Treatment

For periods prior to January 1, 2019, we applied the provisions of ASC 605 in accounting for this arrangement. As of the date of the initial application of ASC 606, we determined that all aspects of the arrangement with Vertex represent a transaction with a customer and therefore should be accounted for in accordance with ASC 606. We identified one performance obligation comprised of: (i) a research, development and commercialization license and (ii) research and development services, including manufacturing and supply of non-cGMP mRNA, during the initial three-year research period. We concluded that the license is not distinct from the research and development services, including manufacturing and supply of non-cGMP mRNA, during the initial three-year research period, as Vertex cannot fully exploit the value of the license without receipt of such services and supply. Our services and supply involve specialized expertise, particularly as it relates to mRNA technology that is not available in the marketplace. Therefore, the license has been combined with the research and development services, including manufacturing and supply of non-cGMP supply, into a single performance obligation. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) Vertex’s right to extend the research period for an additional year and (ii) clinical mRNA supply and/or non-cGMP mRNA supply beyond the initial three-year research period. Therefore, such options will be accounted for as a separate contract upon the customer’s election.

As of January 1, 2019, the date of initial application of ASC 606, the total transaction price was determined to be $24.4 million, comprised of the $20.0 million upfront payment and $4.4 million in research and development funding related to the research and development services and supply of non-cGMP mRNA. We utilize the most likely amount method to determine the amount of research and development funding to be received. We also utilize the most likely amount method to estimate any development and regulatory milestone payments to be received. As of January 1, 2019, there were no milestones included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or Vertex’s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. We will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. There were no changes to the transaction price during the three months ended March 31, 2019.

The transaction price was allocated entirely to the single performance obligation. We recognize revenue related to amounts allocated to the single performance obligation over time as the underlying services are performed using a proportional performance model. We

Table of Contents

measure proportional performance using an input method based on the costs incurred relative to the total estimated costs of the research and development efforts.

For the three months ended March 31, 2019 and 2018, we recognized collaboration revenue of $2.6 million and $4.1 million, respectively, in the condensed consolidated statements of operations, from Vertex. The revenue recognized during the three months ended March 31, 2019 includes $2.6 million related to the amortization of the deferred revenue due to the satisfaction of our performance during the period. As of March 31, 2019, the aggregate amount of the transaction price allocated to the remaining performance obligation that is unsatisfied is $1.1 million, which is expected to be recognized as revenue through June 30, 2019. We had deferred revenue of $0.8 million and $3.3 million, as of March 31, 2019 and December 31, 2018, respectively, from Vertex, which is classified as current in the condensed consolidated balance sheets based on the period the services are expected to be performed.

4. Grants

Biomedical Advanced Research and Development Authority (BARDA)

In September 2016, we received an award of up to $125.8 million under Agreement No. HHSO100201600029C from BARDA, a component of the Office of the Assistant Secretary for Preparedness and Response, or ASPR within the U.S. Department of Health and Human Services, or HHS, to help fund our Zika vaccine program. Under the terms of the agreement with BARDA, an initial base award of $8.2 million supported toxicology studies, a Phase 1 clinical trial, and associated manufacturing activities. Contract options were available, for $117.6 million to support an additional Phase 1 study of an improved Zika vaccine candidate, Phase 2 and Phase 3 clinical studies, as well as large-scale manufacturing for the Zika vaccine.

As of March 31, 2019, three of the four contract options had been exercised resulting in $117.3 million of available funding with an additional $8.5 million available if the final contract option is exercised. For the three months ended March 31, 2019 and 2018, we recognized revenue of $1.5 million and $1.0 million, respectively, relating to the BARDA Agreement.

The Bill & Melinda Gates Foundation (Gates Foundation)

In January 2016, we entered a global health project framework agreement with the Gates Foundation to advance mRNA-based development projects for various infectious diseases. The Gates Foundation has committed up to $20.0 million in grant funding to support our initial project related to the evaluation of antibody combinations in a preclinical setting as well as the conduct of a first-in-human Phase 1 clinical trial of a potential mRNA medicine to help prevent human immunodeficiency virus, or HIV, infections. Follow-on projects which could bring total potential funding under the framework agreement up to $100.0 million (including the HIV antibody project) to support the development of additional mRNA-based projects for various infectious diseases can be proposed and approved until the sixth anniversary of the framework agreement, subject to the terms of the framework agreement, including our obligation to grant to the Gates Foundation certain non-exclusive licenses. In March 2019, the Gates Foundation provided an

additional funding commitment up to $1.1 million to support a follow-on project.

As of March 31, 2019, up to $21.1 million has been committed for funding with up to an additional $80 million available, if additional follow-on projects are approved. For the three months ended March 31, 2019 and 2018, we recognized $0.3 million for each period, relating to the Gates Foundation agreement. Deferred revenue of $0.6 million and $0.8 million was recorded for both March 31, 2019, and December 31, 2018, respectively, related to the Gates Foundation agreement.

Defense Advanced Research Projects Agency (DARPA)

In October 2013, DARPA awarded us up to $24.6 million under Agreement No. W911NF-13-1-0417, which was subsequently adjusted to $19.7 million, to research and develop potential mRNA medicines as a part of DARPA’s Autonomous Diagnostics to Enable Prevention and Therapeutics, or ADEPT, program, which is focused on assisting with the development of technologies to rapidly identify and respond to threats posed by natural and engineered diseases and toxins. The DARPA awards have been deployed primarily in support of our vaccine and antibody programs to protect against chikungunya infection.

As of March 31, 2019 and December 31, 2018, $19.7 million has been committed by DARPA. There was no revenue recognized for the three months ended March 31, 2019, related to the DARPA agreement. We recognized revenue of $0.2 million for the three months ended March 31, 2018, related to the DARPA agreement.

Table of Contents

5. Financial Instruments

Cash and Cash Equivalents and Investments

The following tables summarize our cash and available-for-sale securities by significant investment category at March 31, 2019 and December 31, 2018 (in thousands):



	March 31, 2019
	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value		Cash and Cash Equivalents		Current Marketable Securities		Non- Current Marketable Securities
Cash and cash equivalents	$	502,935	$	—	$	(1	)	$	502,934	$	502,934	$	—	$	—
Available-for-sale:
Level 2:
Certificates of deposit	84,114		72		(1		)	84,185		—		80,483		3,702
U.S. treasury securities	119,347		155		(4		)	119,498		—		79,475		40,023
Debt securities of U.S. government agencies and corporate entities	839,055		1,129		(218		)	839,966		—		446,032		393,934
	$	1,545,451	$	1,356	$	(224	)	$	1,546,583	$	502,934	$	605,990	$	437,659
	December 31, 2018
	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value		Cash and Cash Equivalents		Current Marketable Securities		Non- Current Marketable Securities
Cash and cash equivalents	$	658,365	$	20	$	(21	)	$	658,364	$	658,364	$	—	$	—
Available-for-sale:
Level 2:
Certificates of deposit	173,102		42		(36		)	173,108		—		157,920		15,188
U.S. treasury securities	152,205		18		(48		)	152,175		—		152,175		—
Debt securities of U.S. government agencies and corporate entities	712,065		40		(1,335		)	710,770		—		552,968		157,802
	$	1,695,737	$	120	$	(1,440	)	$	1,694,417	$	658,364	$	863,063	$	172,990

Table of Contents

The amortized cost and estimated fair value of marketable securities, by contractual maturity at March 31, 2019 and December 31, 2018 are as follows (in thousands):



	March 31, 2019
	Amortized Cost		Estimated Fair Value
Due in one year or less	$	605,687	$	605,990
Due after one year through five years	436,829		437,659
Total	$	1,042,516	$	1,043,649
	December 31, 2018
	Amortized Cost		Estimated Fair Value
Due in one year or less	$	864,003	$	863,063
Due after one year through five years	173,369		172,990
Total	$	1,037,372	$	1,036,053

At March 31, 2019, we held 32 available-for-sale securities, or an estimated fair value of $135.8 million, out of our total investment portfolio that were in a continuous unrealized loss position for more than 12 months with a gross unrealized loss of $0.2 million. At December 31, 2018, we held 25 available-for-sale securities, or an estimated fair value of $82.8 million, out of our total investment portfolio that were in a continuous unrealized loss position for more than 12 months with a gross unrealized loss of $0.4 million. We concluded that the net declines in market value of our available-for-sale securities investment portfolio were temporary in nature and did not consider any of our investments to be other-than-temporarily impaired. In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for other-than-temporary impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. Furthermore, the aggregate of individual unrealized losses that had been outstanding for 12 months or less was not significant as of March 31, 2019 and December 31, 2018. We neither intend to sell these investments nor conclude that we are more-likely-than-not that we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.

6. Balance Sheet Components

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets, as of March 31, 2019 and December 31, 2018 consists of the following (in thousands):



	March 31,		December 31,
	2019		2018
Prepaid expenses	$	7,895	$	10,401
Tenant incentives receivables	11,336		10,089
Interest receivable on marketable securities	6,061		7,909
Prepaid expenses and other current assets	$	25,292	$	28,399

Table of Contents

Property and Equipment, Net

Property and equipment, net as of March 31, 2019 and December 31, 2018 consists of the following (in thousands):



	March 31,			December 31,
	2019			2018
Building	$	140,442		$	140,442
Laboratory equipment	98,891			96,907
Leasehold improvements	15,861			13,741
Furniture, fixtures and other	2,122			2,122
Computer equipment and software	9,456			11,513
Internally developed software	7,020			7,020
Construction in progress	11,403			4,688
	285,195			276,433
Less: Accumulated depreciation	(71,735		)	(64,456		)
Property and equipment, net	$	213,460		$	211,977

Depreciation and amortization expense for the three months ended March 31, 2019 and 2018 was $7.3 million and $5.2 million, respectively.

Accrued Liabilities

Accrued liabilities, as of March 31, 2019 and December 31, 2018 consists of the following (in thousands):



	March 31,		December 31,
	2019		2018
In-licenses	$	—	$	22,000
Property and equipment	7,756		12,089
Compensation-related	11,577		23,406
External goods and services	22,850		21,578
Accrued liabilities	$	42,183	$	79,073

7. Commitments and Contingencies

Lease Obligations

We have entered into various long-term non-cancelable operating lease arrangements for our facilities and equipment expiring at various times through 2032. Certain of these arrangements have free rent periods or escalating rent payment provisions, which we recognize rent expense under such arrangements on a straight-line basis over the life of the leases. We have two campuses in Massachusetts. We occupy a multi-building campus in Technology Square in Cambridge, MA with a mix of offices and research laboratory space totaling approximately 200,000 square feet. Our Cambridge facility leases have expiry ranges from 2020 to 2027. We have approximately 200,000 square feet of a manufacturing facility in Norwood, MA. This facility is leased through 2032.

In February 2019, we entered into a new lease agreement for office and laboratory space of approximately 200,000 square feet, located in Norwood, MA. The lease will commence in the second quarter of 2019, and expires in early 2031. We have the option to extend the lease for up to four additional five-year terms.

Table of Contents

Total rent expense, for the three months ended March 31, 2019 and 2018 was $4.8 million and $5.2 million, respectively. Future minimum lease payments under non-cancelable operating lease agreements at March 31, 2019, are as follows (in thousands):



Fiscal Year		Minimum Lease Payments
2019	(remainder of the year)	$	15,190
2020		22,874
2021		24,105
2022		23,455
2023		20,498
Thereafter		140,384
Total		$	246,506

Strategic Collaborations

Under our strategic collaboration agreements, we are committed to perform certain research, development, and manufacturing activities. As part of our PCV Agreement and PCV/SAV Agreement with Merck, we are committed to perform certain research, development and manufacturing activities related to PCV products through an initial Phase 2 clinical trial up to a budgeted amount of $243.0 million for both periods as of March 31, 2019 and December 31, 2018 (see Note 3).

Legal Proceedings

We are not currently a party to any material legal proceedings.

8. Shareholders' Equity

On February 28, 2018 and May 7, 2018, the Board of Directors approved an amendment to our Certificate of Incorporation resulting in a total of 775,000,000 shares of common stock and a total of 509,352,795 shares of redeemable convertible preferred stock being authorized, respectively. Upon completion of our IPO, our authorized capital stock consists of 1,600,000,000 shares of common stock, par value $0.0001 per share, and 162,000,000 shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock are undesignated.

On December 11, 2018, we completed our IPO, whereby we sold 26,275,993 shares of common stock at a price of $23.00 per share. The aggregate net proceeds received by us from the IPO were $563.0 million, net of underwriting discounts and commissions of $33.2 million and offering expenses of $8.1 million payable by us. Upon the closing of the IPO, all of the outstanding shares of our redeemable convertible preferred stock were converted into 236,012,913 shares of the common stock.

9. Stock-Based Compensation

Equity Plans

In connection with the IPO, we adopted the 2018 Stock Option and Incentive Plan (the 2018 Equity Plan) in November 2018. The 2018 Equity Plan became effective on the date immediately prior to the effective date of the IPO and replaced our 2016 Stock Option and Grant Plan (the 2016 Equity Plan). The number of shares of common stock available for issuance under the 2018 Equity Plan was increased by 13.2 million shares as a result of the automatic increase provision of the 2018 Equity Plan. As of March 31, 2019, we had a total of 72.4 million shares reserved for future issuance under our Equity Plans, of which 17.9 million shares were available for future grants.

Table of Contents

Options

We have granted options generally through the 2018 Equity Plan and 2016 Equity Plan. The following table summarizes our option activity as of March 31, 2019:



	Number of Options		Weighted- Average Exercise Price per Share	Weighted- Average Grant Date Fair Value per Share	Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value⁽¹⁾ (in thousands)
Outstanding at December 31, 2018	50,821,132		12.16	6.59	7.1 years	220,434
Granted	5,443,286		20.59	12.16
Exercised	(5,525	)	9.62	5.62
Canceled/forfeited	(2,987,612	)	14.29	8.48
Outstanding at March 31, 2019	53,271,281		12.92	6.99	7.5 years	412,480
Exercisable at March 31, 2019	24,769,502		8.54	4.05	5.7 years	292,602
Vested and expected to vest at March 31, 2019	28,501,493		16.73	9.55	9.0 years	119,876

_______

⁽¹⁾Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of March 31, 2019.

For the three months ended March 31, 2019, 5,525 stock options were exercised. The total intrinsic value of options exercised was $0.1 million. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The total consideration recorded as a result of stock option exercises was approximately $0.1 million for the three months ended March 31, 2019.

Stock-based compensation for options granted is determined using the Black-Scholes option pricing model. The weighted-average assumptions used to estimate the fair value of the options granted for the three months ended March 31, 2019 and 2018 are as follows:



	Weighted Average
	Three Months Ended March 31,
	2019			2018
Risk-free interest rate	2.48		%	2.71		%
Expected term	6.12 years			6.06 years
Expected volatility	62		%	63		%
Expected dividends	—		%	—		%
Weighted average fair value per share	$	12.16		$	8.48

Table of Contents

Restricted Common Stock

We have granted restricted stock awards generally through the 2016 Equity Plan. The following table summarizes our restricted stock activity during the three months ended March 31, 2019:



	Number of Shares		Weighted Average Grant Date per Share
Outstanding, non-vested at December 31, 2018	198,597		$	12.15
Issued	—		—
Vested	(48,911	)	12.15
Canceled, forfeited and adjustments, net	711		12.15
Outstanding, non-vested at March 31, 2019	150,397		12.15

Restricted Common Stock Units

We have granted restricted stock awards generally through the 2018 Equity Plan and 2016 Equity Plan. The following table summarizes our restricted stock unit activity during the three months ended March 31, 2019:



	Units		Weighted-Average Grant Date per Unit
Outstanding, non-vested at December 31, 2018	458,715		$	11.93
Issued	558,208		20.77
Vested ⁽¹⁾	14,334		11.93
Canceled/forfeited	(5,440	)	20.93
Pending settlement ⁽¹⁾	(14,334	)	11.93
Outstanding, non-vested at March 31, 2019	1,011,483		16.76

_________

⁽¹⁾The vested restricted stock units will be settled for common stock on the date which is 360 days after the consummation of the IPO.

Stock-Based Compensation Expense

The following table presents the components and classification of stock-based compensation expense for the three months ended March 31, 2019 and 2018 as follows (in thousands):



	Three Months Ended March 31,
	2019		2018
Options	$	17,487	$	10,048
Restricted common stock and units	1,010		1,803
Total	$	18,497	$	11,851
Research and development	$	10,783	$	7,356
General and administrative	7,714		4,495
Total	$	18,497	$	11,851

Table of Contents

As of March 31, 2019, there were $253.1 million of total unrecognized compensation cost related to unvested stock-based compensation with respect to options and restricted stock granted. That cost is expected to be recognized over a weighted-average period of 3.5 years at March 31, 2019.

2018 Employee Stock Purchase Plan

In November 2018, we adopted the 2018 Employee Stock Purchase Plan (the ESPP), which became effective on December 5, 2018. The ESPP initially reserves and authorizes the issuance of up to a total of 810,000 shares of common stock to participating employees. We had not made any offerings as of March 31, 2019.

10. Income Taxes

We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates that are expected to be in effect for the years in which differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a “more likely than not” criterion. Realization of our deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. We continued to maintain a full valuation allowance against all of our deferred tax assets based on management’s evaluation of all available evidence.

There were no significant income tax provisions or benefits for the three months ended March 31, 2019 and 2018.

Upon adoption of ASC 606 (see Note 2), we recorded a cumulative-effect adjustment of $28.0 million to the opening balance of accumulated deficit as of January 1, 2019 with a decrease in deferred revenue of $30.7 million and a decrease in accounts receivable of $2.7 million. As a result of the cumulative decrease in deferred revenue, our corresponding deferred tax asset decreased by $8.4 million, which was offset by a corresponding decrease to our valuation allowance.

11. Net Loss per Share

Net Loss per Share Attributable to Common Stockholders

Basic and diluted net loss per share attributable to common stockholders for the three months ended March 31, 2019 and 2018 are calculated as follows (in thousands, except share and per share data):



	Three Months Ended March 31,
	2019			2018
Numerator:
Net loss	$	(132,657	)	$	(72,376	)
Cumulative dividends on redeemable convertible preferred stock	—			(3,481		)
Net loss attributable to common stockholders	$	(132,657	)	$	(75,857	)
Denominator:
Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted	328,809,986			65,430,835
Net loss per share attributable to common stockholders, basic and diluted	$	(0.40	)	$	(1.16	)

Table of Contents

The following common stock equivalents, presented based on amounts outstanding as of March 31, 2019 and 2018 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive:



	March 31,
	2019	2018
Redeemable convertible preferred stock	—	260,817,303
Stock options	53,271,281	43,135,998
Restricted common stock	150,397	729,877
Restricted common stock units	1,011,483	458,715
	54,433,161	305,141,893

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited financial information and related notes included in this Form 10-Q and our consolidated financial statements and related notes and other financial information in our Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the SEC on March 13, 2019 and amended by Amendment No. 1 to our Annual Report on Form 10-K/A, which was filed with the SEC on April 25, 2019 (as amended, the "2018 Form 10-K"). Some of the information contained in this discussion and analysis or set forth elsewhere in this Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in Part II, Item 1A - Risk Factors in this Form 10-Q, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We are a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of potentially transformative medicines to improve the lives of patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates. We are developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases, independently and with our strategic collaborators. As we unlock the inherent advantages of mRNA, we aim to address as many diseases and impact as many patients as our technology, talent, and capital permit

We have a diverse development pipeline of 21 development candidates. Of these 21 development candidates, 11 are in various early stage clinical studies. The broad potential applications of mRNA medicines have led us to raise significant capital and adopt a long-term approach to capital allocation that balances near-term risks and long-term value creation. As of March 31, 2019, we had cash, cash equivalents, and investments of approximately $1.5 billion. We use this capital to fund operations and investing activities for technology creation, drug discovery and clinical development programs, infrastructure and capabilities to enable our research engine and early development engine (which includes our manufacturing facility in Norwood), our digital infrastructure, creation of our portfolio of intellectual property, and administrative support.

Since our inception, we have incurred significant operating losses. Our net losses were $384.7 million and $255.9 million for the years ended December 31, 2018 and 2017, respectively. Our net loss was $132.7 million for the three months ended March 31, 2019. As of March 31, 2019, our accumulated deficit was $1.1 billion. We expect to continue to incur significant expenses and operating losses for the foreseeable future.

In addition, we anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:


•	continue our platform research and drug discovery and development efforts;


•	conduct clinical studies for our investigational medicines;


•	manufacture clinical study materials and develop large-scale manufacturing capabilities;

Table of Contents


•	seek regulatory approval for our investigational medicines;


•	maintain, expand, and protect our intellectual property;


•	hire additional personnel to support our program development effort to obtain regulatory approval and secure additional facilities for operations; and


•	operate as a public company.

We do not expect to generate revenue from the sale of potential mRNA medicines unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our investigational medicines. If we seek to obtain regulatory approval for and commercialize any of our investigational medicines, we expect to incur significant commercialization expenses.

As a result, we will need substantial additional funding to support our continued operations and pursue our growth strategy. Until we can generate significant revenue from sales of our medicines, if ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings, government funding arrangements, strategic alliances and marketing, distribution, and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back, or discontinue the development and commercialization of one or more of our programs.

Our Pipeline

This section describes the pipeline that has emerged thus far from the combination of our strategy, our platform, our infrastructure, and the resources we have amassed.

We have 21 development candidates in our pipeline, with 11 in various early stage clinical studies on three different continents. Over 1,000 subjects have been enrolled in our clinical trials since December 2015. Our diverse pipeline comprises programs across six modalities and a broad range of therapeutic areas. A modality is a group of potential mRNA medicines with shared product features, and the associated combination of mRNA technologies, delivery technologies, and manufacturing processes. Aspects of our pipeline have been supported through strategic alliances, including with AstraZeneca, Merck, and Vertex, and government-sponsored organizations and private foundations focused on global health initiatives, including BARDA, DARPA, and the Bill & Melinda Gates Foundation.

Our pipeline is shown below in two formats, with a cell map illustrating the diversity of biology addressed by our mRNA pipeline programs, and a traditional format that shows the current stages of development of our pipeline programs. We believe the 21 programs in our pipeline represent only an initial wave of potential development candidates, and that our platform over time may yield both multiple new programs within our existing modalities and the potential for multiple programs in new modalities.

Table of Contents

Table of Contents

We have developed six modalities. We have 11 programs that have reached clinical trials and a total of 21 development candidates, summarized by modality as follows:


•	Prophylactic vaccines included eight development candidates: RSV vaccine (mRNA-1777 and mRNA-1172), CMV vaccine (mRNA-1647), hMPV+PIV3 vaccine (mRNA-1653), H10N8 vaccine (mRNA-1440), H7N9 vaccine (mRNA-1851), Zika vaccine (mRNA-1893), and Chikungunya vaccine (mRNA-1388). We currently have six programs for which the Phase 1 trial is either ongoing or has been completed;

•

Cancer vaccines included two development candidates: Personalized cancer vaccine, or PCV, (mRNA-4157) and KRAS vaccine (mRNA-5671). We are collaborating with Merck on both programs. PCV is in a Phase 1 clinical trial and we and Merck have submitted a protocol to the U.S. Food and Drug Administration (FDA) for a randomized Phase 2 clinical trial of mRNA-4157, and the KRAS vaccine has an open investigational new drug application (IND) ;


•	Intratumoral immuno-oncology included three development candidates: OX40L (mRNA-2416), OX40L+IL23+IL36γ (Triplet) (mRNA-2752), and IL12 (MEDI1191). The OX40L and OX40L+IL23+IL36γ programs are currently in Phase 1 clinical trials and the IND for a Phase 1 clinical trial of IL12 is open;


•	Localized regenerative therapeutics included one development candidate, VEGF-A (AZD8601). The program is being led by AstraZeneca through clinical development and is in a Phase 2a clinical trial;


•	Systemic secreted therapeutics included three development candidates: antibody against Chikungunya virus (mRNA-1944), Relaxin (AZD7970), and Fabry disease (mRNA-3630). The antibody against Chikungunya virus

Table of Contents

development candidate is in collaboration with DARPA and the program is in a Phase 1 clinical trial. The Relaxin program in collaboration with AstraZeneca and the Fabry disease program are both in preclinical development; and


•	Systemic intracellular therapeutics included four development candidates: MMA (mRNA-3704), PA (mRNA-3927), PKU (mRNA-3283), and GSD1a (mRNA-3745). The MMA program has an open IND, and the PA, PKU, and GSD1a programs are in preclinical development.

Since reporting on the quarter ended December 31, 2018, we reported the following updates for our development candidates:

•

RSV vaccine (mRNA-1777 and mRNA-1172): Merck has filed an IND with the FDA and plans to run a Phase 1 study for a follow-on development candidate (mRNA-1172), a vaccine for RSV which has shown enhanced potency in preclinical studies and uses a Merck proprietary formulation. As a result, further development of mRNA-1777 has been paused and next steps will be determined based on data from the new mRNA-1172 Phase 1 study.


•	CMV vaccine (mRNA-1647): The first three dose levels in our ongoing study of mRNA-1647 are fully enrolled, and the study is currently enrolling subjects into the fourth (300 µg) dose cohort. The Phase 1 study is randomized, observer-blind and placebo-controlled with the goal of evaluating the safety and immunogenicity of mRNA-1647, a vaccine against the pentamer and gB complexes of CMV.


•	VZV vaccine (mRNA-1278): Merck has discontinued preclinical development of mRNA-1278, an investigational vaccine for VZV (the virus that causes shingles). Merck has returned rights to us, and we will not continue development at this time


•	Antibody against Chikungunya virus (mRNA-1944): We completed enrollment of the second dose level cohort (0.3 mg/kg, 8 subjects) in the Phase 1 trial of mRNA-1944 in healthy adults.


•	Propionic acidemia (PA) (mRNA-3927): The European Commission has adopted the recommendation from the Committee for Orphan Medicinal Products for orphan drug designation for mRNA-3927, a development candidate for propionic acidemia (PA).


•	Glycogen storage disease type 1a (GSD1a) (mRNA-3745): We designated mRNA-3745 as a new development candidate for the rare inherited metabolic disease GSD1a. Please refer to the section of this Form 10-Q entitled “Overview-New Development Candidate in our Systemic Intracellular Therapeutics Modality” for the program description for mRNA-3745.

Update to a Development Candidate in our Prophylactic Vaccines Modality

RSV vaccine (mRNA-1777 and mRNA-1172): Summary

Our strategic collaborator Merck has determined to pursue a Phase 1 study with an improved RSV antigen and a proprietary Merck formulation before conducting a Phase 2a study

Respiratory syncytial virus ("RSV") is one of the most common causes of respiratory disease in infants and the elderly. More than 86,000 children and about 177,000 older adults are hospitalized due to RSV associated respiratory infections each year in the United States. To date, no effective vaccine to prevent RSV has been approved, and the only approved prophylaxis treatment is limited to the monoclonal antibody palivizumab, marketed as Synagis in the United States for pediatric patients at high risk for RSV infection. In collaboration with Merck, we designed mRNA-1777 to encode a membrane-anchored version of stabilized prefusion F protein, the main target of potently neutralizing and protective antibodies. This vaccine is administered as a single dose with no boost. The Phase 1 trial is currently ongoing in Australia, for which we are the sponsor.

Our strategic collaborator, Merck, has submitted an IND for a Phase 1 trial of a second mRNA vaccine (mRNA-1172). In preclinical models, the new development candidate, which uses a proprietary Merck formulation, demonstrated enhanced potency over mRNA-1777. Following the first Phase 1 study with mRNA-1172, we and Merck will determine whether to pursue further clinical development.

RSV vaccine (mRNA-1777 and mRNA-1172): Disease overview

RSV impacts young children and older adults, and no approved vaccine exists today

RSV causes upper and lower respiratory tract illness worldwide and is transmitted primarily via contamination of environmental surfaces with infectious secretions, or possibly also via aerosolized droplets from an infected person. Following introduction of RSV into the nose or upper respiratory tract, the virus replicates primarily in the ciliated cells of the respiratory epithelium. Upper respiratory symptoms typically begin within several days of exposure. In healthy adults, the infection may remain confined to the

Table of Contents

upper respiratory tract. However, in those with compromised immune systems, such as premature infants, the elderly, or individuals with underlying respiratory disease, lower respiratory tract infections commonly occur and may manifest as wheezing, bronchiolitis, pneumonia, hospitalization or even death. Infections with RSV follow a seasonal pattern, occurring primarily in the Northern hemisphere between the months of November and April, and in the Southern hemisphere primarily between March and October.

More than 86,000 children are hospitalized due to RSV infection each year in the United States. About 177,000 older adults are hospitalized each year in the United States due to RSV-associated respiratory infections, with approximately 14,000 deaths as a result. RSV infection is common in adults over the age of 60 years, occurring in an average of 5.5% of older adults every season and resulting in physician’s visits for 17% of infected older adults. The cost of RSV disease to society can be considerable.

RSV vaccine (mRNA-1777 and mRNA-1172): Our product concept

Prevent RSV infections with an improved RSV antigen using a single vaccine dose

Our RSV development candidates, mRNA-1777 and mRNA-1172, include an mRNA encoding an engineered form of the RSV fusion (F) glycoprotein stabilized in the prefusion conformation in an LNP. The F protein is present as a homotrimer on the surface of RSV. The prefusion conformation of the F protein interacts with a host cell membrane, and the conformational change from prefusion to postfusion drives virus fusion with a host cell. The majority of RSV-specific neutralizing antibodies in convalescent people are directed to epitopes present only on the prefusion conformation of the F protein. The prefusion state of the F protein elicits a superior neutralizing antibody response compared to the postfusion state in animal studies conducted by others. A schematic of the prefusion F protein on the surface of a host cell, with sites recognized by neutralizing antibodies, is depicted in the figure below; the inset on the left of the figure shows the intended design of the mRNA formulated in LNP, and the inset on the right shows the intended prefusion F protein on the surface of the cell. We believe that neutralizing antibodies elicited by our RSV development candidates may lead to an efficacious RSV vaccine.

RSV vaccine (mRNA-1777 and mRNA-1172): Preclinical information

mRNA vaccines encoding different versions of the prefusion F protein have been evaluated in mice, cotton rats, and African green monkeys ("AGM"). These studies demonstrate that mRNA vaccines encoding the prefusion F protein induce robust neutralizing antibody titers in preclinical species tested, do not lead to vaccine-enhanced respiratory disease (evaluated in cotton rats), and are protective against RSV challenge (evaluated in cotton rats and AGM). The data for a study in AGM are shown in the figure below. In this study, one group of AGM (4 per group) was vaccinated intramuscularly with vaccine, a second group was infected with 5.5 log₁₀ plaque forming units, or pfu, of RSV strain A2 intranasally as a positive control, and a third group received no vaccine as a negative control, each on weeks 0, 4, and 8. Serum neutralizing antibody titers, or SN titers, were measured on the indicated weeks and are shown in panel A. All animals were challenged intranasally and intratracheally on study week 10. On multiple time points after the challenge, virus present in bronchoalveolar lavage, or BAL, fluid was quantified by plaque assay as shown in panel B. In this study, we observed an increase in serum neutralizing titers with each vaccine dose. The animals that received mRNA-1777 showed complete protection (no virus detected) in lungs, similar to the control group immunized with RSV A2. These results are shown in the figures below.

Table of Contents

Serum neutralizing titers for mRNA-1777 in non-human primate study

Panel (A)

Lung viremia detected post challenge in non-human primate study with mRNA-1777

Panel (B)

Recent studies in cotton rats and AGM demonstrate immunogenicity of mRNA-1172. The data for a study in AGM are shown below. In this study, two groups of AGM (4 per group) were vaccinated intramuscularly with the same dose level (µg) of vaccine, a fifth group was infected with 5.5 log₁₀ plaque forming units, or pfu, of RSV strain A2 intranasally as a positive control, and a sixth group received no vaccine as a naïve control, each on weeks 0, 4, and 8. Serum neutralizing antibody titers were measured on the indicated weeks and are shown in panel C. In this study, mRNA-1172 was shown to be significantly more potent than mRNA-1777.

Table of Contents

Serum neutralizing titers for mRNA-1172 and mRNA-1777 in non-human primate study

Panel (C)

RSV vaccine (mRNA-1777 and mRNA-1172): Clinical data

Merck has submitted an IND for mRNA-1172 and plans to conduct a Phase 1 trial for mRNA-1172, data from which will be used to inform planning of a Phase 2a trial for our RSV vaccine

The Phase 1 trial for mRNA-1777 has met its objectives of assessing its safety and tolerability profile versus placebo including capturing solicited and unsolicited local and systemic adverse events. The Phase 1 trial for mRNA-1777 has also demonstrated immunogenicity and we have observed a humoral immune response as measured by neutralizing antibody titers against RSV A for dose levels one, two, and three of mRNA-1777. Based on the interim data and other considerations, Merck will not advance mRNA-1777 into Phase 2a at this time.

The mRNA-1777 Phase 1 study is a randomized, partially double-blind, placebo-controlled, dose-escalation first-in-human study to describe the safety, tolerability, and immunogenicity in healthy adult subjects in Australia. We are the sponsor for this trial. The study evaluated three dose levels in healthy younger adults, and 4 dose levels in healthy older adults. All subjects were given a single intramuscular injection. The key objectives of the study included:


•	assess the safety and tolerability of mRNA-1777 versus placebo; and


•	determine the immunogenicity of mRNA-1777 by measuring serum neutralizing antibody titers against RSV.

The key endpoints for the study included safety and tolerability of mRNA-1777.

The study is being conducted in two parts. Part A evaluates healthy younger subjects (ages > 18 and < 49 years) and Part B evaluates healthy older subjects (ages > 60 and < 79 years). There are four dose levels, where the highest dose, or dose four, is twelve times the lowest dose, or dose one, and dose three, the second highest dose, is eight times the lowest dose. In Part A, dose levels one, two, and three are being evaluated. In Part B, all four dose levels are being evaluated. The first sentinel dose cohort was triggered after review of the first sentinel dose level cohort in Part A. For both Parts A and B, the safety data from the sentinel safety group for each dose level cohort was reviewed before permitting enrollment of the expansion group within that dose level cohort and the safety data of each expansion group was reviewed before permitting dose escalation/enrollment of the sentinel safety group at the next dose level. Part B includes the highest dose level, dose four, which was enrolled after review of the available safety and immunogenicity data of the preceding Part B dose level cohorts. Expansion groups in Part A and B were both randomized 3:1 mRNA-1777: placebo.

This 200-subject study is fully enrolled and all subjects have been dosed. As of April 9, 2018, we have the majority of data through three months (90 days) post-vaccination for younger subjects in dose levels one and two, and for older subjects in dose levels one, two, and three. Based on the interim data as of April 2018, dose levels one, two, and three of mRNA-1777 were observed to elicit a humoral immune response as measured by neutralizing antibody titers against RSV A, neutralizing antibody titers against RSV B (dose level three only, dose levels one and two have yet to be assayed), absolute serum antibody titers to RSV prefusion F protein and

Table of Contents

RSV postfusion F protein, and competing antibody titers to RSV prefusion F protein in a dose-dependent manner up to dose level two in both younger and older subjects. The immune response measured by neutralizing antibody titers against RSV A in older adults that received dose level three of mRNA-1777 was not higher than that of the subjects that received dose level two. We have observed an increase in neutralizing antibody titers relative to placebo in younger adult subjects in panel A and older adult subjects in panel B who received our RSV vaccine, as shown in the figure below. In the figure, geometric mean titer and 95% confidence interval are depicted by time for neutralizing antibody titers against RSV A for older and younger subjects. At day ninety, between 10 and 19 healthy younger subjects and between 11 and 27 healthy older subjects were tested at each dose level.

Neutralizing antibody titers in healthy younger subjects

[Ages > 18 and < 49 years] in Phase 1 trial for mRNA-1777 per protocol set

Panel (A)

Neutralizing antibody titers in healthy older subjects

[Ages > 60 and < 79 years] in Phase 1 trial for mRNA-1777 per protocol set

Panel (B)

In addition, based on interim data as of April 2018, we observed an increase in T cell response relative to baseline at day 15 and day 60 in both healthy younger and healthy older adult subjects vaccinated with dose levels two and three of mRNA-1777.

Based on interim safety data as of April 9, 2018, mRNA-1777 was well tolerated with no dose limiting toxicities at dose levels one, two, and three in both the younger and older adults. As of September 2018, the highest dose level, which was evaluated in older subjects only, dose level four, was not as well tolerated as the lower dose levels. However, across all treatment arms, there were no treatment-related serious adverse events, or SAEs, treatment emergent adverse events, or TEAEs, leading to withdrawals, adverse events, or AEs of special interest, or new onset of chronic illnesses or autoimmune disorders in either of the age cohorts. There were no patterns in clinically significant laboratory abnormalities.

Table of Contents

As of September 19, 2018, we have observed 15 SAEs in nine subjects, all of which were deemed unrelated to study product. These SAEs occurred approximately one to ten months from receipt of study product and included aortic aneurysm repair, paralytic ileus, spinal decompression, death from pre-existing cardiomyopathy, hernia, transient ischemic attack, peripheral vascular disorder, vasovagal syncope, diagnosis of non-small cell lung cancer, anterior cruciate ligament tear, left knee tendon tear, right knee tendon tear, left patella dislocation, right patella dislocation, and bilateral patella tendon repair.

The trial is ongoing and, consistent with the study protocol, we remain blinded to treatment at the individual subject level and continue to collect safety, tolerability, and immunogenicity data through day 365 of the study. In parallel, Merck plans to conduct a Phase 1 trial for mRNA-1172, data from which will be used to inform planning of a possible Phase 2a trial for the RSV vaccine. Merck submitted the IND for mRNA-1172 in May 2019.

New Development Candidate in our Systemic Intracellular Therapeutics Modality

Glycogen storage disease type 1a (mRNA-3745): Summary

Our approach to glycogen storage disease type 1a using an mRNA encoding for intracellular human glucose 6-phosphatase

Glycogen storage disease type 1a ("GSD1a") is an inherited metabolic disease caused by the deficiency in the catalytic activity of glucose 6-phosphatase (“G6Pase”), which is encoded by the glucose 6-phosphatase gene (“G6PC”). The G6Pase enzyme is involved in the metabolic pathways of glycogenolysis and gluconeogenesis which allow the liver and kidney to release glucose into the blood. Those affected by GSD1a present with life-threatening hypoglycemia and a wide range of severe metabolic derangements and long-term complications such as hyperlipidemia, lactic acidemia, hepatomegaly, hepatocellular adenomas, and end-stage renal disease. The standard of care consists of strict diet control. Enzyme replacement therapy (“ERT”) is not an option for these patients due to challenges associated with delivering an enzyme inside the cell. Strict diet control via the frequent consumption of uncooked cornstarch is effective in improving hypoglycemia. However, the underlying pathologies continue and its efficacy in preventing the long-term metabolic complications has yet to be established. With our mRNA platform, cells in the liver may be instructed to produce functional G6Pase, with the goal of restoring the homeostasis of glycogenolysis and gluconeogenesis pathways and correcting the underlying pathologies. We are developing an intravenously administered mRNA which encodes for G6Pase and is encapsulated in our proprietary lipid nanoparticle ("LNP"). We have demonstrated activity in mouse models in the form of reduction in both liver and serum biomarkers and improvements in liver morphology. We plan to conduct a Phase 1 clinical trial for mRNA-3745.

Glycogen storage disease type 1a (mRNA-3745): Disease overview

There are no approved therapies for GSD1a that address the enzymatic deficiency

GSD1a is an inherited metabolic disorder caused by a deficiency in the catalytic activity of G6Pase, an enzyme encoded by G6PC gene and involved in two metabolic pathways associated with glucose homeostasis. G6Pase catalyzes the hydrolysis of glucose-6-phosphate to glucose and inorganic phosphate, the final step of glycogenolysis and gluconeogenesis that mainly takes place in liver and kidney. GSD1a patients suffer from severe fasting hypoglycemia, hepatomegaly, nephromegaly, lactic acidemia, hypertriglyceridemia, hyperuricemia, hypercholesterolemia, hepatic steatosis, and growth retardation. In addition, hepatocellular adenomas occur in 70% to 80% of GSD1a patients by their third decade of life and carries risk of transformation into hepatocellular carcinomas. Proteinuria has been observed in over half of patients above 25 years of age.

GSD1a occurs in approximately 1:100,000 live births in the United States and European Union but is more common in Ashkenazi Jews where the incidence is reported to be 1:20,000 live births. There are an estimated 2,500 people in the United States and over 4,000 people in the European Union with GSD1a. Although strict diet therapy, including frequent feeding with uncooked cornstarch, allows GSD1a patients to live into adulthood by preventing hypoglycemia, the underlying pathological processes remain uncorrected resulting in the development of many long-term complications including liver adenomas and hepatocellular carcinoma.

One option for GSD1a patients may be treatment with gene therapy. We believe there are potential advantages for mRNA therapeutics for this disorder over gene therapy.

Glycogen storage disease type 1a (mRNA-3745): Our product concept

We intend to utilize the cells in the human body to produce G6Pase intracellularly

We believe that our platform can address GSD1a with its ability to instruct cells in the human body to produce complex functional intracellular membrane proteins such as G6Pase. Our program, mRNA-3745, consists of an mRNA encoding for modified human G6Pase encapsulated in our proprietary LNPs. The human G6Pase sequence is modified for improved protein production and G6Pase

Table of Contents

activity. mRNA-3745 is designed to be administered intravenously and encodes G6Pase protein to restore this deficient or defective enzyme as illustrated in the figure below.

Glycogen storage disease type 1a (mRNA-3745): Preclinical information

We have demonstrated the ability to improve hypoglycemia and other metabolic abnormalities associated with GSD1a in a mouse model

We have conducted several in vitro and in vivo pharmacology studies to demonstrate preclinical proof-of-concept for GSD1a therapy. mRNA encoding for G6Pase introduced in human cells resulted in robust production of active G6Pase with subcellular localization into endoplasmic reticulum. We have examined the activity of mRNA encoding for human G6Pase in a liver-specific G6Pase -/- mouse model (G6PC.LKO). Like GSD1a patients, the G6PC.LKO mice are unable to produce endogenous glucose, leading to severe hypoglycemia during the fasting state.

In a dose-response study performed in G6PC.LKO mice, we treated the mice with three different doses of 0.2, 0.5, and 1 mg/kg of G6Pase mRNA encapsulated in our proprietary LNP and examined fasting glucose, serum triglycerides, and liver enzymes (n=5-8). Of note, mice treated with G6Pase mRNA showed a dose-dependent improvement in fasting glycemia and a reduction in serum triglycerides, without a significant increase in liver enzymes (e.g. alanine transaminase – ALT). Fasting blood glucose and triglycerides are shown in the figure below. Each bar represents the mean ± standard deviation. Single and double asterisk denotes p < 0.05 and p < 0.0001, respectively, by one-way ANOVA, followed by Dunnett’s post-hoc test for multiple comparisons.

Serum biomarkers after single dose of G6Pase mRNA in G6PC.LKO mice

Table of Contents

In the same study, a reduction in liver weight compared to the control-treated group was observed after 24 hours of administration of G6Pase encoded mRNA in LNP. The reduction in liver weight was associated with significant improvement in liver morphology presumably due to reduction in liver glucose 6-phosphate, glycogen, and triglycerides.

Reduction in liver weight 24 hours after IV administration of G6Pase mRNA in G6PC.LKO mice

In addition, data for a 7-week repeat-dose study in G6PC.LKO mice receiving G6Pase mRNA in LNP at 0.25 mg/kg IV every other week have shown a pronounced improvement in fasting glycemia, in comparison with the G6PC.LKO mice receiving a control mRNA treatment as shown below (n=7-9).

Restoration of blood glucose above therapeutic threshold with repeat dosing of G6Pase mRNA in G6PC.LKO mice

Glycogen storage disease type 1a (mRNA-3745): Clinical plan

We are planning a Phase 1 clinical trial

We plan to conduct an open-label, dose escalation Phase 1 study of mRNA-3745 in adolescent and adult patients with GSD1a in the United States. The objectives of this study are to evaluate the safety and tolerability of mRNA-3745, to assess the pharmacodynamic response through changes in maintenance of euglycemia, and to characterize the pharmacokinetic profile of mRNA-3745.

Table of Contents

Third-Party Strategic Alliances

Merck (NYSE: MRK)—Strategic Alliances in Infectious Diseases

We have established a multi-faceted relationship with Merck that includes distinct strategic alliances directed to the research, development, and commercialization of mRNA medicines for the prevention of viral infections and for the treatment of cancer.

2015 Strategic Alliance with Merck-Infectious Disease

In January 2015, we entered into a Master Collaboration and License Agreement with Merck, which was amended in January 2016, June 2016, and May 2019, and which we refer to, as amended, as the 2015 Merck Agreement. Pursuant to the 2015 Merck Agreement, we and Merck have agreed to research, develop, and commercialize potential mRNA medicines for the prevention of infections by RSV. Pursuant to the 2015 Merck Agreement, Merck is primarily responsible for research, development, and commercialization activities and associated costs of such research and commercialization. We are responsible for designing and manufacturing all mRNA constructs for preclinical and Phase 1 and Phase 2 clinical development purposes, and Merck pays us for such manufacture, and we are responsible for certain costs associated with the conduct of a Phase 1 clinical trial for an RSV vaccine product candidate (mRNA-1172). Responsibility for manufacturing mRNA constructs for late stage clinical development and commercialization purposes is to be determined.

Table of Contents

Financial Operations Overview

Revenue

To date, we have not generated any revenue from the sale of potential mRNA medicines. Our revenue has been primarily derived from strategic alliances with Merck, Vertex and AstraZeneca, and from contracts with government-sponsored and private organizations including DARPA, BARDA, and the Bill & Melinda Gates Foundation, to discover, develop, and commercialize potential mRNA medicines. On January 1, 2019, we adopted Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606), using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. We recorded the cumulative-effect adjustment of $28.0 million to the opening balance of accumulated deficit as of January 1, 2019 with a corresponding decrease to deferred revenue.

Total revenue for the three months ended March 31, 2019 and 2018 was $16.0 million and $29.0 million, respectively, and is primarily comprised of collaboration revenue from our strategic alliances as follows (in thousands):



	Three Months Ended March 31,
	2019		2018
Collaboration revenue:
Merck	$	10,687	$	15,967
Vertex	2,614		4,143
AstraZeneca	814		7,350
Total collaboration revenue	$	14,115	$	27,460

Cash received from strategic alliances was $4.8 million and $10.6 million for the three months ended March 31, 2019 and 2018, respectively. The timing of revenue recognition is not directly correlated to the timing of cash receipts. Total deferred revenue related to our strategic alliances as of March 31, 2019 and December 31, 2018 was $230.8 million and $274.4 million, respectively.

For further information on our adoption of ASC 606 and our revenue recognition policies, see Note 2 to our condensed consolidated financial statements “Recent Accounting Standards and Accounting Policies”. Our ability to generate revenue from sales of mRNA medicines and become profitable depends upon our ability to successfully develop and commercialize mRNA medicines. For the foreseeable future, we do not expect to generate revenue from product sales. To the extent that existing or potential future strategic alliances generate revenue, our revenue may vary due to many uncertainties in the development of our mRNA medicines under these strategic alliances and other factors. We expect to incur losses for the foreseeable future, and we expect these losses to increase as we continue our research and development efforts. We expect our programs to mature and advance to later stage clinical development, and we expect expenses to increase as we seek regulatory approvals for our investigational medicines and begin to commercialize any approved mRNA medicines.

Research and development expenses

The nature of our business and primary focus of our activities generate a significant amount of research and development costs.

Research and development expenses represent costs incurred by us for the following:


•	cost to develop our platform;


•	discovery efforts leading to development candidates;


•	preclinical, nonclinical, and clinical development costs for our programs;


•	cost to develop our manufacturing technology and infrastructure; and


•	digital infrastructure costs.

The costs above comprise the following categories:


•	personnel-related expenses, including salaries, benefits, and stock-based compensation expense;


•	expenses incurred under agreements with third parties, such as consultants, investigative sites, contract research organizations, or CROs, that conduct our preclinical and clinical studies, and in-licensing arrangements;

Table of Contents


•	costs of acquiring, developing, and manufacturing materials for preclinical and clinical studies, including both internal manufacturing and third-party contract manufacturing organizations, or CMOs;


•	expenses incurred for the procurement of materials, laboratory supplies, and non-capital equipment used in the research and development process; and


•	facilities, depreciation, and amortization, and other direct and allocated expenses incurred as a result of research and development activities.

We use our employee and infrastructure resources for the advancement of our platform, and for discovering and developing programs. Due to the number of ongoing programs and our ability to use resources across several projects, indirect or shared operating costs incurred for our research and development programs are not recorded or maintained on a program- or modality-specific basis.

The following table reflects our research and development expenses, including direct program specific expenses summarized by modality and indirect or shared operating costs summarized under other research and development expenses during the three months ended March 31, 2019 and 2018 (in thousands):



	Three Months Ended March 31,
	2019		2018
Program expenses by modality:
Prophylactic vaccines	$	20,262	$	5,591
Cancer vaccines	10,086		7,848
Intratumoral immuno-oncology	4,418		5,489
Localized regenerative therapeutics	8		75
Systemic secreted therapeutics	4,633		5,349
Systemic intracellular therapeutics	6,743		8,150
Total program-specific expenses by modality⁽¹⁾	46,150		32,502
Other research and development expenses:
Discovery programs	12,915		9,146
Platform research	24,497		21,135
Technical development and unallocated manufacturing expenses	21,347		13,129
Shared discovery and development expenses	14,883		6,856
Stock-based compensation	10,783		7,356
Total research and development expenses	$	130,575	$	90,124

__________


⁽¹⁾	Includes a total of 20 and 18 development candidates at March 31, 2019 and 2018, respectively. Program-specific expenses include external costs and allocated manufacturing costs of mRNA supply and consumables, and reflect these expenses beginning in the period the program was internally advanced to development or these expenses ending in the period the program was ceased.

A “modality” refers to a group of programs with common product features and the associated combination of enabling mRNA technologies, delivery technologies, and manufacturing processes. The program-specific expenses by modality summarized in the table above include expenses we directly attribute to our programs, which consist primarily of external costs, such as fees paid to outside consultants, central laboratories, investigative sites, and CROs in connection with our preclinical studies and clinical trials, and allocated manufacturing costs of mRNA supply and consumables. Costs to acquire and manufacture mRNA supply for preclinical studies and clinical trials are recognized and included in unallocated manufacturing expenses when incurred, and subsequently allocated to program-specific manufacturing costs after completion of the program-specific production. The timing of allocating manufacturing costs to the specific program varies depending on the program development and production schedule. We do not allocate personnel-related costs, including stock-based compensation, costs associated with our general platform research, technical development, and other shared costs on a program-specific basis. These costs were therefore excluded from the summary of program-specific expenses by modality.

Discovery program expenses are costs associated with research activities for our programs in the preclinical discovery stage, and primarily consist of external costs for CROs and lab services, and allocated manufacturing cost of preclinical mRNA supply and consumables.

Platform research expenses are mainly costs to develop technical advances in mRNA science, delivery science, and manufacturing process design. These costs include personnel-related costs, computer equipment, facilities, preclinical mRNA supply and

Table of Contents

consumables, and other administrative costs to support our platform research. Technology development and unallocated manufacturing expenses are primarily related to non-program-specific manufacturing process development and manufacturing costs.

Shared discovery and development expenses are research and development costs such as personnel-related costs and other costs, which are not otherwise included in development programs, discovery programs, platform research, technical development and unallocated manufacturing expenses, stock-based compensation, and other expenses.

The largest component of our total operating expenses has historically been our investment in research and development activities, including development of our platform, mRNA technologies, and manufacturing technologies. We expense research and development costs as incurred and cannot reasonably estimate the nature, timing, and estimated costs required to complete the development of the development candidates and investigational medicines we are currently developing or may develop in the future. There are numerous risks and uncertainties associated with the research and development of such development candidates and investigational medicines, including, but not limited to:


•	scope, progress, and expense of developing ongoing and future development candidates and investigational medicines;


•	entry in and completion of related preclinical studies;


•	enrollment in and completion of subsequent clinical trials;


•	safety and efficacy of investigational medicines resulting from these clinical trials;


•	changes in laws or regulations relevant to the investigational medicines in development;


•	receipt of the required regulatory approvals; and


•	commercialization, including establishing manufacturing and marketing capabilities.

A change in expectations or outcomes of any of the known or unknown risks and uncertainties may materially impact our expected research and development expenditures. Continued research and development is central to the ongoing activities of our business. Investigational medicines in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our costs to continue to increase in the future as our investigational medicines progress through the development phases and as we identify and develop additional programs. However, we do not believe that it is possible at this time to accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our investigational medicines, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time due to the early stage of development of our investigational medicines. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans.

General and administrative expenses

General and administrative expenses consist primarily of personnel-related costs, including stock-based compensation, for executives, finance, legal, human resources, business development and other administrative and operational functions, professional fees, accounting and legal services, information technology and facility-related costs, and expenses associated with obtaining and maintaining intellectual property, or IP. These costs relate to the operation of the business, unrelated to the research and development function, or any individual program.

We anticipate general and administrative expenses will increase as research and development expands. These increases will likely relate to additional personnel and increased costs related to finance, legal and IP-related matters along with increased expenses related to operating as a publicly traded company, such as fees related to audit, legal, and tax services, regulatory compliance programs, and investor relations. In addition, if we obtain regulatory approval for any of our investigational medicines and do not enter into a third-party commercialization collaboration, we expect to incur significant expenses related to building a sales and marketing team to support medicine sales, marketing, and distribution activities.

We have a broad IP portfolio covering our development and commercialization of mRNA vaccine and therapeutic programs, including those related to mRNA design, formulation, and manufacturing platform technologies. We regularly file patent applications to protect innovations arising from our research and development. We also hold trademarks and trademark applications in the United States and foreign jurisdictions. Costs to secure and defend our IP are expensed as incurred, and are classified as general and administrative expenses.

General and administrative expenses, including IP-related expenses, totaled $27.3 million and $16.3 for the three months ended March 31, 2019 and 2018, respectively. IP-related expenses, including our internal personnel-related costs, were $2.8 million and

Table of Contents

$2.1 million, for the three months ended March 31, 2019 and 2018, respectively. We did not incur litigation expenses related to our IP during the three months ended March 31, 2019 and 2018.

Other income (expense), net

Interest income

Interest income consists of interest generated from our investments in cash and cash equivalents, money market funds, and high-quality fixed income securities.

Other income (expense)

Other income (expense), net consists of gains (losses) from the sale of investments in marketable securities, interest expense, and other income and expense unrelated to our core operations. Interest expense is primarily derived from our lease financing obligation related to our Norwood manufacturing facility.

Critical accounting policies and significant judgments and estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these condensed consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, are reflected in the condensed consolidated financial statements prospectively from the date of change in estimates.

On January 1, 2019, we adopted ASC 606, Revenue from Contracts with Customers, using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. We recognized the cumulative effect of the adoption as an adjustment to the opening balance of accumulated deficit in the current period's condensed consolidated balance sheet. Results for reporting periods beginning after January 1, 2019, are presented under ASC 606. Prior period amounts have not been adjusted and continue to be reported in accordance with our historic accounting under ASC Topic 605, Revenue Recognition (ASC 605). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.

Other than our adoption of ASC 606, there have been no material changes in our critical accounting policies and estimates in the preparation of our condensed consolidated financial statements during the three months ended March 31, 2019 compared to those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018, as amended.

Recently issued accounting pronouncements

We have reviewed all recently issued standards and have determined that, other than as disclosed in Note 2 to our condensed consolidated financial statements, such standards will not have a material impact on our financial statements or do not otherwise apply to our operations.

Table of Contents

Results of operations

The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):



	Three Months Ended March 31,						Change 2019 vs. 2018
	2019			2018			$			%
Revenue:
Collaboration revenue	$	14,115		$	27,460		$	(13,345	)	(49	)%
Grant revenue	1,910			1,579			331			21	%
Total revenue	16,025			29,039			(13,014		)	(45	)%
Operating Expenses:
Research and development	130,575			90,124			40,451			45	%
General and administrative	27,283			16,317			10,966			67	%
Total operating expenses	157,858			106,441			51,417			48	%
Loss from operations	(141,833		)	(77,402		)	(64,431		)	83	%
Other income, net	9,152			5,026			4,126			82	%
Loss before benefit from income taxes	(132,681		)	(72,376		)	(60,305		)	83	%
Benefit from income taxes	(24		)	—			(24		)
Net loss	$	(132,657	)	$	(72,376	)	$	(60,281	)	83	%

Revenue

Total revenue decreased by $13.0 million, or 45% in 2019, due to a decrease in collaboration revenue across all our strategic alliances, particularly AstraZeneca and Merck, largely driven by our adoption of ASC 606. See Note 2 to our condensed consolidated financial statements for further information on our adoption of ASC 606.

Operating expenses

Research and development expenses

Research and development expenses increased by $40.5 million, or 45% in 2019, primarily attributable to an increase in personnel related costs of $12.1 million and an increase in stock-based compensation of $3.4 million, an increase in clinical trial and manufacturing costs of $10.7 million, an increase in lab supplies and materials of $6.7 million, and an increase in consulting and outside services of $5.0 million. The increases in personnel related costs and stock-based compensation were largely driven by an increase in the number of employees supporting our research and development programs.

General and administrative expenses

General and administrative expenses increased by $11.0 million, or 67% in 2019, primarily due to an increase in personnel related costs of $2.0 million and an increase in stock-based compensation of $3.2 million, an increase in consulting and outside services of $2.4 million, and an increase in information technology, facility and insurance related costs of $2.4 million. These increases were primarily driven by an increase in the number of employees and increased costs related to operating as a publicly traded company.

Other income, net

The following table summarizes other income, net for each period presented (in thousands):



	Three Months Ended March 31,						Change 2019 vs. 2018
	2019			2018			$			%
Interest income	$	10,972		$	5,209		$	5,763		111	%
(Loss) gain on investment	(3		)	58			(61		)	(105	)%
Interest expense	(1,533		)	(27		)	(1,506		)	5,578	%
Other expense, net	(284		)	(214		)	(70		)	33	%
Total other income, net	$	9,152		$	5,026		$	4,126		82	%

Table of Contents

Other income, net increased by $4.1 million, or 82% in 2019, primarily due to an increase of $5.8 million in interest income from our investments in marketable securities, mainly driven by a higher weighted average balance of cash and investments and market performance. This increase was partially offset by higher interest expense of $1.5 million related to our Norwood lease financing obligation. We began recording interest expense upon the completion of our Norwood manufacturing facility in July 2018.

Liquidity and capital resources

We have historically funded our operations primarily from the sale of equity instruments and from proceeds from certain strategic alliance arrangements and grant agreements. As of March 31, 2019, we had cash, cash equivalents and investments of $1.5 billion. Cash and cash equivalents and investments are invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Investments, consisting primarily of government and corporate debt securities are stated at fair value. As of March 31, 2019, we had current and non-current investments of approximately $606.0 million and $437.7 million, respectively.

We began construction of our Norwood manufacturing facility, or Norwood, in the second half of 2016. Our capital expenditures related to Norwood were $3.6 million and $38.1 million for the three months ended March 31, 2019 and 2018, respectively. Cash disbursements related to Norwood were $5.7 million and $29.6 million for the three months ended March 31, 2019 and 2018.

On January 30, 2018 and February 15, 2018, we issued Series G preferred stock for total gross proceeds of $560.0 million. On May 7, 2018, we issued Series H preferred stock for gross proceeds of $125.0 million of which $13.0 million is determined to be a premium and recorded to deferred revenue as part of the Merck PCV/SAV agreement executed contemporaneously with our Series H redeemable convertible preferred stock issuance. Please refer to Note 3 to our condensed consolidated financial statements.

On December 11, 2018, we closed our IPO, whereby we sold 26,275,993 shares of common stock at a price of $23.00 per share. The shares began trading on the Nasdaq Global Select Market on December 7, 2018. The aggregate net proceeds received by us from the IPO were $563.0 million, net of underwriting discounts, commissions and offering expenses payable by us.

Cash flow

The following table summarizes the primary sources and uses of cash for each period presented (in thousands):



	Three Months Ended March 31,
	2019			2018
Net cash (used in) provided by:
Operating activities	$	(143,927	)	$	(111,385	)
Investing activities	(11,759		)	(483,704		)
Financing activities	(48		)	549,995
Net decrease in cash and cash equivalents	$	(155,734	)	$	(45,094	)

Operating activities

We derive cash flows from operations primarily from cash collected from certain strategic alliances. Our cash flows from operating activities are significantly influenced by our use of cash for operating expenses and working capital to support the business. We have historically experienced negative cash flows from operating activities as we have invested early in our mRNA technologies, digital infrastructure, manufacturing technology, and infrastructure.

Net cash used in operating activities for the three months ended March 31, 2019 was $143.9 million and consisted of net loss of $132.7 million less non-cash adjustments of $24.8 million, plus a net change in assets and liabilities of $36.1 million. Non-cash items primarily included stock-based compensation of $18.5 million, depreciation and amortization of $7.3 million, and amortization of investment premium and discount of $1.0 million. The net change in assets and liabilities was primarily due to a decrease in accrued liabilities of $32.6 million, and a decrease in deferred revenue of $15.6 million, partially offset by a decrease in accounts receivable of $6.0 million, a decrease in prepaid expenses and other assets of $3.3 million and an increase in accounts payable of $1.7 million.

Net cash used in operating activities for the three months ended March 31, 2018 was $111.4 million and consisted of net loss of $72.4 million less non-cash adjustments of $16.9 million, plus a net change in assets and liabilities of $55.9 million. Non-cash items primarily included stock-based compensation of $11.9 million and depreciation and amortization of $5.2 million. The net change in assets and liabilities was primarily due to a decrease in accrued liabilities of $37.0 million, an increase in accounts receivable of $24.7 million and an increase in prepaid expense and other assets of $2.2 million, partially offset by an increase in deferred revenue of $6.2 million.

Table of Contents

Investing activities

Our primary investing activities consist of purchases, sales, and maturities of our investments and capital expenditures for manufacturing, laboratory, computer equipment and software.

Net cash used in investing activities for the three months ended March 31, 2019 was $11.8 million, which included purchases of marketable securities of $429.5 million and capital expenditures of $7.6 million, partially offset by proceeds from maturities of marketable securities of $403.9 million and proceeds from sales of marketable securities of $21.4 million.

Net cash used in investing activities for the three months ended March 31, 2018 was $483.7 million, which included purchases of marketable securities of $660.2 million and capital expenditures of $31.9 million, partially offset by proceeds from maturities of marketable securities of $189.8 million and proceeds from sales of marketable securities of $18.6 million.

Financing activities

We did not generate significant cash from financing activities for the three months ended March 31, 2019.

We generated cash from financing activities of $550.0 million for the three months ended March 31, 2018, primarily from net proceeds from the issuance of redeemable convertible preferred stock of $549.5 million.

Operation and funding requirements

Since our inception, we have incurred significant losses and negative cash flows from operations due to our significant research and development expenses. We have an accumulated deficit of $1.1 billion as of March 31, 2019. We expect to continue to incur significant losses in the foreseeable future and expect our expenses to increase in connection with our ongoing activities, particularly as we continue research and development of our development candidates and clinical activities for our investigational medicines. In addition, we expect to incur additional costs associated with operating as a public company.

We are subject to all the risks related to the development and commercialization of novel medicines, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We believe that our cash, cash equivalents, and investments as of March 31, 2019, will be sufficient to enable us to fund our projected operations through at least the next 12 months from the issuance of these financial statements.

Until we can generate a sufficient amount of revenue from our programs, we expect to finance future cash needs through public or private equity or debt offerings and potential future strategic alliances from which we receive upfront fees, milestone payments, and other forms of consideration. Additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back, or discontinue the development or commercialization of one or more of our investigational medicines, or slow down or cease work on one or more of our programs. If we raise additional funds through the issuance of additional equity or debt securities, it could result in dilution to our existing stockholders or increased fixed payment obligations, and any such securities may have rights senior to those of our common stock. If we incur indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise funds through strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or investigational medicines or grant licenses on terms that may not be favorable to us. Any of these events could significantly harm our business, financial condition, and prospects.

Contractual Obligations

As of March 31, 2019 there have been no material changes to our contractual obligations and commitments from those described under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Annual Report on Form 10-K for the year ended December 31, 2018.

Off balance sheet arrangements

As of March 31, 2019, we did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K.

Table of Contents

JOBS Act and emerging growth company status

In April 2012, the JOBS Act was enacted. As an "emerging growth company," or EGC under the JOBS Act, we may delay the adoption of certain accounting standards until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for EGCs include an exemption from the requirement to provide an auditor’s report on internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements. Additionally, the JOBS Act provides that an EGC can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an EGC to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, while we are an EGC we will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not EGCs.

We will remain classified as an EGC until the earlier of (i) the last day of our first fiscal year in which we have total annual gross revenues of $1.07 billion or more, (ii) December 31, 2023, being the last day of the fiscal year following the fifth anniversary of the completion of our IPO, (iii) the date on which we have issued more than $1.0 billion of non-convertible debt instruments during the previous three fiscal years, or (iv) the date on which we are deemed a “large accelerated filer” under the rules of the SEC.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Our primary exposure to market risk relates to changes in interest rates. As of March 31, 2019 and December 31, 2018, we had cash, cash equivalents, restricted cash, and investments in marketable securities of $1.5 billion and $1.7 billion, respectively. Our investment portfolio is comprised of money market funds and marketable debt securities (including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities, and commercial paper). Our primary investment objectives are the preservation of capital and the maintenance of liquidity and our investment policy defines allowable investments based on quality of the institutions and financial instruments designed to minimize risk exposure. Our exposure to interest rate sensitivity is affected by changes in the general level of U.S. interest rates. Our available for sale securities are subject to interest rate risk and will fall in value if market interest rates increase.

We generally hold investments in marketable debt securities to maturity to limit our exposure to interest rate risk. Due to the short-term maturities and low risk profiles of our investments, we do not anticipate a significant exposure to interest rate risk. If market interest rates were to increase immediately and uniformly by 100 basis points, or one percentage point, from levels at March 31, 2019, the net fair value of our interest sensitive marketable securities would not experience a material change in fair market value.

We currently do not have significant exposure to foreign currencies as we hold no foreign exchange contracts, option contracts, or other foreign hedging arrangements. Further, our operations and revenue generating activities are denominated in U.S. dollars. Our operations may be subject to fluctuations in foreign currency exchange rates in the future.

Inflation generally affects us by increasing our cost of labor. We do not believe that inflation had a material effect on our business, financial condition, or results of operations during the three months ended March 31, 2019 and 2018.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to management, including the principal executive officer (our Chief Executive Officer) and principal financial officer (our Chief Financial Officer), to allow timely decisions regarding required disclosure.

Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Form 10-Q. Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2019.

Table of Contents

Changes in Internal Control over Financial Reporting

During the three months ended March 31, 2019, we implemented certain internal controls in connection with our adoption of ASC 606 on January 1, 2019. There were no other changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2019 that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II

Item 1. Legal Proceedings

We are not currently a party to any material legal proceedings.

Item 1A. Risk Factors

In addition to the other information set forth in this Form 10-Q, including under the heading “Special Note Regarding Forward-Looking Statements”, the risks and uncertainties that we believe are most important for you to consider are discussed in “Part I, Item 1A—Risk Factors” of our 2018 Form 10-K, which could adversely affect our business, financial condition, or results of operations. The risks described in our 2018 Form 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may adversely affect our business, financial condition, or results of operations. There are no material changes to the Risk Factors described in our 2018 Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Recent Sales of Unregistered Securities

None.

Use of Proceeds from Public Offering of Common Stock

There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC pursuant to Rule 424(b) of the Securities Act. We are holding the balance of the net proceeds in cash, cash equivalents, and investments. We invested the funds received in short-term, interest-bearing investment-grade securities and government securities.

Item 6. Exhibits

The Exhibits listed below are filed or incorporated by reference as part of this Form 10-Q.



Exhibit No.		Exhibit Index

10.1#		Amended and Restated Non-Employee Director Compensation Policy
31.1		Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1+		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Labels Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Link Document

Table of Contents



+	The certification furnished in Exhibit 32.1 hereto is deemed to accompany this Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certification will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.



#	Indicates a management contract or any compensatory plan, contract or arrangement.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



		MODERNA, INC.

Date:	By:	/s/ Stéphane Bancel
May 9, 2019
		Stéphane Bancel
		Chief Executive Officer and Director
		(Principal Executive Officer)

Date:	By:	/s/ Lorence Kim, M.D.
May 9, 2019
		Lorence Kim, M.D.
		Chief Financial Officer
		(Principal Financial Officer)

EX-10.1 2 exhibit101amendedandrestat.htm EXHIBIT 10.1 Exhibit

Exhibit 10.1

Moderna, Inc.

Amended and Restated Non-Employee Director Compensation Policy

The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) of Moderna, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries (“Outside Directors”). In furtherance of the purpose stated above, all Outside Directors shall be paid compensation for services provided to the Company as set forth below:


I.	Cash Retainers


(a)	Annual Retainer for Board Membership: $50,000 for general availability and participation in meetings and on conference calls of our Board of Directors (the “Board of Directors”). No additional compensation for attending individual Board of Director meetings.


(b)	Additional Annual Retainer for Non-Executive Chairman of the Board of Directors: $40,000


(c)	Additional Annual Retainers for Committee Membership:

Audit Committee Chairperson: $20,000

Audit Committee non-Chairperson member: $10,000

Compensation & Talent Committee Chairperson: $15,000

Compensation & Talent Committee non-Chairperson member: $7,500

Nominating and Corporate Governance Committee Chairperson: $10,000

Nominating and Corporate Governance Committee non-Chairperson member: $5,000

Product Development Committee Chairperson: $15,000

Product Development non-Chairperson member: $7,500

No additional compensation for attending individual committee meetings. All cash retainers will be paid quarterly, in arrears, or upon the earlier resignation or removal of the Outside Director. Cash retainers owing to Outsider Directors shall be annualized, meaning that with respect to Outside Directors who join the Board of Directors during the calendar year, such amounts shall be pro-rated based on the number of calendar days served by such director.


II.	Equity Retainers

All grants of equity retainer awards to Outside Directors pursuant to this Policy will be automatic and nondiscretionary and will be made in accordance with the following provisions:

(a)Value. For purposes of this Policy, “Value” means with respect to (i) any award of stock options the grant date fair value of the option (i.e., Black-Scholes Value) determined in accordance with the reasonable assumptions and methodologies employed by the Company for calculating the fair value of options under ASC 718; and (ii) any award of restricted stock and restricted stock units the product of (A) the closing market price on The Nasdaq Global Market (or such other market on which the Company’s common stock is then principally listed) of one share of the Company’s common stock on the grant date, and (B) the aggregate number of shares pursuant to such award.

(b) Revisions. The Compensation & Talent Committee (the “Compensation Committee”) in its discretion may change and otherwise revise the terms of awards to be granted under this Policy, including, without limitation, the number of shares subject thereto, for awards of the same or different type granted on or after the date the Compensation Committee determines to make any such change or revision.

(c) Sale Event Acceleration. In the event of a Sale Event (as defined in the Company’s 2018 Stock Option and Incentive Plan (the “Stock Plan”)), the equity retainer awards granted to Outside Directors pursuant to this Policy shall become 100% vested and exercisable.

(d) Initial Grant. Upon initial election to the Board of Directors, each new Outside Director will receive an initial, one-time grant of a non-statutory stock option (the “Initial Grant”) with a Value of $400,000, an exercise price per share equal to the closing price of a share of the Company’s common stock on the date of grant and a term of ten years, that vests in full on the one-year anniversary of the grant date; provided, however, that all vesting ceases if the director resigns from our Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

(e) Annual Grant. On the date of the Company’s Annual Meeting of Stockholders, each Outside Director who will continue as a member of the Board of Directors following such Annual Meeting of Stockholders will receive a grant of a non-statutory stock option on the date of such Annual Meeting of Stockholders (the “Annual Grant”) with a Value of $425,000, an exercise price per share equal to the closing price of a share of the Company’s common stock on the date of grant and a term of ten years, that vests in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the next Annual Meeting of Stockholders; provided, however, that all vesting ceases if the director resigns from our Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. If a new Outside Director joins our Board of Directors on a date other than the date of the Company’s Annual Meeting of Stockholders, then such Outside Director will be granted a pro-rata portion of the Annual Grant based on the time between such Outside Director’s appointment and the next Annual Meeting of Stockholders, on the first eligible grant date following such Outside Director’s appointment to our Board of Directors.


III.	Expenses

The Company will reimburse all reasonable out-of-pocket expenses incurred by Outside Directors in attending meetings of the Board of Directors or any committee thereof.


IV.	Maximum Annual Compensation

The aggregate amount of compensation, including both equity compensation and cash compensation, paid to any Outside Director in a calendar year period shall not exceed $1,500,000 for the first year of service and $1,000,000 for each year of service thereafter (or such other limits as may be set forth in Section 3(b) of the Stock Plan or any similar provision of a successor plan). For this purpose, the “amount” of equity compensation paid in a calendar year shall be determined based on the grant date fair value thereof, as determined in accordance with ASC 718 or its successor provision, but excluding the impact of estimated forfeitures related to service-based vesting conditions.

Date Amended and Restated Policy Approved: March 21, 2019.

EX-31.1 3 exhibit3113312019.htm EXHIBIT 31.1 Exhibit

Exhibit 31.1

CERTIFICATION PURUSANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

CERTIFICATIONS

I, Stéphane Bancel., certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Moderna, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) (Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.



Date: May 9, 2019	By:	/s/ Stéphane Bancel
		Stéphane Bancel
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 4 exhibit3123312019.htm EXHIBIT 31.2 Exhibit

Exhibit 31.2

CERTIFICATION PURUSANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

CERTIFICATIONS

I, Lorence Kim, M.D. certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Moderna, Inc.;

(b) (Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.



Date: May 9, 2019	By:	/s/ Lorence Kim
		Lorence Kim M.D.
		Chief Financial Officer (Principal Financial Officer)

EX-32.1 5 exhibit3213312019.htm EXHIBIT 32.1 Exhibit

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Moderna, Inc. (the “Company”) for the period ended March 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Stéphane Bancel, Chief Executive Officer of the Company, and Lorence Kim, M.D., Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 202, that to our knowledge:


1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and


2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: May 9, 2019	By:	/s/ Stéphane Bancel
		Stéphane Bancel
		Chief Executive Officer
		(Principal Executive Officer)

	By:	/s/ Lorence Kim
		Lorence Kim, M.D.
		Chief Financial Officer
		(Principal Financial Officer)

EX-101.INS 6 mrna-20190331.xml XBRL INSTANCE DOCUMENT 0001682852 2019-01-01 2019-03-31 0001682852 2019-04-29 0001682852 2019-03-31 0001682852 2018-12-31 0001682852 2018-01-01 2018-03-31 0001682852 us-gaap:GrantMember 2018-01-01 2018-03-31 0001682852 mrna:CollaborationArrangementMember 2019-01-01 2019-03-31 0001682852 mrna:CollaborativeArrangementWithAffiliateMember 2018-01-01 2018-03-31 0001682852 us-gaap:GrantMember 2019-01-01 2019-03-31 0001682852 mrna:CollaborationArrangementMember 2018-01-01 2018-03-31 0001682852 mrna:CollaborativeArrangementWithAffiliateMember 2019-01-01 2019-03-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001682852 2019-01-01 0001682852 us-gaap:RetainedEarningsMember 2019-03-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001682852 us-gaap:PreferredStockMember 2019-03-31 0001682852 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001682852 us-gaap:CommonStockMember 2019-03-31 0001682852 us-gaap:RetainedEarningsMember 2018-12-31 0001682852 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001682852 us-gaap:PreferredStockMember 2018-12-31 0001682852 us-gaap:RetainedEarningsMember 2019-01-01 0001682852 us-gaap:CommonStockMember 2018-12-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001682852 us-gaap:CommonStockMember 2018-03-31 0001682852 us-gaap:PreferredStockMember 2018-03-31 0001682852 2017-12-31 0001682852 us-gaap:PreferredStockMember 2017-12-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001682852 us-gaap:RetainedEarningsMember 2017-12-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001682852 us-gaap:CommonStockMember 2017-12-31 0001682852 us-gaap:PreferredStockMember 2018-01-01 2018-03-31 0001682852 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001682852 2018-03-31 0001682852 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001682852 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001682852 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001682852 us-gaap:RetainedEarningsMember 2018-03-31 0001682852 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-03-31 0001682852 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2019-01-01 0001682852 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-12-31 0001682852 us-gaap:AccountingStandardsUpdate201409Member mrna:VEGFExercise2016Member 2019-01-01 0001682852 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2019-01-01 0001682852 us-gaap:AccountingStandardsUpdate201409Member mrna:PCVSAVAgreementMember 2019-01-01 0001682852 mrna:PCVSAVAgreementMember 2019-01-01 0001682852 us-gaap:AccountingStandardsUpdate201409Member 2019-01-01 0001682852 us-gaap:AccountingStandardsUpdate201409Member mrna:Combined2018AZAgreementsMember 2019-01-01 0001682852 mrna:VEGFExercise2016Member 2019-01-01 0001682852 mrna:Combined2018AZAgreementsMember 2019-01-01 0001682852 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2019-03-31 0001682852 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-03-31 0001682852 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2019-01-01 2019-03-31 0001682852 mrna:CollaborativeArrangementWithAffiliateMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2019-01-01 2019-03-31 0001682852 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-01-01 2019-03-31 0001682852 mrna:CollaborationArrangementMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2019-01-01 2019-03-31 0001682852 mrna:CollaborativeArrangementWithAffiliateMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-01-01 2019-03-31 0001682852 mrna:CollaborationArrangementMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-01-01 2019-03-31 0001682852 mrna:MerckMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember 2019-01-01 2019-03-31 0001682852 mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember 2019-01-01 2019-03-31 0001682852 mrna:VertexMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember 2019-01-01 2019-03-31 0001682852 mrna:AstraZenecaMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember 2019-01-01 2019-03-31 0001682852 mrna:MerckMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-03-31 0001682852 mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-01-01 2019-03-31 0001682852 mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-03-31 0001682852 mrna:MerckMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-01-01 2019-03-31 0001682852 mrna:VertexMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-03-31 0001682852 mrna:VertexMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-01-01 2019-03-31 0001682852 mrna:AstraZenecaMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-01-01 2019-03-31 0001682852 mrna:AstraZenecaMember mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-03-31 0001682852 mrna:MerckAgreement2015Member 2016-01-01 2016-01-31 0001682852 mrna:UpfrontPaymentMember mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember 2019-01-01 0001682852 mrna:VEGFExercise2016Member 2018-12-31 0001682852 mrna:VariableConsiderationMember mrna:VEGFExercise2016Member 2019-01-01 0001682852 mrna:CollaborationArrangementMember mrna:PCVSAVAgreementMember 2018-01-01 2018-03-31 0001682852 mrna:MerckAgreement2015Member us-gaap:SubsequentEventMember 2015-01-01 2019-05-09 0001682852 mrna:VEGFExercise2016Member 2019-03-31 0001682852 mrna:ToxicityMilestonesMember mrna:MilestonePaymentsMember mrna:Combined2018AZAgreementsMember 2019-01-01 0001682852 srt:MaximumMember mrna:A2016StrategicAllianceWithAstraZenecaIL12Member 2016-01-01 2016-01-31 0001682852 mrna:VEGFExercise2016Member 2019-01-01 2019-03-31 0001682852 mrna:CollaborationArrangementMember mrna:Combined2018AZAgreementsMember 2018-01-01 2018-03-31 0001682852 mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember 2019-01-01 0001682852 mrna:AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember 2018-06-01 2018-06-30 0001682852 srt:MinimumMember mrna:A2017StrategicAllianceWithAstraZenecaRelaxinMember 2017-10-01 2017-10-31 0001682852 mrna:CompetitionMilestonesMember mrna:MilestonePaymentsMember mrna:Combined2018AZAgreementsMember 2019-01-01 0001682852 mrna:RegulatoryMilestonesMember mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember 2016-07-31 0001682852 mrna:KRASPerformanceObligationMember mrna:PCVSAVAgreementMember 2019-01-01 0001682852 srt:MinimumMember mrna:A2016StrategicAllianceWithAstraZenecaIL12Member 2016-01-01 2016-01-31 0001682852 mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember 2016-07-01 2016-07-31 0001682852 mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember 2013-03-31 0001682852 mrna:PCVSAVAgreementMember 2019-01-01 2019-03-31 0001682852 mrna:Combined2018AZAgreementsMember

2019-04-01

2019-03-31 0001682852 mrna:CollaborationArrangementMember mrna:SeparateAgreementsWithMerckMember 2019-01-01 2019-03-31 0001682852 mrna:Combined2018AZAgreementsMember 2018-12-31 0001682852 mrna:MerckAgreement2015Member 2019-01-01 0001682852 mrna:OptionExerciseFeeMember mrna:VEGFExercise2016Member 2019-01-01 0001682852 mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember 2019-01-01 0001682852 mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember 2016-06-01 2016-06-30 0001682852 mrna:VEGFExercise2016Member

2019-04-01

2019-03-31 0001682852 mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember 2013-03-01 2013-03-31 0001682852 mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember 2019-03-31 0001682852 mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember

2019-04-01

2019-03-31 0001682852 mrna:UpfrontPaymentFundingFrom2016AmendmentMember mrna:MerckAgreement2015Member 2019-01-01 0001682852 mrna:FixedPaymentsMember mrna:VEGFExercise2016Member 2019-01-01 0001682852 srt:MaximumMember mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember 2013-03-01 2013-03-31 0001682852 mrna:AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember 2018-06-30 0001682852 mrna:MilestonePaymentsMember mrna:MerckAgreement2015Member 2019-01-01 0001682852 mrna:UpfrontPaymentResearchAndDevelopmentMember mrna:MerckAgreement2015Member 2019-01-01 0001682852 mrna:RegulatoryMilestonesMember mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember 2013-03-31 0001682852 mrna:VariableConsiderationMember mrna:Combined2018AZAgreementsMember 2019-01-01 0001682852 mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember 2016-01-01 2016-12-31 0001682852 mrna:MerckAgreement2015Member us-gaap:SubsequentEventMember 2019-05-09 0001682852 mrna:CommercialMilestonesMember mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember 2013-03-31 0001682852 mrna:Combined2018AZAgreementsMember 2019-01-01 2019-03-31 0001682852 mrna:PersonalizedMRNACancerVaccinesProductsMember mrna:PCVSAVAgreementMember 2018-04-30 0001682852 mrna:PCVSAVAgreementMember 2018-12-31 0001682852 mrna:MerckAgreement2015Member 2015-01-01 2015-01-31 0001682852 mrna:MilestonePaymentsMember mrna:Combined2018AZAgreementsMember 2019-01-01 0001682852 mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember 2018-12-31 0001682852 mrna:A2016StrategicAllianceWithAstraZenecaIL12Member 2016-01-01 2016-01-31 0001682852 mrna:CollaborationArrangementMember mrna:VEGFExercise2016Member 2019-01-01 2019-03-31 0001682852 mrna:Combined2018AZAgreementsMember 2019-03-31 0001682852 mrna:PCVSAVAgreementMember

2019-04-01

2019-03-31 0001682852 mrna:MerckAgreement2015Member 2019-01-01 2019-03-31 0001682852 mrna:A2017StrategicAllianceWithAstraZenecaRelaxinMember 2017-10-01 2017-10-31 0001682852 mrna:MerckAgreement2015Member 2019-03-31 0001682852 mrna:Combined2018AZAgreementsMember

2019-03-31 0001682852 mrna:CollaborationArrangementMember mrna:PCVSAVAgreementMember 2019-01-01 2019-03-31 0001682852 mrna:CollaborationArrangementMember mrna:Combined2018AZAgreementsMember 2019-01-01 2019-03-31 0001682852 mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember 2016-06-30 0001682852 mrna:DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember mrna:Combined2018AZAgreementsMember 2019-01-01 0001682852 mrna:DevelopmentMilestonesMember mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember 2016-07-31 0001682852 srt:MaximumMember mrna:A2017StrategicAllianceWithAstraZenecaRelaxinMember 2017-10-01 2017-10-31 0001682852 mrna:CollaborationArrangementMember mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember 2019-01-01 2019-03-31 0001682852 mrna:Combined2018AZAgreementsMember

2028-01-01

2019-03-31 0001682852 mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember us-gaap:SeriesHPreferredStockMember 2018-04-01 2018-04-30 0001682852 mrna:DevelopmentMilestonesMember mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember 2013-03-31 0001682852 mrna:VEGFAProductAZD8601Member mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember 2018-01-01 2018-12-31 0001682852 mrna:PCVPerformanceObligationMember mrna:PCVSAVAgreementMember 2019-01-01 0001682852 mrna:RegulatoryMilestonesSubsequentProductsMember mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember 2016-07-31 0001682852 mrna:CollaborationArrangementMember mrna:MerckAgreement2015Member 2018-01-01 2018-03-31 0001682852 mrna:OncologyDevelopmentTargetPerformanceObligationMember mrna:Combined2018AZAgreementsMember 2019-01-01 0001682852 mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember 2019-01-01 2019-03-31 0001682852 mrna:PCVSAVAgreementMember 2019-03-31 0001682852 mrna:MilestonePaymentsMember mrna:MerckAgreement2015Member us-gaap:SubsequentEventMember 2015-01-01 2019-05-09 0001682852 mrna:UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember mrna:PCVSAVAgreementMember 2019-01-01 0001682852 mrna:UpfrontPaymentMember mrna:MerckAgreement2015Member 2019-01-01 0001682852 mrna:DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member mrna:Combined2018AZAgreementsMember 2019-01-01 0001682852 mrna:MilestonePaymentsMember mrna:VEGFExercise2016Member 2019-01-01 0001682852 mrna:CollaborationArrangementMember mrna:A2017StrategicAllianceWithAstraZenecaRelaxinMember 2019-01-01 2019-03-31 0001682852 mrna:CollaborationArrangementMember mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember 2018-01-01 2018-03-31 0001682852 mrna:ResearchAndDevelopmentFundingMember mrna:StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember 2019-01-01 0001682852 mrna:UpfrontPaymentMember mrna:PCVSAVAgreementMember 2019-01-01 0001682852 mrna:EstimatedReimbursementMember mrna:Combined2018AZAgreementsMember 2019-01-01 0001682852 mrna:IL12PerformanceObligationMember mrna:Combined2018AZAgreementsMember 2019-01-01 0001682852 mrna:Combined2018AZAgreementPerformanceObligationMember mrna:Combined2018AZAgreementsMember 2019-01-01 0001682852 mrna:CollaborationArrangementMember mrna:A2017StrategicAllianceWithAstraZenecaRelaxinMember 2018-01-01 2018-03-31 0001682852 mrna:CollaborationArrangementMember mrna:VEGFExercise2016Member 2018-01-01 2018-03-31 0001682852 mrna:MerckAgreement2015Member 2018-12-31 0001682852 mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember mrna:ContractOptionsMember 2019-03-31 0001682852 mrna:TheBillAndMelindaGatesFoundationMember mrna:FollowOnProjectMember 2019-03-01 2019-03-31 0001682852 mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2019-03-31 0001682852 mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember mrna:InitialBaseAwardMember 2016-09-01 2016-09-30 0001682852 mrna:DefenseAdvancedResearchProjectsAgencyMember 2019-01-01 2019-03-31 0001682852 mrna:TheBillAndMelindaGatesFoundationMember mrna:InitialProjectMember 2016-01-01 2016-01-31 0001682852 mrna:DefenseAdvancedResearchProjectsAgencyMember us-gaap:GrantMember 2018-01-01 2018-03-31 0001682852 mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember us-gaap:GrantMember 2019-01-01 2019-03-31 0001682852 mrna:TheBillAndMelindaGatesFoundationMember 2018-12-31 0001682852 mrna:DefenseAdvancedResearchProjectsAgencyMember 2013-10-01 2013-10-31 0001682852 mrna:TheBillAndMelindaGatesFoundationMember mrna:InitialProjectMember 2019-03-31 0001682852 mrna:TheBillAndMelindaGatesFoundationMember 2019-03-31 0001682852 mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2016-09-01 2016-09-30 0001682852 mrna:TheBillAndMelindaGatesFoundationMember 2016-01-01 2016-01-31 0001682852 mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember us-gaap:GrantMember 2018-01-01 2018-03-31 0001682852 mrna:TheBillAndMelindaGatesFoundationMember us-gaap:GrantMember 2019-01-01 2019-03-31 0001682852 mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember mrna:ContractOptionsMember 2016-09-01 2016-09-30 0001682852 mrna:DefenseAdvancedResearchProjectsAgencyMember 2019-03-31 0001682852 mrna:TheBillAndMelindaGatesFoundationMember us-gaap:GrantMember 2018-01-01 2018-03-31 0001682852 mrna:DefenseAdvancedResearchProjectsAgencyMember 2018-03-31 0001682852 mrna:DefenseAdvancedResearchProjectsAgencyMember us-gaap:GrantMember 2019-01-01 2019-03-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2019-03-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2018-12-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2019-03-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2019-03-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2019-03-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2019-03-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2018-12-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2019-03-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:CashAndCashEquivalentsMember 2018-12-31 0001682852 us-gaap:FairValueInputsLevel2Member mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember 2019-03-31 0001682852 us-gaap:CashAndCashEquivalentsMember 2018-12-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2019-03-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:CashAndCashEquivalentsMember 2018-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:CashAndCashEquivalentsMember 2018-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:CashAndCashEquivalentsMember 2019-03-31 0001682852 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2019-03-31 0001682852 us-gaap:FairValueInputsLevel2Member 2019-03-31 0001682852 us-gaap:CashAndCashEquivalentsMember 2019-03-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:CashAndCashEquivalentsMember 2019-03-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2018-12-31 0001682852 us-gaap:FairValueInputsLevel2Member mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember 2018-12-31 0001682852 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2018-12-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember 2018-12-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2018-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:CashAndCashEquivalentsMember 2019-03-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-03-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2018-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2018-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2019-03-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember 2019-03-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember 2018-12-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember 2018-12-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember 2019-03-31 0001682852 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2018-12-31 0001682852 mrna:NoncurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member mrna:USGovernmentAgenciesAndCorporateDebtSecuritiesMember 2019-03-31 0001682852 mrna:CurrentMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-03-31 0001682852 us-gaap:LeaseholdImprovementsMember 2019-03-31 0001682852 us-gaap:ConstructionInProgressMember 2018-12-31 0001682852 us-gaap:SoftwareDevelopmentMember 2019-03-31 0001682852 us-gaap:BuildingMember 2018-12-31 0001682852 us-gaap:BuildingMember 2019-03-31 0001682852 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001682852 us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2019-03-31 0001682852 us-gaap:SoftwareDevelopmentMember 2018-12-31 0001682852 us-gaap:EquipmentMember 2019-03-31 0001682852 us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2018-12-31 0001682852 us-gaap:ComputerEquipmentMember 2018-12-31 0001682852 us-gaap:EquipmentMember 2018-12-31 0001682852 us-gaap:ConstructionInProgressMember 2019-03-31 0001682852 us-gaap:ComputerEquipmentMember 2019-03-31 0001682852 mrna:NorwoodMassachusettsMember 2019-02-28 0001682852 mrna:CambridgeMassachusettsMember 2019-03-31 0001682852 mrna:PersonalizedMRNACancerVaccinesProductsMember mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember 2019-03-31 0001682852 mrna:NorwoodMassachusettsMember 2019-03-31 0001682852 mrna:PersonalizedMRNACancerVaccinesProductsMember mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember 2018-12-31 0001682852 2018-12-11 0001682852 2018-02-28 0001682852 us-gaap:IPOMember 2018-12-11 2018-12-11 0001682852 2018-05-07 0001682852 us-gaap:CommonStockMember us-gaap:IPOMember 2018-12-11 0001682852 us-gaap:IPOMember 2018-12-11 0001682852 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0001682852 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-03-31 0001682852 us-gaap:RestrictedStockUnitsRSUMember 2019-03-31 0001682852 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0001682852 us-gaap:RestrictedStockMember 2019-03-31 0001682852 us-gaap:RestrictedStockMember 2018-12-31 0001682852 2018-01-01 2018-12-31 0001682852 mrna:StockOptionAndIncentivePlan2018Member 2018-11-01 2018-11-30 0001682852 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0001682852 us-gaap:EmployeeStockMember mrna:EmployeeStockPurchasePlan2018Member 2018-12-05 0001682852 mrna:StockOptionAndIncentivePlan2018Member 2019-03-31 0001682852 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001682852 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001682852 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001682852 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-03-31 0001682852 mrna:RestrictedStockAndRestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0001682852 mrna:RestrictedStockAndRestrictedStockUnitsRSUMember 2018-01-01 2018-03-31 0001682852 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0001682852 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-03-31 0001682852 srt:WeightedAverageMember us-gaap:EmployeeStockOptionMember 2019-03-31 0001682852 srt:WeightedAverageMember us-gaap:EmployeeStockOptionMember 2018-03-31 0001682852 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001682852 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001682852 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0001682852 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0001682852 us-gaap:RedeemableConvertiblePreferredStockMember 2019-01-01 2019-03-31 0001682852 us-gaap:RedeemableConvertiblePreferredStockMember 2018-01-01 2018-12-31 0001682852 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001682852 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 mrna:milestone iso4217:USD xbrli:shares mrna:candidate mrna:option mrna:security iso4217:USD xbrli:shares mrna:campus mrna:extension_period utreg:sqft xbrli:pure mrna:contract_option false --12-31 Q1 2019 2019-03-31 10-Q 0001682852 329003270 true false Non-accelerated Filer Moderna, Inc. false 21578000 22850000 22000000 0 12089000 7756000 3747000 2735000 13582000 1137000 152000 550000 33489000 33384000 9889000 10089000 9889000 10089000 4 1285000 105000 33200000 1727000 0 0.12 P180D 200000000.0 100000000.0 100000000.0 180000000.0 250000000 243000000 243000000 55000000.0 220000000.0 3000000.0 243000000 300000000.0 3 40 40 5 10000000 P3Y P12M P12M P1Y P3Y P4Y 0.2 0.3 0.1 0.3 0.1 P90D P90D P90D P90D P90D 19700000 117300000 19700000 21100000 24600000 100000000.0 20000000.0 125800000 117600000 8200000 1100000.0 19700000 4 3 8500000 80000000 14334 11.93 4.05 5.62 8.48 6.59 6.99 9.55 P360D 0 796000 10089000 11336000

31210000

38509000

11686000

5646000

8948000

-2700000

-2738000

899000

965000

79073000

42183000

64456000

71735000

-1320000

591000

2538155000

2556709000

11851000

18497000

11851000

1803000

10048000

4495000

7356000

18497000

1010000

17487000

7714000

10783000

305141893

43135998

260817303

729877

458715

54433161

53271281

150397

1011483

200000

1962149000

1806207000

1563006000

1140827000

120000

40000

42000

18000

20000

1356000

1129000

72000

155000

1440000

1335000

36000

48000

21000

224000

218000

1000

4000

1000

1037372000

1695737000

712065000

173102000

152205000

658365000

1042516000

1545451000

839055000

84114000

119347000

502935000

173369000

436829000

172990000

437659000

1036053000

1043649000

864003000

605687000

863063000

605990000

863063000

552968000

157920000

152175000

172990000

157802000

15188000

658364000

1694417000

710770000

173108000

152175000

658364000

605990000

446032000

80483000

79475000

437659000

393934000

3702000

40023000

502934000

1546583000

839966000

84185000

119498000

502934000

863063000

605990000

172990000

437659000

28527000

14127000

90479000

658364000

502934000

147608000

102514000

670491000

514757000

-45094000

-155734000

0.0001

1600000000

775000000

1600000000

328798904

328853340

328798904

328853340

33000

-74369000

-130746000

4612000

3600000

240924000

800000

115600000

111300000

3300000

41200000

228479000

600000

75500000

115000000

800000

37100000

75700000

125200000

37100000

300000

109056000

73958000

36452000

110410000

81775000

-27281000

165352000

156862000

-29840000

127022000

161911000

-3441000

13582000

10200000

2600000

236012913

27984000

28000000

27984000

82800000

135800000

400000

200000

10006000

10556000

-30700000

-39900000

13900000

-4300000

240000000

10000000

200000000

20000000

10000000

30000000

-8400000

5153000

5200000

7300000

7328000

-1.16

-0.40

0.06

-0.34

23406000

11577000

253100000

P3Y6M

-19000

16317000

27283000

-72376000

-132681000

21907000

-110774000

-24000

1467000

1731000

-3876000

-6040000

28529000

66000

-37031000

-32557000

50000000

6193000

-15604000

183000

484000

2241000

-3313000

7909000

6061000

5209000

10972000

83000

1005000

P5Y

431908000

360174000

1962149000

1806207000

222803000

159159000

549995000

-48000

-483704000

-11759000

-111385000

-143927000

-72376000

-132657000

21907000

-110750000

-132657000

-75857000

-132657000

106441000

157858000

-77402000

-141833000

21907000

-119926000

246506000

20498000

23455000

24105000

22874000

140384000

15190000

5200000

4800000

2644000

2438000

-1993000

1911000

-6000

-3000

-1999000

1908000

540000

3464000

4509000

258000

213000

-183000

-1820000

8100000

10517000

660239000

429517000

31909000

7595000

0.0001

162000000

28399000

25292000

10401000

7895000

549531000

50000000

20000000

189814000

403940000

18630000

21413000

22000

57000

276433000

140442000

11513000

4688000

96907000

13741000

2122000

7020000

285195000

140442000

9456000

11403000

98891000

15861000

2122000

7020000

211977000

213460000

3481000

13000000

90124000

130575000

237000

595000

11798000

11532000

11823000

-1006627000

-1111300000

-6077000

-1117377000

-978643000

27984000

5000000

7350000

1000000

200000

15967000

300000

4143000

27460000

7400000

2000000

14000000

4100000

16025000

814000

25191000

1500000

10687000

11515000

300000

2614000

14115000

36706000

13301000

-1786000

11515000

800000

10200000

500000

2600000

814000

24377000

25191000

21907000

37932000

279500000

102800000

9700000

112500000

115000000

1100000

51000000

292400000

89800000

1600000

8100000

6700000

8100000

206300000

60000000

40000000

120000000

5000000

30000000

10000000

4400000

10000000

60000000

200000000

20000000

13000000

50000000

160000000

15100000

240000000

400000000

65000000

213000000

24400000

55100000

29039000

20110000

7350000

1579000

16025000

13301000

814000

1910000

125000000

563000000

26275993

23.00

11851000

18497000

5440

711

20.93

12.15

558208

20.77

0.00

458715

198597

150397

1011483

11.93

12.15

16.76

14334

48911

11.93

12.15

0.63

0.62

0.0271

0.0248

13200000

72400000.0

810000

17900000

24769502

8.54

100000

2987612

5443286

12.16

220434000

412480000

50821132

53271281

12.16

12.92

119876000

28501493

16.73

9.62

14.29

20.59

8.48

12.16

P6Y0M22D

P6Y1M14D

292602000

P5Y8M

P7Y1M

P7Y5M15D

P9Y0M

65206999

448686791

65543841

504352795

328798904

328853340

55666004

335053

48911

1789

5525

152000

549413000

22000

100000

57000

-551365000

-1157000

71679000

6000

1176661000

-621893000

-613709000

-3150000

83704000

6000

1726074000

-694269000

1530241000

-1320000

2538155000

33000

-1006627000

1446033000

591000

2556709000

33000

-1111300000

509352795

65430835

328809986

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in conformity with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2018 (2018 Form 10-K), except for changes associated with recent accounting standards for revenue recognition as detailed in "Note 2 - Recent Accounting Standards and Accounting Policies." This report should be read in conjunction with the consolidated financial statements in our 2018 Form 10-K.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, income tax provisions, stock-based compensation, and useful lives of long-lived assets. We base our estimates on historical experience and on various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results that we experience may differ materially from our estimates. The condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, but are not necessarily indicative of the results of operations to be anticipated for the full year ending December 31, 2019. </font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following steps: (i) identify the contract(s) with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) each performance obligation is satisfied. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for a contract with a customer that is within the scope of ASC 606 when all of the following criteria are met: (i) the arrangement has been approved by the parties and the parties are committed to perform their respective obligations; (ii) each party’s rights regarding the goods and/or services to be transferred can be identified; (iii) the payment terms for the goods and/or services to be transferred can be identified; (iv) the arrangement has commercial substance; and (v) collection of substantially all of the consideration to which we will be entitled in exchange for the goods and/or services that will be transferred to the customer is probable. We also determine the term of the contract based on the period in which we and our customer have present and enforceable rights and obligations for purposes of identifying the performance obligations and determining the transaction price. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:1px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate contracts that contain multiple promises to determine which promises are distinct. Promises are considered to be distinct and therefore, accounted for as separate performance obligations, provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. In assessing whether a promise is distinct, we consider factors such as whether: (i) we provide a significant service of integrating goods and/or services with other goods and/or services promised in the contract; (ii) one or more of the goods and/or services significantly modifies or customizes, or are significantly modified or customized by one or more of the other goods and/or services promised in the contract; and (iii) the goods and/or services are highly interdependent or highly interrelated.</font><font style="font-family:inherit;font-size:11pt;"> </font><font style="font-family:inherit;font-size:10pt;">Individual goods or services (or bundles of goods and/or services) that meet both criteria for being distinct are accounted for as separate performance obligations. Promises that are not distinct at contract inception are combined and accounted for as a single performance obligation. Options to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer’s election.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">The transaction price is generally comprised of an upfront payment due at contract inception and variable consideration in the form of payments for our services and materials and milestone payments due upon the achievement of specified events. Other payments the Company could be entitled to include tiered royalties earned when customers recognize net sales of licensed products. We consider the existence of any significant financing component within our arrangements and have determined that a significant financing component does not exist in our arrangements as substantive business purposes exist to support the payment structure other than to provide a significant benefit of financing. We measure the transaction price based on the amount of consideration we expect to be entitled in exchange for transferring the promised goods and/or services to the customer. We utilize either the expected value method or the most likely amount method to estimate the amount of variable consideration, depending on which method is expected to better predict the amount of consideration to which we will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.</font><font style="font-family:inherit;font-size:11pt;"> </font><font style="font-family:inherit;font-size:10pt;">With respect to arrangements that include payments for a development or regulatory milestone payment, we evaluate whether the associated event is considered probable of achievement and estimate the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within our control or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, we re-evaluate the probability of achievement of each milestone and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, wherein the license is deemed to be the sole or predominant item to which the payments relate, we recognize revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception. </font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generally allocate the transaction price to each performance obligation based on a relative standalone selling price basis. We develop assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated research and development costs. However, in certain instances, we allocate variable consideration entirely to one or more performance obligation if the terms of the variable consideration relate to the satisfaction of the respective performance obligation and the amount allocated is consistent with the amount we would expect to receive for the satisfaction of the respective performance obligation.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. For performance obligations that are satisfied at a point in time, we recognize revenue when control of the goods and/or services is transferred to the customer. For performance obligations that are satisfied over time, we recognize revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. We generally use input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. With respect to arrangements containing a license to our intellectual property that is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from amounts allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which we are expected to complete our performance obligations under an arrangement. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss includes net loss and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments. Total comprehensive loss for all periods presented has been disclosed in the condensed consolidated statements of comprehensive loss.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,612</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,747</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract Liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240,924</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,137</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,582</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,479</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we recognized the following revenues as a result of the change in the contract liability balances related to our collaboration agreements (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Revenue recognized in the period from:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts included in contract liabilities at the beginning of the period </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,582</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;"> We first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period first applies to the beginning contract liability.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets, as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> consists of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,401</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant incentives receivables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,336</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,089</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest receivable on marketable securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,909</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,292</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,399</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amortized cost and estimated fair value of marketable securities, by contractual maturity at </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">605,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">605,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due after one year through five years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">436,829</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">437,659</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,042,516</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,043,649</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">864,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">863,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due after one year through five years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,369</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,990</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,037,372</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,036,053</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents and Investments</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarize our cash and available-for-sale securities by significant investment category at </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash and</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502,935</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502,934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502,934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,114</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,185</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,483</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,702</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,347</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,475</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government agencies and corporate entities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">839,055</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,129</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(218</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">839,966</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">446,032</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">393,934</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,545,451</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,356</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(224</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,546,583</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502,934</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">605,990</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">437,659</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash and</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">658,365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">658,364</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">658,364</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,102</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,920</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,188</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government agencies and corporate entities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">712,065</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,335</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">710,770</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552,968</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,802</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,695,737</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,440</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,694,417</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">658,364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">863,063</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,990</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amortized cost and estimated fair value of marketable securities, by contractual maturity at </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">605,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">605,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due after one year through five years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">436,829</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">437,659</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,042,516</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,043,649</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">864,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">863,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due after one year through five years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,369</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,990</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,037,372</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,036,053</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we held </font><font style="font-family:inherit;font-size:10pt;">32</font><font style="font-family:inherit;font-size:10pt;"> available-for-sale securities, or an estimated fair value of </font><font style="font-family:inherit;font-size:10pt;">$135.8 million</font><font style="font-family:inherit;font-size:10pt;">, out of our total investment portfolio that were in a continuous unrealized loss position for more than 12 months with a gross unrealized loss of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">. At December 31, 2018, we held </font><font style="font-family:inherit;font-size:10pt;">25</font><font style="font-family:inherit;font-size:10pt;"> available-for-sale securities, or an estimated fair value of </font><font style="font-family:inherit;font-size:10pt;">$82.8 million</font><font style="font-family:inherit;font-size:10pt;">, out of our total investment portfolio that were in a continuous unrealized loss position for more than 12 months with a gross unrealized loss of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">. We concluded that the net declines in market value of our available-for-sale securities investment portfolio were temporary in nature and did not consider any of our investments to be other-than-temporarily impaired. In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for other-than-temporary impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. Furthermore, the aggregate of individual unrealized losses that had been outstanding for 12 months or less was not significant as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">. We neither intend to sell these investments nor conclude that we are more-likely-than-not that we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting,</font><font style="font-family:inherit;font-size:10pt;"> which is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance generally consistent with the accounting for employee share-based compensation. The new standard will be effective for us on January 1, 2020, with early adoption permitted. We early adopted this standard in the first quarter of 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and disclosure. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASU No. 2018-18, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU 2018-18,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Collaborative Arrangements (Topic 808)</font><font style="font-family:inherit;font-size:10pt;">: </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Clarifying the Interaction between Topic 808 and Topic 606, </font><font style="font-family:inherit;font-size:10pt;">which clarifies the interaction between Topic 808 and Topic 606, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">. Currently, Topic 808 does not provide comprehensive recognition or measurement guidance for collaborative arrangements, and the accounting for those arrangements is often based on an analogy to other accounting literature or an accounting policy election. Similarly, aspects of Topic 606 have resulted in diversity in practice on the effect of the revenue standard on the accounting for collaborative arrangements. The standard will become effective for us beginning on January 1, 2021, with early adoption permitted. We early adopted this standard in connection with the adoption of ASC 606 in the first quarter of 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and disclosure. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Standards</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our condensed consolidated financial statements and disclosures.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Leases</font><font style="font-family:inherit;font-size:10pt;"> (Topic 842), which supersedes all existing lease guidance. This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. The new standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments. Lessees are required to classify leases as either finance or operating leases. If the lease is effectively a financed-purchase by the lessee, it is classified as a financing lease, otherwise it is classified as an operating lease. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. ASC 842 provides accounting guidance for transactions that meet specific criteria for a leaseback transaction. If the criteria are not met, the transaction is considered a “failed sale” and the transaction must be accounted for as a financing arrangement. The new standard will be effective for us on January 1, 2020, assuming we continue to qualify as an EGC.. Upon adoption, the new standard, as amended, allows lessees to apply the transition requirements either (1) retrospectively to each prior reporting period presented in the financial statements with the cumulative effect of applying the new rules recognized at the beginning of the earliest comparative period presented, or (2) retrospectively at the beginning of the period of adoption with the cumulative effect of applying the new rules recognized then. We are currently evaluating the potential impact ASU 2016-02 may have on our financial position and results of operations. Our assessment will include, but is not limited to, evaluating the impact this standard has on the lease of our corporate headquarters at 200 Technology Square in Cambridge, MA, the lease of our office and laboratory space at 500 Technology Square, Cambridge, MA and our manufacturing and additional facilities in Norwood, MA, (see Note 7), and the identification of any embedded leases. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Measurement of Credit Losses on Financial Instruments</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2016-13). ASU 2016-13 will change how companies account for credit losses for most financial assets and certain other instruments. For trade receivables, loans and held-to-maturity debt securities, companies will be required to recognize an allowance for credit losses rather than reducing the carrying value of the asset. Assuming we continue to qualify as an EGC, ASU 2016-13 will be effective for us for fiscal years beginning after December 15, 2020, , including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 will have on the Company’s financial position and results of operations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles—Goodwill and Other—Internal-Use Software (Topic 350): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.</font><font style="font-family:inherit;font-size:10pt;"> This standard requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This standard should be applied either retrospectively or prospectively, and will be effective for us in January 2021, assuming we continue to qualify as an EGC, with early adoption permitted. We are currently evaluating the potential impact this standard may have on our condensed consolidated financial statements and results of operations upon adoption.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASU No. 2016-18, Statement of Cash Flows: Restricted Cash</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Statement of Cash Flows (Topic 230):</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:inherit;font-size:10pt;">, which requires the statement of cash flows to explain the change during the period in the total of cash, cash equivalents and restricted cash. When cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new standard requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet. This reconciliation can be presented either on the face of the statement of cash flows or in the notes to the financial statements. The new standard became effective for us on January 1, 2019. As a result of adopting this new standard using a retrospective transition method for each period presented, we include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed statements of cash flows.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASU No. 2014-09, Revenue from Contracts with Customers</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">, which supersedes all existing revenue recognition requirements in ASC 605 and most industry specific guidance. ASC 606 provides a single comprehensive model for use in accounting for revenue arising from contracts with customers. We adopted the new revenue standard on January 1, 2019 using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. We recognized the cumulative effect of the adoption as an adjustment to the opening balance of accumulated deficit in the first quarter of 2019. We have elected to use the practical expedient to aggregate the impact of all contract modifications that occurred prior to the ASC 606 adoption with respect to (i) identification of the satisfied and unsatisfied performance obligations, (ii) determination of the transaction price and (iii) allocation of the transaction price to the satisfied and unsatisfied performance obligations. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASC 606 requires significant judgment and estimates and results in changes to, but not limited to: (i) the determination of the transaction price, including estimates of variable consideration, (ii) the allocation of the transaction price, including the determination of estimated selling price, and (iii) the pattern of recognition, including the application of proportional performance as a measure of progress on service-related promises and application of point-in-time recognition for supply-related promises. We recorded the cumulative-effect adjustment of </font><font style="font-family:inherit;font-size:10pt;">$28.0 million</font><font style="font-family:inherit;font-size:10pt;"> to the opening balance of accumulated deficit as of January 1, 2019 with a corresponding decrease to deferred revenue. </font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our restricted stock activity during </font><font style="font-family:inherit;font-size:10pt;">the three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of<br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Grant Date</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">per Share</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, non-vested at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,911</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canceled, forfeited and adjustments, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">711</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, non-vested at March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> consists of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Building</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,442</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,442</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,891</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,907</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture, fixtures and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,122</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,122</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Internally developed software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,020</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,020</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,195</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,433</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(71,735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">213,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211,977</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaboration Agreements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our total consolidated net revenues from our strategic collaborators for the periods presented (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Collaboration Revenue by Strategic Collaborator:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019 </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">as reported </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(under ASU 606)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019 </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">without adoption of 606</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(under ASC 605)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2018 </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">as reported </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(under ASC 605)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Merck</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AstraZeneca</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">814</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,191</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vertex</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,614</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total collaborative revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,115</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,706</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,612</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,747</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract Liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240,924</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,137</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,582</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,479</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we recognized the following revenues as a result of the change in the contract liability balances related to our collaboration agreements (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Revenue recognized in the period from:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts included in contract liabilities at the beginning of the period </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,582</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;"> We first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period first applies to the beginning contract liability.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the aggregated amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied was </font><font style="font-family:inherit;font-size:10pt;">$279.5 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">AstraZeneca – Strategic Alliances in Cardiovascular and Oncology</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2013 Option Agreement and Services and Collaboration Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2013, we entered into an Option Agreement, the AZ Option Agreement, and a related Services and Collaboration Agreement, the AZ Services Agreement, with AstraZeneca, which were amended and restated in June 2018. We refer to these agreements in the forms that existed prior to the 2018 amendment and restatement as the 2013 AZ Agreements. Under the 2013 AZ Agreements, we granted AstraZeneca certain exclusive rights and licenses, and options to obtain exclusive rights to develop and commercialize potential therapeutic mRNA medicines directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services to AstraZeneca. Pursuant to the 2013 AZ Agreements, AstraZeneca was responsible for all research, development and commercialization activities, while we provided specified research and manufacturing services during a research and evaluation period, as described below, to further AstraZeneca’s activities pursuant to an agreed upon services plan. Under the 2013 AZ Agreements, AstraZeneca could have requested we provide additional services, at AstraZeneca’s expense. Subject to customary “back-up” supply rights granted to AstraZeneca, we exclusively manufactured (or had manufactured) mRNA for all research, development and commercialization purposes under the 2013 AZ Agreements until, on a product-by-product basis, the expiration of the time period for which we are entitled to receive earn-out payments with respect to such product pursuant to the 2013 AZ Agreements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of the effective date of the 2013 AZ Agreements, AstraZeneca acquired </font><font style="font-family:inherit;font-size:10pt;">forty</font><font style="font-family:inherit;font-size:10pt;"> options that it may exercise to obtain exclusive rights to clinically develop and commercialize identified development candidates (and related back-up candidates) directed to specified targets that arise during the research and evaluation period. During the research and evaluation period for research candidates under the 2013 AZ Agreements, AstraZeneca could have elected to designate a limited number of research candidates as development candidates in order to continue preclinical development on such development candidates (and related back-up candidates). From such pool of development candidates designated by AstraZeneca, during a specified option exercise period, AstraZeneca could have then exercised one of its options to obtain exclusive rights to clinically develop and commercialize an identified development candidate (and related back-up candidates). If AstraZeneca did not exercise one of its options to acquire exclusive rights to clinically develop and commercialize a particular development candidate during the defined option exercise period for such development candidate, AstraZeneca’s rights to exercise an option and other rights granted under the 2013 AZ Agreements with respect to such development candidate (and related back-up candidates) would terminate, all rights to exploit such development candidate (and related back-up candidates) would be returned to us and all data and results generated by AstraZeneca with respect to such development candidate (and related back-up candidates) would be either assigned or licensed to us. Upon the earlier of termination of the 2013 AZ Agreements for any reason and a specified anniversary of the effective date of the 2013 AZ Agreements, all unexercised options, and the right to exercise any and all options if not previously exercised by AstraZeneca, would automatically terminate. On a target-by-target basis, we and AstraZeneca agreed to certain defined exclusivity obligations under the 2013 AZ Agreements with respect to the research, development and commercialization of mRNA medicines for such target.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of the effective date of the 2013 AZ Agreements, AstraZeneca made upfront cash payments to us totaling </font><font style="font-family:inherit;font-size:10pt;">$240.0 million</font><font style="font-family:inherit;font-size:10pt;">. Under the 2013 AZ Agreements, we were entitled to receive payments that are not related to any specific program of up to </font><font style="font-family:inherit;font-size:10pt;">$180.0 million</font><font style="font-family:inherit;font-size:10pt;"> in the aggregate for the achievement of </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> technical milestones relating to toxicity, delivery, and competition criteria. We achieved the toxicity and competition milestones in the year ended December 31, 2015. The delivery milestone has expired. Under the 2013 AZ Agreements, AstraZeneca was obligated to pay us a </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> option exercise fee with respect to each development candidate (and related back-up candidates) for which it exercised an option. In addition, upon AstraZeneca’s exercise of each option, we were eligible to receive certain payments contingent upon the achievement of specified clinical, regulatory, and commercial events. For any product candidate optioned by AstraZeneca, we were eligible to receive, per product candidate, up to </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> in payments for achievement of development milestones, up to </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> payments for achievement of regulatory milestones, and up to </font><font style="font-family:inherit;font-size:10pt;">$200.0 million</font><font style="font-family:inherit;font-size:10pt;"> payments for achievement of commercial milestones. Additionally, under the 2013 AZ Agreements, we were entitled to receive, on a product-by-product basis, earn-out payments on worldwide net sales of products ranging from a high-single digit percentage to </font><font style="font-family:inherit;font-size:10pt;">12%</font><font style="font-family:inherit;font-size:10pt;">, subject to certain reductions, with an aggregate minimum floor.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We received from AstraZeneca under the 2013 AZ Agreements an option exercise payment of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> in the year ended December 31, 2016, and a clinical milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> with respect to AstraZeneca’s VEGF-A product (AZD8601) during the year ended December 31, 2018, that is currently being developed in a Phase 2 clinical trial in certain fields.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless earlier terminated, the 2013 AZ Agreements would have continued until the expiration of AstraZeneca’s earn-out and contingent option exercise payment obligations for optioned product candidates. Either party had the right to terminate the 2013 AZ Agreements upon the other party’s material breach, either in its entirety or in certain circumstances, with respect to relevant candidates, subject to a defined materiality threshold and specified notice and cure provisions. If AstraZeneca had the right to terminate the 2013 AZ Agreements for our material breach, then AstraZeneca could have elected, in lieu of terminating the 2013 AZ Agreements, in their entirety or with respect to such candidates, to have the 2013 AZ Agreements remain in effect, subject to reductions in certain payments we were eligible to receive and certain adjustments to AstraZeneca’s obligations under the 2013 AZ Agreements. AstraZeneca had the right to terminate the 2013 AZ Agreements in full, without cause, upon </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;">-days’ prior notice to us.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2016 Strategic Alliance with AstraZeneca</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> –</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> IL12</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, we entered into a new Strategic Drug Development Collaboration and License Agreement, which we refer to as the 2016 AZ Agreement, with AstraZeneca to discover, develop and commercialize potential mRNA medicines for the treatment of a range of cancers.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the 2016 AZ Agreement, we and AstraZeneca have agreed to work together on an immuno-oncology program focused on the intratumoral delivery of a potential mRNA medicine to make the IL12 protein.</font><font style="font-family:inherit;font-size:8pt;"> </font><font style="font-family:inherit;font-size:10pt;">The 2016 AZ Agreement initially included research activities with respect to a second discovery program. During a limited period of time, each party had an opportunity to propose additional discovery programs to be conducted under the 2016 AZ Agreement. We are responsible for conducting and funding all discovery and preclinical development activities under the 2016 AZ Agreement in accordance with an agreed upon discovery program plan for the IL12 program and any other discovery program the parties agree to conduct under the 2016 AZ Agreement. For the IL12 program and any other discovery program the parties agree to conduct under the 2016 AZ Agreement, during a defined election period that commenced as of the effective date of the 2016 AZ Agreement (for the IL12 program) and otherwise will commence on initiation of any such new discovery program, AstraZeneca may elect to participate in the clinical development of a development candidate arising under the 2016 AZ Agreement from such program. If AstraZeneca so elects (as it has for the IL12 program), AstraZeneca will lead clinical development activities worldwide and we will be responsible for certain activities, including being solely responsible for manufacturing activities, all in accordance with an agreed upon development plan. AstraZeneca will be responsible for funding all Phase 1 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan), and Phase 2 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan) up to a defined dollar threshold. We and AstraZeneca will equally share the costs of Phase 2 clinical development activities in excess of such dollar threshold, all Phase 3 clinical development activities and certain other costs of late-stage clinical development activities, unless we elect not to participate in further development and commercialization activities and instead receive tiered royalties, as described below.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and AstraZeneca will co-commercialize products in the U.S. in accordance with an agreed upon commercialization plan and budget, and on a product-by-product basis will equally share the U.S. profits or losses arising from such commercialization. Notwithstanding, on a product-by-product basis, prior to a specified stage of development of a given product, we have the right to elect not to participate in the further development and commercialization activities for such product. If we make such election, instead of participating in the U.S. profits and losses share with respect to such product, we are obligated to discuss future financial terms with AstraZeneca. If we are unable to agree on future financial terms within a short, defined period of time, we are entitled to receive tiered royalties at default rates set forth in the 2016 AZ Agreement, ranging from percentages in the mid-single digits to </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> on worldwide net sales of products, subject to certain reductions with an aggregate minimum floor. AstraZeneca has sole and exclusive responsibility for all ex-U.S. commercialization efforts. Unless we have elected to not to participate in further development (in which case royalties on ex-U.S. net sales will be at the default rates as described above, unless otherwise agreed by the parties), we are entitled to tiered royalties at rates ranging from </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">30%</font><font style="font-family:inherit;font-size:10pt;"> on ex-U.S. net sales of the products, subject to certain reductions with an aggregate minimum floor. Subject to customary “back-up” supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) products for all development and commercialization purposes. We and AstraZeneca have agreed to certain defined exclusivity obligations with each other under the 2016 AZ Agreement with respect to the development and commercialization of mRNA medicines for IL12. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless earlier terminated, our strategic alliance under the 2016 AZ Agreement will continue on a product-by-product basis (i) until both parties cease developing and commercializing such product without the intention to resume, if we have not elected our right not to participate in further development and commercialization of such product or (ii) on a country-by-country basis, until the end of the applicable royalty term for such product in such country, if we have elected our right not to participate in further development and commercialization of such product.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Either party may terminate the 2016 AZ Agreement upon the other party’s material breach, subject to specified notice and cure provisions. Each party may also terminate the 2016 AZ Agreement in the event the other party challenges such party’s patent rights, subject to certain defined exceptions. AstraZeneca has the right to terminate the 2016 AZ Agreement in full or with respect to any program for scientific, technical, regulatory or commercial reasons at any time upon </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days’ prior written notice to us. On a product-by-product basis, we have the right to terminate the 2016 AZ Agreement in certain cases if AstraZeneca has suspended or is no longer proceeding with the development or commercialization of such product for a period of </font><font style="font-family:inherit;font-size:10pt;">twelve</font><font style="font-family:inherit;font-size:10pt;"> consecutive months, subject to specified exceptions, including tolling for events outside of AstraZeneca’s control. On a product-by-product basis, if the 2016 AZ Agreement is terminated with respect to a given product, AstraZeneca’s rights in such product will terminate and, to the extent we terminated for AstraZeneca’s breach, patent challenge or cessation of development or AstraZeneca terminated in its discretion, AstraZeneca will grant us reversion licenses and take certain other actions so as to enable us to continue developing and commercializing such product in the oncology field.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we continue developing and commercializing a given product following termination of the 2016 AZ Agreement by AstraZeneca in its discretion with respect to such product, AstraZeneca is entitled to receive a mid-single digit royalty on our worldwide net sales of such product and a high-single digit percentage of the amounts received by us from a third party in consideration of a license to such third party to exploit such product, in each case, until AstraZeneca recovers an amount equal to specified development costs incurred by AstraZeneca under the 2016 AZ Agreement with respect to such product prior to such termination. Such percentages increase by a low to mid-single digit amount to the extent such termination occurs after such product achieves a specified stage of development.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Strategic Alliance with AstraZeneca – Relaxin</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, we entered a new Collaboration and License Agreement, which we refer to as the 2017 AZ Agreement, under which AstraZeneca may clinically develop and commercialize a development candidate, now known as AZD7970, which is comprised of an mRNA construct for the relaxin protein designed by us and encapsulated in one of our proprietary lipid nanoparticles ("LNP"). We discovered and performed preclinical development activities for AZD7970 prior to the initiation of the strategic alliance with AstraZeneca under the 2017 AZ Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the 2017 AZ Agreement, we will fund and be responsible for conducting preclinical development activities for AZD7970 through completion of IND-enabling GLP toxicology studies and AstraZeneca will lead pharmacological studies, each in accordance with an agreed upon discovery program plan. During a defined election period that commences as of the effective date of the 2017 AZ Agreement, AstraZeneca may elect to participate in further development and commercialization of AZD7970. Upon such election, AstraZeneca will lead clinical development activities for AZD7970 worldwide and we will be responsible for manufacturing AZD7970, certain regulatory matters and any other development activities that we agree to perform and that are set forth in an agreed upon development plan. AstraZeneca will be responsible for funding Phase 1 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan, up to a cap above which such costs are shared), and Phase 2 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan, up to a cap above which such costs are shared) up to a defined dollar threshold. Thereafter, we and AstraZeneca will equally share the costs of Phase 2 clinical development activities in excess of such defined dollar threshold, all Phase 3 clinical development activities and certain other costs of late-stage clinical development activities, unless we elect not to participate in further development and co-commercialization activities and instead receive tiered royalties as described below. If the development candidate is determined to be IND-ready, and AstraZeneca does not timely elect to participate in the clinical development of AZD7970, AstraZeneca is obligated to reimburse us for certain costs we incurred in the manufacture and development of AZD7970, since execution of the 2017 AZ Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and AstraZeneca will co-commercialize AZD7970 in the United States in accordance with an agreed upon commercialization plan and budget, and will equally share U.S. profits or losses arising from such commercialization. Notwithstanding, prior to a specified stage of development of AZD7970, we have the right to elect not to participate in the further development and commercialization activities for AZD7970. If we make such election, instead of participating in the U.S. profits and losses share with respect to AZD7970, we are obligated to discuss future financial terms with AstraZeneca. If we are unable to agree on future financial terms within a short, defined period of time, we are entitled to receive tiered royalties at default rates set forth in the 2017 AZ Agreement, ranging from percentages in the mid-single digits to the low 20s on worldwide net sales by AstraZeneca of AZD7970, subject to certain reductions, with an aggregate minimum floor. AstraZeneca has sole and exclusive responsibility for all ex-U.S. commercialization efforts. Unless we have elected not to participate in further development (in which case royalties on ex-U.S. net sales will be at the default rates as described above, unless otherwise agreed by the parties), we are entitled to receive tiered royalties at rates ranging from </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">30%</font><font style="font-family:inherit;font-size:10pt;"> on annual ex-U.S. net sales of AZD7970, subject to certain reductions with an aggregate minimum floor. Subject to customary “back-up” supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) products for all development and commercialization purposes. Additionally, we and AstraZeneca have agreed to certain defined exclusivity obligations under the 2017 AZ Agreement with respect to the development and commercialization of mRNA medicines for Relaxin.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless earlier terminated, our strategic alliance under the 2017 AZ Agreement will continue (i) until the expiration of AstraZeneca’s election period, if it does not elect to participate in the clinical development of AZD7970, (ii) until both parties cease developing and commercializing AZD7970 without the intention to resume, if we have not elected our right not to participate in further development and commercialization of AZD7970, (iii) on a country-by-country basis, until the end of the applicable royalty term for AZD7970 in such country, if we have elected our right not to participate in further development and commercialization of AZD7970 or (iv) following completion of IND-enabling studies with respect to AZD7970, if we provide AstraZeneca with written notice that we do not reasonably believe that the product is IND-ready.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Either party may terminate the 2017 AZ Agreement upon the other party’s material breach, subject to specified notice and cure provisions. Each party may also terminate the 2017 AZ Agreement in the event the other party challenges the validity or enforceability of such party’s patent rights, subject to certain defined exceptions. AstraZeneca has the right to terminate the 2017 AZ Agreement in full for scientific, technical, regulatory or commercial reasons at any time upon </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days’ prior written notice to us. We have the right to terminate the 2017 AZ Agreement in certain cases if AstraZeneca has suspended or is no longer proceeding with the development or commercialization of AZD7970 for a period of </font><font style="font-family:inherit;font-size:10pt;">twelve</font><font style="font-family:inherit;font-size:10pt;"> consecutive months, subject to specified exceptions, including tolling for events outside of AstraZeneca’s control. If AstraZeneca does not timely elect to participate in clinical development of AZD7970, or the Agreement is terminated, AstraZeneca’s rights in AZD7970 will terminate and, to the extent we terminated for AstraZeneca’s breach, patent challenge or cessation of development or AstraZeneca terminated in its discretion, AstraZeneca will grant us reversion licenses and take certain other actions so as to enable us to continue developing and commercializing AZD7970 in the cardiovascular and cardiometabolic fields.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we continue developing and commercializing AZD7970 following a termination of the 2017 AZ Agreement by AstraZeneca in its discretion, AstraZeneca is entitled to receive a mid-single digit royalty on our worldwide net sales of AZD7970 and a high-single digit percentage of the amounts received by us from a third party in consideration for a license to such third party to exploit AZD7970, in each case until AstraZeneca recovers an amount equal to specified development costs incurred by AstraZeneca under the 2017 AZ Agreement with respect to AZD7970 prior to such termination. Such percentages increase by a low to mid-single digit amount to the extent such termination occurs after such product achieves a specified stage of development.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2013 Agreements with AstraZeneca, amended and restated in 2018 </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, we entered into an Amended and Restated Option Agreement and a related Amended and Restated Services and Collaboration Agreement with AstraZeneca, or the 2018 A&R Agreements, which amended and restated the 2013 AZ Agreements. Under the 2018 A&R Agreements, we granted AstraZeneca certain exclusive rights and licenses to research, develop and commercialize potential therapeutic mRNA medicines directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services to AstraZeneca. The activities to be performed by the parties under the 2018 A&R Agreements are limited to defined biological targets in the cardiovascular and cardiometabolic fields and one defined target in the cancer field.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the 2018 A&R Agreements, AstraZeneca is responsible for all research, development and commercialization activities and associated costs, while we provide specified research and manufacturing services during a research and evaluation period, as described below, to further AstraZeneca’s activities conducted pursuant to an agreed upon services plan. During this research and evaluation period, these research services, and manufacturing services in excess of a specified threshold, are provided at AstraZeneca’s expense, and manufacturing services below the specified threshold are provided at no additional expense to AstraZeneca. AstraZeneca may request we provide additional research and manufacturing services, at AstraZeneca’s expense, following the end of the research and evaluation period. Subject to customary “back-up” supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) mRNA for all research, development and commercialization purposes under the 2018 A&R Agreements until, on a product-by-product basis, the expiration of the time period for which we are entitled to receive earn-out payments with respect to such product pursuant to the 2018 A&R Agreements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of the effective date of the 2013 AZ Agreements, and as further reflected in the 2018 A&R Agreements, AstraZeneca acquired </font><font style="font-family:inherit;font-size:10pt;">forty</font><font style="font-family:inherit;font-size:10pt;"> options that it may exercise to obtain exclusive rights to clinically develop and commercialize identified development candidates (and related back-up candidates) directed to specified targets that arise during the research and evaluation period. During the research and evaluation period for research candidates, AstraZeneca may elect to designate a limited number of research candidates as development candidates in order to continue preclinical development on such development candidates (and related back-up candidates). From such pool of development candidates designated by AstraZeneca, during a specified option exercise period, AstraZeneca may then exercise one of its options to obtain exclusive rights to clinically develop and commercialize an identified development candidate (and related back-up candidates) in certain fields. If AstraZeneca does not exercise one of its options to acquire exclusive rights to clinically develop and commercialize a particular development candidate during the defined option exercise period for such development candidate, AstraZeneca’s rights to exercise an option and other rights granted under the 2018 A&R Agreements with respect to such development candidate (and related back-up candidates) will terminate, all rights to exploit such development candidate (and related back-up candidates) will be returned to us and all data and results generated by AstraZeneca with respect to such development candidate (and related back-up candidates) will be either assigned or licensed to us. Upon the earlier of termination of the 2018 A&R Agreements for any reason and a specified anniversary of the effective date of the 2013 AZ Agreements, all unexercised options, and the right to exercise any and all options if not previously exercised by AstraZeneca, will automatically terminate.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On a target-by-target basis, we and AstraZeneca have agreed to certain defined exclusivity obligations under the 2018 A&R Agreements with respect to the research, development and commercialization of mRNA medicines for such target in certain fields. In addition, we and AstraZeneca have agreed to certain defined exclusivity obligations with respect to the research, development and commercialization of mRNA medicines coding for the same polypeptide as any development candidate being developed under the 2018 A&R Agreements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;"> </font><font style="font-family:inherit;font-size:10pt;">Unless earlier terminated, the 2018 A&R Agreements will continue until the expiration of AstraZeneca’s earn-out and contingent option exercise payment obligations for optioned product candidates. Either party may terminate the 2018 A&R Agreements upon the other party’s material breach, either in its entirety or in certain circumstances, with respect to relevant candidates, subject to a defined materiality threshold and specified notice and cure provisions. If AstraZeneca has the right to terminate the 2018 A&R Agreements for our material breach, then AstraZeneca may elect, in lieu of terminating the 2018 A&R Agreements, in their entirety or with respect to such candidates, to have the 2018 A&R Agreements remain in effect, subject to reductions in certain payments we are eligible to receive and certain adjustments to AstraZeneca’s obligations under the 2018 A&R Agreements. AstraZeneca may terminate the 2018 A&R Agreements in full, without cause, upon </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days’ prior notice to us.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Treatment</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For periods prior to January 1, 2019, we applied the provisions of ASC 605 in accounting for these arrangements, except for the 2017 AZ Agreement which was accounted for under ASC 808. In August 2016, AstraZeneca exercised a product option available pursuant to the 2013 AZ Agreements to obtain exclusive rights to clinically develop and commercialize the VEGF-A product (AZD8601). This option exercise is referred to as the 2016 VEGF Exercise. Consistent with our conclusions under ASC 605 and pursuant to ASC 606, we determined that the 2016 VEGF Exercise and the 2017 AZ Agreement should be accounted for as separate transactions as the agreements are not interrelated or interdependent. Conversely, the 2013 Agreements, as amended by the 2018 A&R Agreements, and the 2016 AZ Agreement, were combined for accounting purposes and treated as a single agreement, as these agreements were negotiated in contemplation of each other. As of the date of our initial application of ASC 606, we applied the practical expedient to include the aggregate effect of all modifications to the arrangement that occurred before January 1, 2019 with respect to (i) identification of the satisfied and unsatisfied performance obligations, (ii) determination of the transaction price and (iii) allocation of the transaction price to the satisfied and unsatisfied performance obligations. Therefore, we aggregated effects of all the modifications prior to January 1, 2019 to the 2013 Agreements, including the effects of the 2018 A&R Agreements, and the 2016 AZ Agreement were combined into one transaction for accounting purposes. We will refer to this combined transaction as the Combined 2018 AZ Agreements. We determined that all aspects of Combined 2018 AZ Agreements and the 2016 VEGF Exercise represent a transaction with a customer and therefore is accounted for in accordance with ASC 606 as of the date of the initial application.</font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Combined 2018 AZ Agreements</font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We identified the following performance obligations in the Combined 2018 AZ Agreements: (i) a combined performance obligation that includes a research license, research and development pool services, and manufacturing obligations related to the 2013 AZ Agreements, as amended by the 2018 A&R Agreements, collectively referred to as the Combined 2018 AZ Agreement Performance Obligation, (ii) preclinical development services for IL12, (iii) preclinical development services for an oncology development target, (iv) a combined performance obligation for a development and commercialization license and manufacturing obligations for IL12, and (v) a material right to receive development and commercialization rights and manufacturing services for an oncology development target.</font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We concluded that the research license is not distinct from the research and development pool services or the manufacturing obligations related to the 2018 A&R Agreements, as AstraZeneca cannot fully exploit the value of the research license without receipt of such services and supply. Our services and supply involve specialized expertise, particularly as it relates to mRNA technology that is not available in the marketplace. Any supply requested by AstraZeneca in excess of the minimum quantities specified in the agreement are considered customer options and treated as separate contracts for accounting purposes. Further, we concluded that AstraZeneca cannot exploit the value of the development and commercialization license for IL12 without receipt of supply as the development and commercialization license does not convey to AstraZeneca the right to manufacture and therefore combined the development and commercialization license and the manufacturing obligations for IL12 into one performance obligation.</font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of January 1, 2019, the date of initial adoption of ASC 606, the total transaction price was determined to be </font><font style="font-family:inherit;font-size:10pt;">$400.0</font><font style="font-family:inherit;font-size:10pt;"> million comprised of the </font><font style="font-family:inherit;font-size:10pt;">$240.0 million</font><font style="font-family:inherit;font-size:10pt;"> in upfront payments pertaining to the 2013 AZ Agreements and </font><font style="font-family:inherit;font-size:10pt;">$160.0</font><font style="font-family:inherit;font-size:10pt;"> million of variable consideration comprised of </font><font style="font-family:inherit;font-size:10pt;">$40.0</font><font style="font-family:inherit;font-size:10pt;"> million of estimated reimbursement for IL12 manufacturing obligations and </font><font style="font-family:inherit;font-size:10pt;">$120.0 million</font><font style="font-family:inherit;font-size:10pt;"> of milestone payments (</font><font style="font-family:inherit;font-size:10pt;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;"> toxicity milestone and </font><font style="font-family:inherit;font-size:10pt;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;"> competition milestone), received prior to the adoption date of ASC 606. We utilize the most likely amount method to determine the amount of reimbursement for IL12 manufacturing obligations to be received. We determined that any sales-based royalties related to IL12 will be recognized when the related sales occur as they were determined to relate predominately to the license granted and therefore have been excluded from the transaction price. In addition, we are eligible to receive future milestones and royalties on future commercial sales for optioned product candidates under the 2018 A&R Agreements and future royalties under the 2016 Agreement; however, these amounts are not considered variable consideration under the Combined 2018 Agreements as we are only eligible to receive such amounts if AstraZeneca exercises its options (including certain options that are deemed to be material rights). We have concluded that the exercise of an optioned product candidate represents a separate transaction under ASC 606. We will re-evaluate the transaction price at the end of each reporting period. There was a $</font><font style="font-family:inherit;font-size:10pt;">0.3</font><font style="font-family:inherit;font-size:10pt;"> million increase to the transaction price resulting from a change in estimate of the variable consideration during the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. We developed the estimated standalone selling price for the licenses included in the Combined 2018 AZ Agreement Performance Obligation and the combined performance obligation for a development and commercialization license and manufacturing obligations for IL12 primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success and the time needed to commercialize a product candidate pursuant to the associated license. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the performance obligation, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated costs, adjusted for a reasonable profit margin that would be expected to be realized under similar contracts. The estimated standalone selling price of the material right to receive development and commercialization rights and manufacturing services for an oncology development target was developed by estimating the amount of discount that AstraZeneca would receive when exercising the option and adjusting such amount by the likelihood that the option will be exercised.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The transaction price allocated to each performance obligation was as follows: (i) </font><font style="font-family:inherit;font-size:10pt;">$292.4 million</font><font style="font-family:inherit;font-size:10pt;"> to the Combined 2018 AZ Agreement Performance Obligation, (ii) </font><font style="font-family:inherit;font-size:10pt;">$8.1 million</font><font style="font-family:inherit;font-size:10pt;"> to the preclinical development services for IL12 performance obligation, (iii) </font><font style="font-family:inherit;font-size:10pt;">$8.1 million</font><font style="font-family:inherit;font-size:10pt;"> to the preclinical development services for an oncology development target performance obligation, (iv) </font><font style="font-family:inherit;font-size:10pt;">$89.8 million</font><font style="font-family:inherit;font-size:10pt;"> to the combined performance obligation for a development and commercialization license and manufacturing obligations for IL12, and (v) </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> to the material right to receive development and commercialization rights and manufacturing services for an oncology development target. As part of the allocation of the transaction price to each of the performance obligations, we concluded that the </font><font style="font-family:inherit;font-size:10pt;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;"> toxicology milestone and the estimated reimbursement for IL12 manufacturing costs can be allocated entirely to specific performance obligations because the variable payment relates specifically to our effort to satisfy the performance obligation and such allocation is consistent with the allocation objectives of ASC 606.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for the Combined 2018 AZ Agreement Performance Obligation and the preclinical development services for IL12 and the other oncology target performance obligations. We recognize revenue related to the amounts allocated to the combined performance obligation for a development and commercialization license and manufacturing obligations for IL12 based on the point in time upon which control of supply is transferred to AstraZeneca for each delivery of the associated supply. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue for the Combined 2018 AZ Agreement Performance Obligation, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend. This ratio is applied to the transaction price allocated to this combined performance obligation. We also estimate the development plan, including expected demand from AstraZeneca, and the associated costs for this combined performance obligation, as we will satisfy this combined performance obligation as the manufacturing services are performed. Management has applied significant judgment in the process of developing our budget estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, we recognized collaboration revenue of </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, from the Combined 2018 AZ Agreements. The revenue recognized for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> includes the amortization of deferred revenue due to the satisfaction of our performance obligation during the period. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the aggregate amount of the transaction price allocated to the remaining performance obligations that are unsatisfied is </font><font style="font-family:inherit;font-size:10pt;">$112.5 million</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;">$102.8 million</font><font style="font-family:inherit;font-size:10pt;"> is expected to be recognized as revenue through December 31, 2027 and </font><font style="font-family:inherit;font-size:10pt;">$9.7 million</font><font style="font-family:inherit;font-size:10pt;"> is expected to be recognized as revenue at the earlier of expiration or modification of the Combined 2018 AZ Agreement. We had deferred revenue of </font><font style="font-family:inherit;font-size:10pt;">$75.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$115.6 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, from the Combined 2018 AZ Agreements, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the services are expected to be performed or control of the supply is expected to be transferred. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2016 VEGF Exercise</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We concluded that the 2016 VEGF Exercise should be treated as a separate transaction for accounting purposes. We identified one performance obligation in this arrangement which is comprised of the exclusive license to develop and commercialize VEGF and the manufacturing of clinical supply. We concluded that the VEGF license is not distinct from the manufacturing obligations because AstraZeneca cannot fully exploit the value of the license without receipt of such supply. This is due to limitations inherent in the licenses conveyed wherein AstraZeneca does not have the contractual right to manufacture during the term of the agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of January 1, 2019, the date of initial adoption of ASC 606, the total transaction price was determined to be </font><font style="font-family:inherit;font-size:10pt;">$55.1 million</font><font style="font-family:inherit;font-size:10pt;"> comprised of the </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> in fixed payments pertaining to a </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> option exercise fee and a </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> milestone achieved prior to the adoption of ASC 606 and </font><font style="font-family:inherit;font-size:10pt;">$15.1 million</font><font style="font-family:inherit;font-size:10pt;"> of variable consideration related to the estimated reimbursement for clinical supply. We are eligible to receive future milestones and royalties on future commercial sales under this arrangement. We utilize the most likely amount method to estimate any development and regulatory milestone payments to be received and the amount of estimated reimbursement for clinical supply. As of January 1, 2019, there were no milestones that had not been achieved included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or AstraZeneca’s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. We will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. When a milestone payment is included in the transaction price in the future, it will be recognized as revenue based on the relative completion of the underlying performance obligation. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> changes to the transaction price during the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue related to the amount of the transaction price allocated to the VEGF Exercise performance obligation based on the point in time upon which control of supply is transferred to AstraZeneca for each delivery of the associated supply. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, we did </font><font style="font-family:inherit;font-size:10pt;">not</font><font style="font-family:inherit;font-size:10pt;"> recognize any collaboration revenue from the 2016 VEGF Exercise. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the aggregate amount of the transaction price allocated to the remaining performance obligation that is unsatisfied is </font><font style="font-family:inherit;font-size:10pt;">$51.0 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized as revenue through December 31, 2023. We had deferred revenue of </font><font style="font-family:inherit;font-size:10pt;">$37.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$41.2 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, from the 2016 VEGF Exercise, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the control of the supply is expected to be transferred.</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 AZ Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We concluded the 2017 AZ Agreement is under the scope of ASC 808 as we and AstraZeneca are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on commercial success of the activities of the arrangement. Additionally, we determined the development, manufacturing and commercialization activities are not deliverables under ASC 606. As a result, the activities conducted pursuant to the development, manufacturing and commercialization activities are accounted for as a component of the related expense in the period incurred. We considered the guidance in ASC 606 by analogy in determining the appropriate treatment for the transactions between us and AstraZeneca and concluded that reimbursement for transactions in which we are considered to be principal because we control a promised good or service before transferring that good or service to the customer, are accounted for as gross revenue. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We did </font><font style="font-family:inherit;font-size:10pt;">not</font><font style="font-family:inherit;font-size:10pt;"> recognize any revenue from the 2017 AZ Agreement for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Merck – Strategic Alliances in Infectious Diseases and Cancer Vaccines</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2015 Strategic Alliance with Merck – Infectious Disease</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, we entered into a Master Collaboration and License Agreement with Merck, which was amended in January 2016, June 2016, and May 2019, and which we refer to, as amended, as the 2015 Merck Agreement. Pursuant to the 2015 Merck Agreement, we and Merck have agreed to research, develop, and commercialize potential mRNA medicines for the prevention of infections by RSV. Pursuant to the 2015 Merck Agreement, Merck is primarily responsible for research, development, and commercialization activities and associated costs of such research and commercialization. We are responsible for designing and manufacturing all mRNA constructs for preclinical and Phase 1 and Phase 2 clinical development purposes, and Merck pays us for such manufacture, and we are responsible for certain costs associated with the conduct of a Phase 1 clinical trial for a RSV vaccine product candidate (mRNA-1172). Responsibility for manufacturing mRNA constructs for late stage clinical development and commercialization purposes is to be determined.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2015 Merck Agreement includes a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year period, expected to end on January 12, 2022, during which Merck may continue to preclinically and clinically develop RSV vaccine product candidates that arose during an initial </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year research period which terminated in January 2019. Merck may, prior to the end of this </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year period, elect to exclusively develop and commercialize up to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> RSV vaccine product candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and Merck have agreed to certain defined exclusivity obligations during the term of the 2015 Merck Agreement with respect to potential mRNA medicines against RSV infection. As part of the May 2019 amendment of the 2015 Merck Agreement, these exclusivity obligations do not restrict Moderna from researching, developing, and commercializing a potential mRNA medicine for the prevention of a specific set of respiratory infections, including RSV, for the pediatric population.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the 2015 Merck Agreement, we received a </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment. We are eligible to receive, on a product-by-product basis, up to </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate milestone payments upon the achievement of certain development, regulatory, and commercial milestone events. To date, we have received from Merck a clinical milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> with respect to the initiation of a Phase 1 clinical trial for a Merck RSV vaccine product candidate. In addition, under the terms of the 2015 Merck Agreement, we are eligible to receive an additional milestone payment unless Merck elects not to continue with further clinical development of mRNA-1172. On a product-by-product basis, we are also entitled to receive royalties on Merck’s net sales of products at rates ranging from the mid-single digits to low teens, subject to certain reductions, with an aggregate minimum floor. Additionally, concurrent with entering into the 2015 Merck Agreement in 2015, Merck made a </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> equity investment in us, and concurrent with amending the 2015 Merck Agreement in January 2016, we received an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless earlier terminated, the 2015 Merck Agreement will continue on a product-by-product and country-by-country basis for so long as royalties are payable by Merck on a given product in a given country. Either party may terminate the 2015 Merck Agreement upon the other party’s material breach, either in its entirety or with respect to a particular program, product candidate, product or country, subject to specified notice and cure provisions. Merck may terminate the 2015 Merck Agreement in full or with respect to a particular product candidate or product upon certain advance notice to us for any reason, or earlier if Merck determines the alliance or product is no longer commercially practicable. If Merck has the right to terminate the 2015 Merck Agreement, in its entirety or with respect to a program, product candidate or product, for our material breach, then Merck may elect, in lieu of terminating the 2015 Merck Agreement, to have the 2015 Merck Agreement remain in effect, subject to reductions in certain payments we are eligible to receive with respect to the terminable rights. Upon a termination of the 2015 Merck Agreement with respect to a program, all licenses and other rights granted to Merck with respect to such program will terminate and the continued development and commercialization of product candidates and products will revert to us. If the 2015 Merck Agreement is terminated with respect to a given product candidate or product, all licenses and other rights granted to Merck with respect to such product candidate or product will terminate and, to the extent we terminated for Merck’s breach, Merck will grant us licenses under select Merck technology for our continued development and commercialization of such product candidate or product. As a part of the May 2019 amendment of the 2015 Merck Agreement, we and Merck agreed to and conclude the collaboration as it relates to development of potential mRNA medicines for other viruses, including mRNA-1278 for the prevention of VZV infection.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Treatment</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For periods prior to January 1, 2019, we applied the provisions of ASC 605 in accounting for this arrangement. As of the date of our initial application of ASC 606, we applied the practical expedient to include the aggregate effect of all modifications to the arrangement that occurred before January 1, 2019 with respect to (i) identification of the satisfied and unsatisfied performance obligations, (ii) determination of the transaction price and (iii) allocation of the transaction price to the satisfied and unsatisfied performance obligations. Additionally, we determined that all aspects of amended 2015 Merck Agreement represent a transaction with a customer and therefore the amended 2015 Merck Agreement is accounted for in accordance with ASC 606 as of the date of the initial application. As of the date of initial adoption of ASC 606, the </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year research period was substantially complete and we concluded there were no unsatisfied performance obligations pertaining to the amended 2015 Merck Agreement. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) research services during the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year period following the initial </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year research period during which Merck may continue to preclinically and clinically develop product candidates and (ii) clinical mRNA supply for Phase 1 and Phase 2 and/or non-cGMP mRNA supply beyond the initial </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year research period. Therefore, such options will be accounted for as a separate contract upon the customer’s election. After completion of the initial </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year research period and as a part of the May 2019 amendment of the 2015 Merck Agreement, Merck elected to establish a new RSV vaccine product candidate and to conduct a Phase 1 clinical trial. We and Merck agreed to focus the collaboration activities on RSV and discontinue the collaboration as it relates to the development of development candidates for other viruses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of the date of initial application of ASC 606, the total transaction price of </font><font style="font-family:inherit;font-size:10pt;">$65.0 million</font><font style="font-family:inherit;font-size:10pt;"> comprised of the </font><font style="font-family:inherit;font-size:10pt;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate upfront payments, including </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> related to research and development funding plus a </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> funding from the 2016 amendment of the 2015 Merck Agreement, and a </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment pertaining to achievement of a development milestone during the year ended December 31, 2017, which had been allocated entirely to the satisfied performance obligation and recognized in full. We utilize the most likely amount method to estimate any development and regulatory milestone payments to be received. As of January 1, 2019, there were no milestones that had not been achieved included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or Merck’s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. We will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. When a milestone payment is included in the transaction price in the future, it will be recognized as revenue based on the relative completion of the underlying performance obligation. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> changes to the transaction price during the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> We had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> deferred revenue as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> from the amended Merck 2015 Agreement as all performance obligations under the amended 2015 Merck Agreement were completed. For the three months ended March 31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, we recognized collaboration revenue of </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> from the amended 2015 Merck Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, we recognized collaboration revenue of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended March 31, 2019, pursuant to separate agreements with Merck related to the exercise of customer options to purchase clinical mRNA supply to further develop a product candidate after the initial </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year research period. Clinical mRNA supply is recognized as collaboration revenue at a point in time upon which control of supply is transferred to Merck for each delivery of the associated supply.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are currently evaluating the accounting related to the May 2019 amendment of the 2015 Merck Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2016 Cancer Vaccine Strategic Alliance—Personalized mRNA Cancer Vaccines</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, we entered into a personalized mRNA cancer vaccines (PCV) Collaboration and License Agreement with Merck Sharp & Dohme Corp., or Merck, which we refer to as the PCV Agreement, to develop and commercialize PCVs for individual patients using our mRNA vaccine and formulation technology. Under the strategic alliance, we identify genetic mutations present in a particular patient’s tumor cells, synthesize mRNA for these mutations, encapsulate the mRNA in one of our proprietary LNPs and administer to each patient a unique mRNA cancer vaccine designed to specifically activate the patient’s immune system against her or his own cancer cells.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the PCV Agreement, we are responsible for designing and researching PCVs, providing manufacturing capacity and manufacturing PCVs, and conducting Phase 1 and Phase 2 clinical trials for PCVs, alone and in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget and under the oversight of a committee comprised of equal representatives of each party. The parties have entered into a clinical quality agreement with respect to Moderna’s manufacture and supply activities. We received an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$200.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck. In November 2017, we and Merck announced the achievement of a key milestone for the first-in-human dosing of a PCV (mRNA-4157) as a part of the alliance. The Phase 1 open-label, dose escalation, multicenter clinical trial in the United States (KEYNOTE-603) is designed to assess the safety, tolerability and immunogenicity of mRNA-4157 alone in subjects with resected solid tumors and in combination with KEYTRUDA, in subjects with unresectable solid tumors.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Until the expiration of a defined period of time following our completion of Phase 1 and Phase 2 clinical trials for PCVs under the PCV Agreement and delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of PCVs by making a </font><font style="font-family:inherit;font-size:10pt;">$250.0 million</font><font style="font-family:inherit;font-size:10pt;"> participation payment to us. If Merck exercises its election and pays the participation payment, then the parties will equally co-fund subsequent clinical development of PCVs, with Merck primarily responsible for conducting clinical development activities under a jointly agreed development plan and budget. Each party may also conduct additional clinical trials for PCVs that are not included in the jointly agreed development plan and budget, in which case the non-conducting party will reimburse the conducting party for half of the total costs for such trials, plus interest, from its share of future profits resulting from sales of such PCVs, if any. Merck will lead worldwide commercialization of PCVs, subject to Moderna’s option to co-promote PCVs in the United States, and the parties will equally share the profits or losses arising from worldwide commercialization. Until a PCV becomes profitable, we may elect to defer payment of our share of the commercialization and related manufacturing costs and instead reimburse Merck for such costs, plus interest, from our share of future profits resulting from sales of such PCV, if any. Subject to customary “back-up” supply rights granted to Merck, we will manufacture (or have manufactured) PCVs for preclinical and clinical purposes. Manufacture of PCVs for commercial purposes will be determined by the parties in accordance with the terms of the PCV Agreement. Under the PCV Agreement, we grant certain licenses to Merck to perform its collaboration activities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If Merck does not exercise its right to participate in future development and commercialization of PCVs, then Moderna will retain the exclusive right to develop and commercialize PCVs developed during the strategic alliance, subject to Merck’s rights to receive a percentage in the high teens to the low 20s, subject to reductions of our net profits on sales of such PCVs. During a limited period following such non-exercise, Merck has the right to perform clinical studies of such PCVs in combination with KEYTRUDA, for which we agree to use reasonable efforts to supply such PCVs. During such limited period, we also have the right to perform clinical studies of PCVs in combination with KEYTRUDA, for which Merck agrees to use reasonable efforts to supply KEYTRUDA. In addition, following its non-exercise, Merck is also entitled to receive a percentage in the high teens to the low 20s, subject to reductions, of our net profits on sales of certain PCVs first developed by us following such non-exercise and reaching a specified development stage within a defined period of time.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and Merck have agreed to certain defined, limited exclusivity obligations with respect to the development and commercialization of PCVs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2018 Expansion of the Cancer Vaccine Strategic Alliance—Shared Neoepitope Cancer Vaccines </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2018, we and Merck agreed to expand our cancer vaccine strategic alliance to include the development and commercialization of our KRAS vaccine development candidate, mRNA-5671, and potentially other shared neoantigen mRNA cancer vaccines (SAVs). We preclinically developed mRNA-5671 prior to its inclusion in the cancer vaccine strategic alliance and it is comprised of a novel mRNA construct designed by us and encapsulated in one of our proprietary LNPs. The PCV Agreement was amended and restated to include the new SAV strategic alliance (PCV/SAV Agreement).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have granted Merck certain licenses and we and Merck have agreed to certain exclusivity obligations with respect to SAVs and particular SAV programs, which obligations are subject to termination or expiration upon certain triggering events.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the PCV/SAV Agreement, Merck will be responsible for conducting Phase 1 and Phase 2 clinical trials for mRNA-5671 and for all costs associated with such activities, in accordance with a jointly agreed development plan and budget, and we will be responsible for manufacturing and supplying all mRNA-5671 required to conduct such trials and for all costs and expenses associated with such manufacture and supply. Under the PCV/SAV Agreement, our budgeted commitment for PCVs increased to </font><font style="font-family:inherit;font-size:10pt;">$243.0 million</font><font style="font-family:inherit;font-size:10pt;">. Until the expiration of a defined period of time following the completion of Phase 1 and Phase 2 clinical trials for mRNA-5671 under the PCV/SAV Agreement and our delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of mRNA-5671 by making a participation payment to us. If Merck exercises its participation rights, then the parties will equally co-fund subsequent clinical development of mRNA-5671, with Merck primarily responsible for conducting clinical development activities under a jointly agreed development plan and budget. If Merck declines to participate in future development and commercialization activities following the initial Phase 1 and Phase 2 clinical trials for mRNA-5671, then we will retain the rights to develop and commercialize mRNA-5671. If Merck elects to participate in future development and commercialization of mRNA-5671, Merck may also conduct additional clinical trials for mRNA-5671 that are not included in the jointly agreed development plan and budget, in which case we will reimburse Merck for half of the total development costs for such clinical trials, plus interest, from our share of future profits resulting from sales of mRNA-5671, if any. If Merck does conduct additional clinical trials for mRNA-5671, we will be responsible for manufacturing and supplying all mRNA-5671 required to conduct such trials. Merck will lead worldwide commercialization of mRNA-5671, subject to our option to co-promote mRNA-5671 in the United States, and the parties will equally share the operating profits or losses arising from worldwide commercialization. Until mRNA-5671 becomes profitable, we may elect to defer payment of our share of the commercialization and related manufacturing costs and instead reimburse Merck for such costs, plus interest, from our share of future profits resulting from sales of mRNA-5671, if any. Subject to “back-up” supply rights granted to Merck, we will manufacture (or have manufactured) mRNA-5671 and other SAVs for preclinical and clinical purposes. After Merck exercises its right to participate in future development and commercialization of mRNA-5671 and other SAVs, we will grant the applicable development and commercialization licenses and the parties are obligated to discuss responsibility for future manufacturing, giving consideration to applicable criteria.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the PCV/SAV Agreement, for a defined period of time, either party may propose that the parties conduct additional programs for the research and development of SAVs directed to different shared neoantigens. If the parties agree to conduct any such programs, then we will be responsible for conducting and funding preclinical discovery and research activities for such SAVs, and otherwise the programs would be conducted on substantially the same terms as mRNA-5671 program. If we or Merck propose a new SAV program and the other party does not agree to conduct such program, then the PCV/SAV Agreement includes provisions allowing the proposing party to proceed with such development, at the proposing party’s expense. If Merck is the proposing party, we will be responsible for manufacturing and supplying material for such program at Merck’s expense. In such case, the non-proposing party will have the right to opt-in to such SAV program any time before the proposing party commits to performing Good Laboratory Practice (GLP)-toxicity studies. Until the expiration of a defined period of time following our completion of Phase 1 and Phase 2 clinical trials for any SAV program mutually agreed by the parties under the PCV/SAV Agreement and our delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of such SAV by making a participation payment to us.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless earlier terminated, the PCV/SAV Agreement will continue on a program-by-program basis until Merck terminates its participation in such program. Following any such termination, we will retain the exclusive right to develop and commercialize PCVs or SAVs developed as a part of such program, subject to restrictions and certain limited rights retained by Merck.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the amendment of the PCV Agreement to include the development and commercialization of mRNA-5671 and potentially other SAVs, Merck made a contemporaneous equity investment in our Series H redeemable convertible preferred stock, resulting in gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$125.0 million</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$13.0 million</font><font style="font-family:inherit;font-size:10pt;"> is determined to be a premium and recorded to deferred revenue.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Treatment</font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We determined that the PCV/SAV Agreement should be accounted for separately from the amended 2015 Merck Agreement, as the agreements were not negotiated in contemplation of one another and the elements within each of the agreements are not closely interrelated or interdependent on each other. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For periods prior to January 1, 2019, we applied the provisions of ASC 605 in accounting for this arrangement. As of the date of our initial application of ASC 606, we applied the practical expedient to include the aggregate effect of all modifications to the arrangement that occurred before January 1, 2019 with respect to: (i) identification of the satisfied and unsatisfied performance obligations, (ii) determination of the transaction price and (iii) allocation of the transaction price to the satisfied and unsatisfied performance obligations. Additionally, we determined that all aspects of the PCV/SAV Agreement represent a transaction with a customer and therefore the PCV/SAV Agreement is accounted for in accordance with ASC 606 as of the date of the initial application. Further, the equity investment in our Series H redeemable convertible preferred stock was considered together with the PCV/SAV Agreement as the transactions were executed contemporaneously in contemplation of one another. Further, the purchase price paid by Merck with respect to the investment in the Series H redeemable convertible preferred stock was not representative of fair value on the date of such purchase. As such, the incremental proceeds received in excess of the fair value of the underlying stock related to the equity investment were included in the transaction price related to the PCV/SAV Agreement and the shares of Series H redeemable convertible preferred stock purchased by Merck were recorded at their respective fair value on the date of issuance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We identified the following performance obligations in the PCV/SAV Agreement: (i) a research license and research and development services, including manufacturing and supply of PCVs, during the proof of concept (POC) term for the PCV program, referred to as the PCV Performance Obligation, and (ii) research license and manufacturing and supply of mRNA-5671 during the POC term for the KRAS program, referred to as the KRAS Performance Obligation. We concluded that the research license is not distinct from the research and development services, including manufacturing and supply of PCVs, during the POC term for the PCV program, as Merck cannot fully exploit the value of the license without receipt of such services and supply. Our services and supply involve specialized expertise, particularly as it relates to mRNA technology that is not available in the marketplace. Therefore, the research license has been combined with the research and development services, including manufacturing and supply of PCVs, during the POC term for the PCV program, into a single performance obligation. Similarly, we concluded that the research license is not distinct from the manufacturing and supply of mRNA-5671 during the POC term for the KRAS program, as Merck cannot fully exploit the value of the license without receipt of such supply which must be provided by us. This is due to limitations inherent in the licenses conveyed wherein Merck does not have the contractual right to manufacture during the POC term. Therefore, the research license has been combined with the manufacturing and supply of mRNA-5671, during the POC term for the KRAS program, into a single performance obligation. Conversely, we concluded that the PCV Performance Obligation and the KRAS Performance Obligation are distinct from each other because Merck can fully exploit the value of each program for its intended purpose without the promises associated with the other program. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) Merck participation election license related to future joint development and commercialization on a program-by-program basis, (ii) manufacturing and supply in support of certain SAV programs and/or the PCV program upon Merck election to not participate in future development and commercialization of that program and (iii) research and development services associated with certain SAV programs. Therefore, such options will be accounted for as a separate contract upon the customer’s election.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of January 1, 2019, the date of initial application of ASC 606, the total transaction price was determined to be </font><font style="font-family:inherit;font-size:10pt;">$213.0 million</font><font style="font-family:inherit;font-size:10pt;"> comprised of the </font><font style="font-family:inherit;font-size:10pt;">$200.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment pertaining to the PCV Agreement and the premium associated with the contemporaneous sale of Series H redeemable convertible preferred stock of </font><font style="font-family:inherit;font-size:10pt;">$13.0 million</font><font style="font-family:inherit;font-size:10pt;">. We determined there are no components of variable consideration that should be included in the transaction price as of the date of initial application, as additional consideration to which we could be entitled is subject to Merck’s election to exercise a customer option that was deemed to be a marketing offer. We will re-evaluate the transaction price at the end of each reporting period. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> changes to the transaction price during the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The transaction price was allocated to the performance obligations based on the relative estimated standalone selling price of each performance obligation. We developed the estimated standalone selling price for the license included in each of the PCV Performance Obligation and the KRAS Performance Obligation primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success and the time needed to commercialize a product candidate pursuant to the associated license. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the PCV Performance Obligation and the KRAS Performance Obligation, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated cost, adjusted for a reasonable profit margin that would be expected to be realized under similar contracts.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The transaction price allocated to each performance obligation was as follows: (i) </font><font style="font-family:inherit;font-size:10pt;">$206.3 million</font><font style="font-family:inherit;font-size:10pt;"> to the PCV Performance Obligation and (ii) </font><font style="font-family:inherit;font-size:10pt;">$6.7 million</font><font style="font-family:inherit;font-size:10pt;"> allocated to the KRAS Performance Obligation. We will recognize revenue related to amounts allocated to the PCV Performance Obligation over time as the underlying services are performed using a proportional performance model. We measure proportional performance using an input method based on the costs incurred relative to the total estimated costs of research and development efforts. We recognize revenue related to the amounts allocated to the KRAS Performance Obligation based on the point in time upon which control of supply is transferred to Merck for each delivery of the associated supply. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, we recognized collaboration revenue of </font><font style="font-family:inherit;font-size:10pt;">$10.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$14.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, in the condensed consolidated statements of operations, from the Merck PCV/SAV Agreement. The revenue recognized during the three months ended March 31, 2019 includes </font><font style="font-family:inherit;font-size:10pt;">$10.2 million</font><font style="font-family:inherit;font-size:10pt;"> related to the amortization of deferred revenue due to the satisfaction of our performance during the period. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the aggregate amount of the transaction price allocated to the remaining performance obligations that are unsatisfied is </font><font style="font-family:inherit;font-size:10pt;">$115.0 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized as revenue through December 31, 2021. We had deferred revenue of </font><font style="font-family:inherit;font-size:10pt;">$115.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$111.3 million</font><font style="font-family:inherit;font-size:10pt;">, as of March 31, 2019 and December 31, 2018, respectively, from the Merck PCV/SAV Agreement, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the services are expected to be performed or control of the supply is expected to be transferred. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Vertex – 2016 Strategic Alliance in Cystic Fibrosis</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2016, we entered into a Strategic Collaboration and License Agreement, with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited, together, Vertex, which we refer to as the Vertex Agreement. The Vertex Agreement is aimed at the discovery and development of potential mRNA medicines for the treatment of cystic fibrosis (CF) by enabling cells in the lungs of people with CF to produce functional CFTR proteins.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Vertex Agreement, we lead discovery efforts during a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year research period, leveraging our Platform technology and mRNA delivery expertise along with Vertex’s scientific experience in CF biology and the functional understanding of CFTR. Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Subject to customary “back-up” supply rights granted to Vertex, we exclusively manufacture (or have manufactured) mRNA for preclinical, clinical and commercialization purposes. The parties established a joint steering committee to oversee and coordinate activities under the Vertex Agreement. We and Vertex have granted each other certain licenses under the Vertex Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Vertex Agreement, we received a </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment from Vertex. Vertex has the right to extend the initial </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year research period by </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> additional year by making an additional payment to us. We are eligible to receive up to </font><font style="font-family:inherit;font-size:10pt;">$55.0 million</font><font style="font-family:inherit;font-size:10pt;"> in payments for achievement of development milestones, up to </font><font style="font-family:inherit;font-size:10pt;">$220.0 million</font><font style="font-family:inherit;font-size:10pt;"> in payments for achievement of regulatory milestones and potentially could receive an additional </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> milestone payment for achievement of a regulatory milestone for second and each subsequent product under the Vertex Agreement. Vertex will also pay us tiered royalties at rates ranging from the low- to high-teens on worldwide net sales of products arising from the strategic alliance, subject to certain reductions, with an aggregate minimum floor. In connection with the strategic alliance, Vertex also made a </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> equity investment in our Series F redeemable convertible preferred stock. During the term of the Vertex Agreement, we and Vertex have agreed to certain defined exclusivity obligations under the Vertex Agreement with respect to the development and commercialization of certain mRNA medicines.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless earlier terminated, the Vertex Agreement will continue until the expiration of all royalty terms. Vertex may terminate the Vertex Agreement for convenience upon </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days’ prior written notice, except if termination relates to a product in a country where Vertex has received marketing approval, which, in such case, Vertex must provide </font><font style="font-family:inherit;font-size:10pt;">180</font><font style="font-family:inherit;font-size:10pt;"> days’ prior written notice. Either party may terminate the Vertex Agreement upon the other party’s material breach, subject to specified notice and cure provisions. Each party may also terminate the Vertex Agreement in the event that the other party challenges the validity or enforceability of such party’s patent rights, subject to certain exceptions, or if the other party becomes insolvent.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Treatment</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For periods prior to January 1, 2019, we applied the provisions of ASC 605 in accounting for this arrangement. As of the date of the initial application of ASC 606, we determined that all aspects of the arrangement with Vertex represent a transaction with a customer and therefore should be accounted for in accordance with ASC 606. We identified one performance obligation comprised of: (i) a research, development and commercialization license and (ii) research and development services, including manufacturing and supply of non-cGMP mRNA, during the initial </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year research period. We concluded that the license is not distinct from the research and development services, including manufacturing and supply of non-cGMP mRNA, during the initial </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year research period, as Vertex cannot fully exploit the value of the license without receipt of such services and supply. Our services and supply involve specialized expertise, particularly as it relates to mRNA technology that is not available in the marketplace. Therefore, the license has been combined with the research and development services, including manufacturing and supply of non-cGMP supply, into a single performance obligation. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) Vertex’s right to extend the research period for an additional year and (ii) clinical mRNA supply and/or non-cGMP mRNA supply beyond the initial </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year research period. Therefore, such options will be accounted for as a separate contract upon the customer’s election.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of January 1, 2019, the date of initial application of ASC 606, the total transaction price was determined to be </font><font style="font-family:inherit;font-size:10pt;">$24.4 million</font><font style="font-family:inherit;font-size:10pt;">, comprised of the </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment and </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;"> in research and development funding related to the research and development services and supply of non-cGMP mRNA. We utilize the most likely amount method to determine the amount of research and development funding to be received. We also utilize the most likely amount method to estimate any development and regulatory milestone payments to be received. As of January 1, 2019, there were no milestones included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or Vertex’s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. We will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> changes to the transaction price during the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The transaction price was allocated entirely to the single performance obligation. We recognize revenue related to amounts allocated to the single performance obligation over time as the underlying services are performed using a proportional performance model. We measure proportional performance using an input method based on the costs incurred relative to the total estimated costs of the research and development efforts. </font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, we recognized collaboration revenue of </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, in the condensed consolidated statements of operations, from Vertex. The revenue recognized during the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> includes </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> related to the amortization of the deferred revenue due to the satisfaction of our performance during the period. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the aggregate amount of the transaction price allocated to the remaining performance obligation that is unsatisfied is </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized as revenue through June 30, 2019. We had deferred revenue of </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;">, as of March 31, 2019 and December 31, 2018, respectively, from Vertex, which is classified as current in the condensed consolidated balance sheets based on the period the services are expected to be performed.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2019, we adopted Accounting Standards Codification (ASC) Topic 606,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> (ASC 606), using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. We recognized the cumulative effect of the adoption as an adjustment to the opening balance of accumulated deficit in the current period condensed consolidated balance sheet. Results for reporting periods beginning after January 1, 2019 are presented under ASC 606, while prior period amounts have not been adjusted and continue to be reported in accordance with our historic accounting under ASC Topic 605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition </font><font style="font-family:inherit;font-size:10pt;">(ASC 605). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our revenue is primarily generated through collaboration arrangements and grants from government-sponsored and private organizations. Our collaboration arrangements typically contain multiple promises, including licenses to our intellectual property, options to obtain development and commercialization rights, research and development services, and obligations to develop and manufacture preclinical and clinical material. Such arrangements provide for various types of payments to us, including upfront payments, funding of research and development activities, funding for the purchase of preclinical and clinical material, development, regulatory and commercial milestone payments, licensing fees, option exercise payments, and royalties based on product sales. We have received grants from various government-sponsored and private organizations for research and related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We analyze our collaboration arrangements to assess whether they are within the scope of ASC Topic 808, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements </font><font style="font-family:inherit;font-size:10pt;">(ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and our collaboration partner are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> If we conclude that some or all aspects of the arrangement are within the scope of ASC 808 and do not represent a transaction with a customer, we recognize our allocation of the shared costs incurred with respect to the jointly conducted activities as a component of the related expense in the period incurred. Pursuant to ASC 606, a customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. If we conclude a counter-party to a transaction is not a customer or otherwise not within the scope of ASC 606 or ASC 808, we consider the guidance in other accounting literature as applicable or by analogy to account for such transaction. We also consider the guidance in ASC 606 with respect to principal versus agent considerations, in determining the appropriate treatment for the transactions between us and the strategic collaborator and the transactions between us and other third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, are accounted for as gross revenue. </font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We receive payments from our customers based on billing schedules established in each contract. Upfront payments and fees are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period when we perform our obligations under the arrangement. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current liabilities on our condensed consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities on our condensed consolidated balance sheets. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. As of </font><font style="font-family:inherit;font-size:10pt;text-align:left;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we had not capitalized any costs to obtain any of our contracts.</font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:1px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration Revenue</font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following steps: (i) identify the contract(s) with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) each performance obligation is satisfied. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for a contract with a customer that is within the scope of ASC 606 when all of the following criteria are met: (i) the arrangement has been approved by the parties and the parties are committed to perform their respective obligations; (ii) each party’s rights regarding the goods and/or services to be transferred can be identified; (iii) the payment terms for the goods and/or services to be transferred can be identified; (iv) the arrangement has commercial substance; and (v) collection of substantially all of the consideration to which we will be entitled in exchange for the goods and/or services that will be transferred to the customer is probable. We also determine the term of the contract based on the period in which we and our customer have present and enforceable rights and obligations for purposes of identifying the performance obligations and determining the transaction price. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:1px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate contracts that contain multiple promises to determine which promises are distinct. Promises are considered to be distinct and therefore, accounted for as separate performance obligations, provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. In assessing whether a promise is distinct, we consider factors such as whether: (i) we provide a significant service of integrating goods and/or services with other goods and/or services promised in the contract; (ii) one or more of the goods and/or services significantly modifies or customizes, or are significantly modified or customized by one or more of the other goods and/or services promised in the contract; and (iii) the goods and/or services are highly interdependent or highly interrelated.</font><font style="font-family:inherit;font-size:11pt;"> </font><font style="font-family:inherit;font-size:10pt;">Individual goods or services (or bundles of goods and/or services) that meet both criteria for being distinct are accounted for as separate performance obligations. Promises that are not distinct at contract inception are combined and accounted for as a single performance obligation. Options to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer’s election.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">The transaction price is generally comprised of an upfront payment due at contract inception and variable consideration in the form of payments for our services and materials and milestone payments due upon the achievement of specified events. Other payments the Company could be entitled to include tiered royalties earned when customers recognize net sales of licensed products. We consider the existence of any significant financing component within our arrangements and have determined that a significant financing component does not exist in our arrangements as substantive business purposes exist to support the payment structure other than to provide a significant benefit of financing. We measure the transaction price based on the amount of consideration we expect to be entitled in exchange for transferring the promised goods and/or services to the customer. We utilize either the expected value method or the most likely amount method to estimate the amount of variable consideration, depending on which method is expected to better predict the amount of consideration to which we will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.</font><font style="font-family:inherit;font-size:11pt;"> </font><font style="font-family:inherit;font-size:10pt;">With respect to arrangements that include payments for a development or regulatory milestone payment, we evaluate whether the associated event is considered probable of achievement and estimate the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within our control or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, we re-evaluate the probability of achievement of each milestone and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, wherein the license is deemed to be the sole or predominant item to which the payments relate, we recognize revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception. </font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generally allocate the transaction price to each performance obligation based on a relative standalone selling price basis. We develop assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated research and development costs. However, in certain instances, we allocate variable consideration entirely to one or more performance obligation if the terms of the variable consideration relate to the satisfaction of the respective performance obligation and the amount allocated is consistent with the amount we would expect to receive for the satisfaction of the respective performance obligation.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. For performance obligations that are satisfied at a point in time, we recognize revenue when control of the goods and/or services is transferred to the customer. For performance obligations that are satisfied over time, we recognize revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. We generally use input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. With respect to arrangements containing a license to our intellectual property that is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from amounts allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which we are expected to complete our performance obligations under an arrangement. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Grant Revenue</font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have contracts with the U.S. government’s Defense Advanced Research Projects Agency (DARPA), Biomedical Advanced Research (BARDA), and the Bill & Melinda Gates Foundation (Gates Foundation). We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Revenues and related expenses are presented gross in the condensed consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities, as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> consists of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.88888888888889%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-licenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,756</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,089</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation-related</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">External goods and services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,578</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,183</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,073</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">The components of accumulated other comprehensive loss for </font><font style="font-family:inherit;font-size:10pt;">the three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Gain on Available-for-Sale Debt Securities</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss, balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,911</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss, balance at March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">591</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following common stock equivalents, presented based on amounts outstanding as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and 2018 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260,817,303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,271,281</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,135,998</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">729,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted common stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,011,483</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">458,715</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,433,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">305,141,893</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502,934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,479</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash, non-current </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash shown in the condensed consolidated</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    statements of cash flows</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">514,757</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,514</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarize our cash and available-for-sale securities by significant investment category at </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash and</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502,935</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502,934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502,934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,114</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,185</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,483</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,702</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,347</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,475</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government agencies and corporate entities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">839,055</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,129</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(218</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">839,966</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">446,032</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">393,934</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,545,451</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,356</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(224</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,546,583</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502,934</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">605,990</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">437,659</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash and</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Current</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Marketable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">658,365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">658,364</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">658,364</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Available-for-sale:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,102</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,920</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,188</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt securities of U.S. government agencies and corporate entities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">712,065</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,335</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">710,770</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552,968</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,802</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,695,737</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,440</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,694,417</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">658,364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">863,063</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,990</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share attributable to common stockholders for </font><font style="font-family:inherit;font-size:10pt;">the three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> are calculated as follows (in thousands, except share and per share data):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(132,657</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(72,376</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumulative dividends on redeemable convertible preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(132,657</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(75,857</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328,809,986</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,430,835</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share attributable to common stockholders, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.16</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the components and classification of stock-based compensation expense for </font><font style="font-family:inherit;font-size:10pt;">the three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended<br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted common stock and units</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,010</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,803</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,497</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,851</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,783</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,356</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,714</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,497</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,851</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum lease payments under non-cancelable operating lease agreements at </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Minimum Lease Payments</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(remainder of the year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,874</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,455</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,384</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">246,506</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effect of the adoption of ASC 606 on our condensed consolidated balance sheet is as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated Balance Sheet</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, non-current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,441</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,911</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,948</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,006,627</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,984</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(978,643</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarize the effects of adopting ASC 606 on our condensed consolidated financial statements at March 31, 2019, and for the three months ended March 31, 2019 (in thousands, except per share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated Balance Sheet</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported under ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance without adoption of ASC 606</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,452</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, non-current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,862</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,840</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,022</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,111,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,117,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated Statement of Operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported under ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount without adoption of ASC 606</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Collaboration revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,301</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,786</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,515</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Collaboration revenue from related party</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">814</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,025</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,907</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,932</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(141,833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,907</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(119,926</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before benefit from income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(132,681</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,907</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,774</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net (loss) income </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(132,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,907</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share - basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.40</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our total consolidated net revenues from our strategic collaborators for the periods presented (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Collaboration Revenue by Strategic Collaborator:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019 </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">as reported </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(under ASU 606)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019 </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">without adoption of 606</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(under ASC 605)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2018 </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">as reported </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(under ASC 605)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Merck</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AstraZeneca</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">814</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,191</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vertex</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,614</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total collaborative revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,115</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,706</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our restricted stock unit activity during </font><font style="font-family:inherit;font-size:10pt;">the three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-Average<br clear="none"/>Grant Date</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">per Unit</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, non-vested at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">458,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">558,208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canceled/forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,440</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.93</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pending settlement </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, non-vested at March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,011,483</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_________</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></font><font style="font-family:inherit;font-size:10pt;">The vested restricted stock units will be settled for common stock on the date which is </font><font style="font-family:inherit;font-size:10pt;">360 days</font><font style="font-family:inherit;font-size:10pt;"> after the consummation of the IPO. </font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502,934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,479</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash, non-current </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash shown in the condensed consolidated</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    statements of cash flows</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">514,757</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,514</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average assumptions used to estimate the fair value of the options granted for </font><font style="font-family:inherit;font-size:10pt;">the three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:74%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.12 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.06 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividends</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value per share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our option activity as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price per</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Date Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value per</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font><font style="font-family:inherit;font-size:7pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> (1)</sup></font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,821,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.1 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,443,286</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.59</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:38px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canceled/forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,987,612</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at March 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,271,281</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,769,502</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.54</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.05</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.7 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292,602</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at March 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,501,493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_______</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;">Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Basis of Presentation and Recent Accounting Standards</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in conformity with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2018 (2018 Form 10-K), except for changes associated with recent accounting standards for revenue recognition as detailed in "Note 2 - Recent Accounting Standards and Accounting Policies." This report should be read in conjunction with the consolidated financial statements in our 2018 Form 10-K.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, income tax provisions, stock-based compensation, and useful lives of long-lived assets. We base our estimates on historical experience and on various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results that we experience may differ materially from our estimates. The condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, but are not necessarily indicative of the results of operations to be anticipated for the full year ending December 31, 2019. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Standards and Accounting Policies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2019, we adopted Accounting Standards Codification (ASC) Topic 606,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> (ASC 606), using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. We recognized the cumulative effect of the adoption as an adjustment to the opening balance of accumulated deficit in the current period condensed consolidated balance sheet. Results for reporting periods beginning after January 1, 2019 are presented under ASC 606, while prior period amounts have not been adjusted and continue to be reported in accordance with our historic accounting under ASC Topic 605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition </font><font style="font-family:inherit;font-size:10pt;">(ASC 605). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our revenue is primarily generated through collaboration arrangements and grants from government-sponsored and private organizations. Our collaboration arrangements typically contain multiple promises, including licenses to our intellectual property, options to obtain development and commercialization rights, research and development services, and obligations to develop and manufacture preclinical and clinical material. Such arrangements provide for various types of payments to us, including upfront payments, funding of research and development activities, funding for the purchase of preclinical and clinical material, development, regulatory and commercial milestone payments, licensing fees, option exercise payments, and royalties based on product sales. We have received grants from various government-sponsored and private organizations for research and related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We analyze our collaboration arrangements to assess whether they are within the scope of ASC Topic 808, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements </font><font style="font-family:inherit;font-size:10pt;">(ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and our collaboration partner are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> If we conclude that some or all aspects of the arrangement are within the scope of ASC 808 and do not represent a transaction with a customer, we recognize our allocation of the shared costs incurred with respect to the jointly conducted activities as a component of the related expense in the period incurred. Pursuant to ASC 606, a customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. If we conclude a counter-party to a transaction is not a customer or otherwise not within the scope of ASC 606 or ASC 808, we consider the guidance in other accounting literature as applicable or by analogy to account for such transaction. We also consider the guidance in ASC 606 with respect to principal versus agent considerations, in determining the appropriate treatment for the transactions between us and the strategic collaborator and the transactions between us and other third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, are accounted for as gross revenue. </font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We receive payments from our customers based on billing schedules established in each contract. Upfront payments and fees are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period when we perform our obligations under the arrangement. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current liabilities on our condensed consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities on our condensed consolidated balance sheets. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. As of </font><font style="font-family:inherit;font-size:10pt;text-align:left;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we had not capitalized any costs to obtain any of our contracts.</font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:1px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration Revenue</font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following steps: (i) identify the contract(s) with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) each performance obligation is satisfied. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for a contract with a customer that is within the scope of ASC 606 when all of the following criteria are met: (i) the arrangement has been approved by the parties and the parties are committed to perform their respective obligations; (ii) each party’s rights regarding the goods and/or services to be transferred can be identified; (iii) the payment terms for the goods and/or services to be transferred can be identified; (iv) the arrangement has commercial substance; and (v) collection of substantially all of the consideration to which we will be entitled in exchange for the goods and/or services that will be transferred to the customer is probable. We also determine the term of the contract based on the period in which we and our customer have present and enforceable rights and obligations for purposes of identifying the performance obligations and determining the transaction price. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:1px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate contracts that contain multiple promises to determine which promises are distinct. Promises are considered to be distinct and therefore, accounted for as separate performance obligations, provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. In assessing whether a promise is distinct, we consider factors such as whether: (i) we provide a significant service of integrating goods and/or services with other goods and/or services promised in the contract; (ii) one or more of the goods and/or services significantly modifies or customizes, or are significantly modified or customized by one or more of the other goods and/or services promised in the contract; and (iii) the goods and/or services are highly interdependent or highly interrelated.</font><font style="font-family:inherit;font-size:11pt;"> </font><font style="font-family:inherit;font-size:10pt;">Individual goods or services (or bundles of goods and/or services) that meet both criteria for being distinct are accounted for as separate performance obligations. Promises that are not distinct at contract inception are combined and accounted for as a single performance obligation. Options to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer’s election.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">The transaction price is generally comprised of an upfront payment due at contract inception and variable consideration in the form of payments for our services and materials and milestone payments due upon the achievement of specified events. Other payments the Company could be entitled to include tiered royalties earned when customers recognize net sales of licensed products. We consider the existence of any significant financing component within our arrangements and have determined that a significant financing component does not exist in our arrangements as substantive business purposes exist to support the payment structure other than to provide a significant benefit of financing. We measure the transaction price based on the amount of consideration we expect to be entitled in exchange for transferring the promised goods and/or services to the customer. We utilize either the expected value method or the most likely amount method to estimate the amount of variable consideration, depending on which method is expected to better predict the amount of consideration to which we will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.</font><font style="font-family:inherit;font-size:11pt;"> </font><font style="font-family:inherit;font-size:10pt;">With respect to arrangements that include payments for a development or regulatory milestone payment, we evaluate whether the associated event is considered probable of achievement and estimate the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within our control or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, we re-evaluate the probability of achievement of each milestone and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, wherein the license is deemed to be the sole or predominant item to which the payments relate, we recognize revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception. </font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generally allocate the transaction price to each performance obligation based on a relative standalone selling price basis. We develop assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated research and development costs. However, in certain instances, we allocate variable consideration entirely to one or more performance obligation if the terms of the variable consideration relate to the satisfaction of the respective performance obligation and the amount allocated is consistent with the amount we would expect to receive for the satisfaction of the respective performance obligation.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. For performance obligations that are satisfied at a point in time, we recognize revenue when control of the goods and/or services is transferred to the customer. For performance obligations that are satisfied over time, we recognize revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. We generally use input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. With respect to arrangements containing a license to our intellectual property that is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from amounts allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which we are expected to complete our performance obligations under an arrangement. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:1px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Grant Revenue</font></div><div style="line-height:120%;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have contracts with the U.S. government’s Defense Advanced Research Projects Agency (DARPA), Biomedical Advanced Research (BARDA), and the Bill & Melinda Gates Foundation (Gates Foundation). We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Revenues and related expenses are presented gross in the condensed consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Loss</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss includes net loss and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments. Total comprehensive loss for all periods presented has been disclosed in the condensed consolidated statements of comprehensive loss.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">The components of accumulated other comprehensive loss for </font><font style="font-family:inherit;font-size:10pt;">the three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Gain on Available-for-Sale Debt Securities</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss, balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,911</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss, balance at March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">591</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Emerging Growth Company Status</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are an “emerging growth company,” (EGC) as defined in the Jumpstart Our Business Startups Act, (JOBS Act), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. We may take advantage of these exemptions until we are no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. We have elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, our condensed consolidated financial statements may not be comparable to companies that comply with public company FASB standards’ effective dates. We may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of our initial public offering (IPO) or such earlier time that we are no longer an EGC.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Standards</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASU No. 2014-09, Revenue from Contracts with Customers</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">, which supersedes all existing revenue recognition requirements in ASC 605 and most industry specific guidance. ASC 606 provides a single comprehensive model for use in accounting for revenue arising from contracts with customers. We adopted the new revenue standard on January 1, 2019 using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. We recognized the cumulative effect of the adoption as an adjustment to the opening balance of accumulated deficit in the first quarter of 2019. We have elected to use the practical expedient to aggregate the impact of all contract modifications that occurred prior to the ASC 606 adoption with respect to (i) identification of the satisfied and unsatisfied performance obligations, (ii) determination of the transaction price and (iii) allocation of the transaction price to the satisfied and unsatisfied performance obligations. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASC 606 requires significant judgment and estimates and results in changes to, but not limited to: (i) the determination of the transaction price, including estimates of variable consideration, (ii) the allocation of the transaction price, including the determination of estimated selling price, and (iii) the pattern of recognition, including the application of proportional performance as a measure of progress on service-related promises and application of point-in-time recognition for supply-related promises. We recorded the cumulative-effect adjustment of </font><font style="font-family:inherit;font-size:10pt;">$28.0 million</font><font style="font-family:inherit;font-size:10pt;"> to the opening balance of accumulated deficit as of January 1, 2019 with a corresponding decrease to deferred revenue. The effect of the adoption of ASC 606 on our condensed consolidated balance sheet is as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated Balance Sheet</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, non-current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,441</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,911</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,948</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,006,627</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,984</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(978,643</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The cumulative-effect adjustment is primarily due to the application of ASC 606 to our strategic collaboration agreements, particularly our Combined 2018 AZ Agreements, 2016 VEGF Exercise and Merck PCV/SAV Agreement (see Note 3). In addition, as a result of the cumulative decrease in deferred revenue, our corresponding deferred tax asset was decreased by </font><font style="font-family:inherit;font-size:10pt;">$8.4 million</font><font style="font-family:inherit;font-size:10pt;">, which was offset by a corresponding decrease to our valuation allowance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A substantial portion of the </font><font style="font-family:inherit;font-size:10pt;">$28.0 million</font><font style="font-family:inherit;font-size:10pt;"> cumulative-effect adjustment is the result of the application of ASC 606 regarding the allocation of the transaction price and the measurement of progress in satisfying performance obligations. In particular, for the Combined 2018 AZ Agreements, the adoption of ASC 606 resulted in the decrease of previously deferred revenue of </font><font style="font-family:inherit;font-size:10pt;">$39.9 million</font><font style="font-family:inherit;font-size:10pt;">. For the Merck PCV/SAV Agreement, the adoption of ASC 606 resulted in a reversal of previously recognized revenue and an increase in deferred revenue of </font><font style="font-family:inherit;font-size:10pt;">$13.9 million</font><font style="font-family:inherit;font-size:10pt;">. These adjustments are due to the change in the way we allocate the transaction price to each performance obligation and measure our performance under each agreement from a straight-line method to a proportional performance model. In addition, the adoption of ASC 606 resulted in the decrease of </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;"> of previously deferred revenue relating to the 2016 VEGF Exercise. Under ASC 605, the product option fee and the clinical milestone payment we received pursuant to the VEGF Exercise were deferred until the consideration pertaining to the clinical supply of mRNA can be reasonably estimated. Under ASC 606, we are required to estimate the total variable consideration to determine the total consideration and recognize the revenue as clinical supply is shipped to the customer based on the proportionate amount of the transaction price. As a result, the balance of remaining deferred revenues at January 1, 2019 was </font><font style="font-family:inherit;font-size:10pt;">$75.7 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$37.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$125.2 million</font><font style="font-family:inherit;font-size:10pt;"> related to the Combined 2018 AZ Agreements, 2016 VEGF Exercise and the Merck PCV/SAV Agreement, respectively.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarize the effects of adopting ASC 606 on our condensed consolidated financial statements at March 31, 2019, and for the three months ended March 31, 2019 (in thousands, except per share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated Balance Sheet</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported under ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance without adoption of ASC 606</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,452</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, non-current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,862</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,840</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,022</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,111,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,117,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Condensed Consolidated Statement of Operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported under ASC 606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount without adoption of ASC 606</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Collaboration revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,301</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,786</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,515</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Collaboration revenue from related party</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">814</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,025</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,907</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,932</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(141,833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,907</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(119,926</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before benefit from income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(132,681</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,907</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,774</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net (loss) income </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(132,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,907</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share - basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.40</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASU No. 2016-18, Statement of Cash Flows: Restricted Cash</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Statement of Cash Flows (Topic 230):</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:inherit;font-size:10pt;">, which requires the statement of cash flows to explain the change during the period in the total of cash, cash equivalents and restricted cash. When cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new standard requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet. This reconciliation can be presented either on the face of the statement of cash flows or in the notes to the financial statements. The new standard became effective for us on January 1, 2019. As a result of adopting this new standard using a retrospective transition method for each period presented, we include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed statements of cash flows. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502,934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,479</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash, non-current </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash shown in the condensed consolidated</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    statements of cash flows</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">514,757</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,514</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting,</font><font style="font-family:inherit;font-size:10pt;"> which is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance generally consistent with the accounting for employee share-based compensation. The new standard will be effective for us on January 1, 2020, with early adoption permitted. We early adopted this standard in the first quarter of 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and disclosure. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASU No. 2018-18, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU 2018-18,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Collaborative Arrangements (Topic 808)</font><font style="font-family:inherit;font-size:10pt;">: </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Clarifying the Interaction between Topic 808 and Topic 606, </font><font style="font-family:inherit;font-size:10pt;">which clarifies the interaction between Topic 808 and Topic 606, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">. Currently, Topic 808 does not provide comprehensive recognition or measurement guidance for collaborative arrangements, and the accounting for those arrangements is often based on an analogy to other accounting literature or an accounting policy election. Similarly, aspects of Topic 606 have resulted in diversity in practice on the effect of the revenue standard on the accounting for collaborative arrangements. The standard will become effective for us beginning on January 1, 2021, with early adoption permitted. We early adopted this standard in connection with the adoption of ASC 606 in the first quarter of 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and disclosure. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Standards</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our condensed consolidated financial statements and disclosures.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Leases</font><font style="font-family:inherit;font-size:10pt;"> (Topic 842), which supersedes all existing lease guidance. This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. The new standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments. Lessees are required to classify leases as either finance or operating leases. If the lease is effectively a financed-purchase by the lessee, it is classified as a financing lease, otherwise it is classified as an operating lease. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. ASC 842 provides accounting guidance for transactions that meet specific criteria for a leaseback transaction. If the criteria are not met, the transaction is considered a “failed sale” and the transaction must be accounted for as a financing arrangement. The new standard will be effective for us on January 1, 2020, assuming we continue to qualify as an EGC.. Upon adoption, the new standard, as amended, allows lessees to apply the transition requirements either (1) retrospectively to each prior reporting period presented in the financial statements with the cumulative effect of applying the new rules recognized at the beginning of the earliest comparative period presented, or (2) retrospectively at the beginning of the period of adoption with the cumulative effect of applying the new rules recognized then. We are currently evaluating the potential impact ASU 2016-02 may have on our financial position and results of operations. Our assessment will include, but is not limited to, evaluating the impact this standard has on the lease of our corporate headquarters at 200 Technology Square in Cambridge, MA, the lease of our office and laboratory space at 500 Technology Square, Cambridge, MA and our manufacturing and additional facilities in Norwood, MA, (see Note 7), and the identification of any embedded leases. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Measurement of Credit Losses on Financial Instruments</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2016-13). ASU 2016-13 will change how companies account for credit losses for most financial assets and certain other instruments. For trade receivables, loans and held-to-maturity debt securities, companies will be required to recognize an allowance for credit losses rather than reducing the carrying value of the asset. Assuming we continue to qualify as an EGC, ASU 2016-13 will be effective for us for fiscal years beginning after December 15, 2020, , including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 will have on the Company’s financial position and results of operations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles—Goodwill and Other—Internal-Use Software (Topic 350): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.</font><font style="font-family:inherit;font-size:10pt;"> This standard requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This standard should be applied either retrospectively or prospectively, and will be effective for us in January 2021, assuming we continue to qualify as an EGC, with early adoption permitted. We are currently evaluating the potential impact this standard may have on our condensed consolidated financial statements and results of operations upon adoption.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders' Equity</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 28, 2018 and May 7, 2018, the Board of Directors approved an amendment to our Certificate of Incorporation resulting in a total of </font><font style="font-family:inherit;font-size:10pt;">775,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and a total of </font><font style="font-family:inherit;font-size:10pt;">509,352,795</font><font style="font-family:inherit;font-size:10pt;"> shares of redeemable convertible preferred stock being authorized, respectively. Upon completion of our IPO, our authorized capital stock consists of </font><font style="font-family:inherit;font-size:10pt;">1,600,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.0001</font><font style="font-family:inherit;font-size:10pt;"> per share, and </font><font style="font-family:inherit;font-size:10pt;">162,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of preferred stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.0001</font><font style="font-family:inherit;font-size:10pt;"> per share, all of which shares of preferred stock are undesignated.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 11, 2018, we completed our IPO, whereby we sold </font><font style="font-family:inherit;font-size:10pt;">26,275,993</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$23.00</font><font style="font-family:inherit;font-size:10pt;"> per share. The aggregate net proceeds received by us from the IPO were </font><font style="font-family:inherit;font-size:10pt;">$563.0 million</font><font style="font-family:inherit;font-size:10pt;">, net of underwriting discounts and commissions of </font><font style="font-family:inherit;font-size:10pt;">$33.2 million</font><font style="font-family:inherit;font-size:10pt;"> and offering expenses of </font><font style="font-family:inherit;font-size:10pt;">$8.1 million</font><font style="font-family:inherit;font-size:10pt;"> payable by us. Upon the closing of the IPO, all of the outstanding shares of our redeemable convertible preferred stock were converted into </font><font style="font-family:inherit;font-size:10pt;">236,012,913</font><font style="font-family:inherit;font-size:10pt;"> shares of the common stock.</font></div></div>

EX-101.SCH 7 mrna-20190331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2106100 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - Collaboration Agreements - Merck – Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Collaboration Agreements - Remaining Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Collaboration Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 2403408 - Disclosure - Collaboration Agreements - Timing of Satisfaction (Details) link:presentationLink link:calculationLink link:definitionLink 2403407 - Disclosure - Collaboration Agreements - Vertex – 2016 Strategic Alliance in Cystic Fibrosis (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments Under Non-Cancelable Operating Lease Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Commitments and Contingencies - Lease Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Commitments and Contingencies - Strategic Collaborations (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 1003001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 1004001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Description of the Business link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Grants link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Grants (Details) link:presentationLink link:calculationLink link:definitionLink 2134100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2434401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2137100 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 2437402 - Disclosure - Net Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 2437403 - Disclosure - Net Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2337301 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2128100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2428402 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2428403 - Disclosure - Stock-Based Compensation - Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2428405 - Disclosure - Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2428406 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2328301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2428404 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Effect of Adoption of ASC 606 on Condensed Consolidated Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Policies) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 mrna-20190331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 mrna-20190331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 mrna-20190331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Statement of Comprehensive Income [Abstract] Unrealized gain (loss) on available-for-sale debt securities, tax Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Commitments and Contingencies Disclosure [Abstract] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Cambridge, MA Cambridge, Massachusetts [Member] Cambridge, Massachusetts [Member] Norwood, MA Norwood, Massachusetts [Member] Norwood, Massachusetts Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Number of campuses Property Subject to or Available for Operating Lease, Number of Units Area of office space (in sqft) Area of Real Estate Property Rent expense Operating Leases, Rent Expense, Net Number of extension terms Lessee, Operating Lease, Number Of Extension Periods Lessee, Operating Lease, Number Of Extension Periods Extension period Lessee, Operating Lease, Renewal Term Equity [Abstract] Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Research and Development [Abstract] Contract Assets: Change In Contract with Customer, Asset [Roll Forward] Change In Contract with Customer, Asset [Roll Forward] Beginning balance Contract with Customer, Asset, Net Additions Contract With Customer, Asset, Increase During Period Contract With Customer, Asset, Increase During Period Deductions Contract With Customer, Asset, Decrease During Period Contract With Customer, Asset, Decrease During Period Ending balance Contract Liabilities: Change In Contract with Customer, Liability [Roll Forward] Change In Contract with Customer, Liability [Roll Forward] Beginning balance Contract with Customer, Liability Additions Contract With Customer, Liability, Increase During Period Contract With Customer, Liability, Increase During Period Deductions Contract With Customer, Liability, Decrease During Period Contract With Customer, Liability, Decrease During Period Ending balance Amounts included in contract liabiliies at the beginning of the period Contract with Customer, Liability, Revenue Recognized Earnings Per Share [Abstract] Net Loss per Share Earnings Per Share [Text Block] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] PCV Agreement Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp And Dohme Corp [Member] Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp And Dohme Corp [Member] Project [Axis] Project [Axis] Project [Domain] Project [Domain] PCV products Personalized MRNA Cancer Vaccines Products [Member] Personalized MRNA Cancer Vaccines Products [Member] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Budgeted amount Research And Development Arrangement, Contract To Perform For Others, Maximum Amount Research And Development Arrangement, Contract To Perform For Others, Maximum Amount Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Options Employee Stock Option [Member] Restricted common stock and units Restricted Stock And Restricted Stock Units (RSU) [Member] Restricted Stock And Restricted Stock Units (RSUs) [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research and development Research and Development Expense [Member] General and administrative General and Administrative Expense [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Stock-based compensation expense Allocated Share-based Compensation Expense Net loss Net Income (Loss) Attributable to Parent Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Unrealized gain (loss) on available-for-sale debt securities, net of tax, $540 and $0 Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Less: Amounts recognized for net realized loss included in net loss Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Total other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Accounting Policies [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Restricted cash Restricted Cash, Current Restricted cash, non-current Restricted Cash, Noncurrent Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Summary of Basis of Presentation and Recent Accounting Standards Significant Accounting Policies [Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Redeemable Convertible Preferred Stock Preferred Stock [Member] Common Stock Common Stock [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance at beginning of period (in shares) Shares, Outstanding Balance at beginning of period Stockholders' Equity Attributable to Parent Transition adjustment from adoption of ASU Topic 606 (Note 2) Cumulative Effect of New Accounting Principle in Period of Adoption Vesting of restricted common stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Vesting of restricted common stock Stock Issued During Period, Value, Restricted Stock Award, Gross Issuance of Series G redeemable convertible preferred stock, net of issuance costs of $10,517 (in shares) Stock Issued During Period, Shares, New Issues Issuance of Series G redeemable convertible preferred stock, net of issuance costs of $10,517 Stock Issued During Period, Value, New Issues Exercise of options to purchase common stock, net (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise of options to purchase common stock, net Stock Issued During Period, Value, Stock Options Exercised Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Unrealized gain (loss) on marketable securities Balance at end of period (in shares) Balance at end of period Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Prepaid Expenses and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Combined 2018 AZ Agreements Combined 2018 AZ Agreements [Member] Combined 2018 AZ Agreements [Member] 2016 VEGF Exercise VEGF Exercise 2016 [Member] VEGF Exercise 2016 [Member] PCV/SAV Agreement PCV/SAV Agreement [Member] PCV/SAV Agreement [Member] Vertex Agreement Strategic Collaboration And License Agreement, With Vertex Pharmaceuticals Incorporated, And Vertex Pharmaceuticals (Europe) Limited [Member] Strategic Collaboration And License Agreement, With Vertex Pharmaceuticals Incorporated, And Vertex Pharmaceuticals (Europe) Limited [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Transaction price Revenue, Remaining Performance Obligation, Amount Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Small Business Entity Small Business Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Summary of Total Consolidated Net Revenues from Strategic Collaborators Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Changes in Balances of Receivables and Contract Liabilities Contract with Customer, Asset and Liability [Table Text Block] In-licenses Accrued In-Licenses, Current Accrued In-Licenses, Current Property and equipment Accrued Property And Equipment, Current Accrued Property And Equipment, Current Compensation-related Employee-related Liabilities, Current External goods and services Accrued External Goods And Services, Current Accrued External Goods And Services, Current Accrued liabilities Accrued Liabilities, Current Investments, Debt and Equity Securities [Abstract] Amortized Cost Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract] Due in one year or less Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost Due after one year through five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Estimated Fair Value Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract] Due in one year or less Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value Due after one year through five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value Total Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value Minimum Lease Payments Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] 2019 (remainder of the year) Operating Leases, Future Minimum Payments, Remainder of Fiscal Year 2020 Operating Leases, Future Minimum Payments, Due in Two Years 2021 Operating Leases, Future Minimum Payments, Due in Three Years 2022 Operating Leases, Future Minimum Payments, Due in Four Years 2023 Operating Leases, Future Minimum Payments, Due in Five Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total Operating Leases, Future Minimum Payments Due Description of the Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Prepaid expenses Prepaid Expense, Current Tenant incentives receivables Tenant Incentives Receivables, Current Tenant Incentives Receivables, Current Interest receivable on marketable securities Interest Receivable, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Statement of Financial Position [Abstract] Preferred stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Future Minimum Lease Payments Under Non-Cancelable Operating Lease Agreements Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Collaboration Revenue by Strategic Collaborator Collaboration Arrangement, Including Arrangements With Affiliate [Member] [Member] Collaboration Arrangement, Including Arrangements With Affiliate [Member] [Member] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Balance without adoption of ASC 606 Calculated under Revenue Guidance in Effect before Topic 606 [Member] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] Merck Merck [Member] Merck [Member] AstraZeneca AstraZeneca [Member] AstraZeneca [Member] Vertex Vertex [Member] Vertex [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Total collaborative revenue Revenue from Contract with Customer, Excluding Assessed Tax Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Restricted Common Stock Restricted Stock [Member] Restricted Common Stock Units Restricted Stock Units (RSUs) [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Shares/Units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Outstanding, non-vested at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Issued (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Canceled, forfeited and adjustments, net (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Pending settlement (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Settled In Period Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Settled In Period Outstanding, non-vested at end of period (in shares) Weighted-Average Grant Date per Share/Unit Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Outstanding, non-vested at beginning of period (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Issued (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Canceled, forfeited and adjustments, net (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Pending settlement (usd per share) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Settled In Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Settled In Period, Weighted Average Grant Date Fair Value Outstanding, non-vested at end of period (usd per share) Settlement period after consummation of IPO Share-Based Compensation Arrangement By Share-Based Payment Award, Vested Awards, Settlement Period Share-Based Compensation Arrangement By Share-Based Payment Award, Vested Awards, Settlement Period Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Cash and cash equivalents Cash and Cash Equivalents [Member] Certificates of deposit Certificates of Deposit [Member] U.S. treasury securities US Treasury Securities [Member] EX-101.PRE 11 mrna-20190331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 a190418gsd1acellimage.jpg begin 644 a190418gsd1acellimage.jpg M_]C_X 02D9)1@ ! 0$ W #< #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" )0!9<# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#[EY]:*![4 M5T#84444""BBB@ HHHH *,TFXYZ<4I.* "@,#T.:*3E"H$Z4I&>^* Y[=:1<]Z6D7=N.['X4 '.[IQZ MTM!SVHH %.1G&*-PSC/--5BW!4CZXHD=8UR>!GTH '56Y8 @<\TJLK+\IR.G M%'$B\C(/."*19%W;0PSZ"@ 2%8V) Y/?K22QF0 ;BGTZTX\XY MH$*.,5&LU&H!'"D3%@""W7 M))HFC,J@;V3G.5X/TZ4W[*OG>82Q(Z DX_*I&7<",X[9'6J =MW]]F<4 (DQ>4J(W '\9 Q^'/\ M2BXNEM5RX8D\!5!)J,W+_:/+6WGSJ0#3#):6<@7]W$[<850"?TH EEMX MYG1W&2AR,DX^N*?YC^88]F?E"@Y_$Y_E3XXS'& 7:0]2S=?Y5"JW+718NBP# MHH!)/U- %@@]AFAOE!)Z#FF3R21QEHXC*_90P'ZYI8F=HP70(Y'*@YQ[9[T M0VMX;IG @DC0=&<8!^@I]U=16:[Y#C/ VJ23[4BW1:Z,0AEP.3(5POX'_"IG M*QJ68X4#))Z4 16\RWL)8(X0\8D7!_+TIGVFUM9! &CC<](U&#^5.M;Y+S?Y M88A3C>5(!^AI9I(;=@\A1"QP"<9/M0 VZL(+MD::,.5Z9SC\JEAFC?*HZG;P M0I!Q1-&MQ&4<91NHR:9;PPVZE(51!GD+C]?>@"38#('YSTZG'Y4RZCEEC"Q2 M^2%H$*M*\QSG<^,_3ITJM>0WLUPGD3I# /O?+ECZ]J +=P[K M$6BC\U^R[@/UIT>_8-X ?'(!R/PIW3O1Q0!"L^ZX,0CD&T9\PKA?H#Z_A27= MQ'9IYDIP.@PN3SV IEQ<2PR1I';--NZL& ^O-6* $AD$T*N 0&&<,,$?45' M!'!&SK"D:'^(( #^-+%.)6=0K#8<$LI /T]OIQ4$UQ9Z6VZ0QP&5L\+@L<\D M\>_ZT +=Z7!>R*TZLX7HI8[?KC/6K.W]V45M@Q@;<9'':H[BWBO8?+D&^-N< M9(!_7I2VRPHOE0[0B<;5(X_"@!EC8_85<&:67-J MB?9K1KMF.#A@ /K5BW:62%&F01R$99%.0/;-+-(T<+LD;2N.B*0">?4G'YFF MVTDLL.Z>+R'S]S<&_,^M ]2*'4!->/;K#-\G!E*83CL#G^0I]W=6]FHFN&6, M= Y'/T%1W%\8;A(4MYIR>K(H"K]23_*K?O0&HGR3P_WHW7N.H(]/I56WN+&W MD%K#)"CYP(D(!]^/6BSU&'4&F2,2$1G!9E(4_0TD-I8:;-^[2&"63@= QSVH M#4L-:HUP)B#O48')Q^6?Z4MQ&\T+I'*87/&]0"1]*BOK"'4(1'.I>/.=NX@? MCS3K6.&")88 H2/@*IZ@J2\ANIGB\BY6! M 5945MI9>1GTS M4OF+YFS<-_7;D9^N* *MQI<=Q>1W#R3908$:R$+USDCUJU(NY2H8J2,!AC(] MQ27%NEQ&4D!*'J Q']12JHC4*HP%& /I0!%9V[6L(C>>2X.S2*2!Z\9]* '7#21PNT4?FR 9 M5-P&?;-,LVN)( US&D4I/*HQ;'ISCK4L898U#D%\88J, G') ],^]9UC<:I- MJ$@N;6&WLP"%(?01/*5_@C&6/..!3X6,D2,4,9(R5;&1['WH I:=K$>I2 M.(8;@(HSYLD953],_P"%/N[^RT^0/<2PPNPP"Y ;'^%1QZU#->&VCAN)'5MK M.L1"#'7)/:GWL6GV[B\ND@1UX\Z11GVP?6@ NM/MM8AB:4-)'C; _F1G@-@@'Z<4RSL;73]R6\4<)<[C MM !;W/KU_6@"*32O-U)+MKJX&T<0!\1^F<8_F:O2*6C(#%21C^,GGO@?TJ.7[2;A0@B$'\3- MDM] /_KTMG#<0J_VBX%P2V5(C" #TQG^=1:E]N**+'R Y/S--DX^@'?ZT 7& M].]1VYF93YRHAWWF,\"2-&T189V/C(]CSUHU ;:W<5]#YL#;XRC M4"I?Z=#J4:),9-BG.V-RH/UQVJ>W@CM84BC&U%X R3W]:66,2QLA+ ,,94D' M\".]0V.FP:;"8X%*JS;FW,6)/KDFC4 ^RG[9]H,\I &%BW (..3C'7ZFII@Y MA<1,$DQ\K,,@'L2*KW-@UQ<12?:KB((<^7&P"MSWXSC\:BUB/4'M NG/$DV[ MEI02,>WO]11J!;M8Y(H42:7SY0/F?:%S^%0>;>_VCL%O&+/&3*9#N/'0+CU] M35+0['5;>1WU&_6X4C C51@'/7.*LZH^HKY0T]+_?M1J! M=;*J2%+L!D*,9/L,GO[FG+EE!Q@D9P<9^E"YVC=@G SC@5!:SS3-)YMN8 K8 M3+ EAZX'3-&H"27R1WD=L5D,CKG(0E0!ZG']:DN)X;6)I9W6-%_B<@ ?C574 M]433?+!@GN'PL9GO)$@@D8_-.X4$\8Z_2C4">ZM5NH]CM(@Z_NW*GZ9%21QB&-$7.Q M1@;B2?Q/^-",DT2NC91AD,IX^H-$:>6H4$D 8RQR?SHU KVMG+#-)+)=23EC M\J, %49X &.OU-2W0F^SN+7^)D4J/P&?ZU5LY[V>XE%Q:+;P M*<(WFAF;WP!P/QI^FPWL*O\ ;+A)W)^41Q[0OMUS^?I1-->_:XTBMHFM_P"* M5Y2#[X&/YFC4":XF\B%G\MY"/X(QDGV'/]:D4DJ"1M]C2U'#)(^_?%Y8!^7Y M@<^]&H%=M6@_M 6865YNY$;;1QGEL?UHOH["W<7EVL*.O FE R,<@ ^OTJ*^ MURVL+N.U99I9W&0D498\G )/_P!>K=U!;W$.+J..2)?F(F4$#'?\*-0'6UU% M>0K+ XEC;E67I3(+6WM7D,4:1/*VYMH +'U-)9WUK>;Q:RQRK'PWED$#T%1W M%K9+>)=SB,7"C:DDC=/H,^_:C4":ZM?M2HOFR1A6R?+;;GV)]/I4]130+=6[ M(68(PZQL5/X$'^5%M;I:PI%'NV+P-Q+'\R:1+*NG6=Y;33/=7QN0Y^5!&%5> M>U3WPO/+ M/)#D\M-D@?0#O^-5K>QO?M1EN-0,D>E0R76I-?".*RC6V#8::249*YZA1^E :A MK&N1Z.(@UO/V_F36TEH<\)(03]?_P!= :C;?5K2\N'A@E\]E^\4 M4E1]6QC/XT7L=E&R75V(@8ONR28^7/H?6E-U;6MQ':CY)'Y"(A(^I(''XT^Z MM[>XCQ>>_)H$$OXT6MU;W2$V\B2(IVGRV! ]J;%I]O#>272H?/<;6=F).,C@<]. M!TH ;?:?]N:(_:)X!&M %#3[6 M_AF>2[OEN%;[L21!5'/7/7\S3[R6_6XC2U@A>,\M+*Y&.>0 !Z4JVMU_:!F: M\/V?&%MUC '3J6SZ\U;;.TX&3V[4 +13(B[1@R*J/W"DD?GC^E1I/*UY)$;= MDB5(QMY4E1&VDH00#@''ZU7O+738[@75TD M FZ+)-C/'3&?2H[O7+#2[A+0D^>W2&&,L>>AP!4UYI-E=3">YMHI71<;Y #@ M9SCZ4 6I(UFC*DG##&58@_@?\*KV.GVVFH4@39NY.6+$_B:LQNDB!D963L5( M(JK:Z3:V=U+@.>!]* &S:?/-?"8WTR0+R+>,*!^)QG!JZ^ M[:=N V.,]*BNKP320\YW1$ _3..GTJ5%V*%R3M&,DY/'=N?;VIJ32-XMXKJ(QS1K+&>2K@$<<]*+B=;6 M%Y9-VQ1D[5)/X "B&430I( RAAD!U(//J/6@".QN+::'_1&C,2';^ZQM&.PJ M%=/L=/N);W8D4LGWI6;'7MG/M5Q9%6Y596".,B2)L'UR#2V\(MX5C5F<*,;G8L?J33U4* , <"@+M8M MDY/OQ^% "TC[MAVXWXXST]L^U+10!#9BY$?^E/"9,_\ +-" /S//Z44BI-]K M=WD5K?: (U3YL^N[-% $E%%%0= 444=>AH *.?6DZ=Z6@ H&>]%)\VX]-M M6/IFEH.>U% "*V[L1]:0LJ=< FA9-Y(P?J12MM7YFP/>@ 90W49I1CM2*PD7 M(Z4 JIVC /7% "T4UHP[ GM[TX].#B@ IN'W]1L].]$<>S/S,_U-0S7"K-'" M)HTE?E49AN..X&: +%"YQR,4<[>N34<>\YW@#TQS0 >:QDVB-L?WN@ISR+&N M6.!3J* &QR"5<@$#IR,4+L5MHVANN!C-,CN%F8JH)QU..*65XX?F8JI/&>] M#I(UE&'&>]+M"K@# %+15D%?[+NDWM(YYR!G ^E-FAGDD^67RT]LYJ=H]S D MMQT&<"G]O2@!J@J "=Q ZU&JS&4EBH3LJ@Y_$TZ*-H\Y=G)YRW]!37$[2C:R MK'WX)- #I&95)5-Y],@4Z,L5&Y=I[C.:5ON],FHX&D*DR($] &S_ $H DW98 MJ.H]C0V%4D\"H&N@)Q&$=CW*C@?4U89@JDDX &30 BGG M%%&?>@!D,)ASF1Y"W/S'./I4OX5&8=TPDWN,<;0Q ^I'>GGZT +^%0)YYF.X M1B+MC):I5Z=:KR&Z-P@18Q#U9F)S[\4 .NIY80/+@:W$J$@DF+?W< M?BXITRR$ _3(I$2WL_D3R MXMYSMR 2:2UOH;QY$A;>8SAN"!^??I4AMT:02&-3(. ^T9_.@"*ZLH[PIO+C M8<@*Q _&K2U'-")HRC%@#UVD@_G3;:WBM%V1C;GGKDGW)S0 YX0TP?>X(&-H M8@?B*CNDG>+%O(L3Y^\R[N.^!GK3;JS^U2*6FF1!_!&^T'ZD?XT^X$WD$6Y0 M2= 9,XH ?$KI& [[W P6P!GWQ4,$ER\\GFQ)'".%(8ECSU/'I2V<<\<.+B42 MR$YW*NT#V IEXU]YR"U2$Q_Q-*Q!Z^@H L2,57*H7/\ =&,_SIU#-M4D9.!G M _E4%CY>!"Q=,[OE(''49Q_6I+B:*WB,DS M*B+_ !-BH[R\^R% ()IRYP/*0D#W)_Q-3L%=?F (ZX8 T ,CDCNX%9&WQN." MI(HM;*WLP1!"D6>6VC!/U-1VFH6UY(\<$HD*?>V@XZ^N/Y&I]L<#._RH6.68 MX&>..: (KVQ6^5%>25%!SB-RN?K5A5"(%'0# [TR:/SH73Q8_7K0+H.MH)(=_F7#3ECD;@ ![#C^=1WWVQE46;0H<_,T MN3^0]?K27%A)0G.43:![#FH[A MK_[:BP1PBVX+22,=WN /\: U+4TGEQE@C2$?PI@GK3E;8P&0,^M5;K7+ M>UO4M"LCS-SMC0M^=:#8VDMTZG/2@-1BM'=0DH^Y&&-R-Z^AJ*QTZVTV,I;Q M+&#RQ&23]319:E;:AYGV:42B,X8J#C^7MVJ:2:.%=TCJ@]6( H$/ILBMY;;- MH?'RE@2,XXS[4CCS$(#$9'WEZ\]Q3;>%;>)8U9F"]W8L>O%#N^8RJ3Q[#/7ZT^&&9;B1WN-\9X6,( %_'UI\W MF^2_D!#+CY=Y(7/OQT_"@"0BHUD: *EKJ%M<3/! V2G4*C!1@XX.,?D: M22.QT^1[N00P2-PTTA )]LGMT_*I&U*!;P6NXM.>2BJ3CW)QP/K27FFVMXT; MW$*2^6VK72#/5HB WT!Q^HI M]O +>%(U9F"C +L6/U)H ;:QS1Q 3RB63J65=H^F/3ZFI,MY@&T%.W8L;Z#BW MD601G:=G0>U/D,,;AW,:OC 9L ^X!]*A;4+6*\2T,BBX?D1J"3]3QQ^-)=:? M9R2?:+F"%RH_UDJ@X'U- %B:/SH7CWL@9<;HSAAGN#ZTRUMDLX%B0L57NS%C M]2?6G6]Q%=1AX)4ECSC=&P(X[9]JAM["*UN)9@\CR2=3(Y;OT SP/H* &_9+ MAKSS3>.(@,_>=I-NWZ#'6H+6WU#[8\MS=QF+.$@BC &.Q M)/.?IQ5B\:Y$>+5(WDSC]ZQ"CWX%&H$TC%4)"ER!D*,<\=/K]:BM)I)X]\EN M]N>FR0J3]>#_ %J2/>(U\P@O@;MH(&<E9]CJ=S>7LL9TZ6WMEX$\K %B M.P7'3\:8$ESK-M:WD5H[,UQ)]U$0L>3U)QP/J:N22+#&7=@B*,EF. /.25V.%6%"S'_ #[U);R+J%J&D@=$<6 $Y+0MM;Z9Q_*G6EJEG#Y:,[\Y)D1U!]:P[1M%\+R212ZG#%<289OM=TH<^AP3TZ]J-0+_ M -AO#J9G:^(M1]VW6, =.[?X5+J37:VK_84C>X/"^:V%'O63>:_IMU(IC\36 M=O%W2.:(D\^I/\A5EO%6CK&=FL:>7Q\H:Z0#..,G/]*+@7]/6Z6U3[:T;W'5 MO*!"_2CSKC[:(_LW^CXR9MX_(+BL33/%5J?--_K.D#)^18+I3^));^E/U#QC M81*@L]0TV=V.&,E[&JK[GG^7I1<#;O+I;*VDF97<*,E8U+-^ J'3=0_M* R_ M9IK=,X7SEVEO<#/3Z]:I1^+-(6 --K&G>9C+".Y0C\.:CL_&VBWBLW]HVL ! MP/.GC4GW W=/K1==P+D^M6EK?+9X=[AL?)'&3UZ9../Q-6+RTM+D*]W#%((^ M095!"^_-9=WXUT&SC\QM4M),G&(95=OR!Z?6I/\ A*M!NH1OU73RC#)22=/R M()Z_6BZ[@:EM<0W$68)(Y$'&8V!'TJ.&QBANGG!D:5Q@[G9@/8#/'X"J$?BK M08AY<>K:>@'15N(P/PYQ59M5\-O?B\;5K)YQPK->J0/H-V/THN!L7UF;R'RQ M<36_.2T+!6^F*-%DC=1K=BA88W+=1Y M&>XYZU4TO5M!TN-U77K: MH^E/U"2[CA_T**.64G'[UB%'N>/TJA-XGTB10$URPC.IMWXLTJ M.VD:WU3399P/E5KR-03[G-&@&G8_:?LJ?:_+\_\ B\K.WKQC/MBHK2^FN;B2 M-K*:"->!+)MP>>PS_2LG2_%=HT;G4-7TE'S\JPW2''KD[NOTJT?&&C>>$&J6 M13&?,^U18^F-W7\*+^8%K5=7M]'C1YPY+$A5C0L3Z_Y)J>SN!?VJRF%XDM/O-/LKAEGNX(9#&.'E4$+_\ 6JA< M>,M M$,C:K9'M^[F5S^0-/\ ^$HT"ZA&_5=/9&&=LEQ'^1!/7ZTKH#5BD22, M-&RM&1\I4@C\*I6.@VMC=/>PJ)/%&A1J%75].11P MS& /; M&:@DUSP_-=1W#:Q9>8@P,7JA?Q7=C\ZFY-B]J5C=7DD7D7S6D2\NL: LWT;/ M'Y5<1=JA(M/M#G+/YT;$CT&6Z_A3=/US1;&- MP?$-M!]!1<-34LX[U9)&NIXI$/W%CC*XYZYSZ>U/OI+F.,? M98%GD)Q\[[0/?.*QF\263:B'_P"$ATM+-1_JEGC+'CN=WKZ5>_X2S1-O_(9T M_P#\"H_\:+AJ:$;/Y:F3'F;O$=,N+:!1GSIOESZ M#'?V-5['Q9IS1LUWJ^EH^X[5CND("]LG=UJ"Z\>:7#=)!#=6T^2-TOVJ)4 / M4YW=OI1<-3;OM0@TV$37#%%+;00I8Y/; 'L:E98[J'#('C<9VNO!!YY&/YUF M/XMT-$+'6+ A1GBY0]/09Z_2H[7QKH5W&775;1!G&)9E0_D3THN(OK>V=M<+ M9H\:2]H8QR/P X'UI]U8P7,D$QEL1)$IR!GC)SUQZ"K583>*- M/-X"- M:N"?<#.R /9[A%/X@GC\JFX&C#<6S,8(9(BZ#F-&&1^'I4S <$]N>I _'_Z]8<.O M>&[-F:#4-+A9_O&.:,$_4@U)-XDT"Y39+JNG2)G.UKF,CCIQFJ UI%,D;JKE M"1@,N,CCJ*JZ;IHTU7_?SW#N/R@2_/(R3T(] MJNU@:AXFTZ:$+:>(--MGW?,[31OQ[#<.?K4MKXHTB&!$EUZPGD ^:0W$:Y_# M- %^S2\5Y3=21."?D2)"-HR>ISUZ=NU.N+B>.XB2.U,L;'#R[P GOCO^%9%K MXLL_M4OVC5M(%M_RS,=XI;KW&>X]#5B;QAHL,99=4L93_=6ZCS_Z%_6IN!KR M.(T+,^*KVEK-!DRWDMR?]I44?D /U- #C'=M=%O.C2W[(L99S[YR._M11 M?K=M"!9R0QR9Y:8%AC\Z* )0:#QZ49&[&.:,"H.@6@8[4B\\T?*OH#0 %0W6 ME/3%(R[NI-+0 BJ5'7-!SD8Z=Z #N)SGVXI)-Y^X0/K0 K-M&0,_2D1BW5=O MXYI5!"X8Y/Y4B[MQR !]>: !I-K8VL?H./SIU-DD,>,*6^E.4D@$C'M0 R69 M+>%Y)76.-!N9F( '4D^E0VM]:7D2SV\\,\3<"2-PP/MFF:I#]HLW3:7 9&9 M ,DJ&!(_$ UQ_AW6/[5\72//9/IDGDL?)\L#8'F(S O\ BH)-,#?&#PPL@VWMW-C^&&TE(/OG;_ M %KCM6\?Z-J'B:'5%AU!%1HV_P"/=F;Y<9PI;;@@#H/6I;0'M%CYZV< N2IN M-@\PKTW8YQ[9J:N"M?C-X:D_UMU>1,>TME( /Q"G^=;-A\1/#NK2)%9:U8O. MQP(I)0C?3:><_A577<#I*1F"*68A0!DDG ^M"].>:Y;QUX@715M0(K>Y).YX M)IMOR]FV_P 0!!Z"@#HK2^M[Z,26TT=Q$>-\1#+P<$9'ORDBGC M ^E)\LB'!RI'4'^M1P6Z6^=N?F.22@J=2O42-6"C>1,O'Y9_NDY/XTYFP"<$X MYP.M-MY&F!+1-%Z!L9J=2M0\U1((]K9Z\*U17=ZEF8P M5=BYPH1 MJCM2-;6\E(?:E&:0YH KI!+YYD>-6RZ_>P#Q^-)-' C>=*J*5_Y:.,8_&D MEOH8;A(&;]ZV"%523UZGCI]:EG5&C/FA2@Y.[&/K0 QT6ZAP'.UAD-&V.#WS M_A26MG#9KMB7 )RP7#%()54WE;?,Q\N[.,^] #V;%5;6XGN'<26Q@0?=+."3 M^'_UZ=:?:/('VED,N70LXPQCEE] MHD+'_/UIUK<-<0AVB>+/\,F ?J13Y'\N,MM9\#.U1S]!52SO9[J8J]G)!&/X MY&&?H!_]>@"1=0M_MAME;,W4J%/'&P33/%'*K MR+U53G'UIDUG;- MW6U@2),[5&/F))^I-.FC\Z(J'9 P^\AP?P-1VMJEI&50N7>AX6,* ![Y]:;?&Y6 _95C,N>/,) __73I(9'FC=9V1%ZQJ!\WU./Y M5+0!';^:(4\\J90RG M(JK::3;64[S1JQE?J[L6/\ZGMY;=U*6[QLJ<%8V!"^V*22&'SA/(%WJ,!V/3 M^E ^HEY:O=J%6XDMQG),6 3[9Q_*IHT\M0NXG QEB2?Q/K2M\Z':V,CAA@_C M0HP "2>.IQGZT!J5;>&Z6YF>:Y$D3'"1+& %'J3Z_C3KZ2Y2'_1(DDE)Q^\; M ]34C12&X5Q,PC48\H*,'W)P3^1[4Z;>L3F)0TF/E#$@9[9/I0&H^J<-W<2 M7CQM9M'".DQ<$'TP/>I;,W!@!N1&)>XBR5]A4%Q>72WD<$%FTD9/SS,P50/: M@.I9N)UMEWLK/SC$:%C], 4Y6\V,$J0&'*L.?H13F;:I)[<\=:J6&H->ER;6 M> +T:90-WT&?YB@-22.XMEG-M')&)E&3$I (]R/Q%4Y]#M);_P"VW!:5UY59 M&RBX'8?XU/)?6EI="$LHN)/FV(I+'W.!_.I;JS@OH0EQ$LJ [MK=/RH!CXIH MKN-S#,DB?=W1L#@^F?457T[28=,#^6TDCR'+/*Y8G_.:DL9+9H]EJT9CC.TB M(C /I]:D^RQ_:A/AO,"[1\QQC/IG&?PH$0W-O618U);GID]OH M*MU'<1M-"R)(8G88#J 2/IQ_2BWC,,*(9&E(&-[XR?<\4 06*7:JYNY(G/N.A'] M* (+6\LVF>U@EA,B DQQD9'.#D?6JTWA^REO1>3AY9%.X>;(2JX[@9Z"KT,- MO;L8H4CC;&XJ@ /7J1]:=<0Q7,+Q3*'C8893T(]#0 L4T=Q&'B=9$.0&1@1Q MZ&H[.U%HI'FS3%CDM,Y8_0=@/H*2R6UC@$5H8_+CXVQ$$#_Z]-M[#R+F6/4#;0+SY4<8+'URQ/\ 2M%L[#CKCC-5=0@N MKB-5M;D6K9^9S&&./09_K4\:LD:*SF1P,%B "<#DD8[^U $5BMUY9^UO$7SP M(5( _$GK1>27,>P6T"RECAFD?:%]^G\A4-J-2-U(URULMO\ P)$&+>V2?Z"K M%U)-'"6@B$LO96;:/KG']* )L\<_C44-P9=X\J2,*< N WN.>GU%+ 96A0S M*B2]65&)'T!QS^50QWS27KP"VF"H,F=E 0]. <_TH BO=8LM-F2.60">4_+& MBEF/8' J[(BS1E'4.C<%6&1]"*&*JI>*<^EP27J74A>21/NAG.U?<+G'YBIK>QM[-< M001Q#OL4"I7C61=K#(]* &7$3W$)C29H">/,4 G\./Z5'8V?V&#R_.FG.GT%27DDT-N[6$GE_A0L%'7 MN:GI')VG'+=L]*8$-D]RUNINDCCF/)6-B0/3G'6DDN)%NHXD@9T89>4G"KZ# MW)JMIK:F9)&OQ:I'_ L!8D>N2?;T%,U7Q!;:7;F1B)3T"J0!^9[4)-[ 7;JZ MBL[=YIFV1H.3@G]*KZ;JBZHKNEM<11C[KS)M#Y[@9Z?45S%Y\2K>) (H]\A' M(3D#\?\ ZU4+?Q)XB\1,5TS39[GL3%&S@?4@?SK94I=0.X:]MK20IM9,GYBD M3%<^Y Z_C1=7%G<)LE=73.=NXX/L1Z?6N9MOAO\ $'66!:V:T1N\TJ1X^H!S M^E3-\'[J!L:OXPTJS/\ $GVAG;\CBER0V<@LS?.K6<*@>8$4<#C ^E8'A'1] M)\5_%;44OH(]3MAIPD59U#*K!U' ]@3^9II^&7A2'_CY\F_M0?'_P"(6D)XI\"_ !9?!TZ>?8OKVN0VM_>0$ K(L.?E MW*01DGJ,$UAH6?2O_"KO"7_0OV/_ 'Z%)_PJ_P )?]"_8_\ ?D5QW[-_[1FD M?M%>$[Z^M=/N?#_B#1[MM.UOP_?D?:=.N5)!1N.5.#AL#H>X->MT: \=?'+2_ WQ<^'OP]GL;JYU?QD;QK:>/ M:(;>.VB$CLYSG)+* .YY&.?25HT Y?_ (5;X2_Z%^Q_[]"E_P"%7>$_^A?L M/^_(KJ:*+ $O^A?L?\ OT*/^%7>$O\ H7['_OT*ZJBBP'*_\*N$?\ M0OV/_?H4?\*N\)?]"_8_]^A75446 Y7_ (5=X2_Z%^Q_[]"C_A5WA+_H7['_ M +]"NJHHL!RO_"KO"7_0OV/_ 'Z%'_"K?"7_ $+]C_WY%=5118#E?^%6^$O^ MA?L?^_0H_P"%6^$O^A?L?^_(KJJ*+ OA^Q_[\BNJHHL!RO_"K M?"7_ $+]C_WY%'_"K?"7_0OV/_?D5U5%%@/GSP_#I6A^+O%D96VLXH;[RX%; M:NU1NX7VZ=*[*[M4OK5X7+"-Q@E&*GKG@YKF=+DM[?QEXUGN#&B1ZAGS),<< MMT-=)!=0ZE:E[>7?$X($B''MD''454=C&6X6-C!IT AMTVH#GEB3SW))ZU V ME^9??:7N[@A3E81(508]0.OXFIK>"'3;/ M90S<0V6XB9\CJ0.1C(.!^E%;6IKNRN5G3LVWK12.VU*6 MM84G?3[A;1W"+/E".3@';G=@GT% &\3BFQR>8,X(_P!X8-*N[:-V,^U>C.?X1GVR>WL>H'1ZMK5EH=J;J^N$MK=>6DD8 M #\:\*+F_\ "NDB[CB82-?7RLD(<]7)+ X_WBH]N]5-3\^^U:!_ M$)E\2^(6^:UT*Q#>3 QX 8 \$<9P<^K#D5Z)H/P2U?Q%' _BZ_-E81_-%HFE ML$2,D*+W7[R49.FZ*I$0_V<*!G\%< M<=:V/#_@+7;R)4T+P!;:7;GD7^M3#_X4WX MQP/^*SBSZ?8WQ_Z,KV\0[?4Y^G'%+Y/;G'KQ0!X'=?!KQHN2FO:/?'TNK+'Z MD-_*N8USX>^)M/C>/6/ NGZ_;=[K2)0KCZ)E>?K&U?49A^H]JC:'OSZ4 ?'V MG30:3>BSTOQ!JGA*\492SU56,7^Z1MZ'_KGCWJ_J>O:DU]87/BFR:2R#*G]H M::%FAX.%=*\469L]7TZWU&V/.RXC# 'U'H?<5Y5KWP+O M=%:>Y\&:DULD@VS:3J#F6WF4E>B>#_B0-6U Z/K-H=(UU!S$^0DQ'4QY.<_[)Y^M;1E?1B.SDF2%@ MK'!8\ G^E$D*2X,B*57GYNE2U1N]0,:R+':3783AO+V =,X^9ASCTJM0U+4 M4D;J=C*0./EH6%5D+@6L4UMM\J15< #@C(X]<&K5&I)7N+> M2;&R9HAWV@$_G4T:^6@4EGQ_$W7\:5AN! )';(J.&$0J1O=R>A.!]:22.1I4*R;(Q]Y=H)/X^E.FWK&Q MC4._8$X'YT:DBPE_+'F8W]]N3<>6/[JQ@\?6G7$TR%1%#YN>I+ M ?S_2J E:E7E 2,'T.,TU<[Z^U;L12(!QN=<9^G_ZJ &_;+>. MY$&\"5C]U5.>?7C^=2SVL5P4,B[]O(W9Q^5-N+J*U ,KA-W S4JL&7(Y!YH M"/E(!(XQD55M]/C@E,NZ220_Q2,3^56MX9B 02.H[TUHE\P28.\# .3_ "H MCN;>2?:%G>%1R=F,G\:FZ#J3398S)$RAS&2,!EQD>XJ.UM?LJX,LDI[M(V?\ M_A0 +'-]HWM*/*Q@1A1^9/\ A4DF_P L^7M+]MQ('XU#-'O&14K,$4L>@&>A)J&TO/MF2(98P/XI% S].?Z4 -MKBS$GV>!XP MXYV1X[=:6XTZ"ZFCDFC#O'RI)/'.>F:3=:6/Z4 (HD#ON*E/X0H(/XG/ M]*@OKB>!4^SVQN"3@C<% ]S2[;IKPL9(UMQT0*2Q^IS_ "%3REDC8HN]\<+D M#/XT +&6V N 'QR M6H2\D8,B>6_4J M&SC\<57NKJ>&0)!:O,>I;<%4?CG^5 %VD9=U-5B5!88..1U_"L^/6GFO1 EE M<%-V#*R[5'O]* +0DM[>9(%,<:7;7S(]Q&)-G3<3C\LTMW? M6U@ ]Q*L6[@9ZGV J=E2XB*LH>-UY!&001W% "02Q2+B)U8+Q\A! XZ4Q;6) M;HS_ #>8W!RQ(Z=AG^0I\,,<$:I&@C4=%4 #\JCEM$EG29GD!48"JY"_4C/\ MZ 'W$;2PLB2-$QX#K@D?2E@C\F%4,C2%1CO4<=13E&% Y/;)ZT M01^?Y[EVC\G^$*#N^I.?Y"I6SM)7!..-QP/SJG-'?27B&.:**V')7:69O4?_ M *JN<@' R: &P^88P90H?N%)(_/']*EJ*W:1H\RHJ/G[JL6'MS@?RI9Y'CC+ M1QF5_P"Z& _'- F24C*&4J1D$8-"DE>1@TM BG#]AT^001>3!(__ "S7 +?A M2WFFVNH;#@SUJ:6))XW1U#HPVLI MZ$'@B@>H1[!&!'MV 87;C''85'':B.>27S)'+<;68E1[ ?A3K>&*WC$,**B) MP%7H,\]*J3:3Y]YY\MU<%%.5A5]J#'J!U_$T!H2:A;W-U&JV]U]F.X7(4$#/' S[^] A5)*@D8)ZC.>W2H_M/\ MI B$4A!&?,VC;QV)SU_"FV5$N, M]?J*C:.PTN0RE8;9Y#@N<*6)[9[\U;DC$T;(V<,,':2#^= "GG/.#Z^E)&IC M0*7+D?Q-C)_3^E-M8(K:(10@*B\;0<]\TT6H^T&;S)"<8V;CM_+UH BU*WN[ MB$):7*VK[LLY0,<>@'K4\,;PPHK.9G5<%VP"QQUX'>H=06[DMBMF\<4IXWR* M2 /8>OUHTV&Y@M0EW<"YFSDNJA1] /:@!MC)>RNYN8(H(^BJKEFZ]2<8_*G: MA<7%O"#;6QNY&;&S>% ]R3VJA&VMW%\24M[.T#=&R[L,_7O6K<2-#"[I&TSJ M,B-3@GV'/]: '1[C&"XP^.0#D9[C-+N^?;@],[NW7I]:9:R2S0*TT/D2'DQ[ M@Q'U/K56?4FBU*.U2TGEWH[*_@U*'S;9S)'G&[:0/PR* &V= MI:V>^.VCCBYRRQ@#Z9_^O3;C2H;FZ$\ID8@8">80HQWQGJ?>DAAL=+F*H(;> M6H]/M9K6$K/=/=R,U69F:.)V1/,<+E5R!D MXX&??WJ.^2XDMV6U=(ISPKR*6 YYX^E%FDT=NBW$JRRC[SJNT'GL,^E $>FS M7DT;M>6Z6QSA463><>I./Y4^YN9(IXHTMI)@Y^9U*A4]SD_TH8W7VH!5B%N. M26)+'V _^O2:A>-8VYE$$MRV-JQ/$;,"<=B?<^E*UY&MXEL0YE9=W"DJ![G'7\: %NM0M['9]H MF2+<<*&."WT%3]1Q3)"B@R/@;1G<<<#OS2PS)<1B2-@Z,,JR\@^]- .3"Y P M/8>_-59-/$MX)VFF^48$0?"?7'K]33;>VL=(WB,1VYD;+9;ECGN<^]-U34K> MQM7,\@08P<-@_G32OH@+5T)&MW$4JQ/VD9=P'J<9ZUAZAXJM-"MPDMR;F8#. MY@,MSV ']*Y>37]3\2W4>F:%;33L?E4("QQG&>>WN370Q?#_ $'P5B]\9ZA] MOU!AN72K1BS$XZNV<_J!QU-;JFH_%]P&!'K7B#QE<-;:-8S3G.#Y:YQ]3]T? MB:W/^%2P:;LN/&7B2#3W(W&UA;S9N>%2T4 M*1GJ6?'4]>!^=2:1\*)KJ0W&IW#2.QW,,D9)/))ZG-:W:6KM^916C\3>"?#N M(]$\,MJDZ\+1W'Y$XJQ:_!MFYGNF'TP/\:]4HJ?;2Z >?0_!^P3[\LC_[S?X 55\"Z%!X M=^,>HV=N,1C2E;J3UD3/?VKTNN'T7_DNFI?]@=/_ $-:QG.4E9E+<\*_X*?- M))\%/"%G,S#0KSQGID&K8^Z;"16#1RK_M(ZJWX8KY]T+1_P!L M'X=^'T\+64_P\\XB7B1@,=#R1SFL!GJOQ.^&WA# MQYX,^*/AGPM-IND>-M8L2U]=:+*D&HK=*F^UEF:,B3A]I&XX(+#N:^6?%W[3 M'B+Q_P#L#^#-,TR\N+3XF>*M3MO DKPR,MRMXDPCGD!SD,\:9)'3SCTKZ4_9 M<_9QO/@C;^)_$7BO7%\5?$?Q==B]UW6E0HAVY$<,0[1H&/8=>F /FSX2_!J MUU+_ (*2^-FTFZ^V^!_!\TWB3[$GS6]GK%_!&DB],;R4=\?P[.Q% "_M#?LY MZ'>?M??L\Z#=:SXA\O5-*O;*ZFM]5E21!9V<2QM$V M?MNSR013QW*(FY70'E0K=?4?2 MLCQA\%?B]\/?C3K/Q1^$:(DGW&%[[B?E#0]<\-PV,NG_%CQW\3?A#^T!]I:7_A*]2>:6H%_P"/WB3Q/\4_B5\#_@SI/CBXT_2/%.FS:OK_ (D\ M.2+!-?P00YQ"XSL61@WW3_$O85B?$+P%<_L2?%3X4:WX$\3^(;CPAXJ\00^& M]:\-ZUJ+WT#F96*3QF0ED<%6.0>P' R#UOBS]C/Q)X;\%_!N^^&OB2SM_B)\ M,+5K2SN=9C M\,>#;S^T['P]X9DFN'O+P+A))99.BJ<' '0$=\TP#]EG_D\;]J/_ *_M+_\ M1$E?75>"_!/X(^(/A[^T!\:?&FIRV+Z1XQNK&;3DMY6:9%AC=7\Q2H"DEAC! M->]52 ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHH MHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU M****-0"BBBC4 HHI&Z4:@>%:1;PW'C+QJL\<(IM'\:^+[>WC,DMQ?D*!]3Q^O:M_2OAG,K_ M /L?3!RL,G$\@Z[57MG\_;O733IJW-)F35V9*WFN?$+4OL&C6\C@G#,. JDX MRQ_A'XUU$$/A[X0KE3%XA\5_WNL-J?\ '/X\=JAO/'4US;_V#X+T\Z3IO1I4 MXFDS_$S=@1WSFM7PC\,X[/9=7W[V?.X9' ^@_J>:W;5O>T78:5C#L?#.L^/[ M]]1UB>4EA\NX@$#J!R,*.?2BO7(H4AC"1J$0= **CVSZ:#.+IJ2;\_*0/<8I M5)VC<,&C=\V,'Z]JXRQLCB,9/KCCJ:?39)%C7+' Z4D M/RH 1EE:0$. GICFN0\9>&[^YM8I;.XD>.T$C1V\*D.78_+@Y[9Z^F:[-U+* M0K;3ZXS7+?$#QDO@W10T6V?5+D^59P,#\S]V(_NJ.3^'K28''#XC:O'9IX?L MHEO/$3D-[<9Z"LKP[H%_JFL7.C>&91>:O(6.J^))CO2+ M=P0C8ZD9Z'+<]%ZMT?PWJ5]JLGAO3)&E\0ZAF;6M49 ?LL98;DSZYP,#J<+T M4U])>#O!^G^#=%@TS38BD$?+.V#(['[SL<M("!(1P#C;_ U* ML/3."^/ZU86,CG&<]13A&-I&3C&=V1Z]* *XAY.W&,_-Z]*58?8>7QMX.:MJ MA.>.G3GKQ1M8<[22< KG@>] %-H?FYQYF#MX.*3R>3C&?XN/:KC1;@1DX/); M."/I2!3\P(P < YZ\=: ,^2(!3G[GT-0M$>0<9/W>*T&B._?DEL8V9XZ]:C: M/:>.03R<].* .-\:> =(\<:;]DU2U$A4[HIT^66%NFY&['^=?/?C'PK=>%98 M-&\4,UQIS';I7B*%2'A93E4?'.1_=SZE>ZU]721<$<@?WLUC>(?#]EXDTNYT M_4;=;FTG4H\3=_0@]B#CD&-$UW4)+O5$E33Y;I<,6#%9&R58E.W'/7K]:P/%7@V?P[J M \)ZS,[VLC-+H6L. &5@0?+9NV#CZ$AAU:NV^'/C.7Q!;W&F:H/*U_3SLN8R MI4NH) D ]R#D#H0:UB[Z,7H=58QV^GV\%I&Z#RT5%7(!. ./7 J>:-95PV< M9SU(IDWDVX,S[4_VL#/YTYECNH<'YHV'N,UIJ2/4C&%Q@<<=*;Y864R98DC& M-QQ^ HA@2W39&H1.P%.8!NHZ'/6C4!U(U(V60A6V''#8S3(8VC7#2&4]=Q&/ MZ4:E=! TJR.TIC2!1D="JSL=K>V.#V)'-=#^V+KVL^&_P!F[XA7^F-Y#QZ8T0=&._;(RQLP MXXPKG\JT?@'I^C_"W]F/PA+86[2Z=:>'H-1E%E%NDN&:!99'51]YF8G ]Q1Y M!J5?@O\ M1Z#\7/$E_X4NM%UGP7XTL8?M$N@>(+8P3M%G!DC/\:@X]."#TKH M_!?QJT[QM\5/'/@6TTZ\@O\ PE]E^U74I3R9?/1F79\V[@*>HZUX=8?M&_"+ MXC?'3P%?ZCX1\5:5XX6673M#O]1TV:S7]ZNUU8[@'7!/#!@-YQUKGM#UR[\. M_'3]KN_T]YH+^WT>QF@N(!S%(EG.ROGL00/RI7#4^T;JZBM(O,E("YQP"3]! M3X9A-&'7(#"_#3QOK>K?L4V/BJ^U2>X\0-X2GO6U*0@RF<02,)"? M[P('Y5Y6OQT\?:E^SS\#-$\.ZT4^(7Q!D6R;7K^(2F"-%+W$^",,RJ5[>M.Y M)]G+Y:.578'/) P#]34=W9QWJ!92V AZ7X:5(GD$1 ,]Q(PS)DD?+TZX(HOY#L?8D:K&@51@ 8%16]N MT+.6F>4N<_.1@>P%?'WAOXY_$[P[\(?C;X;N1#XB^(OPX80VNHP6H_TR"5=T M<[1#@NJ!GVCT%I^--6\(:EX+_ &B;KQ1XEGO(/^$B\(>+YELXI86& M9TM8R@(93D 1[ASU&,%6ZHN'-%L(9]3U33["2>^O;F91(D$3JC>4JQLC%^N3C&*K_L[_M.6 M.E_&J#P GQ4F^*?A#5-.N+RRUG5;.2WO--G@1I9(IY'1?,C,22-O.<%0.*.; M6P6/MROGOQU^V5HWAOQEK?AKPWX+\6?$&]T$[=6F\-Z>9X+)P,E&?/W@ > . MH/H:["U_:6^''B&XEL/#WCGPYK.JM;RR6UE::E'+-,Z1LY"H#S@*3QZ&ODS] MD.[^.NK? 2RNOASIGAC3[26[NKV]U;Q/-*]UK-T\K%V547Y5& NYSDE2>E#? M1"/M/X0_%OP_\;O MEXJ\-322:?<,T;1SILE@E4X>)U[,OU[BNKMKX7$SQB& M9-O.Z2,J#SCBOG+]G3XY>#M)^&WB6]\3Z;H7PIU/3/$=QI_B*S$ZPVYU1@"\ MJL<#]X%XY/W" 2!D^U^ _BOX-^)YO?\ A$O%&E>)/L/E_:O[,NDG\G?NV;MI MXW;&QG^Z::8'1736MJPGF\J-^@D8 'Z U94[E!'3K39 FW+X(7G+8P*9;W45 MU'OAD$B9QE>E4 L,<,,CB-41V.YMN 3[G_Z].DCWLIW,-ISA6(!^M1K#!#(7 M"(DK]6P 3^-+,TM-W4 -B9F M0%UV-W7(/ZU!?W4EJH,=M)N.01T.*%;Q^7,"Z9R5R0#]>>E2R31PJ7D<(@Y+,P _.HKNU6] MMS&9'16ZM&V#],^E $L>Q5"(5 48 ';'&*38?-+^8Q&,;.,?7IU_&J]CIUMI MJ>7 @0GDDG+'W)J/4-+74)HF>XGC1/\ EG$^T'W- #M12^D"+9R11=V>0$GV M '^-3V<,L,(6:;SY.I?:%_ #TIX0K'L0X(7"ELMVX)Y_F:CLX)X0WGW/V@GI MA H'T_\ KF@3"&2[:[D#Q1I; 85@Q+'W(QTHOKJ6TAWQV\ER^<;(\9^I]OSI MUP+DM&(#&%W9O7@_UJOJ&HBP5/]'N+@MQB",M^ M9_Q- B6\NH+.$RW#K'&I^\W^>OTI]O.EU"DL9W(PRIP1Q0N)XU+Q8SSM?!(_ M^O5:QUBSU&22.VE\PQ_>PI'MUQ0 L/V.PF,2R1Q2S-N96?YF)[X)I]]9)?1A M'>5!G)\MRI_'':H_[)LENS=&W0SDY\QN3]1[_2I[FW%U"8V>1 W4QL5./3- M]1;:W2UA2),[%X&XDG\ZCAMYHYWDDN6D1N%CV@*/TZ_4U);6\=I"L40PB],L M2?SJM=Z?+=7"/]MGAB7!\J(A0?QQGGZT!J6I5D8+Y;*A[EE)_ #/6G_P^]1W M'G>2WD;/-_A\S./J?PIEG%/'&1<3">0G.53:![ 9_K0&I)^\\WD+Y6.N3NSG MIC&,?C45]=-:PAT@DN6W8V1 $_4\]*)OM?GQB)8?(_C9V;=[@#'\S3KJN22:%MYENWE:Y8Q$86':H ]\XS^M #K@3M&! T:/GDR M*6&._&1S^-2G.WU..E0W1N/+Q;K&9">#*2%'OP*6T2>.("YD667.247:/H!F M@"K9W&HSW#>?9I:6XZ9E#L?0X'^-6;BX^SM$/*DE,C;?W:Y SW)]!45Q->+> MPQPVZ/;]9)G?!'L!CK]:L7$XMX7DV/)M&=L:EF/L!ZT .91(I5P"AX(8 CZ& MJMCJEG?2216DJR>3PWE@[1[ XQV[&I[:;[5 LAB>+=SLE7##ZBF-<6]O<1VP M($L@R$53^?3@?6@!TEK:^>MQ)%#YJC"RLHW#V!QG]:=XS3K>>*X4M$ZR*#C*,"/IQ0!'8Z?;Z;#Y5M$ M(DSD@9Z^Y_"B:S::XBD^T31B/GRT8!6^O'/YU89U7&Y@/3)J.Z@^U6\D6]XM MXQOC;##W!]: ) WK1Q45K:BUM8X5=Y-@^](Q9C[DYS56TMM02Y9[F\CEB[1Q MP[?IDYH 9J#:K)GN:T%W",9^=P.=HQGZ#/?ZU7U%KQ M;?\ T)(GG)Q^^8A0/7I4UGY_V=/M!C,V,MY8(4>PYH @T^ZN+M7:>T:T ;"A MV5B?<@=/SI;N_6TDBC,J]K?V][YGV>5)1&=K&,Y /IG_ I89!?6 MNZ2!HU?@QS* <>XR>#[US/B7Q7:Z+;FWM F\Y 6,8'H?P%7&+D[) .\3:EI6 MCW!O&@26^/W6Y)R!@8'J,=<<5F^'?!VJ_$-VU+4)_P"R]!A;=)=S'"X'4)G[ MQQW/_P!:KWA;P/ UG_PE7C.5H-,X,%ITDNCV &?N\=OY5+J6L:O\4+V.UMH1 MI^B0-MBM8AA$ Z=!RV/;BNF*2TC]XTNY;G\;6NCPG0_ 5DUNC\2Z@RYGF/3/ M(X^I]>U2>'?AC)>2?;-6D::1VW,&).2>23SR3[UU_AGP99>'[)O#MCXM\.ZI MH>IP_:-,U.UELKJ(,5+Q2(4=<@\95CT.:Y#X+_ ?P7^S_P"&9]"\$:0-+LKB M@KT*BCS **;NIU, HHHI:@%%%%, HHHH **** M "BBB@ HHHH **2OE7]KS]M"[^!WB;0/A[X$\.?\)K\4?$ 5K33-Q\JVC9F5 M7D"G+,Q5L+E> 6) ZJ_<#ZKI*_.?QQ^UE^UG^SK967BSXH?#;0+_ ,&/<)%> M?V6WSVXIZ'K1<#ZXHKG_ ?XE_MOP;X>U6^>&WN=2L;> MZ9 P5=[QJQ"@GH"WKTQ6S->06NSSIHX=QPOF,%S[#GK1J!/15>[U"VTZW>XN MYXK:!!EI9G"*/;_P!\YS^E:32!%+,< #))X ]Z-0'45GZ?X@TS5I)8[+4;6\DB M.)$MYT&8/&'Q/UZ+[ M4L%TS""T@PY!;!&6(C=N6 55R>"*9^Q_^UAXV^+'CGQ?\-_BAX1C\-^./#?[ MQI;$-]FG0$*R\E@&!*D%6(8-D8QR7UL!]9T444P"BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH *1NE+24M0/G^S\71>$_'/C.:#2XKW69+\K;7,P MW>0OS;L#U.1TJ[:^%]=\=:@+[6[B5L\[7."!_= Z*/H*T_!&CVU]X\\;SS1A MWBU#:IQSSN)Y_"O2EC6-0JJ% Z #BNF$U".BU(,C0_#%EH5NJ0Q*".X(I5R5&1@TU9E:0H#N8=>#C\Z $D\N/YVV@]-QZU(#Z4C8Q MSTZ\TH.>1R.O% !4;0[I0Y=N/X<\5#?WD>F0&9HVA[4 ;UQ(L,$CM(L:*I9I&P H R23 MZ 5X5=>))M6OKOQ:XDN)B_\ 9^@VJ*-Q;( D _O98-]73^[7]UN86RQ1DDF+(WX/N2J]?XZB^%OAN+Q1X^^TJ5DT3PM&+6U51\DEP027 MZO08 MHO2H;=1CC[GKFKT29Z].U9@.5=JY(S^&:L)'Q3(_O8X\S&2,^]3KCKD;!][G MTH 58SQS1Y85<[/DQRFWGK3U56P21LR"IW$?2G!?F_A\W;TW'&,_Y[4 -V[6 M&03D_+QTX[TXJ?NC@\$G!Q]/\]*D7;N?&#@X;D\<4GR+&IR!'QM.?7I0!&R[ M5)V_*,Y4#)-,\O;U&5S\HQTX[U9;9YB@G#D':,GVS_2F$#<=A!.?F&3Z?X4 M0-&,].<=<5 8QS@8'?CKQUJTT7[O:#A,==QSU_SWIC?*X#X!)PO/6@"DZ#:. M#CTQS^5598_7D^N*T)%^9MO+\9R3_GUJM(HVG^YSDY.: .'^(W@6U\>>'9]- MG_=2@^9;W 'S12CE6!].Q]037S@VI:EILL>MM$\/B3P_)]DU2U<9\^'A0<]\ MC"Y/?RSW-?7DR$KELM8R&XM3U5X').5_V03N^DBUVTOB"RCN8+6*:.>XF#&*.-Q\VW((! MZ9R#WSQ70GH*QHO,D> SJF3@9('X5'>6HO(?+9V09S\AP?I52&^M)WDDFB^S MSPD!EG4!ER,CG.,'!Z&M".19HPZ$.C<@CI3W$-AA6WA6-,X48&3DT+&?,9B[ M$=EX '^?>G*H7./7-.JA&#X\\'V7Q \&ZSX:U) ^GZK:R6DXQD['4@X]",_H M*^9_ UQ\>/V9M'@\%#P%#\6O">F@PZ3K&FZG'97BVXSLCECD!R5&%X(&,&-,^&WAKP= M=M?VNG->?;KZZD;;E6*X4#Y1S@8]#6QH?P;\2R?%[]HV[OM.EM-(\9Z?9V6E MWNY664BVEC=L Y 5G'45]1Y^E'-%@/ASP7!^T%I/P!E^#? ;Q[9_L]_!*YT'3XX?B9\/'CO( M]+NV CG4@K/;M("5!90O?MC-?8L,DKR.&A\M5.%8L#N]\47=P+6/>R22<@;8 MU+'\J7+W8'S)9^,/CS\7O&7A:TG\#_\ "HO#&FW:7NMZC=W]O?2WL: [K:)- MF KDXW$9Z'C&#S/@G3?BS^RQJ7BGP]X6^'J_%'P1JFISZKI-Y8:K'9S6C3+O/A-SX^&H6ZK 592\J")1(VX G:6/7OUK[\-G"; MC[08P9\8#GK3KB$W$+1^8\6[C=&0#^!Q1RC/E3XG?"?QO\,?C<_Q.\%>$[/X ME66M:7;Z=K^BWDT<-RTL"JD=S$[@C)15!&#T/KE>F^#EO\2_''Q#O-:\5^ M M'^'7@>&R>W@T&1+>ZOKN9_E+O*B#8FPL-O?.#GFOH6VMEM8A&I9^Y9V))/N? M\*<%8.26R.RXQC\:+ Z-X1\/Z=?Q[MMS#IL2.@*E3M*J#R" M1UYR:^<_!=O\8_V4]-O_ )X;^&:_$OPA%#_L]_ &YT MGP9XDO/B?I>E:MXH\7:W+K^IV+1)<6UM(PVQQ+N!4[%SR/[Q&3U/KV@^#?#G M@..Y?0/#UAI'VG;YRZ79)$9=N=NX(HSCW'7\J6 M:0PQL^UI,<[4&2?84[6 (9/.B#-&T>X?=?&?QY_K52/5K8WOV2/<\P;#*B$A M?7)]!4]G-+<1EI(&MSG 5F!/UI6NHH[I("3YKC. I/XDX_G3 6:W@9Q-)&A= M.CL!D?C4B[9$R#E3R"#P?>B:-)DVNJNO7# &H[6[@N0XAD238<,%(./:@"&U ML[/36*0A8C(W!//\ 6H;*WN(2YN+K M[3GD?NPH'T_^N:FMX5@A2,,SA1C+DD_B:@6WN#?^:;G_ $<# A"C'3J3]?2@ M!;XW>$%H(LD_,TIX'T&.M6%!"#=RV.<<#\J;<>:86\G;YN/EWYQ^-$(E$0\X MJ9,?,4! _ 9H KV]U_2DAGCN%S%(LB@X)1@1QU' MUI=HDCP5RK#!##U[$56MYK.&8V<#Q)(O)B3 (]210!)'I]M'UNUNFFGO/,0](5C"J/QZY'UJ>UMEM8]BL[C.=TC%C^=1W5O< MS2#R[K[/&.2%C!8^V3V^@H%J-U"2\1$^Q11R.3\QE<@#WJQ#YGE)YNWS,?-M MSC..<>U/YV^IQ4%K]JPQN?*!S\HBR?S)_P * U',T_G@+$GE?Q.7(;\!M_F1 M27=R+2(R%)9<'&V%"[?D!5>^O+V&=$MK'[0A&6G^15Y<[1D8/<=: U M(;.Z-W%O,$MOZ+, #]<9J!=4LH[[[&DB_:6.3&BDG/7)X_G4UO>-/-)&;::( M+_RTD"A3SVY_I27-S;V'[R0;2[8^5"68XZ8 S0&I-,T:1LTI58P,L6( &.^? M2F6MU#>(7@F2= <%HV!&<#C/XBEFMXKR'9-&)(VY*NN1^(IT,*01A(T5$7@* MHP/RH$0VNFP6X26-C^[C6/;M^ISR<4[3['^SX#&9YK@DY+S-N/T'M39K>YDNHV2[,4"\M&J M*2W/0D]OH* U%OI;J.$?9(HY92<8D8J /7I4\>YD&_ ?'S;>F>^/:B0MY;^6 M%+X^4,2!G'&3CIGVIMKYWDC[0(Q+W\LDC\#B@0_=\Q&" ._^'-,NIA;P/(4> M3;SMC4LQ]@*KS75RM_'!%9L\1Y>=G"J/H.Q M&35==4LQ?BQ$R?:0/]4,YZ9]/2K,4WF;L*PVMCYE(Z=Q[53O-0L-+N$\W:EQ M-]W8A+M^0H MS012%'DC1RARK, =I]14BL&7*D$>HY%17%O#=0M'.BRQ'EE< M CCUS3+&2S\OR;1X2D?&R%@0N?84 .AM8X)I)%,A>0Y.Z1F'T )X'T%22*9% MP&*'KE<9^G3^E47T.WEO#)H(41I6F8=7?&3]<#^E54BO M_P"T7=YX19]%B5#N/N3G^5 #]2FNH8T^R6RW,A.#OD"!1ZDX_D*LQ;O+0R ! M\98*21GO@^E.VU3LY+Z2:7[5%#%$/]6(V+,>N<\?3IZT 68YB\LB&-U"XP[8 MPV?3G^8J*\OH+'9Y[;2YPJA2Q/L !4;7S_V@+9;29TQEI\ (,C/!SR?H*FO+ MI+&W>:4D1J,G:N3^ QF@";ADY'!'0C]"*KVUQ:>:]M!)#YD?+1QD97ZBF:;J M*:G;F5(IHDW8'G)M)]P,]*E:>WAN$B+QI/+RJ\!FP.>/84 ,NK&UN9(Y9X8Y M'CY5I #M]Q5AOF0@'!(QN';WJMJ&FVVJ1"*ZC\V,-NVDD#(_&IX84MXDBB0( MB@!548 ]L4 5M-TT:>LG^D3W+R'+-/(6/?@#MU["EN(;J2ZB:*Y6*!>63RPS M-STSG@8]!4RV^R=Y3+(Y88"EOE7Z#_&F7UO+=6[1PW#6SD_ZQ5!/N!F@"P?N M\54LUO%9S=2Q.#]U8D(P,]2<_P!*L1*8XT4N9"J@%FQD\8R?<^U4(X]5;4-T MDULEFIXC1"7([9)[_2@ U*^OK>:-+.P^U%N6=I BCV^OX5H%RL6YUY RP7)[ M<@HZ/HMMHUJD,$:J%&.!C\JDTS3(-*MDAA1451C@8_#Z5:+DNAK4444]3(****-0"BBBC4 HHHHU ****-0"BBBC4!&K\V/!$D% MG_P6.\7+XDXNI].8:,T_3<;& IL)_P"F(F''?<*_2BOF+]KC]BFV_:,UC0O% M_A[Q'/X(^(NA*$LM;ME)#H&W(DFTA@58MAE/&X]>E2P.-_;$^/GQR^$>J>)+ MG0_A=H7B7X7:;:0W4VK:JP8'A2^Z/S!D+)C^'L/K7@?[:GQ8O?C=_P $VOAW MXSU#3K/2KO4O$\):ST]2L$>R*^0!0>V%'YFN\\2_L7?M7?&;3E\,?$WX[Z/) MX..%EATB%C+.H(.)$6W@#]!]]V_&O2_C?^P1)XP_9+\)?!;P=XACLX]!U2._ M&HZTK,90$N X(C7@EI\C X I:Z@>+?MR3R0S?L=!)'0-<0 A6(SQ8=:ZC_@J M_<2PWWP'\N1X]WB20':Q&>;?KBO4/VKOV,-<^//PP^'5CX=\26FA^,_ ZQFQ MO+I7^S2L(XE;)52R?-$C!@K=.1S7FOQ*_81^.'QWN_ VO?$7XJZ)JFO>'[Q9 M386=DT=A!$&C9O+*QJSRN4&YF4?=4 >CU QOVCM(?]J'_@H1X>^#'BC4[Z#X M>Z1I/]H2Z79SF$7@5MN"2:]Q^"?[%6G_LP_%;7/%O@CQ?J- MIX-N[)TD\%7"--%O"@[_ #FDSD,O&4SAB,\U6_:@_8]\3_$7XK>'_B[\*?%M MOX,^)>C0_9O-OXRUI=Q@, 'PKX.UV4Y1@5(&.,U7_9]_9.^)&C?&R_\ BY\9 M?'=GXF\5RVK6=MIFA*Z6$"%=@)!1,X3("[/XB22:.NP'S?\ LF_ /1/V_-5^ M)'Q-^,5]JNO7*ZL^G:;IL5\\$5A'M#C:%/ 4,JJO3Y26#$U6_9IUCXB^&]<_ M:5_9O\':Y>:E&+V>Y(DM9(IT@,:/_ TBS+CD!70D8R37LLG[$OQE M^!_CSQ3J_P"SQ\2-&T+0?$T[W%WH?B:!G2VD8L08F$,F2NXA3M=G,A8-]DF9(B@4A=Z%B<9%? M6/[<7QRN-'_9#^#_ (>\#>,=4U_1O&+?99O$A4B^O+6W"*T; 8;>SNH8#D^6 M5/4Y[+5_V0?VG]4^&]W\*+OXH^#==^']P6B_M76;2>;5T@9BQ49C*DCGDR9& M>&'&/2O'W_!/KP]XN_92\*_""SUF:RO_ JQN]+UYHLL+IWD>5F3/W':5SM! MX^7'W:+/8#X=\<>&]"^#^L>!O%O[.OP_^+6F>+-&O4.J+K&BW:PZC !EB_#< ML1M*JH4ASQD5]X?'#_@HQ\,?@!X^G\(>)=-\3RZK#;0W+-86,3Q;98PZC+3* M=P!&1]X?0'['_QS^*/@G]I3QG\ M!/BIX@3QG+I5I)?V.M["-BNXJ2B9)"*N B@ 8 I6=P(/A[_P5 ^$ MGQ+^(>A^#-)TSQ7'J^L7T>GV\EU80+")';:"S"#?!>L:UK 1M/L[=I)490=^!P MH!ZDG &>YJ6[)M]#?#TW6JQIQ5VW;0^=_B_^W3HGAWS-/\%VZZ_?7^M3O/?\ L(C_ -FKOJX'X>?\CEX]_P"P MB/\ V:N^JH[$!1115 %%%% '#T,<*3C/M39-VT[,9[;LXHCW[?GQG_9SBH+& MPR/("6C\OTR4!\C.3QA12+)(TA'EX0<;B1^@I\DGEQEL$X[ 9- "\,O M(_ TR.9),JC [>#BGJVY1D8[X-,\U%E$8^\>>AQ^= #+RQ@O(V69001][.", M'((/J"!T]*Y?Q!X"_MRXENC?,+MHEB5BORKA@2X&?O$#U[FNKFBCE7$@! YY MI5E0QEE92%]#D=*7J!X'(S:3XB\0W;3YMO#UJUM#(I.U))"2=I_O R$_6,U] M _!?PR/#7P_TJ%H_+N;E?MER>[22?,<_0%5_X"*^=M+M?^$ETO3-/<_NO$>O M>9PV0?3M2 EV[LJ"5[[@/?I_GUJ=5)^;# #(V\<^_^ M?6O*/CE\9H_A5X?MH]/ABNM:U#(M(9<[(E7[TKC.2H)' ZDUY7\/_CIXY\7+ M>/#KEC)J&G[9'L;C3E$4J$\X=6##D=AQD4 ?5R9!!(8AL87 ^7BGGYF( (RO M#C&*YWX?>,X/'GAN#588&M)RS175K(FE;A4![9/?L 37S/X3_:0\;^,O$G]G2:U9:1<709K6*/3UEBW 9$>6;=T MSSGG%=M'!UJ\'4@M%U/,Q&98;"U8T:LO>ET/L)EW*<'GH&P.*;M.>I&T]>.> M*\_^%/CZX\8VM_I^JP6]MJ^G$"Y6WR$G1P2DJ G(!(8%23@J1GI7H.WIN V9 M&S@YZ=ZY)1<)FF$4. MZT6:54)P))-QZG.<#&!4FA]>-&=H 8]CNXYJO(N,D _[O%>8?#WXD:FWB)/# M/BF6TN+B=6>PO[:+R1,4 +1,F2-P7+ @X(!]*]1D!X!QOQQ_G\J *4R]R,Y/ M;M7)?$+PO'XN\'ZKI,@W&X@;RVX^60?,C#W#!3^%=C(O)(XY^;\JS[A1M/ V M?0^M 'Q]!?/-%X4UAW:+S6.C74@8AD(*JN3_ +.Z+_OV:]"M?AS-:S)(VHXN MPS2P^7$2D;EPP.?3"C@^IKC/'6C_ -E7WQ!TB,8CCO$U.#L%+G=Q[!IST_NB MO9M+U-+S0[&_)^2>".4$ D_,H(X_&M(:B&:?HRVMLXNY!>7$C^;-*X !;&!@ M=@!Q^%:4;*T8*%2G0;<$4??'(R".A%-CECW&-'4NO501D?A6Q(+&BRF3GK:M8^']+N=0U*[B MLK"UC,DUS97 * M,#N_B!!'KD>M8_[5_'[-?Q)[_P#$DN3_ ..&OGWP/^RU\-=:_8LL-1O-&TZ7 M4;KPR=4GUR2%'NQ<>09 PG/S*J$!=H.,+BH;UL@/8/VC/BIXB^'OQ*^#6F:/ MJ<>GZ7X@UU[354FBB998%0-@NRDH!D\J1]:]*\&_&#P3X_U"?3_#OBO1];U" MW7=-;:?>)*Z@'!. 3P"1R!W%?"GB&.X^-7PO_9#M?%TDU^=4U1K6]>5VWW,2 M83YFZG>B %L\Y->F?&OX8^'_ (3_ !\_9^UCPKX>TCPI>W7B)M,F.AVJVPFM MWC"LD@4 ,2K,,D9^8TKO: >*-;T_0()^(YM1NXX=^.NU2 MHVVLZ;(,QW.GRK,CX." 5/4'KS7RG\&_AWX;^ M-G[1'QP\1^.]&L?%&IZ+K:Z%8:?K$*SPV5E&C;'2)P5_>')R1V..IJ#X>^&; M7X$+D>'_".J>$UU=[2!L6^F7C;8S,BYQ'\K;L#'\/913N]R3Z, M@^/'PZN/$0T!?&NAC6S)Y/\ 9YOXO.\S.-F-WWL\;'?#&H6UCJ^ MMV&F7ES%)/##=W"1,\<8W2. 3]U1R3VK\X;CX<#X2_"T>%_B=\!H/$?ANV/V MG_A9?@62*6[EA$GF>>TFTN!@X.YE!'8=:]0^.VD^$/C5\??V:H+BXDU'P=JV MD75RHN)&5KR$1QR)'(>I+%5W ]>%_$NEZ^UJ?WR MZ?=)*T>>,L >A/?%>(?"/]I 0^,_C-%\1/%VG:=HN@>*&TO23?F"V$<0#'RP M0H,A&!RQ8\5RWQ@^'/ACX+_M*? C6_ >CV/AC4-:U.?1M0L=(@6WBO+,QJ69 MXT !V'!)QR2,Y(!K)_9P^#/@SXA_'[]H76?%'AW3_$=Q9^*9;6WBU2W2XAB5 MB[,RHX*AC@?-C/'6G=WL2?8WAWQ)I/B[1[?5=$U&UU;3+@9BN[.998GYP<,# MV(_2N,N_VA/AE#K!T9_B#X?@U,OY7D_VC"6#9QMZXSD'K7RS\%[7PI\.]'_: MJT?4[V^\/^!-'UF1!'I4A22UCEB='$(Q@.P"*O;I7F_CC0=*N/V:]5A\+_LR M/IV@6NDM-'XU\1S6=M?H@7(N2=HED<\':IP?2SJ.MZQ;6DR7\V#;V;LPEN0H(R%V[G:A\3O">B^&;?Q'J7B72K/P M_=*KVVHS72)#*I&05E^)?V:OV7-3U?3[;4]1GU71M/EN[N M%9)9+5HW+0LQ&2AP/E/H#7I?[1EG\.])^+7@/P[#\/\ 5/B/KFB:3(^G^!-) MBB_LRSMW;:+B6-EV DKM&3C"C(Z95V%CZ6\&_%3PC\2$N#X2\2Z3XAD@&9$L MKM)"F3@%@"2 ?<53\1?&[P'X+UA-&\0^,M#TC5V )L[J^C1QGD9!/&01U'0U M\9_"NVO]%_;U\+%OAC8_"-]1\,W1?0K"[@D6Y0>:5FD6 ;(R60# &?W8)ZU3 MU7X7^(/AOKGC^Y\0?!G1_CIX8\1:K=7K>)](EBN=6M%E8DQ8(9U9!C[@ 'KV M#YF&I^@4FM6D-K+=RS)%I\OQ:SW#PL673I[@C:JER,8_A5<8[:7Q*^$_Q'O=-TB]\,?L\>&/A M9X@T>\ANK+Q)H_B6RBEAV-RCA43S0ZY4ABO<=J8;B&.X$!=1*PW!._P!<5X;XQ^/WQ!\.^([G3])^"7B#Q/80K$5U2SO( M8H9F:-&<*K?-A69EY_NFO;=+O);[2[*ZN;9[&XFA222UD(+1,R@E"?4$D<<< M51)9DB61,. 1G//3@Y!_.D5TN(\QOE6X#(0?;@U(PRI!Y&,5';K$L>R(*$7C M:G 'MBF!4L]'M[&X>>/>9G7#/(Y8GG/\P*L7=O-/&%AN#;G=DLJACCTYI/L, M?VHSEI"_92YVCCL,_P!*LT (.*9MGX4 -O+BXCV"WMO/+'#,7"A?<_7V':IHMQC'FA5?N%)(_ X_I1(Q M495=YSCJ!^-1VYG^?SO+'/RA,GCZ^OX4 0M=3_V@(%M6,&,M<%@!TZ 5-=W* M6=N\TA.Q!D[5)/Y4EU-+"J&*!KARV,*P 'N23T^E39/>@"#3[Q-0M4G1)$5N M@D7!^N/2G@10L J%SV &3UJM:ZLMW<&*&"8H.LQ3:G'H2?Y"K_X4 0W%O%= M)LD&]>N,D#\?:G6[1;3'"4Q'\I5"/E]L4]E#J5(X(P:KVD=G9G[/;B*(]3&F M ?J1Z_6@!8]/BCNVNP%27$=Q))%Y,ZQ1J\Q@R!0^/F"DD?@?_ *U/I%W8^8 'V.>] 6*J MWTC7[6XM9A&HR;@X"],X'/\ 2I[B=+:)I9"0B\D@$G\L5'<73PR1HEO+-O." MT>W"^YR:G9MBEF. N23]* U(+*]6^C,B1RHF<#S4*D^X'I]122:E:P726TDZ M).WW8RPR<].*CTS5H]4\PQQ31JAQNEC*AO<>U.N[JSTW]]V3G- #;2R^RO(WGS3EVS^];('L!@<4E_'=31[+69(&/!D9=Q'T&>OU MJ.XTB&ZO8[F5YBT?W4$A"#!]/7ZU;E5GC=4?RW((5L XXX./:@ @C:.%$>0R MN%P9& !/N1@?I4$7VO[5)Y@@%M_!M+%S]>*33[26TC(FNGNY&.2S ?0#T_. MDF%\UTGE-!';#EBRLSGU YXH NT4C,0I(!)QG QD^U1V[220AI4$3G^ -G'I MSZT -2Z1KAX0LFY1DL4(7Z XZ_2EN;B*S@::9MD:\EN?6HIKWRKR.W$$TA<9 M+HF44>I.?Y59D81J6)P ,D_2@"!6@U*S^[YD$HP0ZEPA\BVC6*->=J^_<^] $6FV,UC&XFO);QV.=T@ M Q[ >E1:A#J4UQ"+.XAM[<$&1F4LYYY !&,8J^-V\DMP>@Q5?4(KJ:W*6>UM@EQW]KIRB6YFCA!X4N0#]!0M\&O3;I#,Y'+2; M,(O&<9)_E4\WE1KYDFT",9W-CCU.: &8BO[7J7BD'8E3C^E-M5M[?%M"RJ5& M?+W9;ZXSTI]K=17D(E@<21G@,,XXZU7\FPTR:2?;!;R3$EI&PI8DY//UH 6\ MTN&^EC>8RMLZ*LC*O7J0#U^M6)HG:W*0N(GQA7*[L>^,CGZFG21K/&4;.QA@ M[6(/YT*%C4(O11@#- %/2[&>S63S[V2\=CG,B@ >P ^OKV%5]4@U2:X0VEY# M:6H&69H]S^_7C%:#((Y#,TK !<;"PV_7&.OXUQ7BOQ@[2?8-/#23L=HV#)R3 M@#'K5P@Y,!_BKQ@;.,65LYEN2,%P!UZ9(]3Z5K>'O"]E\/=/C\3>*E%SJLPW MV6EL06W9SO<8X(X^F?7H_1/#]C\*;&/7=?5;SQ),/,L]/)R(B>=[\=0?_K<] M*NCZ'J?Q UA]7UEV='.0K9 VCH!Z*/0=:Z=+66B7XC$TW3=3^).M'5-5=C"6 MRJ'(4+V51V4?K7J^GZ?#IMND4*@*HQP,=/Z4ME8Q6-NL,2 !1Z8JQ6$Y\VBV M&%%%%9 %%%% !1110 4444 %%%% !7#:)_R734O^P0O_ *&M=S7#Z+_R734O M^P.G_H:U,BD>G4445.HPHHHHU 1NE1Q/TG8#OCA^T%X(_9X\&GQ-XUU=;"R=O+MH(5\V>[DQD)$@^\<>IP.Y%/0#TBBO MESX._P#!13X5_%[QQ;>$MNM>$-=O0IL8?$MFMLMWNSM5'#L-QQP&VYZ#)K<^ M.O[<7P]^!'C"'PA>6^M^*/%KQ"X?1O#=B;J:",C(:3Y@ 2,G:"3T) !%+0#Z M'HKQ;]G?]K;P#^TS%JD7A:YO;/6=*.+_ $35[?[/>6XR5W%777_!3WX-QZ3JES9CQ!J>H6-V;0Z/:Z:&NYBH.^15WX\M<C0#ZYH MKP3PO^TQX/\ VC/V>O&OBKP)J5R#9Z5>1W%O.A@N[&86[LH< \' #!E8CCKQ M7QC^Q;^WYX;^"_[.625PJ(6#X&[ MJ&XHN@/U*HKRCPO^U!\.?%OP1E^+%IKZ1>"[>%Y+JZN(V62W9#AXGCP6\P$@ M;0#G%:'_P56^#NJ:]I]G?6'BG0=+U"7RK;7-3TU4LVYQO+"0MMSW"G M&><4: ?99.**_/\ _P""A'[;NJ?!WQ]X.\$>%=2N]+<7-O?:_\^+OV[?A?X)^$'AOXAZC<:H-/\1L\>DZ6EEG4+ID8JP$ M6[ (ZLP'([D"BZ ^B**^;/@)^WM\./C]XZ?P7I\&M^'/%?E-+#IGB"S6![A M54NPC(=OF506VG!QDC.#6?\ %3_@HA\-OAGX\U7PA;Z;XE\8ZSH[%=37PWIH MN8K)E.&1V+K\RG@X& 01G-&@'U'17E_P3_:0\"_'[X?S^,?"FK;M*M2R7R7J MB&:R95W,LJD_+\OS9!(QWKPJ\_X*H_!>T\22V*+XCN]#AN?LLGB:#2RVGA\] M=V[>5[\)GT'2GH!]BT53T76+'Q%I%EJFF745]IU["EQ;74#!DEC=0RNI[@@@ M_C5RC4 HHHHU ****-0"BBBC4 HHHHU *^2?V_O'QTWPQHOA&V.Q4\9B:E>H[N3;"B MBBKU. ****-0/*_AY_R.7CW_ +"(_P#9J[ZN!^'G_(Y>/?\ L(C_ -FKOJ<= MD0%)NHW4E/4 .:*;NHHU XNFQ^9@^9MSGC;GI2JI50"Q8^IQFH_WQDZH(_Q) M-(L5V<,@5-X)Y.X#'X5(> 3UI&8JI(7)["D1F*@L #W .1^>* (X;@R,5\IT M [L,"G37$=N 7.,\ $GZ4-(XE"B(E.[Y&!_C1/,D$>^0X H 5E6= &7(/.U MA_.LCQA=?V7X.URYC 0V]C/*NT=UC8CC\*U8;E)HQ(,J"<#?Q^5<[\36#?#W MQ*@(W_V=.=N1GB-C_(&@#S[X^ M>V>E?,_PW8?\+%^'[9^1]&N A]P\P/\ Z"WZU]-6]X M!+?\!- 'R!\9O&3^//B1K.J1.;BVCD^Q62H<@Q1DJNWV9BS-I=6\[+\^RV8E%'?#X?IUWK7ALLF MH_$SQRY&Z74_$&HX7.?E,CX _P!U%Q] M?HQI.DVVCZ+8Z="G^AVL$=O%'MZ M*JA1^@%?38^7U'"4<)'=^\SX;)Z?]J9AB$]%_$% ML^+?4O\ 0)AG :.X :,'W$JH/^!&OIK<>,#.>O/3BOC_ %C0;NPM_$/AE7,- M]I%T\=I)G&U01-;./8*8_P C7U)X,\1)XN\+:5J\1V"[MXYF&.C%067ZALCV MQ7D8^*;C67VD?1Y3-Q4\/+>#_ \6_;#\=-H_@^P\-6K8GUB7=<,#TMX\$C_@ M3E!] U>9_LM_"RP\>W_B#4]7MOM.G6ENVGQ*P&/-E0AV''58R/IOKD?VBO&W M_"8?%;69E<'3],_XE]L!C&V/)=OQX!5>?[HKFQ&&EAXP8&&.2<_*!Z5Z9+\'_VG<\_'/1B?7_A'8?\ XB@?S-/XGV2GXJ:_;GE+S0?. M(]XQ(W\XA6]\*KW[3\-]#ED/^KMO*)]HR4'Z+7SCXW^&_P =[7XD/!?_ !9T MRZU-=#N)&O%T6-%\CR[C=%MV]6 <;L?QCTJ;X9_#/X]W?@NPFTSXLZ;I]BS3 M&.WDT6-RO[Y\G.WH3EOQ%7'<1]:0S)<1B2/)4]"5(_3%.6-58L% )ZG'/XU\ MVK\,?VB7D>,?&72PRXR3H$8'/H=E2?\ "J_VB_\ HLND_P#@BB_^)K:[["MY MGT9)"LJA7Y&$O#,]CXT\26OBC53=-+%=VMHMLJ0E$"QE0.2&#G:UHUK=7WA6.VC=F: M2-7ECCNBVY(F8GY IZGFOM&^TZ'45,=POFV[*5>!P&C<'J&4CD?6I8;6&UM5 MM[=%MH8UV1I$H544< 8X '3 H:UN(\E\4_LWZ3KE_\ "E]-O3HFG_#VZ6XL M[&&W$BS(L:HL9;<"N H^;!//YZ7Q8^"J?%+QC\/-PRR2G.=TAR?_P!5$RRML\IU3YOF+*3QZ#GK18#P M7XG?LNZAJGC[4/'WPY\#=NGKL M?"']F72/A_I/BF77=0O?&/B?Q;$8M?UK5G#2W491D$2@#"1A6("@^GH,>SG' MIFF6\C21DR1&(YP%+ GZT66X'RE;_L7>*=,TN7P/I_QJ\36OPOF22!M!^PPO M.ML^=UNMV6W!2"5P(^A-<5^T=\(=&N/V@OV?O VG:A?>&--TW1[Z+3[[3)=E MS9M B&*16QR0R*>1SS7W!-(\:Y2(RGT! _K4,FF6=U=07D]G!)=PJ1%-)&K/ M'D&?"W]FFZT_QU9>/_ !WX]U+XE^)M.A>VTFXO+)+&VLHV MR&9(%)^=@3\Y/X5V'PE^"D'PJ\6_$/6HM7?49/&&L-J[P/"(Q:DY_=@[CN'S M=2!TKTEKJ"*:.%Y8TEDY2,L S8ZX&><>U.DDCBP\C*G;)?":6WV>TTNWM(K$#:,1&X<,S7"H0K;25!*J37U'-$EQ"T; [&&# M@D'\Z;NAM82"R1QQKDY( 4#N3Z?6G8#YY\3?L?IXC^!/A+P /&=]::IX5GM[ MK2]?CM5;RYH=P1FMR^" K$8##D Y[5'XI_93\3ZQJ_A_Q;I'Q6OM!^)5EI@T MG4O$<&E1O#JD 8N#):E]JL">H;L/;'T"UI'?S17274C1@9589,(>^>.N?K5N M57:-@C^6Y& Q7./?%*R ^>?"?[(?_"+_ !:\-_$RZ\=:SXE\7V$5Q#J=UJL: M,NHQR1&-8T12JVZ(26"J#UYK%B_9(\8>'O$.N7'P\^*VI_#;P]K-V]]=:#%8 MQ7\:2R',C0,[+Y.?8'''I7T[:0R00[9K@W#YR790OX8%.D\[S8]@C\O^(L3G MZ ?XFG8#P6]_8Y\$?\*.@^&R1ZI<6T-X=2CU<72K?K?$EC=>9MQOR3T7&*P+ M/]C_ ,2^++S2H_BG\6M8\?>&],G2Y@\/M91V<4DB'Y#/7IQ18"NM^/MPM!;S#"Y\S;\G3L:NY]33&;:P&"<]^W MXT,P12S$*JC))XQCN:8!%,EQ&'C.Y#T.".AQ_2J]I!9Z6I@AV0;FW;-W))P, M]?I3[.^@OE+02>8JG!(!Q_GZ5%+9V%K*;F2.".0G/FN #GZ^M $]Q;I<8$FX MA3G 8C\^?YU,34%Q;I>0['+;#S\C%<^W!Z5)%&D2+&@PBC '6@".&%XV)>9Y M<]FP /I@?SIMY'6+>6.(;LN74L2/89Z_6H9=-EDNA*U].$#96&/"K]#QS M^)JY)NV,$(5\<%N1GMF@!U0P23/O\V$18.%^<-N]^E)9QSQP@7,JRR]6*+M' MT ]/K5>^;468I9QPQC(_>RL3V_N^Q]Z +<\CQPNT<9E<#*H" 3[9)_G26

G7"\-:Z!J=]JCZ;;:==W&HHS* MUG% S3 K]X% ,Y&#GCC%-U;0]2\/W*V^J:?=:;<,N\0W<+1.5)(!PP!QD'GV MKN6%H^W]I%ZZ::=%9>>W9V/4C@\.L5[:,O>=G;3HK)[7V[.WD>]_LZ_\B3>_ M]A!__1<5=?\ $K_DG7BK_L%77_HEJY#]G7_D2;W_ +"#_P#HN*NO^)7_ "3K MQ5_V"KK_ -$M7PV9?[U4]3\FS#_D>2_QK\T?!%%%%>"?TX&<)FF'P%:$9X]: M)Z.[3N^BY6GKV\O(]$^%OB'QK\;OV@K#QE;6UJBZ9+$MT%D5([6T8.I4 G^C MOWEC1#U\N#8J(>XQ@ XR#TK)T_X[0P_"W3/"5_X=^VWVCS/"<$8&.,U<7]E+QDUFP^UZ(-;6T^VGP]]OSJ BSC/E[=O7ONQDX MSGBJ'AO]G37/$7@?3_%CZ]X=T;1;PNJS:M?-;^65=DPQ,9&25.,$T]DUZ?K; M\;[$161P;?];UW'I[UK^'_P!FWQ%X@TZSO#J^@:6NHR.FF0ZE?&&74@I MWP)L)96R,9P2"#C!!/1_"W]F^'Q!H/C.[\1ZE9Z7JFC)+;)8W%V(UM)PK 2W M1 .V,'#*02&VD\@8-1;5VNFOW?\ !?XZ@ZF2X*'-%W]G):7D[/6"M=[*[5OA M7J5+C]IC[1\:K3X@?$WM^SV1L_[.^W9W?*PW>9Y?'WNFWMUKGKOXV?:OAMX MH$C1MAUO66U;[9]JSY&YXV\O9L^;_5_>R.O3BG^&OV=]>\263W[:QX?TG3' MO&L;*_U+4/+AU&0.R'[.0I+C*'&0,YXSSBAH/P&\7:]X^O\ P@MG%9ZGIZ^9 M>2W4N(+=-H969U!X8%<8!)STX.)VT_K=2_/4VA3R6FWRM+V2C]IZ*#TZZV;L M]]79ZZ' +ACR<_,,Y;;M!P/ M";VZ:^O)[EHXXFFD:0QPH$1<_L[_P#)'?#_ /V\ M?^E$M>C5V1V1_*6=?\C/%?\ 7R?_ *4SI_!?_+Y_P#_V:NGKF/!?_+Y_P#_V M:NGKFG\3.&'PH****@L**** "BBB@ HHHH :_P!UOI7F=>F/]UOI7F=;T^IA M4Z!1106"@DG '4UL8A7S-J2_VI)KL;\C4O%\=MS_ '5FEBQ^(<5]+Q3)/&LD M;K)&PR&4Y!_&OFJQ_=WFFD_*(_&XW]\?Z8G^!_*L:FR-J>[/K6W'?GZ5?A[ M<@]3Z52M^W*FC!7G!YP-O'%0QG&"03D\<=.*L*&X&<' MNV.OM0!X7^UE\2)O"?A"S\/:?.U3'F8(Z%BR)_NE\U?2OQUT?=X/MM7B7#:)=+T-_P"\]Z /D3]C/Q8-)_:$\1:9=V@M&U>.YMT1""L,Z2&819''W(Y> MG]ROM/X'S'2X/$_A)LA="U60VH]+2X N80/]E3++"/:"OB#X":'//X^^+&JV M4+SZEH+'6[6.,9>0V][ODB7WDB\V+_MI7V)INMVVC_%;P[KMM,LVD^*]..EM M-&@#U[5-3MM'T^[O[V5;:SM8GFFFD/"QJI9F/L M#^5?EAJVC:Y\;/CTUA?B6VUCQ9JR&5>LEG;N@)_"SMDZ3?\ VNVC]+:ZS(/_ ".MT!Z "N\^/?A& MZ\;?"G7K.QB,VJ01I?Z?#CYFN8'$T:Y[;F0(?9C7SI\%?&5OI'Q2\,ZM#,/[ M*\26C:6\O;3?M+?%/QI\0/CIXO\#^%[K6+S0':#3+ MK3-+A,S2"''FD*!Q^\9P>0& &XX Q]M?##P'HGPZ\":5HV@6$NG6,<2R%+E0 M)W=@"S2_[9/7TZ#@"NITOPSI/AQ;G^R]-M=/^T2O//\ 9H50S2,26=R!EF)/ M4\U+-W].PQTH \8^-<*P^+_A[?OP$U)K=_\ =?8Q'XB.J7[/\C#PCJ=JW6UU M2:+'IE8W/ZN:T/CV-USX(0?ZTZVF&_[9R=OJ16?\"?FT_P 5.O$;:W)M7T_< M0=_\]*TI_$9U/A/3:***Z3F"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "N0\%_"/PE\/-8UG5?#VC)IU_K$GF7LRS2/YC;F;@ M.Q"#+,<* .GH*Z^N0\1_%;PYX;8P->_VC?\ \-CIX\^8GW X7ZL0/>MJ5&I6 MG:E%M^1SU\31PT'*O-1CYNQR_BK]ECX7^-?$%]KFL^&/MFJ7LGFW$_\ :%U' MO; &=JRA1P!T K=\,? [P3X-OM#O-'T7['BL3P[XTT;Q5;B;3KU9"7:,PR*8I588)4HP# C([=ZVZ\V<)4WRS5F>Y M3JTZT5.E)23ZK4****@U"OG7X\>,H+?XB6EKYOV]=.LLBUB4/Y%R[#E@?EWF M/&WN 6Z;J^BJ^3=#U:V\1_$O6=66/S/-DN[NW+#AE#A(V_&-$/XBOJ>':"J8 MIU9*Z@K_ #V1^?\ &F+=' 1P\'9U9)?):LYZZ\0:O=1RW=S8/8:HP.GUXJA=7/B'PG#;6.E:?;:AI]O(TH>ZAC$\39.Z-G_BSGCC/IVJ M;XTR)#HY#;F$SPOD-C>2S.2?8%NGM7;Z;IUKJFFV=T(H9[J2!#*%N2DFXJ#_ M +K''?J:_292CIS'XA3C.SY/GY_T]K=CS74/C@&ACMWTV[L[F3*W,-N &:3. M "Y.XKVZ#'I61H-QXK^(5YV<=Z]&USX;V'B** M9D^SW$P4[8Y%,=Q$,8.>><>@XK@_@GY]O->VL1:\>> ;+P-H6E)#'+J$XNT%W)(Q\HR [ O0#FKNA2:OX7DE M8(L^A1,@CN!\WEJPRH=>XQ@'([<9%;?QIO&C\(Q2")I([S5PQ5!E@$[?4X-3 MZ9XLM;'7I=$V+%OCBF+-@Y^7 7OQP1Z'CI5TY/E_KYF5:$>;>W]*QH_#WQ= M)X5^(MMJ]RX@T^Y0QZ@UM\R-$P;;,_\ >VR!/F_A5S[U]95\=>+-!-QI8U'2 M_)AL'MIH)U3[MN[@X)']PL<^U?6?AG6!X@\.:5JBQM"+ZUBN1&W5=Z!L'Z9K MX+B:A"-6%>"^)6?JC]>X#Q526'JX2H[\C37I+]+HTJ***^*/U(**** "BBB@ M HKS7XY?&;_A2NCZ)J!T2;7O[2U*/3_L]O,(Y%W!CN4%3O;YE-K2_Z='?":V4D,?ZNWYGN%%?/'PY_;!L/&WC+2=&O]"@T>UUIF33+N'7+6]E9NJK< M01G?;EAV;/S''J:=J?[5U^D>LZ[H_P /-1UKP!HUV;6]\1I?Q1-\K!9'BMR- MTBC(((8<==O.#F6G]??VW6_<.5WM_7R[_(]F\7> M"\>+IBZ[8_;ETV\2_M/ MWTD?ESIG:_R,,XR>#D>U;]>*?$[]HZZ\&V=EJ'A_PA+XDT6;3TU&76KS4(]+ ML5CD ,21S3+B65ASY:_,,C@G(&7??M8J^F_#NYT3P=>ZW-XRCN!!9I=I%+#- M$0NSYEVLI?JY9<*-V.U',M5YV^?]+\!6;2?E^&_ZW.P\9_LR_#+X@:[+K.N> M%+>YU*8?O9X+B:V\PY)W.(G4,W/WB"3QSQ7:3>"="G\(R^%CI=O'X>EMFLVT M^%?+C\I@05 7&WJ>1@YYZU\_>+OVE_%5_P##CXBP6OA&?PMXV\-"-;JW.H0W M"VL,BDBX639M-/@[:>(K37-,O[_1IW"KKZRVMW M&D.5N+B(1GS'"V_!W3?Z?GV8Y.4??>ZOZJUO\ /\NZ/?O MO@'0/AKX>BT/PWIZZ9I<;M(L D>3YF.6)9V+'\3705\VZI^U]JF? M#6_U3P3I\[6L&N#4HH_/D5U7+0[2Z1Y)^<;N@! ).VYX_P#VO+;PIJMMI6EZ M!:ZMJ2Z=#J%^E_KUMID=N)8U=(XWF_US[6R0H[KUR0'[1/6_;\KK\$/V:+K_A.>&"ZT5;Q+@.TQQ$?/"A0 M"0KU1%PHHHI#,CQA_R*6M_]>,_ M_HMJ^7J^L-2L8]4TZZLI2RQ7$30NR$!@&!!QGOS7!?\ "B]!_P"?O4?^_D?_ M ,17PW$648K,JM.>'2LEU=CRL9AZE:2<.AX917N?_"B]!_Y^]1_[^1__ !%' M_"B]!_Y^]1_[^1__ !%?)?ZJYEV7WGG_ %"L>&45[G_PHO0?^?O4?^_D?_Q% M'_"B]!_Y^]1_[^1__$4?ZJYEV7WA]0K'AE%>Y_\ "B]!_P"?O4?^_D?_ ,11 M_P *+T'_ )^]1_[^1_\ Q%'^JN9=E]X?4*QX917N?_"B]!_Y^]1_[^1__$4? M\*+T'_G[U'_OY'_\11_JKF79?>'U"L>&5?T/7;_PWJ4.H:9=26=Y"QX->R?\*+T'_G[U'_ +^1_P#Q%'_"B]!_Y^]1_P"_D?\ \15PX9S2G)3A M9-=5(/J-<\Y\2?%;Q7XNTXV&JZO)<698,T211Q!B.F[8HR/8\9 /:JOB3XB> M(O%UC;66K:F]W:VQS'%Y:( <8!.T#<<=SGJ?6O4/^%%Z#_S]ZC_W\C_^(H_X M47H/_/WJ/_?R/_XBMI\/YS4YE.5^:U[RWMM?O;IV-GAL7+>7XGAE%>Y_\*+T M'_G[U'_OY'_\11_PHO0?^?O4?^_D?_Q%G6ME$6:*WB6%&<@L0H M&<=^*^MX=RC%9;5J3Q"5FNCN>A@\/4HR;GU+%%%%?.?^1V\0?]A"X_\ 1C5]1D5G4J)]C] X M0BIUJT7UC^I]3:IJ5ZW[3VC6#W5P;!=-:9+9I&\H.4D!<+G&>V:Y/P]XGU7Q M3I/QJ@U6^FOK>VAF^SPS,2D.// "#HH^1>GIGK7DY^.WCEFL&;76=['FW=[6 M%F7*%"22F6^4DM86G^/M>TN/74M;_P I=<5EU >3&?.!W9ZK\OWV^[CK M79#*ZBAROENHQ2^4KM[=4?24LEK1@E+ENE!+?[,KM[:77XGTSJVO:1X-TSX= M+;MXJ\DVB-9VGAL1M!=MM1F65&YD)SG'N3P>:S+3Q&;'P+\6-8TFSOM"E>\W MI!=1_9[F!WBC#,0"=IW,S#![CI7AGAKXR>,O".DC3-*UR6WL5)*PO%'+LSU" MEU)4>P(&23U)K,MO'VOVNB:KI*:B[6.J2>=>I(B2-,^02Q=@6SD#H:?]E5-4 MVGKW>JYN9W5O\_D%/(ZL=)-/5:W>J4N9W5M[>NM]4>S^"-0U'1_A*?%&LZUX M@U--1U+$6GZ7*(YKB8911-<;3-AC&J_*W P "3BO1[A?^,E-+IYYK/%9?6O4JQ2:M*UM]59*UN MEOF8X[*L0O;5HI.ZE9*]W>UERI6TMYMG4^#]:U[Q1X7^+=MXKFN+BPMXIF"W M676WN%\P[(]V,;2J$*, 87IFNV\5>*-*\$^*O"=O GBV8+8J;'3/#\<;V-R@ M# AH^"[!<$^@VD8ZU\X>+OBYXI\5V$VD7NN37>CB7*0E%4NJGY=[!0S]C\Q/ M(!ZBET?XU>-?#^AQZ18:_-!81H8XXS'&[(IXPKLI88[8/';%5++*M3W[)?W; MM+X4KWMO\OF;U_+OIKIUW/4':"]^"_P 5FT^RNK.% MM:$HL[F+9- /,A9E9 3MVX88[!:V9I+S1/!_P3599K.5M1MT?:S1DQN1E3TX M*M@CH0:\&\)_$OQ-X(GO)M%U:6TDO#F*O%D M-E'JNL2W0LYC<6[!$1XY,YW!E4-QVYXXQ6[R^KS*-UR\U^M_AY=K?J;RRFO* MIRW7)S.6[OK#EM:UOQ/HOP_J5[=?M)>,[6XNIYK:UTAQ;PRR,R1!A;$[%)PN M3R<=:X>;4M3\+?LZ^$;OPK-<6EQ<:DS73=( 'P.02J+@]0JCFN F^. M_CFXU".^DUS==QP26RR?9(!B-RA=<;,YK)\'_ !/\4> H)X-"U:2Q M@G;>\)C25"V,;@KJ0#C )')P,]!4PRZM&,;\NG)IK9\O,G?3K>^SU^\SAE.( MBHMJ+:Y-+NSY5)._N];WV>OWGLOASQKX@T/QMXPG\;>&]2M9K^RA2ZOM#MN; M"/#!9-Z$_+MW'?N)!BQSMP,7XWZ;]N\ :!KFF^+;SQ-X=^TM;6W]J6Z_:5<45V4F/&&'8(_'DD+:[JLM^(1B./:L<:]>=B +NY^]C.,#/%:PP%2->%565K7MY M*VB:=O)W6G0Z:665:>*A77*DK7MY1MHFG;R:DM-T>R_LZ_\ (DWO_80?_P!% MQ5U_Q*_Y)UXJ_P"P5=?^B6KD/V=?^1)O?^P@_P#Z+BKK_B5_R3KQ5_V"KK_T M2U?)YE_O53U/S?,/^1Y+_&OS1\$445IOX9U6/0(=;DL9H])FG^S17;KM223! M)5<_>QM.2.!T->%J]C^F93C&W,[7,ROJ'X WOBV^^&:V%EH'AGXC>'H;IC)X M>NKA(KVS9BQ5V\U?+V$AF'WB=QP>"%^??&W@/7?AWK"Z7XAL?[/OVB6<1>=' M+\A) .48CJI[]JP*$U9GDX["T\VPT53DFKII_$OE:47\U)'VQX9;P+X!^/6L M:#HAT[3I]9T80M:22^;:QWYE;-N>>-P*_NQ@< 9(%%-(GUFWN6TG1872]F\F9':5$1FC(VH 68YP0."0*^4Z*7;R_SN>-#AR, M:JJ5*O/I&]U=MQ5DT[Z=-TWIN?6WQ-^#VL_$+XCZ]XSTOQ1:Z3X-U#21(-/V,?['_P]B60/'_:T_*YPV'NL'D9[_K7 MSY11]EP6VGX7_P SKHY/5IJC&I6YE2<6O=MI&+C9N^KUU?EHM3[>LM0U?QYX M'^'FI>!/#_A#Q"+*UCM+N?7H0\FDS1JG0[E9 "N?E!/"L!@@UR_P]U._^)%U M\<].^TZ/J/B35;"&.)-%E9;6X9(I(BT1E()7<4!8_+ELYP0:^2:*J3YG+M*_ MXZ_F<4>&XTZ/5_$?PC\)Z1X<\,>%_$F MMZ#.VEZOIOB**.8Z?(I*-(/G )0DE-,FC_ +;F M\C3C-B,7+9097<1\N74;C\O7G@X33D_7\VK:& =8^'/[)/C'3-=6&WU)]4AG>TBG25H 9+< .4) 8A0V 3PR M^N!\MUJ^*O"NJ>"M>NM%UFU^QZE:E1-!YB2;=RAA\RD@\,#P>]95*_,^;^MK M'T.6X5X>G.;J*?M)<]TK+5+;5Z::.X4444'KGVI^SO\ \D=\/_\ ;Q_Z42UZ M-7G/[.__ "1WP_\ ]O'_ *42UZ-79'9'\I9U_P C/%?]?)_^E,Z?P7_R^?\ M /\ V:NGKF/!?_+Y_P _P#9JZ>N:?Q,X8?"@HHHJ"PHHHH **** "BBB@!K M_=;Z5YG7IC_=;Z5YG6]/J85.@5DZ_8M?BV22)KFP5R;BW0\R#'RY'\2@\E>_ M'7H=:BMC$\PF\!ZW=7ERMOO;BN!^$.O'Q%\/-"O';=. M+98)SG_EK'F-_P#QY2?QKNH6&#SQWYK W+\>$]!NM9U>[!@MWMU7;:,1_K7#$$@=@ !FO?$7B&T:RU:>'[)9VDS!WA@R"[N02-SE5XSD!.>6('T)> M6=OJ%C<6MS"L]K/&T8&7)/[O'+ U(KX1@[G*X,A">C^ M!=#O(I[_ %O4K?['J%]Y<45FQ#&UM8\[(V*DKO)9W;!(&X+EM@)ZK=M8[2#S M\V3TX_\ U4NX'&?N<;3DY- 'Q1^Q+:B/XY_$DD9#1R_^E5>E:IX4_P"$?^V_ M#6YN#I:;_P"T/"&I@9"+'()HHTSP9+60*-G\40C//SXXC]CNW,/QJ^(+C 8I M+UZ8^TU]7>*/"^B^-M*;3];T^WU.Q5Q+Y0/8/A/X.G M\&^"[>'4A&VN7TTFIZH\?*F[F;>Z@]U3(C4_W8UHT7X.^"_#>L6NJ66APKJ- MN6-M//)).T1(P63S&;:V,C(YP2,\FNPWE "-W(QN]<5\1?&'X>/\ M/_%U_HVZ2RT/6+A[_0;Z,8^S3[_-:!3T$D4H,D8[IMQGRVQ]LLR+'][Y>F'O@IX&\'Z M[#K.C^'K6TU2W5XX[K>[O&&&&"[F.,C@X[5U#_ +?IURL0GO+F0JTA4L4= N.W+0[3 MGM^53?%'7EN/B!XGU%F'D:%I L01T,LH(<#WVSG_ +]GTKTWX:Z,^@> M"LI M5VSK:J\R^DC_ #N/^^F-:4U=F51V1AZ"=3M8[^QG%S/K8NA+%)ABD8>-&8,Y M^4QABPVYR<' SC'H-%%="5C!NX4444Q!1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 45\T_'+XD>*-+^/.B^$M/\ B/9_#K0KK1?M MLM]?V5K-$)A)*,9FQRP51C<.G2J_B[Q]XO\ _@'P]J-A\5;'QZ^I>*[/3GU M33].LTC2!E;S(,1[U)) .[AAFIC)2MZV_P#)N7\RY1<=/*_X7_(^GJ*XK0OB MSI'B#Q5XR\/V]M>I>>%1$;V25$$_2J6NJ\G]^Q#]UV?>WS.IHHHH **** " MBBB@ HHHH **** "BBB@ HHHH ***Y#XO>-I?AS\,_$?B2"$7%QI]HTL4;?= M,APJ9]MQ&?;-3.2A%R?0J,7*2BNIU]%?-&A?!?XA^(_ ND>+K3XM>(X/'-]% M#J)AN+H'1U\S#>7]E"%0 C =U)&=HSQPWQK^(7C+P7^TI:W$7B+4/[$T.PT^ M_P!5L+>>6.TFB:9(IF\C>5&?-SSG'')QFJ=XS4):-NW_ ?P$O>BY1U5K_UZ MGVA17Q7\4/B/XG\1?M-:/%I/B/4['PA#K5GH!M]/OI88;F3:))B51@"1YFTD M]MOI73_#_P",FK_#GX3_ !5TKQ/JEUJ'B7P;=3107.H3M+-,LN1;,68DD%^G ML167M%R.3Z7?K:WYJ29?)[RBGO;\;_JFCZMHKSS]G_1=8T3X1^'5\0:G?ZMK M5U;B\NI]2N'GE5I?G";F)("@A<>QKT.MY1Y6XOH8Q?,KH****DH**^>?C9X] M\0>$?VA/A[;:/'J>KI=:?>XT"RN_)COIMI$?F;F" \EVSM )YQ@\=\7OV@] M;\5? _QVD6GZEX \7^'=3M+2[AM=1+O&'E&"D\87.0&! XQCD@UGS^[=?UKR MFG(^;E?]:7/K>BOC"\^+'BUOV=[?PFFN7@^((U]] FOQ<2"Z$<9,[3^9G<1Y M6T;L]":X;3_B5>7'A_X0MXP^(_BSP_HM]9ZD^I:GINI7'VB1DN9!$6*ARW(5 M>5.!Z57,KM+R_%G0G?\1?&[6?&?[-W@*ST/4[JT\:> M*+Z#1&NK>5DN(Y(W"S2;@=P)PI)STDHYK[+73\6U^:^YH.7N]-?P5_R_%,^M MJ*^:_BY^U9HGPCOM!\+:-J\.J:G87\%AKG]JVUU++#;!1OE\P;0\G0Y!?))X M-<9\;OC9X;\7>// -]:?$;Q#X<\ WUI>"[U#0)KJT=I(VPO[ORRQ.[ R4/!_ M&ES)_"[J_P"E[^GZARNUY*VG_ MZGV/17Q3X5\=ZPT'Q4'@WQEXI\6> K3PU M-/#X@UR:4SV^H*@(6&9E1@0"3@!>F>P)W_#OC3Q)X/\ $WP.\2:EKVJ7OA[Q M1I$6E:A%=WDDL/VMERDK!F(WL67YNIVM[U47S-+O;\>:WWN.GJ@<;)OM?\+- M_@_P9];T5\[^%=4\3?%;XW_$JZT;Q->:/HV@VJZ'IV"TUHMX0?,G-ON"2,A# M8SZKUQBL3X1W&O\ @C]HQ_!=[XN\4:K8?V0SSMXOD8KJ-TC#,FG@YQ& 2<;B M82CRJ7E_P/U=ODSZCHHHJB0JKJNJVFAZ=<7]] M.EM:6Z&2660X"J.]6J^>_C!XTB\3>(7TY"K:1I#E6#CY;BZP5(Y_ACR/^!'_ M &:]3+L#/,*ZI1VZOR/ SK-J>3X26(GJ]DN[&?%/XU:;K]CI]OIEYJ-H/M#" MZLU5[>66(IE7W#G9GJ,@G->52>+K8R1V=O&MH1M*QQQF-3S_ !'KT[G)R:Q/ M%%]-/?1);2M)=[C(2I*G;R6Y].!^=3ZQH?\ :$R!;PV5Q&J-$L]?L.#P-#+J?LZ2O^9_-69YMBLZK>VKNVEK*]OU,'Q%KQMM:F:*/R9< M[7E4\R>F2.O!'UJUH_Q%U'3X'$<23(&W-*Z$D9]37"^)-6:36)8TDDNH%D98 MY"V["^N?0XKN_"%PFOZ=/9BQACMU3RH6GD*KOQEO8N3G&<"NM5>9N/0\]X?E M2GU9>L?%"7FM2ZG*&CDEVA6C;#0R @^9&3]U^%Z=A7T;\,/C1=:IJ&G:/K#P MWSWC&*WOX2$=F"EL21]C@?>''M7S%-!!XD9H=)A^R+%/Q$5Y#$!53/J<9S6Y M8W%G:+9I>(ES+]PMMVE6!P>1^A%<&.RRAF-+DE&TNC['K93GF+R7$*I";<+Z MKNOZ^:/NFBO*?@3\2+GQ3H\&CZI:RV^J6=HDGG2RB0W$>XIO..ARO/7J#GFO M5J_&,5AJF$JRHU%JC^GL!CJ.8X>&)H.\9?U89<*TD$BHVQV4A6QG!QUKY7\$ M:?8:1H]C:I;-#J;6[6;R/)N)DA5X753Z%P,?05]5U\K>-K.Y\&_%RZLH'62! MQ]K@#(-X$TTLI'OB4LH/H #TKZ?AJHO;5*+?Q*_W'PG'%%_5:.*2OR2M_P"! M67Z6.4^-NFO-HT-Q+$Z67^B$W2C(CW*1C;G)/!.!ZUP6FZ]XAT^U=K73IM4T M.R&V.ZGMMC&,<(_!X.!C\*[#Q';W/Q UI8IGNET"S0>6N/EEE4!&(^N"H[X M]37HFB6J^';%HP(HY8\&:0IE+:( ?+SP6XZ>I-?>_O(J][=C\@7LINR5UNW_ M %I_PUS@_#_Q477+BSBM[YH=0R'2WN(@QR.J[_ITK+\))-:W.OWUS)&EF;TO M'*ORXV-N=OH.?QXJ[XDOM'M[R.)],CEU+4I0\/DVJ"M[;6;4M!?1?-N9F$,I8@X;/.<L^&?!MO86\<<-I&8MO[J&V8%57&=TDG]!6VNM6VF MJ(TN8(45@OEV:AE+$\LS-CX226V+9VB10IP32O@$ MG:BL2< $\#H#6CXC\9:!X/C@DU[7--T2.=BL3ZE=QVXD8=0I1Q'QT M^%^J_$Z'P>FEW%G;G1]>MM4G^V.Z[HH\[E3:K9;G@' ]ZP?B!\ ;WX@?%?5M M;NKRU@T#4?"TN@NJLQN4E9RPD";=I4<'[V^&?&$T\6@^(M)UN6 !I8]-OHKAHP3@%@C' X[U/*G[OJ_O7*_P+4Y+WEY M?@[K\3PCX2_LX>*?"7B3P^VN0> HM'T)6\N[T;1(SJ6HL,")IY98LQL/O%HV M#$\$G.X5I/V<_B/HWAO7?A]X?\2^'X_AYK%S)(;F]MYCJ=G#(P:2*-5Q&XP" M,L1G)^[V^G:*'%/?Y^?J)2<=O^&MM^;/EWQA^R;K=SXS6XT.Y\.:CH#Z'!H: M#Q3;27<^F1QQB/S+:,?(9/EWAF(PS-Z\Z/@/]G#Q1X:N/A ]Y>:0R^#6OQ>^ M1/*QF$Q)0Q9B&3SR&QCMFOI&BG%)XX\'S5V@ $X^Z6XYQVJIX+^!_CNW\9?#G6/$ M]SX<>'PMI]QIDD>ER3DRPM$(XB!(G+==W*CT%?0U%)12LO*WY_YL)2<[WZ_\ M#_)'YNZQXWU/0_ OC'X36>I"WL/[3>'3M!O-(G.MW#O-&RPY0M"L>XL<[B[; M>% <8]^\4?LQ>)I/$D?B/P[:^#=2N=1T>VLK^Q\8V!N4M9XHDC$L!"-\V%YR M,<1W_ )%JED9Y9T(W0P0QB-1N8Y'R\<\G-5[[X#^*I=?^+NHV.M:7IY\6FT-@ M9;9;Q,1(RO'J*MJ_X_B[O\2+O\OPV/GGX+?L]^(_!O MQ6O?&NN)X6T'S+#[$ND^#(IXK6X8D9DD20 (0%7A!@GDX(.[Z&HHJNB78GJW M_78****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH *\(\2? ?7]8\1:I?PWFFK#=74LZ+)+(&"LY8 X3K@U[O17;AL75PCFJN?.__#.WB3_G]TO_ +^R?_&Z/^&=O$G_ #^Z7_W]D_\ MC=?1%%>A_;.+[K[CV_\ 6K,NZ^X^=_\ AG;Q)_S^Z7_W]D_^-T?\,[>)/^?W M2_\ O[)_\;KZ(HH_MG%]U]P?ZU9EW7W'SO\ \,[>)/\ G]TO_O[)_P#&Z/\ MAG;Q)_S^Z7_W]D_^-U]$44?VSB^Z^X/]:LR[K[CYW_X9V\2?\_NE_P#?V3_X MW1_PSMXD_P"?W2_^_LG_ ,;KZ(HH_MG%]U]P?ZU9EW7W'SO_ ,,[>)/^?W2_ M^_LG_P ;H_X9V\2?\_NE_P#?V3_XW7T111_;.+[K[@_UJS+NON/G?_AG;Q)_ MS^Z7_P!_9/\ XW1_PSMXD_Y_=+_[^R?_ !NOHBBC^V<7W7W!_K5F7=?::2Z:<-;LS+M*(N.0.I\4I*_P!Z/@BO MJWXF>-=O[,'@>7^P=$/]I%K78;/Y;7 <>9 -WR2?+G=SR3ZU\I5ZG'\:;&\^ M$-GX'UGPPNJ2:>TLFGZF+]XFMW8L58QA3OV[V&"<$8XXS7%%I)7[I_)/4_H_ M-L'/$U,-5A#FY)W>J6C35]6MG;S/I?X@:UHM]^T9X?\ ".H>$=%U>/5+#_2M M0U&W\Z=5"S%%B).(P"IR0,G=VP#7#^!?A'H'AO0_'FNI;^&I;VTUZXTK3V\9 M2$Z=;01R@?,#U=@2 3SPN",L#YIKG[1G]M?&K1?B!_PCWD_V;;_9_P"SOMN[ MS/ED&?,\L8_UG3:>GO4&A_M!I:S>,K+6_#,.O^%_$E_+J,FD2W31-!,[[LK, MJYZ!1T!RJD;>0<8[/OK^:M^%SY*GD^8T,/"G232Y:?,N9:M2?,E>5MK=5%K2 MY[1H'@3P#JGQK\,36,/A;5AJ&DW!U32])DBO+&*YC"?.B'.P'<<9 ^[G&WF]3VSXA>#/"FL^!?!/B"SL?#RG!D998@I)\Q R@"0YW $C ;%:.N3^"X?V@A\.#\//#YTG4(!'/ M=+9".X29H2X:)Q@(NT*,( =VYMV"M.\(0^'],M]=L[BR M^SWK2>4HD7*R;DS(Q9G.[*]1P<$GO_C9\:M+^&GQDU&Y3P59:EXGM+-(K+6I M;IT\I7BR-\0!#D%F&X%6VG;D=:6S5]FW^2_7^N_E?5,=&I]5G"3DXU'%-J'ER736DL4[-N9@Z*2 3DX M&/O-S@D4FF_'UM!^*EIXMT;POI>BV%O$;7^QK"-85DA.:27?4ZWX4^&](N/A7\6 M]2NM%T^]N=.8FTFNK1)#"0'.$)&5'3H17?\ Q4\30:O;_!+3;GP[H4EMKPLI M9=UB";5=]LQB@R<)&0VTJ01VEDCU)Y7 M69P0SG'/!=IJ?A%+S6?"KV_P!CU2/47C_=Q21L M5,6PC+)&JDDG!RP Z5<&DX\VRY?P3O\ H54R['8C$_6JE%_$[+FC=)TTD_BM MI):V=_)GJ4_P]\+:;\4/B[X@G\/V-U9^%;*WGLM&\E4LS(]L6):,#:1E#QC' MS$XS@CS>+QI\-OB/XH\#IK/A6T\+LLK1ZW/IW^B6,B?-Y:A$.0"Q7KLZ@E#G)'7(!SD#"CHX_+_@G1 M0R_'1DE5A)ODBE)3MR_N^5JU]7SZ[-7=[Z6/8_C#\/7N/ NOZEI_@?P;JV@? M-=:9K'A606=U:0JKGS9OE*SJ!@%4;!P3CH5^0J]IO/V@M&TS1/$=IX.\ VOA M2]U^-H+V[749+A?+8-D1Q;56,_.<;< >G QXM4*]SV MC5W1V1_.^=?\C/%?]?)_^E,Z?P7_ ,OG_ /_ &:NGKF/!?\ R^?\ _\ 9JZ> MN:?Q,X8?"@HHHJ"PHHHH **** "BBB@!K_=;Z5YG7IC_ '6^E>9UO3ZF%3H% M%%%;&(5YK\;K&6SL-&\3VJ!KC0[Q7?(R#"Y4,#[;A&3[ UZ55'7H+&[T:^M] M2V?8)H)$G#G ,94[OTS2DKJPT[.YP'P1U:+0_$NN^%UD/V.X*ZMIC,>6B<+N M7Z@&,D>K/Z5[C#(>O?L,]:^0=/NKW1F1[.5;O7?",_F0L#@7EDQR?P(JD=F!R".Q!%<9V'2Q-[U81N -V! MQ\V>M4(I#QS5E9 %7Y,C(XQTH \T_:,^*MQ\-_!D46F3"#7M5.-%T.TUF_U/5;NZG@_M73XKK4)IQ?60?8\31R M,5#D!&5U&0)XSGJ*Q?CC?3_%SX]0>&K*9C%#+'HL,D?.PD[[F4>Z L#_ ->] M?0'QFT.'2_#F@:A90+!!H]PEF4C'"VLP$.T#T$GV=O8)0!ZCINI0:M86E]:R MB:TN(UF@D4\2HRY4_B#FN4\WM5R%17'*&1 M@_SCD+%)@JVT@^&,GV/2;W16/SZ/>26L:\82!@)8 O\ LK%(B?5&]*Y"//BZ M103YW_"5:IN)[?V7;#C_ +9RK&/QO* /(_V+H6_X6)XOE=9HA- [J)V9I54W M&5#EN=P! .>^:^P&)&64$D X7.,U\Q?LQP>3\4O&CXX*2:3KSFO"_C5XBC\2:Y;>$8IC'I]IMU#6KA.?+C7#)'[D\-CU\H M?Q4 >=Z3I-SXFGT/2+L;[WQ#J#:SJG?$*ECM/IG,H'M(E?2E>0_!E[35-6U7 MQ'=20P7E\5M;"T)QY5JH.U4SUR$&!R=L:'O7KU=--61S5'=A1116AF%%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X5XW^#E MSXT_::T'Q#JOARSUKP=;Z"]I.]^L$T0N/,E91Y3DL3\P.0N!GK4OQT^#LNJ> M$?">D>!?#=C:P6/B:TU.YM-/2"TC2-0XDDVY52>5Z9)KW"BIC%122Z.__DW- M^93DVVWU5OPM^1\UZKX,^)W@GXO?$74O"_A:S\1:5XR@@6+4)M3BMDL)%B:/ M=)&P+N%))PHY&.(++^S]6M3<&:W\U)=NZ>1U^9& M*G*L#P>]>IT4X+DCRKR7R5[?F*;YW=][_.U@HHHIB"BBB@ HHHH *\.;]K'2 M9]9UG3M+\!^.]?;2;R2QN;C1]'2YA61&((W++QTR,@'':O<:^'/ ^C_%"0?& M/6/AQXI&G3V/B2Z9]$_LV"=KQ@Q)*RR!BK;>B@8)'49K&VT.TRES%/"1<0S A?)9 3\^64<$CD M'..:R_"/[3'A_P 6WFHZ>="\2:)K-KIS:I#I6LZ>MO<7T"@DM "Y5NG&6&<\ M< D>2>'KCX;-^QW?7-[;Z_JNA7UUYFMO;^5)J%M?-(N^4YVJ KA"#@_*5R#D MU%\*/$4_ASXW^#O#D/C+1_B]IU[I\X@U;[+&^I:,@5V*M.I=MK9 (=\\XVK@ M;M/>YW#K^%^6_P">W1KK*OA3+\0K5KB' M0H;>>XE2X11/&(BP=2H8C=\O W)+*RO;"SU",RPPZ M@BI-LW$!B%9A@@9'/0BOBKQ-;ZCX1USQ?\ =-$T4'B;Q':7&GR@9$-E-\\WX M+LC&.X#U]UZ/I5OH6DV6FVB".ULX$MXD'9%4*!^0IPESQYUL[??:\ON;2^3% M-J^'M35FL=1MW MMY=OWE##AA[@X(]P*PO^%'_#C_HG_A?_ ,$UM_\ $4?\*/\ AQ_T3_PO_P"" M:V_^(J91YDXM:,:?*TT>30_"CXYV?A6S\#V?C;PY9^'+4I;Q^(+>*YCU@6RM M\HVC]V&"@+@,"0/O\DUJ>*/V=M3\5?$SQ1K-]?V=WH^K^$SH(:9V%T;C*$3. MJQA ,INRIZ]%KT7_ (4?\./^B?\ A?\ \$UM_P#$4?\ "C_AQ_T3_P +_P#@ MFMO_ (BE*/,O>UW_ !37Y-@GRNZ_K5/]#Q/PS^RCX@\/^'?AI:_;]+EU+0O$ M$FMZS.9I2+C)['4;.T\.70M?[> ML97<2W7D297:H0JV5"#EAC%>K_\ "C_AQ_T3_P +_P#@FMO_ (BC_A1_PX_Z M)_X7_P#!-;?_ !%5]I2[._X)?DD+HUW5OQ;_ #9VP&!@# HKB?\ A1_PX_Z) M_P"%_P#P36W_ ,11_P */^''_1/_ O_ .":V_\ B*>HM#MJ*\:^,7P=\ Z7 M\(_'%Y9^!_#=I>6^AWTT-Q!I-NDD3K;N596"9!! ((Y!%>RT#/,?%GPPU77O MCIX)\:6]Q9II>B6EU;W$,CN)W:52%* *5(YYRP_&O,_'W[,?BGQ5:_%>*TO] M(C;Q9J5C>6/G32@1I"V7$N(S@GMMW?45[=\7=-NM:^$_C33[&![J]N]$O;>" M",9:21H'55 ]22!^-5?^%'_#C_HG_A?_ ,$UM_\ $5'+LNW^?-^:*YG>_I^" ML>6R?LOW3?&R^\9BXL?[.FT=X8K4R/O74&@$!EV[-H3;D[L[L]JI_"C]FOQ/ MX%UKX7WE_?:3-%X7M=0@O1;32LTC3R2,ACS&,@!QG=M[XS7KW_"C_AQ_T3_P MO_X)K;_XBC_A1_PX_P"B?^%__!-;?_$52]UW7];_ .;_ )E:4>5G;5\X_#K M]EW4O!OQXO\ Q7C'_ M !(^%.D_%!O#YU6XO;?^Q-1CU.W^QNB[Y4Z!]RME>>@P?>L3Q9\,-5U[XZ>" M?&EO<6::7HEI=6]Q#([B=VE4A2@"E2.>64'B;1X+1[6^W MOY$=S#@%@VS=@KO&=N>>E=Y_PH_X%_$OQ&U[1] M1'A6S>UTU=)$QENG=2K37#R ?-C!.,@GTYW>E?\ "C_AQ_T3_P +_P#@FMO_ M (BCX'_\D5\ ?]B_I_\ Z31U2TGS?UIHON3)^RX]_P!=7]YVU%%%,1B^-=?/ MA7PCK.L*H=[&TDG1&Z,RJ2!^)Q7Q1\1+Z\AUBXENGMWFF)>X:UB,*RR$AB[+ MN*[L]U SG)R:^KOCW--#\-+[R@762XMHI81P9D:9%,>?X=V<9/K7RE\3+5M1 MU*!K;#-,S1%0Q^&>(6*F\12PM_=M=KYO7\#C/ M$'C,2M9S0)<1W-N0(W:4N$_V=N.1]:Q=7\17.I737,2M;L8A')Y+';C'.!V! M].E=/IO@62[T^\FO%\D<)$_<,02K>ZM@C-=#X%TB?3-'/VV6,V\QCBB"NB"- MG4L"V5^9>.>:^OES2>I^;4^2*TW.#^&T6H77B*(V<;21>9'%.59%X9L!A:WI.I0ZB;W3;F.RM)&>*7[3&@ED"9\QY$&0=I! .!G('%<+=0WOPQU M8W8DAU&.]?8UK$"#,F<[D'48(P#^-:_@F.7Q9:ZQ_:.H2V4-U=) WG.%>//+ M,[8Y. 3M'4UC"5O=>YTU(:C.T@A\O3K>ZE\Q)U/DQ_+_=/&!ST M]ZZW5+RXTRQL[.95N0H^4^?(57'&0IQCK5KQ%I^F^'/"EG:O;W4,-SN99VBQ MNDW#;(I/J@Y ]*=JGB)+&UL3$TE]&\0A:8R[_E!R-N3E"1C(KJIWB<%:TMD= M_P##SQ9_9FO^%IXI(_[5@N5LGL]^))X)66-@!@YVDJ__ &S/(KZ[KX:T*$KX M=N?$5FTPU6!9IDDMWV/"PR001V Y(/45]OV=P+JS@G7.V2-7&1@\C/2OSOBN MDHUX58]4_P"OQ/VGP]Q$I82K0E]EI_>O^!J35YA\>? IP-RC^\JUZ?17QN'KSPU6-:GO%W/TS&82ECL//#5E>,E;_@ M^JW1\GZ;<0P:;:7S6ZW\;QK-YD<9Y(!Y4=">!E>#D?6N<\6_$BQ?1V^S![5X M&9H[>[;;)-(W_+1E],G/X5[WXZ^&\^FW-SJF@VAO+&Y)>_T>-MC;RW/9\ M\E.C=1ALY\KO_!^C>)IY"D;7DL"XEANH62Y@SR-X;:RCC^+%?K&!S/#XZ*GM M+L?SOFN1XS*9NDUS0[VW_KK_ )'F'PIT>S\4:\VJ:O=&6[CES;B1_D1ASN8' MG!/ [5W7CCP7'JFAW<2C[.%?!CDP?L\G48;^Z:R+KP"W@G7-/ELHEDL9HQ%. MI)4@DG).<\CLN:.J9X MJ]Z3A/1KK_7]6OY'AMEXN\2Z'H=QI,K1Q+8JB)&S%96W%@.G$@ '5C@#'6NJ M\+^$H[S3UU?Q'=7EU)#)O;3U V \;00,[BS$* ,9S@U)%H%AJGBR6YGQ+< M6EA;JUS.$'W2\489L5[S\//A;<7'V/5/$"RV\5O,+BTT=MN P'RRSD9W/G)" MYVKD<$C->=F&/HX"D[R][HNI[>39/BLWKKEA:"WD]OE\NA<^#'P]NO#OV[6M M5M1::C>*L$%K\I:VMU.[:=I(WL[,S8)'W1VKU"BBORC$8B>*JRK5-V?T-@L' M2R_#QPU!>[$****YCN/@7QOJ7C^/XF?'G3O ^GRR0SR0W&K:C!)LEM[:*-BR M1G^^X8],G"M@=QUGQ;@\'Q_L0Z=)X'MQ#H\UU:2.KD-,9]^)/.;O(&&">G Q M\N*^F_"/PITGP7XR\6^);*XO)K[Q-+%+>1W#HT2&,,%$8"@@?,#_ *_POT#X/>((;RWU=-5 MBN8C+2 6QE,<&K7[2WC3P3XP^.5[X?\7ZTFGZ-X?T&X@MF\ MB6<'4IU&#B-6QL4HW6HO&\C.<_*-B* MH); QWH<')_P YQFN0^&&DI\/_ (K?#RV\ M9>"%\':P(Y=/TO7O"UQ"=.UK*[5^TH S$LO(8L&)8$J!]WZ!L?V>_"EF_CB. M07EYIWC"7SM1TV>5?LZ/DDM%M4,A).<[CR!C&*R?!/[+_AOP;XDTC6I]<\2^ M)[C1XS'I<&OZB+B"QR ,Q($4+@# '('!QD C17=7VCZVO]SO^>G375$NRINF MO.WX6_X/730]AHHHIB"BBB@ HHHH **** "BBB@ HHHH *Y[QEXR'A!=)5=) MO];O-4O#8VUGIQA$C.(99B29I(T "0.>6SG .:Z&N=\4>';G6M<\(7D#Q+% MI&J27LXD)#,C65U N */\ P)TK_P"3J/\ A8&N_P#1-/%'_@3I M7_R=7;44 <3_ ,+ UW_HFGBC_P "=*_^3J/^%@:[_P!$T\4?^!.E?_)U=M10 M!Q/_ L#7?\ HFGBC_P)TK_Y.H_X6!KO_1-/%'_@3I7_ ,G5VU% '$_\+ UW M_HFGBC_P)TK_ .3J/^%@:[_T33Q1_P"!.E?_ "=7;44 <3_PL#7?^B:>*/\ MP)TK_P"3J/\ A8&N_P#1-/%'_@3I7_R=7;44 <3_ ,+ UW_HFGBC_P "=*_^ M3J/^%@:[_P!$T\4?^!.E?_)U=M10!Q/_ L#7?\ HFGBC_P)TK_Y.JMJ'Q6O M]'CMYM1^'_B:QMIKJWLQ<23::ZK)/,D,>0EXS8+R(,@'&)(Y-/>U:&/$5X#\C>9MW_ #%XQ@MC[W%TW4-0MX97 MTN32-,,L,CJ"82#("6!.W[H.1TKN-?\ &GCOXF?%G6_ W@C7K;PA8>&H87U/ M7)=/2\GFFD0E8DB?Y N.IX.5.#C@Z.Z?+;77\/P(Z7OI_GM]Y[W17BFBS?%G MP7X;^(*^+M6T[6[;3M/FNM&\0P01P7$KB)FP]NHV *0.O?CYP04"B"3S0H8[VR.6(X;VPT[S4._P#PR^]NR"WNN7;_ (+_ "1] M:4444Q!1110 5B^-].N-8\%Z_86D?G7=UI]Q!#'N"[G:-E49)P,DCK6U10:4 MJCI5(U([II_S1^C?Z_9G_ ,^Z?W2_^2/BO_AG?X@_]"__ .3MO_\ '*/^&=_B#_T+ M_P#Y.V__ ,#WKM:**U6FA^?8K$2Q=>IB)K6;N8\%_\OG_ #_ -FKIZY9_$QP^%!1114%A1110 44 M44 %%%% #7^ZWTKS.O3'^ZWTKS.MZ?4PJ= HHHK8Q(-0DGBL+E[9/,N5B8Q) M_>8 X'YUYY?_ _36+BP2VEF:T+;KQ;N.6-RY4AI4)7[YX)'3*CMD'TJBDU< M:=CR;QU\.)-"T^T\0Z C7&L:8,W2L-QOH=N'4KW.,G:/O;G'):LGX;^.K7P' MJ43++GP3KLGF12LV[^S[D@;D8_W3D9/NK\;FQ[?7B?Q$\%#P7<7VJ6MF;WPG MJ!W:IIR#FV;)_?Q^@R2>GRDG.49@,IQZHUA+HSZ,AEW8._$Q_ *V>EZU=_;_"T_RZ M;KG)\A1C]U-UP%R!SRO&^6MTDT2/&ZO$P#(RG((Z@Y]*P-SYS_91^'= M[=:S>>.-:CE= LD5E)<(0US-(@KZ9US2+;Q'HM_I=\OF6MY! M);R 9!V,NTX/8\]::DWYU,DGIT[\T >+>)/$5]X=N!;WVK6.AZW=0+HVIW%Y M.+83P;CY=]:D\,RAY#L'W3*0Q^09] ^'^G1WE[+K:VOV;38X$T[1X&C*[+92 M"TH4\J)&" #ND,;=ZZ[S 6&>H/'-.$PW'!^;C- '@G[/,/D_$?Q8V,,R/SC_ M *;5]",PVD$97N*\&^!ZBW\=>)9.BLK\_P#;6O;FF/MOP<.W- $DDF[_ '?3%59)#Z\_2DDF_.N'^(WQ M,T[P%9JL@-[JEP"+73H6_>2MG&3_ '4!ZL?H,G H 9\4?B)%X%T<"",7>M7I M,5C9/M07:=N1!H\/IWV%&;A5^RVEM-->016BI+<21N!YB;5!#,.2P)SCI MM'K70T5ORZW.>^E@HHHJA!1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %>.^+O'4GA7]H;2;:ZN-7ETB7PS/(;'3;2ZO5,WVF,"0PP(YR%R-Y7C. M,\U[%7$7/@>_F^-5CXO66W&FP:%-I;1%F\XRO.D@(&W&W"GG.--Q M )&\*<9(SVI_P]U+Q@?CCXGLO%6IV\R_V+:W4&F::7^R68:>90JE\&1R%!:0 MJI)., "NLN? ]_-\:K'Q>LMN--@T*;2VB+-YQE>=) 0-N-N%/.6W.G7FD6VGI$&;S1)'+*[$C;C;AQCG/7BE%/W/^WOQY[?H-[3_ M .W;?^2W_4\@FUK6I/@O=_%O^V]4&OPW4FHQV<=[*+'[*EP8OLIM2_E%3$IR M^W?N.[=D"GWWQ$\0^$?CUXQUBXO[B[\"V*:;;ZCI\CLZV"3PY%W&N<*%(K76/C+_ &3KS6R6<.C_ &5I M[U(X[>.5,3&!I6$:2.I.T\98KWQ72_"W6F?XK:II>C7VM/X9&D17+V?B>>Y- MXMUYA7?%'>'[0(BF 6QY>X#:<[JYG2_V8=OVT\,M]IM[X?>[#2M$ MMFQ:*"Y&T90#$>Y23@ ]MI]+T;PCXCUCXBVGBWQ+'I>F'3;"6PL[#2;J2ZWF M5D:2225XHN/W:A4"<9)+'@5=-6:?]6Y=+_/IT>H2V:_K=?HM^UT>AUXO8_$; M_A'_ (\>/[#4YM--7<=U>*A,\S":5^$)"+C R&/7&.]T/P M/J>C_$_QOXF\VU:UUJTL8;2,.V]7@20-Y@VX )<8P3WZ4GPS^']WX)^$]GX; MNI+>35?L\WVN>%V:.2XE+,[[BH8@LQY(S[5E)/EE;>S^]W_3\UV-(M<^NUX_ M6?L[_$3Q!'X!L-#\7:E/?ZAJ>COJ^B:Q/(QDNHMN9861_#'0]?\0ZK#IUWX7;4RT&HS6USJ=X'"%6N$=96"(Q< MH&YR"V0HKM(_@;=W'P&\/^$+B_@L_%&AVL9L-6M"62WNT! 92R@E&!*L"O*L MPQ573/@[K^D_#_P5H5W8>&/%]OH]A]EO-$UM1]D:8?=N89C;R.&4;EVE,$.> MA'.TOCD^EU\U:7^:^:3>^FXA0*T9=Q]]@KA2_5MN3R2:].KD/ACX'E\#Z+>)=S07&J:E M>2:C>O:Q>7"LKA0(XQUV(JHBYY(7/&<#KZ?1)[V5_6VOXD]7;:[^Z^@5G:1X M:R$0";9O\DR?=\S:,[HQV&B:= M91ZBS/>I;VD<8NF;.XR@#YRJD?Q0\*S1ZJ\>MVKKI:-)=X)^10=I8GAJU1VA!G+6QV&H MQO5J))^?G_F=[<>$]#NO$%OKL^C:?-K=NGEPZE):QM./B*_A6_73['3EU&^^RM= MR>?="WAACW;5+OAFRQW8"JWW#7F_AWXQ>+OB*;J^MH;/PGH5L&B2Z4&_:\?/ M)BW+& %P?F(*DGO@BN7^-GBF#Q)<>+-0TF8W5E)HEO96\Z*RQRMNN6)1R,'[ MXZ9&"ISS6%8^/-6'A;3DB\-R&)K598I[*>,6FPCC;O8,@Y^X1E1VXK[[+\HH MRH4YU(>]+O?\MC\?SCB/$T\75IT*GN0Z*VOSW_$ZZ3XZ:KX-\16MFFHR:_8W MUS!!,VL)MFLLOAY<00CY64\*1P0""02*^E*^._ACX9UGXD_$+0)M0TO4[#18 M2-3:Z6(K#(8G5XMLC+AE9U'3DCGC%?8E>-GM+"T:\886VVMMKGT_"6(S#%82 M=7'W^+W;[V_K;\PHHHKYH^Y"BBB@ HHHH ***Y3QUX]C\'K:VT%G)JFL7H)9MR2:+;PDM%(O7=*0$V=P^<$<^U3>'_BAJTWC"RTG7M.T[2[;4 M$D6UDM[QIB9DVGRR2BC+*6( _N'KFNGZGB%&4G"R6YP+-,&YQIQJ)N6UOZT/ M2Z***XCU0I))%B1G=@B*,EF. !ZFEKSOX]7$=K\.IY9W7[,MW;>=;GG[3'YR MAHP/XLCG'<*1TS6M*G[6I&%[7=CGQ%;ZO1G5M?E3?W'H4U?['>Z=-,L3:M)Y9> MU$A$1$CD"3"E1G.>1GFO3[6ZAOK>.XMIH[B"0;DEB8,K#U!'!%>#6HSH3<)+ M8^NPN)IXNE&K3>ZOZ$M%%%8'6T^3P_'!J27TNIP3(S032*5.UEQR#W&>]??YYX/2OD7XJ^"=2 M\,ZY%H]O9-:Z9->32:?>G;Y21,OF>6,W:O0;P6]G81/JUO!,\1973#%I25 M(5LD_,,]0*I:*HU7Q$]TD9&D^1LD<1*X(C !;8PR0"1P,5^@5(=C\:Q(;&0K;S".6>- M5VJ9]N&;'KDFNMU<:GX=N+LVFE6\=@Z>?^^@RO.%+J#RN[C"GT-_1;6SC5I)2@$:;57H . .,?C7/):VZL[*;LN9[(VKCQ5J>K:"S0Z5;-'#A M6D5=Y7C@X).WOSBH/#/A]M6LWE$CPO'@NICW(,]"6!_/BNRM[.RT?2;V32TA MN@VUBT;C*L0=T(!RSK@C\:E\.G[3(MA';R1909$>5VG;@JV.<#TKJIT];MG# M5K67+%6+W@LP/IEQH@N(A/=S0V_V?>-[M)*B' [_ "L2<=J^XU&U0 ,8%>%? ML^^&9$UK4]3MU\K1XE^S;&;7NO-N]377RO^&H4445\@?I 5B>)/!&@>+D UC2+2_D5=L+LR)0C47+-71YCJ'P T;4P7N-9UN2X3_ %$S MW"-Y([C:4VOGUD#'W%.TG]G?P9I\ 6ZM;K5Y\Y:XOKIR6]MB%4 ]@HKMO%GB M"'PKX M,QWL>9U)8VV[L]Z,5%6BK(****104444 VO-: MU55$DEGIL:NT*'HTC,RHF>P9@3@X!P:\8^)WCJ3QQXCTG3XO[:\.V]L+^&6- MKCR&-RBVICDW0R'.T3\ G@L2:Q??:?5L7,I0GU^1E M()YP1Z#%*UT2+QSHM_H6G30Q^*-'U&?5M/65MJWL$Q)DC+?5F0_W2D1/!YZL M#6A3Q,95/A.;'493PTE3W-KP+^TC;Z;I-OIOQ!@NM)UZV012WD-J\MO=D<>8 MOE@E<]3D;U-E(C$EO);V\;>KM(JD@>B D]. M.H\XO[N>U:?3]0M[G3+^)-S6=ZA1P,XRO9ES_$I(/K7E5]X?U?Q[KDNE>'M, MNM6O X1O(C)CC)_ON?E4<]2<"OK997A+^VO[OKI_7S/EXYEBK>RMKZ:_U\CZ M-_95^-^N?$:'7T\7ZM923K=QQZ>-D<#.2K-)&BC&X*-A[D;N2:^B58,,@Y'M M7S!X4^%^E?#C_A'O#,T5CK.IVUI=WFMM-"LT'FW#0!(]K#!XA^7(SB+/&ZO0 M/ 5Y<>'?'T&B:U*UDG6P7.VSECQO>(9PL;;XQL' 8Y&.<_'XJI3EB)> MR5H]#ZO#4YQH1]H]>IZ_116=XDNY[#P[JES;<7,-K+)%\N?F"$CCOR!6!L5- M>\=>'O"]Q';ZMK5CIT\B[EBN)U5ROKC.<>]>/>./CSJECK>HW_AN6TU30-(M MX;B2UBCWO?!B?- ?/R%5Z<=5.?2I/!;/H_A])XKPSZAJ"_:Y[^8AY9W=01N< M\D#( [ #@"O.[J&#PWIWAG7[;$-AJ%A'87TO_/&_B9P_F^[LS@D]U'J*]#+/ M95<0J=5:-/[S@S+VE+#\])ZI_@?2?A7XD:)XT\,Q:QI-[#.DB9,)<>9$_38Z M]00?6L#XC?'CPU\*].D;6[GS=5&[RM-M!NFFQT(&?E4_WF.*^;?$'A?2&62\ MCL([6X8?R->->++5?M!@M(/,N)G"+'$,O(QX ]237OK)81E>4_=_KJ M>'_:]24;*.O]=#[]^&'QHT[XH>%;+6K2QN+,7$[V[P3$$QLK8SN'!!X-=TM\ MC-MS@]<]J^7_ (7_ [;P;"N@W&L:M:75IIMK/,VGW0$<%S,97E3RV4HV/D/ M(SSUP:];^'?BNXU+5K[0K^,?VEIX&ZY1-D5W"2=DRKD[3\I5EZ9&1P:^5K2I M>UDJ>UW8^FI1J>SBZF]M3T=;I7W;1R/6IE;<*J*JJSXX'I5I/Z5F:#J***0P MHHHH **** "BBB@ HHHH \X_:*\7:MX$^#'B;7=#N_L.JV<,;07'EI)L)E13 M\K@J>">HKDM#^)7B2\^/7@[PY-J._1M0\')JMS;>1&/,N2Q!DW!=PZ?=! ]J MZW]HKPCJWCOX,>)M"T.T^W:K>0QK!;^8D>\B5&/S.0HX!ZFO+_$7A'XB>$_B MWX/\7>'_ /_ ,)5#I_A.+2+FW_M:VL]DVYBPW.3G''0$'/6LHMJHV]KK_TF M?ZV^=C2R<--]?SA^E_Q/6/C)-X^.A6%E\/H(4U.]O8X+G4Y_*9=/MS]^8)(P M#L./EPW&>.E>;?#3QW\1]0\0?$SP.-;TOQ?K6@)#_9_B*\M!9VXFD4;HIDA# M#Y#NX SE6!//$GQ&\5?'+Q9\.+VRT#X=-X5\074XM_.CUZTN'CMBI+R(^Y C MDX4=2,DC!P:J?"[P=\0/#WPQUKPMH'@M?ACJZ0"YM-=N]8M=4>^N]PWF8",X MW $;B" #P.*.L[WM;[]%MVM][>@^D=KW_7KZ[=K:C_@3\1?&=[\8_$'@G7?% MUKXWM]+T]9;V\73DL6LKP2;&@C50IE3DY?;CA?N]#]&5\[^ ?!?Q%\:?&C0_ M'7C?P_:^$1H6D'3_ "X+Z.YDU*5]VYSY>0D8W,VTG(.,;LDCZ(K97Y5??7\W M;\+;Z]]3%_$[;:?DOU[:=@HHHI#"BBB@ HHHH **** "BBB@ HHHH \J_:7^ M&NH_$SX7W%IH47F>(]/N8=0TSYU0^=&W0,Q !*ENI SBN&\)_!GQ1I_[-OCC M3M2L%D^('BL7MY>P+-%EIY20B>9NV8P ?O8!8\U]'45FX)J2_F_X%_R7W%J; M3B_Y7?\ K[W]Y\E^#/"?BKPMX>T6QN/V8/#VI:AI]O#$^J2:OI:RSR(H!F), M9(8D;OO$Y/6NR\2> O'?@'XG:YXV\':#:^+=-\4VT,.L>&YM06TGCE2,J)(Y MG^3:.A[_ #G [K]!45&8]7-_<&9U0AVF8E,,RG^(8XR!C)]2_9_^!6C^#_AOX7'B M+P9HMOXPLD+SW4EG;RW*2B1BK>$/$_C'Q%XAU*&:"VT34-;C-A#Y[;79$D"JHC5F*_- MQ@=:\_\ $7[&-_:_!VUM-)\5^*+[Q)IT$5W::)<:I'_9J7@PSB.,J G+2!6W M#!.23S7UO147RM>UOON7SNZ;\_G>W^1D>#[K5;SPKI$VNV?]GZT]K&; MVU#JXCFVC> RD@C=G&">*UZ**V;N[F25E8\J_:<\=7G@3X0ZK+I4LD6N:D\> MEZ<8&*R>?,VT%".0P7>P([J*Y']GG6M?\)^-O&?PS\5Z[?:]J>GI#J=A?:C. MTTLMO(BB0!V))"N5XS_$:WOC9\#[[XT>-_!Z:I-:/X$TLRSW^GFXECN+J9E( M4 (H P.=X/S-BL*']EFT^'OQ0\*>*/AK!9Z%9VOFP:S9WEY<2&Y@< ?(6\S MYAR<$J,A>:YK2]Y_S77RMIZ>]U[&LK#_A##K6M M>$]:\5>'K2_ECU+Q1=:HK21!I@ (XGW/*JAE&(;:/PV^N6Z M7&HV?V7[9&EC"TTLZ;-RB-!RS,,8'?-?+FB_LT?%K3OAA+\.F\1^%H_#&I73 M37TZ)3;OVWT_#<\S\%_M37> MM?$[2O!OB+P4_ABZU2-WMC_:\-U<1D)YBKF?#6_U3P3I\[6L&N#4HH_/D5U7+0[2Z1Y)^<;N@! ).W$^'O[*WBW MPWXR\!ZY?Q^"[.+P]YEO!]/L[VP\"3ZG8-IT5_=ZA?Z MG'IMG$9%#+#%-*N)Y,9RJ?-TP"20,ZW^,5IXZ^)'P9O[$:[9VWB*SOIUM8]3 M$-J"D;!A<0"-O/(*G:=ZXX.#TKF/%'[+/BOQ%XJDU2*?PQ>V>I:#;:7-_P ) M':R75QI+)"$8VB#]WG(W!B006;CJ6Z#P#^SOXG\,ZM\'[J]N])9/!MMJ%O?+ M;SRL93-O\LQ9B&?O#.[;CG&:VC\>NUW]WO?\ Q=O9Z;N/X^[_P $H#]L+7+C MPOJ_B2S^%]Y=Z!HM])::EJ"ZO$J1!750R*4WR'YLD!0%X^;DD;7CK]JR30_% MEEH'ACP@WB:\N=-AU,+7N!PISA3VJC\1/V?O&WB"QTBTL_ M^$)\0V46APZ5+9^)[!MUE(B*K26MS"@F^8@GYF&.N.?EYTZG*N]H_>XNZ^^Q MK[KD^VOYJWX7*GQL^-'CFWU3X42>'/#6IV=MK-W'--IMW9D5GAW!MC$[M:$HM9"Q+% 8P7VJV% XR.Z]*^B]/^U?8;;[;Y/VWRU\ M_P"SY\OS,#=MSSMSG&><5T+3G7][3TLO^&^2\V\7KROR_5_\/\_2T]%%% PH MHHH **** "BBB@ HHHH Z?P7_P OG_ /_9JZ>N8\%_\ +Y_P#_V:NGKEG\3. MJ'PH****@L**** "BBB@ HHHH :_W6^E>9UZ8_W6^E>9UO3ZF%3H%%%%;&(4 M444 %(RAU*L RL,$$9!I:S?$5U/9Z-%8S)X7E? M7M!3)G\/W3[;JRQ][R^.@YS@8XY6/-=S!X(N[KQHUQJEQ%=QJ!,)89F1]P 7 M!CY 5@.1R.N,=*T?&'PKTCQ5<"^B,FCZRF"FH66%?(Z;QT<#WY'8BL'!O5&Z MG;1G1^"?BEH'CF,)I]YY=Z%W26-S^[N$_P" ]Q_M+D>]=BL_OS]:^6_%7@_6 M]-;?XDT(Z]#&=R:YH>5N4/\ >=0"V>Y."?\ IH*G\,_$CQ#8QA=#\766OVZ_ M+]B\0 13I[>86 S]9&/M6336YJFGL?42S>^<]>>E.$O"C<<#OGK7BD'QVU+3 M(5DU[P7JEI'WN;!EGB;W!?9Q]"?QK0M?VCO"$@!FEU&U)_ADT^5MO_?"M2&/ M^$J^3XPUYNA96X_[:5ZNTW!^;CG)STKYQ\#_ !L\(Z5KVJ327UTRR!MNS3K@ MD_/G_GG763?M&:-<2>5I>C:UJLYX5(;94!_[Z8'\@: /7VF]\53U#5;;3;66 MYN[F*UMHQNDFF<(B#U)/ KQ'6OBWXTNE98M+TWPE"?\ EMK$^^<#U$7RG\E> MO/9;K_A,-2'F3:M\1]5C;B- 8K&%O7C: /PB/N: /4?$WQPGUMI['P3;"[*# M]]K=V/+M+=>FX;L;O8G"],;NE>66MW--JDYT:ZEU;6YY E[XHND9EA8_PPC& M<@=, $#&!&,D]_H_PAU/7EA;Q7>QVVGQG='H6E'RX5_WW&,G'7;R>[FNK\9^ M$M+7P7);000V%M8QEXA#$=L:C!8!%(SD C\<^]:J#M=F3J+9%GP#X)TKP;I. MS3G^URW&'GU!B&>X;LGKDO!"7VFZ991WMU'<"Z9O)BB";(8P M@VJ-O'&WL2/FZGJ>MK=;&#W"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BN)^*GQ O/AWI=A?6VE+J4$UR(;B66?R8K9"" M=[OM;:,\9(P,\UF:;\8KFXM6EN?!NN_(=S3Z;$+VU>/&1)'.GRR#KTY!!S6\ M:%2<>:*NCCJ8NA3G[.ZKJ-HTL42 M.66*(('0[V9']@%K+\7?#_XF>)"=+N_%5B-'"M,;ZRC-K,TH!V( DC'9NP3D MCI6\,).5N9I>IRU_OKE[>))0P 0R!&"9!S\PP?7BO4Z^4/BWXD/C+XF-_8 M6J+/%]C:UM3?&2.QE<[HIHD<#:[8;=WY7 KLP-#V];EY;K^NO0\S-L7]4PW. MI\K;6NCZ[V>_F>GR?M$)I=A!>:WX0UK2[8QJ\\^(Y$CR<97# NOHP'.>!7.> M)OB]XB\2>,-1LO#6K6^@Z'9N;/[;=6JRM/,I/F,N2=J@@*,CDYK$\8Z/%K/A M;2]$GQ/;V,,$3*Y($WECD''8G^0KF);:UTFS6ULX4MK:/A8T& *^^P/#^'E4 M4YK2VSUU/Q_-.,L9&BZ5.5I76JTT6Z^;(?$_B+QTVO:5JVJ>)K#5FT6=9K2W MMW,0N,.I83! J\@;1@=":^C?@_\ %B+XJ:1>S-8G3-0L9_(N;8R"1>5#*ZM@ M9!!_,&ODW5K@X;!P>QKK/V7/&5QI_P 6)M%\O?%JENXF5?\ EFT2[DD_W2/E M^I%:Y]DN&HX+VM&-I1_*^NAEPCQ1C<3FGU?$SO"IWU:=K+7?I8^Q****_+#] M_"O!/$'A^UF\5>(_"]]&E[IIN%UJ'/6*29BS _[0<,0?[K 5[K?7D>GV5Q=2 MY\J&-I&P.< 9/\J\3ANK[QIX@TWQ-=6]IIXNK(Q6=E!(9)GC;]X'F; 4$*/N MC.,GFO=RA3]OS)>[U/D>)94_JJ@W[[=UY]_S,/6_!,7B:?1K2Q"Z58:;<*9[ MM5 4PA@S01KU8ED0YZ#;G.:ZC4&BDBEB<>9"X92K]U(P0?PJ7<$3C@=A6-J= MX%!YK[JE2YI7/R:O64*:78KZ1\9-1^&NE6^AW>DMKT-I&3;7D=P(W^S(.D@( M.74<#^]CM7O6FW\6J:?:WL!S#<1+*F?[K $?SKY,\03VRBXWD*]PIC9V/)!! MXS7OOP*UB]USX7Z+<7T*QE$,$,B@@30H=J28/3#A"O35N9 MN^OZ'W7".?5\SJU<+7=^1*VGJG=_<=]4-\T4=E<-.=L"QL9&]%P-_$+XGQ:M;PZ/HDDEE8 MYAB5HPJ#$<,:G'W2J@DCC/MP?LC5?V=_#EY9 MSI:37=I=$L+>:20RI;1$$&!8S\OE88_*>?N\_*,?(<_@U--U(>'I(++2M5;4 M/LLL]^'$:%"9(]ZDM@, H &0?,'/-?J.6XZGC5)0;O%7U[>5O,_ L\RFMED3,D=M([*'MX6!V#Y\Y*]/FQ MP#SCFOH&SO(-0MUGMIH[B!ONR1,&4X.#@CWKY*^+O@73;Z\TV6"VBL],TWS9 M(;6!%1-S,IP1Z9&?S/)Z=##?6Z3MKMO_5C[/(N):V+QSR[$)/2_,M-N_K\NQ]*4445\ MZ1$=\$[0Q."< \=>#5^SO(-0M8KF MUGCN;>50\IP.@ MKYR\&E?$FK7OBJ6X%Q?7;W$CU\^>-+J&RL[ M"^D7)L+V"]W+PX1) 9-A[-MS]1D5]!*P=0PZ$9%?!YGA(X6JN3:1^NY#F,\? MAVJOQ1TOW\Q:\E^(5Y:^)O'5GIB72W5MI%M+IK MJ?B=XQN/">CVL>GB)M6U&X6UMO.!*)P6DD;'9$#'W.!WKSS1;=-%TY+,3-/( M6,LTTC?/-*W+R-[D_ETKKRC!2J3^L/9;'F\1YI3HTW@EK*6_DO\ @_D:@ 4 M 8%%0_:A1]J%?9\K/S'G15D\/V5U?)>7-NE[=1Y\I[@;O*![(#PO;.!S@9S6 MQ^SLRW'AO5[I9$C\_490;&W3%O;LAV-Y9W-N#$;BPP,D_*#FJ)N 0<':>QZX MK&^'UBUQ\5+(6&FOI]S9K)=:I<*^V*>&19$0*-WS;I!NQ@8*$]^?'S6DYX9N M]K:GT?#^(5+'P2C=RT]//Y(]_HHHKX _8PKGO''@G3O'6C_8[^-B\3>;;S1O MLDBD (!5NWH?4&NAHK2G4E2FIP=FC&M1IXBG*E5C>+W3/BO6O =]IL(TC4)+ MFWUC:SM!>*-LP!/S1,/E8#\ZX.*/4+""\LK578J<%X1N,9/WE/L17WOXL\(: M9XTTMK'4X!*F=T>XA87 U69@SR[B1 M)E5(/! Q@=.M?IN!XEHUHJ&*TEWZ'X1FW V)PU1U6WC>([OG5(R@''&_@9/2O?EF6 C:3JI_-'R$,CS:I>"P\E\GJ>:V/A._>]N18ML M@D+,OEH < =?;)KTOX=_!SQ'?Z;IMY:2VT5EJ 69KZ.3$EJ WSKL8'<_& >G M->E:'\ 1B$Z]J[7D0.^2RL8S!&QQP"X.]@/J,^E>K:?I]MI-C!9V<"6UK @2 M.*,855'8"OEI-:-%%?GX!GD/&]L-L4>N,,3Z?+7:_!UKO_ (5YI$-[$T,\ M,00;OXD(W1D?\ 9?Q!K@/VG+II8O#VG1\O))+)M]QM5?_0C7M>GVBZ?I]M:K M]V&)8QCT4 ?TKZG%34,GP].WQ2D_NT_&_P"1\!E]*57B7&UU)VA&$;=/>5_P MM^+[D]%%%?+'WX4444 %-DW&-@A ?'READ9IU% 'R=J?PX^)>BW%]=W.C'59 M+J5KBYNK&X20R3,?F81Y#!< #@ "N$U2T\7P7T%W'H7B#3-1MWWPW,-I*D MB-C_ '>>, ^HX/%?^('B1IM M+O[CPUX7M@4MK@1*TM[*?^6C*PXB&,;>"?&/BC4=>^#/B2X#'3M:T<$:G!;RE#^Y9 M)94C<<@2PC*'KB1>AZ><6-T?+"YFLP>'L]9A^WV;GT^ MZU),P>[CT]%L=K;E\GS3]H/'0E_(R/0+[U2OK66: C3_ 3X.\]Q\MR+'<@X M^]M95'X UT'@>TO?"OBC0H;5K&6ZU9G^W6MGID-NBV\<9W2JR %560QJ Q.= M^.M0K7+E>Q[96+XVUFZ\/^$]4U&RTZ35KNW@9X[.,$F4],8 )([G )P#@$UM M45N8'Q%I_CP:'IMMI5U,\4]M&(=MQ&868 <$*V#C&!^%9L/Q*OO#=W&--D"7&M)9Q>=(H/[V6WB,>)$3N<\C<5!QS MBX\NMS;FYM+'CZ^)=%UBPU*ZMH-5\.V%MY?VBUM88KF"-W.T",D_NB3G@_+Q MPO:IM"\9>&/#LJGPCX1FBU'&W^U-982,">KE>2+\)=,3=,UC=36TG* M7GAZ%?%@L;>9I[ MCS[JXD,]S<2-EY9#C+,>!T ' KTKX)W2^(KK7?$"NI%S,+&)!@,L<& M<9!YRS.[?[I6O$CX-\.6,*0V][XQU74)9%1+6&VAML@D Y:1 1@9R1G%>T_! M?2X?".HSZ)+87=I=WR-J:SW%ZETLZQ[8L95$VE=R]5YSU.....YURV/78HR, M[OK5I,\9ZXJ!3U/J:L+WKK7Y!86 MMCJ,,TN!U.Q6)P/I7E?[9FIW5G\+-.L8KJ2RT_5M:M=/U*>(D$6K[BX+#H#M M /J..]8'[2WP<\!^"?@C>:UH>C:?X9UC03;SZ9J>GQK!<^R=O/9/]?F:*',U%;O_ (;]/D?0EOXHT:ZUVYT2#5K&;6;9 M!+/IT=RC7$2'!#-&#N4'M&C^*-&\0SWL&E:M8ZG-8R>3=QV=RDK6\G M(V2!2=K<'@X/!KY'_:MUB7P_I/PZ\;:+?W&D_%"ZL1$RV,8:2>V:#=,77'1& M8X./XC_=!7K/#/CSPK\"_P!E?1M3\+7<5[?ZUB*WNKIEC,^I2@AY)RQP@C*G M=N. L8&>*KJZM=%\0:7J]S:_\?$-A>QSO M#R1\X1B5Y!'/I7P[\/\ 5H/!O@G]H&PLO%5KK.L26<,B7\%ZCO>DHWVB:(@_ M,H:1N1G&1DYKO?#WAK2? ?Q-_9WF\,Z=;V5QJVCS)J$EJGEM=H;9'+RXY8@L MS9.3P/04XMRE&/=+[VG^"L*6BDUTO]RM^.I]8Z+X@TOQ):R7.D:E9ZI;QR-" M\UE.DR+(OWD)4D!AGD=15^O _P!B_P#Y)GKW_8R7_P#-*]\HB^:$9=TG]Z3$ M])-=FU]SL%%%<=XX^)EKX)N!;?V5J>LWGV5[QH-,A$ACB4A=S98<%CCC)ZG& M!65:M3P\'4JRM%=63*2BKR=D=C17DD?[0UG836EMK>@WFG7-\=EC]GGBN8[J M0@$1JP(VL<]6 7WKHM'^,6@7VI0:7?R2:/J\T@BCM;H;ED+?=VRIF,[N@&[. M>,9KBI9I@JS4:=5-O;4RC7I2LE):G1#]ISPLW@E/%'V#5_[/;7 M/[ $?DQ>;]HSC=CS,;/?.?:O7:^ WFCMOV:XYII%BBC^)!=Y'("JH;)))Z " MLW*TU'II_P"E07Y-E6]UO^OAD_S2/O/5-2M=%TV[U"^G6VLK6)IYYI/NQHH+ M,Q]@ 37EGP^_:<\+_$3Q/8Z);:9KVDRZE%+-I=WJ]AY%OJ2Q_>,#ACNX!/(' M ]>*Z2X^-G@IM/OY]*\1Z7XDN[2VENO[-T74+>YNYDC0NPCC$GS' />OGIOB M%H7C#]HCX:>,/!NL7'B&\\01S6UWH=_*DIT:#RT5G1%)^SO\KLPR=WS$<&GS M>^ENO\[V_%?+6X->XWU7Z6_3[]+'K.I?M5>#=,\6/H[VNM2V$>H#2IO$45CG M2X;KO$TQ8'<#P<*?7IS7LE?G/X6UG5_ASX-GO--\W?%Z#QQX1\36GA73O%NM7>H?$"YVP723O&NF; M+H2/Y(#'RU6!]IV$;MF<\ONNTG^K_4JI%1E)+9?DFTW^'^1]545! M8VHL+&WMEDDF$,:QB29R[M@ 99B/^_(5!P/;DXYQCFNBT_4+;5; M*&\LYX[JUF0/'-$P974]""*T<)12DUHS65&I"*G*+2>S[D]%%%9F05XIXN^+ MGC+7OB;J'@7X::9HMQ?Z/!'<:KJOB"27[+"7&5A58OF+D%3GD=1CC->UU\ZZ MFGB#X%_'#Q;XJC\*:UXO\+>+8K=G;P_;"ZNK2YB0KM:+(.PC<=W ^8#)-0_B M2>VOW]/Z[V74M?"VM]/SU_ 7Q+\=/B1X*^$/BW6O$/A"QTKQ'H-[#:1W!WOI MVHJ\B@R0KO$FT*PY)(R>N0RKZ%X,_:"\">./$'_".:7XDM+SQ$D)>2UCCD"% ME +A)"NQ\9/"L3@$]C7CWQ8UKX@_&/X >.#>> K[2(9KZW&BZ?Y,C:E/ LR[ MVFMP"RD%2>W!Z8 =NC\=>"[\?&+X'W.G:'Z_('-8E\ M0^*%T6ZN-.MKM+=82Y4F,3%'$@QU8%<] :]-NOCUX%L[+Q)>R:X6LO#LJP:I M=16=Q)#!(SA @=8RKMN8 A"Q'?%?**?"7Q9K7P#^&WA\Z-KFE7__ F$CW,D M=C,L]C"[N/M#+@%%&=P8X'O767'PS\5Z/\#/B9\(K?0;R]?3I%O=%U*.TV1: ME:F:.4IO4;7G4*05SN/ '2B4G&+=O/\ \EA?[KM^>O8MPC[1*^E[?+FDK_EZ M:=SZ(_$EKIMY?J'@C*/)E"^++O7/"UC:Q6.DK%->6+)'$CQSQ,RF&(D EWP.G7!QP/@?1-'0/'LVH7.G:1'Y\HA_=@^4JXW@8QD<=#P,XI2]ZSV_P#MU'\M M?ZUEKW4UO;_VQR_/3^M/LK7/B]X2\-ZQK&E:CJWV>_TC3_[5O8?LTS>5:Y \ MS*H0W4?*I)]JP-!_::^&/B?Q%9:%I?BRWN]4O%5K>%8)@)"R!PH ^);?Q5\1_&WQ3\0IX$\2:/9:EX*>ST^'4-/=9YW#)A"J[@)"0V( M\EL ''-=+XH^'^JK\-?V=[6R\.WOVG2M6TR:^AALG+V8V!IFE 7,8W\L6QSU MHAS2M?NE]\I+\$D_\@E97MV?X1B_Q;:/<[/XS>#;[P+?^,8=94^'+!WCNKM[ M>9#$Z,%93&R!\Y(&-N3D8K*\8?M(?#GP%_9HUWQ*EC)J-LMY;P_99Y)#"P!5 MF1(RR9SP' )P?0U\^^*O 6HR?M 7WPIM57_A#_$VJ0>+KQ8W/[N)%?SXF'82 M2HGTPGKQ:^.FB^.-9^)'C?2HO#_B5--U+38X])N/!^GV\4=ZPB(VW]Z5W^6# MN4PEN1C Z;LN>7(I);_HM?\ R;1>CWZ:*"YG%O\ IO3\-7ZH^MM'UBQ\0:7: MZEIMU%?6%U&)8+B%@R2*1D$&KE>:?LUZ;>:/\#?"%CJ%E=:=?6]GY0/# M+&P=N&1@"/RKTNNJ249-(YXMN*;"BBBH*"BBB@ HHHH **** .G\%_\ +Y_P M#_V:NGKF/!?_ "^?\ _]FKIZY9_$SJA\*"BBBH+"BBB@ HHHH **** &O]UO MI7F=>F/]UOI7F=;T^IA4Z!1116QB%%%% !39(TFC:.1%DC8%65AD$'J"*=10 M!%:VD%E$(K>&.",<[(D"C\A4M%% !7.>*/ _AGQ!'+\%_ M#+,DKXY%V/2_P!/,I_, MRG^5=AX/\/V.BM=R:=%/';W!!+7&09&&>0I P.>N,GZ $])6:@K:EN;OH> ^ M%_A?XI?5KP1^)K"U8 YD32P3][MAQ_.NLD^$6MW%K(FH>.M6O$VD^1:@0JQQ MT =G KL_#\'E:C=MCKG^=;5XLTEI.MNZQSLC"-W&55L<$CN,T*$1<\NYXU\, M?AUX=U22Z?4=(FU!HR&CDU!C)"?4 ;RDGU" 5[+:V<%C;I!;01V\"#"Q1(%5 M1Z #@5Q7A'P[9Z5J$P_*K=%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >$?M >)DU+7]!\-Z? MKRV=SOF\^,RM%"D^Q6MQ/(!A5.&7:W4N#CBN_P#!O@G4M+^$-QX?O'AT[5+X MWT[+9ONBM&N)'<)&P X4. "!VS63KNC_ -@_%3P\ECCFST335TY9=K3+YAD9F5=H!8\D =/K6 MW)6A$$>94==RO\OTSWK)AD+0C<=S*S(6]=K%<_I77%W>IYTXJ,=#R[QSKTGA MSQYX:U6946[LIC:-&A(^UVER54E!_?21$)7G@$]Z]IKR+XT:?#)X?BUMKF&R MN_#\ZZI;7,\'FJ'C_@*Y!(;[N 7VI>&M*N]4MUM-2GM8I;F!#D1 MR,@+*/H217%F$+!W& MPK_M(Y) [AFI954C3Q45-Z/3_(OB+#SKY?4=)>]'7Y=?P.'U&X=8@)&4N!@E MEW:(< M37;+!GN$ZM^>,5^U4Z7[K0_EVM77MTY;:W^XY;4KK?&&/5@#^E'PV\2:WX<^ M)FBW'AU89-5O95T_R9XMZRQNX+CU7 7.0>,QU[5H_!CXF#X<>.[2 M\N]*T^2VN+GRIKZ9"]S#$X"XC;.% /)P.4%6<9O5[+HSX[B:%66%C*G M&ZB[M]5Z?J6[ZY$:D9KD-8U#:K%_$VD^&]3NI-2\/74D=C )OFELV) M"1[6ZLF<*5;.!@@C&#Y5XGU:9C)L=8U[$C<37T7\"?V:X=)FT7Q?K]Y)=WWD MK]_7H>QP5A:Z^1]&T445^.'],!7A7QO\ @KH,T&N^-=]X-341W"P*X^S_ &A2 MB)(ZD)@I*.JTO:6R9X=JVGZ]?0:SI6HZ MM_:UA'&GVBXD41R^9*#E$QT4!&8?[P%>2?#>WN=0^*6@:?IO5_$^MS^$9-7)@^W:?>2?:7*D"6)L8;_ 'Q@+@=L'UKJ M_P!E?X;:%XLU.^\=74L-_TM<$&V=6W"5L]25*E?3)[]/TS,*T<%@92 MGN[I*W=:'X5DV&GF>:PA2U2LV[VM9Z^=^A]55X_\4/>P:;;P3!?+C6)=L:H%P/D'RENOS$$\XSBLG2O&5S\/_ !-I=KIVJ73Z M?>:AB?18T%P"KN6D,28W)@L6PI]>O2MZ_FO?L$B2/"+G;\DD0.PGMP M^#'@^Z\176F^-[ZYCMXXVG6VTV%,R(WS0L9I,\D?-\H'!(Y.*^YQTJ%'"2== M7OMZ_H?DV54\7B[=7]?0]NHHHK\T/W4XSXR36<7PR\0+>W M'V:.2V,<;!2S-*2!&@4/0DC\ M*](^,.@RZ]X U$6T@BN[$IJ,#-T+PL) I]F"E?QKPNVUY;JWBF#8$B*X&<]1 MFOO>&Z*JTZEGJGM_7S/R#C?$2P]>CS+1K1_/5?D=A_:'^U2?V@/6N2.K#^]2 M?VL/[U?9_5&?F7]H+N7?'L@NO"UX^06M=MV%9MH?RV#E"?1@I'XU]):;>)J. MG6MW&K)'/$LJJPP0& (!';K7RQIMQ'XK\;>'/#[JSVEU>J]SA=VY(P9-N/0E M0&., 'WKZOK\^XCY8UH4UNE^?_#'['P3SU,-5KM^ZVDODM?S.7^)'A_3=>\* M7S:CH%OXB:SADN+>SN$!+2!#C:>JD],CGFO!_!\WV?P_9O)>F_FDC4K-M8!( M^H0;F+-C.,MSQTKZ?90RE2,@C!%?,_Q8\#R_#77-.O-)>^3PQ/YC7*L#/%#* M3\J X+1J,,#7JX=8J@K\E[JVO3:RN:?]H>] M']HCUK@Y/%"PW4%M-#=6UQ,-T<5U;20,ZC&6 =1D $Q$AU*=.(UMGC?;&YZ$M((V"]1M)Z=>%NO[7O+=X ME\.^(&+J0-NE7"_J4'>OH7X1^"8/ W@C3[1;(6=_-&LU]ER[O,5&XLQ)R1@# MVQBOEQUW8W!U,#6]C4WLG] MZO\ AL>3E>94LVPWUFC\-Y+[FTG\U9_,****X#UPHHHH **** "BBB@#PCXC M ^)OCIX?TK[\5J8=Z?B97_\ '<5[O7@_PR_XJSXU:[KB_-!;^:T;]>I\M/\ MQS/Y5[Q7TF<_NO887^2"OZO5GQ'#'^T+%X__ )^U)6_PQT7ZA1117S9]N%%% M% !1110!X1X^\4+XI\?7>F3OOT?1)$C6US\D]SM5VDRJ!D_I7B6J>(&L_B)XKAD;#KK-YGZ>>^W_P =Q7:6NO/<:7+Y M0,LB@.(P?]9M(.S_ (%C'XUS/5G2M$=K8Z--XXU#QYI=LWV2*\T2WM'DDY47 M!\X1DXZD+C=[%*X7PWK;W5K%)(A@F/RR1$Y*.#AES[$$?A77>&?&:^'9O%VK M66+RU?P^VLHH_P">EN&&/^!*R#';8:\D\+WAM;&WB>4RR*HWR$\NQY9C]3D_ MC3Z(2W9Z_87@D4 FNF^&\9UCQ3?ZO I.FV5K_9D5P1Q/-YK//M_V5(1<]V## MM7FNEZCG'->N?!.82_#73% QY,MU;,?5H[F6,M^)4G\:<-Q3V.XHHJIJ]X=/ MTF]NAU@@>4?\!4G^E;F!XWXP\3M\2M4OM*2Y:W\+VLK6[I"V'U"13A]S=HE8 M%=H^\02?EP#HZ/%'I1MX[9([>W@ 7&$5!U!]L5XE\/O$7EZ38(TF6$*;FSU M8@$G\R:]-AUI;AM/B9\)+.%;W(5F4?F!^5_[N5/P7VJEI.I<*-V<4V"/2;/9)Q&BB1N/E'+5 MN_#N.&]\1>+=44+,ZW<6G17'7$<4$99%/91*TF0/X@?2O-=6UJXL_#&K7%I( MR74-G-)$R]58(2"/QKV7P7IMKH^@VMCI\>VTAC3R]HSE2H.XGN2>N*FK$=(\=>'[S0]=L8]1TN M[79-;R9 /.00005((!!!!!&17D^D_LC^%+.\TLZIKWBKQ1I>ENLEEHFN:IY] MA RC";8@B\*. N<8X((XKV^N<\1>/M*\-WJ6,OVF^U)T\P6.GVSW$P3^^RJ# ML7W; /09-8U*E.@G5J244NKT_KR%*?+'WGH8EI\%M"A^*5YX_NKB^U36YK;[ M)!'>O&UO918P5A0("N1D')/WF]369X3_ &;O!/A./5[46']LZ-?WAOTT;688 M+JSLIB""T"-'E,@[>2> *]!T#7K+Q-I,&HZ?*TMK-G:61D8$$AE96 (((((( M[4:IXBTK0Y($U'4[/3WN&V0K=7"1F1O10Q&3["JC*'*I)Z6_!Z_GJ/FOK?\ MK;\C@/#/[-W@/PKK'BB_M='A<>($,,]K)!"L-O$5*O% $13&C \C)R0/2JOP MX_9I\,?#7Q);ZW;:CKFLW5G;M:Z='K-Z+B+3HF)RD"A5VC!QSGCZG/K-%6DD MTUTT&VVFGU/";']D?2]&-TND?$/X@Z);W%P]R]KINMI;P^8YRQ"K$!^/7@5[ M5H^F_P!CZ396'VJYOOLL*0_:;R3S)I=J@;W; W,<9)[DUR%NVTK, 2)"W95!SQUX%><:S?^)])N+G4);NUFM[&^_M&WCECW MJZQ O&A4%2!N5,\YR#V.*[:/4[6W'V:.1;J.WQ&\+,"R CA2.H..F>:X;Q-J M$ODW,,/E7!MYPK^<9S4]9GA?6&\1>&=)U5H?L[7UI#?$;I_P\TWQ'"N-4O=-CMK6*"(N2JR;) $>9 MB#Z' )+#(SW_ (O\1P^$?"^JZU.N^.QMWG\O."Y ^5![DX ]S7B>AZ;)ILMQ MJ]\XG\1:@1-?7@)Y;.1&N3PB<*H]%%?*<09L\MI1C2_B2_!+HZ5X?TO3-0N\_:+NSLHX99LMN.]U4%LGGD]>:^?#87?@N74-;$^( M[W1;N:&OA?97>D:E>:5=-K-G$9[*=X7*,QW*64@X/<=Z;=FEW:7WNP=& M^R;^Y7/;**\2\%^(-4NOVJOB%I$^I7DVE6NDV,#HP(%2? 74M5L/C9XU\+:;XKUGQMX-TRTB\W4=;N_M< MD%^2 T22X&1@/E1P"OKDG;:HX>OX*_W=/70S^QS_ -;V_P"#Z'T;1112&%%> M::C\6-3CO]573?#]O?V>GW+6"7R1R%Z9X#6O$VORQ MW.I7_B2^AU""!Y;:+39!!;0N 6V^7@B8'&/WN[U %>K0RVO65TK(^DPG#^-Q M2YK**M>[??TN=M\2M/DT+QMH.NV^MO$FG6'V6:&Z1KZ/2T$9NX6.UP\8PLC#<&&1G*\=:XWPKXBL/$FN:K MJS6BW-\)5E_M*YMA%.'= 7CPQW!5.0IX!4\"MZZUZT3<]_GZA;ZM86U[ M:2K/:W$:RQ2HC>7LR.@. M:[NOAZD>2G[&K.FG>S:^YA11169B%%:Z@K'G(^\1Z]*Z.&:.XC62)UD1N0R'(/XT&TZ%6E&,YQ:4MFUOZ M#Z**^5_VB?$%W\!?BA<>.=.AE:'Q5H<^DR^6N574(U!MI#COC ^BM43ER]._ MY.WWO3U9$8\VG];Z_+O[!\0:%I7]BZQJ/\ :TDD?VVPM?-MK/: M=UP^1Y8.< X.2#6_7R&/ )^&GB?]FK0Y5'VY9[Z>]?J7N)(XWD)/4X+8R>RB ML?X5?"C0_%'AOXQ^*M0LI=0UC3-8UF+3 9Y-EN_E-N98@0I9MRC)!/R+C&*4 MI.,)2>O+S?\ DO+_ )CC%2Y;?:M^+E_D?2GQ$^ 7@'XK:E;ZCXI\.Q:E?01^ M4EPL\T#E,YVL8G7;IT4RM/"$DDW,Z Y4 MEW^%G?_R;_@BC%U$F][+]5;\/7R/T#HK(\':O_;_A+1=3 MV7$?VRRAN-MX )AN0-\X W<\X &>PK7K:47%N+Z&47S),XWP;\'?!WP_P!? MU?6]!T2.QU;5G9[R[,LDKR$L78#>S; 6.2%P#@>@QV5%%3LDET*W;;W84444 M %%%% !1110 4444 %%%% '3^"_^7S_@'_LU=/7,>"_^7S_@'_LU=/7+/XF= M4/A04445!84444 %%%% !1110 U_NM]*\SKTQ_NM]*\SK>GU,*G0****V,0H MHHH **** "BBB@ HHHH ***1ONGZ4 4=/A\N>5L=?\:OU#;8VDCUJ:@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** .)^*.BWDMGIWB+2=G]L^'IFO(4D;:LT10K-"3VW+W]5%=%H'B: MT\4Z3IVH6@=8[ZTCO4CD&&5'Z9]ZXSXV7FNPZ):6FE"ZATZ\:6'4KVQLA>30 M1&,XVQ$\@L<$CD8I/A)X@\-_8XM#T_7Y-8UB&TB\W[5:O;2^5&HC0+&RC"J! MT&>22>M>QADW2NSYC'RC'$62M=:^?:WZG>7U]_9MG<7?\4,99?\ >[?K5&VM M_LEK%"3EE7YB><74EG $DF4 M8#N22Q [#).!Z5RYE[/EAK[WZ'I9'[;FJ77N=_/]?T.AKP/]I"T\6ZM?06-M M!J3>$_(BFDDTFW2>3[0LI8AU/S;0%CQM'M]7JJJHIV[GT&.PJQN M'EAW-Q4NJW/BF+4+L?%]O(KVM^8]+O(6R&1@':*1?4=5(_W:\%U:8, MK*W(Z$5^XY3CHX_!*JM'LUV9_*?$64SR?,Y8:5W%ZI]T_P#@W1AZG<=>:Z#X M2_!/5OC-JDP@EBL=%LYD2]NY&R^#R5C4=6([G &?PKA[BX*PLC$DQDIZD@'C M]*^E_P!A_P 66\UMXG\/E(%G26.^28,!)*&!4J1U(78/^^Z\7/<55HX64Z6_ MZ,^FX3R_#XK,(TL3MJUYM'U+'&(XU0=% IU%%?CY_2@5Q/Q7\&ZGXXT.SLM M-N+:(17:7$\%V&\N=5!(4E>>&VM[[<5VU%:4ZDJ4U..Z,*U&&(IRI5-I*SZ' MRY\1_#^O>#+[0X+_ %;3[F;4I7:2&WM701P1A3(X=G.3ED4#'.[MBO)_&6K. ML_3I=6L?SMQ5DL:& M]SVC]G7X4>&_'&G#6M9TG5#J.GSH,WDA6VG<#=N1,#(! M['/:OJ6BBORW%8JIBZKJ3;^;O;[S]]R_+Z.6T%1I12[M)*_G9!1117&>F%> M^,KA8?B3XCAN)8[RXN(H;BWDC<2>3;QJJ>4P'^K*RN[#/7S>"UF.VT?36M;&VALH".8X$ M"[L=,^OXU]AD.#J>T5?H]/\ @GYKQ=F5+V,L&M6M;I[/L>+?$B\_=RC-==^Q M;XOL]/\ $6N^'IDE%[J:IJGDFF?L[_\ M)#8_%C1=0T&RN-0D$P@O!$O[M;5B!+N/08!W MJWHL9+IY[?3[<8)N)3@ %,,X+MD(3C+?3'>^(KP(KDG K@_#+6VM?$WP[:Z MAJ T*R^UI.MU(PW-+&PD2/J F_:1DD^F,D5^L2A2IX65:K'FY5=:7UMH?SM" MK7KX^&&P]1P]HU%V=M&U=:GU[X+AN;;P=H4-['/#>1V$"3QW4OFRK((U#!W_ M (F!SENYR:V:**_$Y/F;9_5$8\L5'L,FA2XA>*10\&4=-PYX&17UC7/_$+0X?$G@?7M-FCC MD6XLID7S%R%?8=K?4-@_A7JY9F-7+JZG3>CW7='SN>Y+A\ZPKI5E[RNXOL_\ MNZ/C[^W.,%LFDL]6NM6UB#2=-M9-0U.?'E6T/+-DXR?[JCJ6/ KSBWUUWMXF M8\E03S[5[_\ L=74=YXM\52._P"_6RME1>Q7S)-Q_/;^=?L.:9C]3P94\)7DU%WO;?17_&Q[!\%_A?-X$L;Z]U=+237]0EWR26Z[ MO(C"JJQ"0@$CY2QZ#+&O2J*-P]:_#J]>IB:LJU5WD]6?U;A,+2P-"&&H*T8J MR"BDWK_>'YT>8O\ >'YU@=1\Q?M/27-A\1='N98BEG)IC16\V[(:02EI%QVP M/+/ON]A7G7A?4I+[QGX7@B?;*^L6A5O0"56;\U##\:[[]LOQ#9KJ?A;38BKW M\23W3L.J1-M11_P)E/\ WP:\[_9QN([[XT>'EF*GRQ/(@;^\(F /Y$U^JY?B M73R&2:VC+]3^?IOVJ+^_\ H: NB6BHOM47]_\ 0T?:HA_'0%T2UC^,/LX\*ZLUT-ULEM(\ MB[BH954DJ3Z'&#[&M+[9#_?_ $-<%\;_ !#'IGP]OHT?][>,MJO7N*6&^UY@R3QS_9HV!X9 M=F64CTRR'ZJ*]XK@?@O8Q:+\.],5V"RW(:Y?C^\?E_\ '=M=Q]LA_O\ Z&NW M.<0\3CZL[W2=EZ+0\OAG!QP.4T*:5FTI/UEK_P FHJ'[9#_ '_T-'VR'^_^ MAKQ3ZBZ)J*B^U1?W_P!#1]JB_O\ Z&@+HEHJ,7$9Z-2^?'_>H"Z'U@>/M;'A MWP;J]]NVO';LL9SCYV^5?U(K=\U/[PKQW]H;6GFM=)T"U)DFNI?.=%ZG'RH/ MQ)/_ 'S7IY;A_K6+ITGM>[]%JSPL\QWU#+JU=?%:R]7HOQ9=_9TT0V/A.[U% MUP]]<84^J(,#_P >+UZO65X8TF+PWX=T[3488MH5C)SU;'S'\3D_C6GYB?WA M^=1F&(^MXJI6[O3TZ?@:Y/@_[/R^CA>L8J_J]7^+8ZBDWK_>'YT;AZBO//9% MHHR** "BBB@#X?\ VF/#]UX'^+]YJ*HPT[6U6\A<#Y?,"JDJ_4%0W_;051\* M^+5"*S2!5 R23C K[*\??#W1/B5H+:5KMH+B#=YD4BG;)"X& Z,.0>3]0<&O M-?"G[)/A'PWJ:W=Q=ZAK42$,MI?.GDY!R-P11N'LI>-)?L&FPRC_CWM-KL\NT]-Q:60>\D>:\S\-WOV6".(2%D3A- MQR0.PSWKW3]L[P_/<>#=!UB!";?3+QHIPHX1)5"JQ]MRHO\ P,5\P:3J9C8 MFI>FA4=5<]CL]1GDA"6\BQ2-QYC#.P>H'\M[CX7:-!$NV>R5[2[]6 MN$_9SL9H? 4^HRJ535KZ2]@4_\ /+8D2-]& M$6\>H8&G#QZC45U;K>6LT#_I#4H(E.%\J%(XU8_P"RR*6'_75:RM#U;S(XVY4D9VMU'M6E^UE+/9?%6P@V M>590Z1"MK&HPBKYDFX =N0!] *\^T75?N\T/L..USTW6/$1L]!O B&662%EQ MC*HI&&=_]E0$--_LO1+6$.9$CACB1SU944*&_'&?QKY$TO4$FC, M';C49QYL_^KM; M5?OW$Q'R1J/4G\@"3P*\0\/:Q=VNDBXGF_XF>H,+J^N$)S+*??KM P%'90!5 MG6/$H\2-+K^HQ[Y[V-H],M)>EC:-T?':608)/4#"]CGC]2U1X8#]G52R#Y8\ M[0<=O:OQ?B#-_P"T:WLJ7\./XOO_ )?\$^:QF(]M+ECLCTSPUXYC\$_".QOT M"S:IK%[<):0R'"^:97!9O]E57<<<\5S\VJV;K=)($U.XO%V7VH7D:M+=9ZKS M]V/T0< >_->+Z=XQU#Q)8Z9;W\ AL=)GF:TASC$C.Q:1N,EN=H'0 'DYKH8M M<_VJY,TS*6*C3P]-^Y"*5O.VK_R,\17)GGM[[PY<3-,^F!9+ M621BS-;/G:">^TAEYYP!67;_ !(\1:M=:CJNF75K+9V\\BVVBM;\W=NC$%A- MG*RL 2O&WD CJU>/^&OBA!X)\1:A?M<_Z;/IK6=A"2 OVEI%V[AU(^;([85O M6NE\,2#2["UMHW)$*!=V>3CJ:]:OGV(AE^'C2J6FKW]%HK^IT2Q4U1@HO4^D MM#UFU\1:/9:G92>;:7<*S1-C&589&1V/M5VO+OV>=4DN/!MUIMS(IO;"]E+J MHP DS>>FT?W0)-H_W".U>HU^I8/$+%8>G77VDF>[3G[2"EW"O)OVBOAZ_C;P MO936FES:CJ%G&*HRHSVDK#G% M3BXOJ?".KZ/J$FM:KI^B:?>:=XMN\M/:W$;^;%&J%S($&0 1DAAD$MZ\5R]U MJD,\,%E8J\\K$(UK"IDE P2^Y1EL@9)/K7Z&7-Y:V=U;I*RK<73>7&,?,V 6 M/X T\:?:K=FZ%M"+G&WSO+&_'INZXKX67"5&?NQK/1ZZ7TTLM^B_/8\MY?! MZ*1ROP;FOYOA7X5.IP26]ZNGQ1R1RH4?Y5V@E3R"0 <>]=C117W]./LX*%[V M1ZJ5E8\0^,6L77B3QA9:#9P"2PT?%S?FYDVPM.X5H/D',FP!FP<+DKSD<8FL M:LEA9S3REF6-2QQU/_US7J'C#X1V'BS5IM5BU74M&U":%8I)+&1-DFS.PNCJ MP)&X],9'!KQWXF>$]9\ :;))KUQ;:MXWG61A[%F;'M7U7"5"=3$RKMOEB MK?-_TSOR^+E-SZ(ZFO,OVA?ACJGQ9\"VVBZ1<6=M=1:E;WA>]=U39&Q+ %58 MYYXX_&O3:RO$'BO1O"MH;K6-4M=-M]P7S+F54&3T'-?JLFDN:72S^[4]^^C_ M *W/&/$/PQ^*.C?&SQ)XV\$7'A!K;6+2WM&A\0/=%U$:J"0(E '(_O'BO1-* MTOQKKGPYUG3?&#:"GB&\AN+>)M$,XM CQ[4+>:"^*O$EIX/\ #FH:U?!VM;*%I76,9=L=%4>I. /&\U#[1,L0@ M:1W81.(BVXAE7.T<%L'I6W^SW\/?'GPOL8M UFR\$V?AJ"W)0^'?M9NYKG*_ MO)6EX;(#9/7[H& ,"YX7_::\+>)->LM&-IJ>GW]Q,+5AN5.'Q-'%H7]H-M[)MM;>9B D,LC!$=B0<*"P/0^E=D(.I)0CNSIHTI5J MD:4-Y-)?,\-M->U"X^T:U@6,ED*GG(SG.M MZR&5P3D8YJO<7BV]L(;.,"LVZUCK\U M:/Y]#_LU^,M7N-;O/#(4WFA6]NUVLC#YK)FD^6/=W5SYA /(V''& /H>O ME;]D/7;^3Q=X@TZ*U6;39K5+FXN]IW0RJP6--W3# R''JI/>OJFO@:?M&:E MJ.B_"35]0TZS%^UH\,\]N!95:4$=QM!S[9KRGHKGD8.A]:Q-.A>W-)*_J M['(>$(;NXT5?M6G^6LFZ66>:6/-P6))D9"=P+C#;2,C..U:FB_;O!]Y/<: M MHEK*F^?2Y(RDF:Y$VG<_=L1AX5JJPPRK/%'?6Z3+'(N=KJ&!PPR<$E728/#6H0^3J&FVJ;'!^6XAR5##T8;<,.V1R017H==:=U<_"\;A9X/$3H3 M5K/\.GWHH7_A_2]5U"PO[W3+.\OK!F>TN;B!'EMF8 ,8V(RA( SC&<4:/X>T MKP\MRNE:99Z8MU,US.MG D0EE;&Z1MH&YC@98\G%7Z*9Q'*Q_"?P1"TK1^#? M#\;2RK/(5TN %Y%)*N?DY8$D@]1DU:UGX=^%/$>JQZGJWAG1]4U*,*$O+RPB MFF4*$IM'DENIM O9H6\T M/)L.V-7R20HSM/'I6,_A+I^C-=W.L^)!-,T=W&03%"\B(2=AR5 '7GL:ZOXRLW55N((SOMRP[-GYCCU-:)IM);O_-K\;:=R6FDV]E_ MP_X7U['T-17S7\%_BAX@TOX7>,M6EL=<\=ZM%XIN[&QL(Y))Y",H$0NV[RHE MY)8_*H[=JW_AM^TMJ'Q'_P"$OTVV\(0Q^*=!MA=1Z;;:Y#>6]V"/N+@^%[M8X=/ M:YUV[N+@PC2IOF @&8_WKDJ<'Y>.<<,!R/@G]HYO!7P=\":DFC:[XG?7]8GT MU8]1U@7=\&\U@,2&)!(2>%4A<<#=WJK[_+\7;\Q3?"_P"- MVI^,O'>L^#?$W@^;P=XBT^U2]6W-_'>I+"Q W>8B@ Y9>!GJ>01BO6:>Z374 M75H**** "BBB@ HHHH Z?P7_ ,OG_ /_ &:NGKF/!?\ R^?\ _\ 9JZ>N6?Q M,ZH?"@HHHJ"PHHHH **** "BBB@!K_=;Z5YG7IC_ '6^E>9UO3ZF%3H%%%%; M&(4444 %%%% !1110 4444 %-E.(G/L:=4=R<6\I_P!@_P J ([%MT)/^U5B MJFEMNM<_[1JW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !7G?Q8ANO#;6'CJPBCN&\/QS->VKG:9K M-E_>[3CAE W#/7&*]$KQOXN?$!-9O-7^'5F;.QNKRT$-UJ&J7B0+'%*"&,4? M+S-MST />NK#1G*JN1?\-U//Q\J<4NGVP@D$L*Q*J2+T8 8S^E>&=,\16V9#N$B/C@@B MMCX&^(M4\4>"S?ZC=OJ,#74J6.H2Q".2ZMP<+(RCCDY''7%<>98=JU=/1Z'J M9%C5)RPC6JN[]+?\.>A4445X)]@?(7QV^-K>.-2N/"B:=_9=EI>H;YGNF)N) MFC+ $1[?D0GD$DY%>0:I<_VM='CTWQ/H.MH=K7UO)9S*/XO+RZM^&XC M\:^",BOV7()48Y=%TE:[=_78_F3B^.)EG4XXB7-9+EV7NO5+Y:F M%)-ODG]#*?TP/YYJ72=EN0)&CS\P7/&[&<9KIJVG3ES*^FVYPX=RIUHN M$N5IK6]K?/H?IAX"EUB;P3HSB:\VXQYI4;NG&<^G%;U<]X'U[1M8 M$Z1>:+<"32I+6,V[2MM;8 V?XAC!]P:U)-:LHB1)1:WT+M%8\GBK3HS_P ?*./]G)_I563QM8+]QG?_ ( :.678?M(+J5DU:W4_0R 5]._M*7ES MXT^&<]II=M--/;W,5TT*J"TB+G( SR1D-C_9KX_\,R:Q#XHT^;0X))]7M+F. M>&..$R.)$8,,KZ9'.<5]UDRBLOK0NE)WW]-#\EXG9^$_%7BR\\.Z>=7T]1J[1 W"P1N4#^P!X_.MR/\ X2J\YBTNX/NMN?ZU M\0Z;B[-H_58XA22:3.PW =3BF^8@_B7\ZY7^Q/%\WWK=H?\ KILCQ^=(WAKQ M'TGU&WMQ_M7Z#] :GE7\R*]K+^5E7XB^"4\36KZCIF8O$EK$/LLR2L@E"MN\ MJ3'#(WS#D'&XDRK:&19% M7[.FT@K\[%FC(/I&?:OI,IS)X%VDN9;GQ'$&1K-8J<&H2>C>FM]%U6WY&9\& MOA#X7\5>'6\3^*;*.^GU%V-M:WDZ^7% "0C! V-S#YLG)Y'2O9?">E^&?A_H ML.D:*D-E8QL[!!+O.68LQ+$DGDUF0Z+X4LX4B36[@Q1J%2.#3RJJ!P ,MT'T MI^SPC%]Z76)_]Q(D_F:\W%XJKC*LJE23=W>VMOZ1[F78"AEE"%&C"*<5:^EW MWN_,Z>3Q1ID>?],B8^P;_"O%/B1>G2?'0U6SQ>V.MJEM,TC[3;SQJ?+521]Q MUW<= ^3_ !UZ)]L$Q?U>.>*M2DCF5X6(G5U:+: 3O!!7 /4YQQ7>:_KAU&SN+JSM;RYMX MCMDF2UE\N)NZNVWY2.X/3OBKW[/&@OJGC:;Q+/I1NX]-C_T2*]LV>&1Y 09 M3A6V@,!C/W@?2OUO&8^AA<%*2DI/M<_G;+,IN?M,I>#J= MROTNL?R-%H^7WA>7=_GE3"+.\GMA&YY4)(R@'U( KZ%_8_T M759XO$FL:99S74_F1V198]ZJH7?CZY;]!7HWB3]FW1/%E_<7VHZ5']ON)6GF MNH9G221V.69F4\DDY/O[UUGACX92^$=+73=&$>FV2G?Y4+. S8P6/')XZFOJ M,;G$,3A%06^E^VA\#E?#=7 YB\7)IQULEOK^6AOC3?&\>Z^X^^Y9=G] M_P#P"S_87BUN'F5%[LUS$!_.FMX?\2,/GU"U1?[S7L8'\ZC'@&OP]X%NT#27#7(D"",*A^\_923M]]V* M^V]0^%-GJUJ]M?)'>VS_ 'H;B%'1OJ"2*K:/\$]$\/S2RZ9I]KI\DP"R-:V\ M<98#H#@5]!1SA4L$\*U=ZJ_KY'QV)X;=?,XY@G9)IM=[>9:_X1NZ_P"ADL/_ M ,:D;PV0?WGB>P#=QY[M^N*O_\ "O(O^>K_ /?0_P *L?^ALLO^^9?\*U?^%> MV_\ SUE_[['_ ,33_P#A7]K_ 'W_ .^__L:/:1[_ (![.7\OXLQ_^$>L?^AL MLO\ OF7_ I/^$=TS^/Q99Y]H93_ $K9_P"%?VO]]_\ OO\ ^QIR^ +3'+,? MJY_PH]HN_P"0>RE_*OQ,3_A'=*_Z&NT_[\2UY-\7+.WO/$FBZ#9:Q#>B0JSS M+&ZHC.VT9SSP 3]#7N4O@6Q@B>21]D: LS%S@ =37C7PQ\-IX^^(NJZP59=/ MM=S1DD]3\L8^NT$_A7T.3R5*53&R>E./EN]$?'<21EB(4KR2>_PQUD_ MR/2+?PKH]K;Q0Q^*[01QJ$4>1+T P.U2?$[I7_0UVG_ 'XEK;_X0&T_O'_O MHT?\(#:?WC_WT:^?=6[NY/\ ^P5%Q22BK?/_,Q/^$=TK_H:[3_OQ+1_PCNE M?]#7:?\ ?B7_ K;_P"$!M/[Q_[Z-'_" VG]X_\ ?1I>T7=_@/V4OY5^/^9B M_P#"/6/_ $-EE_WS+_A1_P (]8_]#99?]\R_X5L?\*_M?[[_ /??_P!C1_PK M^U_OO_WW_P#8T>T7?\A^SE_+^9D+X=@(_=>*K%E[_-(O\Q2_\(XO_0T6/_?U M_P#"M1OA];9XDD'TLO\ WV/_ (FCVD>_X"]G+^7\3._X M1NY'_,R:?C_K\:O(O#.DW7Q$^)=Q=KJ%J;;3_G2:YN-BE5.$P3W)^;\Z[?XL M:=;^#_"[LLSF[NSY$*[AZ?,W3L/U(I?A=\*VL_"MO=7#-%G[L?_;G^GJ?&YA!YCFE# 17NT_WD]?\ P%?K;L=2OAG6 M%Y36M-;UVZBO]:IVWP\':=A^ /]:8WP]8?=N&'_ M ?_%5\[S1[_@?9Z^X7++L_O+9T?QJO73I MW/KM5L_CFF&/QA#\QTN; _Z=LU6_X0?4!TN@/3[]/_X1O7(?F2_8'_9D]YE?_ (3._AXDTX ]?FWB@_$!VZVJ MK_N.?ZYJS_:GC*'_ )?96QS\TBM_.G?$%XQ;^+SOK;1/C_QVBT>R^\.:2ZO M[O\ @F5K7B+3O$FBWFE:IIS75A>0M#-$9!\RD8/;CZ]J^>OB5\%_!WAGP'=Z MAH\FK6VIVB QM/<+,MRY8*L97:.22 -N.2*^E7\1>(O^6^E6TH_Z::>G7UX% M3W\M9(^?P:F'7-!;_6>%5!_Z9WTJ M_P P::II='^ O;2>\E^)TS +=1-[[L?SQ7*_P!I M>%I/O:1?0_\ 7*\#?S6C=X0DXVZU"?4F)Q_2CV:\P]K+NCL8]5M)/NW$/_?U M?\:E2\BD^ZV[_=YKB?[/\+2_^M_\ KI9A_P .&I?[#T*3_4^)E!_Z;6DB M?XTO9KO^ _:R\OO1R?[2?P?N?B?H5A>Z-&AU[37(B25O+$\+D;TW'@$$!AGT M([U\U:S\&?&_@W4-,M;O2!*?#^KZA\3_!>E?VO;3P1QWFJ1>7>C:T\0CC4$D\$+.Y MQW_"L94UO+->\2)HNK:3=Z+8+\U]>2E=OE=TB=20SMR.# M\O)/8'["M;:*RM8;>"-8H(4$<<:C 50, #V KE_^$?\ %L/*@3?]5:EKAN&,A?=D<$=,=JYV]U;#$[JQVNTLX1&KL^.K.C:9J' ).!3?8# MW+P+K4=AXP\-W,>V--2ADT:Y11@%XU:>W8_0+,O_ &T%>WU\R_#&.X\2>/-" MLH 6M]/E;5+IQT15C>.,9]6=Q@=PC^E?35?L7"LJCRZT]E)V]-/UN?1X"_L= M>X4R:58(GD;.U1D[02?P ZT^L/QKKP\.^';JZ#8F9?+A_P!\\#\N3^%?5UJL M:%*563LDKG?*2C%R?0\YTWQ%<^)/BA8SS*T4<4KQ1PGG8NUN#[GO7L5>?_"? MPVEOH;:A<1AIKJ0/&6'*JN0"/J2WX5Z!7BY)2K1PSK5G>51\WW_\!'-A8R4. M:6[U"BBBOH#L"J^HW%M:V,TUXR+:HNZ0R#*XJQ7D'Q5UJ_U+7$T6'_4J WDQ M-EG8\@M^'('X_3R\RQRR_#NK:[V2\SGK5?8PYK'3>.O!5K\9/!UC;O?76EP& M>.]CDA568[0P4,K @_>S[$ ]J\3^(G[)^L6]A/-X8UC^V1C_ (\=358YCQU6 M5 %)SC *CZU]*^'8?L_A_3(L8V6T2_D@K0K"ME>%S"G&>*A>;2UV?R)E0A62 M=1:GPW^S[\+M5\6_$JPGUC1;V/2-((?MO]@:G_9@SJ/V:7[-T_P!;L.SK_M8K MYDEO++3='(TKPW /$-A:O-JEYJEDRSVP1,S37$S MEN< ;B^>!CD?551W%O' M=V\L$R+)%*I1T89#*1@@_A6.9Y3#-'#VDVE&^BV=R:V'5>UWL?(/P\\0Z_X+ MNDU^;0(+1Y?.BN=/TN<0_:H74&.0K@KO5N_7!/3)%4-'\1:[)X#C\/:WXBN# MI>$DELVA6YF9EE$AC\\MD#<.^>"17MMI;]]-CR9TL13I.[LE^IY7KFM26>H2ZO8S M+%>02IW!QP:_0RPDFDL;9[@(+AHU,@C.5W8&<>V:^1?@#\' M?!WQ5TW6#KBWG]L6,L4$T<&H-MEC* ^;MVC =MXQD@;2%Q7U_'&L4:H@VHHP M!Z 5]-PO@JF%H2J2DG&=FK7\[]$=N!I2IP;;NF.KXV\99_X2SQ"-4#W&H0ZK M<%O.=F&/,+0G:3CB)H]O' QBOLFOACXH>(DU#X@^*KN.Y-U')J#QI,1MW+&% MCP!Z*4*@]PH/>OU;)OXTM.GZGZ5PHKXJIIIR_JC(U'6/LY/DMY6#D;3C%<-J MFJ7%]?7:0QA]P#$EPN"1@G'I]*?JFJ%F(!K#>62._7KN\O+?0]*^Q1^IHWUO MOLMK%#NR44+FJ%QJ1;H:HR3'!9FP!R2:)+>Y@O%@FMIX+B3:([>2)EDDR>"J MD9.<\8'-3?N0VNI]5?L0QW$B^,+DS_Z,6MHQ;X_C D)?/T('X?2OJ2O(?V8_ MAC>?#?X?L=41H=6U2;[7/;L # NT*D9YZX&3Z%B.U>O5^?8ZI&KB9RB]#\0S MBO#$8^K4INZO^2L%07]E#J5C<6EP@D@GC:*13T*D8(_(U/17 >0FT[H_)[5; MKQA^SW\4ML._9):_9MJ\=0#G.?3FOO;Q1\#/"7BK7KC7;O3$?5Y(BJS,24$FW"RE.A M8<SMY7[ZZGTKX1NIM<\3^%_+C\J>%9;Z?'/EQ&(QF//HSNAQW\ MHGM7L=>=?".U2XGU[5#M\QYTLD5>"D42Y (_WGD8>S"M;Q9\0K?19SIVG(NI MZT1_Q[JV(X!_>E8?='MU/85M'W8W9^49W&KF&:2H8>%W'3]7?YMZG7T5YA)X MZ\2:6HF*6&KQ_>D@1'@D7_9C/(;_ (%BM6S^*D>I1H;70-5W_P :W,:P[?8% MFY_"GSQ/.K9#F%'_ )=W7EK_ ,,=U7EFO_"O5=6_:&\,^/(KBR71],TJ:QF@ M=W^T,[^9@JNW:5^<=6!Z\5Z%X?UZS\2Z7%?V3EH7)4JPPZ,#AD8=F!X(K1JK M)M/M_DU^IX^T?Q-XUTS1+ZSL_AOXNL)$N]++N) M;"[92!+;IL*%?6X/ 4.D:"K>7=Z-HD9U+4 M&&!$T\LL68V&-Q:-@Q/!)SN'TG6!JOQ \.:)>O9WVM6=O=1X,D1E!:('H7Q] MP>[8%**46GV_X-ONOH:1IU<0W&$7)O717[7^^Q\\ZG^RMXKOOA7J?AY-5TC[ M?+XJDU^.VEDF-E=0-C$,Y5 X]?E!Y'7G(T? /P%^('P[\1>,O$6F-X,M-5US M2H[>UM=,BEL[&QN05!VQ"-LH "V>K-U49)'TA;W$5Y;QSP2I-#(H=)(V#*RG MH01U%24E!)67:WX#4II \MX2S?:+M'-*4DB,A8+&3'DM@]&"CWKZ8HJUH[KR_!W7X_AH3)N2:?7_*WY'F.F_## M5;/]H;5_'CW%F=(O-$CTV.%7?[0)%=6)*[=NW Z[L^U>G45Y%KW[6GPH\,ZU M?Z1J7BK[-J%C.]M<0_V==OLD1BK+E8B#@@\@D5-U%*-^_P"=W^+"SDW*W;\K M?H>NT5F^&?$FG>,-!L=:TBX^UZ9?1":WGV,F]#T.U@"/Q JEXD\>:%X1U/0] M/U:^^R7FM7/V2PC\F1_.EX^7*J0O4%Q_US;^5 $&BMNL<_[1J_69X>;=IP/^V:TZ "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***"P'4XH **;Y MBG(!W$==HS4$VI6T*DO-&OLS@'\LTQ719HK(N/%6G0?\O2.>X0$G^549O'5E M&Q\M)I1_NA?\:I1D^AFZL%U.EKSWXLK_ &1>>$?$D("W6G:S;P,0.7AN&\B1 M<_\ ;0-_P&K[^/))&*P6F\GH&8D_I7(?$J]UO4-+TJYN=+O#H=EJ=O>ZA);6 MKR-' C;BV,9('!..PS730A*-6+?6^NZ-'YFJP;8YK?S=BWD&>8VSQN&25/;ITKZ&FM M;,^*JRO%212\5/>?V7??8%B>_P#)?[.L_P#JVDVG:&]LXS57X%^(M%TOX=V> MGQSS1WMK)(+^WNDV20W+.7D78N0J[F.T#C;C%2/?<^8Q561\XP"#NSTQ5CX8QVBZAXBUOQ!H]_:RZC/%Y%F)D0JD:;2SXS MR23T[ 5>8QA+#I-ZI[=R,DG4CC)2C'W6FF^W4]7D\;6*9P7?TV)_B1523QY& M,A+>1SV^8+_0U27Q!H\9Q:^&(9".C3SR.?R&!5B/Q-J;'%GH6GV_H5L06'XM MFOF.1=OQ/O?:2?VON1\]_M5:EJFK?V+JGV.5M*T^*<,\8+^7(^WE\=%PH&?> MOG.>0K;1*3R$'\J_1#4;CQ7KNFW.GW4CI97430RP[$C5D8$,.!Z&OG2Y_8GU MAD9;;Q)"BKQ"D]MORHZ!F5NOOBOLLISBCA:'U>OHEM;7?>Y^9<1<-XC,,4L7 MA+R;W3LMEI8^9)(Y(IC)$N\-]]-V.?6M[P3X3U;X@:I+IVC00O>0PO/)'<3K M$ JX&-QXR2PQS7N5E^Q%XMEN$6[\0Z1;VY^]);Q2RN/^ L%'ZU[[X"^ .D> M-%AL;.1YI,9FNG15DF8G))(SWZ#M77C,^H4X6PTKR?EHCSLMX3Q=:I?'0Y8+ MSU?W/0P/A/\ #FQ\&> =*TS5_$L"7T:M)/;VT$DRQLS%BH;@'&>HXKKOLGA. M#[]_JEP?^F,"(/U-=!'X"L5 SO8]]SY_D!5N/P?IL8_X]TSZ\G^9KX.=;GDY M2;N_0_6Z6&]E"-.$59*W7H;JE+R^XXF/Q-=+C M[)X=T^#TV6A?^>:F7Q'XG;B*"&W_ .N5K''_ $KM%M85Z1K^/-/$2+T11^%3 M[1?RE>SE_,<3_:/C&XX.HW" _P *R@#]*A?1_$5X?WVH3-G_ *;.:M>#?B!' MXD\6>)]&8J)--N=L P6C "-]<.#S_MBNTK:M"IAY\DXV=D_O5SEPM6CC:?M M:4VU=KYIM/\ %' ?\(3?S_ZV[9O7<&/\S4L?P[/\.1[JSW^3()2-N\888'4$ <'T%=I12]I M/N/V-/L<^O@G34;_ %08?[1)JS'X5TR/_ETBSCK@_P"-:]I7 MT.XW7EF.#:,G>0<'_@(RQ]E-:48U*]2-*+U;L98BI1PM&=>HO=BFW\B?08]' MUNT>YL4CEB2>2 ML7[R.4/X9&1[$5K#3;95P(8Q]$4?TKR#]F75G?1=5TV7= M^[G%S$S?Q!AM;!]BH_[ZKVFNK,<-]2Q4Z"=TGIZ'GY+CEFF I8MJSDM?5:,A M2TBC^Z,?0T]H49<,-P]R33Z*\T]NQ&+>,=$7\J=Y:#^%?RIU% Q-J_W1^5+1 M10!RGC;QU!X3U#0+$X>YU2]CMPI_@C+ ,_YE1^)]*ZNOF7XC6^L>+?C(;*UV MRWMN56VA#?+&J*9 "?4]3Z%L=J^EX9/.A1]I7&?6!1110!D^*O$EK MX2T"\U6\;$5NFX+GEVZ*H]R<"D\(:R_B'PMI.I2!1+=6T]U]'CO\ 8L)3P*^)^]+Y[+Y(^*RK M_A4S&MFK^"/[NGZ+XI?-[>6@4445\X?;!1110 4444 %%%>=_&CQJ?#7A[[! M:OMU#4 8UQU2/HS?4YP/J?2NG"X>>*K1HT]V<&.QE/+\-/$U=HK[^R^;T.(U M GXO?%J.V0^9HNG<$C[IC4_,?^!MQ],>E>]*H50J@ 8 ':N(^$?@G_A#_#: MM<1[=2O,2SY'*#^%/P'ZDUW%>CFF(A4J1H4?X=-67GW?S9X^0X.K0HRQ6)7[ MZL^:7EVC\D%%%%>*?3A1110 4444 %%%% ";1Z#\JCF:&WA>64QQQ1J6=WP% M4 9))["I:^8?VZ_'6H>'_ ^G:'8ZC'9IJ\K">&//GS1(,L,_PIDKGJ6)QP < M]&'HO$58TUU.>O55"FZCZ'L'PI^*6E_%R'Q!?:1"K:3IVHG3[>Y(YN-L:.T@ M'9PSWP.Z6"-6RJ!3[<5X;^QOX)U3P%\*[S3M9LWL;^74VNFA?&=KV\!7 MIWQC/H01VKW:GB(PA5E&GLA8>4ITHRGNR-K=&ZY/XFHO[-M^OE*3_M*#_.K- M%2WV/=F^'ULQ.V5T'^]G^ ME4YOAK$TBN)"SKD*S*I(SUP?P%=S16'M)]S7V,.QP)\ W4/^JN=OT4C^1I!X M[Z1=UKXG4/W26P."?KYIQ^5 M>=^)O@3XYM)HY$M;36(8R3_H,X#XQC.V3;S["OT)DT2SDSNA1O\ >4'^8JI) MX3TZ3.ZWC/\ P''\L5\]6X;RJJO=IN/HW^MSEE@4]C\T_P#A"O$PG>%O#.M+ M(@R?^)?*1^!"D'\*Q[C=9W3VUPK6URAPT$RE)%^JG!%?IS)X%T^0\(4'^PQ' M\\U@ZW\%?#WB%P=0TVUO\# :\MXYR/\ OI:\.MP=0&@W@@U28;P,QKD9[Y->@Z7J'3FOJ"__93\%W3$+HEI%GO!&8/_ $6PKEM4 M_9 T]%)T6_N-,F_@&\RQY_VA(-V/HPKR*W"&+BKTZD9?>G^*M^)C+!55L9W[ M/'B1=!O/$MG#;(\L[0709B]>WQ>/ HQ+;.#ZAQ_+%> M:_"GX3^+_ACKEYJC:A ]U+;_ &1%LAD%"P9BP;.22%X[8/)S7IKA\!3I8B*4E?KYNVQWT>>G!1DVOD68?'%FWWUE0^Z M C]#7!>-O$,?C3Q'8Z7;R[+.%L22'@;C]YOP''US6QXE\:VMCIXG/R/;R* J>X(YR>?P%IV.IZ?%;Q06\L8CC4(BJX. !@#K5Y;J)NCU MQ/V'PK\'807B2$_@32NOBW2^9M-G(]3!O_P#0 M:GD[-%^U?6+.@US5X=!TJYOK@_NX5SCNQ[ >Y/%>>_"S29M7U6^\2WPW2.[+ M$2.K'[Q'T' ^I]*Y_P 9^++WQ/>PZ1L$:0R9D R,OWSG^Z,UWNB^++#2]-M[ M**VEBBA4(#D-]3CU)YKYB,99GC^=:TZ/XS_X'YG)[6-:JF]H_F=FJA5 P!P M **Q(?&&FS$#S_+'5KH=ZG%[,NT4Q9 MT9=V?E]<<4X.K=&!_&I+N+1163XJU:31-!O+V)HD>)"5:;.,]N.YSC ]ZSJ5 M(TH2J2V2N*4E%-L?>^(+6SU:RTS=YE[=$[8EZJH!)9O0 = M1T&-K>*YF,^9+NBD83R#[[ M952!] U>Q5Y& Q#S3#3G5C:,FTE_=M^NIST9^W@W):/\CYN^%WP5^(?PI\>6 MNI6\VB7^E7JBVU*-)Y%*1!LAE!099>#I8&G[&C?E[7O8U MITXTH\L=@K\\/C&MMHOQ,\56%@[M:QZA(R;UVE2^'=0/179@/8"OT/KR7XP_ MLY:#\5I#J$BD_RK3\.Z7J7C_6--T/1M.DO=6D?;'@; M"(\9.\G@*.N3TKZ1/[#9P>O4G^E?1WA/POH7A M>SM].TJUMHWT^!+0R1QJ) N,@,0.ISN(]3GO7O5\WI0C^Y]Y_/0^RQG$V'IT M_P#9/?>O=)=F[H\N^%/[+/AOPE8Z;?\ B"S36/$<7[V1I)6>WCDSD!4X5MO& M"PZC->V26D$TD4DD,"_'J+3;?Q+82Z7;+-XC>"5+H0L%(B=0$:0G@'(X[G MGM7I/Q:\;KX!\$7VHK/'#>MB"T\P9S*QP..^.3^%?)L<>K>+M0OV7/ 4=!WX%>>_$GXP0Z#IBV7AZWD MC@21WN+@R%#-@$ A@2S9;!W'J!7U=;_!?PM'X3L]"?3T9+94*W:C;/YBC'F; M^N3D_F:\G^,G[-'ARR\,:MK]D]X7L;)YS8LV];F50<,[8W8Z9 XPHJ'"1[N7 M<19-*LZ?LI1!?CAX2 M\>:>L]OJ45AO!'N*R/M<=A90FYQC[K.P:QFTC5DU32@MOJ< M4H,J;RL=PO1XW XR1T.,@@&O5_"^O)XH\.Z=JT<30)>0K*(F.2N1TSW^O>O+ M-)\)^(/&TEUJ,%S'I.CWQ5%:6-OM+H% :9.<*6' R.P;OBO7].T^WTG3[:RM M(Q#:VT2PQ1KT55 'Y"NBFFMS\:XFQ&$K2@J33J+2373R\]3'^(6I7.C^!M> MO;.0PW,%E+)'*!GRR%/S?AU_"N!L8X]+L(K*SC6WMH\_*G5V)RSN>K,3R6.2 M37J6M:=%K&CWUC.NZ"Y@>%U]592#_.O$])U62;P_ITLYST;OUS4 MU.AZ?"*C4I58):II_>G;[K/[S)^PPZ'K-[!'J-_I<%RRW%I':WTL,,!?:6T8+^[Q2,NT_[K-GT'2N/U._6 M6-DO[=MA8P/IT\*_#_ $#P5?:W>:+8?8[G6KMKZ_?SI)/.F))+89B%ZGA<#VI:6_F?*Q 9VQ^6V?ER03QY3_PE6M_$#X;_ JZUKQ+<6NI-XEN+,:W M(5>>)0RHKEFX9P#C<$YKZ^\>? _P)\2-:L=9\3^'K;4[^Q4+%/+)(@VAM MP5PK 2*#V<$FVGQ1]U;+?UC;\]?/U/"_%'B'Q-\+]8^+7@F MQ\::]X@T^S\,KJ]MJ&I7S2WVGW!:-=GG@ C<&W #& 1@9R3H:EH?BWX?_!_P MC\4U\=>*];OX6T[4=8T^]U-VM&M7 $D:0K@'[Z9+;B=I;@DU[MX?_9W^'GA? MPSK7A_2_#<5KI>LIY=_&+B9I)U[*96Z+X8M7686, 66=5V^=*3ND?&>,L2<=A@5U MU;-*-HIWM_3?S>IDFY>\^O\ 2_ Z?P7_ ,OG_ /_ &:NGKF/!?\ R^?\ _\ M9JZ>N.?Q,ZX?"@HHHJ"PHHHH **** "BBB@!K_=;Z5YG7IC_ '6^E>9UO3ZF M%3H%%%%;&(4444 %%%% !1110 4444 %5]2_Y!]U_P!%FW:6?^NA_I6O6%X-;=I4GM,1^@K=H **** "BBB@ HHHH **** M "BBB@ HHHH **1F5>I ^IJ*2\BC4EG&!W[4"N345EW'B6PM\[KB//LV[^6: MS9_'%I']Q9)3WP H_,_X5:C)[(S=2"ZG349 ZFN+;QI=73E+6SWLW122S?IB MK,=IXQU3#QV,UNH_C,8AQ[Y;%5[-K?0CVR?PJYU3.%0O_#Z@<55N-6M+7_63 MQJ/7>*Y>?PS=Y+:GX@L+;U4W1E]+N_P !9_#%V?\ D)>(-/MCW66[\QOR7-5S MI/ANWYN->FNF'5+6T/Z,Q%:=O\/8E&9)G)_N\ 5HP^!].AQF+?Z[V)_PI>T7 M=OS)_I M78P>'[&W.4MXQ[; ?YYJVEI%&NU5^7TSQ4.HNWXFBI2[I?(XY?$7BJ1<6\2V M,9Z"&V2(?GC/ZU'):^*-1XN-1G(/9KAB/TS7\F>- M:'\.O'7A!+NP\/:OH\>CRW4MW%#?V3R-$TC;G0$.OR;B2/3-7Y;7XHS+Y#:3 MX6W=/M0U"X"_7R_*)'TW'ZUZM175''5H]ON//EE6&ET?WL\O\*_!:.'5IO$' MB>>WUKQ),%19TAVQ6L8! CA!Y4/&V,"IO)3CY <>M/HKG.RR$"A>@ I:**!F'XS\56W@O09-4NANBCDC M0J.IW. <>X!)_"MM6610RD,K#(8'((KQ/]IF\NFTO2[-(V^QK-YLTF<#>0PC M7WX$A_*O0?A7?7EYX$TC[?&T=U% D9W?Q+M!1@>^4*GZY[U[5; JGE]+%WUD MVGZ=/R?WH^7P^;2K9Q7R]KW81BT_/6^OS7_@+.LHHHKQ3Z@**** "F3.8XG9 M4,C*I(4=3[4^B@1\T?"W2=4M?C%>H+B/[=:-,]RO.R8;PLB@_P# B0?517TO M7AOPK7[5\:O%=RO"#[5^.9UQ_*O,<* M!_*K-<.*K/$5YUOYFW][/5R_#+!X2EAU]F*7W*P4445RGH!1110 54U;4H=& MTN[O[@[8+:)I7/L!FK=>0_'CQ-))#9^%[ F2ZO'5YT3KMS\B?BW/_ 1ZUWX' M"O&8B-%;/?R74\C-L?'+<'4Q+W2T7>3V7W_@9OP'TN;7O$FN^+;Q09))&CC] M-[G<^/H-H_X%7N%8?@GPS'X1\,V6F)@O&F96'\4AY8_G^@%;E:YGBEB\5*I' MX5HO1:+_ #.?(\!++L!"C4^-^]+_ !/5_P"7R"BBBO+/?"F7$\=K!)-*XCBC M4N[MP%4#))I]>3_'#QA)';P^&--S)?7V!,$Y(0G"I]6/Z?6NW!X66,KQHQZ[ MOLNK/+S/'T\MPL\3/6VR[OHOFNK-,5'$U[4O@@N6/H MO\SS\AP%3 X7FK_Q:C-#HNBKHUFY_M#4 M!AMGWDBS@_BWW?SKO/$.O6OAG1[G4;QML,*YV]W;LH]R>*\B^&F@W7C_ ,67 M/B[6%+012Y@C;E2X^Z!_LH,?CCWKWK/HL+A:>"H0P]%6C%67]?F%%%%8'6%%%% !1110!3UC5K;0M+N;^[?R M[>W0NQ[_ $'N>GXUXSX%TBY^*'C:X\3:JF;"UD'E1-RI8/ M=>NOB9XFM_#.B'=9129EF'W68<%S_LJ.GJ?PKU[0-#M?#>CVVG6:[8(%V@]V M/=C[DY-?2?\ (KPNO\:HO_ 8_P";_K8^(?\ PO8]):X>B_E.?ZJ/]:,T**** M^;/MPHHHH **** "BBB@ HHHH @OKZWTNQN+R[F6WM;>-I999#A411DD^P K MXL\%VMU^U9^T9+XEO(''A'0F5HXY0=IC1B88B.FYVR[#T##TKKOVKOBM>^)= M4M_A9X2#7>H7DBQZ@T!Y+$_+ #_X\W8# ]:]S^#/POM/A'X#L="@*RW0'G7E MRHQYT[?>/T'"CV KUJ?^QT'4?QST7DNYY53_ &NLJ:^"._F^QW-%%%>2>J%% M%% !112.ZQHSNP5%&2S' ]: ./^+OCK3_AQ\/-9US41OBAA*1P!RC32M\J1 M@@Y&2>HZ#)[5\J?LF? >?Q;>1?$G4F^QM#J:S:?!$@CBE"LWG':!PN3A<=U- M+\1-:U/]K;XS6GA30IGC\(:2Y9[I1\NT'$EP?4G[J ^HZ9-?9?A[0+'PKH=C MI&F0+;6%E"L$,2_PJHP/J?4]S7LRD\%0]FG[\]_)=OF>1&*QE?VC^"&WF^_R M-"BBBO&/7"BBB@ HHHH **** "BBN7^(/BJ#PWH)M/T+29?]&>Y1+FY0_?&X;E7VQG) M[_3KZ37E_P -? 3+'9Z[>%DN6E\V-#_SS*,.?2 MW?XI>-#*49-'M#_XYG@?5C^GTKU&3P[8R*%,";0, ;1_A4/A7PW!X7T>*RBP MS_>EDQ]]SU-;%8Y;A9X:#J57>I/63_3T1G1I"M/EZ1*O\ NY'\ MC5&;X?VS?<=U^C?XBNNHKV5.2ZFKI0?0X27X?RQ\Q7##_@(_F#7-^++_ %7P M/:JL.I2Q7,V1&L4KJP'=J]0US6K;P_IDU]=-MBC'"CJQ[*/'?[R?_ )*NK?Z''6@DU"G\ M3_ K^!=+U_PW&VH10DW5VG/F1I*VP\X(8'KU-=)-XGN.FH>'=.G/=FM#&_YJ M17?%5;JH/U%,^SQ\X7&>N.*]+!T:>#HQH4XZ+\?,VC0Y(\L9'GO]K>&[CBXT M">T/=K6\;_T%P?YT?8_"EU_JM2U&P/\ T\VRR_JAKN9M'M)EPT*'W* G\\50 MN/!VFS=+=4]=N0?YUW*HO-"=*7D_Z\CF8O#,#L#I_B;3V)Z++(\+G\"/ZU;_ M + \60*'A/VY.QAF2?/X9)JU/\/K5\^7))&.W.[^=9[^ [JV)>WN2A^A!_,& MJYXOK]Z(]G)?9^YC9M5\0:7Q=Z=+'_OPLO\ +BN \9>+KKQAJ%OI40,=O$^9 M,'.YNY/L!G]:W?%GBSQ#X1C%A#J]P+F=<;$F9BJGC//0GM3/!>GZAX3MY)I] M)ANI;@#>+FW\S:O4 'M[U\MCY/,\0LNH_"M:C7;^7U?]=3DJ2=1^S3=NIU>A M^(M*TO3[:SA4PQ0)L7-&$(J,59([(U&E9-?D=Q',LF M=AWX_N\BG*ZMT(-<3'X;MY/^0;XGL7/99V>W/_CPQ5P:+XOM8P\*F_A7D-!( MDZ_@ <_I2Y%W-55E_+]VIU=%<7)XFU?36*WVGM&Q_P">D;1G\!T_2K-OX\@; M EAEC]2"'_PH]G(?MH=2M\3_ !X?!>C?Z-&TE_/\D3%?DCSGYF/KP<#OCT%9 MWP,,L_A*[O+B1II[J^DE>1SDL=JCG\0:X;Q9KB_%#QY9Z='+Y>D6IPTF<#&? MWC_4\*/P]:]JT6/3=.MC!IX2. L7V1D%03UZ5ZM>,<-A8T6O?EJ_3HC['%^Q MP&70PK7[VI:3\ET3_P C4HIJR(W1@?QIU>*?+!1110 51UW7++PUH]WJFHSK M;65K&9)9&[ >@[GT'>KU?+_[2WQNTC5K*?PGI3&Z^S7(>_O.D:-$V?+3^\P8 M#)Z#&.3T4GRJY[63Y95S;%PP\$[77,UT75_Y>9QGQ,^*\_Q?\3Z;;0VDGV>V MN-ECID?+L[D*'F;H#_LCH,_>KZ.^%OP=L/ <9U&\2&]\1S?ZV\53B,8 V1YZ M =>IKR;]FOX#:IIMY9^*?$EJEBG-W:6);=*TCY*R2?W<*>%SG)YQC%?3W3D MU$5]IGUG$N:4:,(91E@ )/ ->!+=#3;6& MP>=);JWB19MO7=@9)]">N#SS7M_Q'\%S^,M+LQ9W,=KJ%C>0?)_%GP7UWP_'#=:-%+X@EN@\NI+'(B-]H)SYD:NP^0@[=H) M(V)@$EC6-1-GZIPCC#D CD9.,XK'UW7ELQ<1S/\ 9;F'*O#< HZ,/X64\@U@W&KF M>&-U5F9P"J("6)/0 =R:P/VUZCC]$"K$I M_P"!>7NS_M"O6ZY'X2^&[SPC\.]#TJ_D,EY#!F49R$9B6V ^B[MH]@*ZZNR. MB/Y4S;$?6LPKUKW3D[/ROI^ 5Q'Q"\;W6D3PZ+H@1];N$\Z2:1-T=E!G!E<= MR2"J+W.3T4UK^//$\GA#PO&1MJM+)(L:;CV7+ GV!KQ*\\1 MW5C8ZC-J%PD^LZASQ)L1E3Y84C&21&J\@$DY+$G)J)RMHCWN&\CEF555 MIQO3B[>K_P DOOT7VT?2B5G2TO-S7%VO4#RU^XIX^\02.W-<]W>Y^Z?V?@ ML/A98644HS332TO?LE^GJ?6>E?&3PMK%Q8QP7=TD=]Q;75S83P02,5W!1)(@ M7) ..><5V-K=07L(EMYHYXCP'B8,I_$5\L^);Y=:M!;ZEMNXE96$3C* J,W)V9^0Y[PG2RO! M/&4ZCTLK.SO=]]/R/:J***U/S4Z?P7_R^?\ /\ V:NGKF/!?_+Y_P _P#9 MJZ>N6?Q,ZH?"@HHHJ"PHHHH **** "BBB@!K_=;Z5YG7IC_=;Z5YG6]/J85. M@4445L8A1110 4444 %%%% !1110 5%=+NM9E]48?I4M!&X$'H: .:\!R;]- MN%])L_FH_P *Z6N0^'&8XV+:MXDLH6_B2.1KB0?4 M+_C4?_%)V'?4M5:HKXJU/4 MFVV5BTAZ?(K/_*DA\201L%TKPU91-_"\R-<2#\6_PJR^K>+M079]HEM4_NQ; M81CZ+BJY4NGWLRYY2Z_?UK2CLX8?N(%[<<5#J+U-%2EY+Y''C7/%UU'L@8V$+=%MXDA7\P,_K5 M=_"VLZHQ:]OGE.?^6LC2'\Z[Q45>B@?A3JCVC6RL7[&_Q-LXRW^'L:X,L\C^ MH&%_QK2M_!.GP_>C#GMN)/\ ];]*Z&BI=23ZE*E!="A;Z'9V^-D*J1_=4#^0 MJTMK"O2-?QYJ6BHN:62V$"A>@Q2T44%!1110 4444 %%%% !1110!\Y?%+Q) M?6?QILKVQC>66P,,$*#@3=W0?4N5-?0]G=)?6D-S%N\N9 Z[A@X(SR.QKQ+X M^Q+:>*O#%TH"[=Q/&!Q(K?S8U[G7TN:2A/!X2<8V]UK[G;_@_,^&R*%2EF>8 MTYSNN>+M_B5]/EI\D%%%%?-'W(4444 >1?M)-GPKI[OR1O\ &O2/"KG-15,=4:V5E]RL?/\,T71RFBI;M.7_@3;_)A1117BGTX4444 (S!% M+,0J@9)/05XAX)0^/_BY?ZZ^7LK(EXL]./DB'Y9;ZBNX^+WB<>'_ G-!&V+ MN^S!&!U"D?.WY2]?LK]?0[:BBBOGS[$**** "BDVT, MP12S$*H&23T% C,\3>(;;PMHMSJ5T?DB7Y4SR[=E'N37EOPD\/W/BGQ%>>,= M6!=C(WV?=T+]"1[*/E'_ -:JOB2^NOB]XQATG3V9=&M&RTP'&.C2'^2__7-> MSZ;I]OI-A!9VL8BMX$"(@[ 5]'/_ (3,*Z7_ "]J+7^['MZOJ?%TO^%S'JO_ M ,N*+]W^]/OZ1Z?\.6:***^#-#EO9B'G8;;>'O(_;\!U/M7GWPA\'SZQJ4W MC#6+GU*_5H=$M3M$8/&.HC!]3U)_ M^M7M\,*6\211(L<: *J*, = !7T-:2RR@\-!_O9_$^R_E_S/C<+"6>8M8ZJ MOW%-_NU_,_YWZ=/^''T445\X?:A1110 4CNL:LS,%51DLQP /6EKR/XH>-[C M6+X>%-!S-/,WE7,D9ZG_ )Y@_P#H1_#UKMP>%GC*OLXZ+J^B7<\O,LPIY;0= M6>KV2ZM]$C'\3:E>?&#Q?%HNF.R:+:ON:8#C X:4_F0H]_>O:-(TJVT/3;>P MM(Q';P($51_,^YZ_C6+X!\%P>"=$2V7;)>28>YF'\3>@]AV_^O735U9ABH5. M7#T-*<-O-]6_4\_*,OJ4.;&8O6O4W_NKI%>2"BBBO(/I HHHH **** "O+_B MUX]>W7_A'='+2ZC60'C8,?Q']!]:V/B5\0H_"=G]DM&635IU^1>OE M_P 9]_05G_"WX>OI(_MS5PTFJW&719>6B!ZDY_B.?P_.O>P=&&&I_7<2M/LK M^9]_1?UY_)9EBJN.K/*\$[-_'+^5=O\ $_Z\MCX:^ X_!>C_ +T*^I7 #3R# MG;Z(#Z#]378445Y%>M/$5'5J.[9]%A<+2P=&.'HJT8A13=QIU8'6%%%% !11 M10 4444 %>/?M%?'2'X2^'Q9Z>RS>)[]#]EBX(A7./-<>G7 [D>QK?\ C+\9 M=*^$/A\W-QMNM6N 19:>K8:5O[S>B#N?P'->+? 7X2ZI\3/%$GQ+\>*USYLG MG6-K.N!*P/RR;3TC7HJ]^O0<^AAZ,5'V];X5^+//Q%:3?L*/Q/\ !'1?LK_! M&Y\+V\WC7Q*DDGB/5%+0K)-87X7^"-]YJ-X_V?4)K8Y8D];=3].7/ M8 @_Q5N?M$?M"7&CW)\%>"BUYXENF$$UQ;#>UN6X$:8ZRG_QWZ]-W]G/]GV/ MX7V+:WK6R[\5WJ?O'.'%HIY**W=C_$W?H..3ZE&G'#Q]O66OV5^OH>76G+$2 M="EM]I_IZG2_ CX,V7P9\'K8H5N-7N]LNH7:]'D X5?]A*T@CAAC6**,;511@ #M7SE.$\WJ*M55J,?A7\S[OR[(XXIXB7-+ MX5MYCP H P!2T45].=P445R/CSQU%X8M3;V[+)J<@^1.OEC^\W]!7-B,13P MM-U:KLD1.<:<>:14^(WC@Z+#_9FGL7U.X&"4Y,2GC_OH]OS]*G^'?@G_ (1N MT-W>+NU.X'S9Y\M?[OU]35#X?^!Y89AKFL;I-0E^>..7DIG^)O\ :_E_+T&O M'P="IBJOU[%*S^S'^5=_5_UY3>)=>O/B-K*:)HY8:>IS))R ^#]]O]D= MAW/X5YF.QL<'!67-.6D5W?\ EW,*M54UW;V1#=W%[\6O$BV\&Z#1[4Y+$=!_ M>/\ M'L.WYUZSI]C!I=G#:6T8B@A4(BCL*I^'?#UKX9TN.SM5X7EY"/FD;NQ MK4K++\'+#J5:N[U9[O\ 1>2)HTW"\I:R>X4445[!TA1110 5@>,O%UOX1TII MY"'N7RL$.>7;U^@[U:\2>)+/POIKW=V_'2.-?O2-Z"O-?#.@WOQ)UQ]=KXZ(O^R.Y[_GCP\?C9PDL+A=:LO\ R5=W^ARUJC3]G3^)_AYEWX=^ M$KC7-0;Q1K699)'\RW1Q]X]GQZ#L/;Z5ZSCJWJWU;[FE*DJ<>5%2;2[:?AXP1Z'D?K6=<>#]/GS^Y0'V&W^1 MK![VU8R6UV49>AP5;]*[ MZBM/:2[F;HP?0XF.\\8Z7\L=[/<)_<9Q,"/HV:XKXD?$6ZL=+ET^YTK3QJ-T MA59EMA'+&IX+94CGL.*]3\6>)K/PEHD^HWG*(,)'QF1ST4?YZ9KRCX;>%;KQ M]XCG\6ZXFZV60F"$CY78=,#^ZOZD?6O4P<86>)K+W8_B^Q]#E6!A!/'XI_NJ M?1_:ET2_49\.-$T#1]&']KV]\FI3G<\MNZ%47LNTC/'?GJ:ZU=#T*Z;-EXB$ M#=EOH&C_ %&:[.Z\/V-WGS($/_ 163=> [.3/EYC/^RQ'^-,JUL97EB*UFY/\ I?(S8_#/B&-=UA>0:BG86]RLA/\ P$\U')JGB#1FVWNG M2J%Z[XF7]1Q3IO ,\)W6\[*?I_4&EB_X2K1_EM[^9HU_@\W*_P#?+5%XR[?D M<-G'HU^(^V\?1-Q-;NI]4((%:EOXLTZXZ7 0XZ2 J36-<>*-0_YB^BV5]_MS MVNQOP9<57^W>%K[(GTR^TUS_ !651\C"D]B#CG&> M/35\/Z1<\Z?XDAB?M'?1-!C_ ($,BK@T'Q3:1A[9O[1A'W6MY5G'X#)/Z5E* MG%]?OT/7P&;8W+7*6&ER\RL[6>G]==T=;7BW[3'CG4?#>@6VE6#K;#4MRRS; M_P!Z4'54 Z#H"3Z@#/..QF\6:CHZO_:%H8%C!9VD#1X ZDYXKPNQU4?&;XO+ MJVH!ET'3BI2)@2-BDE$..[-DGVR*SG&2T[GT'#-.C+$3Q^)7[J@N:5^_V5ZM M['K?[..E3Z1\-UANH6M[@WDS/'(,,IR!R/PKU&LRSUVPN2?*EC#,Y.TG/\ M5T_D1B8R^6OFD;3 M)M&['IFHE'F1]5E.;U>',36A4ASZ1^3=O" MC31_W7*C4?M#:XUKX?TK1X$\R[O[V.<[B%5(8&61W+' MH WECCGYN!7SIXI\3%F<>:'_ -I00#[XKV3]K358]-T_PMLCD:\:ZG(9< "' MRL2 Y_VFB./]D^E?*&L:PTLFU=SNQVJJC+,2< =SFN:I\1_0W!-&,,IC-+6 M3DW]]OR2+UOJ$5]XFT:&X'FV\E_;K)&>C*95R#[5[UKVN-/=32,^69BIZUV^IZIUYK,^Y=-2FILMSZU M'!=))-&MQ$I^:)R0&'<9!S7NW[-+6"^#=8BL2SF/6+CS))&+,^0C1DD]<1&- M?^ U\HZIJA8$*^T^HKZ^_9QT2VT;X.^'W@&Z6^B-]/*>6>20ECN/<@;5^BBM M:>Y^=\>5(QRV$7>\I+TT3W/2Z***Z#\#.G\%_P#+Y_P#_P!FKIZYCP7_ ,OG M_ /_ &:NGKEG\3.J'PH****@L**** "BBB@ HHHH :_W6^E>9UZ8_P!UOI7F M=;T^IA4Z!1116QB%%%% !1110 4444 %%%)N&['4^@Y- A:*IW6L6EF,RSQQ M_P"\W/TP.:Q;OQQ:19$*O*<=A@9^IJE%O9$2J1CNRAX";R=6UJW/!5QQ]&8? MUKLVE1>KNVF\+ZS(N[5=1M],C[ MKRCFEDO_%NK*(VN9;2''$<9$"@?1<9IEOX#GF;?:Y-?/W6Q@./IN>A=;T&S.VQ\/FZ?L]].7_':N*Z M"U\#6,."Z^8?]MB?\*U[;1;2U7"1*O\ N@#^52ZB\V6J4NR7X_FQ MV<,2[50;>NWM^53*JK]U0/H*^2_!-A^TMX\\)Z7XAT_XA^'X;+48%N(H[FUB M615/0,!9D _0FO=/ M]K_@'P&)OBKXIT>74EN&#ZIYL=M;;&(\M,E(AGKV_. MC9M2TL7;:VIZ#16#_P + \+C6(M)/B32!JLVTQV/VZ+SWR,C";MQR.1Q6EJV MM:?H%C)>ZI?6VFVZCM=9\1:3I%S(,I#?7T4+N/4*S FF!NT4R M*:.>%)8G62)U#+(I!5@>00>XKR3XV?&*RTGX6>*[[P?XITN;Q#ID*.%L[B"Y MD@)E126C.X#J1\P[U$Y*";?0J,7-I+J>O45P'PE\:RZM\&?#GB7Q+J4*3SV" M7%Y?7!C@CR>K-@*JC\A75>'_ !9H?BR"2;0]9T_688SM>33[J.=5/H2A.*TD MN63CV(3NE+N:M%8NM>-O#OAN]@L]6U_2]+N[C_4V][>1PR29.!M5F!//I7CW MP%^*'B7QI\7OBEHNL:G]MTO1;XPZ?!Y$2>2GG2KC)Z5,7S2Y5V;^ M[_ARFFHN3\OQ/>Z***8@HHHH **** "BBB@ HHHH \6_:0AW)X?E'53.O_HL M_P!*]GBD\V)''1@#7DG[0R[M/T7_ *ZR?R6O5=/_ .0?;?\ 7)?Y"O>Q;OEV M%\N?\SY'+URYUC_-4_\ TEEBBBBO!/K@HHHH \9^-Z_VCXL\-:>.6;M_OR*O M_LM>S5X[X@7^V/CEIT&-PM3%[_=4R_S->Q5[F8/EP^&I=HW_ / G<^4R=>TQ MF.Q'>:C_ . *WZA1117AGU8445&Q.Z@!VP5YC\>-5\O0['3$;]Y=3>8RCJ54 M=/S(_*O3E;L:\@NE_P"$Z^+T<8_>66FGGN-L9R?SSE44J_MY_#33E_E M^)\QQ!4D\(L+3^*JU%?/?\#TOPGI/]@^&]-L,;6A@4./]HC+?J36M11FO)G- MU).4?0#J*0&EH M*\J^)_C*XU2\'A?1,S3S-Y=PT?4D_P#+,'^9_#UK5^)'CYM(0Z3I;>9J[[OR1\ECZ]3,JSRW".R_P"7DNR_E7F_ZZVU? ?@V#P;HZVZXDNYP[?_7KI**3=7CU:LZ\W4J.[9]+A\/3PM*-&BK1CHA:**JZIJEKH]E) M=WDRPP1C)9OY#U/M6<8N3M%79K*481UGR( UGHMN^3NZ#W/JY M'0=OU/K&BZ+:>']/BLK*(10QC\6/7*8\SUK/_P E_P"#_7K\?+GX M@JO1U&O\ VW^O1^DZ3:Z'I\-E91+#;Q#"J/YGU)]:MT45\_*3DW*3 MNV?81C&G%0@K)!1112+"BBO//B+\2/['+:1I!\_59/D9H^?))XP/5O;M73AL M-4Q514Z:U_+S9P8W&TOAX#!UL77698]6E]B'\B[_P") M_P!=D4445X9]6%%%% !1110 5QGQ#^(4/A&T,%OMFU65?W _AS/)>#7O$6Z>^D/F1P2\E3_>? MW]!V_E[6&PM.E!8K%_#T767_ #Y?'9A5Q%5X#+M9_:ET@O_ )+LB/X=_#N> MXNAXB\0[I[V5O-BAFY(/9V]_0=J]2HHKAQ6*J8NISS^2Z)=D>M@,!1RZC[*E MZMO=ONPHHHKC/2$VTM%% !1110 4444 %>;_ !D^-FD_"72?GV7VMS+_ *-I MZO@_[[_W4_GT'?'/_&C]HJP\ K-H^A[-4\2-\FU?FBMB?[^.K?[(_''0\I\( M_P!GV_\ $&L-XS^(WF7NH3OYT6GW7)+=0TH]!VCZ#OZ5WTJ$8Q]K7TCT75G! M4KRE+V5#675]$8GPE^#.L?%[Q,WC[XA^9-:RL)+:RF4KYX'*_+_#$.P_B^G7 MZLCC6*-410B*,*JC '84[IP.!16%>O*O*[T2V78WHT8T8V6K>[[A1117.= M4454U75K/0]/GO\ 4+F.SLX%+RS3,%50.Y-&^B%MJRWG')X%?-?QN_:+N[O4 M#X,^'?F7^LSOY$U_:#?M)ZI#CJWJ_1<<<\C$\>_&3Q-\<=;?PA\/+>>'3'^6 MXO.8WE3."S-_RSC_ %/3OMKV#X,_ C1_A+8B;"ZAK\RXGU!E^Z#_ 1@_=7W MZGOV ].-*&%7/75Y=(_YGFRJ3Q+Y*.D>K_R.?^ O[.\'PU3^W-<9-0\57 ), MF=Z6H/4*3U8YY;\!QDGVQ,T^BN&K5G6ESS>IW4Z<:,>2"T"BBBLC48S'-*K9 MI2H:E Q0 4444 %%-DD6)&=V"(HR68X 'K7GGBCXE/<3?V;X=5KFYD.S[0JY MY]$'?Z]/YUPXK&4<'#FJOT75^B,JE2--7D;WC#QY9>%86C!%SJ##Y+=3T]V/ M8?K7(>'?!M_XVOAK7B%W^SMS'"?E+CL /X5_G^M;'A'X9I9RC4=:/VR_8[Q$ MQW*A]6/\3?I]:[ZO*AA:V835;&JT%M#]9=_0YU3E6?-5V[?YC(88[:%(HD6. M)!M5%& !Z 4^BBOHEIHCL"BBN \9?$0PR'2]$S./'T7AV-K2S*S:FPX7J(L]S[^U9G@?P!*UP-: MUW=->R'S$AEY*G^\_OZ#M_*WX)^'HTN0:EJO^D:DQWA6.X1D\Y)[M[UW->50 MPM7&5%BL:K)?##MYOS.>-.51^TJ_)!1117T)V!39)$AC:21@B*,LS' ]:CN M[R&PMI+BXE6&&,;F=C@ 5Y7K7B#4OB3JG]E:0KPZ:IS)(V1N']Y_;T7O_+S< M9CH81))R'>)O$U]X^U(:'H8;[%G]Y+T#@'JQ[*/U MKOO"OA6U\)Z:+>W^>5OFEF8?,[?T'H*=X7\+V?A73Q;VR[I&YEF8?-(?\/05 ML5SX+!3C-XK%.]5_=%=D13I-/VE367Y!1117M'4%%%% !65XD\26?A?36N[M M_:.-?O2-Z"JWBSQA9>$[/S)SYEPX_=6ZGYG/]![UP.@^&=1^(^J#6=;9H]/! M_=Q+D;QG[J^B^IZG]1XF,Q\H3^JX5LOR(]%T74?BAK/] MJZKNATN,X2-3@$9^XOMZG_(]*S@CAAC6**,;511@ #M1;V\5G!'##&L4 M48VJBC ':I*WP.!C@XN4GS3E\4NK?\ D72I*FKO5O=A1117J&X4444 %5M2 MU*VTBQFO+N58+:%2[R-T I;^_M]+LY;J[F6"WB7<\CG KP_5-3U3XU^)!IV MG[[30K=MS,PX _OL.['LO_US7=A<,Z[8Q(]0^.7B_>_F6OAZR;&!QM7T_WVQ^ _7W2QLH--LX;6VB6&WA4(D:C 4#H M*J>'_#]EX8TF'3["/RX(QU/+,W=F/YR]SX"LI?\ 5EXCZJW'Y'_&LJ3P/>63>99W3(W8C*M^8KO:X3XO M?$ZW^&OAMIP5DU6Y#1V=N>UE'J:X? 2QM:-"A&\I.R M/(_C5\1/$<:CP+;7\U[<7FU+B%6\P@,1MC!(R"W&?;ZUU?PYTG3? ?AF#2M1 MT&.ZN&)EN+I7>.5G/8'I@=!QV]ZI_ 'X8W4UQ+XX\2!I]2OBTEJDXRP#=96] MVSQZ#ZC'M\VFV\RD-&,&IC+7FDCZ?.JM/"8>&38*=XP=YR_FG_E'9?\ N<% M]G\*ZACR[J_TJ0]ID$R#\1@U9M_#-\"&T?7+.^_NI'<>7(?^ /BM^Z\&Z?<9 M(B53ZJ-O\O\ "L>Z^'XY,$SKZ!@&_7BNA5(OJ?#NG)?9^XBGO/$N@_\ '_I\ MNQ>2TD1Q_P!]K_C4EKX\A; G@DC.>60AA^7'\ZCM[3Q-H'_'C?RA%.-L3*?\ @:8_E3Y8RZ?<3S./5KU-VU\36%U@ M+<(">S':?U_QK22YCD4$,,'I7$^9X4U'[T>H:/(>ZD7$8_#AJFM_"[R$MHVO MV=T?^>?FF%_Q#<5+@O0UC5EZG9[AMSD8ZYKY+\961GMK2%_\ M29'9U8)DYY.%#,0J@8'.?6ND^,'Q$UVUN)?!=@S2ZE.1%<^1AG 8?ZL%>Y!Y M]!]>.M^#MA8_#?P^;66%FU&Y8/=W"X()'11WPH)_$D]ZYW!S=EJD?HF6U?\ M5W!_VG6TK55:G%]NLVNW;_@Z>I>&='3P]X=TS3(_NV=M'!]=J@$_F*TJS+/Q M'87F EP@8GA7.T_KQ^M:*RJR@@\'H>QJK-'P\JOMI.;=V]1U%%%(1\R_M@>' MM>U;5/#-SINEWNI6<<-Q"QLX'FV2,T9&54'&0O![X-?,/ARWGN?%VG0RG['/ M;W'FR+.-K(8SRN#_ !9XQ]?2OTXKF]2^&OA/5IKR:\\-:3/<7@(N+A[*/S9, M]27QG/OG-92A=W/TS(^,EE>%A@ZM'FC&]FG9ZN^M_4^0=4U3[W-J]?FK M?\=>!-8\'^+=2T&WT_5;^-)R;.46TDS3PG!0AE7#$#Y3CN.:W/#/[+WC?Q=; M_:;[[-X;MV^XM\2\[>_EK]T?[S ^U8\KV/UZIG67T:$<35K)1DDUKKKY+4Y? MX4_#.\^,GBQ].BNVT_3[./S[R\5-Y4'Y511TW,%2.*QKSQE96^0C>:?^F8S^O2LB3P[86K;] M8\0PF0=8;,&X?_OK[M-75_#^GG;8Z-)J$O:2_E./J$6K4%ZF+K[4 M)/*L;-I&;H "[?D*GD\/>)+R(/J%Q'I5LW5KV98%_P"^>OZ4BZ[XFU&/RK55 MTRW;C9:QB!?Q(YI(? UW>2>9>W3,Y^\W+-^9ZU6D>R_$SUEW?X%8Z;X:T_)N M]7N-3E[QV$.U<^[OU'T%.C\16-LP72/#MN).TMT6N)/J,\#\JZ"S\$V%O@O' MYC=_,);_ K8@TVWMUVI&H'H!@?D*AU(^II&E+R1XL]YXBOOB8TOK^9YJCXTVZ9\0M N@ B2>6AP,='()_) MJ])K/VC6BT-G13LY:G/V?@O3[7!:(2-_M$FMB"P@MUPD848QP,?RJQ14.3>[ M+48QV0BJJ\* /I2T44BPHHHH **** "O)/VL/^3??&'_ %PB_P#1T=>MUSOQ M"\#6'Q*\':EX;U.:X@L;]%262T95E #!AM+*PZJ.H-8U8N<'%&E.2C.,GT9\ MM?"7]G'QOXH^&OAW5M/^-'B#0K*\M$EBTVV6?R[=3T1<7*C ]E%=+^TWX6U# MP7^RDFC:IKUSXFOK:]@$FJ7F[S9\RLP)W.YX! Y8]*L?\._?AY_T&?$W_@5; M_P#QBNSMOV4_"5K\*[OP FHZT='N;X:@\[3P_:!( HP&\K;M^4?PY]ZJHN=- M)6U3_$(M1E%MW_X8\+_:$^&?AOPI^S1X+US2]*M[373)9RRZI&@%S,TL+.YD MD^\V6YY/&.,5T?Q2;_A.OVBOA'X:\29NO#DVF1WK6TQ)BN+@I(26'0Y*(N#V M)[&O=?'WP/T+XC?#O3/!NI7>HP:7I_D>5-:R1K,?*0HNXLC+R#SA1SZ4[X@? M WPQ\2M'TFRU5+J&YTD*+'4[*;RKNWV@#*N!C^$'D8R,X%7]N4NG,FEY6M^> MOR)3]R,7ORM7\[G.Z5\,_ /P[^*UYJWA[58M%\37MBRCPK:7<$4%PH4D,+8+ MOZIG*G&03ZUY+^R;X!\-?%KPSXQ\1>--/M?$7B&]U.2&ZDU!!(\";%8;,_<. M6;YEP?E '2O=/AW\!/#OP[\076OQW>K>(/$-PGE-JVO7?VJY"?W0V !T'.,X MXSBL3Q%^ROX2UG7-2U33]1U_PM)JF?[0M] U#[/#=Y))\Q"K<')X&!R>*CE: MZ7TMZ:W_ .'*YE;>VJ?KI;_ACYJ\*^+M>TG]E_XJZ;IM[<3:5IFJ1V5C#/V??#RZ(M#_:8\,W]EX'TGX;1W-N;?4-#M?$-C(UU M"0_[U;=&5CC /RH>8\^M>[ZS^SQX1\0?#K1?!VH1W=Q9Z,BK87WG!+N @8W! MU4#/J-N#@<<"E^'OP \._#WQ'/XA%]K'B/Q!)'Y(U3Q!>?:IXX\8VJ=H &., MXSCC.#BME_$]SP[]GCPCHOQ5^*OQ8U/QKIUM MKNK6^H?9H[?4HQ*((R\J_*K<# 15![ <8J7]C73;/1_BU\6K#3Y#+86MTL$# MEBV8UFF"\GKP!7KWBO\ 9H\,>)O&%SXGMM2U[PSJMXNV]?0+_P"RB[!QGS/E M)YP,[2,]3SS6C\*O@#X9^#FL:W?^'I+\?VJ$$EO=3*\<04L0$^4-_$?O,QJ* M*Y'&^EHM?/\ K\V74DI*5NK3/1#(:D5MR@TAC!.:=5F84444 %%%% !1110 M4444 >3_ !^PUCHP[^9)_):]0T\_Z#;@C!$:_P A7E_QV4S-H<2]C M7MV3M\F%G'U X_7%5&+E)16[(G-4XN8>!$.N?%36=3^]'"92K?5MB_^ M.YKUVO-_@GIQATG4;UAS/,(P?4*,Y_-C^5>D5ZN:R3Q+A':*2^Y'SW#]-QP* MJRWJ-R?S?^5@HHHKR#Z0*8R\YI]% &#XPUP>'/#UW>Y E"[(0>[G@?EU_"N: M^#F@-9:3<:I,,S7K80GKL4GG\3G\A6=X\N)?&/BZST"U;]S ^)&'3=U8_P# M1^N:].L[6*QM8;:!=D,2!$4=@!@5[53_ &7!JE]JIJ_1;?YGR]%?VAFS M7\2>_DNWJSY6FO[8Q:K/^#2?N_WI=_1=/^')J0FEHQ7AGU84W!IU% " 5P_C M[X@+HBMIVFD3:I)\I*C<(<^W=O0?_JIGC7Q^UK(=+T;]_?N?+:1!GRSTPOJW M\JE\"_#\:/C4=2 FU-_F 8[O*S[]V]Z]FAAZ>'@L1BEZ1[^OE_7K\SBL96QE M1X/ /_%/I'R7>7Y?E7^'_@$Z4PU;51YVIR_,JRQ@\'2P-%4:*T_%ON_,6BBN:\6^.+3PS"8P1<7[#Y(%/3W;T'Z MUG2I3K34*:NV;5\12PM-U:TK)&EK_B*R\-V+7-Y+M'1(Q]YSZ 5YE#9ZO\6- M4$]P6L]&A;A0?E'LO]YO?M^E7=$\':EXVO5U;7Y76V/*1?=+#L /X5_G^M>G MV]O%9P)##&L42#:J*, "O8]I3RY;[+ MR_X<@TO2K71;&.TLXEA@C'"CO[GU-6Z**\.4G)N4G=GU,8QIQ48JR04444BP MHJ.XN(K6%YII%BB0;F=S@ >I->6>)O'%_P",KS^Q/#:2>5)E9+@<%QWY_A7W MZG^?;A<)4Q4K1T2W;V1Y>.S"E@()SUD]HK=OR_S+GCKXE/YS:-X?W7-](?+: MXAYVGIM3U/OV_E?^'WPVC\.JNH:CBXU9_FY.1#GT]6]3^7OH>!_A_9^$8!*V M+C477#SD<+ZJGH/U/Z5UE=F(Q=.E3>&PFD>KZR_X!YF$R^KB*RQV8ZS7PQZ0 M_P WYA1117C'TX4TTZDQ0 B]:=2 8JOJ.I6VDV;W5Y,L$"=7;^0]3[4XQ;>-/B(S:3H8!\M/[53](_Y_T\;P'\-5T>0:GJ^+G56.\*QW"( MGG.>[>__ .NN_HHKR\1B*F*G[2H]?R]#WL'@Z.!I*C05E^+?=^84445S'<%% M%% !1129H 6BBN&^(WQB\/\ PWMW6\G^UZEC,>GVY!E/H6_N#W/X U<(2J/E MBKLB4XP7-)V1V5_J%MI=G-=WD\=K:PKODFF8*J#U)/2OG#X@?'_6?'FI'PO\ M-[6XD>;*/J"*1(XZ$QY_U:_[;8/TZUFQ:5X\_:4O4GOI/[$\*(^Y%"D1CV@1F'[VZDPTTQ]6;^@P!Z5W\M/"ZS]Z M?;HO4X>:IB=(>['OU?H;#P%Y>L:WY>J^)&^?>WS1VQ/\ (?B'=/JF MHRD2&P>4R#/;S7S\V/[HXXZD<5]"001VL*0PQK%%&H5(XU"JH'0 #H*Z_:4\ M+I2]Z7?MZ')[.IB=:ND>W?U.>\"?#W1/ASHJZ;HEHL$?669N99F_O.W<_H.P M%=)117G2DY.\G=GH1BHJT5H%%%%(H**** "BBJ]]J%MIMNT]U.EO$O5I#@5, MI**O)V0MM66*QO$/B[3O#41-W-F8C*V\?+M^'8>YKC]8^(]YK-Q]@\.6TCNW M'GE,L?<#L/<_I5CP_P#"\-,+W7IFO+ECN,.XD9_VF_B_E]:\*>85,3)TL!'F M[R?PK_,Y76Z1-KGC'4O&5ZVDZ!'(MNW#S8PS#H23_"OZ_P JZKP? MX%M/"$D;%Q?L/GF(X7V7T'ZG]*U]%T*S\/V:VUG$(TZLQY9SZDUH5&&P#53 MZSBGS5/PCY+_ #%3I._/4=W^04445[1U!6?KFO6?AZQ:ZO9?+3HJCEG/H!WK M%\7?$"S\,JT$8%W?X_U*GA/]X]OIUKE]&\'ZGXVOEU77Y)([8\I#]TL/0#^% M?U/ZUXN)S!\_U?"+GJ?A'S;_ $.6=;7DIZO\BLS:Q\5-0VKNLM'B;W*C_P"* M;^7\_2]#T&S\.V*VME%Y:=68\LY]2>YJW:VD-C;I!;Q+##&,*B# %2UI@\ L M.W6JOGJ/>3_)=D53IIGCRQRL?NWO[5A^)?B)=ZY=?V1X:221Y#M M-R@PS>NWT'^T?TZUL>#/AM;Z$RWNH$7FI'YLGE(S[>I]Z^=JXVKC9NA@-NL^ MB].[_KS..5655\E'[S&\+?#V[UN\&L^)7>5W.];:3[S>F_T'^S_^JO3E41J% M4!548 P *6BO3P>"I8*'+3U;W;W;\S>G2C25D%%%%=YL%%%% !5/5M7M-#T M^6]OIUM[:(99V_D/4^U4O%7BW3O"&G&[OY=N>(X5Y>0^@']:\@AL]?\ C1JR M75X6L-!A;Y57[H'<+_>;_:/ _2O0P^%]JO:5'RP77]$>S@O+DI+=] M_)=V+J&I:Q\;->%E8J]EH5NV79N@']YO5CV7_P"N:]C\.>'+'PKI<5A81>7$ MO+,?O.W=F/\<>.-+\ :')J6IR[5 M^[%"I&^9^RJ/\XI&M&C4KU(TJ4;R>B2$\>>.M-^'^@3:GJ,G0%88%/SS/V51 M_,]J$^'/@G4OC=XLE\9>*E/]DQR 06^,)-M/$:C_GFO?U.?>HO"OA;6OVA/ M%3>(?$!>U\.V[[8X5) 8 _ZN/V_O-_7I]+6-C;Z;9PVEI"EO;0J$CBC&%51T M %1\6O0^UK5*?#E"6&H2OBIJTI+["_E7GW9,JA5"J, < "EHHK0^%"BBB@ Z M]>:C:WCD7#(".N.WY5)10(R+SPM87F=T"!O[P&#^E>,_&[7+'X=V*6ME-YFM M72YBAR&\I.GF-_0=S]*[CXP?&"R^&NF>5%LNM$'_/1_1?;J3^) M'!_!WX1ZAX@UA?''C(O<7M1]EY=V5/A#\*]=\)^7XEN T>MW"EXU<_O(5;KG/\3 \]\''K M7IUQXINV(76]%M+X?\])(/*?\&7%=]UX/(J&2TBD4@H!GKCBM(R45:Q\_F6+ MQ&9XF6)K2U?3HET279' 8\*:ET-_HLA^ES$/Y-5FU\+WX;?H6LVNH^B03^7+ MCW1\5T5YX3T^\R6@53ZJ-I_3_"L.\^'H^];SLIZ@.,@?CUK95$^OWZGCNG)= M/NT*TVKZ[H;A=0L9$[9DB*9^A'!JY9^.+:3 F5XC[C)+*Z;;K'AZ OWEM,V[_ )=/TI\JET^XGF<>MO4ZFUUJ MTO/]7,K?0YKE;SXK:;)XVT_PMI6W4]2FD(N7C;]W;(H+-N/=L C Z'KZ'@/C M-K?AW0_",LFF:EJ%OJ=R?+ALV4 G^\?,'$'I@DX'>N?^!/PR\3:/"_^7S_ M (!_[-73URS^)G5#X4%%%%06%%%% !1110 4444 -DX1L^E>8M*JJ6)PHX)[ M#\:[SQ-]H_X1_4/LJ-)<^2WEJJ[B6QP .]>*7/A?4I,2:]JMOI:$9V7$N^3' MM&N3^'%=5&*:=V<>(FXM)(V;[Q586>1YPD?^['\QS6'-XQNKV3RK&U=V/08+ M'\A4/G^%]*XBMKO6IA_'<-Y,6?91R1]:LQ^)->O(_*TRVBTJV/06<0C'_?9Y M/YUV**73[SSW4E+1O[@?P[X@O8_,U&>/2K8\EKR41#'^Z.3^55_L?AC2_P#C MXOKK6)A_RSLT$<>?]]N2/H*G@\%WNH2>;?7+NQY)R6/YFMVQ\%V%K@M&)']7 M.ZDYI=?N!4Y2Z?>8-MXHG1@F@Z';6+=I1&9YO^^V_P *672-?\0,'U"]D<=0 MLDA;'T4<#]*[>*TBA7:J +Z8X_*IO;M6?M/Y4;>Q;^)G(V?@&WCP9F:4_P"T M<#\A_C6[::#9V8_=Q*#_ +(Q6C16;E*6[-8TXQV0U(TC^ZH7Z"G445)H%%%% M 'FOQIC:&VTB^0',,S+GMD@$?^@FO1K>=+JWCFC.4D4.I]01D5R/Q$:%+H/B%#O /[6_C?4?&^@?\)'I,ELD,=K]BANMLIC@( M?9*P48"L,YSS[U'_ ,2CX[?&3P7??"CP/<>&=/TFZCDU'44LX[6)=LBOEA$2 M@(4-CG6G@R]UE;;Q)=!3#9 MO!+A]P)4>9MV9.#@%O:K/CCXG>&?ANVF#Q%J7]G'4IOL]I^XEE\R3CCY%;'4 M\):KXR_:=GM-#D:/5[?1DOK7R_O,\*-(%7T8[>/?%6/C)\5(?B] M\//A%K6574H]9-MJ$(X\NX7RMW'8-PP]FHA+F2[W2^3ERW_/\!2CRO3:WX\M M_P"OF?;>LZQ9^'])O-3U&=;6PLX6GGF8$A$4$L<#D\#M7+?#WXS>#OBM]N'A M765U5K+89U^SRPE-V=IQ(BY'RGIFO,/VV/&4NB_"N#P[9$MJ7B2[2SCC3[S1 MJ0SX^IV+_P #KSCPWX83]F7]I+PC8(Q31/$VE0V$[9^4W(548_4RJC?]M33A M+FG9[7LO6U_\EZBE'EAS+>U_E=+_ #^X^LO%?C#1_ _AZ[US7;U-.TNU ,UP MZLVW) "J"222!@ FM+3[Z'5+&VO+=F:WN(UEC9D9"58 @E6 (X/0@&OFW]J MZ\?Q-X_^%WP^#8LM4U-+N]3/WT5U4 ^V#)^GI70?&[]H+4_ /Q T7P3H$>@V M-]>VWVF35?$T[PV,"Y8*IV$')V'G/<#%"DFK]W9?):_UY>8.+O9=KOYO3^O, M]VFD6&)Y&W;44L=JEC@>@')_"L;P;XVT3X@Z#%K/A^_74=.D=HQ*J,A#*<,I M5P&4@]B!V]:\^^"WQ2\7>,-:U?1?%OAV&UELU\RVUW1DE?2KY,@'RI6R">0? MO$GG@%37"?L]WS>#_P!H3XJ> XSC3GG.KVL/:,L5+ ?A*@_X *J.LE'NFU\O M^!^1+5HM]FE]_P#2/IBBBBF(**;)VI$ZT /HHHH **** "BBB@#RSXJ)]N\7 M:#:=<[>/]Z3']*]3KS'7U&H_%G3HAR;M1I1H4HTH[127W M!11169N%8GB_Q"GAS19;C(^T.-D*^K'O]!UK:9EC5F8A549)/0"O,&63XC>+ M.=PTNU_#Y<_S8_I]*[\'1C4FYU/@CJ_\OF>/F6*G1IJE1_B3TC^K^1J?"[PZ MUO:RZQ= FZN\A&;KLSDG\3_+WKO*:B+&BHBA448"@8 'I3JQQ%>6(JNI+J=6 M"PL<%0C0AT_%]6%%%%(MB61>CD=>?[H_6KOC/Q M7-J$_P#8NC[I99#LEDC[_P"R#_,UT'A'PI#X9LL'$EY(,RR_^RCV%>Q1A'!P M5>JO>?PK]6?-8FI/,ZCPE!VIKXY?^VK]?ZO:\->'K?PUIB6L W-]Z63'+MW/ M^%:M%%>5.:CJOQ#O#:V:-:Z:K?,3T^K'N?]D?\ UZ[?P[X9L_#=KY=NNZ5A^\F8 M?,Y_H/:O7C3IX%<];WI]%T7K_D?.3K5\T;IX=N%+K+J_*/\ F9G@[P-;>&HQ M/-MN-08?-)V3V7_&NII,&EKS:U:=>;G4=V>YA\/2PM-4J,;)!2,ZQJ69@JJ, MEB< 5GZUX@LM!@\RZEPQ'RQKR[?05P= MQ\S?X#VK8K:IBXTX>QPJLNKZO_(Y:.7SK5%B,>^:2VC]F/\ F_,****\L]\* M::=10 B]*S-?\26'ANT\^]FV9^Y&O+N?0#_(KF_%GQ,MM++6FF!;Z^SMW#F- M#^'WC["LK0?A[?>(+P:IXEEDW5^A\ M]B,SE4F\-@(\\^K^S'U?Z+_@&;))KGQ7OMB#[#HT;\]=H_\ BF]N@]J])\.> M&+#PO9"WLHL$\R2MR\A]2?Z5I6UM%9P)#!&L42#"H@P *DK+$XQUHJE37+!; M+_/N;X++8X:3KUI<]5[R?Y+L@HHHKSCV@HHHH **JZCJEII-LT]Y.EO$/XG/ M7V [GV%>=:MX\U7Q1='3O#EO)&K<-/CY\>N>B#WZ_2NW#X2KB-8Z16[>R/,Q MF8T,'93=Y/:*U;^1U'BOQ]I_AA6CS]JO>UO&>G^\>W\ZXNP\.ZW\2KI+_5YF MM--!S&BC&1_L+_[,?UKI/"_PQM-+9;K4R+^]SNPW,:GZ'[Q]S^5=O7;]9HX- M/?+3Z07_MSZ^A2TG1[/0[-;6R@6"%>R]2?4GN:NT4 M5X\I.35M<@S;>NT+]V(? MAGVKMCA^5M?\=:D="^'^G7 ,GRF\,>9B.FX# MI&O^TW/^[6S\//V:[6QNAJ_C"<:UJC-YAMBQ:$-URY/,ASZ\?6O6_#/A+2/! MVGBRT>QBLH.K;!EG/JS'EC]36O1+$@%.HHKB.T***X7QY\9?#G@)7BN;G[;J*CBQM2&<'MN/11]>?8U< M82J.T5=D2G&"O)V.ZKR[XC?M!>'O OFVEJPUK5ER/LUN_P D9_VWY ^@R?I7 MFUQKWQ%^/$C0:7"="\/L2K2*S)&5SR&DQF0^RC'M7I/P\_9]\/>"?+NKM!K6 MJKSY]P@\M#_L)R!]3D_2NSV-.CK6=WV7ZLX_:U*VE%67=_HCRVU\'?$/X_W4 M=YK]TVB>'\AHXV0JFWK^[BSEO]YC]#VKWCP'\,M ^'-CY&DV:B=AB6\EPTTO MU;L..@P/:NKHK*KB)5%RK2/9&M/#QIOF>LN["BBBN4Z@HHHH *3;2U'<7$5K M$TLTB11KU=V _$TFTE=B)*CGN(K6%I9I%BC499W( 'XUQ>M_%"TMF,&F1-? M3G@.00F?;N:R8?"?B'QE,MQK-RUI;9RL;#G\$Z#ZGFO&J9E&4O9X6/M)>6R] M7LF>'E'V6W'FXP9Y/F<_CV_"M9FQ6:R^KBGSXZ=U_*M( M_/N+V,JFM5_+H4M'T*QT&W\FRMUA'\3 ?,WU/4U?I%.12U[<(1IQ48*R1U)* M*L@HI"0H))P!7'>(OB59:;N@L +^ZZ J?W8/U[_A^=88C$TL+'GK2LB)SC35 MY,ZB\NX;&%YKB5(8EZNYP!7G^M_$2ZU2X^P>'H'D=^//V98^ZCL/ M\:3K=:S.]I:DY6)@00/]E.WU//UKOM$\/V.A6_E6<(C'\3'EG]R:\GGQ>8:4 M_P!U3[_:?IV.>]2MM[J_$Y3PS\-4CD%]K;_;+ICN\ECN4'_:/\1_3ZUWJJ$4 M*H"J!@ #@4M%>IAL)1PD.2DK?F_5F\*<::M%!117->)_'FG^'%:/<+J][01G M[O\ O'M_.M:U>GAX.I5E9%2E&"O)G0W%S%9PO-/(L42#+.YP!7G.O^/KS7KK M^R_#D4C%N#<*,,W^[_='^T?TJK;Z/K_Q$F2XU&5K/30.L\2>+=/\ #$&ZZEW3,/D@CY=OP[#W->>%?$'Q M2NAD?8-(5O?9_P#9M^GTK8\._#%YKC^T/$,K75RYW&W+[N?]MN_T''UKT..- M(8UCC1411A548 'H!7D_5\3F6N*]RG_*MW_B?Z'/R3K_ !Z1[?YF5X=\+V'A MBU\JSB =A\\S_3IPHQ4*:LD=<8J*L@HHHK4H***KZAJ%MI= MI)=7ZKT\D'Y8O=R/_ M $'K]*Y;Q%\3M4\77QT;PG!*HDRIN5&)&'?I70^!?A)9^'72^U)EU M#5,[@6YCB/J >I]S7JPPU/#+VF*WZ1ZOU['TE/ 4<#%5LQWZ06[]>R_KR.:\ M,_#?5/&^HKKOBR601,0R6K?*SKU Q_ OMU^G6O7;>TALTC@@B6&",;4C0851 MZ 59HKDQ&)GB'[VB6RZ(\O&X^KC9+GTBMHK9!113&DVG&*Y#SA]%(6"C)H!S MR* %HHHH ***\K^*WQTL/ X?3=+":EKK#'EJ*I)+;0U/[B!'P$E.N])5.D?*'ZO^E%8V-OIEG#:6D*6]M"H2.*-<*JCL!4]%%6?$-N3N M]PHHHH$%%%% !7F_Q>^,EC\.-/>VMVCN]>E7]S:YR(P>CR>@]!U/TYKGOBU\ M>DT.=M!\+[=0UMV\IYXQO6!B<;5'\3Y[=![GBJ_PI^!,MO?+XE\8LU[K$C^= M':S-O$;==\A_B?VZ#W[0W?1'V&#RNC@Z2Q^;:0^S#[4_\H^?_ O1^$?P=O?$ M&J?\)GXV$ES>3OYT%I0=@.-J=L#V%>_P!%%-*QXF99E6S.M[6KHEHD MMHKLD%%%%4>4%%%% ",H88(!'O7-^.MN=5U;"6\0P(U +2L>B*#U) M_P 3T%:^M:U9>'=*N=2U"=;:SMT+R2-V']2>@'V,#C8A[#L96[GL/IS+E;8^BRC*HXYRQ&*?+0IZRE_[:O-_UTO7\ ^!=1^.7 MBJ?Q)JL0M=!MY-L<*\*Q'(C3V'5CWZ=^/;V\':AI<@DL+IHF7[I4F,CZ$5VF MEZ7::)IUO86,"6UI;H(XHHQ@*!5JM(2<#DSC'K-*L>6/)3@K0BNB_P WU9PD MWB37K6,1:K9PZM;C@?;8!)^3CG/OFJWVGPMJF?-M;S1)C_%;MY\0]]I^;]:] M!:%&ZJ/3TK,OO#-C?#YX$#?W@,']*U51=K>A\]*E+O?U.7M_"]V^QN"?RIT/ANTNF#Z M'K\+2=K>[)MY<^@)^5C^-2X+T+C5EZGKO@D@_;,<_<_]FKIZX7X86>KV2:@F MK0R1R938[@'=][.&'7M7=5Y]16DSU:3YH)V"BBBLS4**** "BBB@ HHHH R_ M%"32>'=12WX:M_R#;G_K MF:X>NFE-Q32..M3C.2;,BQ\+V-CC;"NX?Q$9/YG^E:B0QQ_=0 ^O>GT5;;>Y M"BH[(****104444 %%%% !1110 4444 4->T_P#M70]0LP,M<6\D8SZE2!^M M<'\"=4%UX:O+,G]Y:W!./16 (_4-7I=>/>!'_P"$9^,&O:,?DANP[Q+_ .1$ M_)&:IZCZ'L-%%%4(**** "F2L0IQU-/J*:0;: (/.'<8JS%]W\:A90PYZ5/& MNU *!#J\"_;4\-:OXJ^$$%EHNE7NL7@U.&0V]A;O/(%"29;:@)QR.?>O?::^ M=IQ6=2'M%R^GX.YI"7([GS#^T]X/U[Q!H'PGCTO1-1U*2RO(FNEM+224P )% MDN%!VC@]?0U;^.OA/7-7_:8^%6J6&C:A>Z99O&;J]M[622&#$Y)WN!A>.>37 MTE'G!S3ZT>M3VG][F_"Q'V.3RM^)\W>!?".LV_[97CK6+K1;Z+0[K2_*BU": MU<6TS8MOE60C:Q^5N >Q]*YCQ9\/_$O[/?QVM/%O@;0]2U?PCK3XU/2=)M7F M\D$_.-B X SO0]CE>G7ZT56WYJ2IC'EY+?9T]5V9&=4OXM1:+3[62:.TFWCS P0$*.2P)QP2/X:^[:*2BDXM?9;_ !=_ MS_(7,[23ZK]+?UZGR;\8_ACJ_P ?OVDK#1-3T[6M/\$Z38LCZI';-'&[E=[> M5*Z%"2S(O?A#7/?&3]BNP\!^"WU[P'/XAU?7K*XBD%G(8YW9-V"42.)6+ E6 M[\ \5]IT5*@E%):/>_SN5[1N5WMM;Y6/D+XK:I?W'Q*^ /C?5[&XTM[EX[2] MM[R%H7MY]Z[@RL 1R[$9[#-=I^TEX=O]8\4:1+K'PZB\=^"5B*RS:/#+_;-I M(<$4E&Y"=IQMQU!QP3Z?\9?A3:?&#P8^B3W;:;=1SQW5IJ"1^8UM,AX8+D9 MX)&,CK79V$,]O8V\5S.+FY2-5EG5-@D8 MMR<9/.,G&:KENFMO>;^__ "=_ MP%SU;6]%T?Q%X5\ M:F,6/B7$=Q<2D#'[H= ME.2&.<#C)R:V/@[:G7OVO_BIKL&3:6,"Z>S#H9"8UQ^<#U]-R!FC8(P5\':S M#(!['&>:\^^#OPGB^$NBW]J=0;6-4U*]DO[[46A\HSR.?[NYL #MD\DGO51T MFGV37W_T_P !2=XR75M?A_PR/0Z***9(8S2 =*6F&3TH ?12 Y%+0 4FX9Q M2TW9SF@!U%%5]0NA8V-Q<-TBC9_R&::3D[(F4E%.3Z'G_AM?[2^)>I7?58?, MP?H0@_2O2*X3X6V)6&_O7Y:1Q&"?;D_S'Y5W=>CF$E[?D6T4E]QXF31:POM' MO-N7WL****\T]TBNKA+.VEGE.V.-2['V S7 ?#FU?4M:U+69A\Q)5?\ >8Y/ MY# _&M;XC:H;?2X[*,_O+IOFQUVC_$X_6MGPSI(T71;>V(Q)C?)_O'D_X?A7 MJ0_<824NL]/DMSP*B^M9A"'V:2N_\3V^[ M2C$:_P!W_:-:4ZB,7QWKTEPXT2PS)-*0LNWKST0?UK MH?"^@)X>TM+<8,S?/*X[M_@.E9/@GPR;-#J5X"UY-RN_JH/?ZFNMKNQ-2,(+ M#4MEN^[/+P5"=6H\;B%[TME_+'_-]0HHI'=8U+,0JJ,DGH*\T]H6N&\5>+); MV;^R=')EED.QY8__ $%?ZFDU[Q+M[PSX6M_# M\.[ ENV'SR^GL/0?SKU*=.&%2JUE>71?JSP:U:IF$G0PSM#[4OT7^9%X3$0 M^'H/,DQ+?2#YY.R_[(KH:**\^I4G6FYS=VSUZ%"GAJ:I4E9(**BN+J*SA:6: M18HUY+,<"N+U3Q=>:S/]BT:)QNX,H'S'W']T>_\ *M*.'G6?N[=^ACB<92PJ M]_5O9+=FUXB\86F@JT8(N+S'$*GI_O'M_.N:T_PWJ/C"Z6_U>1XK;JD>,$CT M4=A[]_UK;\/^!X-/9;F^(NKO[V#RJG^I]ZZFNQUZ>&7+A]9=9?Y'G+"UL=)3 MQFD>D%_[=W]""SLH-/MT@MHEAB7HJBIZ*P]<\76>CAD!^T7(_P"62'I]3VK@ MC"=:5HJ[9Z]2I2PT+S:C%&U)(D,;/(P1%&2S' %<;KGCW,AM-'C-S.WR^<%R M,_[([_YZU46SUKQHZO.WV2PSD#&%_ =6^IKK-&\.V6AQ8MX\RD8:9^6/^ ^E M=RA1PNM7WI=NGS/)=7$X[2A[D/YGN_1?JK.<5PFK?$2YU*?[%H%L[R/P)F3+?55[?4UU4 M,+5Q#]Q:=^AY^*QU#!K]X]7LEJW\CKM<\2Z?X>AWWDX5B,K$O+M]!7G]SK.O M?$2=[73XS9Z=G#MD@8_VF[_[HK3T;X:O=3?;=>G>YG8[C"')S_O-W^@_.N\M MK:*SA6&&-8HEX5$& /PKN]IA\'_"]^?=[+T74\IT<9F7\=^RI?RKXGZOIZ&! MX7\"Z?X;59 OVF\[W$@Z?[H[?SKI***\RK5G6ESU'=GNT,/2PT%3HQLD%%%% M9'0%%-DD6)"[L$4C0J5Y@>$=-\.KFVAW3D8,\AW.?\ M#\*]#V6&PNM5\\NRV^;/&=?'9AIAX^RA_,_B?HO\SC-/\!ZMXHN!?>(;J2-# MRL.1OQZ =%'ZUZ#I>CV>BVX@LK=((^^TH%%%% !1163K_BS1_"\/F:IJ$%F,9".V7;Z*.3 M^ II.3LA-I*[-:JVH:G::1:O=7US#:6Z#+2S.$4?B:\:U[X^WVK70T_PAI$M MS.YPLTT9=C_NQK_,G\*I6'P7\4>.KI;_ ,8:O) I.X0;A)(!W ^1/PS]*ZE MA^57JOE_,Y7B.;2DK_D:WB[]HJSMY#9^&;-]7O&.U9G5A'GV7[S?I7.6OPM\ M;_%2ZCOO%NHR:=8YW);N/F _V8A\J\=SS[&O9?"GP]T'P7$!IEA&DV,-[F^:9 M_JW;Z# KJ***Y)23N=<8J*M%!14%Y?6VFV[W%W<16T"\M),X11]2:\N\6 M_M#Z'HX>'1XWUFZZ!ERD(/\ O$9/X#GUJH4YU':*N1.I"FKR9ZQ7 ^,_C7X9 M\'>9"UU_:-^N1]ELR'(;T9NB_P _:O-O[,^)GQ;)-U*VB:/(1\C9@C*^R_?? M\>*[OP;\ ?#GAADGO$.MWJ\B2Z4>6I]H^G_?6:Z?94J7\65WV7^9S^TJU/X< M;+N_\CSR;Q/\2/C-(T.C6[:'HKG!E1C&F/\ :EQN;Z(/PKM/ _[.6@^'62ZU M<_V[?CG$RX@4^R?Q?\"S]!7K,<:0QJD:JB*,*JC ] *=4RQ,K-^:H^9^?\ D,AC6&-8XU5$4855& !Z 4^BBN0ZPHHHH ***Q=6\8Z5H^1- M3'&Q9OQ8_TK MR7F$Z_NX.FY>;TC_ ,$Y_;.6E-7_ ")-4^)WF2?9]&M'N9FX#R*>3[*.3^E4 M[?P7KGBB07&MWCP1GD1GEOP4<+_GBN[TO0['18]EG;)#Q@L!EC]2>35ZE_9] M3$/FQM3F_NK2/^;#V+GK5=_+H9&B>%--T!1]EMQYO>:3YG/X]OPK7HHKUZ=. M%*/)35EY'1&*BK)!12,P4$DX [FN8UOXA:7I*E(7^W3_ -R$_*/JW3\LU%;$ M4L/'FJRLA2G&"O)G45S6N^/]+T;=&DGVRY''EPG(!]VZ"N8_XJ;QU_TXZ>WU M1"/YM_+Z5TFA?#W3-'VR2K]NN!_',/E'T7I^>:\KZUB<7IA8VK+-9^L:]8Z#;^;>SK$/X4ZLWT'>N,U;XC76IW'V/P_ M;/)(W'G,F6^JKV'N?RHTCX:S7]Q]MU^Y>:9CDPJV2?\ >;^@_.O%EF$J\G3P M,>9_S/X5_G\CE=9R=J2OY]"K?>,M9\83-9:%;200'AINCX]VZ+_.MKPQ\-[3 M266YU K?7N<_,,QJ?8'J?@_G6-:M3 MH1YZLK+S(E*,%>3-]6]37*^)/B1INA[HH"+^['&R-OD4^[?T%+];Q.-TP<> M6/\ /+]%U.;VDZNE)67=G)V^@^(OB%,EQJ@>'_"^ MG^&K?R[*'#'[\S\N_P!3_2M:BNS"Y?2P\O:/WIO[3W_X!I3HQ@^;=]PHHHKU M#H"BBB@ IGFCTK(\3>+-,\+VIDO[E4)OB-<-9:%;/ M8V!;#3 D''^W)V^@Y^M=M#"5*RY]H]WL>KAT^&"WD]%_P3M_&7Q2TO MPINMX_\ 3]0'_+")N$/^TW;Z=:X>S\*^)OBI=QWVM3MI^EYW1IC''^PG_LQ_ M6NN\&_"/3?#_ )=U?XU+4!\VYQ^[0_[*GK]3^E=]73]8I85M+373=7ERD MYOFD[L^>G4G4DYS=V^K'=:*15VKBEJ2 I"H;J*6B@!KKN]J55VKBEHH *KW^ MH6VEV7$=K;1+N>:9@JJ/4DUQGQ!^,6@_#^*2*67[=J@'RV-NP+ _[9Z( M/KSZ UY-9>&_&GQ^OH[_ %F9M(\.*^Z*,*54C_IFA^\?]MO4X]*ERZ(^DP.2 MSK4_K6+E[*C_ #/=^45NR_XS^-FL^.M4_P"$<\ P3'S"4:^5<2..Y7/^K7_: M//TKK/A9\"[#P4R:KJ[KJFN-\X9ANC@;K\N>K9_B/X8KL_!_@?2/ NF_8]*M MA$#_ *R9N9)3ZLW?^5;V"6&*$NK-L9G$(47@LLC[.EU?VI_XGV\E_P F60- M]:=4:1D-DU)5'RH444C,%&3Q0 M% .1D=*Y+X@?$[1?AW8^;J$WFW;KF&RB( M,LGO[#W/Z]*1O0P]7%5%1HQ.UMHAN>65@JJ/.;*2WB@H\@[[3_ F.K'!^G?.@TWQI^T3J*W-W)_8W MAB-_D4 ^7_P%>LC?[1P/ITKWGP7X"T;P#IHL])MO+W8\VXD^:68^K-W^G0=A M4ZR/L8T<%P_[^)M5Q*VC]F#_ +SZM=O^ SEOA1\%=.^'<"WESLU#77'SW3+\ ML61RL8/3_>ZGVZ5Z53&D56P:?56L?)XS&5\=6=?$2YI/^K+L@HHHIG&%%%% M!69XD\2:=X3T>XU/5+A;:TA&2S=6/95',O'&D> ])?4-6N1"G2.%<& M29O[J+W/Z#OBOGW3]-\0_M*>*#>WS2:9X5LW(55/"CC*I_>D(ZMT'Y RWT1] M'E>4_6XO%8J7LZ$=Y=_*/=O\/P&7$WB/]ICQ4(81)I?A.S?))Y5/<_WY".@Z M ?B3]&^%?"^G>#=#M]*TN'R;6$?\"=N[,>Y-2^'_ _8>%])M],TRW6VLX%V MHB_J2>Y//)0A\,?UEW;_KNRBBBJ/G0HHHH *:R+(,, MH8>XIU% %"\T2TOEQ+$K?[PS^O6N?OO ,$F3;NT1]/O#\CT_6NOHJE*4=F9R MIQENBS\*]-N]*LKV"YF,J!U\L;B0HYZ ]*[JL#PG_JKC_>%;]L?M&:%:L4TZPOM2/:7:L49_[Z.[_QVK/@/XWVWB_6/[.N=/;3 MY'_UH)[>M,MO@IX.\)Z=-?ZNUQJ*6Z>8\UW,0HQZ(FT'V!!K# MTS1(=2U6.VL]/ATZXU.9)9(8(POV6UC((!Q_%[_WG Y S2U"R/;J***L@*** M* "BBB@ HHHH **** "F;#FGT4 (HVC%+110 4444 %GIRD> WMGDG\L5VX.*E63>RU^X\O,JCCAI1CO+1 M?,W?!]A_9_A^T0C#NOF-]6Y_EBMFD50J@ 8 X%+7+4FZDW-]3NHTU1IQIQV2 ML%(S!5))P!R2:6N=\::I]DT_[+&W[ZXX..H7O^?3\ZJE3=6:@NI.(K1P]*52 M70Q+!#XL\7-=L";2V(*Y] ?E'XGFN]K(\+Z2-(TN-&7$TGSR?4]OP%:];XJH MJD^6/PQT1RX"A*E2YZGQRU?S_P @HHJEJVK0Z3:F64Y;HB#JQKEC%R?+'<[Y MSC3BY2=DB+7-:BT6S,K_ #2MQ''W8_X5SGAW09M:O3JVI_."=T:-_%Z''H.P MI=+TN?Q-?G4+_P#X]@?E3LWL/:NS50JA5 P .U=\I+"P=.'Q/=]O)'CTZ< ML?45:JOW:^%=_-_I_5UHI&SCBLK5M?@T="&/F3D?+$O7\?05P1A*H^6*NSUJ ME2%*+G-V1?O+R'3[=IIY!'&O<_R%<7>7VH>,KHVUFI@L5/S%N/Q8_P!*FM]) MO_%5PMS?.8K7^%0,<>BC^IKK[.SAL+=88(Q'&O8?SKO3AA-O>G^"_P"">2U5 MS#?W:7XR_P D5-%T.VT.W\N%=?R?:92!CS>U MKOGEY[+T0 8&****XCU HJO>ZA;:="9;F9(4]6/7Z>MK7^!:=^AQ8C&4,+_%EKVZ_<=C<745G"TL\J0QKU=S@"N-U MCXD)O^SZ1 UU,QP)&4[<^R]3^E5K?P?J_B*9;C6;IH4ZB/JWX#HM=?I'A^PT M./%K JOC!D;ES]377RX;#?&^>79;??U/-=3'8W2FO90[OXODNAQ=EX(U3Q'. MMWKEU)&IY$75\>F.BUV^E:+9:+!Y5G L0[MCYF^I[U>HKGK8JK7]UNT>RV.W M"Y?0PKYHJ\GO)ZMA1117&>D%%9^I>(+#2%/VFY1''_+,'+G\!7)WGCZ]U*;[ M/HUDQ8\"1EW-]<#@?CFNNEA:M;6*T[O1'G8C'X?#OEG*\NRU?W';W%U#9PM+ M/*D,:]6=@!7(ZQ\2;:W8PZ;"U[,> Y!"9]NYJG!X&U/6Y5N-9OF7_IF#N8>W MH/PKJ](\-:=H8S:VZB3H97^9S^/;\*Z>7"X?XWSOLMOO.)U,?B]*RT.C#Y;0HR]I+WY]Y:O\ X 4445PGK!1110 45S&N_$GP M]X?WK<:A'-.O_+&V_>/GTXX!^I%<'??&K5M;F:U\-Z*[.>DDBF5_KM7@?B36 MT:,YZI&$JT(Z-GL$TR6\;22NL<:C+,YP!]37"^)/C3X& M7\7Z?EFN0C^&/B_QNZ3^)-6:UASD0N=[#Z(N%%=OX=^$/AOP^%8V?]H7 _Y; M7F'_ "7[H_*M>2E3^-W?D9\]6?PJR\SSZ3QSX]^(K&+0;!M,L6./.BXP/>5L M?^.X-:>@_L^1RS_:_$NIRZA<-\S10L0"?]IS\QX],?6O8E58U"JH51P !@"E MI/$-*U-D^[.C2*[(UJ*\FUSX_6BL8-#TZ:_G8[4DF^1 M">Q"CYC].*QFTKXD_$-LW4S:-8/_ %C N/3:/G/7^*NA8>6\WRKS.=XB.T% M=^1Z;XB^(WA[PMO6^U*(3KUMX3YDGT*CI^.*\TU3XY:WXDN6LO"6BR%VX$TB M>;)]=H^5?Q)%;_A_]G_0]-(DU.:;5I>ZG]U'^0.?UKT?3=*LM'MA;V-K#:0# MI'"@4?I3YJ-/9(V?P5\3^-+I+SQ=K,D2]1"'\V0>P'W$_ M#/TKTSPK\+_#G@\*]E8))=#'^E7'[R3/J">%_P" @5UE(:B=>I-6;LNQ<*$( M.]KL-U+3*<*YSH%HHJ*YNX+.,R3S)"@_BD8 4FTE=B):*Y;4OB)IEGE8-]XX M_N#:OYG_ K&_MSQ-XFRMA;_ &2!O^6BC;Q_OG^E>94S*A%\D/?EVCK_ , P ME6@G9:OR.YOM3M--CWW5Q' O;>V"?H.]1FFU=/+:,9<]6\Y=Y:_AL-4(WO+5^8EO#%;QK'#&L4:\!4 'X5)3*?7J MI)*R-PHK%U7QAI>D[EEN1+*/^64/S-_@/QKEY_&^LZ[(T.C6+1CIYFW>P_$_ M*/QKSZV84*+Y;WEV6K,95H1TW9WMU>064)EN)4AC'5I& %SCW>LONZ?,B]6IM[J_$XQ=#\2^,&5]0F-E:$YV,-OY M(.OXUTNB^ ]*T?:YB^USCGS)^<'V'05T2TM;TTG[\N\M2HT8Q=WJ_, M***S-6\2:=H:G[5WF%=S_7T7\O'W'_EDK;G^F>BCV'Z5W.F:/9Z/#Y5G;I OEZ+8Z+#Y5E;I O MJ-?O5)7LQC&$5&"LD=*22L@HI&8*"2<#U-.-*T'*O M'#8A4Z?8-_$,HI'UZM^'%;NA?#'3=-*RWG_$PGZ_.,1@_P"[W_&O)^N8G%:8 M2G:/\TM%\ENSG]I.I_#6G=G/R:WXD\>.T6G1&QL3PSJV!^+]_H*WO#_PQT[2 M]LM[_P 3"Y'/SC$8/LO?\:[&.-(8U2-51%& JC %.K6EEL.;VN)?M)]WLO1; M%1H*_--W8BJ(U"J JC@ # %+117L'2%%%%, HK-UKQ'IOAVW\[4+N.W'\*DY M9OHHY-><:I\6-4U^X:R\,:=(7/\ RV=-[X]<=%^IS771PM6MK%:=WL>CA>DZUX@T_P_;&?4+J.W3L&/S-[ =37F>J_%35_$UT=/\ "UA* M"W'GLNZ3&>N/NJ/RT M6U%O8VT=M"/X8UQGW)[GZUU7PV%V_>2_#_@GHWP& V_?5/\ R5?Y_D><^'?@ MV9YOM_B2[>\N7.]H%J1]3]6Q] M*3:1ZN!RO%YB[4(:+=O2*]7_ $SUWQ)XJTGPE8M=ZM?16<6#M#M\SX[*O5C] M*\+U[XQ>)_B/?R:1X'L+FVMV^5[K \W![EONQ#WSGW[5<\._ ?6_&&H+J_CO M4YG=N?LJR[I<==I;[J#_ &5]>U>V:)X7?#W]GS3M#F34/$,@UK4S\YC;F!&ZYP>7 M/N>/:O8E4*H & . !0JA>E+5)6/G<;F&)S"I[7$SYG^"]%T(I% ^M.C48R*< MRANM &W@4SSQ:**A9B6- $U5]0O;73K.6YO)X[:VC&YY9F"JH]237G_C[XXZ M%X'22VC?^U=648%K;L-J'_;?H/IR?:O-;/PCXZ^.=S'>Z]8;)I-XS_TU;OC M^Z...XXKU#P7\.]#\ V?D:5:!96&)+J7#32?5O3V&![5TM+EZLZ*V& MRB'LXO1S?QR^?1>2_ 9##';PI%$BQ1( JH@ 50.@ ["GT459\EN,:(,VS'RQ?)&6)/<1)CD_[1 MX]N]:'PK^ ::3<+KWBP_VCK;MYHMY&\Q(F/.YS_&^?P'OUJ+WT1]EA\HHY?3 M6,SC1/X:?VI>O\J[]?UYCP;\*?$'Q>U:/Q/XWN)H]./F6;5\RDE/W81^&*TC M%?Y^8445',Q51CBJ/%)**9&Q9>:'DV=1Q0 ^BD4[AFEH **** "BBB@#I/"? M^JN/]X5OU@>$_P#57'^\*WZYY;G5#X4%%%%06%%%% !1110 4444 5-6_P"0 M;<_]*U,B:BBB@ M HHHH **** "BBB@ HHHH *BO+6*^M9K:=!)!,C1R(>C*1@C\C4M% 'AGP+O MI_"OBSQ%X+O&Q+&[30%NC,N 2!_M*5;Z"O7)+B]M9@)'5CV&/D;^H->.?':U MF\$>./#WCBR0@>8L-SMZ,RC@'_>CW+]%KVZ.2#6M,AG@<207$:S0R+W!&58? M@:E=BGW)K6Y6ZA#KP>A4]0?2F:@P6V*DX\Q@GX$\_IFLZUG-K<;FX&=DH[ ^ MO^>U2>(IO+A@ [R _ES3$66A,UQ,Z';)'A4/;IDC\&W\SC^ MM"C-]+_LHJ_S/]1^50;BS0VSG,BR#/NHR0?R'YU/;?.\\G]YR ?8I_U4WZ-_P#7'\J%O#_9LS.<2QJ0Q]\<'\:N7$*W$+1MT:L2\MKAHVB" MMYI&UMH^61: &>&H\W,K_P!U /S/_P!85T59^BV+65LWF#$CG)'IZ"KLQ80N M4^_M.WZXH$<+XH8^(KZ>2YD:#P]H[YD*C+7-R,851WVD@#/&XY[ C=\)^'QI M4,MY/$J7]W@R <^4@^[&#WQDY/9U(P5%=--JNK7"LS"PT&!?O27]RCR >H",5'XFIOU9HT]D=)17$- M)8WS,OVO7O$LW86+/:1?@ZM%&?\ OHU4TS4)[2\DOK.PO--T^WO8=.N+:\O# M<^>\KHNY#O?:8RZYP<')'4<.Y/*>A44451(4444 %%%% !112'H<=: #<,XS MS2U7YS[U8H **1ONTQ?O"@"2BBB@"*YNH[6"261L(BEC7+^$;9KS4KO4I1EB M2%/N>3^0_G4_BZ\;RX[&/EY""P'IG@?G_*MK2;$:;I\, ZJ,M[D]:[8_NJ#? M67Y'E27UC%)?9AK\W_D7****XCU2.XN$M8'FD.U$&2:Y/1;5_$&LR:C<+^YC M;Y5/3/8?AUJQKEW)K%XFGVO*!OG;L3_@*Z"PLTT^UC@C^ZHY/J>YKN3^KT[_ M &I?@CR9+ZY62^Q#\7_P"Q1165J^N1Z>#''B2X_N]E^O^%C4J1I M1YINR)]6U:'2H-[_ #2'[D8/)_\ K5S^G:3/X@NOMU^3Y/\ "G3(]!Z"K6FZ M#+?3?:]1)8MR(SW^OH/:NC "@ # '05U.<<.N6F[RZO_ "//5*>+DIUE:"V7 M?S8*JQJ%4!548 X%))(L:%W8(HY+,< 50U+7+?3\KGS9O\ GFI_GZ5C?9=0 M\12!YF\BV[#''X#O]:SA1 M/Y-A"P)_B89/_P!:DM?"[3R>=J$K2.>2@;)_$_X4E14-:KMY=2I8J53W:I(8--A90?X\?-_@*EL/"(:3SM0D,\AY* G'XGJ:WH8(;&';&BPQ MCKC@?4U0O/$5M;9$>9W_ -GI^=:*K)^Y0C9?C]YC*A"+]IBY\S_#Y(TXXTA0 M(BA$7@*HP!5*^UNTT_(>3?)_SS3D_P#UJR#)JNM<*#;P'N/E&/KU-7+'PM;6 M^&F)N']#POY=ZS]G"&M66O9&OMJM72A&R[O_ ",^36-3UIS'91&&+H6'7\6[ M?A4]CX/C5_-O9#<2'DJ"<9]SU-=$B+&H55"J.@48%+0\0TN6FN5?C]XXX.,G MSUWSOSV^X9##';QA(D6-!T51@4^BH;J\@LH]\\R1+ZN<9KEUD_,[[Q@M=$B: MBN8U#QU;0_):1-84K\E%.;\O\SH]3\2:?I.1/.#(/^64?S-^7;\:YFX\8:GK$AATBS9!T\S&Y MA_0?C6CIO@2RMSQN)_B2]G'LM7]_^1QEIX#N-0F^T:O=LSMU1&W-]"QZ?A75Z=H]GI,>RUMT MB]6 RQ^IZFKE%<]7$U:VDGIVZ'7A\#0PVL(Z]WJ_O"BH+J^M[)=T\R1#_:8" ML*^\=6-OD0+)?TJ*=&I4^"-S6MB:-#^))(Z2H;J\@LH]]Q-'"OJ M[ 5QYU;Q#KW%G!]EA;^-1CC_ 'C_ $J2V\ R7$GFZE>M*YY*H23_ -]'_"NK MZM"G_&FEY+5G#]>J5M,-2;\WHO\ @EC4OB#96N5M8WNW_O?=7]>?TK,:3Q/X MD^X#8V[>G[L?G]XUU>G^'=/TO!@ME#C_ ):-\S?F:TJ?UBC2_@PN^[U_ GZG MB<1_O-6R[1T_'S/=/W5?E7_$UU%I96]A%Y5M"D,?]U%Q4]%< MM7$5:WQRN=U#"4,,OW4$OS^\***S]2\0Z9I(/VR^@@(_A9QN_P"^>M8)-Z(Z MVTMS0HKA-2^,&CVNY;6*XO7[$+L4_B>?TK$_X3?QAXFRND:8+:)N!*L>[T]3%UH+1:GJDDBPH7=E1%Y+,< 5S&L?$SP]HVX-?+=2@?ZNU' MF$_B./S-C_"70-,VM-"^H2CG=<-\ MO_?(P/SS3Y:4?BE?T)YJDOA5O4YF[^,6JZQ,;?P_HS.YZ-(IE?Z[5X'YFJW_ M A7CGQE@ZQJ1L;9NL3OCC_KFG'YXKUVULX+&$0VT$=O$O1(D"J/P%34_;*/ M\.-@]BY?'*YY_H?P4T#3-KW8EU.4?\]CM3_OD?U)KN;'3[;3;=8+2WBMH5Z1 MPH%7\A1=7UO8QF2YN(K=/[TKA1^M1V%%>3W'Q:UK6F:+0M%)/3>5:9A[X 'XYJ%O"?COQ:@_M/4/L5N MW6-Y-N1_N(.?QJ_8-?&TB/;)_ FST+6?&VAZ!N%[J4,88='TN:\D/"O,=H)]E&2?TJ_H_P1T>SPU_/-J,G=<^6GY#G]:[;2_#^F MZ'&%L+&"UXQNC0!C]3U/XT?N8=Y?@'[Z7E^)Y.R?$CQQU+:-:-_V[C^KG^5: MFB_ 2PB<3:O?S7\I.YHXOW:GU!/+'Z\5ZI10\1*UHZ+R!4(WO+5^9E:+X5TC MP[&%T[3X+4XP75,N?JQY/XFM6BBN=MO5G0DEH@HI"P4$DX%9E]XGTS3\B2[1 MF_NQ_.?TK*=2%-7F[">K_ ,A?O9;:'*-K_B77N+&T-M$W1U7''^\W'Y5);_#VYOI!-JNH M-(YZJA+'_OH_X5W5%"RZ$W?$2E3IPI+E@DEY&RBHZ)!165?^*=+T[(ENT9_[D?SG].GXUSEU\19 M+B3R]-L&D;L9,DG_ ("O^-CI*6O9:O\#.56$=V=Q6;J7B#3M+S]HNX MT7!LX&_@9MH_[Y7^M=U9Z?;:?'LMK>.!?^F:@9^M6*7U&K6_WFJWY+ M1?\ !#V4I?'(Y;2OAWIECM:X#7LHY_><)_WR/ZYKIH88[>,1Q1K%&O14& /P MI]%>A1P]+#JU**1M&$8:104FVL?4O%VE:7D272R2#_EG#\Y^G' _&N:N/B#? MZG)Y&D:>Q8_Q,"[?7 X'XYKGK8_#T7RN5WV6K(E6A'1L[N26.WC:21UC1>2S M' 'XUS&K?$;2]/RL!:^E_P"F?"_]]'^F:R(_!6M:]()=8OFB3KY>=Y'T ^45 MTND^"])TG#1VPFE'_+2?YS^'8?@*YO;8W$?PH/)_"M'2?AG:PMYNI3->2DY**2J?B>I_2NUHJX9; M3>WR6PU15[S=V16UK#9Q"*")(8QT6-0H_2I:*1F"J68@ (V,>D6)@CZ>8HW$?5C\HKS M*V98>D^1/FEVCJS"5:$=-WY'>WNH6NEPF6ZGCMX_61L9^GK7':K\4(58PZ5; M-=RGA9) 0N?9>I_2H++X:W6H3?:-:OWD<]4C8LWXL?\ "NQTO0=/T5-MG:I$ M>[XRQ^K'FN?FQ^*^%*E'SUE_DB?WM3;W5^)PH\/^)_%S!]2N#96K'/EMQQ[( M/_9JZ71? &E:.RR&,WCEM"G+VD_?EWEJ5&C"+N]7 MYA1117JG0%%%175W!90M+<31P1+U>1@H'XFC?1#2;=D2T5P>N_%_2=.REBCZ ME-TROR1_F1S^ KG]_C?Q]C:#I>GR=QF)"/\ T)OY5WPP51KFJ>ZO/_(]BEE5 M>4?:5VJ<>\M/PW.\\0>/-&\.;EN;M9+A?^7>'YY/Q';\<5P=U\1/$?C"9[7P M[I[V\70R@;G&>Y8_*O\ GFMWP_\ !W2M-VRZ@[:E/W5OEC!^@Y/XG\*[>WAB MLX5AMXD@A7A4C4*!^ K3VF&H?PX\[[O;[C;VV P?\&'M9=Y:1^[_ #/-]%^# MC74WVOQ#?274['+11N3G_><\G\,?6O1-+TFST6U%O96T=M$/X8UQGW/J?6>9LA9Y8S)(?]H1C M@8]6)]Q4MI'L8+*<9CUS4H6C_,](KYO]#VG5M:L-!LWN]1NX;*W7K),X4?0> MI]A7C_BK]HM)ICI_A+3I=2O)#LCN)8S@GU2,?,WXX^E4-)^!?B'QE=+J/C76 M)D9CG[,KB24>V?NI]%S^%>O^%_ ^B>#;?RM)T^*V.,--C=*_U<\GZ=*6K/6] MGE.6?Q']8J+HM(+Y[OY:'C.E_!?Q5\0KQ-3\:ZK-;1GE;?(:4#T"_=C'Y_2O M9?"?@;1/!5KY.DV$=N2,/-C=*_\ O,>3].E;U%-)(\S'9QB\2?CCA?Q(KR>\^ M)7CGXL7$ECX5T^33-/)VO/&<,!_M3' 7Z+S]:ER2/?P>28O%Q]M)*%/^:6B_ MX/R/5_&WQ:\.^!5=+V[%Q? <65MAY?Q[+_P(BO(;CQ/\0?C5(\.C6S:-H;': MTJL40C_:EQEO<+^(KL?!/[.NE:0RWOB"7^V]0)WF,DB!6SG)'5S]>/:O7(8( M[>%(8HUBB0;5C10%4>@ Z"E9O<]+ZYEN4Z8*'MJB^W)>ZO\ #']6>6> ?@-H M?A%HKR_']LZFOS>9,O[I#_LIZ^YS^%>JCH,=*;Y0SUI]5:VQ\WB\;B,=4]KB M9N3_ *V6R^04444SB"F^8N[&>:=48APV165I'UD ME./P ZD^PYKPSQ1\>=:\8Z@=$\!:?,TDGRB[*9E8=V4'A!_M-^E2VD>QE^4X MK,FW2C:"WD](KU9ZGX_^*6A_#NT+7\_FWK+F*QA.97^O]T>Y_#->(K#XX_:) MU ,Y_L?PPDG'!$0^G0RN/R!_NYKK? _[.J_;%U?QG=MJU^Y\QK3S"Z;O^FCG MES[=/J*]M@@CM88X88UAAC4*D<:A54#@ =!2UEN>]]=P&2+EP'[VM_S\:]V M/^%?K^:T.7\!_#/0_AY9^7IMOONG7$U[-@S2>V>P]AQQZ\UU=%%4?(5\15Q5 M1U:TG*3ZL****9@%%%% !1110 4444 %%%% !1110!TGA/\ U5Q_O"M^L#PG M_JKC_>%;]<\MSJA\*"BBBH+"BBB@ HHHH **** *FK?\@VY_ZYFN'KN-6_Y! MMS_US-M3444 %%%% !1 M110 4444 U2^Y2UT/>]2@$0<'.../?/ M:NOK)UB:*]AFLW59+9U*3[AE64C!7\1UH$>#_P##96DQI+Y7AG6KAV;='YC6 MR* >V1*3C\*Y+Q!^UMXLU%732].T_1(>TTC&>4?@1M_G7I'_ R3X,O9&N!- MJ]A$[;EM+>Z7RU'H-R,P'MGBNGT']G'P!H)5_P"PX]1F4Y$VH,9F'Y\?I46D M:7B?(W_";>,/&E]=+!KFNZK17>5C\N%9LG&">G&*^\I7TWPMH\LS"WTW3K2,N[ !(X MT R3["O!/$'C1]3XH\6,;VZ MF4Y-K;8& #_LH5 _VG'UKU.%+'0-/A@5HK2UA4*N]@H 'N>]7'7,C-419G54444Q!1110 4444 %%(Q(' S3/,YZ4 248'I2 Y&:6@ M IDTRV\+R.<*HR:?6)K$S7EPEG#SS\WU_P#K5I3ASRL85JGLX76_0KZ-;MJ6 MI2W\PR%/RCW[?D*Z.H;2U2SMTB0<*/S/K4U55J>TE=;$X>E[*%GN]7ZA61KF MJ?9HS;PG,[C!(_A'^-6M3U$64>%P9FZ#T]S572=,*M]JN.96Y4'M[_6JIQ45 M[2>WYF=:P]*TV8(I9B%4M91CNM:?YOW< /X?_7-'+*JW.;L@YH4(JE35WV_S'7VM27#>18J2QXWX MY_#_ !J;2]#6U(FN/WD_7GD+_B:LQQVFDQ8R%/N[RZ)=#2NKZ&S7,KX/91U/X5BS:E>ZLYBM$,4?0M MW_$]JL0:&N3+=R;CU(SQ^)JQ)JEM9ILA7?CHJ# _.E%1C\"YG^ YN<_XCY(_ MB0Z?X=AML//B:7KR/E'^-7KK4;>SXD<;O[J\FLTRZAJ7"#R8_47[&.SB*#^]U/^ IUOX;, MC>9>2F1CU4'^9JS)K$4*[+>'('3C J$C4=0_Z8H?^ C_ !J[R2]U+XE^ M6"!Y#V+<"JWG:[JOW%^S1GN!L_4\_E5+#3WEHO,B6-IWM3O)^2.DN+J&U7=- M*D0_VF K%O?&5E;Y$(>X;V&U?S/^%00>#C(V^\NF=NX3_$UL6>AV5C@Q6Z[A M_&WS']:JV'I[MR?W(CFQE7X4H+SU?^1SS:EKNL\6T)MHC_$HV_\ CQ_I3[?P M2\[^9?W;2,>2$Y/_ 'T?\*ZHN%&2<#WJE<:Y8V^=URC'T3YOY5:Q%3:C&WHC M.6#HKWL3/F]79?<.L=%LM- \BW56'\9&6_,U=-<[<>,H5X@MY)#_ +1"C^M5 MSJFN:A_Q[V_DJ>A"8_5JCZO5E[TW;U9HL7AZ:Y*2OY11TY(49)P*H7/B'3[/ M(>Y5F_NQ_,?TK&'A?4-0.;V\P/[N2_\ ]:K]KX/T^#!D#SG_ &VP/R%'LZ$/ MCG?T#VV*J?PZ:C_B?Z(I7/CA2VVTM7D8]#(M;EEH&GZ?@PVJ!A_$PW'\S5FXOK:S&9[B*$?\ 31PO\ZR+KQQHUKD?:_-; MTB4M^O3]:B5:M5T;9M3PF&H:QBK^>K_$WJ*XBZ^)\"MMM+&68] 9&"_H,U5_ MX2+Q7JQQ9V/V=3T818_5^*R]E+KH=/M8]-3T&J%]K^G:9G[5>PPD?PLXW?EU MKB6\(>)=6/\ I^IF-&ZH92?_ !T<5=LOA581\W5U-<'T0!!_4_K3Y(+XI"YI MO:)/??%+1[;(@6>[;ML3:OYM@_I6._Q$UW5B5TG2, \;MK2D?B, ?C78V/A' M1].P8=/AW#^*0;S^;9K69EB7)(11Z\ 4^:G':-_4.6I+>5O0\T_X1OQGXA'^ MG7YLXFZH9-N1_NI_6KEA\';",[KV]GN6ZD1@(/ZFNLO/%6D6.?-U"'(ZJC;S M^0S6%>?%'3(,B"&XN6[?*%7\R<_I5J566D58CDI+63N;.F^#]&T@@VVG0JXZ M2.-[?FV36S7G+?$36M2;&F:1D'@':TI_3 IC:;XWUS_77!LHV_Z:"/'X+S^= M2ZE<*/UKG;_XDZ#8Y'VLW+#^&W0M^O3]: MP[7X2^8X%9MQXFTVV^]=*Y](\M_*N6=2%/6/(%XM[:24]MY"_XU6.M>(=2XMK4P*>C"/'ZMQ7%+'T;VA>3\E66<^G"C_ !_6H]OBJG\.E;U?Z"YIO:/WC+SX@64.1!#+<'U/R+_C^E4O M^$B\0:MQ967DH>C[,_\ CS<5U-IHMA8X\BUB0_WMN3^9YJ[1]7Q-3^+5MY15 MOQW#DG+XI?<<3_PB>LZK@ZA?[$_N%B^/PZ5I6?@+3;?!F\RZ;_:;:/R%=)15 MPR_#Q?-*/,_/4:HP6K5R"UL+:Q7;;P1PC_84"IZKW6HVMG_K[B*(^C. ?RK' MN_'&F6^0C27##_GFN!^9Q71*M1H*TI)%N48[LZ"BN+?QM?WS%=/T[^/M,MLB+S+EO]A<#\S52V^'D;-OO+R29CR1&,?JG_ _T MVUPT_F7;_P"V=J_D*Z"ULX+)-EO#'"OI&H7^52K4=Q=0VD9>>5(4_O.P KMI MX>CAU[D4OZ[FD8QALB6BN=O?'FE6F0DCW+>D2\?F<5CR>.-3U1S'I=ACMNVE MR/?T'XUSU,PP]-V4KOLM2)5H+K<[HG')X%9&H>+-*TW(DNT=Q_!%\Y_3I^-< MS_PBOB#7&W:C?>3&>J%L_P#CJ\5K:?\ #[3+3#3;[M_^FAPOY#^M8_6,76_@ MTN5=Y?Y(GGJ2^&-O4S;KXC373^3I=@TDC=#(-Q_[Y'^-5_[!\2^(^;^Z-K W M\#'''^XO]:[NULX+*/9;PQP)_=C4*/TJ:E]1J5O]YJN7DM%_P0]DY?'*YRVF M_#O3+/#3[[R0?\]#A?R']:Z6WMH;6,1P1)"@_AC4*/TJ2D=UC4LS!5'4L<"N M^CAZ.'5J<4C:,(P^%"T5A:AXVTC3]P-R)W'\$ W?KT_6N?N/B)>7\GE:7IQ9 MCP"X+M^0Z5SU=C-_[(O'YUL:7\.=,L\-I+X8V]3,NOB/>7\IATC3F=LX#."[?7:.GYFH5\*>(O$C!] M5O#;PGG8QS^2#C\Z] MK6"SC$<$*0H/X8U"C]*EI?V?.MKBJKEY+1?@'L7+^ M)*YS>E_#_2=-PSQ&\E'\4_(_[YZ5T:(L:A54*HX"J, 4M%>G1H4J"Y:44C:, M8P5HH***1F"J23@#J36Y8M%<]JWC[0]'W++>K+*O_+.W_>'Z<<#\37)WGQ6O MM3E-OH6EO(YX#R*7;Z[5Z?F:ZZ>%K5-5&R[O0]*CEV*KKFC"R[O1?B>F,P52 M2< =2:YO6?B+H6B[E>\%S,/^65M\Y_/H/Q-<?+9L_DB M\?G72Z/\*]#TO#31-J$O]ZX/R_@HX_/-;>QP]+^)/F?:/^9U?5L%A_X]7G?: M/^;.;N?B9KOB&1K?0-+9.WF;?-8>_P#=7\8X] MO[J_AFO48+>*UC$<,:11CHD:A0/P%24?7/9Z4(*/GN_O!YI[%6P=-0\]W][, M#0_ NB^'RKVMFK3KTFF^=_P)Z?ABM^BBN&;NSR*E6I6ES5)-OS"F%/2 ME<$]*5<[>:@R%''%%%% !116!XB\>Z!X54_VEJ<$,@_Y8J=\G_?*Y-(UI4:E M:7)2BY/LE*GF['T<,AJ4DJF/J1HQ\ MW>7RBCO_ !1\N9FP/^^0#7H/A?X'>&/#9262V;5;I>?,O<,H/LGW?S!KOXXU MAC5$5411@*HP /046;W-/KN5X#_=*/M)?S3V^45^NIXKX=_9R2:X%YXIU274 M;ACN>&!C@G_:D/S'\,?6O7-%\/Z;X M1C8?QYW7;9+Y+0*:7PP%.HIGE!116?K/B#3?#MMY^IWT%C%V:9PN[Z#J M?PH*C"522C!7;+^X=,\T,P12S$*H&23T%>+>)OVBK1+@VOAO3Y=4N&.U)IE* MH3VVH/F;]*Q1X)^)'Q1D$FNWC:1IDAW>1*=@QZ"%>3_P/GWJ>9=#Z:ED-:,5 M5QTU1A_>^)^D=_R/0/&'QT\->%?,BBG_ +6O5X$%F05!_P!I^@_#)]J\YDU[ MXC_&+Y-,MVT71I/^6BDQ1D=.9,;F^B\>U>A>$_@3X;\,%99K?^U[L?\ +:\ M90?9.@_')]Z]'11&H4# P *5F]S98_+LNTP-+VD_P">>WRC_GJ>3>#_ -G3 M0M$:.YUB1M;NQ\Q20;8 ?]WJWXG!]*]5M;6&R@2&WAC@A086.)0JCZ 5+156 ML>#C,PQ6/ESXFHY?DO1;(****9YX4444 %,DD"].345]=Q6-K)//*D$*#+R2 M,%51W))KQ[QG^T-IFENUGX?@.LWQ.Q9<$0ANG&.7_#@^M%TMST<%E^*S"?)A MH.7Y+U>R/7+O4HM/MWN+J>.WMXQEY)6"JH]R:\C\:?M(:?9,UCX8MFU>^<[% MG92(@QZ;1]YS^0]S7,6?PU\!(Q_9MDINL8:\G^>9O^!=OHN!4ZO8^@^KY7E6N*E[>HOLQ^%>LNOR^ M:/(=%^#?BGXF:BFL^-[^:T@;E;7CS2O]T+]V,?AGV[U[EX9\)Z3X/TY;+2+* M.TA'+%1EG/JS'DGZUKT4))'DX_.,5F"5.;Y::VC'2*^7^844451X@4444 %% M%% !4*1L'!/XU-4+S'=A>E $U%1Q2%N#UJ2@ HHHH **** "BBB@#I/"?^JN M/]X5OU@>$_\ 57'^\*WZYY;G5#X4%%%%06%%%% !1110 4444 5-6_Y!MS_U MS->']7U#X;^(3Y.H M6,CFSWGKCEXP>X_C7U!;MBOH*O"/VD/AM>S?9O'GAS=#KFD;9+CR1\TD:'(D M'JR=_5?]T"N\^#OQ2M/BIX3COTV0ZE!B*^M5/^KDQ]X#^ZV,C\1U!J5IH4]= M4=W7D?QT^)#:'9_$_IDYBU"Y3=/+/P%H;W4Q M66\D^2VM<_-(_;\!W->&?#/P;=?$WQ7/JNK$SV$4WG7DK#B>7J(A[#C(] !W MH?8$NK+GA'XH73)B&,[78;F;^ZOK7)2:_-Y#7]K902:/#*L(N; MNY\A)G+A?DRIW $]>Y!K2\00'7]6&DQ3&*W$8DU*93C9#DD(#V+\_P# 037- M^(;>?Q387%Y':M%HMG$5TZ *F%_Y:X]\?+[?6A[@EI=G=Z7K2ZA]HCF@DL; MNV?9-;S%=-RN.>G7#BI/%NH3Z+X>U*[2.W66&VDE7:OW2%.#^>*:8FM;'(^*K6?XH:[ M<6+7"67@S0I2U_=2GY;NY3DI[QQ8R<\%Q@$AI?"/A.V\53#7)8)+;245ETB M"7_6OD$&\DS_ !L/N+_"O/WC\OG?Q7\90>!_!WA'P;:S1#S[6/4M3,N7\Z/A MBAP06\R0\\\A?K7?>$?CA9ZPK6WV234KE8T>(:+"TROD#Y2#C8PSR"<>]0K- MW9HTTK(LV\$UA>LNH7NL6%Y;V\=D%TNP\^.2*/.'5O*?;NSR,@C '8&J^LZ1 MJNL((?#^CRAI!MDUCQ [,5]TA<\'W""NG35O&>LP%0^"?#L&F^)=,33+=[2>>[:]>,R,YMH%C*["Q) MSD, >?O.<<*,-U_QIJ.J:E_9>KM;RPV0^TV]QIY+0ZJ-VQ9(Q_LM\I7^\17I M?@/PO)H5G)=WH!U2\PTW.?+4?=C!]L\^I)IK783NEJ=31115F8C$C&!FEHHH M **** "HVCYR#4E% " 8&*6BF32B%"S4;BVU9!J%W]EA^7_6-P/\:@TJQ\E3 M,X_>/Z]A20PFZF,THR,\"M%6R*VD^6/*OFY?S).NPX^2VCV*.,@?YQ4/[J/MO;_:.!^5.:221<9*K_ '5X M%.U]7J3>VD=/3?[Q!9PQ-NNIM[]U4Y/XFI1?G'EVD 4?3)J..'/W8]YJPMG/ M(N"PC7T''Z"DVOM%1C+["M_7[NSJ_?VLN6*&MXEN)FVVUID^^6_ ME3?^)Y>?],5/T7_Z]/D\7VL:XB@E;'L%'\ZKMXNN9N+>QR?OA:XN"#0@^BL&/Y"N?7P/),VZYOBQ[X4G]2:E3PKHUKS/=% MCWWRJHK"T7JW*M%6+5QXXTR'.QI9S_L)C^>*SIOB TC;;6P9SVW/_0#^ MM757PU8]%@?ZJ9/\:D_X2S2[5=L,;D>D<84?KBG:/2+%=]9&0=9\47X_<6?D M ]#Y6W]7--_X1WQ+J7_'SJ'DKW7S3_)>*O3>.EZ0V;,>V]\?H!49\2:W=?\ M'OI^T?WO+8_KTJ_>6R2)]U[MLBM_AK#G=DP] M;8RGUDC;& MDQ^/ KL;?2;*UQY-I#&1W6, U;I\T%M$.6;W9P)M?&.I_?E-JA_VE3_T'FA? MAS>WK;K_ %3EV/\ J;"!3_>9 Q_,\U))KEA#G=*@OBG^(?NX]C8 "C &!2US4GC!W;;!9EC_M-G] *9_:6N MW7^JM?*'KY>/_0JYOKE)_#=^B#VD>AU%,DFCA7,CJ@]6(%NW?\ K;KR MAW'F8_\ 0:3VB:T_B+3K?[UTC?[F6 M_E6=<>-K2/\ U<,LA]\**L0^$=/B^\KS?[[?X8K0ATNSM\>7;1*?78,_G1;% MSZJ/XA^\?D^UG_EBD^S^(]0^_(;93_M!/YNQ#]-M^3$TQ]9'/\ 3%:5KIUK:_ZFWCBQW5 #^='+C)[R M4?17_,5JCZI'+GQ!KVH#_1++RE/1A&3^K<4G]@^(-2&;J]\I>ZF0_P EXKLZ M*7U+G_BU)2^=D'LK_$VSE+?X?VX(-Q=22GOL 7_&M:U\+Z99X*6B.W]Z3YS^ MM:F:JW.KV5GGSKJ)"/X=PS^5:1PN&H*_*EZ_\$I0A'H6E4(H50% Z #%+7/W M7CC38,B,R7!_V%P/UQ6:_CB[NFV66G[CVSES^0Q2ECL-#3FOZ:B=6"ZG95'- M<16Z[I9%C7^\Q %<:5\4ZIQDVD9]Q'C_ -FIT/@&:X8/?7[.W<("Q_,_X5G] M;JU/X5)OUT%[23^&)MWGB_2K//\ I(F;^["-WZ]/UK%N?B$9&V65BTC'H9#S M_P!\C_&M>S\%Z5:XS 9V'>5B?TZ5KV]K#:KMAACA7TC4+_*E[/&U/BFH^BO^ M8K59;NQQ9?Q5K0^5391-["/_ .RJ2V^'CS-YFH7S2,>HCY/_ 'T?\*[6BA9= M2D[UFYOS8>QC]K4Q;+P?I-C@K:K*X_BF._\ 0\?I6PB+&H5%"J.@48%076I6 MEC_Q\7,4/L[@'\JQ;OQ[I5OD1M)<'_IFF!^N*WY\+A5:ZC]Q=X4_(Z.BN'D\ M>7]\VS3M-+'U(,A_(8J-M+\4ZUS<7!M8S_"7V#'T7^M<_P#:$):4(.?HM/O9 M'MD_A5SLKS5;/3US?TJ"S^&]LOS M7=U).W<1@*/ZUNV7AG2]/P8;*+_\ (7[V79'+'Q5X M@UH[=-L?)C;@.$W?^/'BA/ ^KZLP?5-1*C.=FXR$?AT'X5WM%']G*IKB*CG^ M"^Y#]CS?&[G.:?X!TFQPSQ-=..\S9'Y#BM^WMXK6,1PQ)$@Z+&H _2I**[Z5 M"E15J<4C6,8Q^%!12,P522< =2:Q]0\9:-IN1-J$)?R7-=482F[15S M>G3G5=H1;]#9HKS_ %'XN6J'9I]E+SC=*^%.BZ?AKA9+^3_I MLV%_ #^N:ZNTL;?3X1%;01V\8_AC0*/TJ>BN2I6J5?CE<\VMBJV(=ZLVPHHH MK(Y@HHHH **1F"*68A5'))Z5RNN?%+PQH#,EQJL4LR_\LK;,K9]/ER ?J12- MZ.'K8B7+1@Y/R5SJZ*\8U3]H*:\F-MX>T.2YE)^5[C+$_P#;-.?_ !ZJ3:+\ M4/'61>7+:/9OSL9Q ,>FU,O_ -]4N;L>]'(:\%SXN<:2_O/7Y)'K&N^-M"\- M9_M+5+>V<:Y^T5:JY@T+2IKZ=OE62X^1=W;"C)8?E5C M0OV=])M<2:M?7&HR]2D?[I,]_5C^8KT;1?"ND>'(]NFZ=;V?JT:#SZI+U,:?NH\]\X.X_7(KURBGRHSJ9]BN7V>&2I1[05OQW*&D:#IN@6X MATZQ@LH\8Q#&%S]3U/XU=9MM.IK+N%4?.RG*I)RF[M@K;J=357;233);QM)* MZQQJ,EG. /J:"=Q]%%-!=3T\YD,SCT. -J_CFIYD>[ALDQV)7/R\O=7X_H>Y33QVT32S2+ M%&HRSNP ]R:\^\2_';POX?W1P7+:M<*<>79C*_BY^7'TS7%0_!WQCXVF2X\ M5:VT$6<^27\UA]%&$7\#^%=_X;^"OA7PWM<6/]HW _Y;7Q$G_CN-OZ4M6=OU M7*<%KB:SJR[0V_\ GO\CSR3XJ>//'TC0^&-(-C;,=OGHF\CZR/A1^ S5K1? MV?+[6[@7_BW6IKB9N6B@HI M>G2J/FZE6I6DYU)-M]7JPHHHH,QNX[2<8IL;%C@U)1@#H* $9=RXH5=JXKE/ M%7Q2\->#PZWVI1O6ZA\=O$OC"X-CX.T.2-B<&=D M\Z09Z$C[B=^N14\R/1CDPQ2>9(?8N>%^@!KU_PSX)T/P?#Y>DZ=#:$C#2@;I&^KGD M_G2U9Z7+D^6_&WB*G9:07SW?Y,\23X7^._B9.EYXKU)M.LV^9;=SEE]EB'RK M^//UKU#P;\,="\#*&L+-9;O&&O+CYY3]#_#^&*[AE##!JNZ[6(JHQ2//QF=8 MO&0]C=0I_P L59?\'YA$VULL*DDFQ]T9J&D52HP:L\$DMYFD8@U8J&%3G-35 M+$%-DSM..M.HH&1PAAG-2444 %%%% !5=XRK=,BK%% $,:E,LW%/20.<8Q3S MSP::L83I0 ZBBB@ J Q.9,^_6IZ*!!1110,Z3PG_ *JX_P!X5OU@>$_]5MJ>QSU-PHI-P!P3@TM:F0C*'7!I$38,4ZB@!DK%5XHB8LO-/HH **** M#IUI%8-R.:21=ZXI(T* YH ?1110 44QI@IQUH$RGO@T /HHHH .O!Y%?*?Q M"T+4/V:OB1!XR\.V[3>%]03VWPU\,_%A8/%.G:[?S6E\3(RO M+YFS)^:,!O\ 5X/!45ZYH>AV7AS3(-/T^!;>UA&%1?U)/*=(MM4TF\BO["X7?%/"<@CT]01 MT(/(/!I(;%U[2QK>BWU@QVBXA:/=Z9'!KDO^$ANS?:;J%G8MJ6)MI(1PL M-U&R_)(?X0NZ7)_Z9G&20*[RL6^\'Z7?737)BEMYW;>\EK.\);K6H ;?.D."85/8D8! ^Z@ SD@GI-:M@V@7L$2!1 M]G=411@#Y3@"K&GZ?;Z7:1VMK"L$$?W44>IR3[DG))[YJ=B I)Z8YII6$W$C((2('L7/ M'L-Q]*S_ +==:+#I5K:B$ZSI>^Q2&ZE"*]M)MVS9/4#RT)Q]*L-H]GK]O_81 MG^VV2W"W6KWQZ7HR!D=@H%1Y&G6YQOPKT/Q'9^$K&XN_">D^(D"[;" MZOI56\CMA_JXR'C(VCG;AL[2.*WM'^)?C+Q1=Z=8V%AI.BV]Y 94::=YGC 4 M'&Q5"_Q>M>G1WT2[8XXI=HPHVQ' _2O'? ;?8O$F@QL"IB,]JV[J#T /_?(I M!K_5,_VYXIU?4(SUM[6;[%&/;,.UL?5JY_7O 7A_4-2B\*:+H]I+ MJETGF7VI7=9_!]JGAG0Y_MWC#6";J_U61Y?T X6-?90.! M52LM$*-WJQEGH>B:I\0=+L-(LX8]&\#V36,:Q\JMS((RL8]?+1=Q_P!J13U4 MUZ+7,>!/ -EX L[VVL9[BX2ZN#DI-(P^H5,?K79'"UIZI??H9&/&^B>,; M?S=)U"*ZQ]Z,'$B>S*>1^-;4B;N17&XN+M)%#%E56C-U)EN$%0SZ@,\*Q_"JTFH2OPD9 K:,'N/IM']*:8K MF3G:?^^C_2E>!7)4Z:%C^TKE^.0OL *8QED^^Y(]VS4*V=PW\ _\>-2_8;C^ MZ!_VS)_K1SQ6R#V,Y?$R)8\-R,_CQ4@POW5C'UP?YT[^S[@]0?\ OC%*-+G/ M9C^5#J@L.A#BCZFI]I MV-/81>^I4\VV7_EG*_U(%*MTO_+*P#?[Q+5=72+@=)57Z$T[^QYF^]7Z_ZNTCA'M'C^=-:?5'^].D8_WD%7/[!7O/\ ^.__ %Z=_8=N M/O3-^8%1S1-.5HRVAN)/];J<8'IYI/\ *HFT^SSF6_W'_9C)_6MG^Q[%>LA/ MU<4Y=/TU/[A^KD_UI>TBNH1O]T ?XU:_M>Z;[EMG\":3[9JA:?#]VTB/\ O+N_G53_ (F\G^S_ -\BD^PZG)UN M-O\ P,C^53]8D]HL>G2)L1010C$<:QCT50*'GCC^\ZK]2!6-_8-Q)_K+K/YF MD_X1V%?]9<_D *CVM5[0_$KFEV-1M2M5ZW$?X,#4#Z]9)_RUW'_94U372=-C M'SW&3[R"G_9]'CY)1O\ @1-0ZE;O%?,7-+R%D\3VR_=CD;\ /ZU7;Q4S'$=K MD^[?_6JR+S28?NK'GVB_^M2MX@LXQA5<_P"ZH']:R1_P#5VN?^!9_I6;E3 M?Q56_0F\>LB/^P=2N/\ 77G'IO8TZ/P@G62Y9O\ =7'^-+_;6I2?ZNS_ /(; M&CSM;F^ZFS_@*C^=3RX>_P +E]X6AV;+,?A:Q3[RR2?[S?X8JW%H]C#]VUCS M_M#/\ZR38ZU-]ZXV?\#Q_*D_X1V]F_UU[D?[S-_.M8V7P4?R*TZ1-[=#;KC, M<0^H%02:Q91?>N8_^ G/\JRE\(IG,ERS?[JX_K5B/PK9)]XR/_O-_@*VY\0] MH)>K_P BKSZ(?)XHL(^DC2?[J'^M59/&$ _U<$C?[Q _QK0CT"PCZ6RG_>)/ M\ZM1V5O#]R"-/]U *.7%2WDEZ+_,+5'U.>/BJ[F_X][')_%OY8IOVWQ!=?ZN M#RO^ !?_ $*NIHI?5ZDOCJOY:"Y&]Y'+?V3KMU_K+ORQW'F$?RI5\&R2G,][ MD]\*3^I-=+),D?WW5/\ >.*K2ZQ8P_>NHOP;/\JB6%H+^([^K%[.'4S8O!MD MGWVEE/NP _057'%O8Y/_ G_ )8I#?>( M;O\ U<'DC_<"_P#H55]=I?83?HA^TCT.KIDDR0KF1U0>K'%\9SWVK_4FCZQ6E\%)_-V#GD]HFU-X@TZW^_=QG_=.[^5 M9]QXVL(L^6LLQ_V5P/U-/A\&:=']_P V7_>?'\L5>@T+3[;[EI%GU9=Q_6E_ MMD_Y8_>P_>/LC ;QM<"L^X\6:9;Y_P!)\P^D:D__ %JS>&P=-WJ. M[\V+V=..Y+;^&]-M<;+.,GUD&[^=:*JL:A54*HZ # KEY_'UNO\ J;663_?( M7_&J_P#PE&LWO_'II^%_O"-F_7I36,PM/W:?X(/:4XZ1.QILDB0KN=E1?5C@ M5Q_V3Q1J'^LF^SJ?]M4_]!YI4\"3W+!KR_+-_L@M^I/]*KZU6G_#HOYZ#]I) M_#$W;KQ/I=IG?>1L?2/Y_P"59-U\0K./(@MY9C_M84?UJU;^!],AP762<_\ M31^/TQ6K:Z396>/(M88S_>5!G\Z7+C:F[C'\7_D'[U]DMZC_QY:=M4 M_P 01F_7I1_8OB75/^/F\^SH>JF3'Z+Q7;&D6CZBY_QJLI?@OP%[*_Q2;.1M MOAU;J0;F[DE/<1@+_/-;-GX5TJRP4LT=O[TOSG]:U<'-))*D*[I'5%]6.!6] M/!8>G\$%^?YFD:4%LA518U"JH51T &!2UD77B[1[//F:A"?:,[S_ ..YK'NO MB;ID/$,5Q<'UVA1^IS^E>I'#U9?#%G?3P>(J?#!_<=?17GK?$35=18KIND[C MTSAI3^@%-%KXUUG.^8V4;>K+'C_OGYJV^J2C_$DH^K.O^S:D?XTXP]7_ )'H M$UQ%;1EYI$B0=6=@!^9K%O/'.B6.=U^DC#^&$%\_EQ7.0_"^XNFWZAJC2-_L M L?^^F/]*V++X;Z+:8,D,ETP[S.?Y# I\F&A\4V_1?YC]E@:?QU'+T5OS,R\ M^+%JORV=C-.W0&4A!^0S53^WO&6N?\>=E]CC/\0C"\?5_P"E=Y9:39::,6MI M#![QH ?SJW1[>C#^'3^_4/K>&I?P:*?G+7\#S=FYI2/P. M /PK8L/A;HUK@SB:\;OYC[5_)3NR2BBBD2%%(S!% M+,0H'4FL'4O'WAW2=WVG6+4,O5(Y/,8?@N32-:=&I6?+3BV_)7-^BO,]5^/6 MAV>5LK:ZOW]<"-/S//Z5A_\ "SO&WB;"Z'H0AB;I,(FDQ_P-L+^E+F1[-/(\ M;)<\XJ$>\FE_P?P/:*Q]6\8:)H>[[=JEK;LO6-I 7_[Y'/Z5YW5^^>57$2'\.3^M%WV-?J.7T/\ M>,3S/M!7_%Z$NL?'W0;'*V,%SJ+]F"^6A_%N?TKG3\3/'GBS(T+1?LT+?=E2 M$OCZN_R_I7J.C^!/#^@[39:3;1NO21DWN/\ @39/ZUO468_KV78?_=\-S/O- MW_\ )5H>(?\ "I/&/BR19/$6NB*,\F(R&4K]$&$'X&NIT7X#^&M,97NEGU.0 M?\_#[4S_ +JX_4FO1J8S'M1RHQK9YCJD>2,^2/:*Y?RU_$K:;HUAHT/E6%E; MV3H^DSWCM MPK3L$R?91DG]*S#JGQ3\9,?L]L^D6S=P@MP!ZY?Y_P J7,CW89#BK<^(<:4> M\FE^&Y[3?:G9Z7#YMY=0VD7]^>0(/S)KA]=^.7A?1]RPW$FIS ?=M$RN?]XX M'Y9KEK/]GZ\U.X^T^(?$$EQ,WWA"#(Q_X&_^%=OHOP?\*Z(4=-,6[F7GS+QC M*3[X/R_I1J:>QR?"_P 6K*J^T59?>_T//Y/C!XP\8.8?#.A&!&^7S@AF*G_? M("#\138_@[XP\82";Q-KOD1MSY)YQ1)#&L<:+&BC 51@#Z M"G4N7N']M_5],!1C3\_BE][_ ,CS[0?@9X5T7:\MJ^IS#^.\?&.WB7I'$H51^ J6BJ/#Q&,Q&+?-7J.7JPHHHIG(%%%% !15/4 M]8L=%MS/?WD%E#_?GD"#]:\V\1?M$^']*W1Z=#/J\P[H/*B_[Z89_):5TCT, M+E^+QKMAZ;E^7W['JM9^L>(=,\/P>=J5_;V4?4&:0*3]!U/X5X@WB[XF_$/Y M=*LFT>R;CS8T\H$>OF/R?^ XK0T?]G-[Z;[7XEUR:[F;[Z6Q))^LC\G\JF]] MCVO['PV%US#$J+_EC[TO\D7_ !/^T=I-BQ@T*SEU>XS@2N#'%GVXW-^0^MQ>&_A_X?\)*#IFEPP2C_ENPWR_] M]MD_ATKH:+/J5_:N"P6F7X=7_FG[S^2V1Y+X9_9Y\.Z.RRZI)-K5P.2)#Y<6 M?]T')_$D>U>GZ=8V>F6ZVUE;16D"_=BAC"*/P%3O&'B\PQ6. MES8FHY?E]VR)J***9YX4UE#=:=10 Q857WI5E.I .@H 6BBB@ HHHH MCDDVG ZTLF!;HIL; M%E!/6G4@"BBB@ HHHH **** .D\)_P"JN/\ >%;]8'A/_57'^\*WZYY;G5#X M4%%%%06%%%% !1110 4444 5-6_Y!MS_ - & MXPDH'1@-KX&?0?8=5M3TRTUK3[BQO[:*\L[A#'+!,@9'4]00>M)JXT['/>"? MB3X<\=:#8:IH^IQ3V]Y)Y*1NP61)MA?JCX'_%1?BIX16ZN M8#8:[9$6^IZ?(I5X)L==IY"L/F'XC)(-)/N-QZH]$HHHJB3,NM%MKQ?+NK"S MU"(-N3[5&'*^PR#4T-FUK"L5M;VEK$HPJ1Q@!?H !5VBD%RBUO*?F>X= .25 M _45Y+XNTG4/#.N2:I;6DUS:R7":A R*6Q(I&Z-L#@-M!'^^?2O5KF]23DY M:!3]T?QG_#^=6K6.1B9IN)&& O\ ='I2*3L>9:3XQM+[^W?B#+#-<6UN?[)T M>U*8E=@X1U"GI))<'RO^V?7!-=AX)\-3:!97%YJK&O-_$6D1:#JD6D:UK=WH&CV^HS:SIVJVZIM>25G8Q2,Z,H*- M+(1D<@J>HJ/5/$WP^M=-N;S4_%FL>,%@0N;9;K<&Q_LP(GZG%0M'YFC5TK'H MOB_XH^'/!=C<3WVHPR3Q+N%G;L))W/8!!SS7F'A?6I?CFDNK:G)=)H,,FU-- M6.2"WX_ONP!F;UQ\HKC-,GU#XIW[P1Z+_P (EX.AP_V6)0)KK/(#ODL?<9KU M>-C;Z9!I\(6&S@4)'#& J@#H.*^@P6%J6YY*WKN&/O5V),"XM3'=)>VTLEE?1\I=6[;)!^/<>QKUKX9_& M:2^O(-#\3&.*_D.RUU!1MCN3_=;^Z_Z'ZUYG-'M)':LJ^LTNHGBD&5/IP1Z$ M'L:Y<1AH5XVEOW+C)Q/L"HFC;L:\S^"?Q#F\0V$VB:K+YFKZ>H(F;K<0] _U M'0UZ:LG/(KY*I3E2FX2Z'7&6ET9\\$BN?DR/7%1>9MXZ?2MFF/"DGWE!KE<9 M=&;*4.L3,\TD<$'ZBCSG'51^56I-.CZKE:KR6,J_=.?UK/;XD7[.E+9C?M7M M@THN3ZU$5D'#"FE?]G-"Y9;2']7\RQY['HXS]:59I/[U4V9>^Y?QHX[-^8_P MI^S?1D/#R[EYI)NS?SIHEF'1OYU4W,O&X9^N/YTJR2CLQ_6I]G/N9^QF6C)/ M_?'YFF^9.?XA_P!]&H?M3+U_P_G0+HGL3].:7),ATIKH3;[CL<_B:3=9'++L.W7'K_ ./&FEI3U/ZFI%N%/27]:=YC=IB/ MQ-1;S)L52[]S^M'S&IPTN?\ 79_$U())P,"9?^^A2Y4!3VGO_*CR_8U=$EWV M=3^*T[?>>F?RHY%Y_<%BAL']QC^/_P!:D\L?\\G_ #_^M6AYEY_=_04GGW@_ MY9Y_X#1R+S^X+%'RQV@8_B:/+_Z=<_\ ?57?M-[_ ,\O_'32?:[S_GC_ ..& MCEC_ $@LBFJR?PV0_P"^6/\ 6I!Y_:R0?]LJG^V7O_/#_P <-'VZ]_Y]_P#Q MPT6CW?W!H19O/X;=1_P 4[=J79,?@M.^W7O_ #[_ /CC4?;KW_GW_P#'#3]W M^9AIW&%=5;OC_OFC[/J3=9=C]%Q1YFJG^''X+28U=N^/^^:7+2_Y]L/=[$@\. MV_>20_B/\*>OA^T'4.?JU5_)U9NKX_%:3[%JC=9\?\#_ ,*JT.E)CT_E+JZ) M9+_RQS]6/^-2#2[1>EO'^*YK-_LG46^]=_\ D1J/["NF^]=?J357M\-+\@]( MFLMK$GW8D7Z*!3S)''P65?QK%_X1IV^]=?\ CN?ZTY?#"?Q7#'Z+C^M7SU>E M/\4.\NQJ-?6R];B(?\#%1MJUFO6X3\#FJ2^&+?O+*?Q _I4B^&[,=1(WU:CF MQ#VBAWGV)&UZQ7_EOGZ*?\*B?Q+9KT\QOHM2KH%BO_+'/U8_XU(NDV4?_+O' M_P "&?YT6Q+ZI?>+WS/?Q9 OW89&^N!4+>+"W$=ID_[_ /\ 6K9$5G#T2!,> MP%#7UK&/^/B%?^!BH<:W6HE\D*TOYC$_X2#49/\ 56.?^ ,:/MFNS?=@\O\ MX !_.M8ZQ9)UN8_P.:C?Q%8+_P MBWT0_P"%9N*^W6_%(7K(S/L>O3_>F\O_ M (&!_*C_ (1O4)O]=?9]?F9JN-XJLEZ"5OHH_P :A?Q?"/NV\A^I K%QPOVJ MC?S9-J?5D2^#5ZO=,3_LIC^M6(_"%DOWFED^K #]!58^+Y).([//_ R?Z4G] MN:M-_J[+ _ZYL:2>"7PQO\F+]UT1JQ^'=.BZ6RG_ 'B6_F:M16-O#_JX(T_W M4 KG_-\0S?=3RQ]$'\Z3^R]=G^]=^7_VT(_D*WC5BOX=%_=8OF72)U%127<$ M/^LFCC_WF KG/^$3O)O]=?\ _H3?S-2Q^"X!_K+F1O\ =4#_ !K3VV(E\-+[ MV/FGTB:4GB'3H?O72'_=RW\JJ2^,-/CZ>;)_NI_B13H_".GQ_>623_>?_#%7 M(]#T^+[MI$?]Y=W\Z7^UR_E7WA^\?8Q9O',:\16CM_O,!_C4?_"3:M=?\>]A M@'OL9OUKJ([>*'_5Q(G^ZH%/)"\DXI>PKR^*K]R#DF]Y')[?$MYU/DCZJO\ M]>D_X134[K_CZU#(_P!]G_GBNEEU2S@SYEW"A_VI /ZU3F\5:5!]Z]C/^X"W M\A5K+E/XG*7S9K'"SGLFS,A\!VZ_ZVZD?_< 7_&K\'A'3(>L!E/K(Q-5I?'> MEQC*M-+_ +L?^.*I3?$:V7/EVC>2Q_4G%=Q;V<%J,0P1PCTC0+_*IJ/;4H_#3^]C^LX:'P45\V MV>?G3O&6I_ZVY-JO_714_P#0.:(_AKEV>/)L(%/]YD#'\S6E MFBL95JD_BDSEJ8JO4^.;?S$4!0 !@>@I:**Q.409S2U1O->TW3\_:=0M;&K+(.HB9A_##&S?KC'ZTCIIX6O6_AP;]$SJZ*\WO/CCI461 M;6-U.>Q?:@/ZG^59;?%[7M4R-)T#=GH=KS?^@@4N9'I0R7'25W#E7FTCUR@G M')X%>1>;\3-=^ZAL(B?2.+'Y_-2'X0^(=8(.K^( PZXWR3_^A8%%_(T_LRC3 M_CXF*]+R?X'H]]XNT73<_:=5M(F'5?.4M^0YKF[_ .-'AFSSY'T@A(_] M"Q5&Q^!>CPX-U>7=TWHI5%_+!/ZUT=C\-?#.G_ZO2()#ZSYE_P#0B:-1\N4T M=Y3F_))+\=3B+GXZ7%Y)Y.DZ&TTA^[YCEB?^ */ZU!_:GQ-\1\06ITR)NO[I M8O6]G;V,>RW@C@3^[$@4?D*D#@T6?/4JU*TN:I)M^>HZD(S6)J'CCP_IF1<:Q:*PZJLH=OR7)KF-2^.7AVSR+<7 M5\W;RXMJ_FQ!_2BZ.NCE^+K_ ,.DW\M/O/0Z*\;F^-FMZNWEZ)X?WMTR0\Y_ M)0*88?BCXDP2[:9"WND./R^>ES=CTO[#KPUQ,X4_\4E?\+GLDT\=O&9)9%B0 M=6=@ /Q-NZ4_RKUG2_#N MEZ(N+#3[:TXQNBB"L?J>IJMKGB-=/D%K;1_:;Y^D8Z+[M347+0?]H8&A_NV% M3?>;IK5A\<:1(P#SM;D_ M\]HRM']M:>_P G'\J@EMM-U%3M6-O>,XJO=['B3=,EGJ86*=N$F' M".?0^AHY>L3)JQU]%%5=0U:RTF'S;V[@M(O[T\@0?K681BY.T5=EJBO/M9^. M7A;2MRQ7$VHR#^&UC)'_ 'TV!^5UZ1H?#GAPR/TW,'G8>^% _$FI MYD>Y1R/'UES>SY8]Y>[^9[=6%K_C;0_#2M_:&J6ULZ]8B^Z3_O@9/Z5Y.WA7 MXH^,CG4-0;2[=OX&F$0QZ;8^3_P*M?1_V==*MF$NJW]QJ4G4QQCRD/UY)/YB MB[Z(ZO[.P&&UQ>)3?:"YOQV&:U^T=IEM)Y6DZ?<:DYX#RGRDSVP,%C^0K&.O M?%3QXN+*S;1[1O\ EHB?9QCUW.=Q_P" UZUH?@G1?#JH-.TNWM67CS0@,GXL M?F/YUT%%GW'_ &E@,+_N>&3?>?O/[MD>'Z;^SS<:AD>'?AGX:\+[6L=*A\]?^6\X\V3Z@MG'X8KI3&"V:?3Y4C@Q6<8[& M+EJ5'R]EHON7ZC64-UI0-HP*6BF>,%%%% !1110 4444 %1F8!L?K3V^Z<>E M5:8%L$'DM.HH *** M* "BBB@ HHHH *8\@3CJ:?5>7[YS0!*L@;V-/JG;R%I@,<5J.1"B9 MVK(VUF]!@G^E7*CN+=+J%HG&5:D!CVM]9J1-)(/E^Y&!G'N?>II/$ENN=B2. M?]W'\Z;_ ,(U%G_728_"IH_#]HA!(=_]YJ!E)_$H; -LI'7YG_\ K5QGQ2UH M:_\ V-X(C*'']YRH]QFO25TVT3I;Q_\ ?.:\BU2)/^%I M>(B$"&&VM88P.,*5+DCZLWZ5Z&!IJ==7Z:F=1VCH6X88[>,1Q1K%&.BH, 4^ MBBOJSD(ID_6LRXCPQ':M=EW#%4KB/(SWJT!BS1\$&LZ>/@YK:N(^]9UQ'WH$ M8DZ;@?6L^XCXS6S-%M.:SYX]I- &;8ZU)X3U[3]=A)_T*4&95_CA)Q(O_?.3 M^%?6L.V9$D1@\; ,K*<@@]Z^2+RV$T4D3#*NI4_B,5]&?!_5&U?X:Z#-(2TL M=LL#D]2R?*3^E>#F=/2-1>AO2?0[*F/(5.!3Z8T>XYS7@'0+&VX4,GIP:55V MBEH8$#8Z2+FF-9JW*'%664,,$5 VZW;/5:YYQ7VE=&T9/[+*LD#1_>7*U']G MAD_V36HD@D7(J.2UCDZC!]14>SDM8,T5;I(S&T]E'RL0/KBHFMI%]"?]W_"K M[QRVH)C;4W\* MY_V3BK/]FR[: MB\IH_O*R_44N6'6)+HP?0N;ITZC'YBD^U3+W/_?9JLLSK]V1U^AIXO)Q_P O M!/\ O9/]*GDI_P OXDO#0[?F3_;9Q_&__?6:7^TIQ_&X_*H/MT_B'_OFE_M.X_OQ_F/\:J?:M-/ M5+A?RIPDTMO^6TR_4?\ UJ/90_G9'U7U+7]I778(?P_^O3O[0O>T8/\ P&J> MW3&Z7C#ZJ?\ "E^QV#=+]!_O8_QI>QC_ ,_&3]775O[BW]NU#_GAG_@!H^W: MA_S[_P#CAJLNEV[?X_[:-_A1]6_P"G MK#ZO'_GX/^T:L?\ EGC_ ("*3S=8/1,?@M,_L?4_^?W_ ,BM_A1_8^I_\_O_ M )%;_"CZJO\ GZQ_5X?\_!^W66[X_P"^*3[/K#?\M,?\"%,_L?5/^?W_ ,BO M_A2'1M4/_+[_ .17_P */J<.M5_>+ZM#_GX2?8=6;K<8_P"!FD_LG5&ZWF/^ MVC?X5'_8>J'K?/]^[S_P) MC2?\(LS??NL_\ S_ %J/_A&KT];W]6H_X1:X/6\_0_XT?4D IPL-%BZM!_P*;_Z]55\&1=[ES]%% M/_X0NU[S3'Z8_P *T6%PJ_X8?L<*OM?@60VB1?Q69_%6IPU32(?NRVZ_[J_X M"JZ^#;%>KS-]6'^%/7PCI_=)#]7K14\/';\D5R85=7]R)&\4:7'P+C/^ZC?X M5$_C#3EZ-(_^ZG^-2KX6TQ?^7;/U=O\ &IE\/Z72;)/NV< _[9C_ J9;6&/[L,: M_10*?-1_E_$?M,,O^7;?S.6;QU(_$=AD_P#70G^E)_PE&L3?ZG3>/^N3M77T MF:/:4UM#\0]O07PTE][.0_M#Q-F\O_@2#^5=A M11[>VT5]P_K=OAIQ7R../AO79_\ 6ZE@>GG.?Z4G_" SS-F?4<_\ +?S-=BS M!1DG ]Z@DU"UA_UES"G^](!_6G]9J+;3Y%+&XA_!IZ)'.Q_#VS'^LN9G_P!W M"_T-6XO ^E1_>BDE_P!Z0_TQ5Z3Q'I4?WM2M!_VV7_&JTGC31(OO:C"?]W+? MR%0\15>\A^TQM3;F^2?Z$T/AG2H?NV,1_P!\;OYU[%]5QM3>$GZW_4["BN M#F^+EBN?+L;A_P#>95_QJDWQ=FF.VWTC8M^@6L[HTCE.,E]C\5_F>DT5Y MK_PG_B:Z_P"/;0^#T_<2/_(BD.M^.[O_ %5AY/\ VQ"_^A&BY?\ 959?'*,? M62/2FH6O-/[-\?WW^MNOLX;_ *:1KC_OD4G_ KOQ->N]>WGR/_047'_9 M]&/\3$1^5V>DS7$5NN99$C'J[ 5G7'BK1K7/FZI:*?[OG*3^0-<3'\&0[%KC M5V=O]F'^I:KMO\'='C.9;B\F/^^JC_T'^M&H?5\OC\5=OTC;\S7N/B5X25S^@(%: MMKX3T:R_U.EVJG^\8@3^9HU'S973VC.7JTOR.#G^-$LS;+/1R[=MTI)_(+4: M^-O&^HK_ *+HGE*>C?9G_FQQ7JD<20KMC147T48%.HLQ_7L)#^'AE\VV>4&R M^(^J?ZR:&^%OB751C4]?#*>WFR2_H<"O5Z*+#_ +8K1_A0 MA#TBO^">:6?P-TZ/!NM1N9SZ1*L8_7-;EG\*?#5I@FR:X;^]-*Q_0$#]*ZUY M%C7+L%'JQQ6?<^)M(L_]?J=G$?1IUS^6:+(QEF.88C15)/TT_(+/PSI&GX^S M:9:0D?Q+"H;\\9K2KEKKXG>&[7.=261O2*-V_7&*R+KXU:+%D0V]Y.?78JC] M6S^E.Z(6!QV(=W3D_6_ZGH%)N&<5Y7-\;I)FV66B,[]MTQ/Z!?ZU"?'/C?4V MS9Z'Y*'HPM7/ZL<4N9'2LEQ:UJ)1]9(];HKR7[#\2M7_ -9.;)&[[XX__0>: M3_A4>OZISJOB#?GK\\DW_H1%%_(K^S:%/^-B8KTO+\CTF^\1:5IX(NM2M8"/ MX9)E!_+-<_>?%3PS9DC^T//8?PPQ,WZXQ^M8UG\"M+CP;K4+J?VC"QC^1K$4G^6QXZMI\3=?SOG.GQ'I\Z18_P"^?FIR_!36-58/ MJ_B#S&ZG&^8_FQ%>P8 Z"EHY0_MO$0_@0C3_ ,,5^MSS>P^!.@V^#E8^SZ/;%AT:9?-/YMFNBHIV1PULRQE?^)5;^>GW(;' M&D*!(T5$'15& *=113/-"BBB@#)\1:S_ &/9CRQONICLB3W]?H*J>'])338# M=W#^9=2_.\K=>>]<]KFKP3:WF>E;6LK'32HU*GP1;^1U>L>(I)RR6Y*Q#^(=6^GI7"ZIXWTS3+ MG[//)*]WQFW@B:5P3T4[0<$^AKGM:^+"0*T6FZ;/>W;*2B,0 /XCC/ R*XU M/$3:?#^\?==&1II9,8+2-R3_ $'L!2NH['T>!R6KB&Y5URH[35-8UB\YDN8] M$@;D0P[9;D#MN8Y53[8;ZU0;Q7JEC&K+K=G,Z]I;)U;\65\9]P!]*\_U#Q8S M9^?]:YN\\6)NYF'_ 'T,U%V?60R7"J*C**_KSW/=-!^.D2S266L6^VX0!EEM M6WHRDD Y.".1T(_.K'B+Q1<:M"SZ7IZRSXR %H\;2".U6EV9\GF M-'#8&NXQI-KS>ASNBZA\2/&.-/COFL51,\NL!V].H&\UT=A^SV]Y)Y^NZ[-< MRM]X0#)_[[?.?RJ4:@NCZ]9WJ-@JWSJ.ZDX:O7U8,H(.01D5$XKXCD6=XJC# MV>'4::_NQ5_O.*T7X/\ A;1V5AI:74B_QWA,N?\ @)^7]*[*WMXK6%8H(DAB M485(U"J/H!4E%0>/6Q5?$N]:;EZNX4444SF"BBHW4EO44 .9POUI58-TJ$]3 MFG19W4 2T444 %%%% !1110 4444 %-\M3SBG44 ( %X Q2T4C<*2* %HJ** M0LV#4M !1110 4444 %%%% !1110 4444 %%%% !1110!'+#YG(.#1'%Y>3G M)J2B@1TGA/\ U5Q_O"M^L#PG_JKC_>%;]<\MSKA\*"BBBH+"BBB@ HHHH ** M** *FK?\@VY_ZYFN%D7=&0*[K5O^0;<_]IN4JLP*5CYI^U>N!F MEK4Q"BBB@85#,YS@<5-5:1@TAQ0 BL5.15E6W*#5;KP*L(NU0* '444=.: " M@]..M1"89Y'%2T (N=OS=:" W49I:* &K$J'(7!IU%% !4=Q<16=O+//*D$$ M2EY)9&"JB@9+$G@ #O3I,[3CK7.>/MW_ K[Q1G./[+NNO\ UR:LZDN2$I]D M7"/-)1[E"'XV?#NYFCAA\>^&)99&")&FLVQ9F)P 'Y)-=!J7BK1=&DN8]0U M>PL9+6W%W.MS@)( W&G_%V\UW0?!GBKP+>:K_:%GIO MP^M969T4>9="=HGE+D;N0@X)QWQFM)>[)Q[.WK9-OTM9?>O45-)OACXB\&1:QXDF\3V&O>;9W4$UG!%]FN$@:9 M7M_*16\O]VZE9&D;!4[L@YYM/'WC.'X2Z;\5G\0F:.YF@NIO#)LX%LEM)95C M\I'V>?YJJP;>9""P/R8. =;?+_+_ #(5^52?57]?ZV/H:BO =9^('B'P_P"+ MM:/BSQ'K/@FTM]3B&G3'0XKK0+BS:0(@EN%C9T=@#O+S0A3(I P.=N'6O%?Q M$UCQ[-I'BB7PU:^';LZ;86MO9P2I<3)"DK2W!EC=F1C(%"QF/"J3DD@B.9>2,[&GC?"';R""< 8(.2<_PO\1?&TWP\\#^-K_Q.UW-J.N6^D76 MDK8V\=I+"]PULTF0AE$N1YF5D"9XV <5:U?+YV_\F(M(\1>(M+U#Q!#?VE]<1Z3X=L?"L]WI]U'!*4V37*VKDO+L8%H MYE"$CCY3GW"_\8ZI9V.FSV_@O6]6:[MUGDCLI;-#;,0#Y;BXGB.X9[ ].U*+ MYH\R\OQ_KY=>@27*[/S_ .IKY]^*FK:E8_%*ZN],2$06=G!#=B7(60N7*[C MVQMP#[UZ7_PL+7O^B9>*O_ G2?\ Y.KRGQ/XLU>S^)%])/X!\01+JUC"4MYI MM.+,8BZMTNRI&'7C.?;%>C@))5U M)X3VWW&G2 ?@;K^M?2\_E^#_ ,CGY3WJ*>*908Y$D'JK TDT??%?+EUH?B[3 M9#)IVA:Y&B]-US:*1^"W)KK/ ?Q-E-Q_9_B'^UO#UR#M66>5)(V/^T,MC\Z( MU$W9IH31[-/'AB*SIH^H-3"'45B5TN[>_B(R&*;"WI@@D5$\Q;Y98FAD]^0? MH:W),RXCZBLZ>/W? -6'PULV/W6N+C9]!*R M_P P:\3U29;&UGG;[L:%S^ KZ$^&&DOX>^'^@V,BXF2U5Y!_MM\[?JQKQLS? M[N,?,VI[G644FX>M+7S9TA1110 4$!A@C(HHH HS[[-PR?<-6X9A-&&%.90R MD,,@U0;=8S CF-JY9/V+O]G\C=+VJMU+Y&[BH9+..;[PS[]ZF5@RA@<@TM=# M2DK/5&*;B]#-DLYK8EHG++Z?_6I\-]OPK'8WZ5?JO<64=QR1M?\ O"N1T94] M:3^1TJK&6E1?,<7;;RN1^=0/#!)UCVG_ &>*@\R?36PWSQ?I_P#6J]#/'=+E M<'U!ZBE&4:ONRW[,:IS:>O7:T9_2LW4Q%/?5?<:Q5.6SL6FT6(_==E^O-1'2)H_\ M53X_,535KNT_U3EE] <_H:FC\1&-ML\>#[<'\C1',*2TJ+E_(T]C7^P^9!)8 MWJ_PI*/< _SJ!XY(_P#662D>H5A_(UL6^IVUSC;( ?[K<&K5>A&<:BO!W.=U M9TW:<;?@'MW0_[+_XT>78/TDF3_> /\JZ1HUDX90P]QFH7TZVDZP)^ M Q_*K&L0NMU\S!%C;,08[\*?]I2M2?V7/)_J[V.3_MH:TI-#M7Z*R?[K?XU7 MD\-Q-G9,Z_[P!I&BKQ?VOO12?1[Y>1'&Y^B_U%0MI]XGWK)7^B_X&K_]@W,/ M^INL?B5_E2?9=7A^Y+O_ .! _P Z#55>TE^1F-"R_?TXK] X_F:A+6F21_P"]%G^1K3_MVRE_UM@I_!6_I2?;-$F^];&/_@./Y&@O MVDUO&7X,SUL;7^#50/K&PIRV?]S5XQ]79:OK#H,W1]OU9A_.G?V/I$W"7 _" M44$NM;?F^:106SO/^6>M0G_MY85(+75OX-1C?Z3YJZ/"=G(N4FE_[Z4_TIC> M#8?X;F0?50:"?K%+K+_R4@^R^(!]R?=]'4TF/$R]#G_OW4C>"_[MX1]8_P#Z M]-_X1&Z3[E]C\"/ZT#]K1?6/_@+&>;XF7JF?PCI/M?B1?^6.?^ +3_\ A'-6 MC_U>H8_[:N/Z4W^R-?CZ7N[_ +:D_P Q05S4O[GW#?[1\1K_ ,NV?^V8I/[8 M\1+_ ,N6?^V1_P :>;7Q)']V7=_P)3_.D\SQ/'U3=^$9_E0.T'LJ?WC/[>\0 MC_F'?^0&_P :3^WO$/\ T#O_ " _^-*VJ>(XCS:[O^V>?Y&E_M[Q /\ F'9_ M[8/_ (T#Y%TA#[QA\0>(NVF_^0'_ ,:;_P )!XC_ .@;_P"0'_QJ0^(M?'_, M,S_V[R?XTG_"3:Z.NF?^0)/\:!^S?_/N'WC/^$A\1_\ 0,_\EW_QIO\ PD7B M7_H&?^2[_P"-//BO6EZZ9_Y">D_X2_5QUTS_ ,AO05[-_P#/J/WC#X@\3-TT MW'_;!O\ &D_MKQ2W2QQ_VQ/^-2'QEJB]=,_\=>F'QQJ/?3./HW^%!7LY]*,? MO_X(TZGXM;I:8_[9C_&D^V>,6Z08_P" )3AX\OEZZ9^K?X4?\+ NAUTS_P > M/^% _9U^E"'X?YC#+XT;HF/PBI/)\:2=7V?C$/Y5(?B-,O73/_(A_P#B:;_P MLMQUTSG_ *[?_8T#Y,5TP\/N7^9'_9/C"3K>;?\ MJ!_(4A\,^*Y#SJNW_MX M0YEU7/TAS_[-4\?PIM>/,OYF_W4 _QIG_"3^*FZ M:3M_[=G_ *FF_P!N^+VZ:?C_ +8'^IHT!RS![UHKYK_(NQ_"S2E^]<7;_P# MU'_LM6(_AIHB=8YI/]Z4_P!*R3J7C5_NVNW_ +9H/YFD\_QT_2/;_P !A'\Z M>AFUC);XF*_[>-^/X?Z!'_RX!C_M2N?ZU:B\(:+#]W3+8_[Z!OYUROE^.Y.K M[?QA'\J3^S_'$G6YV_\ ;1!_*CY&3HUI?%BH_P#@3.XATFQM_P#565O'_N1* M/Z5:50HP /:O//^$?\ &=QP^I>7_P!MR/\ T$4G_"!^))_]?K>1_P!=Y&_F M*+F#PE-_Q,1'\6>BU!)?6T.?,N(D_P!YP*X#_A5-U/\ Z_6,_P#;,M_-JEC^ M$-N/]9J4C?[L0']31J+ZM@E\6(^Z+.PD\2:3#]_4[-?^VZ_XU4D\;Z%#][4X M3_NDM_(5AQ_"32E^_&/^U*Y_K5 MJ/P;HA:;#S'I]K&?]F!1_2K<<$ M9_\ "U-8NN+70]S'IP[_ ,@*3_A*/'=]_J=)^S[NG^C%:3_A ?&%Y_P ?.O;5[C[3(WZ8Q7J5 M%%@_M:K'^'3A'TB>6K\%YKAMUUK18]]L)8_F6J_:_!728^9[R[F]E*J/Y&O0 MZ*+(F6<8Z6GM+>B2_0Y*V^%?ANWQFQ:8CO),Y_0$"M:U\(:)98,.DV:D=&,* MD_F16O13.&>,Q-3XZC?S8R.%(5"QHL:C^%1@4^BBFWEQ #]6%*Z.V&78RI\-*7W,[E_O4JL.YKRZZ^.MOTM](ED/8 MR3!?Y U4/Q.\5ZEQIWA_"GHP@DD_7@4N9':LDQMKSBHKS:7ZGK]%>1>9\3=6 M "I]CC/M%'C\_FH/PW\::IS?^(-BGJOVF1OT HOY%?V73A_&Q,%Z._Y'JUS M?6UFNZXN(H!ZR.%_G6)>_$+PW8 ^;K%JV.HA?S#_ ..YKBK7X#1,VZ\UF64] M_*A"_J2:V+/X*^&[=AYHNKLCKYLV ?\ OD"C4?U?*J?QUY2_PQM^8R^^.'AZ MVR($N[L]C'$%'_CQ!_2L.?X[75VQCTS06E?MOD+G_OE1_6N^L? 'AW3<>3H] MKD=&E3S#^;9K:CMH[>,)#&D2#^&-0!^0HU']9RNE_#P[E_BE;\$>0?\ "4_$ MO7,_9-+^PJ>A%N$_64FFS>"/B%JT3R7^MFUC"DLANF' _P!E!BO9$'.:2XC\ MZWE3^\I7\Q1R]P_MET_X%"$/^W;O[V?/^E_#A)+>.2[OY)"W)V+@G\3G^5;M MAX#TC[1%%Y/F/(ZH'N)#@$D 9Q_A6G9M_HJ \%(1+8RZL8I@OWLNIC&"WRG'TKY[NM>+YP^?QKW3]I?QAX.C^(WBC1;CX M>MJGB*2)8DUA-9GC(D:!=DGD ;?DRO&<';SUKVWX)>&[WP?X6\$Z.[3-97=@ M;B:'2=-C^QLS1Y9KN=RY9SD8\LKR,8*XKCC)N/,_ZW_R/NJ>+E@,)!RC>ZT3 MLNEVTUS?C8^2O#_PMU/Q)X.B\72WEM'X?%\;*:-)&^TE@N[@;=H!Z9W9]JWE MAT2WM6@72-/6)1A5D@#D_5CS7NWA^WUCP=\(_$__ A-B7O[7Q1=F*.VM1,\ M*&3:?*CP1PI"]#A2:Z^WN8M-\37&J7EK!#XCD\(F[U6U5009%*XW+WR0Z]>B M@=J'/>73_P"UN3+,)7ESQYM6E9VV:W5O/<^3%U(64/E6[M%&HPJJQPH]![5M M?"N_O%EN[%)9)M*LHXTB,N#YX"[3CMFO0/ WBC5OVCO!_B7PCK.JQM MKRRP7^GW4D:#8JLJR (H4<+G_OX:Z3XA7MM'J=OHNG_+IFBP+86ZYS]P $_7 M(Q^%:Q;O9_TO^'T//SG&1]D\-.FN>_K;9IIV6^OXW,&_=)[9SCYMO![UZ]X= MN#=:#82GDM"N?RKQ&XF_M!)U'A/_ %5Q_O"M^L#PG_JKC_>%;]<\MSLA M\*"BBBH+"BBB@ HHHH **** *FK?\@VY_P"N9KAR<#)KN-6_Y!MS_P!_TV=G2"\@DMY&C( M#!74J2,@C.#Z50R:CH$>GQZ:5NF!D>-$" MJQ90/G&T'( P1D8KE[K]GG0[_1[O3[_6]$S&V25I%;<(@# M(-VW<0<@#()R3ZF> 35:J:YFY/K_ ,%?J_O"+<4DNG_ _P E]QR'A_X36>CZ MY8:K>ZWK'B*?3(&M]-35IHF2R1AM;8(XTWL5PI>0N^!][DYS+;X!Z';QV^G' M4]7E\+6UX+Z#PQ)-%]@CE#;U (C$Q02?.(VE*9_AP *]&@;J.U34=;_UW_/7 MU%TL>>^(O@W!XH_M*TOO%/B*30-2G$]UH37$,EM(,J6C$CQ-.D;%?N)*H&2% MVCBEUCX+Z;?:IJUWI^LZQX=BUB-(]4L])EB2&]"KL!;?&[1L4^0M$R,0!SD MCT&BIY5:P^9[_P!?UYG):#\,-$\,>(H=6TN.6T,.CPZ)#9HP\B.WC=G3 (W; MLL1DL=KG4?#]K-$+. MY=CF7DQF6-9#]Y8Y$!R>.3GT2&&.VACAB18XHU"(BC 4 8 ]*?126BLOZ_X M;H#=W=A7$_%7PG<>(=%@O=-&=8TN3[3:C_GIQ\\?_ AQ]0*[:BM(3=.2E'=" M:OH>+Z+JT&O:;%>6^0K\/&W#1N.&1AV(-2W5J&7@5I>./ 5[I.IW'B/PW#YS M3?-J&E X%QC_ ):1^DF/SK(T?7+/7K8RVLF2IVR0N-LD;=U93R#7U^'Q$:\; MK*Y3Q!X;L]8A:.Z@63T?HP^AKT2\ML@X%8-Y:]>*ZR#S?3-2 MUSXVG7BN/U M;PK;37'VB'?:7(.1- =IJ=5L!ZK/'C(K-GCZBN#M?$WB+25\M[J'48U''VA, M/^8J.Z\=:]J4T5E96,/VV<[(TA!=V)]!0W978':Z/H#^,O%=AHD:EH5=;F^< M=$A4YP?=C@"OICRU"J ,!1@ 5POP=\ R>!?#+"^D\_6;Y_M%[-G/S8X0'T4? MJ37>5\GC,1[>IILCKA'E1&T9+<=*DHI&.%-;YE5C?T9]*T5\U?\)9KG_09U#_P*D_QI/\ MA+-;_P"@SJ'_ (%/_C6W_$1\)_T#R^]&7^I&(_Y_1^YGTJRB12" P/4&LRZT M][9O.MB>.=HZ_P#UZ^??^$LUO_H,ZA_X%/\ XTO_ EFN?\ 09U#_P "I/\ M&L:OB#@JJUP\K][HUI\&XJF]*T?N9]$66I)=#8_RR^GK]*GKYK/B/5F;<=4O M2V%5+Y,^DXSU M%.9MM?-7_"6:W_T&=0_\"G_QH_X2S6_^@SJ'_@4_^-:_\1'PG_0/+[T9_P"I M&(_Y_1^YGTCY<G4?K7SI_PEFM_]!C4/_ I_P#&E_X2 MS7/^@SJ'_@5)_C6,?PK\WZ?X5XI_P )9KG_ $&=0_\ J3_ !H_X2S7/^@SJ'_@5)_C7F3X MTRYOFI4)P?E)([X\+XU+EJ5HR7FF>W6_C+RVV7ELT;#J5R/T-;%KKEG>+E)? MP-?.DWB+5KC'FZG>2XZ;[AS_ #-1+K%^C K>W"GU$K?XU5+Q!G2=I4W)>=D_ MP%4X,C45U-1?E=H^G4D23E&5OH)-6'(U2]!_Z^'_QJ7_A+-<_Z#.H M?^!4G^->G'Q'PWVL/+[T<#X(K]*R^YGTK17S5_PEFN?]!G4/_ J3_&D_X2S7 M/^@SJ'_@4_\ C5?\1'PG_0/+[T3_ *D8C_G]'[F?2U!XKYJ_X2S7/^@SJ'_@ M5)_C1_PEFN?]!G4/_ J3_&C_ (B/A/\ H'E]Z#_4C$?\_H_..0_/&C_ M .\H-1R:39R=;:/_ ("N/Y5XS\-_$&J7WC33H+G4KRXA;S-TO&A*=VU?3U:_0S)/#=@W2) MD_W7/]:K2>$;5N5EF4^Y!_I6Y17T9Y*Q%6.TFP_ZVPQ^#+74T4#^L4W\5)' M+KXX7^.S8?[LF?Z5(OC:VR-T$P^F#_6NB:))/O(K?49J%M/M9/O6T+?6,'^E M >TPSWIV^9DKXTT]NJS+]4'^-2KXNTQNL[+]8V_H*MOH>GR=;.'\$ _E4+^& M-,DZVB_@S#^1HU'S81])+[@7Q-IC=+M1_O C^8J9=!]/;H\Z_1Q_44:ARX1_:DON-E=2M&Z74)^D@_QJ1;F%_NRHWT8 M5S;> [0GY;F8?7!_I4;?#^(_=O''U0'^M&H_985_\O']QU@(/0YHKCF^'IZK MJ&/^V7_V5-_X06\C_P!7J7Z,/ZT:C]AAWM6_!G9T5Q9\'ZPO^KU3'_;1Q2?\ M(UXCC^[JF[V^T/\ U% ?5:3VK+\3M:*XDZ)XH7I?Y_[;'_"D_LKQ6O2\S_VU M'^% _JT5P7E>-S_'^L-)]E\;'_EKC_@45%Q_4%_S^A]__ #OJ*\_ M^P^-F_Y>,?\ XZ3^S?&S=;K'_;1/\*=P^HQ_P"?T/O/0:*\]_LGQHW_ "^X M_P"VJ_X4G]A^,S_S$,?]MO\ ZU*X_J,/^?\ '[ST.BO/#X>\9-_S$\?]MS_A M33X9\8M_S%L?]O+?X47']1I?\_XGHM%><_\ ")>+Y.&UG:/^OJ3^@I/^$!\2 M2?ZS7,_]MY#_ $HN'U*AUQ$?Q/1Z0L%Y)Q7G/_"K]2F_UNL_HS?UIH^#[/S) MJ^?^V&?_ &:C4?U7!K?$?^2L]#>^MX_OSQ+_ +S@5!)KFFQ??U"U3_>F4?UK MB4^#UN/O:G(?]V(#^M3+\']._CO;IO\ =VC^E&H_J^ 6]=O_ +=9TTGB_1(? MO:K:'_=E#?RJI+\0O#T/WM20_P"ZCM_(5F1_"71(_O27@HU']:P$=L/?UDSR_\ X6)XLN_^/70.#T/V:5OUR*;_ &U\0[W_ M %5CY&?^F*+_ .AFO4Z*+#_M&C'X,-'YW9Y7_9GQ&OO]9=_9\_\ 32-?\?/B#:OI]JE/Z8Q7JU%%@_M>K'X*<(^D4>51_!6YN&#WNN%V M[A8BWZEOZ5H6_P $=(7_ %]Y>2_[I51_(UZ+119$2SG'2T]I;T27Z''6OPD\ M-6^-UG).?629_P"A%:MMX'T"TQY>CV9QT,D0<_F;:_9G2=;GBQB&X/G1'MS]X?G5$3-#(KHY213N5E."".A!KT'Q)H2:[8&, M'R[B,[HI/[K?X5YK+YMO.]O<1F*YCX9#_,>U="?,KEIGF?QET2VMUE\6 S2: MQ)+'%/+),6,ZL0H!W'J.,?05PT?Q*\06%C;V5KKNHVMI;MOBMX+R1(T;.[&8?%^BO833/;G"58=.#U%>27WP-UQ=WDZI8S^F]& MCS_.LVNQ]WE&98>.']EBYZIZ73>AD#XH>);)F-OXCU6 M,UR3'>RKF5@0TG# M?>()RW4Y-8UQ\2-=COKZ\&NZDM[>1>7=7 NY/,G3&-KMG+# P<]!6A;_![7 MY-0@M]2N+32XYI3#')O,IE8*SX10!GY48\D=*]0T7X5^&O#L4$@L5O+N$[_M M-S\[,WKCH/PZ4N6YZ>)SC X?X/?;[?JS;^ %G:_#'2WUFZTK[=XKNHW\F\EN M7"VD3JN(Q']T\C);@\D9Q6I-,\TC.[%Y'.2Q.22>]1QW&] X^7-);QS7E]%; M6T3S7$GW549Q[GTK3EU/SO$8BIB*CJ5'=LT?#NC2:YKMM:;3L#"24^B#G]:] MP50J@ 8 X%8/@_PNGARQ.\^;>36YU0^%!1114%A1110 4 M444 %%%% %35O^0;<_\ 7,UP]=QJW_(-N?\ KF:X>MJ>QSU-PHHHK4R"BBB@ M HHHH *9)*(^#R:?56;/F'- BPD@?ZTZJT&?,%6: "BBB@845'YPSTXJ2@ H MHHH **** "HFA_N\5+10 U$"#WIU%% !113)'* 8ZT /HJ%9CWY%2J=PR* % MHHHH 3<,XSS2U&8CCZ\^] M=BN>]+5QG*F^:+LQ6ON>):AIWBWPQE=2TH:U:+TO-,Y;'JT9Y'X5A7'B[1V9 MEFGDL9!]Z.\A:,C\Q7T54%Q86UXI6>WBG4]5D0,/UKUJ>9U(JTU01TK26:.WNP%[+NSYOE^$ M/C";3TU'4-+;0=)WJL]Q=8:6)2?OF,O7/AURQL]GVK3'8Y_<9P\6>YC8C_@+I7E5<;5KOEF[(W]E&*NC95=M+117. M 4R4\ 4^D9=PQ0!!4D:XY- BYY/%24P/*OCI_P P3_MO_P"TZY3X:^!_^$^\ M2"P>Y^R6T<9GGE RVP$#"CU)(Y[=>>E=7\=/^8)_VW_]IUC_ 7L+N^\8 :? MK*:/J,<+/#YD7F)<8QNB(W#@CGC)X)'(S7\[9U1IXCBZ5*K#GBW&\;I7_=Q[ MM?==7V6K/VW**DZ/#D:D)EY/\C;U3X8^$]8\-ZK?^#]=N;^ZTQ/ M.GANAPR $D#Y%.< X/(.,=\UP.K^#=9T*[L+:]LC%-?*K6RK(CB4,<#!4D=2 M/SKW>3PO<^*-,UE_&WA72M(DCC><:Q92HCLP7 )P68XY.6;'0;:H?#>WMO'7 MA/PU?WTH$WAB[<2NYY,2H63\!^[_ .^#6F(X?H8RM""C[*4HJ6EXII3M-N$U M>+47=>\T^5O6YEA\XJX:E*5M4FKH\GA^%OBBXUN? M2(M*:2_MXUEEC6:,K&K?=W/NV@GL,YJQ9?"7Q'-XJM-#N[(V$\Z^89)&5D$8 M(W,"#AL9Z YY%=MX.\6ZGX@O_&%R= ?Q%H>HS W<,$ZI<11\JNU,[F^3@ 8Y M7@CFM;5-%L-+\1> -1M9=4TZVGO1%%HNJRLS6ZC"@HC,Q09QD9/WEZ=*X\+D M.7UZ=+$4^:47.-[OE]V53E7V%?2UY1EO=NL=N-Z%)&)P%#@[F?VU#);-=P$;@ M. ?F]!SGO6SX*Y7N\*6=8MJV/-[GX.^,K6UFGDT*8QPG#".2-V/\ NJK$MU[ UG^( M/A_K_A..UFU?39+2"X?8CAT<$]=I*D[3CH#CH?0U[5H>H7$?QF\Y M44/Y5?F3O_=M]J^F]'-L8Y0]HHV;ALFG[\6^[VM\_(Y3QAX"DT_QA;Z'H^FZ MGY\\2LEO>O#),22)OA_X@\&PPS:OIKVD,S;$DWI(N[& M<$J2 <=CUP?0U]!SS1+\9M1A#*E_/H02U+'!+;R2![\ _0&O%M8\.^,=)\ * MVIR2VFBI>,OV"X?9)YA_CVD9920<\N9/X=>EK:IWUU11^'_A6W\4RZFMQ M:ZC="VMC,O\ 9\D*%3ZOYI&5_P!WFFZ/\+?%&O:?:7UAI37-I=;O*E6:, [2 M00>N*Z[]G__ (^O$W_8-;^=+XGNIK?X"^$1%*\0:[DUK*$5>[M>,F]$UV,3PE\ M'=9USQ9-H^H1-IBVBK)=R,58JK9V[<'#9P1D9 Y],57F^#OBIM0O;:VTEI?L MTH1O](BR W*$_-W!!]N^*]GGE5/CUI.]L/)H>!GJQWN?Y _E7(Z%;7NA_#7X MBQW$$MI<>>P*3(5.UP!G![$'K7I8G(,OP\>249OD==N2:U5-)I?"TFUMZ2T= MUR^7#.,;-J:<5S*G9-/>4FF]T_Z79W\_M?A'XMO;Z\M(='9YK0JLW[^(*K$! M@-Q;:3@@D DC(SUK(N_!NMV/B!-$FTV==4<@);*-Q;/<$<$<'D''!]*]0\$Z M&8?A;::C:Z7<>*;VXOBL>G27#FUMG!8!WA!VL. 3N'\0Y YKO+J:&'XY6Z2M M''=P]\C@!IM1G- ML-^K/JAB@EAVKD8<>6,8^[UXS[USX?A_"5JE?.,31E&G!PF]6VFDG9K3WIJSUUUETT/)+7X>Z=-X'\,:RTUT+K5 M-46QF0.NQ4+NN5&W(.%'4D=>*9XN^%EU9^+-8TS0(9KZUTV!)Y7N)HPZJ4W$ MG[N>_05UMHRM\*? A1=B'Q$I5./Q8?G78\FPF(P]&*A:4E!W6]_J\IVZ[R2O^!QRS3$T*M2?-=1Y]'MI4C%? M8@PYQQMSN_B';O76^.OA6^E^-;70/#D5W MJ,DUHMQMF92P)9@26 4!>!R?7K72+H-]H'[/][%J%M-9SS:BDHAG0HX7>BC( M/(^Z>M=MK&AQ:Q\5;F62XN@UMH:.+.SN6@>YR[C:64AMN<<#N1GT-4>',/+# MQI.+YY>RD[Z-T74M+>W^UR"&%O,1U9ST4LK$ GW(Z'T-2ZW\+_$_AS3Y[_4=+-M M:0$!Y3-&0,XQC#'/4=/Z5Z_K22CX8Z!YVBQZ !K$'E6"J0T2>80N[/)8CDDX M)SGO7 _M"7#S?$:5&.5BMHD3V&"W\V->1FF38'+L-.NN=N\%%-I6YX.7O7@F M[6VM%^AU8'-<5C*\*+Y5\5W9OX6EI:5E>_>2]3FOAO<+:^--.E?.U?,SMZ\Q ML*]XCU*VN"-DRY/\+<']:\)^&423>.--210R'S<@_P#7)Z]NN/#MO+DQLT)] MN17W_ +Q$?#_4Y2UHR4O3?[CH M:*HV>LVMZ0$F4,?X6X-7J]&G4A57-!W7D<4H2INTU9A1116A 4444 %%%% ! M1110 4'I110 RGT44 %%%% !1110 4444 %%%% !1FBDV\T +1110 4444 % M%%% !1110 UFVT*V>M(XYI%^\* )**** "BBF>9Z4 /HHHH **** "BBB@ H MHHH :S8%(K'.#3F7=0J[: %HHHH **** "BBB@!K+DY%*J[:6B@ HHHH *** M* "BF2-MZ=:9YA]: )J*CC4AL]JDH *R=>\-6>OQ 3*4F7[DR<,M:C2!>*56 M##(IJZU0'EVJ>#=7TTDI%]OA[/#P_P"*_P"%<]<%X6*RQ2Q-_=="*]SIKQI( M,.JL/1AFM.?NBN8^9O$\H;6O"A!SC4W)_P# .YK?CAFO&V06\L['^%(R:[_Q M_9P)XL^&H6"-0WB"8-A!R/[*U X/X@?E7=I&L:X50H]%&*.==A\QY+H_PXU7 M464W(73X/]KE_P !VKT7P_X7L?#D)6VCS*WWYGY=OQK7HJ93;)N%%-9MM-67 MGFH$24444 %%%% !1110 4444 %%%% #)'*XQ1')NR#2NFZDCCV9[F@!]%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% '2>$_\ 57'^\*WZP/"?^JN/]X5OUSRW.J'PH****@L**** "BBB@ HH MHH J:M_R#;G_ *YFN'KN-6_Y!MS_ -IN%%%%:F04444 %%%'UH M *1E#=1FA6#=#FEH KM&RR?*"!VQ5BBB@04'D$444#*_E-G&/QJ<< "EHH * M*** "@]#2,VU2:K[VSG- $RCRUP32AU;H:K>89,D_2EIV M44R.0, ,\T^D M4V1-X]#3J:BLI.3F@"/R#Z@U(H"+C/ [TZFR_P"K?Z&HG+EBY=@.,3XW?#J2 M98E\?>%VE9MH1=9MBQ/3&-_6NUKYF^"FM:SJ/[-6EZ#:?#[5-*W?!ND>+M#\9Z!\.CXQN+'3=$\(V=U&39P"R^QI*8C$SE//\TJI??Y@&XXV;>*RKOQ3JGPPU[XY>*[74+S5KFVG MTU+?3[J*)H7EGAA6)G$42R$1[PH"L,J.=S?-4\UM^W^7^8^6[LCZ<9EC4LQ" MJHR6)P *KZ;JEGK5A!?:?=P7UE.N^*YMI%DCD4]U9201[BO$_#OCCQ-I_BS1 MK&+4O$_BS3KZUG34+G6O"TVFII\R1%TFCD^R0KY;L"FQRYR4PW7.1X"\<>-? MB!?_ [TY_%4VFQZMX5FU74;FULK8SR3)/$JM'OB9$/SX/RE<%OESAA:U=E_ M6DG_ .V_UTFUE?\ KHOU/HRBO//@CXLU3Q-X=UB#6;U=2U#1];O=(:]\E8FN M%ADPKLJ@*&*D9V@#V%>ATMTFNJ3^_46S:[:?<%%%%,#$\3>;I_V/6[4$W>ER M>;A?XX6P)4/L5^;ZHM;7Q*6*;PY8^(;8[SILB7:,O5X'&UU^A#*W_ !3;B%; MB"2)QE)%*,/8C!J3X?S)JGA2YT"]P\VF,^G3(>\.,PM]#$R<^JMZ5E/N:PU5 MAH8, 0<@]#2UA^&&ET]+G0;PDWNDL(-S=98"/W,OOE!@G^\KCM6T) 3BM-S) MZ!+*D,;22.L:*,LS' IEO=0WD8D@E2:,]&C8$?I6/XB2V;5?#QU-?,T8WP2 MZ5ON;F1EAW^J^:8QZ9(SQFKOB[0K?P=J-KKFFP+:Z?/*EIJ-O$-L8WL%CF"] M 0Y53C^%R>U2Y6=BE&ZN:%%%%62>5?'3_F"?]M__ &G7ED,TEO,DL3M'*C!D M="0RD<@@]C7J?QT_Y@G_ &W_ /:=>4U_+W&;:S_$-?W/_2(G[[POKD]'_M[_ M -*D:FH^*M:UBW^SW^KW][!D-Y5Q7%C/MV^;;2M&V#U&00<<4M] MK%_JEVMU>7US=W2@!9IY6=P ROW-2 MX\4ZU>7=O=3ZO?S75OGR9I+EV>//7:Q.1^%7&D\4ZWJ?FEM8O]0L!OWDRR2V MX!SG/)3GG/%:OP;-H?B)I*7EFMX)'Q%N8@1R#E7QWQCH?7/:O7_#=WIMU\3? M&B16#6(BM72[E28R&=M_+@$84X[#BOL,KRN>8TZ=2>):YYR5M;WA#FO?;MZ+ MN]%\SF&81P-25.%"_+&]]-G*UN_?Y^6I\^)XBU:.\N+Q-3O%N[A=DUPMPXDD M7CAFSDC@<'TJ)=8OUT_[ M]5N_O;$?#OC#X?G6-" MTN31;R'4([+;)=-,)=[(H+9Z??!X []:[+_A1^D?:O['_P"$?NS;^1_R,?V] M=_F]<>1G&.V=O_Q571X[=;:\ZBK[L*F=8&@OWD' M%IM-/ENN6WG9VNK)-OLCP.[US4;^^CO;G4+JXO(]NRXFF9I%PI1WD MEJ\:WDD(D82,N,@\ $\#M5WP/X'\/ZUI=I?7'A2;[+>7+;[S4-2-O! K/A( MX0K%Y.H4%@-S?Q>F-'(<;B)1HJO&\XQFU[[LI6LY6B]=?.V[:5F:3S;"THNK M[)V@W%/W5JM^6\E^E^FIX[I^KW^DM*;&]N+(RKLD-O*T>]?0X/(]J)M6OKBP MAL9;RXDLH3NBMGE8QH3G)5LM_!>@>._"%KK'A[3Y-!N8]1CL;BW>=[A,.RJ&!;D MXWJ>W<>AJ/[!Q_LN6-1.5I>Y=W:C/EETY?B5]]M>CM2S?"2FI.#M[OO65DY1 MO'K?9VVT/.)O$6JW&H0WTNIWDE["-L5R]PYD0#. K9R!R>GJ:DNO%>MWL4\5 MQK&H3QS@"9);IV$@'0,"><>]>ZS?!'2;B:YTB/P]=6L*09A\0MJ =I)0 <&' M/ )R#QV[=:\X\1>$=.TWX1Z%JZ6GE:O<7CPSS>8QR 91C;G:/NCH.U:8S(LS MP<*DJM3W4G)ZR5[-0EHTKOWEKLULV1A\VP&*E%4X:MI+2.ETVMF[+1Z;I[I' M&Z9KNK:;&]KIVH7MK'.<-#:SN@D)XY"GD]JLR?\ "0ZMON9/[3O?[+ 5IF\R M3[(!G )_@ P?3I7NN@>%] \*_%32+6RTE5>XTS[0DK3NWE2#=N8!BKTJ?)5Q%Y+VG MNIRLO9J^C:M^6ZMUMS+.:4Y.=.CI:+N[?:ER][_UZ7\EU3Q%JNMI&FHZG>7Z MQG*+=7#R!2>I&XG%.D\3:Q+IHT]]5OGL H06K7+F+:.@V9Q@8]*],;PSX-\" M:?X;B\2:=-J5QJT7VBXO!<2(MHI"X"HGW@,_7@GT%/\ 7@'P]KFBZ[J5CIT MWBB>"[\JUT^XO!:.(3C#L5/7!;D\'8< 'BN&.18^I7E05>+J-/G5Y.222=I) M1;EHTERJ75=';JEFF$A2]I[)\B>CM%)N]KIMV6O\W+W/*UUS45L[>U6_NEM; M>3SH8!,VR-\D[E7. G'7 MI6[\3-%LM#\0^38Z5J&C(T8+VE^ 0K9P3&X9MZ<=<]<_AR5?.8CV^%K.C*;O M!]&^FBM>S]-$>U0='$4E6C'22\NN^U_^":=UXFUB_AFAN=5OKB&9Q)+'+H-JM\U_&NQ+HW+F55YX#9R!R>/7# RW$AD<@=!DG-5J*B=:K45IR;]6.-*G!WC%+Y'5_"W_D M>],_[:_^BGKZ KYM$V]U=>(K2.R)%U\[)M;: M6"NNJ5Y:^AUI4-3)8(YUVR1K(OHPS4E%?LC2DK,_,4VG=&+>>%K6?)A+6[^W M*_E5 V^M:/S$WVF$=A\P_+J/PKJ:*\NIEU&3YZ5X2[QT_#8]"&-JQ7+4]Y>> MIS]GXOA9MEU$T#="R\C\NHK;M[J&[CWPR+(OJIS45YIEKJ"XGA5S_>Z,/QKG MKSPK/9R^=IMPRL/X6.#^!_QK!RQ^%^)*K'RTE]VS-5'"8C9^SEYZHZNBN1@\ M5WNFR"'4K9C_ +0&UO\ UT-AK%IJ0_T>96;NAX8?A75A\PP^)?)&5I=GH_N M_P C"M@JU!/=:HNT445Z1P@::#3J3;0 M%%!H **;DTX4 %%%% !3=U. MINV@!5I:0"EH **** $6EHHH **** "BBB@ HHHH **** "F,I)XI]% !111 M0 4S9S[4^B@ HHHH ***1C@4 +145/3I0 ZDYS[4M% !1110 W<*=494YIZC M H 6BBB@ HHHH **** "BBB@!K-M%*K;ES2]:* &2+NY'6F+&2>E344 %5]2 MU"#2=/NKZZD\JUMHFFEDVD[44$L<#DX /2K%<]\1/^2?^)_^P7=?^BFK*I)P MA*2Z(NG'FFHOJ6]"URR\3:+8:OILWVG3[Z!+FWFV,F^-U#*V& (R"." :THN M_I7"_ N)9?@CX$4Y&="LQE20?]0O>O*]#\3:]<7FC?"V36=0EU_3_$TJ7^H_ M:'%S)I< %TDCR9W8D62"(G/.XBNFHE&JZ:_I7L_NO?[S*%Y4U-_UHW^EO6Q] M)45\ZQW&M?#O74U#X@?$7"?[;5(O%&DZT;C2IXY6(BBFL6?$"898CB X8!A M("0U(T^I>+/ ?Q&\;7'B?6=)UW1;_48K!+;49(K6P6S=O*1[96$4NX*"_FJQ M8/V&,<_.N7F?17?RM^/O(V]FW+E75I+YW_#0]VUCP[;:YJ.A7L[RI+H]XU]; MB,@*SM;S6Y#Y!RNR=SQ@Y"\XR#JU\Y>(9/%M[YOBO7=/\3ZGX;O="M[RVD\& MZV;*?2)! K2AK0RQ+.2S.X9C+PBJ4Q6YH6KP_&;XBWMD?$.L'PU8Z#87VG#3 MKZ73I+UKGS"US(T!CXT5\P>&]=U[QSJWPYT74?$VJFU_M/7=/NKJPNWM9-2AM3MB,CQ%?FPH MRZX.9;]+7^6G^:_'YWR.ZCUO;YZ_Y'U/*.AJ,#)Q7S@FO>(OB'XH M\;&\L/&%S#I;Q6.G_P#",:O!I\-D3;I(9G1[N$RNS2!AYBNF /XA7M/PFUK M5O$7PW\/:CKK6LFKW%HK7,EE+%+#(_0NK1,R$'&?E)'/%:*]M?+\=B#K:*** M0!1110 4444 %%%% $4A.ZG1_=IS*&ZBE QTH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#I/"?^JN M/]X5OU@>$_\ 57'^\*WZYY;G5#X4%%%%06%%%% !1110 4444 5-6_Y!MS_U MS-N<8IU XX' M2B@ ILB[U(IU% $*+Y*EB:9]H;/MZ5/(N]"*K>6V<8-!)91MZ@TZFQKL4"G4 M%!1110 C':I-1QR%FP:EI H7H,4 +1110 R8$QL!UJM#'(<[AGWJY10! T.Q MG7R2-@%2P^"[./QW<>+#+/\ VE-IR:88MR^2(EE:0$#;G=ESSG&,<5XI MI&J>,--\8?&?5-!?2+"*QN(;R:'5K:2Y>:1;")O)!CE01@!>7_>9W<+\O/0: M]\=+C^S?"U]!J6A^%;+6-(AU-9]61M0N)Y)2H6UM[.&:*:5ANR7 (^Z I).U M\W-:771_>G^E_P"FBFGJNC_1K]6OZ3.@?X!Z&\3V7B*WC@U+2"T8MIC M&@1)00GFHX4 960#@'&0"//=$^,EUXPM?AS=WNB:;)J%UXAO-*N)+BSD!@DA MBG!FMUD(>%FV#AP64,RGUJ+1OC5XX?P%X;\<:E%X?71[_58M.N=-@MYEG$ ?GYX2BG:/>R^]*WWW7]+0=TV^N_W-W_ ">O7YZ][H_P MGM['4[/4-4\0:UXFNK"W>VL'U:2 _9%==KLOE11[G90 7DWMC//)S9\'?!W1 MO!-[X>N[&YOY9-$TA]%MQ<2(0T+R)(6?"#+Y0-/B3XHM- M+?Q#=>#H%TS1M+ASN:9H5FN& )WL6C3@$[8\#J0=CX4_$*;XE-+#/XG\'^+ M--GL=UQ:Z5;RVEW;.6VM'-;2RRL4(+#+^601C:=W#4F]5O:_WIV^]-_>*2LM M=MONM^3_ ".P\)_#W3_!]MKEO9SW^S/>O2:+*RMM96]+:?@+6[OO=_??7\3B/^%.Z#_S_P#BK_PKM6_^ M2:/^%.Z#_P __BK_ ,*[5O\ Y)KMZ*+!=G$?\*=T'_G_ /%7_A7:M_\ )-8^ MJ?"G2/#M]#K5O=^*I+9<1ZC##XKU4220\X<,+G<3&2Q"YQAF[XKT^BDTF"DT M)XB\+KJVEZ9J_AR83W]G;A;:269I!>6Y S$\C$LQ. 0S$D-U/)K,T75H=:MS M)&&BEC;9-;R#$D+CJK#L:BT_4)_AW<2.D >H)K-7B[,U:4E=$VJ:;! MK&FW5CKOA]9/'?PQ:QOVW7EQ:26%R_I,%*%A^.#3*E M^%K%O#-Q> 82YU"ZF0?[*R&/(]CY9(]B*AWA#7O^$8\3:;JIC,JVLRR,B]67HP'O@FO2K7XI>%=-\4:[JU MI;ZN1JUJZ2)-'$=LI/48?A<>Y->9_P#")ZY_T!M0_P# 63_"H8?#^J7$C1Q: M;>22+]Y4@J/-Q.'P.,DZE2:VL[26U[ MZ_,ZO0OB!;:+\-;[0D2X&JR7T=W#,J*8EVM&1DDYS\A[>E;.O>/? _BB\;6M M4T+4KC6GMA&]HLP2T:0S?KU,I8;+Y3=55;2;;NIV>MKK M1[:(Z*^\<6%U\++/PTD$Z7T-XUPS;1Y.TES@'<6S\PZC\:Z"Q^*'AJXT/PPN ML:;J,VI: !]G2V=%@D(VA2Y)S_"IX'4>AKSW_A$]<_Z VH?^ LG^%'_")ZY_ MT!M0_P# 63_"E1QN;49VZLOU">%RZHK.I;WG+25G>6CZ M[-,]L\*^*M,\2ZA\2MYU/87=T8,HPAP1E5].%]R:Y6STGQ5I\-S#:V6L6T5RN MR>.&*5%E7D88 ?,.3P?4U5_X1/7/^@-J'_@+)_A7?7S3,JE"$*5%QG:7-+EU M]ZHYNSM=+5?TSCHX# TZLI3JIQ]VRYM/=BHJ_<[OQ%XX\#>(KNZUN[T'4KC6 M[B!5:UDG"6@E W[E8/P!Z ''0$YJMH_COPW=^ ;+P[XBLM2E^P7+3PM8,@$ MF2QVL6.0/G(. >,'-<;_ ,(GKG_0&U#_ ,!9/\*AN/#NJVB@SZ9>0@\ R6[K MG\Q7!+,,S52=:5!+F34OW>DKM2;>FKNEO\M+G9'!X%PC2C5;LTU[^JLK*VNF MC_K0]0U+XS:7/\1]%\06UG>+96MJ;:>&14$ASN^[\Q!QD=2,XK/C^('AK3+# MQE:Z=!JI37(AY7VE(\I(?,W9PW"_,,=3UK@T\+:U(BNFD7[JPR&6V<@C\J=_ MPB>N?] ;4/\ P%D_PK>6:9Q4YG*DWS.3OR/[:M*WDS)8#+8)152R22^)?9ES M*_HSOK/XD>%]@W1$L"GJF&8*!C/('\1&!7+?\(GKG_0&U#_P%D_PH M_P"$3US_ * VH?\ @+)_A64L=FE2<:E2AS275T]6[)7;M>^BU5M=3187 14H MPJV3Z*>BUOHKVLV^M^QT'Q.\?0^-KC3(;2*X6STZ#R8YKUPUQ,2%RTA'&?E] M3W/? XFM;_A$]<_Z VH?^ LG^%'_ B>N?\ 0&U#_P !9/\ "O)Q=/,,=7EB M*].3E+?W7_D=^'G@\+2C1I32BO-&316M_P (GKG_ $!M0_\ 63_ H_X1/7 M/^@-J'_@+)_A7)]1Q?\ SZE_X"_\CI^MX?\ Y^1^]&316M_PB>N?] ;4/_ 6 M3_"C_A$]<_Z VH?^ LG^%'U'%_\ /J7_ ("_\@^MX?\ Y^1^]&K\+?\ D>], M_P"VO_HIZ]<\6>#XM>C,\&V&_4U6Q\::=/6\*^9ND MEMW51F-@,DCU->X5^Y\%9?&ODU7#XNGHZCT:L_ACJO\ ,_)N*<9*CFE.MAIZ MJ"VU^U+1G!>&/&DMC=?V3K>Z*9&V+-)U!]&/\F__ %UWMF445YGK/Q+O M[^?4K/0(+:$VL[VCW][(6*R(=K%85'.""!O9,XS@CK]1C<=A\OI>UQ,N5'S^ M%PE;&5/9T(W9Z9367=7B<7CSQCHM]"XN8=5+\B/E=W(QOP0>X_ >7EV?X#-)^R MP\O>U=FM;*WRZG?C C[2M'W>ZVU.IEM8KB,QS1K*AZJPR*YW4O!<;-YM MA*;>0HKIZ*]7$X*ABU:M&_GU^\\^ABJV&=Z73[CC(?$FHZ#*+ M?5(&E3M)_%CV/0UT^FZQ::M'NMIE<@9*=&'U%6+BWBNHFBFC66-NJN,BN4U7 MP.8V^T:3*T,J\B(MC_OENWX_G7D.&89?K2?MJ?9_$O1]3TE+!XS2HO9S[KX7 MZKH=?17%:7XVFL9OL>LQ-&Z\>;MP1[L._P!178V]Q%=PK+#(LL;S6S]&24C#(I:*](XB/:?2G@8&*6B@ HH MHH **** "BBB@!BYS3Z** "C-%(!S0 M%%% !1110 4444 %%%% #2-R,"&&1R,@GI5BBDTFK,$VG='$:#\'/#GAC[ NF2Z];06.P6]K_P MDFI/;HJ8VIY37!0J -I4C'&*K>$O %[#\2->\<:Y;V%MJM[:PZ9;6^GS-.L M=M&Q8LTC1QDN[$9&W"A%&6KT"BGUO_6H=+'#P_!3P?;WT5PFFW BANC>QZ>= M1N381SEB_F+:&3R =Q+#"<,;2;R? M3Y4M^/W.^W=&,? ^0DJ",XKK:*5E:U@NSG;/X=^'--FT"6STF&S.@I+'IJ6Y M:-+=95VR (I"GO=W=A<17$ENMI.]CJ%S:?:8 M5&%CG$,BB90"1B3=P2.A-=99V=OIMG!:6D$=K:P(L<4$*!$C0# 55' ' J M7G=[4M @HHHH&(EHHH **** "BBB@ HHHH *;("5P.M.HH 9$"JG-/ MHHH **** U%$[,V#R*EHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** .D\)_P"JN/\ >%;]8'A/_57'^\*WZYY;G5#X4%%%%06% M%%% !1110 4444 5-6_Y!MS_ -6H('-/H(#<$9% #(Y/,7)&*?2 !> ,4M !1110 4444 % M%%% !112,P49- $,J'<3U%(D98].*G5@PR*6G+!H&C>(+DWE[;_V?YMS!,_$TEK.)4$3. #\Z2;6R MPZXKTVBE97N.[//M'^$JZ/!XZA75I9U\3*JAYXR\EN!:K;Y9BY,I.W<2<$D_ MC7/:#\%=6\%WFCWOAOQ1:V^H6N@6WA^ZDU+26NHID@Y26-%GC,39+9!9PVM4T;1GM&99 -YD!FF:4X7Y47: 6. 21CTNBIM9*VZ_X*_)V!N^_ M];?Y7.!^#WAR]TO2=8UK5;9[+5O$FI2ZM/9RX+VRL%2&)O\ :6)(\_[1:N\< M,P^4XIU%5V2Z:?=HA=6WU_4**** "BBB@ K(A\):1;W2W$=C&DBR>:H&=JO_ M '@O0'\*UZ*0&/K1O-2O[#0=/E^RW.I"0O=]X(4"^8R^K_, ON<]JV/&ES%X M7\)VOAW1A]GO+N(:?8QQGF&,+M:7_@"9.?[V/6L_5-)&H26UQ%<2V5]:L6@N MH#\R9&",="I'4'K3;#1F@OYM1O+N74M2F4(US, -JC^%%'"CV%0XMLT4DD7+ M&SBT^S@M8$$<$$:Q1HO1548 'X"IJ**T,PIK2!>*=43H=QP,T / #.KJ'IYV_]1OKLJXK56-KX^LWZ>9L_4%:^>SA^S]A5 M[3C]SW/9RU<_MJ?>#^]':T445]">,%%%% !1110 50US31JVFRP<;\;D)[,. MG^'XU?HK*K3C6A*G-73T+ISE3FIQW1RW@?5#)#+I\W$L!)4'KMSR/P/\ZZFN M'\31OX>\0V^J0K^ZE.7 ]>C#\1^N:[6&9+B%)8SN1U#*?4&O$RFM**G@JK]Z MD[>L>C^X]7,:<9..*I_#4U]'U0^BBBOH#QPHHHH **** "BBB@ HHHH *QM8 M\*6.L31W+(;>]B8/'=0\."#D9]>?6MFBN>OAZ6)A[.M%27G_ %OYFU&M4H2Y MZ4K,:\BPQL\C*JJ,LS< =3["OFG3[6QAU2YO=)<'2TN)XK29D >>W;:V2PY M8"0/M8\E2#DYR?5/CC/<1^%;.%9I(M.N[U+2_6)MK20R(ZA-PY 9R@.,'!/( MYKR&XN1:[ECFD,(&%CD;?M^C'DCZYK\AX^S14W3P,8^]\5_)W5E^OR/TG@_ M.?/BW+3:WW/7]"6^UQ9EE^SNDS1MM90^,'T/6N?TCQIJWP_UV;Q!:O9B+RF^ MV6?E,1/&,'E@PRZ@'#8XR1@@U5U2XBDG68C]['PKJ<''H?4>QK"N5U'6%G:P MBB:*TEB,LDQR,Y#[0F/WGRC)4D A@,\U^1Y?BJV%Q<,10GRR3W[+KZ_KL?I& M,P]+$8>5&K&Z?3N^A]8>(_BMI'AV[:W6WO=4DB@%S<+I\0D,$9 *E@6!)(.= MJY;') '-<9J'Q7U_5Y3?:3;KIMG"DUU9H6ENFNWN[JXF-S-=28W2N8RO*4<)[D;Z::VZ7_5'QN"X1PU*,7B/>E;7M<]DT7X\>']4: M!+NUU+1G=O*D:_MML<$O]QW4D#V;[IR/FYKTBOD+7/$.GQV\UO?/A+B%ED"J MQ/EX(8G X SU/K7T3\(?$U]XJ\#VMSJ2-]KA=K9KAD*"Y"' E ('WAC/;<&Q MQ7WO"G$U;/)5*.)@E*.J:3LUL_G?^M#Y#B'(:64QA4H2O%Z.[5T^GR.GU71K M36H/*NH@_P#=<<,OT-<3=:/K'@N5[K3Y3(R]W2WA]I>G='=T4BL M&4,I!4C((Z&EKZH^>"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #"G-. P M,4M% !1110 4444 %%%% !1110 4444 %%%% !1110 45$TAW8!Q3T;NXU;_D&W/\ US-< M/6U/8YZFX4445J9!1110 445 S2>9CG&>E B>BBH%=S)C]* )Z***!A1110 M4444 %%%% !373>,=*=10 BJ%7 I:** "BBB@"&93NSCBEA4KDGBI:JMG<<] M:8%JBFQYV#-.I %%)N&<9YI: "BBD#J3@'F@!:*** &K(&8@=J=28'7'-+0 M4444 %%%% !1110 4444 %%%% "*V[-+110 4444 %%%% !7#>,&\OQ=I#]/ M]7^DAKN:X+QXW_%1Z0!U^7_T.OF>(7RX+F[2C^:/=R55?% $M%%% &=X@TL:QI,UOC]YC=&?1AT_P_&L+P#K0E ML9+&=MLMNWR;CR5)QC\#Q^(KK6&Y2.F?2O--5TNZT'Q7:W,K>9!-J/3**IZ MGJUMI,.^=^3]V->68^PKGIIM0U]L2%K2U/2&,_,1_M&OKDKGSJ5S6O\ Q19V M;F*/==S_ //.$9Q]3T%9LFK:O?9\L162#D\;V ]STJ]8Z-;V<8&T >B\#\3W MJOJ/B*PL898DG@(C4F8@AEB4==V/Y&AM1-8PN[)'(R:]=27!^T27AM@3^]\X M*6'J$'8^Y%=)?>'(+6S%R+N9UX.6D(R#WKPS7/'[*MP+"(!2[;&D8L 2 / MP[UVWA_Q/:^)=#A\J9KA80L-KU*52:=MNGW=SZ/,,OC MAZ<)PBUW.L17B_X][^X3_=EW"K=OXBU.Q(\PI?1]]PVO^8KC9DB7YD'E,.AC M.T_I4EGXB^SLT5RS2A<8D5P0*^>;[PUXVTO6;N&+PKXJUK1Y,O::HVDSDR M@L<%HECW1X!QC SM! YKM;JZU/5]:U?5;VXOK.[DG,<$CNNV2U!+1+Y)!";0 MY'][.XD\U[GXYUBPTG6M"EO_ !U>>'?+L[>1["WMIG290Q);*':-V",$'ISF MOQ;-L1@N(*E9U8I*E*,5+FC%V?-]J4N6VC=MWV/U3+:&*R>%+V><\K[5]->&=2T?Q_JWQ8U=[A-) M\-7UG8QR7*QJMPOEB82R.,'DKMV]>W&>6&<&<-&A&KAZO.I\MK6O[TFN9]HZ*V MEVWR]V>Y3SRO*O[&M3Y6N]_Y5*WG+5]=M3B[Z'4M/U-=-N=/NK;46956SE@9 M)26QM 0C.3D8XYS69J2R:!?2VUYI3VFH1=8KA# T9(S\R[=W((XXZUZ1\:]3 M-C^U5HJ3 0QW&H::D3,X&\GRSP,Y(X(^N/45QG[3-QJ#_&CQ9+:Z;>75I#-! M"]S#"S1K*;="J$@<$]AU_,5\_7R*K1A5E3O)QJ2@E;>*O[WX'IX?.*=9TU4L ME*"D]=F[:?B-^#^AV?C3QX--\07#HDW^D6\%BH\N<1_,T,S%=V,4X"-*LHJH]79?=?NUM?_AS\=SW,(YCC'4I-\BT5_P ;=DPHHHKZP^>"L7Q) MX5L_$EN5E41W*C$=PH^9?8^H]JVJ*Y\1AZ6*INC7CS1?1FU&M4P]15:4K21Y M=8^)M3\!33:9J41GA5"8#G@'^$@]U)ZCM^E>D:=?PZI8P7<#;HIE#+_@?<=* MS/$7@ZP\2KFX$D/0^M?*Y=0S'+,7]5G[^&?PO=Q[)];=.J6FI]!C:V"Q^']O#W*Z^);*7=KI M?K]YTU%%%?9'S(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%,\P[L=J?0 4444 %%%( MQPI- "T4R-BVE*!M&!2T4 % M(0&X-+10 BJ%Z"EHHH 1E#=:%4+P*6B@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "H9XV9@0,U-10(BAC* YZFI:** .D\)_ZJX_WA6_6!X3_ -5MJ M>QSU-PHHHK4R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K2*IP3@TZH MY(?,;.<4]1M4"@0M%%% PHSVHIOE_/NS0 ZDVCTI:* "CI37;:N:@DF)7D<4 M ''F=>,]:L]:J58ASL%-@$N?+.*@JU2;1Z"@!(VWKG&*=0!C@<44@"BBB@ H MHIGFC=MH ?1110 4457D8LY]J +%%00L0V.QJ>@ HHHH **** "BBB@ HHI MP8X% "UY=XZN+F'Q?;J4\WRRCP+W8$YQ_P!]9%>HUB:AX=2_\2Z?J3X*VT; MKW+9^7\LL?P%?.YY@JN/PT:5%V?-'[KZ_=O\CVLIQ5/!UY5*JNN5_?;]=OF: M]OYOV>/SBIFVC?MZ9[X]JDHHKZ"*Y4D>,W=W"BBBJ$%&!UQS110 4444 %8/ MBC4+?[.;'RA=7,O*Q_W/1B>V*L:]K7]FQK# /,O)>(T]/]H^U<9KEK-:64$X MN9DF>Y4S7"'DG#8!_P!G=M&.]88B4(493J*\;:KNCIP\)3JQ479WT-VQTMYI MC=7WLH["J^J>/-"T-DMVU&U%P[^6L7F@?-T^8]OQKAM3^)&I>&8Y M0CQW['##[2>5QU'&.#Q]/2O$=3&H>*]<@LK7;+>WLQ2*)Y J98DA+!'906JZE&+B\Y7RI@-L8&25 M /)(X!^I[5Y)=7\,+3P0/Y>W;YD<;X##MN /.#GK6W?_ +.?Q&L[.T2#PZ9U MM<.V+NV;,@#Z5PV@> ]?\;>)+_2M#LKA=5A@>=8& A;(8!E8R%0! MD]#W-?,YE4Q688A2E"4-+)6?S^\]_ QP^$HN,9*5M6[KY?<5M7U(MG# '.*2\D\T*RX 4# ^F1SS[5Y#XHTO4_#6L7>E:W:M8ZG:L M(YK=R&PQ (.5)4Y!R,'O7H&A_$QUM[>&>VWP(@B)1B9!MXR2>&SCVK?(ZF&P M.(]IB96MHO5]R,QC6Q5+EHJ]STB:XW+P<^]4VD5%( Y]W)^5QO7V(Z_P"?:NW\%W!B MU6: GY9DW8]Q_P#6)KS?1@S:M&<8V!B1^&/ZUZ#X.4R>((R.0J,3^6/ZUG,Y MYG?JOM7,_$KQ9;>#_"=S=SQ6]T\S+:0VURX6.9Y&"!6S_#R2>.@-=37EOQG\ M&W-Q'_PE5AMN;C3[4QSVJN 2<#[P 'H:\3-*N(H8.K4PL.:: M3LOZWMO;KL;X"G1JXJG#$2Y8-ZO^N_?H>-P6]_IL,%M+?Q/9V^XQI;QE"P)) M522S?*H.!SDX&3ZR_$OXA:AXTN(+B[=+0P6R6BK9Q\$(6*L0VX[OF/3 ]JPG MOX%C?[+< @_=]![US.IZHYN4A$,LCRG;&(5,A8X)QM'/0'M MVK^2_K&(J.5*+OSM-I+=J]M/FS^C?8T8*,Y+X=GV^?R.@T3XK:AX9\+>(-%L MTMKBVUJ)8+J6XC;S5V[AE<, #\QZ@]JH:#\1M=U/X9W_ (,FBTRZ\-ZE+YH6 M\CD>XM3D?-$RNH1@5W#((!SZD'C_ !AX-US3+'2MM6-]>+F\E(2Y269R" JH%*!V!'(( M4D=%%>(>';J:X>.)_+61FVKA^&].O3)[5V7@_1M4\4^)K)-+AFN+C3[N"XDN MI 4MK,)(C,"V,,[(2-HR2#V%>QD.=9M4S*E&-24[O5;W3MS-_A=O4\W.,KRZ M.!J2E!1LM'M9ZVM_DCZHHHHK^F#\("BBB@!&8*I). .235>QU2SU-7:SNH;I M4.UC#(' /H<5P_QZN+FU^%^K20,Z19C6Z:,X80%U$A'_ $\^V:\J\0^#=+L MO(OO#$K>')Y8!]DU/26\E\8P4?;@,,]0:^,SKB2&2UX4ZE.\6KMW\[:=_/U1 M]/E>1RS2E*<)V:=DOQ_KT9[1XY^)6F^!VM[5X;C4]8N@3;:78J&FD ZLT>,\BWO;J6>7'N5"@'\#7 ^ [YM)AOKV\N;C4?$ MM;;:QN)).2>YYK\\S'C:M5J/ZM+ECTVO\V[_ M ('VF!X5I4X+V\>:7S_#_@G1I\5_%FDMOU7PI;:E;#[TNB7P:0#N1'*%S^#5 MK3?'SP@NEV]S;WDU[>3[E32K>%FO%<'!5X^J$'CYL#ODBN&_M<#N*Y[PNT&F MZAKKF*,7T]X999]HW2(579D^@ QBLL/QQC*4)*;4GTNMONM$[*RMNJKJ6HGSB/=8T*J?^!&K%I\;+[3)H?^$E\/FQ MLI)%B;4+*X$T4)8@ N.&"Y(YQQFN9_M<>M4M9:UUS2;JPO 3:W$9CDVMM.T] MP>QKDI\:YA&HIRJ)KM9'1/A;!R@XQA9][L^B))HX5#2.L:YQN8X&?2GU\HQP MRZU:2ZGXOU2\\0_9T<6R7C!5AA'<*@4&0@9);VS8\N-G_B(&3[;L=J_5,GXDI9UB9T:%-\L5>_^9^?9GD=3*Z$ M*M::O)['H%%%%?9'S(4444 %%%% #.M+&VY#Y/,AN>,88?RKHJYSP;&8 MX;K/]X?RKHZYY;G5#X4%%%%06%%%% !1110 4444 5-6_P"0;<_]>34M% #?+7TIU% M% !1110 WS!NQ3LU'Y(W9[>E))&6;(H EHI!P *6@ IAB!;.:?10 4444 %1 MR1;FR#BI** &1Q[.3R:?110 4444 %%%% !139)$A0N[!$7DLQP!6!=>*O-8 MQZ;#]I;H9FXC'^--*XTFSH&QMY.!69=>)-.LLJ;A7?\ N1?,?TK$;3[S5/FO M;EY5_P">:G:GY=ZOVVDVUJO"J@_V1C]:=EU*Y1LGBN63_CUTZ9QV:8A*B_MW M5W^[;6J?[Q8_R-0WGB_PYH\K17.I6D,J\%6<$Y]/K6#?>+K36[IOWK)IZ+A8 M,LIE)_B=5P<>@/XBN#%8ZAA8WD]>USOP^#J8B5HQT[G2KK.M#DVUJX_V=P_K M4B^)KN'_ (^=+D _O0MN_2N,L_B FBY%N1_90?!\Y"/+RP7"WD.>/\ 9/:NUQ.) MQ.ZHJGI>JP:M;^;">1PR'JI]#5RH,PJKJ>H1Z7927$O11PO=CV%6JX_6KS^U M-7\H'-M:'&.S2?\ UJ:5QI7([&.2XF>[NCFXFY;_ &%[**H>-!+<:?##:G?= M^8'BB)PKX!SGTX/'OBM&:\CLH'EE;:BC)-<\M]-=:DTTX"?NZ#=7>G,]L+Z)#Y@&Z-BZX?;UP/7M7IWC*_CO\ 5H[-B'6UC\[RWZ&0 MGY6QWV@'GL6]:XN]OIK"\BNX7V3PNLJ/@'# Y!P>O(K\@QU.AEN/Y*3;46KW M_&UK'Z/A95<;A>:I9-W_ *9Z_P#$36O 7@WXUW?B2]A\2W/B:P972W@>!;*1 MS %7G_68P1GWSP1P9_A_<2>)/!GC/QJM_IN@7VNL]E9W6H7 @BMRQ)E DQG( M/ XY,=?,WC3Q)K'B[6[O4M6NVNKB=@9)M@B9L *HVJ !Z#.*+/X@>(-6\+ MVWAN>\C_ .$ND=;+RO^![G^T=X#A/PKYTNITTNZ! 5(I,Y5 < CN!6I-XL\3:AX-;PQ#?B/PVM MP+GRKB)"JR9SE'*[Q_P%@.3ZFL74F58RV=V5VAV//'^->=BZD*V(=6.BEJUV M;W_&]CMPU.5&C[.7V=GY=/P/3_AUJ7GZ!*WF,\/G%(PP.$ X&>G/Y5U,:O= M2".(;G/10:\+^&.L74/CC2K(7;QV4UQB2$N?+;(].F3@?I7T\JI'N"1JI/\ M=&*_5,EQ$:F#C!+X=-3X;,XNEB&W]K4JZ7I_V"-F8[I6^\1T'H*]#\!::T<, MUZXQYGR)]!U/Y_RK$\.^%YM6D664&*T!Y;NWL/\ &O1884MXDCC4(BC"J.PK MUY,\.3'T445!F:$DJ6MU .3GY@!AAGG#9YJQH7P_ M\,^%[HW.D:!INFW)!!FM;5$?!ZC5R=O4Y MCXD> =/^)/A&_P!#U"./$\9$-P\*R-;R8^610>X]L<9&:_/[=;:+JUUI]O=1 M7T4,\D4=Q;H52=58CS #R <9Y]17Z45P'B3X#^!_$FGRVKZ#:Z9@@G#D<]*^1XDX?>=0BZ32G&^KOKV7W^3/I,CSG^RY251-Q?:V MGG_3/CN._A^Q.DURELLB[1([ 8/8C/I7UU^SS97UC\+].&H6*V=Q([R^9M*O M=*3\L\@8DAF&#@GH!T' T_ ?P=\+_#Q9&TRQ,UW)]^\O2)9L#HH)'RCV4#WK MMJX>&.%YY'.5>K4YI25K):+Y[O\ #YG5GV?QS:,:-.%HQ=[MZOY;?F%%%%?H M9\8%%%% %?4;2'4-/N;6X@6Y@FB:.2%QE9%((*GV(XKY@^%*'5+;P_X:OC)# M+;ZM]AO+=R?,@#.%"$GDX4 ;N_!KZGKY6_:$U0^$OC5IU[H_^BW1@ MT4=.&G_: \/:WJ%MJWB'P% M:ZKK\.W=?0:A);+*4/R%H@I#$# .+Q_=^)KVSL[M;VW% MI=:>@9(I(0 -H)+$'CJ<]3QCBOS6IFF&]K1JO%.X^*)M5N/^$2NKM] M/\20)K4*1^)M-E3)0RX$4D:KA>3U5B,J,\GFGXD^+6O:9\9Y?#[W,=WH;W<- MHVGRV\95DD"AOFV[C]_N>WIQ7D5W\?K"UTW3-+\.^%XM!TFWU&/4;J#[:]P] MRZ,K!?,9Y>7_<2S?VGU,(9;67\7#\R MY9I?!HVTTVN:T>OP7MT70].TRW\/>#?C.NFOITEW=7>H^78MO @LQY7F$E>I M<$@*.F"#D$5S3Z+9^*OBUXHM;Y]0:&WN)G%OIELTT\QWX"@[2J#)&6? Z#(S MD>2K\7[JS^)FEZW=Q+J-S97#:E>QJ_EAY9%(6,'!V@+CL>@K>\/_ +0":1XD M\6WUSH:WVF^(MWGV(O&B=,EL 3*N<89@>!G(Z8Y\N./RZM"C2K)1@ISER\KL MHN*Y;\JU][2_O-*VCC9';]4QM&4ZE.\I>SC&]U\2>MK[::]+OJGJ=!^T#X3M M?A9H=M>VWVV2&]M)F:SO3&TT;*%R"R?*?OCIG&#R:]?^'FEOHO@/P]8R3I=2 M6]A"C31G*N0@R0>X/K7@]YXJF_:(OM!\'Z7I]KX6@T>VFD:X\\SC[,S*@1(V M7)%_#^G:1;.\EO8VZ6\;2'+%5 S^5?IG"6$I0Q. M)QF$A:A/EY7KT7O:.S^*^Z7DK'PO$>)J2HT,-B)7JPYN9>K]W576UNK\]32H M)P,T4C+N6OTP^$&>=[5(#D9J/8*Y]RG!J2W5BV"J$24445(P MHIJR*QP*=0 4444 %(R!NHS2T4 '3@4444 %%%% !1110 4444 %%%% !111 M0!TGA/\ U5Q_O"M^L#PG_JKC_>%;]<\MSJA\*"BBBH+"BBB@ HHHH **** * MFK?\@VY_ZYFN'KN-6_Y!MS_US-GN?:N>MK=O-:>=_-N7^](W\A5*/9C-GAMVE0<;F(4'Z#J:XKQQXXO]-CC2-4EOG!D:VSE+>(=689&YO0$BN9LM8C M\+ZX]]??:+M;B,1P2QAI-\O5BR\X/IV &*XJZTW5->M[[59$DM3 S3/YVY&F M8D\+[*OKQVKQ\=G2^KQ>&^*5_DE_F>MA>_/4_C7&V.H1P6T:1'$8&5SZ'FK MB:I_M5^72JRYFT]S[R-./*E;8ZK5-4ACTV\#JK!HI&VMT8A2?SKLM+N-NDV: M^:TN(5&]^IX[UY3)>07EO+;72%HI5VDJ<.O'53ZUHZ7XJNM/OH8YI_M=C(5B MY4*Z-T!XZ@\"OM.&\QHX>I*G6>L[)'S><8.I5BITUI&]STB2X5U(;D'M3])U MA+>9K:27]WQY98]#_=S6,]P)%!#<&HGD3R]N/J.U?J35SXAJ^AW=O?-I-\EW M#DKTE3^\O>O0(I5FB21#N1P&4CN#7DFBW37.FIYAW%
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a190430rsvmrna1172andmrna177.jpg begin 644 a190430rsvmrna1172andmrna177.jpg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a190502pipeline.jpg PIPELINE2 begin 644 a190502pipeline.jpg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end GRAPHIC 19 a0001193125183449821_image43.jpg begin 644 a0001193125183449821_image43.jpg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a0001193125183449821_image44.jpg begin 644 a0001193125183449821_image44.jpg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ɛ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end GRAPHIC 21 a0001193125183449821_image45.jpg begin 644 a0001193125183449821_image45.jpg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�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end GRAPHIC 22 a0001193125183449821_image46.jpg begin 644 a0001193125183449821_image46.jpg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end GRAPHIC 23 modernalogo.jpg begin 644 modernalogo.jpg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ⅅ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~~LCG']:VO#_ ,-_%'C"&,Z=H%Q?ANDGE[(<_P#71\*/ MSKV.'QW\+_ .5\,>$_[5NEY%W>+@$^H:3~~
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�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end XML 25 R1.htm IDEA: XBRL DOCUMENT v3.19.1

Document and Entity Information - shares
3 Months Ended

Mar. 31, 2019

Apr. 29, 2019

Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Mar. 31, 2019

Document Fiscal Year Focus 2019

Document Fiscal Period Focus Q1

Entity Registrant Name Moderna, Inc.

Entity Central Index Key 0001682852

Current Fiscal Year End Date --12-31

Entity Filer Category Non-accelerated Filer

Entity Emerging Growth Company true

Entity Ex Transition Period false

Entity Small Business false

Entity Common Stock, Shares Outstanding 329,003,270

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Document And Entity Information [Abstract]
+ References
No definition available.
+ Details

Name: mrna_DocumentAndEntityInformationAbstract

Namespace Prefix: mrna_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R2.htm IDEA: XBRL DOCUMENT v3.19.1

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Mar. 31, 2019

Dec. 31, 2018

Current assets:

Cash and cash equivalents $ 502,934 $ 658,364

Investments 605,990 863,063

Accounts receivable 5,646 11,686

Accounts receivable from related party 965 899

Prepaid expenses and other current assets 25,292 28,399

Restricted cash 0 595

Total current assets 1,140,827 1,563,006

Investments, non-current 437,659 172,990

Property and equipment, net 213,460 211,977

Restricted cash, non-current 11,823 11,532

Other non-current assets 2,438 2,644

Total assets 1,806,207 1,962,149

Current liabilities:

Accounts payable 38,509 31,210

Accrued liabilities 42,183 79,073

Deferred revenue 73,958 109,056

Other current liabilities 4,509 3,464

Total current liabilities 159,159 222,803

Deferred revenue, non-current 156,862 165,352

Deferred lease obligation, non-current 10,556 10,006

Lease financing obligation 33,384 33,489

Other non-current liabilities 213 258

Total liabilities 360,174 431,908

Commitments and contingencies (Note 7)

Stockholders’ equity:

Preferred stock, par value $0.0001; 162,000,000 shares authorized as of March 31, 2019 and December 31, 2018; no shares issued or outstanding at March 31, 2019 and December 31, 2018 0 0

Common stock, par value $0.0001; 1,600,000,000 shares authorized as of March 31, 2019 and December 31, 2018; 328,853,340 and 328,798,904 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively 33 33

Additional paid-in capital 2,556,709 2,538,155

Accumulated other comprehensive income (loss) 591 (1,320)

Accumulated deficit (1,111,300) (1,006,627)

Total stockholders’ equity 1,446,033 1,530,241

Total liabilities and stockholders’ equity $ 1,806,207 $ 1,962,149

X

- Definition
Lease Financing Obligation
+ References
No definition available.
+ Details

Name: mrna_LeaseFinancingObligation

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864
+ Details

Name: us-gaap_AccountsReceivableRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044
+ Details

Name: us-gaap_ContractWithCustomerLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.26(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 25
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707
+ Details

Name: us-gaap_DeferredRentCreditNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_RestrictedCashCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 305
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84242212&loc=d3e2352-115587
+ Details

Name: us-gaap_RestrictedCashNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R3.htm IDEA: XBRL DOCUMENT v3.19.1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares

Mar. 31, 2019

Dec. 31, 2018

Statement of Financial Position [Abstract]

Preferred stock, par value (usd per share) $ 0.0001 $ 0.0001

Preferred stock, shares authorized 162,000,000 162,000,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par value (usd per share) $ 0.0001 $ 0.0001

Common stock, shares authorized 1,600,000,000 1,600,000,000

Common stock, shares issued 328,853,340 328,798,904

Common stock, shares outstanding 328,853,340 328,798,904

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R4.htm IDEA: XBRL DOCUMENT v3.19.1

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Revenue:

Total revenue $ 16,025 $ 29,039

Operating expenses:

Research and development 130,575 90,124

General and administrative 27,283 16,317

Total operating expenses 157,858 106,441

Loss from operations (141,833) (77,402)

Interest income 10,972 5,209

Other expense, net (1,820) (183)

Loss before benefit from income taxes (132,681) (72,376)

Benefit from income taxes (24) 0

Net loss (132,657) (72,376)

Net loss attributable to common stockholders (Note 11) $ (132,657) $ (75,857)

Net loss per share attributable to common stockholders, basic and diluted (usd per share) $ (0.40) $ (1.16)

Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted 328,809,986 65,430,835

Collaboration revenue

Revenue:

Total revenue $ 13,301 $ 20,110

Collaboration revenue from related party

Revenue:

Total revenue 814 7,350

Grant revenue

Revenue:

Total revenue $ 1,910 $ 1,579

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599
+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=mrna_CollaborativeArrangementWithAffiliateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_GrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R5.htm IDEA: XBRL DOCUMENT v3.19.1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Statement of Comprehensive Income [Abstract]

Net loss $ (132,657) $ (72,376)

Other comprehensive income (loss):

Unrealized gain (loss) on available-for-sale debt securities, net of tax, $540 and $0 1,908 (1,999)

Less: Amounts recognized for net realized loss included in net loss 3 6

Total other comprehensive income (loss) 1,911 (1,993)

Comprehensive loss $ (130,746) $ (74,369)

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e689-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17A
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL34724391-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R6.htm IDEA: XBRL DOCUMENT v3.19.1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Statement of Comprehensive Income [Abstract]

Unrealized gain (loss) on available-for-sale debt securities, tax $ 540 $ 0

X

- Definition
Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e640-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R7.htm IDEA: XBRL DOCUMENT v3.19.1

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands

Total

Redeemable Convertible Preferred Stock

Common Stock

Additional Paid-In Capital

Accumulated Other Comprehensive (Loss) Income

Accumulated Deficit

Balance at beginning of period (in shares) at Dec. 31, 2017 448,686,791 65,206,999

Balance at beginning of period at Dec. 31, 2017 $ (551,365) $ 1,176,661 $ 6 $ 71,679 $ (1,157) $ (621,893)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Vesting of restricted common stock (in shares) 335,053

Vesting of restricted common stock 0

Issuance of Series G redeemable convertible preferred stock, net of issuance costs of $10,517 (in shares) 55,666,004

Issuance of Series G redeemable convertible preferred stock, net of issuance costs of $10,517 152 $ 549,413 152

Exercise of options to purchase common stock, net (in shares) 1,789

Exercise of options to purchase common stock, net 22 22

Stock-based compensation 11,851 11,851

Unrealized gain (loss) on marketable securities (1,993) (1,993)

Net loss (72,376) (72,376)

Balance at end of period (in shares) at Mar. 31, 2018 504,352,795 65,543,841

Balance at end of period at Mar. 31, 2018 (613,709) $ 1,726,074 $ 6 83,704 (3,150) (694,269)

Balance at beginning of period (in shares) at Dec. 31, 2018 0 328,798,904

Balance at beginning of period at Dec. 31, 2018 1,530,241 $ 0 $ 33 2,538,155 (1,320) (1,006,627)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Vesting of restricted common stock (in shares) 48,911

Vesting of restricted common stock $ 0

Exercise of options to purchase common stock, net (in shares) 5,525 5,525

Exercise of options to purchase common stock, net $ 57 57

Stock-based compensation 18,497 18,497

Unrealized gain (loss) on marketable securities 1,911 1,911

Net loss (132,657) (132,657)

Balance at end of period (in shares) at Mar. 31, 2019 0 328,853,340

Balance at end of period at Mar. 31, 2019 $ 1,446,033 $ 0 $ 33 $ 2,556,709 $ 591 $ (1,111,300)

X

- Definition
Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate value of stock related to Restricted Stock Awards issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 32 R8.htm IDEA: XBRL DOCUMENT v3.19.1

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical)
$ in Thousands
3 Months Ended

Mar. 31, 2018

USD ($)

Statement of Stockholders' Equity [Abstract]

Issuance costs $ 10,517

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 33 R9.htm IDEA: XBRL DOCUMENT v3.19.1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Operating activities

Net loss $ (132,657) $ (72,376)

Adjustments to reconcile net loss to net cash (used in) operating activities:

Stock-based compensation 18,497 11,851

Depreciation and amortization 7,328 5,153

Amortization of investment premiums (1,005) (83)

Loss on disposal of property and equipment 19 0

Changes in assets and liabilities:

Accounts receivable 6,040 3,876

Accounts receivable from related party (66) (28,529)

Prepaid expenses and other assets 3,313 (2,241)

Accounts payable 1,731 1,467

Accrued liabilities (32,557) (37,031)

Deferred revenue (15,604) 6,193

Deferred lease obligation 550 152

Other liabilities 484 183

Net cash used in operating activities (143,927) (111,385)

Investing activities

Purchases of marketable securities (429,517) (660,239)

Proceeds from maturities of marketable securities 403,940 189,814

Proceeds from sales of marketable securities 21,413 18,630

Purchases of property and equipment (7,595) (31,909)

Net cash used in investing activities (11,759) (483,704)

Financing activities

Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs 0 549,531

Proceeds from issuance of common stock through equity plans 57 22

Reimbursement of assets under lease financing obligation 0 1,727

Payments on financing lease obligation (105) (1,285)

Net cash (used in) provided by financing activities (48) 549,995

Net decrease in cash, cash equivalents and restricted cash (155,734) (45,094)

Cash, cash equivalents and restricted cash, beginning of year 670,491 147,608

Cash, cash equivalents and restricted cash, end of period 514,757 102,514

Non-cash investing and financing activities

Issuance costs included in accounts payable and accrued liabilities 796 0

Purchases of property and equipment included in accounts payable and accrued liabilities 14,127 28,527

Leasehold improvements included in prepaid and other current assets 10,089 9,889

Lease financing obligation $ 10,089 $ 9,889

X

- Definition
Increase (Decrease) In Deferred Rent Credit
+ References
No definition available.
+ Details

Name: mrna_IncreaseDecreaseInDeferredRentCredit

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Lease Financing Obligations Incurred
+ References
No definition available.
+ Details

Name: mrna_LeaseFinancingObligationsIncurred

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Leasehold Improvements Incurred But Not Yet Reimbursed
+ References
No definition available.
+ Details

Name: mrna_LeaseholdImprovementsIncurredButNotYetReimbursed

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Payments For Lease Financing Obligation
+ References
No definition available.
+ Details

Name: mrna_PaymentsForLeaseFinancingObligation

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Reimbursement Of Assets From Lease Financing Obligation
+ References
No definition available.
+ Details

Name: mrna_ReimbursementOfAssetsFromLeaseFinancingObligation

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Stock Issuance Costs Incurred But Not Yet Paid
+ References
No definition available.
+ Details

Name: mrna_StockIssuanceCostsIncurredButNotYetPaid

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Future cash outflow to pay for purchases of fixed assets that have occurred.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in operating liabilities classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562
+ Details

Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from the stock plan during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromStockPlans

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 34 R10.htm IDEA: XBRL DOCUMENT v3.19.1

Description of the Business
3 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of the Business
Description of the Business

Moderna, Inc. is a Delaware Corporation, incorporated under the laws of the State of Delaware on July 22, 2016 (collectively, with its consolidated subsidiaries, any of Moderna, Company, we, us or our). In August 2018, we changed our name from Moderna Therapeutics, Inc. to Moderna, Inc. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. We are creating a new generation of potentially transformative medicines based on messenger RNA (mRNA), to improve the lives of patients. Since inception, we have incurred significant net losses. We expect to continue to incur significant expenses and operating losses for the foreseeable future. In addition, we anticipate that our expenses will increase significantly in connection with our ongoing activities to support our platform research, drug discovery and clinical development, infrastructure and Research Engine and Early Development engine, digital infrastructure, creation of a portfolio of intellectual property, and administrative support.

We do not expect to generate significant revenue from sales of potential mRNA medicines unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our investigational medicines. If we seek to obtain regulatory approval for any of our investigational medicines, we expect to incur significant commercialization expenses.

As a result, we will need substantial additional funding to support our continued operations and pursue our growth strategy. Until we can generate significant revenue from potential mRNA medicines, if ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings, government funding arrangements, strategic alliances and marketing, distribution and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our programs. We believe that our cash, cash equivalents, and investments as of March 31, 2019 will be sufficient to enable us to fund our projected operations through at least the next 12 months from the issuance of these financial statements.

Because of the numerous risks and uncertainties associated with pharmaceutical development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenues from the sale of our medicines, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R11.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Basis of Presentation and Recent Accounting Standards
3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Summary of Basis of Presentation and Recent Accounting Standards
Summary of Basis of Presentation and Recent Accounting Standards

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in conformity with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2018 (2018 Form 10-K), except for changes associated with recent accounting standards for revenue recognition as detailed in "Note 2 - Recent Accounting Standards and Accounting Policies." This report should be read in conjunction with the consolidated financial statements in our 2018 Form 10-K.

We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, income tax provisions, stock-based compensation, and useful lives of long-lived assets. We base our estimates on historical experience and on various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results that we experience may differ materially from our estimates. The condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, but are not necessarily indicative of the results of operations to be anticipated for the full year ending December 31, 2019.

Recent Accounting Standards and Accounting Policies

Revenue Recognition

On January 1, 2019, we adopted Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606), using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. We recognized the cumulative effect of the adoption as an adjustment to the opening balance of accumulated deficit in the current period condensed consolidated balance sheet. Results for reporting periods beginning after January 1, 2019 are presented under ASC 606, while prior period amounts have not been adjusted and continue to be reported in accordance with our historic accounting under ASC Topic 605, Revenue Recognition (ASC 605). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.

Our revenue is primarily generated through collaboration arrangements and grants from government-sponsored and private organizations. Our collaboration arrangements typically contain multiple promises, including licenses to our intellectual property, options to obtain development and commercialization rights, research and development services, and obligations to develop and manufacture preclinical and clinical material. Such arrangements provide for various types of payments to us, including upfront payments, funding of research and development activities, funding for the purchase of preclinical and clinical material, development, regulatory and commercial milestone payments, licensing fees, option exercise payments, and royalties based on product sales. We have received grants from various government-sponsored and private organizations for research and related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin.

We analyze our collaboration arrangements to assess whether they are within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and our collaboration partner are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606. If we conclude that some or all aspects of the arrangement are within the scope of ASC 808 and do not represent a transaction with a customer, we recognize our allocation of the shared costs incurred with respect to the jointly conducted activities as a component of the related expense in the period incurred. Pursuant to ASC 606, a customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. If we conclude a counter-party to a transaction is not a customer or otherwise not within the scope of ASC 606 or ASC 808, we consider the guidance in other accounting literature as applicable or by analogy to account for such transaction. We also consider the guidance in ASC 606 with respect to principal versus agent considerations, in determining the appropriate treatment for the transactions between us and the strategic collaborator and the transactions between us and other third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, are accounted for as gross revenue.

We receive payments from our customers based on billing schedules established in each contract. Upfront payments and fees are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period when we perform our obligations under the arrangement. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current liabilities on our condensed consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities on our condensed consolidated balance sheets. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. As of March 31, 2019, we had not capitalized any costs to obtain any of our contracts.

Collaboration Revenue

To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following steps: (i) identify the contract(s) with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) each performance obligation is satisfied.

We account for a contract with a customer that is within the scope of ASC 606 when all of the following criteria are met: (i) the arrangement has been approved by the parties and the parties are committed to perform their respective obligations; (ii) each party’s rights regarding the goods and/or services to be transferred can be identified; (iii) the payment terms for the goods and/or services to be transferred can be identified; (iv) the arrangement has commercial substance; and (v) collection of substantially all of the consideration to which we will be entitled in exchange for the goods and/or services that will be transferred to the customer is probable. We also determine the term of the contract based on the period in which we and our customer have present and enforceable rights and obligations for purposes of identifying the performance obligations and determining the transaction price.

We evaluate contracts that contain multiple promises to determine which promises are distinct. Promises are considered to be distinct and therefore, accounted for as separate performance obligations, provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. In assessing whether a promise is distinct, we consider factors such as whether: (i) we provide a significant service of integrating goods and/or services with other goods and/or services promised in the contract; (ii) one or more of the goods and/or services significantly modifies or customizes, or are significantly modified or customized by one or more of the other goods and/or services promised in the contract; and (iii) the goods and/or services are highly interdependent or highly interrelated. Individual goods or services (or bundles of goods and/or services) that meet both criteria for being distinct are accounted for as separate performance obligations. Promises that are not distinct at contract inception are combined and accounted for as a single performance obligation. Options to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer’s election.

The transaction price is generally comprised of an upfront payment due at contract inception and variable consideration in the form of payments for our services and materials and milestone payments due upon the achievement of specified events. Other payments the Company could be entitled to include tiered royalties earned when customers recognize net sales of licensed products. We consider the existence of any significant financing component within our arrangements and have determined that a significant financing component does not exist in our arrangements as substantive business purposes exist to support the payment structure other than to provide a significant benefit of financing. We measure the transaction price based on the amount of consideration we expect to be entitled in exchange for transferring the promised goods and/or services to the customer. We utilize either the expected value method or the most likely amount method to estimate the amount of variable consideration, depending on which method is expected to better predict the amount of consideration to which we will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. With respect to arrangements that include payments for a development or regulatory milestone payment, we evaluate whether the associated event is considered probable of achievement and estimate the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within our control or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, we re-evaluate the probability of achievement of each milestone and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, wherein the license is deemed to be the sole or predominant item to which the payments relate, we recognize revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.

We generally allocate the transaction price to each performance obligation based on a relative standalone selling price basis. We develop assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated research and development costs. However, in certain instances, we allocate variable consideration entirely to one or more performance obligation if the terms of the variable consideration relate to the satisfaction of the respective performance obligation and the amount allocated is consistent with the amount we would expect to receive for the satisfaction of the respective performance obligation.

We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. For performance obligations that are satisfied at a point in time, we recognize revenue when control of the goods and/or services is transferred to the customer. For performance obligations that are satisfied over time, we recognize revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. We generally use input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. With respect to arrangements containing a license to our intellectual property that is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from amounts allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which we are expected to complete our performance obligations under an arrangement. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.

Grant Revenue

We have contracts with the U.S. government’s Defense Advanced Research Projects Agency (DARPA), Biomedical Advanced Research (BARDA), and the Bill & Melinda Gates Foundation (Gates Foundation). We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Revenues and related expenses are presented gross in the condensed consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.

Comprehensive Loss

Comprehensive loss includes net loss and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments. Total comprehensive loss for all periods presented has been disclosed in the condensed consolidated statements of comprehensive loss.

The components of accumulated other comprehensive loss for the three months ended March 31, 2019 are as follows (in thousands):

Unrealized Gain on Available-for-Sale Debt Securities
Accumulated other comprehensive loss, balance at December 31, 2018
$
(1,320
)
Other comprehensive income
1,911

Accumulated other comprehensive loss, balance at March 31, 2019
$
591

Emerging Growth Company Status

We are an “emerging growth company,” (EGC) as defined in the Jumpstart Our Business Startups Act, (JOBS Act), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. We may take advantage of these exemptions until we are no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. We have elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, our condensed consolidated financial statements may not be comparable to companies that comply with public company FASB standards’ effective dates. We may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of our initial public offering (IPO) or such earlier time that we are no longer an EGC.

Recently Adopted Accounting Standards

ASU No. 2014-09, Revenue from Contracts with Customers

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements in ASC 605 and most industry specific guidance. ASC 606 provides a single comprehensive model for use in accounting for revenue arising from contracts with customers. We adopted the new revenue standard on January 1, 2019 using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. We recognized the cumulative effect of the adoption as an adjustment to the opening balance of accumulated deficit in the first quarter of 2019. We have elected to use the practical expedient to aggregate the impact of all contract modifications that occurred prior to the ASC 606 adoption with respect to (i) identification of the satisfied and unsatisfied performance obligations, (ii) determination of the transaction price and (iii) allocation of the transaction price to the satisfied and unsatisfied performance obligations.

ASC 606 requires significant judgment and estimates and results in changes to, but not limited to: (i) the determination of the transaction price, including estimates of variable consideration, (ii) the allocation of the transaction price, including the determination of estimated selling price, and (iii) the pattern of recognition, including the application of proportional performance as a measure of progress on service-related promises and application of point-in-time recognition for supply-related promises. We recorded the cumulative-effect adjustment of $28.0 million to the opening balance of accumulated deficit as of January 1, 2019 with a corresponding decrease to deferred revenue. The effect of the adoption of ASC 606 on our condensed consolidated balance sheet is as follows (in thousands):
Condensed Consolidated Balance Sheet

Balance at December 31, 2018

Adjustments

Balance at
January 1, 2019
Deferred revenue, current

$
109,056

$
(27,281
)

$
81,775

Deferred revenue, non-current

165,352

(3,441
)

161,911

Accounts receivable

11,686

(2,738
)

8,948

Accumulated deficit

(1,006,627
)

27,984

(978,643
)

The cumulative-effect adjustment is primarily due to the application of ASC 606 to our strategic collaboration agreements, particularly our Combined 2018 AZ Agreements, 2016 VEGF Exercise and Merck PCV/SAV Agreement (see Note 3). In addition, as a result of the cumulative decrease in deferred revenue, our corresponding deferred tax asset was decreased by $8.4 million, which was offset by a corresponding decrease to our valuation allowance.

A substantial portion of the $28.0 million cumulative-effect adjustment is the result of the application of ASC 606 regarding the allocation of the transaction price and the measurement of progress in satisfying performance obligations. In particular, for the Combined 2018 AZ Agreements, the adoption of ASC 606 resulted in the decrease of previously deferred revenue of $39.9 million. For the Merck PCV/SAV Agreement, the adoption of ASC 606 resulted in a reversal of previously recognized revenue and an increase in deferred revenue of $13.9 million. These adjustments are due to the change in the way we allocate the transaction price to each performance obligation and measure our performance under each agreement from a straight-line method to a proportional performance model. In addition, the adoption of ASC 606 resulted in the decrease of $4.3 million of previously deferred revenue relating to the 2016 VEGF Exercise. Under ASC 605, the product option fee and the clinical milestone payment we received pursuant to the VEGF Exercise were deferred until the consideration pertaining to the clinical supply of mRNA can be reasonably estimated. Under ASC 606, we are required to estimate the total variable consideration to determine the total consideration and recognize the revenue as clinical supply is shipped to the customer based on the proportionate amount of the transaction price. As a result, the balance of remaining deferred revenues at January 1, 2019 was $75.7 million, $37.1 million and $125.2 million related to the Combined 2018 AZ Agreements, 2016 VEGF Exercise and the Merck PCV/SAV Agreement, respectively.

The following tables summarize the effects of adopting ASC 606 on our condensed consolidated financial statements at March 31, 2019, and for the three months ended March 31, 2019 (in thousands, except per share data):

March 31, 2019
Condensed Consolidated Balance Sheet

As reported under ASC 606

Adjustments

Balance without adoption of ASC 606
Deferred revenue, current

$
73,958

$
36,452

$
110,410

Deferred revenue, non-current

156,862

(29,840
)

127,022

Accumulated deficit

(1,111,300
)

(6,077
)

(1,117,377
)

Three Months Ended March 31, 2019
Condensed Consolidated Statement of Operations

As reported under ASC 606

Adjustments

Amount without adoption of ASC 606
Revenue:

   Collaboration revenue

$
13,301

$
(1,786
)

$
11,515

   Collaboration revenue from related party

814

24,377

25,191

Total revenue

16,025

21,907

37,932

Loss from operations

(141,833
)

21,907

(119,926
)
Loss before benefit from income taxes

(132,681
)

21,907

(110,774
)
Net (loss) income

(132,657
)

21,907

(110,750
)
Net loss per share - basic and diluted

(0.40
)

0.06

(0.34
)

ASU No. 2016-18, Statement of Cash Flows: Restricted Cash

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires the statement of cash flows to explain the change during the period in the total of cash, cash equivalents and restricted cash. When cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new standard requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet. This reconciliation can be presented either on the face of the statement of cash flows or in the notes to the financial statements. The new standard became effective for us on January 1, 2019. As a result of adopting this new standard using a retrospective transition method for each period presented, we include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed statements of cash flows.

The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows (in thousands):

As of March 31,

2019

2018
Cash and cash equivalents

$
502,934

$
90,479

Restricted cash

—

237

Restricted cash, non-current

11,823

11,798

Total cash, cash equivalents and restricted cash shown in the condensed consolidated
    statements of cash flows

$
514,757

$
102,514

ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting

In June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance generally consistent with the accounting for employee share-based compensation. The new standard will be effective for us on January 1, 2020, with early adoption permitted. We early adopted this standard in the first quarter of 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and disclosure.

ASU No. 2018-18, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606

In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which clarifies the interaction between Topic 808 and Topic 606, Revenue from Contracts with Customers. Currently, Topic 808 does not provide comprehensive recognition or measurement guidance for collaborative arrangements, and the accounting for those arrangements is often based on an analogy to other accounting literature or an accounting policy election. Similarly, aspects of Topic 606 have resulted in diversity in practice on the effect of the revenue standard on the accounting for collaborative arrangements. The standard will become effective for us beginning on January 1, 2021, with early adoption permitted. We early adopted this standard in connection with the adoption of ASC 606 in the first quarter of 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and disclosure.

Recently Issued Accounting Standards

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our condensed consolidated financial statements and disclosures.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes all existing lease guidance. This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. The new standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments. Lessees are required to classify leases as either finance or operating leases. If the lease is effectively a financed-purchase by the lessee, it is classified as a financing lease, otherwise it is classified as an operating lease. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. ASC 842 provides accounting guidance for transactions that meet specific criteria for a leaseback transaction. If the criteria are not met, the transaction is considered a “failed sale” and the transaction must be accounted for as a financing arrangement. The new standard will be effective for us on January 1, 2020, assuming we continue to qualify as an EGC.. Upon adoption, the new standard, as amended, allows lessees to apply the transition requirements either (1) retrospectively to each prior reporting period presented in the financial statements with the cumulative effect of applying the new rules recognized at the beginning of the earliest comparative period presented, or (2) retrospectively at the beginning of the period of adoption with the cumulative effect of applying the new rules recognized then. We are currently evaluating the potential impact ASU 2016-02 may have on our financial position and results of operations. Our assessment will include, but is not limited to, evaluating the impact this standard has on the lease of our corporate headquarters at 200 Technology Square in Cambridge, MA, the lease of our office and laboratory space at 500 Technology Square, Cambridge, MA and our manufacturing and additional facilities in Norwood, MA, (see Note 7), and the identification of any embedded leases.

In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (ASU 2016-13). ASU 2016-13 will change how companies account for credit losses for most financial assets and certain other instruments. For trade receivables, loans and held-to-maturity debt securities, companies will be required to recognize an allowance for credit losses rather than reducing the carrying value of the asset. Assuming we continue to qualify as an EGC, ASU 2016-13 will be effective for us for fiscal years beginning after December 15, 2020, , including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 will have on the Company’s financial position and results of operations.

In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Topic 350): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This standard requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This standard should be applied either retrospectively or prospectively, and will be effective for us in January 2021, assuming we continue to qualify as an EGC, with early adoption permitted. We are currently evaluating the potential impact this standard may have on our condensed consolidated financial statements and results of operations upon adoption.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R12.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration Agreements
3 Months Ended

Mar. 31, 2019

Research and Development [Abstract]

Collaboration Agreements
Collaboration Agreements

The following table summarizes our total consolidated net revenues from our strategic collaborators for the periods presented (in thousands):

Three Months Ended
Collaboration Revenue by Strategic Collaborator:

March 31, 2019
as reported
(under ASU 606)

March 31, 2019
without adoption of 606
(under ASC 605)

March 31, 2018
as reported
(under ASC 605)
Merck

$
10,687

$
11,515

$
15,967

AstraZeneca

814

25,191

7,350

Vertex

2,614

—

4,143

Total collaborative revenue

$
14,115

$
36,706

$
27,460

The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the three months ended March 31, 2019 (in thousands):

January 1, 2019

Additions

Deductions

March 31, 2019
Contract Assets:

Accounts receivable

$
4,612

$
2,735

$
(3,747
)

$
3,600

Contract Liabilities:

Deferred revenue

$
240,924

$
1,137

$
(13,582
)

$
228,479

During the three months ended March 31, 2019, we recognized the following revenues as a result of the change in the contract liability balances related to our collaboration agreements (in thousands):
Revenue recognized in the period from:

Three Months Ended March 31, 2019
Amounts included in contract liabilities at the beginning of the period ⁽¹⁾

$
13,582

⁽¹⁾ We first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period first applies to the beginning contract liability.

As of March 31, 2019, the aggregated amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied was $279.5 million.

AstraZeneca – Strategic Alliances in Cardiovascular and Oncology

2013 Option Agreement and Services and Collaboration Agreement

In March 2013, we entered into an Option Agreement, the AZ Option Agreement, and a related Services and Collaboration Agreement, the AZ Services Agreement, with AstraZeneca, which were amended and restated in June 2018. We refer to these agreements in the forms that existed prior to the 2018 amendment and restatement as the 2013 AZ Agreements. Under the 2013 AZ Agreements, we granted AstraZeneca certain exclusive rights and licenses, and options to obtain exclusive rights to develop and commercialize potential therapeutic mRNA medicines directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services to AstraZeneca. Pursuant to the 2013 AZ Agreements, AstraZeneca was responsible for all research, development and commercialization activities, while we provided specified research and manufacturing services during a research and evaluation period, as described below, to further AstraZeneca’s activities pursuant to an agreed upon services plan. Under the 2013 AZ Agreements, AstraZeneca could have requested we provide additional services, at AstraZeneca’s expense. Subject to customary “back-up” supply rights granted to AstraZeneca, we exclusively manufactured (or had manufactured) mRNA for all research, development and commercialization purposes under the 2013 AZ Agreements until, on a product-by-product basis, the expiration of the time period for which we are entitled to receive earn-out payments with respect to such product pursuant to the 2013 AZ Agreements.

As of the effective date of the 2013 AZ Agreements, AstraZeneca acquired forty options that it may exercise to obtain exclusive rights to clinically develop and commercialize identified development candidates (and related back-up candidates) directed to specified targets that arise during the research and evaluation period. During the research and evaluation period for research candidates under the 2013 AZ Agreements, AstraZeneca could have elected to designate a limited number of research candidates as development candidates in order to continue preclinical development on such development candidates (and related back-up candidates). From such pool of development candidates designated by AstraZeneca, during a specified option exercise period, AstraZeneca could have then exercised one of its options to obtain exclusive rights to clinically develop and commercialize an identified development candidate (and related back-up candidates). If AstraZeneca did not exercise one of its options to acquire exclusive rights to clinically develop and commercialize a particular development candidate during the defined option exercise period for such development candidate, AstraZeneca’s rights to exercise an option and other rights granted under the 2013 AZ Agreements with respect to such development candidate (and related back-up candidates) would terminate, all rights to exploit such development candidate (and related back-up candidates) would be returned to us and all data and results generated by AstraZeneca with respect to such development candidate (and related back-up candidates) would be either assigned or licensed to us. Upon the earlier of termination of the 2013 AZ Agreements for any reason and a specified anniversary of the effective date of the 2013 AZ Agreements, all unexercised options, and the right to exercise any and all options if not previously exercised by AstraZeneca, would automatically terminate. On a target-by-target basis, we and AstraZeneca agreed to certain defined exclusivity obligations under the 2013 AZ Agreements with respect to the research, development and commercialization of mRNA medicines for such target.

As of the effective date of the 2013 AZ Agreements, AstraZeneca made upfront cash payments to us totaling $240.0 million. Under the 2013 AZ Agreements, we were entitled to receive payments that are not related to any specific program of up to $180.0 million in the aggregate for the achievement of three technical milestones relating to toxicity, delivery, and competition criteria. We achieved the toxicity and competition milestones in the year ended December 31, 2015. The delivery milestone has expired. Under the 2013 AZ Agreements, AstraZeneca was obligated to pay us a $10.0 million option exercise fee with respect to each development candidate (and related back-up candidates) for which it exercised an option. In addition, upon AstraZeneca’s exercise of each option, we were eligible to receive certain payments contingent upon the achievement of specified clinical, regulatory, and commercial events. For any product candidate optioned by AstraZeneca, we were eligible to receive, per product candidate, up to $100.0 million in payments for achievement of development milestones, up to $100.0 million payments for achievement of regulatory milestones, and up to $200.0 million payments for achievement of commercial milestones. Additionally, under the 2013 AZ Agreements, we were entitled to receive, on a product-by-product basis, earn-out payments on worldwide net sales of products ranging from a high-single digit percentage to 12%, subject to certain reductions, with an aggregate minimum floor.

We received from AstraZeneca under the 2013 AZ Agreements an option exercise payment of $10.0 million in the year ended December 31, 2016, and a clinical milestone payment of $30.0 million with respect to AstraZeneca’s VEGF-A product (AZD8601) during the year ended December 31, 2018, that is currently being developed in a Phase 2 clinical trial in certain fields.
Unless earlier terminated, the 2013 AZ Agreements would have continued until the expiration of AstraZeneca’s earn-out and contingent option exercise payment obligations for optioned product candidates. Either party had the right to terminate the 2013 AZ Agreements upon the other party’s material breach, either in its entirety or in certain circumstances, with respect to relevant candidates, subject to a defined materiality threshold and specified notice and cure provisions. If AstraZeneca had the right to terminate the 2013 AZ Agreements for our material breach, then AstraZeneca could have elected, in lieu of terminating the 2013 AZ Agreements, in their entirety or with respect to such candidates, to have the 2013 AZ Agreements remain in effect, subject to reductions in certain payments we were eligible to receive and certain adjustments to AstraZeneca’s obligations under the 2013 AZ Agreements. AstraZeneca had the right to terminate the 2013 AZ Agreements in full, without cause, upon 90-days’ prior notice to us.

2016 Strategic Alliance with AstraZeneca – IL12

In January 2016, we entered into a new Strategic Drug Development Collaboration and License Agreement, which we refer to as the 2016 AZ Agreement, with AstraZeneca to discover, develop and commercialize potential mRNA medicines for the treatment of a range of cancers.

Under the terms of the 2016 AZ Agreement, we and AstraZeneca have agreed to work together on an immuno-oncology program focused on the intratumoral delivery of a potential mRNA medicine to make the IL12 protein. The 2016 AZ Agreement initially included research activities with respect to a second discovery program. During a limited period of time, each party had an opportunity to propose additional discovery programs to be conducted under the 2016 AZ Agreement. We are responsible for conducting and funding all discovery and preclinical development activities under the 2016 AZ Agreement in accordance with an agreed upon discovery program plan for the IL12 program and any other discovery program the parties agree to conduct under the 2016 AZ Agreement. For the IL12 program and any other discovery program the parties agree to conduct under the 2016 AZ Agreement, during a defined election period that commenced as of the effective date of the 2016 AZ Agreement (for the IL12 program) and otherwise will commence on initiation of any such new discovery program, AstraZeneca may elect to participate in the clinical development of a development candidate arising under the 2016 AZ Agreement from such program. If AstraZeneca so elects (as it has for the IL12 program), AstraZeneca will lead clinical development activities worldwide and we will be responsible for certain activities, including being solely responsible for manufacturing activities, all in accordance with an agreed upon development plan. AstraZeneca will be responsible for funding all Phase 1 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan), and Phase 2 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan) up to a defined dollar threshold. We and AstraZeneca will equally share the costs of Phase 2 clinical development activities in excess of such dollar threshold, all Phase 3 clinical development activities and certain other costs of late-stage clinical development activities, unless we elect not to participate in further development and commercialization activities and instead receive tiered royalties, as described below.

We and AstraZeneca will co-commercialize products in the U.S. in accordance with an agreed upon commercialization plan and budget, and on a product-by-product basis will equally share the U.S. profits or losses arising from such commercialization. Notwithstanding, on a product-by-product basis, prior to a specified stage of development of a given product, we have the right to elect not to participate in the further development and commercialization activities for such product. If we make such election, instead of participating in the U.S. profits and losses share with respect to such product, we are obligated to discuss future financial terms with AstraZeneca. If we are unable to agree on future financial terms within a short, defined period of time, we are entitled to receive tiered royalties at default rates set forth in the 2016 AZ Agreement, ranging from percentages in the mid-single digits to 20% on worldwide net sales of products, subject to certain reductions with an aggregate minimum floor. AstraZeneca has sole and exclusive responsibility for all ex-U.S. commercialization efforts. Unless we have elected to not to participate in further development (in which case royalties on ex-U.S. net sales will be at the default rates as described above, unless otherwise agreed by the parties), we are entitled to tiered royalties at rates ranging from 10% to 30% on ex-U.S. net sales of the products, subject to certain reductions with an aggregate minimum floor. Subject to customary “back-up” supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) products for all development and commercialization purposes. We and AstraZeneca have agreed to certain defined exclusivity obligations with each other under the 2016 AZ Agreement with respect to the development and commercialization of mRNA medicines for IL12.

Unless earlier terminated, our strategic alliance under the 2016 AZ Agreement will continue on a product-by-product basis (i) until both parties cease developing and commercializing such product without the intention to resume, if we have not elected our right not to participate in further development and commercialization of such product or (ii) on a country-by-country basis, until the end of the applicable royalty term for such product in such country, if we have elected our right not to participate in further development and commercialization of such product.

Either party may terminate the 2016 AZ Agreement upon the other party’s material breach, subject to specified notice and cure provisions. Each party may also terminate the 2016 AZ Agreement in the event the other party challenges such party’s patent rights, subject to certain defined exceptions. AstraZeneca has the right to terminate the 2016 AZ Agreement in full or with respect to any program for scientific, technical, regulatory or commercial reasons at any time upon 90 days’ prior written notice to us. On a product-by-product basis, we have the right to terminate the 2016 AZ Agreement in certain cases if AstraZeneca has suspended or is no longer proceeding with the development or commercialization of such product for a period of twelve consecutive months, subject to specified exceptions, including tolling for events outside of AstraZeneca’s control. On a product-by-product basis, if the 2016 AZ Agreement is terminated with respect to a given product, AstraZeneca’s rights in such product will terminate and, to the extent we terminated for AstraZeneca’s breach, patent challenge or cessation of development or AstraZeneca terminated in its discretion, AstraZeneca will grant us reversion licenses and take certain other actions so as to enable us to continue developing and commercializing such product in the oncology field.

If we continue developing and commercializing a given product following termination of the 2016 AZ Agreement by AstraZeneca in its discretion with respect to such product, AstraZeneca is entitled to receive a mid-single digit royalty on our worldwide net sales of such product and a high-single digit percentage of the amounts received by us from a third party in consideration of a license to such third party to exploit such product, in each case, until AstraZeneca recovers an amount equal to specified development costs incurred by AstraZeneca under the 2016 AZ Agreement with respect to such product prior to such termination. Such percentages increase by a low to mid-single digit amount to the extent such termination occurs after such product achieves a specified stage of development.

2017 Strategic Alliance with AstraZeneca – Relaxin

In October 2017, we entered a new Collaboration and License Agreement, which we refer to as the 2017 AZ Agreement, under which AstraZeneca may clinically develop and commercialize a development candidate, now known as AZD7970, which is comprised of an mRNA construct for the relaxin protein designed by us and encapsulated in one of our proprietary lipid nanoparticles ("LNP"). We discovered and performed preclinical development activities for AZD7970 prior to the initiation of the strategic alliance with AstraZeneca under the 2017 AZ Agreement.

Under the terms of the 2017 AZ Agreement, we will fund and be responsible for conducting preclinical development activities for AZD7970 through completion of IND-enabling GLP toxicology studies and AstraZeneca will lead pharmacological studies, each in accordance with an agreed upon discovery program plan. During a defined election period that commences as of the effective date of the 2017 AZ Agreement, AstraZeneca may elect to participate in further development and commercialization of AZD7970. Upon such election, AstraZeneca will lead clinical development activities for AZD7970 worldwide and we will be responsible for manufacturing AZD7970, certain regulatory matters and any other development activities that we agree to perform and that are set forth in an agreed upon development plan. AstraZeneca will be responsible for funding Phase 1 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan, up to a cap above which such costs are shared), and Phase 2 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan, up to a cap above which such costs are shared) up to a defined dollar threshold. Thereafter, we and AstraZeneca will equally share the costs of Phase 2 clinical development activities in excess of such defined dollar threshold, all Phase 3 clinical development activities and certain other costs of late-stage clinical development activities, unless we elect not to participate in further development and co-commercialization activities and instead receive tiered royalties as described below. If the development candidate is determined to be IND-ready, and AstraZeneca does not timely elect to participate in the clinical development of AZD7970, AstraZeneca is obligated to reimburse us for certain costs we incurred in the manufacture and development of AZD7970, since execution of the 2017 AZ Agreement.

We and AstraZeneca will co-commercialize AZD7970 in the United States in accordance with an agreed upon commercialization plan and budget, and will equally share U.S. profits or losses arising from such commercialization. Notwithstanding, prior to a specified stage of development of AZD7970, we have the right to elect not to participate in the further development and commercialization activities for AZD7970. If we make such election, instead of participating in the U.S. profits and losses share with respect to AZD7970, we are obligated to discuss future financial terms with AstraZeneca. If we are unable to agree on future financial terms within a short, defined period of time, we are entitled to receive tiered royalties at default rates set forth in the 2017 AZ Agreement, ranging from percentages in the mid-single digits to the low 20s on worldwide net sales by AstraZeneca of AZD7970, subject to certain reductions, with an aggregate minimum floor. AstraZeneca has sole and exclusive responsibility for all ex-U.S. commercialization efforts. Unless we have elected not to participate in further development (in which case royalties on ex-U.S. net sales will be at the default rates as described above, unless otherwise agreed by the parties), we are entitled to receive tiered royalties at rates ranging from 10% to 30% on annual ex-U.S. net sales of AZD7970, subject to certain reductions with an aggregate minimum floor. Subject to customary “back-up” supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) products for all development and commercialization purposes. Additionally, we and AstraZeneca have agreed to certain defined exclusivity obligations under the 2017 AZ Agreement with respect to the development and commercialization of mRNA medicines for Relaxin.

Unless earlier terminated, our strategic alliance under the 2017 AZ Agreement will continue (i) until the expiration of AstraZeneca’s election period, if it does not elect to participate in the clinical development of AZD7970, (ii) until both parties cease developing and commercializing AZD7970 without the intention to resume, if we have not elected our right not to participate in further development and commercialization of AZD7970, (iii) on a country-by-country basis, until the end of the applicable royalty term for AZD7970 in such country, if we have elected our right not to participate in further development and commercialization of AZD7970 or (iv) following completion of IND-enabling studies with respect to AZD7970, if we provide AstraZeneca with written notice that we do not reasonably believe that the product is IND-ready.

Either party may terminate the 2017 AZ Agreement upon the other party’s material breach, subject to specified notice and cure provisions. Each party may also terminate the 2017 AZ Agreement in the event the other party challenges the validity or enforceability of such party’s patent rights, subject to certain defined exceptions. AstraZeneca has the right to terminate the 2017 AZ Agreement in full for scientific, technical, regulatory or commercial reasons at any time upon 90 days’ prior written notice to us. We have the right to terminate the 2017 AZ Agreement in certain cases if AstraZeneca has suspended or is no longer proceeding with the development or commercialization of AZD7970 for a period of twelve consecutive months, subject to specified exceptions, including tolling for events outside of AstraZeneca’s control. If AstraZeneca does not timely elect to participate in clinical development of AZD7970, or the Agreement is terminated, AstraZeneca’s rights in AZD7970 will terminate and, to the extent we terminated for AstraZeneca’s breach, patent challenge or cessation of development or AstraZeneca terminated in its discretion, AstraZeneca will grant us reversion licenses and take certain other actions so as to enable us to continue developing and commercializing AZD7970 in the cardiovascular and cardiometabolic fields.

If we continue developing and commercializing AZD7970 following a termination of the 2017 AZ Agreement by AstraZeneca in its discretion, AstraZeneca is entitled to receive a mid-single digit royalty on our worldwide net sales of AZD7970 and a high-single digit percentage of the amounts received by us from a third party in consideration for a license to such third party to exploit AZD7970, in each case until AstraZeneca recovers an amount equal to specified development costs incurred by AstraZeneca under the 2017 AZ Agreement with respect to AZD7970 prior to such termination. Such percentages increase by a low to mid-single digit amount to the extent such termination occurs after such product achieves a specified stage of development.

2013 Agreements with AstraZeneca, amended and restated in 2018

In June 2018, we entered into an Amended and Restated Option Agreement and a related Amended and Restated Services and Collaboration Agreement with AstraZeneca, or the 2018 A&R Agreements, which amended and restated the 2013 AZ Agreements. Under the 2018 A&R Agreements, we granted AstraZeneca certain exclusive rights and licenses to research, develop and commercialize potential therapeutic mRNA medicines directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services to AstraZeneca. The activities to be performed by the parties under the 2018 A&R Agreements are limited to defined biological targets in the cardiovascular and cardiometabolic fields and one defined target in the cancer field.

Pursuant to the 2018 A&R Agreements, AstraZeneca is responsible for all research, development and commercialization activities and associated costs, while we provide specified research and manufacturing services during a research and evaluation period, as described below, to further AstraZeneca’s activities conducted pursuant to an agreed upon services plan. During this research and evaluation period, these research services, and manufacturing services in excess of a specified threshold, are provided at AstraZeneca’s expense, and manufacturing services below the specified threshold are provided at no additional expense to AstraZeneca. AstraZeneca may request we provide additional research and manufacturing services, at AstraZeneca’s expense, following the end of the research and evaluation period. Subject to customary “back-up” supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) mRNA for all research, development and commercialization purposes under the 2018 A&R Agreements until, on a product-by-product basis, the expiration of the time period for which we are entitled to receive earn-out payments with respect to such product pursuant to the 2018 A&R Agreements.

As of the effective date of the 2013 AZ Agreements, and as further reflected in the 2018 A&R Agreements, AstraZeneca acquired forty options that it may exercise to obtain exclusive rights to clinically develop and commercialize identified development candidates (and related back-up candidates) directed to specified targets that arise during the research and evaluation period. During the research and evaluation period for research candidates, AstraZeneca may elect to designate a limited number of research candidates as development candidates in order to continue preclinical development on such development candidates (and related back-up candidates). From such pool of development candidates designated by AstraZeneca, during a specified option exercise period, AstraZeneca may then exercise one of its options to obtain exclusive rights to clinically develop and commercialize an identified development candidate (and related back-up candidates) in certain fields. If AstraZeneca does not exercise one of its options to acquire exclusive rights to clinically develop and commercialize a particular development candidate during the defined option exercise period for such development candidate, AstraZeneca’s rights to exercise an option and other rights granted under the 2018 A&R Agreements with respect to such development candidate (and related back-up candidates) will terminate, all rights to exploit such development candidate (and related back-up candidates) will be returned to us and all data and results generated by AstraZeneca with respect to such development candidate (and related back-up candidates) will be either assigned or licensed to us. Upon the earlier of termination of the 2018 A&R Agreements for any reason and a specified anniversary of the effective date of the 2013 AZ Agreements, all unexercised options, and the right to exercise any and all options if not previously exercised by AstraZeneca, will automatically terminate.

On a target-by-target basis, we and AstraZeneca have agreed to certain defined exclusivity obligations under the 2018 A&R Agreements with respect to the research, development and commercialization of mRNA medicines for such target in certain fields. In addition, we and AstraZeneca have agreed to certain defined exclusivity obligations with respect to the research, development and commercialization of mRNA medicines coding for the same polypeptide as any development candidate being developed under the 2018 A&R Agreements.

Unless earlier terminated, the 2018 A&R Agreements will continue until the expiration of AstraZeneca’s earn-out and contingent option exercise payment obligations for optioned product candidates. Either party may terminate the 2018 A&R Agreements upon the other party’s material breach, either in its entirety or in certain circumstances, with respect to relevant candidates, subject to a defined materiality threshold and specified notice and cure provisions. If AstraZeneca has the right to terminate the 2018 A&R Agreements for our material breach, then AstraZeneca may elect, in lieu of terminating the 2018 A&R Agreements, in their entirety or with respect to such candidates, to have the 2018 A&R Agreements remain in effect, subject to reductions in certain payments we are eligible to receive and certain adjustments to AstraZeneca’s obligations under the 2018 A&R Agreements. AstraZeneca may terminate the 2018 A&R Agreements in full, without cause, upon 90 days’ prior notice to us.

Accounting Treatment

For periods prior to January 1, 2019, we applied the provisions of ASC 605 in accounting for these arrangements, except for the 2017 AZ Agreement which was accounted for under ASC 808. In August 2016, AstraZeneca exercised a product option available pursuant to the 2013 AZ Agreements to obtain exclusive rights to clinically develop and commercialize the VEGF-A product (AZD8601). This option exercise is referred to as the 2016 VEGF Exercise. Consistent with our conclusions under ASC 605 and pursuant to ASC 606, we determined that the 2016 VEGF Exercise and the 2017 AZ Agreement should be accounted for as separate transactions as the agreements are not interrelated or interdependent. Conversely, the 2013 Agreements, as amended by the 2018 A&R Agreements, and the 2016 AZ Agreement, were combined for accounting purposes and treated as a single agreement, as these agreements were negotiated in contemplation of each other. As of the date of our initial application of ASC 606, we applied the practical expedient to include the aggregate effect of all modifications to the arrangement that occurred before January 1, 2019 with respect to (i) identification of the satisfied and unsatisfied performance obligations, (ii) determination of the transaction price and (iii) allocation of the transaction price to the satisfied and unsatisfied performance obligations. Therefore, we aggregated effects of all the modifications prior to January 1, 2019 to the 2013 Agreements, including the effects of the 2018 A&R Agreements, and the 2016 AZ Agreement were combined into one transaction for accounting purposes. We will refer to this combined transaction as the Combined 2018 AZ Agreements. We determined that all aspects of Combined 2018 AZ Agreements and the 2016 VEGF Exercise represent a transaction with a customer and therefore is accounted for in accordance with ASC 606 as of the date of the initial application.

Combined 2018 AZ Agreements

We identified the following performance obligations in the Combined 2018 AZ Agreements: (i) a combined performance obligation that includes a research license, research and development pool services, and manufacturing obligations related to the 2013 AZ Agreements, as amended by the 2018 A&R Agreements, collectively referred to as the Combined 2018 AZ Agreement Performance Obligation, (ii) preclinical development services for IL12, (iii) preclinical development services for an oncology development target, (iv) a combined performance obligation for a development and commercialization license and manufacturing obligations for IL12, and (v) a material right to receive development and commercialization rights and manufacturing services for an oncology development target.

We concluded that the research license is not distinct from the research and development pool services or the manufacturing obligations related to the 2018 A&R Agreements, as AstraZeneca cannot fully exploit the value of the research license without receipt of such services and supply. Our services and supply involve specialized expertise, particularly as it relates to mRNA technology that is not available in the marketplace. Any supply requested by AstraZeneca in excess of the minimum quantities specified in the agreement are considered customer options and treated as separate contracts for accounting purposes. Further, we concluded that AstraZeneca cannot exploit the value of the development and commercialization license for IL12 without receipt of supply as the development and commercialization license does not convey to AstraZeneca the right to manufacture and therefore combined the development and commercialization license and the manufacturing obligations for IL12 into one performance obligation.

As of January 1, 2019, the date of initial adoption of ASC 606, the total transaction price was determined to be $400.0 million comprised of the $240.0 million in upfront payments pertaining to the 2013 AZ Agreements and $160.0 million of variable consideration comprised of $40.0 million of estimated reimbursement for IL12 manufacturing obligations and $120.0 million of milestone payments ($60.0 million toxicity milestone and $60.0 million competition milestone), received prior to the adoption date of ASC 606. We utilize the most likely amount method to determine the amount of reimbursement for IL12 manufacturing obligations to be received. We determined that any sales-based royalties related to IL12 will be recognized when the related sales occur as they were determined to relate predominately to the license granted and therefore have been excluded from the transaction price. In addition, we are eligible to receive future milestones and royalties on future commercial sales for optioned product candidates under the 2018 A&R Agreements and future royalties under the 2016 Agreement; however, these amounts are not considered variable consideration under the Combined 2018 Agreements as we are only eligible to receive such amounts if AstraZeneca exercises its options (including certain options that are deemed to be material rights). We have concluded that the exercise of an optioned product candidate represents a separate transaction under ASC 606. We will re-evaluate the transaction price at the end of each reporting period. There was a $0.3 million increase to the transaction price resulting from a change in estimate of the variable consideration during the three months ended March 31, 2019.

The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. We developed the estimated standalone selling price for the licenses included in the Combined 2018 AZ Agreement Performance Obligation and the combined performance obligation for a development and commercialization license and manufacturing obligations for IL12 primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success and the time needed to commercialize a product candidate pursuant to the associated license. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the performance obligation, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated costs, adjusted for a reasonable profit margin that would be expected to be realized under similar contracts. The estimated standalone selling price of the material right to receive development and commercialization rights and manufacturing services for an oncology development target was developed by estimating the amount of discount that AstraZeneca would receive when exercising the option and adjusting such amount by the likelihood that the option will be exercised.

The transaction price allocated to each performance obligation was as follows: (i) $292.4 million to the Combined 2018 AZ Agreement Performance Obligation, (ii) $8.1 million to the preclinical development services for IL12 performance obligation, (iii) $8.1 million to the preclinical development services for an oncology development target performance obligation, (iv) $89.8 million to the combined performance obligation for a development and commercialization license and manufacturing obligations for IL12, and (v) $1.6 million to the material right to receive development and commercialization rights and manufacturing services for an oncology development target. As part of the allocation of the transaction price to each of the performance obligations, we concluded that the $60.0 million toxicology milestone and the estimated reimbursement for IL12 manufacturing costs can be allocated entirely to specific performance obligations because the variable payment relates specifically to our effort to satisfy the performance obligation and such allocation is consistent with the allocation objectives of ASC 606.

We measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for the Combined 2018 AZ Agreement Performance Obligation and the preclinical development services for IL12 and the other oncology target performance obligations. We recognize revenue related to the amounts allocated to the combined performance obligation for a development and commercialization license and manufacturing obligations for IL12 based on the point in time upon which control of supply is transferred to AstraZeneca for each delivery of the associated supply.

We recognize revenue for the Combined 2018 AZ Agreement Performance Obligation, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend. This ratio is applied to the transaction price allocated to this combined performance obligation. We also estimate the development plan, including expected demand from AstraZeneca, and the associated costs for this combined performance obligation, as we will satisfy this combined performance obligation as the manufacturing services are performed. Management has applied significant judgment in the process of developing our budget estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up.

For the three months ended March 31, 2019 and 2018, we recognized collaboration revenue of $0.8 million and $7.4 million, respectively, from the Combined 2018 AZ Agreements. The revenue recognized for the three months ended March 31, 2019 includes the amortization of deferred revenue due to the satisfaction of our performance obligation during the period. As of March 31, 2019, the aggregate amount of the transaction price allocated to the remaining performance obligations that are unsatisfied is $112.5 million. $102.8 million is expected to be recognized as revenue through December 31, 2027 and $9.7 million is expected to be recognized as revenue at the earlier of expiration or modification of the Combined 2018 AZ Agreement. We had deferred revenue of $75.5 million and $115.6 million as of March 31, 2019 and December 31, 2018, respectively, from the Combined 2018 AZ Agreements, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the services are expected to be performed or control of the supply is expected to be transferred.

2016 VEGF Exercise

We concluded that the 2016 VEGF Exercise should be treated as a separate transaction for accounting purposes. We identified one performance obligation in this arrangement which is comprised of the exclusive license to develop and commercialize VEGF and the manufacturing of clinical supply. We concluded that the VEGF license is not distinct from the manufacturing obligations because AstraZeneca cannot fully exploit the value of the license without receipt of such supply. This is due to limitations inherent in the licenses conveyed wherein AstraZeneca does not have the contractual right to manufacture during the term of the agreement.

As of January 1, 2019, the date of initial adoption of ASC 606, the total transaction price was determined to be $55.1 million comprised of the $40.0 million in fixed payments pertaining to a $10.0 million option exercise fee and a $30.0 million milestone achieved prior to the adoption of ASC 606 and $15.1 million of variable consideration related to the estimated reimbursement for clinical supply. We are eligible to receive future milestones and royalties on future commercial sales under this arrangement. We utilize the most likely amount method to estimate any development and regulatory milestone payments to be received and the amount of estimated reimbursement for clinical supply. As of January 1, 2019, there were no milestones that had not been achieved included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or AstraZeneca’s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. We will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. When a milestone payment is included in the transaction price in the future, it will be recognized as revenue based on the relative completion of the underlying performance obligation. There were no changes to the transaction price during the three months ended March 31, 2019.

We recognize revenue related to the amount of the transaction price allocated to the VEGF Exercise performance obligation based on the point in time upon which control of supply is transferred to AstraZeneca for each delivery of the associated supply.

For the three months ended March 31, 2019 and 2018, we did not recognize any collaboration revenue from the 2016 VEGF Exercise. As of March 31, 2019, the aggregate amount of the transaction price allocated to the remaining performance obligation that is unsatisfied is $51.0 million, which is expected to be recognized as revenue through December 31, 2023. We had deferred revenue of $37.1 million and $41.2 million as of March 31, 2019 and December 31, 2018, respectively, from the 2016 VEGF Exercise, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the control of the supply is expected to be transferred.

2017 AZ Agreement

We concluded the 2017 AZ Agreement is under the scope of ASC 808 as we and AstraZeneca are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on commercial success of the activities of the arrangement. Additionally, we determined the development, manufacturing and commercialization activities are not deliverables under ASC 606. As a result, the activities conducted pursuant to the development, manufacturing and commercialization activities are accounted for as a component of the related expense in the period incurred. We considered the guidance in ASC 606 by analogy in determining the appropriate treatment for the transactions between us and AstraZeneca and concluded that reimbursement for transactions in which we are considered to be principal because we control a promised good or service before transferring that good or service to the customer, are accounted for as gross revenue.

We did not recognize any revenue from the 2017 AZ Agreement for the three months ended March 31, 2019 and 2018, respectively.

Merck – Strategic Alliances in Infectious Diseases and Cancer Vaccines

2015 Strategic Alliance with Merck – Infectious Disease

In January 2015, we entered into a Master Collaboration and License Agreement with Merck, which was amended in January 2016, June 2016, and May 2019, and which we refer to, as amended, as the 2015 Merck Agreement. Pursuant to the 2015 Merck Agreement, we and Merck have agreed to research, develop, and commercialize potential mRNA medicines for the prevention of infections by RSV. Pursuant to the 2015 Merck Agreement, Merck is primarily responsible for research, development, and commercialization activities and associated costs of such research and commercialization. We are responsible for designing and manufacturing all mRNA constructs for preclinical and Phase 1 and Phase 2 clinical development purposes, and Merck pays us for such manufacture, and we are responsible for certain costs associated with the conduct of a Phase 1 clinical trial for a RSV vaccine product candidate (mRNA-1172). Responsibility for manufacturing mRNA constructs for late stage clinical development and commercialization purposes is to be determined.

The 2015 Merck Agreement includes a three-year period, expected to end on January 12, 2022, during which Merck may continue to preclinically and clinically develop RSV vaccine product candidates that arose during an initial four-year research period which terminated in January 2019. Merck may, prior to the end of this three-year period, elect to exclusively develop and commercialize up to five RSV vaccine product candidates.

We and Merck have agreed to certain defined exclusivity obligations during the term of the 2015 Merck Agreement with respect to potential mRNA medicines against RSV infection. As part of the May 2019 amendment of the 2015 Merck Agreement, these exclusivity obligations do not restrict Moderna from researching, developing, and commercializing a potential mRNA medicine for the prevention of a specific set of respiratory infections, including RSV, for the pediatric population.

Under the terms of the 2015 Merck Agreement, we received a $50.0 million upfront payment. We are eligible to receive, on a product-by-product basis, up to $300.0 million in aggregate milestone payments upon the achievement of certain development, regulatory, and commercial milestone events. To date, we have received from Merck a clinical milestone payment of $5.0 million with respect to the initiation of a Phase 1 clinical trial for a Merck RSV vaccine product candidate. In addition, under the terms of the 2015 Merck Agreement, we are eligible to receive an additional milestone payment unless Merck elects not to continue with further clinical development of mRNA-1172. On a product-by-product basis, we are also entitled to receive royalties on Merck’s net sales of products at rates ranging from the mid-single digits to low teens, subject to certain reductions, with an aggregate minimum floor. Additionally, concurrent with entering into the 2015 Merck Agreement in 2015, Merck made a $50.0 million equity investment in us, and concurrent with amending the 2015 Merck Agreement in January 2016, we received an upfront payment of $10.0 million from Merck.

Unless earlier terminated, the 2015 Merck Agreement will continue on a product-by-product and country-by-country basis for so long as royalties are payable by Merck on a given product in a given country. Either party may terminate the 2015 Merck Agreement upon the other party’s material breach, either in its entirety or with respect to a particular program, product candidate, product or country, subject to specified notice and cure provisions. Merck may terminate the 2015 Merck Agreement in full or with respect to a particular product candidate or product upon certain advance notice to us for any reason, or earlier if Merck determines the alliance or product is no longer commercially practicable. If Merck has the right to terminate the 2015 Merck Agreement, in its entirety or with respect to a program, product candidate or product, for our material breach, then Merck may elect, in lieu of terminating the 2015 Merck Agreement, to have the 2015 Merck Agreement remain in effect, subject to reductions in certain payments we are eligible to receive with respect to the terminable rights. Upon a termination of the 2015 Merck Agreement with respect to a program, all licenses and other rights granted to Merck with respect to such program will terminate and the continued development and commercialization of product candidates and products will revert to us. If the 2015 Merck Agreement is terminated with respect to a given product candidate or product, all licenses and other rights granted to Merck with respect to such product candidate or product will terminate and, to the extent we terminated for Merck’s breach, Merck will grant us licenses under select Merck technology for our continued development and commercialization of such product candidate or product. As a part of the May 2019 amendment of the 2015 Merck Agreement, we and Merck agreed to and conclude the collaboration as it relates to development of potential mRNA medicines for other viruses, including mRNA-1278 for the prevention of VZV infection.

Accounting Treatment

For periods prior to January 1, 2019, we applied the provisions of ASC 605 in accounting for this arrangement. As of the date of our initial application of ASC 606, we applied the practical expedient to include the aggregate effect of all modifications to the arrangement that occurred before January 1, 2019 with respect to (i) identification of the satisfied and unsatisfied performance obligations, (ii) determination of the transaction price and (iii) allocation of the transaction price to the satisfied and unsatisfied performance obligations. Additionally, we determined that all aspects of amended 2015 Merck Agreement represent a transaction with a customer and therefore the amended 2015 Merck Agreement is accounted for in accordance with ASC 606 as of the date of the initial application. As of the date of initial adoption of ASC 606, the four-year research period was substantially complete and we concluded there were no unsatisfied performance obligations pertaining to the amended 2015 Merck Agreement. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) research services during the three-year period following the initial four-year research period during which Merck may continue to preclinically and clinically develop product candidates and (ii) clinical mRNA supply for Phase 1 and Phase 2 and/or non-cGMP mRNA supply beyond the initial four-year research period. Therefore, such options will be accounted for as a separate contract upon the customer’s election. After completion of the initial four-year research period and as a part of the May 2019 amendment of the 2015 Merck Agreement, Merck elected to establish a new RSV vaccine product candidate and to conduct a Phase 1 clinical trial. We and Merck agreed to focus the collaboration activities on RSV and discontinue the collaboration as it relates to the development of development candidates for other viruses.

As of the date of initial application of ASC 606, the total transaction price of $65.0 million comprised of the $60.0 million in aggregate upfront payments, including $50.0 million related to research and development funding plus a $10.0 million funding from the 2016 amendment of the 2015 Merck Agreement, and a $5.0 million payment pertaining to achievement of a development milestone during the year ended December 31, 2017, which had been allocated entirely to the satisfied performance obligation and recognized in full. We utilize the most likely amount method to estimate any development and regulatory milestone payments to be received. As of January 1, 2019, there were no milestones that had not been achieved included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or Merck’s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. We will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. When a milestone payment is included in the transaction price in the future, it will be recognized as revenue based on the relative completion of the underlying performance obligation. There were no changes to the transaction price during the three months ended March 31, 2019.

We had no deferred revenue as of March 31, 2019 or December 31, 2018 from the amended Merck 2015 Agreement as all performance obligations under the amended 2015 Merck Agreement were completed. For the three months ended March 31, 2018, we recognized collaboration revenue of $2.0 million from the amended 2015 Merck Agreement.

Additionally, we recognized collaboration revenue of $0.5 million for the three months ended March 31, 2019, pursuant to separate agreements with Merck related to the exercise of customer options to purchase clinical mRNA supply to further develop a product candidate after the initial four-year research period. Clinical mRNA supply is recognized as collaboration revenue at a point in time upon which control of supply is transferred to Merck for each delivery of the associated supply.

We are currently evaluating the accounting related to the May 2019 amendment of the 2015 Merck Agreement.

2016 Cancer Vaccine Strategic Alliance—Personalized mRNA Cancer Vaccines

In June 2016, we entered into a personalized mRNA cancer vaccines (PCV) Collaboration and License Agreement with Merck Sharp & Dohme Corp., or Merck, which we refer to as the PCV Agreement, to develop and commercialize PCVs for individual patients using our mRNA vaccine and formulation technology. Under the strategic alliance, we identify genetic mutations present in a particular patient’s tumor cells, synthesize mRNA for these mutations, encapsulate the mRNA in one of our proprietary LNPs and administer to each patient a unique mRNA cancer vaccine designed to specifically activate the patient’s immune system against her or his own cancer cells.

Pursuant to the PCV Agreement, we are responsible for designing and researching PCVs, providing manufacturing capacity and manufacturing PCVs, and conducting Phase 1 and Phase 2 clinical trials for PCVs, alone and in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget and under the oversight of a committee comprised of equal representatives of each party. The parties have entered into a clinical quality agreement with respect to Moderna’s manufacture and supply activities. We received an upfront payment of $200.0 million from Merck. In November 2017, we and Merck announced the achievement of a key milestone for the first-in-human dosing of a PCV (mRNA-4157) as a part of the alliance. The Phase 1 open-label, dose escalation, multicenter clinical trial in the United States (KEYNOTE-603) is designed to assess the safety, tolerability and immunogenicity of mRNA-4157 alone in subjects with resected solid tumors and in combination with KEYTRUDA, in subjects with unresectable solid tumors.

Until the expiration of a defined period of time following our completion of Phase 1 and Phase 2 clinical trials for PCVs under the PCV Agreement and delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of PCVs by making a $250.0 million participation payment to us. If Merck exercises its election and pays the participation payment, then the parties will equally co-fund subsequent clinical development of PCVs, with Merck primarily responsible for conducting clinical development activities under a jointly agreed development plan and budget. Each party may also conduct additional clinical trials for PCVs that are not included in the jointly agreed development plan and budget, in which case the non-conducting party will reimburse the conducting party for half of the total costs for such trials, plus interest, from its share of future profits resulting from sales of such PCVs, if any. Merck will lead worldwide commercialization of PCVs, subject to Moderna’s option to co-promote PCVs in the United States, and the parties will equally share the profits or losses arising from worldwide commercialization. Until a PCV becomes profitable, we may elect to defer payment of our share of the commercialization and related manufacturing costs and instead reimburse Merck for such costs, plus interest, from our share of future profits resulting from sales of such PCV, if any. Subject to customary “back-up” supply rights granted to Merck, we will manufacture (or have manufactured) PCVs for preclinical and clinical purposes. Manufacture of PCVs for commercial purposes will be determined by the parties in accordance with the terms of the PCV Agreement. Under the PCV Agreement, we grant certain licenses to Merck to perform its collaboration activities.

If Merck does not exercise its right to participate in future development and commercialization of PCVs, then Moderna will retain the exclusive right to develop and commercialize PCVs developed during the strategic alliance, subject to Merck’s rights to receive a percentage in the high teens to the low 20s, subject to reductions of our net profits on sales of such PCVs. During a limited period following such non-exercise, Merck has the right to perform clinical studies of such PCVs in combination with KEYTRUDA, for which we agree to use reasonable efforts to supply such PCVs. During such limited period, we also have the right to perform clinical studies of PCVs in combination with KEYTRUDA, for which Merck agrees to use reasonable efforts to supply KEYTRUDA. In addition, following its non-exercise, Merck is also entitled to receive a percentage in the high teens to the low 20s, subject to reductions, of our net profits on sales of certain PCVs first developed by us following such non-exercise and reaching a specified development stage within a defined period of time.

We and Merck have agreed to certain defined, limited exclusivity obligations with respect to the development and commercialization of PCVs.

2018 Expansion of the Cancer Vaccine Strategic Alliance—Shared Neoepitope Cancer Vaccines

In April 2018, we and Merck agreed to expand our cancer vaccine strategic alliance to include the development and commercialization of our KRAS vaccine development candidate, mRNA-5671, and potentially other shared neoantigen mRNA cancer vaccines (SAVs). We preclinically developed mRNA-5671 prior to its inclusion in the cancer vaccine strategic alliance and it is comprised of a novel mRNA construct designed by us and encapsulated in one of our proprietary LNPs. The PCV Agreement was amended and restated to include the new SAV strategic alliance (PCV/SAV Agreement).

We have granted Merck certain licenses and we and Merck have agreed to certain exclusivity obligations with respect to SAVs and particular SAV programs, which obligations are subject to termination or expiration upon certain triggering events.
Under the PCV/SAV Agreement, Merck will be responsible for conducting Phase 1 and Phase 2 clinical trials for mRNA-5671 and for all costs associated with such activities, in accordance with a jointly agreed development plan and budget, and we will be responsible for manufacturing and supplying all mRNA-5671 required to conduct such trials and for all costs and expenses associated with such manufacture and supply. Under the PCV/SAV Agreement, our budgeted commitment for PCVs increased to $243.0 million. Until the expiration of a defined period of time following the completion of Phase 1 and Phase 2 clinical trials for mRNA-5671 under the PCV/SAV Agreement and our delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of mRNA-5671 by making a participation payment to us. If Merck exercises its participation rights, then the parties will equally co-fund subsequent clinical development of mRNA-5671, with Merck primarily responsible for conducting clinical development activities under a jointly agreed development plan and budget. If Merck declines to participate in future development and commercialization activities following the initial Phase 1 and Phase 2 clinical trials for mRNA-5671, then we will retain the rights to develop and commercialize mRNA-5671. If Merck elects to participate in future development and commercialization of mRNA-5671, Merck may also conduct additional clinical trials for mRNA-5671 that are not included in the jointly agreed development plan and budget, in which case we will reimburse Merck for half of the total development costs for such clinical trials, plus interest, from our share of future profits resulting from sales of mRNA-5671, if any. If Merck does conduct additional clinical trials for mRNA-5671, we will be responsible for manufacturing and supplying all mRNA-5671 required to conduct such trials. Merck will lead worldwide commercialization of mRNA-5671, subject to our option to co-promote mRNA-5671 in the United States, and the parties will equally share the operating profits or losses arising from worldwide commercialization. Until mRNA-5671 becomes profitable, we may elect to defer payment of our share of the commercialization and related manufacturing costs and instead reimburse Merck for such costs, plus interest, from our share of future profits resulting from sales of mRNA-5671, if any. Subject to “back-up” supply rights granted to Merck, we will manufacture (or have manufactured) mRNA-5671 and other SAVs for preclinical and clinical purposes. After Merck exercises its right to participate in future development and commercialization of mRNA-5671 and other SAVs, we will grant the applicable development and commercialization licenses and the parties are obligated to discuss responsibility for future manufacturing, giving consideration to applicable criteria.

Pursuant to the PCV/SAV Agreement, for a defined period of time, either party may propose that the parties conduct additional programs for the research and development of SAVs directed to different shared neoantigens. If the parties agree to conduct any such programs, then we will be responsible for conducting and funding preclinical discovery and research activities for such SAVs, and otherwise the programs would be conducted on substantially the same terms as mRNA-5671 program. If we or Merck propose a new SAV program and the other party does not agree to conduct such program, then the PCV/SAV Agreement includes provisions allowing the proposing party to proceed with such development, at the proposing party’s expense. If Merck is the proposing party, we will be responsible for manufacturing and supplying material for such program at Merck’s expense. In such case, the non-proposing party will have the right to opt-in to such SAV program any time before the proposing party commits to performing Good Laboratory Practice (GLP)-toxicity studies. Until the expiration of a defined period of time following our completion of Phase 1 and Phase 2 clinical trials for any SAV program mutually agreed by the parties under the PCV/SAV Agreement and our delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of such SAV by making a participation payment to us.

Unless earlier terminated, the PCV/SAV Agreement will continue on a program-by-program basis until Merck terminates its participation in such program. Following any such termination, we will retain the exclusive right to develop and commercialize PCVs or SAVs developed as a part of such program, subject to restrictions and certain limited rights retained by Merck.

In connection with the amendment of the PCV Agreement to include the development and commercialization of mRNA-5671 and potentially other SAVs, Merck made a contemporaneous equity investment in our Series H redeemable convertible preferred stock, resulting in gross proceeds of $125.0 million, of which $13.0 million is determined to be a premium and recorded to deferred revenue.

Accounting Treatment

We determined that the PCV/SAV Agreement should be accounted for separately from the amended 2015 Merck Agreement, as the agreements were not negotiated in contemplation of one another and the elements within each of the agreements are not closely interrelated or interdependent on each other.

For periods prior to January 1, 2019, we applied the provisions of ASC 605 in accounting for this arrangement. As of the date of our initial application of ASC 606, we applied the practical expedient to include the aggregate effect of all modifications to the arrangement that occurred before January 1, 2019 with respect to: (i) identification of the satisfied and unsatisfied performance obligations, (ii) determination of the transaction price and (iii) allocation of the transaction price to the satisfied and unsatisfied performance obligations. Additionally, we determined that all aspects of the PCV/SAV Agreement represent a transaction with a customer and therefore the PCV/SAV Agreement is accounted for in accordance with ASC 606 as of the date of the initial application. Further, the equity investment in our Series H redeemable convertible preferred stock was considered together with the PCV/SAV Agreement as the transactions were executed contemporaneously in contemplation of one another. Further, the purchase price paid by Merck with respect to the investment in the Series H redeemable convertible preferred stock was not representative of fair value on the date of such purchase. As such, the incremental proceeds received in excess of the fair value of the underlying stock related to the equity investment were included in the transaction price related to the PCV/SAV Agreement and the shares of Series H redeemable convertible preferred stock purchased by Merck were recorded at their respective fair value on the date of issuance.

We identified the following performance obligations in the PCV/SAV Agreement: (i) a research license and research and development services, including manufacturing and supply of PCVs, during the proof of concept (POC) term for the PCV program, referred to as the PCV Performance Obligation, and (ii) research license and manufacturing and supply of mRNA-5671 during the POC term for the KRAS program, referred to as the KRAS Performance Obligation. We concluded that the research license is not distinct from the research and development services, including manufacturing and supply of PCVs, during the POC term for the PCV program, as Merck cannot fully exploit the value of the license without receipt of such services and supply. Our services and supply involve specialized expertise, particularly as it relates to mRNA technology that is not available in the marketplace. Therefore, the research license has been combined with the research and development services, including manufacturing and supply of PCVs, during the POC term for the PCV program, into a single performance obligation. Similarly, we concluded that the research license is not distinct from the manufacturing and supply of mRNA-5671 during the POC term for the KRAS program, as Merck cannot fully exploit the value of the license without receipt of such supply which must be provided by us. This is due to limitations inherent in the licenses conveyed wherein Merck does not have the contractual right to manufacture during the POC term. Therefore, the research license has been combined with the manufacturing and supply of mRNA-5671, during the POC term for the KRAS program, into a single performance obligation. Conversely, we concluded that the PCV Performance Obligation and the KRAS Performance Obligation are distinct from each other because Merck can fully exploit the value of each program for its intended purpose without the promises associated with the other program. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) Merck participation election license related to future joint development and commercialization on a program-by-program basis, (ii) manufacturing and supply in support of certain SAV programs and/or the PCV program upon Merck election to not participate in future development and commercialization of that program and (iii) research and development services associated with certain SAV programs. Therefore, such options will be accounted for as a separate contract upon the customer’s election.

As of January 1, 2019, the date of initial application of ASC 606, the total transaction price was determined to be $213.0 million comprised of the $200.0 million upfront payment pertaining to the PCV Agreement and the premium associated with the contemporaneous sale of Series H redeemable convertible preferred stock of $13.0 million. We determined there are no components of variable consideration that should be included in the transaction price as of the date of initial application, as additional consideration to which we could be entitled is subject to Merck’s election to exercise a customer option that was deemed to be a marketing offer. We will re-evaluate the transaction price at the end of each reporting period. There were no changes to the transaction price during the three months ended March 31, 2019.

The transaction price was allocated to the performance obligations based on the relative estimated standalone selling price of each performance obligation. We developed the estimated standalone selling price for the license included in each of the PCV Performance Obligation and the KRAS Performance Obligation primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success and the time needed to commercialize a product candidate pursuant to the associated license. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the PCV Performance Obligation and the KRAS Performance Obligation, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated cost, adjusted for a reasonable profit margin that would be expected to be realized under similar contracts.

The transaction price allocated to each performance obligation was as follows: (i) $206.3 million to the PCV Performance Obligation and (ii) $6.7 million allocated to the KRAS Performance Obligation. We will recognize revenue related to amounts allocated to the PCV Performance Obligation over time as the underlying services are performed using a proportional performance model. We measure proportional performance using an input method based on the costs incurred relative to the total estimated costs of research and development efforts. We recognize revenue related to the amounts allocated to the KRAS Performance Obligation based on the point in time upon which control of supply is transferred to Merck for each delivery of the associated supply.

For the three months ended March 31, 2019 and 2018, we recognized collaboration revenue of $10.2 million and $14.0 million, respectively, in the condensed consolidated statements of operations, from the Merck PCV/SAV Agreement. The revenue recognized during the three months ended March 31, 2019 includes $10.2 million related to the amortization of deferred revenue due to the satisfaction of our performance during the period. As of March 31, 2019, the aggregate amount of the transaction price allocated to the remaining performance obligations that are unsatisfied is $115.0 million, which is expected to be recognized as revenue through December 31, 2021. We had deferred revenue of $115.0 million and $111.3 million, as of March 31, 2019 and December 31, 2018, respectively, from the Merck PCV/SAV Agreement, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the services are expected to be performed or control of the supply is expected to be transferred.

Vertex – 2016 Strategic Alliance in Cystic Fibrosis

In July 2016, we entered into a Strategic Collaboration and License Agreement, with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited, together, Vertex, which we refer to as the Vertex Agreement. The Vertex Agreement is aimed at the discovery and development of potential mRNA medicines for the treatment of cystic fibrosis (CF) by enabling cells in the lungs of people with CF to produce functional CFTR proteins.

Pursuant to the Vertex Agreement, we lead discovery efforts during a three-year research period, leveraging our Platform technology and mRNA delivery expertise along with Vertex’s scientific experience in CF biology and the functional understanding of CFTR. Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Subject to customary “back-up” supply rights granted to Vertex, we exclusively manufacture (or have manufactured) mRNA for preclinical, clinical and commercialization purposes. The parties established a joint steering committee to oversee and coordinate activities under the Vertex Agreement. We and Vertex have granted each other certain licenses under the Vertex Agreement.

Under the terms of the Vertex Agreement, we received a $20.0 million upfront payment from Vertex. Vertex has the right to extend the initial three-year research period by one additional year by making an additional payment to us. We are eligible to receive up to $55.0 million in payments for achievement of development milestones, up to $220.0 million in payments for achievement of regulatory milestones and potentially could receive an additional $3.0 million milestone payment for achievement of a regulatory milestone for second and each subsequent product under the Vertex Agreement. Vertex will also pay us tiered royalties at rates ranging from the low- to high-teens on worldwide net sales of products arising from the strategic alliance, subject to certain reductions, with an aggregate minimum floor. In connection with the strategic alliance, Vertex also made a $20.0 million equity investment in our Series F redeemable convertible preferred stock. During the term of the Vertex Agreement, we and Vertex have agreed to certain defined exclusivity obligations under the Vertex Agreement with respect to the development and commercialization of certain mRNA medicines.

Unless earlier terminated, the Vertex Agreement will continue until the expiration of all royalty terms. Vertex may terminate the Vertex Agreement for convenience upon 90 days’ prior written notice, except if termination relates to a product in a country where Vertex has received marketing approval, which, in such case, Vertex must provide 180 days’ prior written notice. Either party may terminate the Vertex Agreement upon the other party’s material breach, subject to specified notice and cure provisions. Each party may also terminate the Vertex Agreement in the event that the other party challenges the validity or enforceability of such party’s patent rights, subject to certain exceptions, or if the other party becomes insolvent.

Accounting Treatment

For periods prior to January 1, 2019, we applied the provisions of ASC 605 in accounting for this arrangement. As of the date of the initial application of ASC 606, we determined that all aspects of the arrangement with Vertex represent a transaction with a customer and therefore should be accounted for in accordance with ASC 606. We identified one performance obligation comprised of: (i) a research, development and commercialization license and (ii) research and development services, including manufacturing and supply of non-cGMP mRNA, during the initial three-year research period. We concluded that the license is not distinct from the research and development services, including manufacturing and supply of non-cGMP mRNA, during the initial three-year research period, as Vertex cannot fully exploit the value of the license without receipt of such services and supply. Our services and supply involve specialized expertise, particularly as it relates to mRNA technology that is not available in the marketplace. Therefore, the license has been combined with the research and development services, including manufacturing and supply of non-cGMP supply, into a single performance obligation. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) Vertex’s right to extend the research period for an additional year and (ii) clinical mRNA supply and/or non-cGMP mRNA supply beyond the initial three-year research period. Therefore, such options will be accounted for as a separate contract upon the customer’s election.

As of January 1, 2019, the date of initial application of ASC 606, the total transaction price was determined to be $24.4 million, comprised of the $20.0 million upfront payment and $4.4 million in research and development funding related to the research and development services and supply of non-cGMP mRNA. We utilize the most likely amount method to determine the amount of research and development funding to be received. We also utilize the most likely amount method to estimate any development and regulatory milestone payments to be received. As of January 1, 2019, there were no milestones included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or Vertex’s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. We will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. There were no changes to the transaction price during the three months ended March 31, 2019.

The transaction price was allocated entirely to the single performance obligation. We recognize revenue related to amounts allocated to the single performance obligation over time as the underlying services are performed using a proportional performance model. We measure proportional performance using an input method based on the costs incurred relative to the total estimated costs of the research and development efforts.

For the three months ended March 31, 2019 and 2018, we recognized collaboration revenue of $2.6 million and $4.1 million, respectively, in the condensed consolidated statements of operations, from Vertex. The revenue recognized during the three months ended March 31, 2019 includes $2.6 million related to the amortization of the deferred revenue due to the satisfaction of our performance during the period. As of March 31, 2019, the aggregate amount of the transaction price allocated to the remaining performance obligation that is unsatisfied is $1.1 million, which is expected to be recognized as revenue through June 30, 2019. We had deferred revenue of $0.8 million and $3.3 million, as of March 31, 2019 and December 31, 2018, respectively, from Vertex, which is classified as current in the condensed consolidated balance sheets based on the period the services are expected to be performed.

X

- References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 730
-URI http://asc.fasb.org/subtopic&trid=2197926
+ Details

Name: us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R13.htm IDEA: XBRL DOCUMENT v3.19.1

Grants
3 Months Ended

Mar. 31, 2019

Revenue from Contract with Customer [Abstract]

Grants
Grants

Biomedical Advanced Research and Development Authority (BARDA)

In September 2016, we received an award of up to $125.8 million under Agreement No. HHSO100201600029C from BARDA, a component of the Office of the Assistant Secretary for Preparedness and Response, or ASPR within the U.S. Department of Health and Human Services, or HHS, to help fund our Zika vaccine program. Under the terms of the agreement with BARDA, an initial base award of $8.2 million supported toxicology studies, a Phase 1 clinical trial, and associated manufacturing activities. Contract options were available, for $117.6 million to support an additional Phase 1 study of an improved Zika vaccine candidate, Phase 2 and Phase 3 clinical studies, as well as large-scale manufacturing for the Zika vaccine.

As of March 31, 2019, three of the four contract options had been exercised resulting in $117.3 million of available funding with an additional $8.5 million available if the final contract option is exercised. For the three months ended March 31, 2019 and 2018, we recognized revenue of $1.5 million and $1.0 million, respectively, relating to the BARDA Agreement.

The Bill & Melinda Gates Foundation (Gates Foundation)

In January 2016, we entered a global health project framework agreement with the Gates Foundation to advance mRNA-based development projects for various infectious diseases. The Gates Foundation has committed up to $20.0 million in grant funding to support our initial project related to the evaluation of antibody combinations in a preclinical setting as well as the conduct of a first-in-human Phase 1 clinical trial of a potential mRNA medicine to help prevent human immunodeficiency virus, or HIV, infections. Follow-on projects which could bring total potential funding under the framework agreement up to $100.0 million (including the HIV antibody project) to support the development of additional mRNA-based projects for various infectious diseases can be proposed and approved until the sixth anniversary of the framework agreement, subject to the terms of the framework agreement, including our obligation to grant to the Gates Foundation certain non-exclusive licenses. In March 2019, the Gates Foundation provided an
additional funding commitment up to $1.1 million to support a follow-on project.
As of March 31, 2019, up to $21.1 million has been committed for funding with up to an additional $80 million available, if additional follow-on projects are approved. For the three months ended March 31, 2019 and 2018, we recognized $0.3 million for each period, relating to the Gates Foundation agreement. Deferred revenue of $0.6 million and $0.8 million was recorded for both March 31, 2019, and December 31, 2018, respectively, related to the Gates Foundation agreement.

Defense Advanced Research Projects Agency (DARPA)

In October 2013, DARPA awarded us up to $24.6 million under Agreement No. W911NF-13-1-0417, which was subsequently adjusted to $19.7 million, to research and develop potential mRNA medicines as a part of DARPA’s Autonomous Diagnostics to Enable Prevention and Therapeutics, or ADEPT, program, which is focused on assisting with the development of technologies to rapidly identify and respond to threats posed by natural and engineered diseases and toxins. The DARPA awards have been deployed primarily in support of our vaccine and antibody programs to protect against chikungunya infection.
As of March 31, 2019 and December 31, 2018, $19.7 million has been committed by DARPA. There was no revenue recognized for the three months ended March 31, 2019, related to the DARPA agreement. We recognized revenue of $0.2 million for the three months ended March 31, 2018, related to the DARPA agreement.

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueFromContractWithCustomerAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_RevenueFromContractWithCustomerTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R14.htm IDEA: XBRL DOCUMENT v3.19.1

Financial Instruments
3 Months Ended

Mar. 31, 2019

Investments, Debt and Equity Securities [Abstract]

Financial Instruments
Financial Instruments

Cash and Cash Equivalents and Investments

The following tables summarize our cash and available-for-sale securities by significant investment category at March 31, 2019 and December 31, 2018 (in thousands):

March 31, 2019

Amortized
Cost

Unrealized
Gains

Unrealized
Losses

Fair Value

Cash and
Cash
Equivalents

Current
Marketable
Securities

Non-
Current
Marketable
Securities
Cash and cash equivalents

$
502,935

$
—

$
(1
)

$
502,934

$
502,934

$
—

$
—

Available-for-sale:

Level 2:

Certificates of deposit

84,114

72

(1
)

84,185

—

80,483

3,702

U.S. treasury securities

119,347

155

(4
)

119,498

—

79,475

40,023

Debt securities of U.S. government agencies and corporate entities

839,055

1,129

(218
)

839,966

—

446,032

393,934

$
1,545,451

$
1,356

$
(224
)

$
1,546,583

$
502,934

$
605,990

$
437,659

December 31, 2018

Amortized
Cost

Unrealized
Gains

Unrealized
Losses

Fair Value

Cash and
Cash
Equivalents

Current
Marketable
Securities

Non-
Current
Marketable
Securities
Cash and cash equivalents

$
658,365

$
20

$
(21
)

$
658,364

$
658,364

$
—

$
—

Available-for-sale:

Level 2:

Certificates of deposit

173,102

42

(36
)

173,108

—

157,920

15,188

U.S. treasury securities

152,205

18

(48
)

152,175

—

152,175

—

Debt securities of U.S. government agencies and corporate entities

712,065

40

(1,335
)

710,770

—

552,968

157,802

$
1,695,737

$
120

$
(1,440
)

$
1,694,417

$
658,364

$
863,063

$
172,990

The amortized cost and estimated fair value of marketable securities, by contractual maturity at March 31, 2019 and December 31, 2018 are as follows (in thousands):

March 31, 2019

Amortized
Cost

Estimated
Fair Value
Due in one year or less

$
605,687

$
605,990

Due after one year through five years

436,829

437,659

Total

$
1,042,516

$
1,043,649

December 31, 2018

Amortized
Cost

Estimated
Fair Value
Due in one year or less

$
864,003

$
863,063

Due after one year through five years

173,369

172,990

Total

$
1,037,372

$
1,036,053

At March 31, 2019, we held 32 available-for-sale securities, or an estimated fair value of $135.8 million, out of our total investment portfolio that were in a continuous unrealized loss position for more than 12 months with a gross unrealized loss of $0.2 million. At December 31, 2018, we held 25 available-for-sale securities, or an estimated fair value of $82.8 million, out of our total investment portfolio that were in a continuous unrealized loss position for more than 12 months with a gross unrealized loss of $0.4 million. We concluded that the net declines in market value of our available-for-sale securities investment portfolio were temporary in nature and did not consider any of our investments to be other-than-temporarily impaired. In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for other-than-temporary impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. Furthermore, the aggregate of individual unrealized losses that had been outstanding for 12 months or less was not significant as of March 31, 2019 and December 31, 2018. We neither intend to sell these investments nor conclude that we are more-likely-than-not that we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for investments in certain debt and equity securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2209399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2324412

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-URI http://asc.fasb.org/topic&trid=2196928

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2176304
+ Details

Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R15.htm IDEA: XBRL DOCUMENT v3.19.1

Balance Sheet Components
3 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Balance Sheet Components
Balance Sheet Components

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets, as of March 31, 2019 and December 31, 2018 consists of the following (in thousands):

March 31,

December 31,

2019

2018
Prepaid expenses

$
7,895

$
10,401

Tenant incentives receivables

11,336

10,089

Interest receivable on marketable securities

6,061

7,909

Prepaid expenses and other current assets

$
25,292

$
28,399

Property and Equipment, Net

Property and equipment, net as of March 31, 2019 and December 31, 2018 consists of the following (in thousands):

March 31,

December 31,

2019

2018
Building

$
140,442

$
140,442

Laboratory equipment

98,891

96,907

Leasehold improvements

15,861

13,741

Furniture, fixtures and other

2,122

2,122

Computer equipment and software

9,456

11,513

Internally developed software

7,020

7,020

Construction in progress

11,403

4,688

285,195

276,433

Less: Accumulated depreciation

(71,735
)

(64,456
)
Property and equipment, net

$
213,460

$
211,977

Depreciation and amortization expense for the three months ended March 31, 2019 and 2018 was $7.3 million and $5.2 million, respectively.

Accrued Liabilities

Accrued liabilities, as of March 31, 2019 and December 31, 2018 consists of the following (in thousands):

March 31,

December 31,

2019

2018
In-licenses

$
—

$
22,000

Property and equipment

7,756

12,089

Compensation-related

11,577

23,406

External goods and services

22,850

21,578

Accrued liabilities

$
42,183

$
79,073

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-URI http://asc.fasb.org/topic&trid=2122208
+ Details

Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R16.htm IDEA: XBRL DOCUMENT v3.19.1

Commitments and Contingencies
3 Months Ended

Mar. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
Commitments and Contingencies

Lease Obligations

We have entered into various long-term non-cancelable operating lease arrangements for our facilities and equipment expiring at various times through 2032. Certain of these arrangements have free rent periods or escalating rent payment provisions, which we recognize rent expense under such arrangements on a straight-line basis over the life of the leases. We have two campuses in Massachusetts. We occupy a multi-building campus in Technology Square in Cambridge, MA with a mix of offices and research laboratory space totaling approximately 200,000 square feet. Our Cambridge facility leases have expiry ranges from 2020 to 2027. We have approximately 200,000 square feet of a manufacturing facility in Norwood, MA. This facility is leased through 2032.

In February 2019, we entered into a new lease agreement for office and laboratory space of approximately 200,000 square feet, located in Norwood, MA. The lease will commence in the second quarter of 2019, and expires in early 2031. We have the option to extend the lease for up to four additional five-year terms.

Total rent expense, for the three months ended March 31, 2019 and 2018 was $4.8 million and $5.2 million, respectively. Future minimum lease payments under non-cancelable operating lease agreements at March 31, 2019, are as follows (in thousands):
Fiscal Year
Minimum Lease Payments
2019
(remainder of the year)
$
15,190

2020

22,874

2021

24,105

2022

23,455

2023

20,498

Thereafter
140,384

Total
$
246,506

Strategic Collaborations

Under our strategic collaboration agreements, we are committed to perform certain research, development, and manufacturing activities. As part of our PCV Agreement and PCV/SAV Agreement with Merck, we are committed to perform certain research, development and manufacturing activities related to PCV products through an initial Phase 2 clinical trial up to a budgeted amount of $243.0 million for both periods as of March 31, 2019 and December 31, 2018 (see Note 3).

Legal Proceedings

We are not currently a party to any material legal proceedings.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R17.htm IDEA: XBRL DOCUMENT v3.19.1

Shareholders' Equity
3 Months Ended

Mar. 31, 2019

Equity [Abstract]

Shareholders' Equity
Shareholders' Equity

On February 28, 2018 and May 7, 2018, the Board of Directors approved an amendment to our Certificate of Incorporation resulting in a total of 775,000,000 shares of common stock and a total of 509,352,795 shares of redeemable convertible preferred stock being authorized, respectively. Upon completion of our IPO, our authorized capital stock consists of 1,600,000,000 shares of common stock, par value $0.0001 per share, and 162,000,000 shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock are undesignated.

On December 11, 2018, we completed our IPO, whereby we sold 26,275,993 shares of common stock at a price of $23.00 per share. The aggregate net proceeds received by us from the IPO were $563.0 million, net of underwriting discounts and commissions of $33.2 million and offering expenses of $8.1 million payable by us. Upon the closing of the IPO, all of the outstanding shares of our redeemable convertible preferred stock were converted into 236,012,913 shares of the common stock.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R18.htm IDEA: XBRL DOCUMENT v3.19.1

Stock-Based Compensation
3 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation
Stock-Based Compensation

Equity Plans

In connection with the IPO, we adopted the 2018 Stock Option and Incentive Plan (the 2018 Equity Plan) in November 2018. The 2018 Equity Plan became effective on the date immediately prior to the effective date of the IPO and replaced our 2016 Stock Option and Grant Plan (the 2016 Equity Plan). The number of shares of common stock available for issuance under the 2018 Equity Plan was increased by 13.2 million shares as a result of the automatic increase provision of the 2018 Equity Plan. As of March 31, 2019, we had a total of 72.4 million shares reserved for future issuance under our Equity Plans, of which 17.9 million shares were available for future grants.

Options

We have granted options generally through the 2018 Equity Plan and 2016 Equity Plan. The following table summarizes our option activity as of March 31, 2019:

Number of
Options

Weighted-
Average
Exercise
Price per
Share

Weighted-
Average
Grant
Date Fair
Value per
Share

Weighted-
Average
Remaining
Contractual
Term

Aggregate
Intrinsic
Value⁽¹⁾
(in thousands)
Outstanding at December 31, 2018

50,821,132

12.16

6.59

7.1 years

220,434

Granted

5,443,286

20.59

12.16

Exercised

(5,525
)

9.62

5.62

Canceled/forfeited

(2,987,612
)

14.29

8.48

Outstanding at March 31, 2019

53,271,281

12.92

6.99

7.5 years

412,480

Exercisable at March 31, 2019

24,769,502

8.54

4.05

5.7 years

292,602

Vested and expected to vest at March 31, 2019

28,501,493

16.73

9.55

9.0 years

119,876

_______
⁽¹⁾Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of March 31, 2019.

For the three months ended March 31, 2019, 5,525 stock options were exercised. The total intrinsic value of options exercised was $0.1 million. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The total consideration recorded as a result of stock option exercises was approximately $0.1 million for the three months ended March 31, 2019.

Stock-based compensation for options granted is determined using the Black-Scholes option pricing model. The weighted-average assumptions used to estimate the fair value of the options granted for the three months ended March 31, 2019 and 2018 are as follows:

Weighted Average

Three Months Ended March 31,

2019

2018
Risk-free interest rate

2.48
%

2.71
%
Expected term

6.12 years

6.06 years

Expected volatility

62
%

63
%
Expected dividends

—
%

—
%
Weighted average fair value per share

$
12.16

$
8.48

Restricted Common Stock

We have granted restricted stock awards generally through the 2016 Equity Plan. The following table summarizes our restricted stock activity during the three months ended March 31, 2019:

Number of
Shares

Weighted
Average
Grant Date
per Share
Outstanding, non-vested at December 31, 2018
198,597

$
12.15

Issued
—

—

Vested
(48,911
)

12.15

Canceled, forfeited and adjustments, net
711

12.15

Outstanding, non-vested at March 31, 2019
150,397

12.15

Restricted Common Stock Units

We have granted restricted stock awards generally through the 2018 Equity Plan and 2016 Equity Plan. The following table summarizes our restricted stock unit activity during the three months ended March 31, 2019:

Units

Weighted-Average
Grant Date
per Unit
Outstanding, non-vested at December 31, 2018
458,715

$
11.93

Issued
558,208

20.77

Vested ⁽¹⁾
14,334

11.93

Canceled/forfeited
(5,440
)

20.93

Pending settlement ⁽¹⁾
(14,334
)

11.93

Outstanding, non-vested at March 31, 2019
1,011,483

16.76

_________
⁽¹⁾The vested restricted stock units will be settled for common stock on the date which is 360 days after the consummation of the IPO.

Stock-Based Compensation Expense

The following table presents the components and classification of stock-based compensation expense for the three months ended March 31, 2019 and 2018 as follows (in thousands):

Three Months Ended
March 31,

2019

2018
Options
$
17,487

$
10,048

Restricted common stock and units
1,010

1,803

Total
$
18,497

$
11,851

Research and development
$
10,783

$
7,356

General and administrative
7,714

4,495

Total
$
18,497

$
11,851

As of March 31, 2019, there were $253.1 million of total unrecognized compensation cost related to unvested stock-based compensation with respect to options and restricted stock granted. That cost is expected to be recognized over a weighted-average period of 3.5 years at March 31, 2019.

2018 Employee Stock Purchase Plan

In November 2018, we adopted the 2018 Employee Stock Purchase Plan (the ESPP), which became effective on December 5, 2018. The ESPP initially reserves and authorizes the issuance of up to a total of 810,000 shares of common stock to participating employees. We had not made any offerings as of March 31, 2019.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-URI http://asc.fasb.org/subtopic&trid=2208855
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R19.htm IDEA: XBRL DOCUMENT v3.19.1

Income Taxes
3 Months Ended

Mar. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes
Income Taxes

We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates that are expected to be in effect for the years in which differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a “more likely than not” criterion. Realization of our deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. We continued to maintain a full valuation allowance against all of our deferred tax assets based on management’s evaluation of all available evidence.

There were no significant income tax provisions or benefits for the three months ended March 31, 2019 and 2018.

Upon adoption of ASC 606 (see Note 2), we recorded a cumulative-effect adjustment of $28.0 million to the opening balance of accumulated deficit as of January 1, 2019 with a decrease in deferred revenue of $30.7 million and a decrease in accounts receivable of $2.7 million. As a result of the cumulative decrease in deferred revenue, our corresponding deferred tax asset decreased by $8.4 million, which was offset by a corresponding decrease to our valuation allowance.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R20.htm IDEA: XBRL DOCUMENT v3.19.1

Net Loss per Share
3 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

Net Loss per Share
Net Loss per Share

Net Loss per Share Attributable to Common Stockholders

Basic and diluted net loss per share attributable to common stockholders for the three months ended March 31, 2019 and 2018 are calculated as follows (in thousands, except share and per share data):

Three Months Ended March 31,

2019

2018
Numerator:

Net loss
$
(132,657
)

$
(72,376
)
Cumulative dividends on redeemable convertible preferred stock
—

(3,481
)
Net loss attributable to common stockholders
$
(132,657
)

$
(75,857
)
Denominator:

Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted
328,809,986

65,430,835

Net loss per share attributable to common stockholders, basic and diluted
$
(0.40
)

$
(1.16
)

The following common stock equivalents, presented based on amounts outstanding as of March 31, 2019 and 2018 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive:

March 31,

2019

2018
Redeemable convertible preferred stock
—

260,817,303

Stock options
53,271,281

43,135,998

Restricted common stock
150,397

729,877

Restricted common stock units
1,011,483

458,715

54,433,161

305,141,893

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R21.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Basis of Presentation and Recent Accounting Standards (Policies)
3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Basis of Presentation and Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in conformity with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2018 (2018 Form 10-K), except for changes associated with recent accounting standards for revenue recognition as detailed in "Note 2 - Recent Accounting Standards and Accounting Policies." This report should be read in conjunction with the consolidated financial statements in our 2018 Form 10-K.

We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, income tax provisions, stock-based compensation, and useful lives of long-lived assets. We base our estimates on historical experience and on various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results that we experience may differ materially from our estimates. The condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, but are not necessarily indicative of the results of operations to be anticipated for the full year ending December 31, 2019.

Revenue Recognition
On January 1, 2019, we adopted Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606), using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. We recognized the cumulative effect of the adoption as an adjustment to the opening balance of accumulated deficit in the current period condensed consolidated balance sheet. Results for reporting periods beginning after January 1, 2019 are presented under ASC 606, while prior period amounts have not been adjusted and continue to be reported in accordance with our historic accounting under ASC Topic 605, Revenue Recognition (ASC 605). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.

Our revenue is primarily generated through collaboration arrangements and grants from government-sponsored and private organizations. Our collaboration arrangements typically contain multiple promises, including licenses to our intellectual property, options to obtain development and commercialization rights, research and development services, and obligations to develop and manufacture preclinical and clinical material. Such arrangements provide for various types of payments to us, including upfront payments, funding of research and development activities, funding for the purchase of preclinical and clinical material, development, regulatory and commercial milestone payments, licensing fees, option exercise payments, and royalties based on product sales. We have received grants from various government-sponsored and private organizations for research and related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin.

We analyze our collaboration arrangements to assess whether they are within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and our collaboration partner are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606. If we conclude that some or all aspects of the arrangement are within the scope of ASC 808 and do not represent a transaction with a customer, we recognize our allocation of the shared costs incurred with respect to the jointly conducted activities as a component of the related expense in the period incurred. Pursuant to ASC 606, a customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. If we conclude a counter-party to a transaction is not a customer or otherwise not within the scope of ASC 606 or ASC 808, we consider the guidance in other accounting literature as applicable or by analogy to account for such transaction. We also consider the guidance in ASC 606 with respect to principal versus agent considerations, in determining the appropriate treatment for the transactions between us and the strategic collaborator and the transactions between us and other third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, are accounted for as gross revenue.

We receive payments from our customers based on billing schedules established in each contract. Upfront payments and fees are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period when we perform our obligations under the arrangement. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current liabilities on our condensed consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities on our condensed consolidated balance sheets. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. As of March 31, 2019, we had not capitalized any costs to obtain any of our contracts.

Collaboration Revenue

To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following steps: (i) identify the contract(s) with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) each performance obligation is satisfied.

We account for a contract with a customer that is within the scope of ASC 606 when all of the following criteria are met: (i) the arrangement has been approved by the parties and the parties are committed to perform their respective obligations; (ii) each party’s rights regarding the goods and/or services to be transferred can be identified; (iii) the payment terms for the goods and/or services to be transferred can be identified; (iv) the arrangement has commercial substance; and (v) collection of substantially all of the consideration to which we will be entitled in exchange for the goods and/or services that will be transferred to the customer is probable. We also determine the term of the contract based on the period in which we and our customer have present and enforceable rights and obligations for purposes of identifying the performance obligations and determining the transaction price.

We evaluate contracts that contain multiple promises to determine which promises are distinct. Promises are considered to be distinct and therefore, accounted for as separate performance obligations, provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. In assessing whether a promise is distinct, we consider factors such as whether: (i) we provide a significant service of integrating goods and/or services with other goods and/or services promised in the contract; (ii) one or more of the goods and/or services significantly modifies or customizes, or are significantly modified or customized by one or more of the other goods and/or services promised in the contract; and (iii) the goods and/or services are highly interdependent or highly interrelated. Individual goods or services (or bundles of goods and/or services) that meet both criteria for being distinct are accounted for as separate performance obligations. Promises that are not distinct at contract inception are combined and accounted for as a single performance obligation. Options to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer’s election.

The transaction price is generally comprised of an upfront payment due at contract inception and variable consideration in the form of payments for our services and materials and milestone payments due upon the achievement of specified events. Other payments the Company could be entitled to include tiered royalties earned when customers recognize net sales of licensed products. We consider the existence of any significant financing component within our arrangements and have determined that a significant financing component does not exist in our arrangements as substantive business purposes exist to support the payment structure other than to provide a significant benefit of financing. We measure the transaction price based on the amount of consideration we expect to be entitled in exchange for transferring the promised goods and/or services to the customer. We utilize either the expected value method or the most likely amount method to estimate the amount of variable consideration, depending on which method is expected to better predict the amount of consideration to which we will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. With respect to arrangements that include payments for a development or regulatory milestone payment, we evaluate whether the associated event is considered probable of achievement and estimate the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within our control or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, we re-evaluate the probability of achievement of each milestone and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, wherein the license is deemed to be the sole or predominant item to which the payments relate, we recognize revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.

We generally allocate the transaction price to each performance obligation based on a relative standalone selling price basis. We develop assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated research and development costs. However, in certain instances, we allocate variable consideration entirely to one or more performance obligation if the terms of the variable consideration relate to the satisfaction of the respective performance obligation and the amount allocated is consistent with the amount we would expect to receive for the satisfaction of the respective performance obligation.

We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. For performance obligations that are satisfied at a point in time, we recognize revenue when control of the goods and/or services is transferred to the customer. For performance obligations that are satisfied over time, we recognize revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. We generally use input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. With respect to arrangements containing a license to our intellectual property that is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from amounts allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which we are expected to complete our performance obligations under an arrangement. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.

Grant Revenue

We have contracts with the U.S. government’s Defense Advanced Research Projects Agency (DARPA), Biomedical Advanced Research (BARDA), and the Bill & Melinda Gates Foundation (Gates Foundation). We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Revenues and related expenses are presented gross in the condensed consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.

Collaboration Revenue
To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following steps: (i) identify the contract(s) with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) each performance obligation is satisfied.

We account for a contract with a customer that is within the scope of ASC 606 when all of the following criteria are met: (i) the arrangement has been approved by the parties and the parties are committed to perform their respective obligations; (ii) each party’s rights regarding the goods and/or services to be transferred can be identified; (iii) the payment terms for the goods and/or services to be transferred can be identified; (iv) the arrangement has commercial substance; and (v) collection of substantially all of the consideration to which we will be entitled in exchange for the goods and/or services that will be transferred to the customer is probable. We also determine the term of the contract based on the period in which we and our customer have present and enforceable rights and obligations for purposes of identifying the performance obligations and determining the transaction price.

We evaluate contracts that contain multiple promises to determine which promises are distinct. Promises are considered to be distinct and therefore, accounted for as separate performance obligations, provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. In assessing whether a promise is distinct, we consider factors such as whether: (i) we provide a significant service of integrating goods and/or services with other goods and/or services promised in the contract; (ii) one or more of the goods and/or services significantly modifies or customizes, or are significantly modified or customized by one or more of the other goods and/or services promised in the contract; and (iii) the goods and/or services are highly interdependent or highly interrelated. Individual goods or services (or bundles of goods and/or services) that meet both criteria for being distinct are accounted for as separate performance obligations. Promises that are not distinct at contract inception are combined and accounted for as a single performance obligation. Options to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer’s election.

The transaction price is generally comprised of an upfront payment due at contract inception and variable consideration in the form of payments for our services and materials and milestone payments due upon the achievement of specified events. Other payments the Company could be entitled to include tiered royalties earned when customers recognize net sales of licensed products. We consider the existence of any significant financing component within our arrangements and have determined that a significant financing component does not exist in our arrangements as substantive business purposes exist to support the payment structure other than to provide a significant benefit of financing. We measure the transaction price based on the amount of consideration we expect to be entitled in exchange for transferring the promised goods and/or services to the customer. We utilize either the expected value method or the most likely amount method to estimate the amount of variable consideration, depending on which method is expected to better predict the amount of consideration to which we will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. With respect to arrangements that include payments for a development or regulatory milestone payment, we evaluate whether the associated event is considered probable of achievement and estimate the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within our control or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, we re-evaluate the probability of achievement of each milestone and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, wherein the license is deemed to be the sole or predominant item to which the payments relate, we recognize revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.

We generally allocate the transaction price to each performance obligation based on a relative standalone selling price basis. We develop assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated research and development costs. However, in certain instances, we allocate variable consideration entirely to one or more performance obligation if the terms of the variable consideration relate to the satisfaction of the respective performance obligation and the amount allocated is consistent with the amount we would expect to receive for the satisfaction of the respective performance obligation.

We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. For performance obligations that are satisfied at a point in time, we recognize revenue when control of the goods and/or services is transferred to the customer. For performance obligations that are satisfied over time, we recognize revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. We generally use input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. With respect to arrangements containing a license to our intellectual property that is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from amounts allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which we are expected to complete our performance obligations under an arrangement. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.

Comprehensive Loss
Comprehensive loss includes net loss and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments. Total comprehensive loss for all periods presented has been disclosed in the condensed consolidated statements of comprehensive loss.

Recently Adopted Accounting Standards and Recently Issued Accounting Standards
ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting

In June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance generally consistent with the accounting for employee share-based compensation. The new standard will be effective for us on January 1, 2020, with early adoption permitted. We early adopted this standard in the first quarter of 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and disclosure.

ASU No. 2018-18, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606

In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which clarifies the interaction between Topic 808 and Topic 606, Revenue from Contracts with Customers. Currently, Topic 808 does not provide comprehensive recognition or measurement guidance for collaborative arrangements, and the accounting for those arrangements is often based on an analogy to other accounting literature or an accounting policy election. Similarly, aspects of Topic 606 have resulted in diversity in practice on the effect of the revenue standard on the accounting for collaborative arrangements. The standard will become effective for us beginning on January 1, 2021, with early adoption permitted. We early adopted this standard in connection with the adoption of ASC 606 in the first quarter of 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and disclosure.

Recently Issued Accounting Standards

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our condensed consolidated financial statements and disclosures.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes all existing lease guidance. This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. The new standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments. Lessees are required to classify leases as either finance or operating leases. If the lease is effectively a financed-purchase by the lessee, it is classified as a financing lease, otherwise it is classified as an operating lease. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. ASC 842 provides accounting guidance for transactions that meet specific criteria for a leaseback transaction. If the criteria are not met, the transaction is considered a “failed sale” and the transaction must be accounted for as a financing arrangement. The new standard will be effective for us on January 1, 2020, assuming we continue to qualify as an EGC.. Upon adoption, the new standard, as amended, allows lessees to apply the transition requirements either (1) retrospectively to each prior reporting period presented in the financial statements with the cumulative effect of applying the new rules recognized at the beginning of the earliest comparative period presented, or (2) retrospectively at the beginning of the period of adoption with the cumulative effect of applying the new rules recognized then. We are currently evaluating the potential impact ASU 2016-02 may have on our financial position and results of operations. Our assessment will include, but is not limited to, evaluating the impact this standard has on the lease of our corporate headquarters at 200 Technology Square in Cambridge, MA, the lease of our office and laboratory space at 500 Technology Square, Cambridge, MA and our manufacturing and additional facilities in Norwood, MA, (see Note 7), and the identification of any embedded leases.

In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (ASU 2016-13). ASU 2016-13 will change how companies account for credit losses for most financial assets and certain other instruments. For trade receivables, loans and held-to-maturity debt securities, companies will be required to recognize an allowance for credit losses rather than reducing the carrying value of the asset. Assuming we continue to qualify as an EGC, ASU 2016-13 will be effective for us for fiscal years beginning after December 15, 2020, , including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 will have on the Company’s financial position and results of operations.

In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Topic 350): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This standard requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This standard should be applied either retrospectively or prospectively, and will be effective for us in January 2021, assuming we continue to qualify as an EGC, with early adoption permitted. We are currently evaluating the potential impact this standard may have on our condensed consolidated financial statements and results of operations upon adoption.

ASU No. 2016-18, Statement of Cash Flows: Restricted Cash

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires the statement of cash flows to explain the change during the period in the total of cash, cash equivalents and restricted cash. When cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new standard requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet. This reconciliation can be presented either on the face of the statement of cash flows or in the notes to the financial statements. The new standard became effective for us on January 1, 2019. As a result of adopting this new standard using a retrospective transition method for each period presented, we include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed statements of cash flows.
ASU No. 2014-09, Revenue from Contracts with Customers

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements in ASC 605 and most industry specific guidance. ASC 606 provides a single comprehensive model for use in accounting for revenue arising from contracts with customers. We adopted the new revenue standard on January 1, 2019 using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. We recognized the cumulative effect of the adoption as an adjustment to the opening balance of accumulated deficit in the first quarter of 2019. We have elected to use the practical expedient to aggregate the impact of all contract modifications that occurred prior to the ASC 606 adoption with respect to (i) identification of the satisfied and unsatisfied performance obligations, (ii) determination of the transaction price and (iii) allocation of the transaction price to the satisfied and unsatisfied performance obligations.

ASC 606 requires significant judgment and estimates and results in changes to, but not limited to: (i) the determination of the transaction price, including estimates of variable consideration, (ii) the allocation of the transaction price, including the determination of estimated selling price, and (iii) the pattern of recognition, including the application of proportional performance as a measure of progress on service-related promises and application of point-in-time recognition for supply-related promises. We recorded the cumulative-effect adjustment of $28.0 million to the opening balance of accumulated deficit as of January 1, 2019 with a corresponding decrease to deferred revenue.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for collaborative arrangements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790
+ Details

Name: us-gaap_CollaborativeArrangementAccountingPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for comprehensive income.
+ References
No definition available.
+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue from contract with customer.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388
+ Details

Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R22.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Basis of Presentation and Recent Accounting Standards (Tables)
3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Components of Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive loss for the three months ended March 31, 2019 are as follows (in thousands):

Unrealized Gain on Available-for-Sale Debt Securities
Accumulated other comprehensive loss, balance at December 31, 2018
$
(1,320
)
Other comprehensive income
1,911

Accumulated other comprehensive loss, balance at March 31, 2019
$
591

Effect of Adoption of ASC 606 on Condensed Financial Statements
The effect of the adoption of ASC 606 on our condensed consolidated balance sheet is as follows (in thousands):
Condensed Consolidated Balance Sheet

Balance at December 31, 2018

Adjustments

Balance at
January 1, 2019
Deferred revenue, current

$
109,056

$
(27,281
)

$
81,775

Deferred revenue, non-current

165,352

(3,441
)

161,911

Accounts receivable

11,686

(2,738
)

8,948

Accumulated deficit

(1,006,627
)

27,984

(978,643
)
The following tables summarize the effects of adopting ASC 606 on our condensed consolidated financial statements at March 31, 2019, and for the three months ended March 31, 2019 (in thousands, except per share data):

March 31, 2019
Condensed Consolidated Balance Sheet

As reported under ASC 606

Adjustments

Balance without adoption of ASC 606
Deferred revenue, current

$
73,958

$
36,452

$
110,410

Deferred revenue, non-current

156,862

(29,840
)

127,022

Accumulated deficit

(1,111,300
)

(6,077
)

(1,117,377
)

Three Months Ended March 31, 2019
Condensed Consolidated Statement of Operations

As reported under ASC 606

Adjustments

Amount without adoption of ASC 606
Revenue:

   Collaboration revenue

$
13,301

$
(1,786
)

$
11,515

   Collaboration revenue from related party

814

24,377

25,191

Total revenue

16,025

21,907

37,932

Loss from operations

(141,833
)

21,907

(119,926
)
Loss before benefit from income taxes

(132,681
)

21,907

(110,774
)
Net (loss) income

(132,657
)

21,907

(110,750
)
Net loss per share - basic and diluted

(0.40
)

0.06

(0.34
)
The following table summarizes our total consolidated net revenues from our strategic collaborators for the periods presented (in thousands):

Three Months Ended
Collaboration Revenue by Strategic Collaborator:

March 31, 2019
as reported
(under ASU 606)

March 31, 2019
without adoption of 606
(under ASC 605)

March 31, 2018
as reported
(under ASC 605)
Merck

$
10,687

$
11,515

$
15,967

AstraZeneca

814

25,191

7,350

Vertex

2,614

—

4,143

Total collaborative revenue

$
14,115

$
36,706

$
27,460

Reconciliation of Cash and Cash Equivalents
The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows (in thousands):

As of March 31,

2019

2018
Cash and cash equivalents

$
502,934

$
90,479

Restricted cash

—

237

Restricted cash, non-current

11,823

11,798

Total cash, cash equivalents and restricted cash shown in the condensed consolidated
    statements of cash flows

$
514,757

$
102,514

Reconciliation of Restricted Cash
The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows (in thousands):

As of March 31,

2019

2018
Cash and cash equivalents

$
502,934

$
90,479

Restricted cash

—

237

Restricted cash, non-current

11,823

11,798

Total cash, cash equivalents and restricted cash shown in the condensed consolidated
    statements of cash flows

$
514,757

$
102,514

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accumulated other comprehensive income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580
+ Details

Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of cash and cash equivalents.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e765-108305

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e725-108305

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794
+ Details

Name: us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(1)(a))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(2))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R23.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration Agreements (Tables)
3 Months Ended

Mar. 31, 2019

Research and Development [Abstract]

Summary of Total Consolidated Net Revenues from Strategic Collaborators
The effect of the adoption of ASC 606 on our condensed consolidated balance sheet is as follows (in thousands):
Condensed Consolidated Balance Sheet

Balance at December 31, 2018

Adjustments

Balance at
January 1, 2019
Deferred revenue, current

$
109,056

$
(27,281
)

$
81,775

Deferred revenue, non-current

165,352

(3,441
)

161,911

Accounts receivable

11,686

(2,738
)

8,948

Accumulated deficit

(1,006,627
)

27,984

(978,643
)
The following tables summarize the effects of adopting ASC 606 on our condensed consolidated financial statements at March 31, 2019, and for the three months ended March 31, 2019 (in thousands, except per share data):

March 31, 2019
Condensed Consolidated Balance Sheet

As reported under ASC 606

Adjustments

Balance without adoption of ASC 606
Deferred revenue, current

$
73,958

$
36,452

$
110,410

Deferred revenue, non-current

156,862

(29,840
)

127,022

Accumulated deficit

(1,111,300
)

(6,077
)

(1,117,377
)

Three Months Ended March 31, 2019
Condensed Consolidated Statement of Operations

As reported under ASC 606

Adjustments

Amount without adoption of ASC 606
Revenue:

   Collaboration revenue

$
13,301

$
(1,786
)

$
11,515

   Collaboration revenue from related party

814

24,377

25,191

Total revenue

16,025

21,907

37,932

Loss from operations

(141,833
)

21,907

(119,926
)
Loss before benefit from income taxes

(132,681
)

21,907

(110,774
)
Net (loss) income

(132,657
)

21,907

(110,750
)
Net loss per share - basic and diluted

(0.40
)

0.06

(0.34
)
The following table summarizes our total consolidated net revenues from our strategic collaborators for the periods presented (in thousands):

Three Months Ended
Collaboration Revenue by Strategic Collaborator:

March 31, 2019
as reported
(under ASU 606)

March 31, 2019
without adoption of 606
(under ASC 605)

March 31, 2018
as reported
(under ASC 605)
Merck

$
10,687

$
11,515

$
15,967

AstraZeneca

814

25,191

7,350

Vertex

2,614

—

4,143

Total collaborative revenue

$
14,115

$
36,706

$
27,460

Changes in Balances of Receivables and Contract Liabilities
The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the three months ended March 31, 2019 (in thousands):

January 1, 2019

Additions

Deductions

March 31, 2019
Contract Assets:

Accounts receivable

$
4,612

$
2,735

$
(3,747
)

$
3,600

Contract Liabilities:

Deferred revenue

$
240,924

$
1,137

$
(13,582
)

$
228,479

During the three months ended March 31, 2019, we recognized the following revenues as a result of the change in the contract liability balances related to our collaboration agreements (in thousands):
Revenue recognized in the period from:

Three Months Ended March 31, 2019
Amounts included in contract liabilities at the beginning of the period ⁽¹⁾

$
13,582

⁽¹⁾ We first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period first applies to the beginning contract liability.

X

- Definition
Tabular disclosure of contract balances and changes in contract balances.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045
+ Details

Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e765-108305

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e725-108305

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794
+ Details

Name: us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R24.htm IDEA: XBRL DOCUMENT v3.19.1

Financial Instruments (Tables)
3 Months Ended

Mar. 31, 2019

Investments, Debt and Equity Securities [Abstract]

Summary of Cash and Available-for-Sale Securities by Significant Investment Category
The following tables summarize our cash and available-for-sale securities by significant investment category at March 31, 2019 and December 31, 2018 (in thousands):

March 31, 2019

Amortized
Cost

Unrealized
Gains

Unrealized
Losses

Fair Value

Cash and
Cash
Equivalents

Current
Marketable
Securities

Non-
Current
Marketable
Securities
Cash and cash equivalents

$
502,935

$
—

$
(1
)

$
502,934

$
502,934

$
—

$
—

Available-for-sale:

Level 2:

Certificates of deposit

84,114

72

(1
)

84,185

—

80,483

3,702

U.S. treasury securities

119,347

155

(4
)

119,498

—

79,475

40,023

Debt securities of U.S. government agencies and corporate entities

839,055

1,129

(218
)

839,966

—

446,032

393,934

$
1,545,451

$
1,356

$
(224
)

$
1,546,583

$
502,934

$
605,990

$
437,659

December 31, 2018

Amortized
Cost

Unrealized
Gains

Unrealized
Losses

Fair Value

Cash and
Cash
Equivalents

Current
Marketable
Securities

Non-
Current
Marketable
Securities
Cash and cash equivalents

$
658,365

$
20

$
(21
)

$
658,364

$
658,364

$
—

$
—

Available-for-sale:

Level 2:

Certificates of deposit

173,102

42

(36
)

173,108

—

157,920

15,188

U.S. treasury securities

152,205

18

(48
)

152,175

—

152,175

—

Debt securities of U.S. government agencies and corporate entities

712,065

40

(1,335
)

710,770

—

552,968

157,802

$
1,695,737

$
120

$
(1,440
)

$
1,694,417

$
658,364

$
863,063

$
172,990

Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity
The amortized cost and estimated fair value of marketable securities, by contractual maturity at March 31, 2019 and December 31, 2018 are as follows (in thousands):

March 31, 2019

Amortized
Cost

Estimated
Fair Value
Due in one year or less

$
605,687

$
605,990

Due after one year through five years

436,829

437,659

Total

$
1,042,516

$
1,043,649

December 31, 2018

Amortized
Cost

Estimated
Fair Value
Due in one year or less

$
864,003

$
863,063

Due after one year through five years

173,369

172,990

Total

$
1,037,372

$
1,036,053

X

- Definition
Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.
+ References
No definition available.
+ Details

Name: us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of cash, cash equivalents, and investments.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R25.htm IDEA: XBRL DOCUMENT v3.19.1

Balance Sheet Components (Tables)
3 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets, as of March 31, 2019 and December 31, 2018 consists of the following (in thousands):

March 31,

December 31,

2019

2018
Prepaid expenses

$
7,895

$
10,401

Tenant incentives receivables

11,336

10,089

Interest receivable on marketable securities

6,061

7,909

Prepaid expenses and other current assets

$
25,292

$
28,399

Schedule of Property and Equipment, Net
Property and equipment, net as of March 31, 2019 and December 31, 2018 consists of the following (in thousands):

March 31,

December 31,

2019

2018
Building

$
140,442

$
140,442

Laboratory equipment

98,891

96,907

Leasehold improvements

15,861

13,741

Furniture, fixtures and other

2,122

2,122

Computer equipment and software

9,456

11,513

Internally developed software

7,020

7,020

Construction in progress

11,403

4,688

285,195

276,433

Less: Accumulated depreciation

(71,735
)

(64,456
)
Property and equipment, net

$
213,460

$
211,977

Schedule of Accrued Liabilities
Accrued liabilities, as of March 31, 2019 and December 31, 2018 consists of the following (in thousands):

March 31,

December 31,

2019

2018
In-licenses

$
—

$
22,000

Property and equipment

7,756

12,089

Compensation-related

11,577

23,406

External goods and services

22,850

21,578

Accrued liabilities

$
42,183

$
79,073

X

- Definition
Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R26.htm IDEA: XBRL DOCUMENT v3.19.1

Commitments and Contingencies (Tables)
3 Months Ended

Mar. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Future Minimum Lease Payments Under Non-Cancelable Operating Lease Agreements
Future minimum lease payments under non-cancelable operating lease agreements at March 31, 2019, are as follows (in thousands):
Fiscal Year
Minimum Lease Payments
2019
(remainder of the year)
$
15,190

2020

22,874

2021

24,105

2022

23,455

2023

20,498

Thereafter
140,384

Total
$
246,506

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R27.htm IDEA: XBRL DOCUMENT v3.19.1

Stock-Based Compensation (Tables)
3 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Options Activity
The following table summarizes our option activity as of March 31, 2019:

Number of
Options

Weighted-
Average
Exercise
Price per
Share

Weighted-
Average
Grant
Date Fair
Value per
Share

Weighted-
Average
Remaining
Contractual
Term

Aggregate
Intrinsic
Value⁽¹⁾
(in thousands)
Outstanding at December 31, 2018

50,821,132

12.16

6.59

7.1 years

220,434

Granted

5,443,286

20.59

12.16

Exercised

(5,525
)

9.62

5.62

Canceled/forfeited

(2,987,612
)

14.29

8.48

Outstanding at March 31, 2019

53,271,281

12.92

6.99

7.5 years

412,480

Exercisable at March 31, 2019

24,769,502

8.54

4.05

5.7 years

292,602

Vested and expected to vest at March 31, 2019

28,501,493

16.73

9.55

9.0 years

119,876

_______
⁽¹⁾Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of March 31, 2019.

Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted
The weighted-average assumptions used to estimate the fair value of the options granted for the three months ended March 31, 2019 and 2018 are as follows:

Weighted Average

Three Months Ended March 31,

2019

2018
Risk-free interest rate

2.48
%

2.71
%
Expected term

6.12 years

6.06 years

Expected volatility

62
%

63
%
Expected dividends

—
%

—
%
Weighted average fair value per share

$
12.16

$
8.48

Restricted Common Stock Activity
The following table summarizes our restricted stock activity during the three months ended March 31, 2019:

Number of
Shares

Weighted
Average
Grant Date
per Share
Outstanding, non-vested at December 31, 2018
198,597

$
12.15

Issued
—

—

Vested
(48,911
)

12.15

Canceled, forfeited and adjustments, net
711

12.15

Outstanding, non-vested at March 31, 2019
150,397

12.15

Restricted Common Stock Units Activity
The following table summarizes our restricted stock unit activity during the three months ended March 31, 2019:

Units

Weighted-Average
Grant Date
per Unit
Outstanding, non-vested at December 31, 2018
458,715

$
11.93

Issued
558,208

20.77

Vested ⁽¹⁾
14,334

11.93

Canceled/forfeited
(5,440
)

20.93

Pending settlement ⁽¹⁾
(14,334
)

11.93

Outstanding, non-vested at March 31, 2019
1,011,483

16.76

_________
⁽¹⁾The vested restricted stock units will be settled for common stock on the date which is 360 days after the consummation of the IPO.

Stock-Based Compensation Expense
The following table presents the components and classification of stock-based compensation expense for the three months ended March 31, 2019 and 2018 as follows (in thousands):

Three Months Ended
March 31,

2019

2018
Options
$
17,487

$
10,048

Restricted common stock and units
1,010

1,803

Total
$
18,497

$
11,851

Research and development
$
10,783

$
7,356

General and administrative
7,714

4,495

Total
$
18,497

$
11,851

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the changes in outstanding nonvested restricted stock shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the changes in outstanding nonvested restricted stock units.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R28.htm IDEA: XBRL DOCUMENT v3.19.1

Net Loss per Share (Tables)
3 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

Basic and Diluted Net Loss per Share Attributable to Common Stockholders
Basic and diluted net loss per share attributable to common stockholders for the three months ended March 31, 2019 and 2018 are calculated as follows (in thousands, except share and per share data):

Three Months Ended March 31,

2019

2018
Numerator:

Net loss
$
(132,657
)

$
(72,376
)
Cumulative dividends on redeemable convertible preferred stock
—

(3,481
)
Net loss attributable to common stockholders
$
(132,657
)

$
(75,857
)
Denominator:

Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted
328,809,986

65,430,835

Net loss per share attributable to common stockholders, basic and diluted
$
(0.40
)

$
(1.16
)

Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share
The following common stock equivalents, presented based on amounts outstanding as of March 31, 2019 and 2018 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive:

March 31,

2019

2018
Redeemable convertible preferred stock
—

260,817,303

Stock options
53,271,281

43,135,998

Restricted common stock
150,397

729,877

Restricted common stock units
1,011,483

458,715

54,433,161

305,141,893

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R29.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Dec. 31, 2018

Dec. 31, 2017

AOCI Attributable to Parent, Net of Tax [Roll Forward]

Balance at beginning of period $ 1,446,033 $ (613,709) $ 1,530,241 $ (551,365)

Other comprehensive income 1,911 (1,993)

Balance at end of period 1,446,033 (613,709)

Accumulated Other Comprehensive (Loss) Income

AOCI Attributable to Parent, Net of Tax [Roll Forward]

Balance at beginning of period 591 (3,150) $ (1,320) $ (1,157)

Other comprehensive income 1,911 (1,993)

Balance at end of period 591 $ (3,150)

Unrealized Gain on Available-for-Sale Debt Securities

AOCI Attributable to Parent, Net of Tax [Roll Forward]

Other comprehensive income $ 1,911

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_AOCIAttributableToParentNetOfTaxRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R30.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Basis of Presentation and Recent Accounting Standards - Narrative (Details) - USD ($)
$ in Thousands

Mar. 31, 2019

Jan. 01, 2019

Dec. 31, 2018

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Cumulative-effect adjustment $ 27,984

Remaining deferred revenues $ 228,479 $ 240,924

Combined 2018 AZ Agreements

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Remaining deferred revenues 75,500 75,700 115,600

PCV/SAV Agreement

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Remaining deferred revenues 115,000 125,200 111,300

2016 VEGF Exercise

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Remaining deferred revenues $ 37,100 37,100 $ 41,200

Accumulated Deficit

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Cumulative-effect adjustment 27,984

Accounting Standards Update 2014-09

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Increase (decrease) in deferred revenue (30,700)

Decrease in deferred tax asset 8,400

Decrease in valuation allowance 8,400

Accounting Standards Update 2014-09 | Combined 2018 AZ Agreements

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Increase (decrease) in deferred revenue (39,900)

Accounting Standards Update 2014-09 | PCV/SAV Agreement

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Increase (decrease) in deferred revenue 13,900

Accounting Standards Update 2014-09 | 2016 VEGF Exercise

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Increase (decrease) in deferred revenue (4,300)

Accounting Standards Update 2014-09 | Accumulated Deficit

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Cumulative-effect adjustment $ 28,000

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.
+ References
No definition available.
+ Details

Name: us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R31.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Basis of Presentation and Recent Accounting Standards - Effect of Adoption of ASC 606 on Condensed Consolidated Financial Statements (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Jan. 01, 2019

Dec. 31, 2018

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Deferred revenue, current $ 73,958 $ 81,775 $ 109,056

Deferred revenue, non-current 156,862 161,911 165,352

Accounts receivable 5,646 8,948 11,686

Accumulated deficit (1,111,300) (978,643) (1,006,627)

Total revenue 16,025

Loss from operations (141,833) $ (77,402)

Loss before benefit from income taxes (132,681) (72,376)

Net (loss) income $ (132,657) $ (72,376)

Net loss per share - basic and diluted (usd per share) $ (0.40) $ (1.16)

Collaboration revenue

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total revenue $ 13,301

Collaboration revenue from related party

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total revenue 814

Accounting Standards Update 2014-09

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Accounts receivable (2,700)

Balance without adoption of ASC 606

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Deferred revenue, current 110,410 109,056

Deferred revenue, non-current 127,022 165,352

Accounts receivable 11,686

Accumulated deficit (1,117,377) $ (1,006,627)

Total revenue 37,932

Loss from operations (119,926)

Loss before benefit from income taxes (110,774)

Net (loss) income $ (110,750)

Net loss per share - basic and diluted (usd per share) $ (0.34)

Balance without adoption of ASC 606 | Collaboration revenue

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total revenue $ 11,515

Balance without adoption of ASC 606 | Collaboration revenue from related party

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total revenue 25,191

Adjustments | Accounting Standards Update 2014-09

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Deferred revenue, current 36,452 (27,281)

Deferred revenue, non-current (29,840) (3,441)

Accounts receivable (2,738)

Accumulated deficit (6,077) $ 27,984

Total revenue 21,907

Loss from operations 21,907

Loss before benefit from income taxes 21,907

Net (loss) income $ 21,907

Net loss per share - basic and diluted (usd per share) $ 0.06

Adjustments | Accounting Standards Update 2014-09 | Collaboration revenue

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total revenue $ (1,786)

Adjustments | Accounting Standards Update 2014-09 | Collaboration revenue from related party

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total revenue $ 24,377

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044
+ Details

Name: us-gaap_ContractWithCustomerLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=mrna_CollaborativeArrangementWithAffiliateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R32.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands

Mar. 31, 2019

Dec. 31, 2018

Mar. 31, 2018

Dec. 31, 2017

Accounting Policies [Abstract]

Cash and cash equivalents $ 502,934 $ 658,364 $ 90,479

Restricted cash 0 595 237

Restricted cash, non-current 11,823 11,532 11,798

Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows $ 514,757 $ 670,491 $ 102,514 $ 147,608

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_RestrictedCashCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 305
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84242212&loc=d3e2352-115587
+ Details

Name: us-gaap_RestrictedCashNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 57 R33.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue $ 16,025

Balance without adoption of ASC 606

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue 37,932

Collaboration Revenue by Strategic Collaborator

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue 14,115

Collaboration Revenue by Strategic Collaborator | Merck

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue 10,687

Collaboration Revenue by Strategic Collaborator | AstraZeneca

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue 814

Collaboration Revenue by Strategic Collaborator | Vertex

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue 2,614

Collaboration Revenue by Strategic Collaborator | Balance without adoption of ASC 606

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue 36,706 $ 27,460

Collaboration Revenue by Strategic Collaborator | Balance without adoption of ASC 606 | Merck

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue 11,515 15,967

Collaboration Revenue by Strategic Collaborator | Balance without adoption of ASC 606 | AstraZeneca

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue 25,191 7,350

Collaboration Revenue by Strategic Collaborator | Balance without adoption of ASC 606 | Vertex

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue $ 0 $ 4,143

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=mrna_MerckMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=mrna_AstraZenecaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=mrna_VertexMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R34.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details)
$ in Thousands
3 Months Ended

Mar. 31, 2019

USD ($)

Contract Assets:

Beginning balance $ 4,612

Additions 2,735

Deductions (3,747)

Ending balance 3,600

Contract Liabilities:

Beginning balance 240,924

Additions 1,137

Deductions (13,582)

Ending balance 228,479

Amounts included in contract liabiliies at the beginning of the period $ 13,582

X

- Definition
Change In Contract with Customer, Asset [Roll Forward]
+ References
No definition available.
+ Details

Name: mrna_ChangeInContractwithCustomerAssetRollForward

Namespace Prefix: mrna_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Change In Contract with Customer, Liability [Roll Forward]
+ References
No definition available.
+ Details

Name: mrna_ChangeInContractwithCustomerLiabilityRollForward

Namespace Prefix: mrna_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Contract With Customer, Asset, Decrease During Period
+ References
No definition available.
+ Details

Name: mrna_ContractWithCustomerAssetDecreaseDuringPeriod

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Contract With Customer, Asset, Increase During Period
+ References
No definition available.
+ Details

Name: mrna_ContractWithCustomerAssetIncreaseDuringPeriod

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Contract With Customer, Liability, Decrease During Period
+ References
No definition available.
+ Details

Name: mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Contract With Customer, Liability, Increase During Period
+ References
No definition available.
+ Details

Name: mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044
+ Details

Name: us-gaap_ContractWithCustomerAssetNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 59 R35.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration Agreements - Remaining Performance Obligation (Details) - USD ($)
$ in Millions

Mar. 31, 2019

Jan. 01, 2019

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price $ 279.5

PCV/SAV Agreement

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price $ 213.0

PCV/SAV Agreement | Upfront Payment

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 200.0

PCV/SAV Agreement | Upfront Payment, Premium Associated With Contemporaneous Sale Of Preferred Stock

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 13.0

PCV/SAV Agreement | PCV Performance Obligation

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 206.3

PCV/SAV Agreement | KRAS Performance Obligation

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 6.7

2015 Merck Agreement

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 65.0

2015 Merck Agreement | Milestone Payments

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 5.0

2015 Merck Agreement | Upfront Payment

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 60.0

2015 Merck Agreement | Upfront Payment, Research And Development

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 50.0

2015 Merck Agreement | Upfront Payment, Funding From 2016 Amendment

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 10.0

2016 VEGF Exercise

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 55.1

2016 VEGF Exercise | Fixed Payments

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 40.0

2016 VEGF Exercise | Option Exercise Fee

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 10.0

2016 VEGF Exercise | Variable Consideration

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 15.1

2016 VEGF Exercise | Milestone Payments

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 30.0

2013 AZ Agreements

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 240.0

Combined 2018 AZ Agreements

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 400.0

Combined 2018 AZ Agreements | Variable Consideration

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 160.0

Combined 2018 AZ Agreements | Estimated Reimbursement

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 40.0

Combined 2018 AZ Agreements | Milestone Payments

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 120.0

Combined 2018 AZ Agreements | Milestone Payments | Toxicity Milestone

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 60.0

Combined 2018 AZ Agreements | Milestone Payments | Competition Milestone

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 60.0

Combined 2018 AZ Agreements | Combined 2018 AZ Agreement Performance Obligation

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 292.4

Combined 2018 AZ Agreements | IL12 Performance Obligation

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 8.1

Combined 2018 AZ Agreements | Oncology Development Target Performance Obligation

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 8.1

Combined 2018 AZ Agreements | Development And Commercialization License And Manufacturing Obligations For IL12

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 89.8

Combined 2018 AZ Agreements | Development And Commercialization Rights And Manufacturing Services For An Oncology Development Target

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 1.6

Vertex Agreement

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 24.4

Vertex Agreement | Upfront Payment

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 20.0

Vertex Agreement | Research And Development Funding

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price $ 4.4

X

- Definition
Amount of transaction price allocated to performance obligation that has not been recognized as revenue.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045
+ Details

Name: us-gaap_RevenueRemainingPerformanceObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_PerformanceObligationAxis=mrna_PCVPerformanceObligationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_PerformanceObligationAxis=mrna_KRASPerformanceObligationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_MerckAgreement2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_MilestonePaymentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentResearchAndDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentFundingFrom2016AmendmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_FixedPaymentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_OptionExerciseFeeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_VariableConsiderationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_EstimatedReimbursementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_ToxicityMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_CompetitionMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_PerformanceObligationAxis=mrna_Combined2018AZAgreementPerformanceObligationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_PerformanceObligationAxis=mrna_IL12PerformanceObligationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_PerformanceObligationAxis=mrna_OncologyDevelopmentTargetPerformanceObligationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_PerformanceObligationAxis=mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_PerformanceObligationAxis=mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_ResearchAndDevelopmentFundingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 60 R36.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details)
1 Months Ended 3 Months Ended 12 Months Ended

Jun. 30, 2018

option

Oct. 31, 2017

Jan. 31, 2016

Mar. 31, 2013

USD ($)

milestone

option

Mar. 31, 2019

USD ($)

Mar. 31, 2018

USD ($)

Dec. 31, 2018

USD ($)

Dec. 31, 2016

USD ($)

Jan. 01, 2019

USD ($)

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Transaction price $ 279,500,000

Total collaborative revenue 16,025,000

Deferred revenue 228,479,000 $ 240,924,000

Revenue 16,025,000 $ 29,039,000

Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue 13,301,000

Revenue 13,301,000 20,110,000

2013 AZ Agreements

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Number of options | option 40

Upfront cash payments $ 240,000,000 $ 10,000,000

Estimated arrangement consideration $ 180,000,000.0

Number of milestones | milestone 3

Option exercise fee $ 10,000,000

Termination period 90 days

Transaction price $ 240,000,000

2013 AZ Agreements | VEGF-A product (AZD8601)

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Upfront cash payments 30,000,000

2013 AZ Agreements | Development Milestones

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Estimated arrangement consideration $ 100,000,000.0

2013 AZ Agreements | Regulatory Milestones

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Estimated arrangement consideration 100,000,000.0

2013 AZ Agreements | Commercial Milestones

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Estimated arrangement consideration $ 200,000,000.0

2013 AZ Agreements | Maximum

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Earn-out payments 12.00%

2016 AZ Agreement

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Termination period 90 days

Suspension period 12 months

2016 AZ Agreement | Maximum

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Tiered royalties at default rate 20.00%

Tiered royalties 30.00%

2016 AZ Agreement | Minimum

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Tiered royalties 10.00%

2017 AZ Agreement

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Termination period 90 days

Suspension period 12 months

2017 AZ Agreement | Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue 0 0

2017 AZ Agreement | Maximum

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Tiered royalties 30.00%

2017 AZ Agreement | Minimum

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Tiered royalties 10.00%

2018 A&R Agreements

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Number of options | option 40

Termination period 90 days

Combined 2018 AZ Agreements

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Increase to the transaction price 300,000

Transaction price 400,000,000

Deferred revenue 75,500,000 115,600,000 75,700,000

Combined 2018 AZ Agreements | Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue 800,000 7,400,000

2016 VEGF Exercise

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Increase to the transaction price 0

Transaction price 55,100,000

Deferred revenue 37,100,000 $ 41,200,000 37,100,000

2016 VEGF Exercise | Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue $ 0 $ 0

IL12 Performance Obligation | Combined 2018 AZ Agreements

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Transaction price $ 8,100,000

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Earnout Payment, Percent
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent

Namespace Prefix: mrna_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Maximum Amount
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Number Of Milestones
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones

Namespace Prefix: mrna_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Number Of Options
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions

Namespace Prefix: mrna_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Option Exercise Fee
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Product Suspension Period
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod

Namespace Prefix: mrna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Default Percent
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent

Namespace Prefix: mrna_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Percent
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent

Namespace Prefix: mrna_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Termination Period
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod

Namespace Prefix: mrna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredRevenueAdditions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of transaction price allocated to performance obligation that has not been recognized as revenue.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045
+ Details

Name: us-gaap_RevenueRemainingPerformanceObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_VEGFAProductAZD8601Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_DevelopmentMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_RegulatoryMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_CommercialMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2016StrategicAllianceWithAstraZenecaIL12Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_PerformanceObligationAxis=mrna_IL12PerformanceObligationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 R37.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration Agreements - Merck – Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details)
1 Months Ended 3 Months Ended 52 Months Ended

Apr. 30, 2018

USD ($)

Jun. 30, 2016

USD ($)

Jan. 31, 2016

USD ($)

Jan. 31, 2015

USD ($)

Mar. 31, 2019

USD ($)

Mar. 31, 2018

USD ($)

May 09, 2019

USD ($)

candidate

Jan. 01, 2019

USD ($)

Dec. 31, 2018

USD ($)

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Upfront payment $ (15,604,000) $ 6,193,000

Total collaborative revenue 16,025,000

Deferred revenue 228,479,000 $ 240,924,000

Amortization of deferred revenue due to the satisfaction of our performance obligation during the period 13,582,000

Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue 13,301,000

2015 Merck Agreement

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Proceeds from equity investment $ 50,000,000

Upfront cash payments $ 10,000,000

Increase to the transaction price 0

Deferred revenue 0 0

2015 Merck Agreement | Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue 2,000,000

2015 Merck Agreement | Subsequent Event

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Performance period 3 years

Research period 4 years

Number of product candidates | candidate 5

Upfront payment $ 50,000,000

Estimated arrangement consideration 300,000,000.0

2015 Merck Agreement | Subsequent Event | Milestone Payments

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue $ 5,000,000

Separate Agreements With Merck | Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue 500,000

PCV Agreement

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Estimated arrangement consideration $ 250,000,000

Upfront cash payments $ 200,000,000

PCV Agreement | Series H Redeemable Convertible Preferred Stock

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Aggregate net proceeds from the offering $ 125,000,000

Premium recorded to deferred revenue 13,000,000

PCV Agreement | PCV products

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Estimated arrangement consideration 243,000,000 243,000,000

PCV/SAV Agreement

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Increase to the transaction price 0

Deferred revenue 115,000,000 $ 125,200,000 $ 111,300,000

Amortization of deferred revenue due to the satisfaction of our performance obligation during the period 10,200,000

PCV/SAV Agreement | PCV products

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Estimated arrangement consideration $ 243,000,000

PCV/SAV Agreement | Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue $ 10,200,000 $ 14,000,000

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Maximum Amount
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Number Of Product Candidates
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates

Namespace Prefix: mrna_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Performance Period
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod

Namespace Prefix: mrna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Research Period
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod

Namespace Prefix: mrna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredRevenueAdditions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share.
+ References
No definition available.
+ Details

Name: us-gaap_RedemptionPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Cash received on stock transaction after deduction of issuance costs.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_MerckAgreement2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_MilestonePaymentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_SeparateAgreementsWithMerckMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_PersonalizedMRNACancerVaccinesProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 62 R38.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration Agreements - Vertex – 2016 Strategic Alliance in Cystic Fibrosis (Details) - USD ($)
1 Months Ended 3 Months Ended

Jul. 31, 2016

Mar. 31, 2019

Mar. 31, 2018

Dec. 31, 2018

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue $ 16,025,000

Amortization of deferred revenue due to the satisfaction of our performance obligation during the period 13,582,000

Deferred revenue 228,479,000 $ 240,924,000

Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue 13,301,000

Vertex Agreement

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research period 3 years

Upfront cash payments $ 20,000,000

Research extension period 1 year

Proceeds from equity investment $ 20,000,000

Termination period 90 days

Written notice period 180 days

Increase to the transaction price 0

Amortization of deferred revenue due to the satisfaction of our performance obligation during the period 2,600,000

Deferred revenue 800,000 $ 3,300,000

Vertex Agreement | Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue $ 2,600,000 $ 4,100,000

Vertex Agreement | Development Milestones

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Estimated arrangement consideration $ 55,000,000.0

Vertex Agreement | Regulatory Milestones

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Estimated arrangement consideration 220,000,000.0

Vertex Agreement | Regulatory Milestones, Subsequent Products

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Estimated arrangement consideration $ 3,000,000.0

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Marketing Approval, Termination Period
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod

Namespace Prefix: mrna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Maximum Amount
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Research Extension Period
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod

Namespace Prefix: mrna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Research Period
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod

Namespace Prefix: mrna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Termination Period
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod

Namespace Prefix: mrna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredRevenueAdditions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_DevelopmentMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_RegulatoryMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_RegulatoryMilestonesSubsequentProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 R39.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration Agreements - Timing of Satisfaction (Details) - USD ($)
$ in Millions

Mar. 31, 2019

Jan. 01, 2019

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price $ 279.5

Combined 2018 AZ Agreements

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price $ 400.0

Combined 2018 AZ Agreements | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 9.7

Combined 2018 AZ Agreements | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil)

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 112.5

2016 VEGF Exercise

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 55.1

2016 VEGF Exercise | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 51.0

PCV/SAV Agreement

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 213.0

PCV/SAV Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 115.0

Vertex Agreement

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price $ 24.4

Vertex Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price $ 1.1

X

- Definition
Amount of transaction price allocated to performance obligation that has not been recognized as revenue.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045
+ Details

Name: us-gaap_RevenueRemainingPerformanceObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-04-01

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=None

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 64 R40.htm IDEA: XBRL DOCUMENT v3.19.1

Grants (Details)
1 Months Ended 3 Months Ended

Mar. 31, 2019

USD ($)

contract_option

Sep. 30, 2016

USD ($)

Jan. 31, 2016

USD ($)

Oct. 31, 2013

USD ($)

Mar. 31, 2019

USD ($)

contract_option

Mar. 31, 2018

USD ($)

Dec. 31, 2018

USD ($)

Disaggregation of Revenue [Line Items]

Total revenue $ 16,025,000

Deferred revenue $ 228,479,000 228,479,000 $ 240,924,000

BARDA

Disaggregation of Revenue [Line Items]

Award amount $ 125,800,000

Amount committed for funding 117,300,000 117,300,000

Available funding $ 8,500,000 $ 8,500,000

BARDA | Initial base award

Disaggregation of Revenue [Line Items]

Award amount 8,200,000

BARDA | Contract options

Disaggregation of Revenue [Line Items]

Award amount $ 117,600,000

Number of contract options exercised | contract_option 3 3

Number of contract options | contract_option 4 4

BARDA | Grant revenue

Disaggregation of Revenue [Line Items]

Total revenue $ 1,500,000 $ 1,000,000

The Bill & Melinda Gates Foundation

Disaggregation of Revenue [Line Items]

Award amount $ 100,000,000.0

Available funding $ 80,000,000 80,000,000

Deferred revenue 600,000 600,000 $ 800,000

The Bill & Melinda Gates Foundation | Initial project

Disaggregation of Revenue [Line Items]

Award amount $ 20,000,000.0

Amount committed for funding 21,100,000 21,100,000

The Bill & Melinda Gates Foundation | Follow-on project

Disaggregation of Revenue [Line Items]

Award amount 1,100,000.0

The Bill & Melinda Gates Foundation | Grant revenue

Disaggregation of Revenue [Line Items]

Total revenue 300,000 300,000

DARPA

Disaggregation of Revenue [Line Items]

Award amount $ 24,600,000 19,700,000

Amount committed for funding $ 19,700,000 19,700,000 19,700,000

DARPA | Grant revenue

Disaggregation of Revenue [Line Items]

Total revenue $ 0 $ 200,000

X

- Definition
Revenue From Grants, Current Funding Capacity
+ References
No definition available.
+ Details

Name: mrna_RevenueFromGrantsCurrentFundingCapacity

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Revenue From Grants, Maximum Award
+ References
No definition available.
+ Details

Name: mrna_RevenueFromGrantsMaximumAward

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revenue From Grants, Number Of Contract Options
+ References
No definition available.
+ Details

Name: mrna_RevenueFromGrantsNumberOfContractOptions

Namespace Prefix: mrna_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Revenue From Grants, Number Of Contract Options Exercised
+ References
No definition available.
+ Details

Name: mrna_RevenueFromGrantsNumberOfContractOptionsExercised

Namespace Prefix: mrna_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Revenue From Grants, Remaining Funding Capacity
+ References
No definition available.
+ Details

Name: mrna_RevenueFromGrantsRemainingFundingCapacity

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DisaggregationOfRevenueLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_InitialBaseAwardMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_ContractOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_GrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_InitialProjectMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_FollowOnProjectMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 65 R41.htm IDEA: XBRL DOCUMENT v3.19.1

Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details) - USD ($)
$ in Thousands

Mar. 31, 2019

Dec. 31, 2018

Mar. 31, 2018

Debt Securities, Available-for-sale [Line Items]

Amortized Cost $ 1,042,516 $ 1,037,372

Level 2

Debt Securities, Available-for-sale [Line Items]

Amortized Cost 1,545,451 $ 1,695,737

Unrealized Gains 1,356 120

Unrealized Losses (224) (1,440)

Fair Value 1,546,583 1,694,417

Level 2 | Cash and Cash Equivalents

Debt Securities, Available-for-sale [Line Items]

Fair Value 502,934 658,364

Level 2 | Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value 605,990 863,063

Level 2 | Non- Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value 437,659 172,990

Cash and Cash Equivalents

Debt Securities, Available-for-sale [Line Items]

Amortized Cost 502,935 658,365

Unrealized Gains 0 20

Unrealized Losses (1) (21)

Fair Value 502,934 658,364

Cash and Cash Equivalents | Cash and Cash Equivalents

Debt Securities, Available-for-sale [Line Items]

Fair Value 502,934 658,364

Cash and Cash Equivalents | Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value 0 0

Cash and Cash Equivalents | Non- Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value 0 0

Certificates of deposit | Level 2

Debt Securities, Available-for-sale [Line Items]

Amortized Cost 84,114 173,102

Unrealized Gains 72 42

Unrealized Losses (1) (36)

Fair Value 84,185 173,108

Certificates of deposit | Level 2 | Cash and Cash Equivalents

Debt Securities, Available-for-sale [Line Items]

Fair Value 0 0

Certificates of deposit | Level 2 | Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value 80,483 157,920

Certificates of deposit | Level 2 | Non- Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value 3,702 15,188

U.S. treasury securities | Level 2

Debt Securities, Available-for-sale [Line Items]

Amortized Cost 119,347 152,205

Unrealized Gains 155 18

Unrealized Losses (4) (48)

Fair Value 119,498 152,175

U.S. treasury securities | Level 2 | Cash and Cash Equivalents

Debt Securities, Available-for-sale [Line Items]

Fair Value 0 0

U.S. treasury securities | Level 2 | Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value 79,475 152,175

U.S. treasury securities | Level 2 | Non- Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value 40,023 0

Debt securities of U.S. government agencies and corporate entities | Level 2

Debt Securities, Available-for-sale [Line Items]

Amortized Cost 839,055 712,065

Unrealized Gains 1,129 40

Unrealized Losses (218) (1,335)

Fair Value 839,966 710,770

Debt securities of U.S. government agencies and corporate entities | Level 2 | Cash and Cash Equivalents

Debt Securities, Available-for-sale [Line Items]

Fair Value 0 0

Debt securities of U.S. government agencies and corporate entities | Level 2 | Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value 446,032 552,968

Debt securities of U.S. government agencies and corporate entities | Level 2 | Non- Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value $ 393,934 $ 157,802

X

- Definition
Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=mrna_CurrentMarketableSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=mrna_NoncurrentMarketableSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 66 R42.htm IDEA: XBRL DOCUMENT v3.19.1

Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details) - USD ($)
$ in Thousands

Mar. 31, 2019

Mar. 31, 2018

Amortized Cost

Due in one year or less $ 605,687 $ 864,003

Due after one year through five years 436,829 173,369

Amortized Cost 1,042,516 1,037,372

Estimated Fair Value

Due in one year or less 605,990 863,063

Due after one year through five years 437,659 172,990

Total $ 1,043,649 $ 1,036,053

X

- Definition
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 67 R43.htm IDEA: XBRL DOCUMENT v3.19.1

Financial Instruments - Narrative (Details)
$ in Millions

Mar. 31, 2019

USD ($)

security

Dec. 31, 2018

USD ($)

security

Investments, Debt and Equity Securities [Abstract]

Number of available-for-sale securitiesin a continuous unrealized loss position for more than 12 months | security 32 25

Estimated fair value of total investment portfolio in a continuous unrealized loss position for more than 12 months $ 135.8 $ 82.8

Gross unrealized loss of total investment portfolio in a continuous unrealized loss position for more than 12 months $ 0.2 $ 0.4

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer.
+ References
No definition available.
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 68 R44.htm IDEA: XBRL DOCUMENT v3.19.1

Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands

Mar. 31, 2019

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Prepaid expenses $ 7,895 $ 10,401

Tenant incentives receivables 11,336 10,089

Interest receivable on marketable securities 6,061 7,909

Prepaid expenses and other current assets $ 25,292 $ 28,399

X

- Definition
Tenant Incentives Receivables, Current
+ References
No definition available.
+ Details

Name: mrna_TenantIncentivesReceivablesCurrent

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 69 R45.htm IDEA: XBRL DOCUMENT v3.19.1

Balance Sheet Components - Property and Equipment, Net (Details) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Dec. 31, 2018

Property, Plant and Equipment [Line Items]

Property, plant and equipment, gross $ 285,195 $ 276,433

Less: Accumulated depreciation (71,735) (64,456)

Property and equipment, net 213,460 211,977

Depreciation and amortization 7,328 $ 5,153

Building

Property, Plant and Equipment [Line Items]

Property, plant and equipment, gross 140,442 140,442

Laboratory equipment

Property, Plant and Equipment [Line Items]

Property, plant and equipment, gross 98,891 96,907

Leasehold improvements

Property, Plant and Equipment [Line Items]

Property, plant and equipment, gross 15,861 13,741

Furniture, fixtures and other

Property, Plant and Equipment [Line Items]

Property, plant and equipment, gross 2,122 2,122

Computer equipment and software

Property, Plant and Equipment [Line Items]

Property, plant and equipment, gross 9,456 11,513

Internally developed software

Property, Plant and Equipment [Line Items]

Property, plant and equipment, gross 7,020 7,020

Construction in progress

Property, Plant and Equipment [Line Items]

Property, plant and equipment, gross $ 11,403 $ 4,688

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 70 R46.htm IDEA: XBRL DOCUMENT v3.19.1

Balance Sheet Components - Accrued Liabilities (Details) - USD ($)
$ in Thousands

Mar. 31, 2019

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

In-licenses $ 0 $ 22,000

Property and equipment 7,756 12,089

Compensation-related 11,577 23,406

External goods and services 22,850 21,578

Accrued liabilities $ 42,183 $ 79,073

X

- Definition
Accrued External Goods And Services, Current
+ References
No definition available.
+ Details

Name: mrna_AccruedExternalGoodsAndServicesCurrent

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued In-Licenses, Current
+ References
No definition available.
+ Details

Name: mrna_AccruedInLicensesCurrent

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued Property And Equipment, Current
+ References
No definition available.
+ Details

Name: mrna_AccruedPropertyAndEquipmentCurrent

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 71 R47.htm IDEA: XBRL DOCUMENT v3.19.1

Commitments and Contingencies - Lease Obligations (Details)
ft² in Millions, $ in Millions
3 Months Ended

Mar. 31, 2019

USD ($)

ft²

campus

Mar. 31, 2018

USD ($)

Feb. 28, 2019

ft²

extension_period

Operating Leased Assets [Line Items]

Number of campuses | campus 2

Rent expense | $ $ 4.8 $ 5.2

Cambridge, MA

Operating Leased Assets [Line Items]

Area of office space (in sqft) 0.2

Norwood, MA

Operating Leased Assets [Line Items]

Area of office space (in sqft) 0.2 0.2

Number of extension terms | extension_period 4

Extension period 5 years

X

- Definition
Lessee, Operating Lease, Number Of Extension Periods
+ References
No definition available.
+ Details

Name: mrna_LesseeOperatingLeaseNumberOfExtensionPeriods

Namespace Prefix: mrna_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Area of a real estate property.
+ References
No definition available.
+ Details

Name: us-gaap_AreaOfRealEstateProperty

Namespace Prefix: us-gaap_

Data Type: num:areaItemType

Balance Type: na

Period Type: instant

X

- Definition
Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseRenewalTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLeasedAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717
+ Details

Name: us-gaap_OperatingLeasesRentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of units (items of property) under operating lease arrangements.
+ References
No definition available.
+ Details

Name: us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits

Namespace Prefix: us-gaap_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Details

Name: srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 72 R48.htm IDEA: XBRL DOCUMENT v3.19.1

Commitments and Contingencies - Future Minimum Lease Payments Under Non-Cancelable Operating Lease Agreements (Details)
$ in Thousands

Mar. 31, 2019

USD ($)

Minimum Lease Payments

2019 (remainder of the year) $ 15,190

2020 22,874

2021 24,105

2022 23,455

2023 20,498

Thereafter 140,384

Total $ 246,506

X

- Definition
Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 73 R49.htm IDEA: XBRL DOCUMENT v3.19.1

Commitments and Contingencies - Strategic Collaborations (Details) - PCV Agreement - USD ($)
$ in Millions

Mar. 31, 2019

Dec. 31, 2018

Jun. 30, 2016

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Budgeted amount $ 250.0

PCV products

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Budgeted amount $ 243.0 $ 243.0

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Maximum Amount
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_PersonalizedMRNACancerVaccinesProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 74 R50.htm IDEA: XBRL DOCUMENT v3.19.1

Shareholders' Equity (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended

Dec. 11, 2018

Mar. 31, 2018

Mar. 31, 2019

Dec. 31, 2018

May 07, 2018

Feb. 28, 2018

Subsidiary, Sale of Stock [Line Items]

Common stock, shares authorized 1,600,000,000 1,600,000,000 1,600,000,000 775,000,000

Redeemable convertible preferred stock, shares authorized 509,352,795

Common stock, par value (usd per share) $ 0.0001 $ 0.0001 $ 0.0001

Preferred stock, shares authorized 162,000,000 162,000,000 162,000,000

Preferred stock, par value (usd per share) $ 0.0001 $ 0.0001 $ 0.0001

Offering expenses $ 10,517

IPO

Subsidiary, Sale of Stock [Line Items]

Shares of common stock issued (in shares) 26,275,993

Price per share (usd per share) $ 23.00

Aggregate net proceeds from the offering $ 563,000

Underwriting discounts 33,200

Offering expenses $ 8,100

IPO | Common Stock

Subsidiary, Sale of Stock [Line Items]

Preferred stock converted into common stock (in shares) 236,012,913

X

- Definition
Payments Of Underwriting Discounts
+ References
No definition available.
+ Details

Name: mrna_PaymentsOfUnderwritingDiscounts

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued for each share of convertible preferred stock that is converted.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644
+ Details

Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Cash received on stock transaction after deduction of issuance costs.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SubsidiarySaleOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TemporaryEquitySharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 75 R51.htm IDEA: XBRL DOCUMENT v3.19.1

Stock-Based Compensation - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended

Nov. 30, 2018

Mar. 31, 2019

Mar. 31, 2018

Dec. 05, 2018

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Aggregate number of shares authorized for issuance (in shares) 72,400,000.0

Stock options exercised (in shares) 5,525

Total intrinsic value of options exercised (less than for the year ended December 31, 2017) $ 100

Exercise of options to purchase common stock, net 57 $ 22

Total unrecognized compensation cost related to non-vested stock-based compensation $ 253,100

Weighted-average period of cost expected to be recognized 3 years 6 months

2018 Equity Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of additional shares of common stock authorized for issuance (in shares) 13,200,000

Shares available for future grant (in shares) 17,900,000

ESPP | Employee stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Aggregate number of shares authorized for issuance (in shares) 810,000

X

- Definition
Unrecognized cost of unvested share-based compensation awards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of additional shares authorized for issuance under an established share-based compensation plan.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=mrna_StockOptionAndIncentivePlan2018Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=mrna_EmployeeStockPurchasePlan2018Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 76 R52.htm IDEA: XBRL DOCUMENT v3.19.1

Stock-Based Compensation - Options Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended

Mar. 31, 2019

Dec. 31, 2018

Number of Options

Outstanding at beginning of period (in shares) 50,821,132

Granted (in shares) 5,443,286

Exercised (in shares) (5,525)

Cancelled/forfeited (in shares) (2,987,612)

Outstanding at end of period (in shares) 53,271,281 50,821,132

Weighted- Average Exercise Price per Share

Outstanding at beginning of period (usd per share) $ 12.16

Granted (usd per share) 20.59

Exercised (usd per share) 9.62

Cancelled/forfeited (usd per share) 14.29

Outstanding at end of period (usd per share) 12.92 $ 12.16

Weighted- Average Grant Date Fair Value per Share

Outstanding at beginning of period (usd per share) 6.59

Granted (usd per share) 12.16

Exercised (usd per share) 5.62

Cancelled/forfeited (usd per share) 8.48

Outstanding at end of period (usd per share) $ 6.99 $ 6.59

Outstanding and Exercisable

Number of Options, Exercisable (in shares) 24,769,502

Weighted- Average Exercise Price per Share, Exercisable (usd per share) $ 8.54

Weighted- Average Grant Date Fair Value per Share, Exercisable (usd per share) $ 4.05

Weighted- Average Remaining Contractual Term, Outstanding 7 years 5 months 15 days 7 years 1 month

Weighted- Average Remaining Contractual Term, Exercisable 5 years 8 months

Aggregate Intrinsic Value, Outstanding $ 412,480 $ 220,434

Aggregate Intrinsic Value, Exercisable $ 292,602

Vested and expected to vest

Number of Options (in shares) 28,501,493

Weighted- Average Exercise Price per Share (usd per share) $ 16.73

Weighted- Average Grant Date Fair Value per Share $ 9.55

Weighted- Average Remaining Contractual Term 9 years

Aggregate Intrinsic Value $ 119,876

X

- Definition
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value
+ References
No definition available.
+ Details

Name: mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue

Namespace Prefix: mrna_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Grant Date Fair Value
+ References
No definition available.
+ Details

Name: mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: mrna_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Grant Date Fair Value
+ References
No definition available.
+ Details

Name: mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: mrna_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value
+ References
No definition available.
+ Details

Name: mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue

Namespace Prefix: mrna_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value
+ References
No definition available.
+ Details

Name: mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue

Namespace Prefix: mrna_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Share-Based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value [Roll Forward]
+ References
No definition available.
+ Details

Name: mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: mrna_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 77 R53.htm IDEA: XBRL DOCUMENT v3.19.1

Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details) - Options - $ / shares
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Risk-free interest rate 2.48% 2.71%

Expected term 6 years 1 month 14 days 6 years 22 days

Expected volatility 62.00% 63.00%

Expected dividends 0.00% 0.00%

Weighted average

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted average fair value per share (usd per share) $ 12.16 $ 8.48

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_WeightedAverageMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 78 R54.htm IDEA: XBRL DOCUMENT v3.19.1

Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details) - $ / shares
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Restricted Common Stock

Number of Shares/Units

Outstanding, non-vested at beginning of period (in shares) 198,597

Issued (in shares) 0

Vested (in shares) 48,911

Canceled, forfeited and adjustments, net (in shares) 711

Outstanding, non-vested at end of period (in shares) 150,397

Weighted-Average Grant Date per Share/Unit

Outstanding, non-vested at beginning of period (usd per share) $ 12.15

Issued (usd per share) 0.00

Vested (usd per share) 12.15

Canceled, forfeited and adjustments, net (usd per share) 12.15

Outstanding, non-vested at end of period (usd per share) $ 12.15

Restricted Common Stock Units

Number of Shares/Units

Outstanding, non-vested at beginning of period (in shares) 458,715

Issued (in shares) 558,208

Vested (in shares) 14,334

Canceled, forfeited and adjustments, net (in shares) 5,440

Pending settlement (in shares) (14,334)

Outstanding, non-vested at end of period (in shares) 1,011,483

Weighted-Average Grant Date per Share/Unit

Outstanding, non-vested at beginning of period (usd per share) $ 11.93

Issued (usd per share) 20.77

Vested (usd per share) 11.93

Canceled, forfeited and adjustments, net (usd per share) 20.93

Pending settlement (usd per share) $ 11.93

Outstanding, non-vested at end of period (usd per share) $ 16.76

Settlement period after consummation of IPO 360 days

X

- Definition
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Settled In Period
+ References
No definition available.
+ Details

Name: mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInPeriod

Namespace Prefix: mrna_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Settled In Period, Weighted Average Grant Date Fair Value
+ References
No definition available.
+ Details

Name: mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: mrna_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-Based Compensation Arrangement By Share-Based Payment Award, Vested Awards, Settlement Period
+ References
No definition available.
+ Details

Name: mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAwardsSettlementPeriod

Namespace Prefix: mrna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(3)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 79 R55.htm IDEA: XBRL DOCUMENT v3.19.1

Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock-based compensation expense $ 18,497 $ 11,851

Research and development

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock-based compensation expense 10,783 7,356

General and administrative

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock-based compensation expense 7,714 4,495

Options

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock-based compensation expense 17,487 10,048

Restricted common stock and units

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock-based compensation expense $ 1,010 $ 1,803

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=mrna_RestrictedStockAndRestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 80 R56.htm IDEA: XBRL DOCUMENT v3.19.1

Income Taxes (Details) - USD ($)
$ in Thousands

Mar. 31, 2019

Jan. 01, 2019

Dec. 31, 2018

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Cumulative-effect adjustment $ 27,984

Decrease in accounts receivable $ (5,646) (8,948) $ (11,686)

Accumulated Deficit

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Cumulative-effect adjustment 27,984

Accounting Standards Update 2014-09

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Deferred Tax Assets, Valuation Allowance 8,400

Decrease in deferred revenue 30,700

Decrease in accounts receivable 2,700

Decrease in deferred tax asset 8,400

Accounting Standards Update 2014-09 | Accumulated Deficit

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Cumulative-effect adjustment $ 28,000

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.
+ References
No definition available.
+ Details

Name: us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 81 R57.htm IDEA: XBRL DOCUMENT v3.19.1

Net Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Numerator:

Net loss $ (132,657) $ (72,376)

Cumulative dividends on redeemable convertible preferred stock 0 (3,481)

Net loss $ (132,657) $ (75,857)

Denominator:

Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted 328,809,986 65,430,835

Net loss per share attributable to common stockholders, basic and diluted (usd per share) $ (0.40) $ (1.16)

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1377-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RedeemablePreferredStockDividends

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 82 R58.htm IDEA: XBRL DOCUMENT v3.19.1

Net Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares
3 Months Ended 12 Months Ended

Mar. 31, 2019

Dec. 31, 2018

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Anti-dilutive securities (in shares) 54,433,161 305,141,893

Redeemable convertible preferred stock

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Anti-dilutive securities (in shares) 0 260,817,303

Stock options

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Anti-dilutive securities (in shares) 53,271,281 43,135,998

Restricted common stock

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Anti-dilutive securities (in shares) 150,397 729,877

Restricted common stock units

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Anti-dilutive securities (in shares) 1,011,483 458,715

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 83 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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
=6B[B/6X0]H,[%O M-#3S!! ZW!HR8-XJ0LK,ESI<#3I7%S1LFKIM='O/EUC?\F8&P,FM>A."$!]8 M5?-\R5M_4$*8"1W,@!^M9)*M%+S4N)4.;'96)+>FSS#]A&:6'XP^&WG^0&/] MPF.][!J+QGE?-+^>D/W7O+ 47C=&6O=/\)_I"/[STL@+DO?S 1!%)AKG@^&Y M?+1G/E9H-B;3(9#6?TK.)_X(Y%Z'O37FB_@G[Y-M0Z'K <^T"PK9&U#,&)%D M;$4!!\5B*]$*EK9B#EZ[YT1VXDC]7H[^=.;=GD+9N'>3]A^SS]Y;)^NQ:L>? M/;:4D@7OHS"'+HXZN@1><#D5.)XEKS$ 8V['H/\5_G)T>@&*" :A\M/*+,ED M*=R2-'Q748]5MNEH)*_L6%VT\Q%P^PDLC=_K.UGLTMN6T)Y\OE])8FO-NRV+ MS6>?O.Y-R(R>.AXU_O2TDSX]NTBG(PH#& V \\M)G\'7X^$%"DC3J9WS" 6= M= *B%#_<)16=29 LO E/O)/0(_2\+-GB2!*>#',L SWA^$'M'5%@.\HH)HR( M.()G(:]VPMPU6N4%,64-Y =?N;.LHLDYUUF4D%!)2J53]FN(@7:GS*9+Q16? M5Q?"!-Q\YB)0R'2QQ$PFOU1:T\?/OL"OO<,DW\$I'']0Y0*#GN%!ASF$?R^&$QP$2*(T"WY^-PGH0OLV9YIFR3YCR 7[B6RRD!CT8 M9(Q'%7P*. Y2,HQ\UCM1;P(^I361V6E\-O$D$#QT&@OCP"P9*3@/BGWS[-_; M4K"S]P3C6GF^Y-M"::%K2(,R[H_%&?A.U+\-$J7(>9JU)137R6]BBDC[Z@V$ M(JXH62T72OMN"P^1>P9)Y.O(I-)MK]DY!!D[7MZ\>W>L[N,N XQ1LK/4L]W@ M:^I,H*I#9!V0(NAJUVTLII"KS"S,OV"FAHO13G/UQN\D2#9#V9#ZH#F$=H71 MJAP^R[;%'G=$RTR'=G78\(?L4SMXP?UV6*2"/U:0-X=%B:4X&HPE45?D;_4" M+Y20&$Z)+01?H7:/F#DZ$^NCQ;\Z=:0)]!$7^NEB8$DI@=%N,[&Y=J^$SK?) M@Z$I=I%R3 )!/2\SN2/99DMN8QR?&UM+JXX\OB162-AVS+? FGC'\_KO=87<'9XK'<2K K B$(P,.Z M%QHLV5G!%0L,BEF7J^FW,^\G0R];F)UZ_CM29\V/+.7U>F^103BV++L=[UQ# M*J60:\G9Y@+Z,9[8$&3R>';A697]Q'@@VO@PM7N,AY0EB%>T V-;)!V#5'^F MS!'5R%J^WJPNB4>\,YVMGZJWATLZOKK:@+QPN]UHB+6O(JF-!P15[-].F1_+ M+34*@H&6.A#KTUDTD,\-=:#/M%&$1L).$=2JA\MBRKFW-.QKTBVC=EDSWF 6 M!<82_4#PHFUB9M]DG)Z?32FW[V@Z3B=3C#F]]K#.C!)DR#K(;Z=:\M$$Y&+4 MCFW&0\#96M492*GX^45>5E3J&#?1,H?H4"RXD+D)\WL^ZTA3BKD+D6,RO@!Q M_3*]O#A/SD'7FPS3B\F9V]H73P!;'0XDS?)HA$:R:)@*9I5PN!H*N]LFEVR*0JNZ M)P]46!G*XF337=/P]/Q.9PE*'$3T,9N B.OY[0XG:2C"3K^ M^_4[M=!,Q^@OF/8^YW1 5NC5%'%VBD'BZ>A\E$R&9^GH%/2SRU;$[PV96"CQ MY#E'ABXPNP#/WP5]O\]GE*3AZGO>(!*0T>?H'2:>@6AYW,X'Z1OO':>E2!-F M#'Z',>9=+O3DTVKY X4K_LMW:]%#OOL]&?5GJ/"!6L"UH++MO)!1J%V0_G*_J,A:2@Y*D7F,XD)C$[%R3J$VJQ<,E9.& MYA="=5L]^NGJZMVQEGS"TM6(1O5V:=&N=W(S+ K!RV2G;(U/H.!AI_)K"\-( MCFY>7A]+(6V455==ZD&J43>4&U=R47HK19Q+FIA$"*#31PO?%]P^^ZHLT>GX M/N=**B4Z>E;):'CR;X&@+WRJ(R:,_K67CH-&%KRGQB]A*.H[89T'S,:PCGOY M!<51M"#Z/ ,EK_XY%O^1D)PHC:+T?%*$'WW& +D/1Z]$ 4HNBPU] (@^C M*_:CG< T!(D+?R5U5QT;O+B_;.=W$@G*RKNH:*X9N=2-E*&?<@G4FQ7<)[H$ MW!\+$[WO*A9YM2^697'B9+94OZX8*DX4>>A?!8$K![WK_CRS3L>!IMT*0]IK M^>& ,*#\H 2!5O>120RE!BRYG"GI. 1N*L49; %1&XX<9 )K]% 7Y ^DV*;2 M$@"L5Y'OE=*4/$O1$\,1=E*CN^Z"1:)62/B5-I0SA8\"1O$7#MFG%.GL5X2D MAP^WF)+-C#5(&.PW 3CE'75AQ&5,-88+GU&<-'%J3GQJ #8SK7TH<0>Z2MVK M!R+LQ)3$$*_!4)EC#6SD9U3( MB;L3H&MK^1A93C3S//7A+B'8UI..BH8L2))6,J=$5B0.$+VV#I@Z/5>>(E&$ M[&R+^(#=1((D?D*M3D5JO))5W&DK\VC0JC*L]83?NRL4/_*V[.Y0)-;%3@IY M[7772(Y N09ALEJ#R$E%H3N+&#=A%>.&7L/G@?@[(Q.W[2#5:NTXLE7 H5WITE?>"]HPRPMSWM$N>%>4M 3VJ<0F!S:;J3SOMS0Z MUV;H'&\G:U*60JP(PXKVJ61425X. M,;AF6^/VTC@OP<^Z0B Y2E.XDF.-:.G,AW-"F2.E=:\(54)J;D-=;VJ/8 M<9!$4@[ZED/W*>\Q[6C]>VC+BQT=4L+F*'XI]DT5]!7SJ_+[M7+9,RA_*-O" M!NQQ*IWVB/TH!?AU]9@MNG3<#ELZLU:E%C!7.8,W7G__.RX^&TI\L^5I2S;$L49K>*! M:[I'J=^K@]+E(*4!_+K+F:T'YE]05_;Z3LSW69DM'[5\X([;6)$@AV4N[G,B M4/#/8R\-0YL4V8G'N^P$DI11FS>//\B4K$.H@-),&6E01Z^2Z$NFA^58V9 T]L N=Z MT:0"A^&P'VV0PEOS,KX^2+"Y5&6Y#[NS%4TOI G&#WE\0EE8>,4?3!UYTE.Z M??@(F!+'V,FD/&:Z1!\551ZBSJ9>GQ4&3(/Z$]9M";M^Q0L[L)T7;Y=G]Z)$ M=PS1#K3V0;H[&^WHO2:KA6-RZGC:CJ-24&Z6BS\ MA=7]'CV>S'4%*J\!DEVNC$KQK+>V5G[9M7&M@4^A[.EMDOL2L=%*!#$7RJI- M--SZ;4%V!HV)2^3S15.GZTY$2Y9]54MFB"2?S-O[H#:ZF5JR>5>B5UIY?"_* MEGF VZ5XFAN_95>\.;X)K9E;.(['COWOZA.7]!A@I;:%\K8J);(>"C91[KQ4 M51W0)BM!1I[H;<'R.9J*^BE)PE'#:J1$_^PC,2QJ754%!(#;C+OENUI%O3/K M2N-+X^H582@ DDCJ@QT<#9^D\BLSA6&(,[S.G5*U/Z\YT_S>J1$%)A!VI!M7 MUKEPY^N5L.2BGBO#$P-'*]XL&,9EU80\-@B;-DD*5^%5E_/K6(;M9WSRB%8O M9YB4URTTVBP0\HW/D+GI6!QW;H:Z$);<8JHBQ@-J@=JM<6U$2+GETKG5KF] MA"95-?=NCU;((B2+?P-@$4Q==T+6LI68$]6*&^IR+4&A*FH-R%DD4;%0;5:F M3;J3N"TXZK^9W>=SLMV#W R7I !U?/6SK5>?AJR]?T6:G;%N%05V@('3/%3VN+NO!B%WC25D00M=\_ MYY[\,:OIW"D/1=*VF?&2Z.^P-F/49C:M4I&T.3)X!^6C7+PDX1@%E5A9.^>G M]4X'_8EQV5DA\<+7X8EBY?3XW5F19"[DY'0^?")Z3="[W*O;:5:D05BXPBQ7 M'WP]*N9*KMB"(E@+^8A"!;J?0,.-NDOFU:[5>I\W@;^_V>1K:5IKC1E$[J%= M'37'GA=+"-^/W+4U>&%/RUP=[T=IX!I"I-4V\$=ISLIB=L]#2MH/GAHQ$3NN M^O62/#'RB%C!L35,Z6H&"YAD/:I9I/%D'@_OXW;'VMASEX1&B_"2V[VH#(XX MS"0J<\,'%K-VJQ%J92:DGZ^JW"JYV-]]!4DV4OG43.\>6.7P&4@HJ9JH+ZUH M,:NNMG9*5I+L^T!]("3WV;3T0'(MF153>,%<_8JE&I7?OFCHC]WP"TP#M^R* M"P!;FZ12KO MA.[HOF$BF5LLHVP@5IIJZ0ER:IC0B8@.FP:-IAD,A)CE','@^A+'34FU#2RN M0&F(E^?8>9?9%AI*]RV"$!83CLS[O5;KV-"%V[7?R'XD[8X'6+'&?>T+M81S MUA99[IFVJ6$F]8IMV>WJ8MIQJ6[VVZ@9Y2FV%@7114+PE*[MF(%N7HHB2M6 M=VR-8E<,?80C9*>N4^O- VQQO#&:T9VP"\J H8<$-3N7U(&K"@S7&HB;LWHN M9SN-B*)S!6PRLE$G(K6SV7**Q@XE5'JESK.Y"L$&(KOE"0@!C/:2[BD>YUW M/SP/'N9DY?;LG[<701/!D^ZW<6%8:)PNQ6*;MNFD(_? M@IHBD62=[2&/==8H]:!+$5;M2-H[U8&%A\ MRGY+:'(FQ!,C3I9WR_YVSF^=3RV;L1[HU.'FW%354+6>_7(=P%A\FK5(P3*H%U@63W:=! L()X)(^& M9U)AF;UP2,"$\VF UZY9[2 MN4.AX'(DEMHD[$.G,%OXJ;)!+^JLU?Z:=?UN M_ &4Z6EP+7>3M?I%Z.^JXN[V>K;R5\L12$NPW8(PB,%-FB3AFLI3ISET+C,A M-X_H/84KKEFW$@";4 188)7R"SH1(KS8"3VW MNGB:(>,,D/DG"H"4*(TR[,0E_GJ.BQ:3O$CP+1L=@HGPV^]V3A=_[Y"6@T2+ M23I';YRXB4&H&"R#>J[)4OQJU*94T87+2).A3PR362E=[3K8G H6F)2DJR7 M23Y8CS86R(]>"XC0@JYJO\A,_8*P2K@F&89&_ ZQW[]VM-XM%D+XFPE"@SNV^F<< MK$DX6U#OHA(NM"O!]T(->K5JTBBZTYC0]"FR)M^#"J#H:%](V$/6Q M:'#M4O@LIXUJ,(4AP/A['XF+>FZB9+NDSJI_CIP*;8N*DIR +F9A6\O:#Y9H M$<4P#-9SS/M;X+;((>\QR%*DF".EI%1UX)WF5>X[2C^DK@>U!\DO;=H>""P> MP3.KO):))O*:NY H=G9%N8YFJ%X$H29DI*!.]1:C%RE4?6!Q+9$W('G<26E! M@BNA44,=D-A-U]\:1MRZ)W9@0F5NM>U)-*N.XXZ=Q+/RT9P@,RK8CTC+P2\@ M.5GL:2KARZ(MQX]S,"_<8V3A6VH%;OO*S)*D_Y") MCT1)^_YX0$DU'CLABY++7Q"QW-5MZM46B(7%25QM\M,IH1)G]M)C]IIX=YEC M72I:XOHT4:3F$I$M+,9%]X&FMQC .$Y?_68:2Q]J0NP4[AG=;[7=:3DN(UY5 M+7QGNK0?,X^+QC))1@''&YR(8#USC:K<'5.;AFNTAL#'Z@E:JKW,[ZI-D;E, MD;!2=D !@)SP>G$QQ%4R&=!ZJ.?! M\:$/F@LS9)JONF=DOI0JUO!UR,R(R]?6#-T]TUD^C&3BV_53/LY)5 9&>R&GL_:SUAN+J1IQX)O.=FB4?"[47OVGYPL/.PULJ#!_A*R!7AB_19 M*-#O,!(R\^DS#)NHXJ;BZL@4CHC\H5CUD7-6(MN1!IT$;X?)_MY7/6-@L,6H!R!]I])Q&'N4!'$@,!!5XM@5 MW6Y7S+<(A)X"8YYBZ.[S9)KKRO0KM[(>'**A-7$CN.2^Q&12B2="=6"Z2OI& M".T+I" 6><"_MQP3\C!?$Y<88 ' 9*N=^Q9SEU'PX-1XGRE+:"V.'H8PF>VT M7\QJ1S4?\F+1B3-$!5OT!L&0(H_R+OHF\OSOO'^QFTR/E_L!29#2C:=_NZ(L M#DR4I4KRS+PK.,X$ZWRQ0(.1/Y\QZ(>?'0&TKQ5M,=N(]Z-/J3N MFB;TX)'B*A>?%0"&3J;G%_F"[O?5_"-N?.YJO[VKJ[]0$.L5MMAZ3(Y>7+U_=W6<)L^+"NNO M8^9(^ZVCYU?O7^!3BAC/T9+SS]EJ_6/R2PYR\3Q+?J+LV5= @N:2)!A_<]PC MR2CI"%+Z*(/"8A2,FUA 6MQ=RVB;)LL4C0MW&"@PFP '7._$($6.PP.=#MP$9&72%VC=-PA"COS7_RP<7Y:EA#=G9? MNCSF3:N83F<04_S0MYBFV&'[+::IZY2^Q31]BVG:M:]O,4W?8IJ^Q33Y*/LM MINE;3-.WF*9O,4W?8IJ^Q31]BVGZ%M,4V\F_Q31]BVGZ%M.T&[6_Q31]BVGZ M%M/T+:;I6TS3MYBFV+SS+:;I6TS3MYBF;S%-\:#?8IJ^Q31]BVGZ%M/T+:;I M'Z5_M0-/5J#/W&-Q69@1NRWM?D(FD,IA-J4KOS8+'I>6 4?XT''4(T9MN;O> M$)&(4!>;4DIU(&J>1I/B8ZZ 4T'=**7 \P?IV-U:_D)T(BW<[2*.3 >:H$GI8%MUX,'M6BYNOEC\J;B7IX"%M.Y$.G9TUY,CB^,O69B5O6N(R5)[%"IG"Z]C[)%7 MW93*BG;U,I5-;"JJ)&8],DG,XGX0)/EI>47?#=,AVCN8D)(6[H/0?GY\3#EB4'Y0EU9B^FOD9!S9![22_>%Y[3QO'X >-?K=U==Z6Z7,K5GH( EP?+2S MV/(/R?42]#L7*?(:O88BYVE%22O;3#-9@X6.;K"]"+Y[%8K55/3Y2Y:D:#VC M$0KM!?N4 0YK&C& SU0Y;PG\T(UE+B=U 85$T*][B)HX,T^ZFG9-N!JM#RE? M7';!KM&%D6K'4N_6F6!5+O"*I3RP< M51UUO*!V[M3.I)IKQ*4"_/:1ZDV:NCJT/=[-=8Y]C"D)9+MGU362! MFJ$J@1IP\S&C5Q34T21F0O5..Z!I&57%1*\6?ZK8&(HV?99=<9;;#-MO>^6( M.]B\*%2-C*>5KT5/QV+@U@" 5RY!PQ2=>82:NH DVTQM6"3!K0R0YRP55^2YTD S@;WA$K0J(W MHN+'=5L?I=\+KDN<[XPF1*^C;7-Y;S<+.A<4-Y%>Z:OS$VO<(7=0SXG=TV'- MV,R+M*!Q4^\^=;[0.@]!H*@,-=V6M@F!UVY%7[V0E'G UMRU(V8/>H\7A$"J M)+D0\227.#ZW+F,[PGT8N2N+I$KEIV,O,*L'L8/JV2[\S2Y$$ *7=>.YG540 MDLX]P26Z*JK#'H182NR.OW.$&UH,O$[7)'421 MI*XU.&(U,#G1-? $7_YT/8@:9O/&_8E3>GA%^DK*[9@#.H">GT>WX4(\%723 MF(3*O3D:8;Z"U]J+723L::*^4RU#B%.,C55WD&C/Y=/1NXO6IW(M;HR[;/IU MGIE<>$*)5"H&*:- M*9NB"+RQ"NC>-2C<7MK?:/Z5A$1+KYT _"#5-JOK;$8 MK$#[LZOEO4+US^.&HBD@CZ+RX<0TA46VN^.)@:FC;QTWD6([IOC@EDNUT7!7 M/.EBL 0!E@UK:;PZ65,H9*$Y1/W4N?0YDG[DZXK"%;$3CTANV 0:]C-,/F"R M4T4B]PW^1F;^_[^\*]UMY$C2KU+ RK,24*3KKF(;6("MPZ/9/@1)W<;:&!AL MD>KFCD1J>?0Q\,-O1.19>561HJ>Q6/]H4V3>&1E71GQY.GG\L)I//\* 7H]C MNTF0J7/N19.@_]\B\F5@NZ6KW;C=JLPK4 ],T;$FS4E&K<(/ O5[CL;"E#S*[=&EDZ0Y]*<90M#D*09ML=?. MF3?K0A+ I7JT#-\)>B?:.!E&VE]LTWG8VZ?E%W9H%G/%Q9G]P/KA7K-[NAM= M;S1RTQZJ%->O3#%MO9UVP83 5%SVH^,>7ZE:3KA;[M/L83K8+ >/:%NA 32= M?<"P=_&&;JR-3W!67?RWM!OY!KUC"D H,@X1?MC>"8)N/\*IW2CA0W[COOPY MMM?8)0/P?_>@I4[8*Y'V6X#ROH-#Z/SMF$V7^NV M&4HM$0T[7^_ BZ0%T+;3C*D+#K51W =+-S-\G[S!?D/U_SS,CEY(3T:HE[3Z30[MYXVFBCGM);BE=W&/7@I%%=7\M)TSE<,H/&'W$U\=7G MUVLGYK#5X\OB(5"N8)@2F$*EM"\82_6>H;G2HY@?HK<2U<=EL9MH;HM!4SCO M:K^Z7YO=ZGK?T) 0<"1N1",D'_#YVPO4_5[HK\_3UX9/LE/Z^-L6!R7+\:"8 M_0BC6=(MCV)2+6F/]*)F^?7I82*N3YA@FFJ!"#(OD'17NJOA3<2L(>P&]DE? M1C$>_!VVE:(N>ECT;2-T*\W9NN%1T)IX404J*7JK8HXDZX'B?6 .<,X M^"*#F]FS*P9%B+455-J?ENP-ES9_S*\AA?*I69BMQYK:UXK&3:+/6G:I?'RL9)E!2\I8F4)GI/ES M7X)RP@FWL98WQB.0VE<.C\OI[(%3(&VMX4.7=^:K.7M1%:=L@'K(A" F/*2G MFUN #F>]^=KS_]>'M3W>? &>0K!.1\_(@ C]Y0 MGFG]I6F^MG=Z@!P%2[-"Z4W[AR2"DEN15_'1I[QTP23JA9:Z!0; M2[MU'GXM0P572_*DD<.A%21$R:Z.0"2HQX,:!]HKQ1PB8#&U.L 8L<%\,:"K M)YW#(H/#Q+V';U9#DBNLIA9/&'">H)U^Z.8H:X8)IEP\$"W'=B!DS%)-)/6 M3<)T!C;]A,5 LK?S5 S5,#(C:&ZVCPRWYSYZR5S:]]$5D_@JQ)I=WKGO[(YO MR5UQX@ITHC1*:G*LS8G%*76'2MWR^%'5BKXRKO@H&8]$1/QI-9N)U^U8@(KQ M7-J$/0?*\%Q@)LQ'L%W#U-:@L;]3$5(_D^<&)*R 71A +X,;O'HZ0U?,C73% MM&;J&V,LMQLXK'1F\'$UT5%TG,9YED0GH9BN-!ZEZ>[=&6MP%)6CU%SY!G:@;$6 M5*@5-,_?F7&\8OF:XU&4@AZ8E!5N9E;'69/";AY%31K7=>FHJ+^EF%9EG)=9 M=)S'18'UTDINMO4(8IK&55-!)W&=-U"VB4=%TR(+P4. J)*DBJNLAF(PIE%3 M1,>CNHFK(H=O<)>T1R#I5 /S0_: GD,59+%N&1K]ML]MS9O4R,1%_P/Y#%>\PL<&7@K)NJB#0&9X*+K$)'4>3PJ\<#G M55S C@/9I$E5W%2(P70 MMW6JJ0A2+%.3U4W:1%E!6T%ED9IZ.4A[N**BDL6E9&&1S# MI(YR.#MY1C*+P^&H>1^G11HW.1XH7OHX!<(>93@PJL'?_6U%XW.6OIE\QM)A+@&P5\\P9HDT?SBMA>*E[69O$RX<5)*JI#,:"[ZSL>"_*PQ54X M3H9$1"R)]Q^QQHZB+0I$ZCW7:+HUJC;L'472V MNOL'"0K8[%H1[1'>:HRJ&HX03.-7().["2-01IEP9&%KW\^@T:\1[#S\PMWU M41&GP,I%I+8>VZ8=%RA$O0#+J1.43\ YBBIQA%8;+AER6R+5T(=SY=)QR7N3 M<#0W@^WLV<%3% X@-$OR((%DA7*MO2+,J/OD;^^+;)QUI\0C*NW+\DB4>>; MO$0'8Y$5Z[$"?\U&+R]KV;$0;I17ZBWL?D>#>-Y:.@3:KNJUN-1?&?U) MMXW^]K;VF+V/[Y)5IQ93NT784>,"DC>>WNQ@!D4Y%_:MN-K?1NH+DGUVU7 M\3]5P!'WZ"/M.P6J,4F!7*,#FCB)KB,Z"&.E2$_#)<<_?A&.39E]KJ'LDG]2 MXY^M:#_>DV)I&YZ'O2ZIO"?->MOG6/JTI5PSP_ MZMOA[,!F;6/?/#_V*8!]^2?IF[ AAE=HK7_! XXN)O-5])X"9;PZDTC_P-[^ M,6."0%O:-R#6.XITZQ3(-87R@#R/V)U2-]0G54A\&EN+_R)Z18FI&5ABH'LR MOSX33M,9!:E$#:J6151GK"_\LREEDPUH-TT.O+M.,@;QOEF1[_:;OJ]H+.7 MYM.RC([1"L$O"E!G1#,U_%F7$;#T!'2=LW8@%([&0(\'3CF#0R!EIHBU(^0. M_+K)T5%3HFS(0,!E*7E1X,M152G-N@ +$&R^?)3S-0-EO2C!:$_I<\X]/5G! M[$_XL0)VE[>6&=3^>#1*4+:!"5F5(Y?GZ?\@M55E$^<54EN6T"HP2F-?%ZU/ M!Z*TM,YCT#*C IUD:%FS+Q25I"78Z# :,*72I@F06YG%60*;#VR@P(W'+]*Z MU!IJ_WT @JO3+$XJ)&'R\\(Q/8'OT,!/9#Y&ATQ:P:FRIB9,-" M#4-A_9H'*+KX_D1V=B.?@8F6 MN4D<;<>K=F_DU53N/H%QP?#GKD!OFLR!;N6C%PMYP\09&C,SS$9$Q9E>D=^@ M\(HL>C?FEV^]2$S/L&_;!'YJ,UOA/@-K@$<1\()1R5Q&19)&MS.&FK; VSG8 MC'7+1$2/+_!&*)LT(Y8#B^'_FHV%L1*NDQ;!-E7H:!HE(WL8OG5"]E_&V8AL M-F!!HU%XWS@8"S$=$"=/##,%C'1[I[2B,U44/8W?9VM>;NIE&7\7Q8Z"U^J_B@S3L2>@L8$Z@FY%_-(Q/0^?!.QKS.M*%XB M)/S?4X)-W-X)F#1YO0XM%< DP$ 'T9HUZ)8LHZRNXB+/*07MA7$-\01$Q[T^ MQW5*]CQ>1!0TKI,HM,% 2[ >1970IS0>U76(K*#?%49D!5PPHHAFP'ZO(WZY M&$C8'5TWRD!!2!+/NL#NU+B=&9UK'=M!QBC@5N-5!BQ<4@%K9#NN4)\4Y!/T MU)0)7AR4=1,YE@:55: RTF1!]4YJBWV?TDLE*C[WE(*+A0[DX^$76TH3?SU? MS!^WC^Q$")@)U'+158YJZ2F*!O;2P5N9!LA**X>@I_%'WG@[2Y)?1Y'C5#5N MYGQJ_A5;O8B[5(D+EF3P7R@N/5-D[K35[!'4^BF+[4)J0GEZPNX 4A"DF-Q MFU07%,>-MU0IZ*L9WO7A_I;T.8=_R$JZ1?1-)J^1'^5-(65QAA9)4EFG!R%" M.,R' 13BWCD!8S]FX9=];'SSVDB$R/$6W*?O1?1F2V>&+A99G[_,, -S-AV MV0#[]7$&Q(W/PN#"4D 77G,1<(FC*'M_[ QU<4T9"M6XIMW!:>A*[BWF>HYE M/!TPU!589O,[WB ZN-KT$+UM.ZILGE(FH/2AQH6&51B?^P@S2;_@AFUOV, M@LR.05EK:G*S@N%3#$'M;(9@!1G#-?:EA(Z!B6-$ W0+XKX:CG"LI=!@@3,5 M32)&0_MOMP)T7%5!8>EJ<#6:&SQ]5H M PV"_L/]HJM9%SN9',$,&4G\G#'9=B M'%-Q.L=T=0*F%T@@%!DAR)#%%?+#3)R&I3LNGQ1Z*(LBUPT>?-X(@]8(KD>A M<2S;L>M09.8Y+);O3Q*SH.6QAJGZ;LV6\5S'L&[;>^+$<8IS'?(OHHL)[T*' M;=WR+EHPV>U)L_ W5OPC)^P=@K=@(1U6W0MYC.4I[G9T4SO7\_4_!O=85&: MD]V>X9'X ?Y7I_"_Z1]*9N[5A&J-6W%EC2NS6\S-G#2Y^FH*^78YJOCRE !T1JRO^S[G+<=%0 M>-4)+RU891PI7LGR7F7D"E-.ZS3E50*C,V:> J_/86A4K^^&O5O@4U&>;7/C ME.VSE]L%AIKNN:%LC!;?P1W$GW;;P*)LXIH%0Z1#8.=\ TOX.DL:E'J@WXKM M2U%Z@;%;\,(N45=R7QG4A!)7_ T(A(5A^8%,;/-F3GA#.^QJG*!5U##!(R4, MES&X%[RJ<\U5UBX;T)2C$VE"@2S:#KYMN8>&GZA2+NLAW-? M7KUU!/[Z]#[N2=GIYGK3#M4EQV<;G@-QX*A'!PZ<0.?8A_G[=7 'VU?,7H@W M=(W"MK&HA3@!3J]'6.@;P#(#<*]PKQ/XMTERY>AJ0.O@03Q-F:HW9B<&,#?U M4S-SBFX-?F:H=IS!H,E"=_;H6P-#+P7-"%HN?1V9NX0Q#J]$O!=CG#X]_J6, M COC46".RN,-+,:'[49@R>I<"1T8,SM:XJ457;:P@] F1KOZ4O-V]]4%VCJ; MDSIDJ"@?S&)J!XWVU!I C,UX=)F,M3O28_+@CSJ+\QH=':+QS(P$A1B"^."*3Q0]MAG.:U1E4! ^/ELMJ '&&@2EMHAFL*U MX6H=0=;OLZ6Q(_0P!Z6]249@B8#5 UPZ!U,H+UV!BWMV<"2C&W$%4%ERY2HH M6:M?FYVW7E,XY93%^9EU;*[$L0GSSA9;T6[28BWZ44$3B=>#=)O,YZPBBJ2T M-OL9B+OVX ]T-D7<)@9L,"!K3%[EN6CS%0L=65.&&.6Y4]8:>RICL9D/:!1P M'*S+%Z:1[W8LL@I(!R.:@2^SK136A6:R@MF*371\-MM,Y@_K$ZC^[N8L M.C["8P$'^E;P1G.).OT6_70/V(O\.(R_(_>5-B NWR!X?<+>Z5Z/,G[.<;Q)4@Z;#[-OUMLAA& M"3\^ME;P1>_SJ@VB"$?Y5 :EM8K!LM*3O+^]PF3^R\WL<6UMWFD@Z\TV;X0_ MS4Q,<^%D,]AW=JOY:\#;>W7Z_L>;\7M5PBR 0 W1^_.?+Z2'S'$G8&_(NR?2 MMGE2MUGEP&C@A=HH5*'6^9^G1UT,_IUV6?+6J?Q&?E$V@D,GSNPIZ79 M-N)'U1YB.Q''DG'2&./Y$;8PX-D^MJX@DG\L: 'FPO TZ$SI<42M=J:E=&>E M[+!?RFRYTM!'WJHWJ+QL\34#^_ K:EU-Q^JZ\';^R"=QH[^E%E+9;DTJ[%$E1BG].-\^(F&))^?H#;=3]O(EK/)B!H0;D6']EJ0Z5R[) M<=.G3_C.LV9]:O_G]?BF9W4X0"5/U@U9F%89Y'SR>5T1]M.S8L<>]*L5JUN( M,46RR5N(?=N[V++32^\TD+DV1BCM?C8W-'@Q_SJ;AM;"KL(N:M0W%S.+B)WU MW@O4H];;NKVJ]MJU/&PX!VSLWH,+MZ$BNZ]G\\4&V:E[MFN_]>>G"#<_.6K-#M(0V_!:"9<;NW$1K>3UL$@#)'YT@3)Y]HH_.HF_OF[!?[_5'@I$V&J<]*%[O\8;J+6C\QL1 MM8H]CQ>AA3+'Q.$2O S<_+V;!SMJ^-BMX)L[J!PZ]L- 4U#'H$\PA9%0X%?3 M^?+S9(T7.^PU%+DD4B4Q.TU;=YK6KUGPY[]M%Z!5)BQ(@^G"EGL>H9E]]P7D MI>8_6O:'KK+F7(V2#]2[.],O)QJ/EJN7J3QE6MYS3YG6E7Z+BO4W7Z4&BQA*;NC/B-Z%!)$:@=P. M',2CCPUSF2UC(N]MF7VKP0>Z]?$1"VWI%KTH3T&"#\:8H(!F1W0\_O6LJ9+4 MVD)G97TKI63IU^_U["/Z4C'58\>:BNOM6O/UY"N&DUO;.EDM!FBC^O8]S89) M\H-3 =*[L'UP:PS.\>\3< P6FM'9M'_PMW-ZAV:U_#9Y$( "T]G]!&$3D//9 M3;OF8K9B_IX[:SF'R4+VK:GZ&JB#2V@5Z.MK=57TK*"SJ'L63"K_9?+X]--U M0(.5]UL".Z?+ENQ2OOI-V%;'>]4,*%^[W7@%9#(SD"C:(/W))Y,O%P3:C<;M M&8Q_(C+F*"81XZOO[N8+W8]C#J ,2^#QTTI)8)\TTZ1T4.+UD8J\3.DI@Z#8 MB'BM"M;91\RS^P6C(H M$')]H\>>GI@4@!(]C>6^!.ZJ>Z-P0\X_NWPNVLS<<\A9Z+E79W'7*MRUE+P7 M$E5N*1YE[_[VG%TON_-F1H]4Z5E>S(7$VN^YWN@D\O+EUH\X3E@CF.!?];BC M4RWNJ,-)I1)),*;JJ454E.J B2,.*T#XRA26L(W;VS5T_)OO57=XQ![E>RUV M@'5R8TGP3N+S-@,EF^8;Z*=WT<7\PVJ)5WX.UZK-[A[\1H4\ ;.OF[ >0V?! M_/:7%3YZLD!L[KGW\*6-6U=UF(B]%M)1KY^2ZK1)>ZBH?>O%^EF^\M!/@ P\ M+NR=W>=A5>-PSG5ZVF7%4U%^&W^=K__^@B3=("D&B15\_5V'=;R8/[@,'ENA M^F[KX^(LWVTP3IK_3F.AA*> 3NBZS!,W7K^[?0$@/SMU0-U5D_N\)_.U>#I" M@C8R;2SDRG@YOCX;6P(2@S]Y0+/[3H_B:^F5*?8&G-MM)F,S?06H=_3(\BBH M#Y30C;W[2DJO#7>Q^#6B.Z.D]'),43,*[TF@EE;35A1TA_\&^M^_H0N*AA^0+?G,IH(K88>WK$L]@79EBK$H(N\U?KACVS)'S?L?F1V':88+"1@PQ[OT7P@++] M$7G(IK/"3HO2I[F>O1?(BSGE7J;O&+LO4K[7#SFBOA3H H)YW20_9]BZ+ M?^A^O]=Z[K6A/L'YIX$-[B,]W0AXKF*=X'?^"S:_M/.MD2L#*&@)NRP#OOE6 M.+7KLM175JFJ01A>>K^7OR:++N^M4@!8@/]RK1[24N^#RCLC(##?",X]V) , MPU_#^T78Y/LEK$[TW-'89AG6,EOYUX[!"XXXZ ]]N,7%B#%D,*@0TZ_%PAO$'G]OL0!^VVW:"#.]"% P-P#WK0L/E\&][> M:=GZ7F?+_YR[^E=?.3+DGBW06+:.8.3/*M M34*S#T-$X*(:HJCTNO_N2>9M8_I-!<<*G3?-C4(#X9=2KC%=(VT*>)$_HB/; M,'K\L)I//P+9O[;]5<"YZ6[Q_AY]_X2P0S@2Z_^YWUB.LC?+U1?81%=#:L#J M$@+AHW#<70MTWG%M4;J5D"YJ.2C\8O^D!&=W#J>U%QG1+IM9J-:(D^CXSK(. M$#?1X7;B^(F[KJ@KB<0XAH.H?6_7\[:C=9UOBP:@7HKF.1.5=,V4ZYHV;_D6);7[-YV+6#_B[=-\.I^L0-:2EPW=[H3%$(ZK MZP,C$8LI3K:;3TL$R;*9%;_!]6I%EU=OG8N\MC#^^,/AQ$VHA$79"L^29RL&; MY6<5_>*DN:3TD Z.DX-/M0:D16^2IU8KQQE4Q"XN@MY4=?;U%3J3RX\:3 MXM*U>(X+AD"56VZ1M!$LM9A1K17">B>K0Z"XD&7+D)5,*+;:TQ7:-?()FQ:: M%Z'[:V\7:;AI/@0PLXM?3&1)_B0.G:+UI@4%^D%_3,=L*!?@C/X8Q49P/E3[ M V:P>A5H[3[2^VPT)Q%UH46W7B2:"1$S5/G\YNH*\T >GQZ6WV8S-HH=SJ&) MXWLHUF^A]EILM TOZX!\"4U;0."&5J;/B6&:C8$2Z"]N#+J%)Q.JUQ^Q>)]E M"LL$N53A8MIRA0LZERQ<);QLX;H[(S@'.T=S7B$2=Q)MW,(O/L@&&TT>>/+/ M;-T/=1WK,)AF0P*ON10.O;1TAD*)T.SC)0*S"6 M '9U)_D=AN(.209FW9';\/0NU0Z2Z<#8U2W!)GX;:*+-,AC<2-"6\C L&CL; M8%BGUI[J4@@+G!;TN>L9IC&QIN%28EW[J$U]UK:W+M6QON%V M@B#CEC_ @90=<%HX2G<<9E62CYY=N)HXU@[7BD"_WH$_=(%>[^&2>+9C(6Y7 MH\OQD*_AI@-&VW:Q.ZVP3IQK^T($L=P0SG.O^Q0=RG!B/_AL%^=N*(0/'?.' MV-Y+",2Q#P+1B:_H"?%SX%T/HD/!8A_0G.8 TQ9?>1::M+UP"@6ZUT(=&C2Y MM6!N 3Q>;.8",EB/L#1ZI.M)V2-FQ@)/TGL*NO)T7&(]D"; ]OIYF(-NOI[' ML^\I-D[PC^OUYC_^%U!+ P04 " \A*E.8E=I:U@" !># #0 'AL M+W-T>6QEBV+(M MT,63YZ=:L&TT>XJ-S='[G+^LX5L)*;2B^+S!6H&&45Q$LE"H_ M>%Z5%)BAZDR4F.M()B1#2@]E[E6EQ"BM3!*CWM3W%QY#A,,XY#6[8:H"B:BY MBN"\=P&7?RU2',&'D[??:Z&NW@!WG;R;3/R'TZNQ_\0&3B%PC,]I!(/%>^C] M.?3,UY^]9!L=X>?/Q#\%'Z$7ST,_01Z!S_> !]">Q N3Z+6;%H>9X,/>S:!S M:#)B&*P1C> UHF0EB]:J>/ MW(""24]@*GT#GBL$1*8=B^93OL)@-NCMD2'P*CHC/UJEMSV#7?2MZF.?8V=GH0%Y1D+=2G6B^' MV['I.7PG<48:.VZR7H"FH[*DFX^4Y)QAMYC?%@P.+!B'J*L#"B')H^:95DFT M TL(UE@JDFQ[?DA4+G&CNG9JLD,U3X]0\TO?YQQS+!'=%JU[_S7?Y?^L>';^ M]Y+MK\I8\ MJ-*_.(Q Y/P:1BV,0>10]>?'Z1L M:D(5X:W:@J0I=GK,&2V"7\WAC^Z\J(>3@L8KM-*'_1V^SDUQAFJJ[LP2;3"" M@_W%" \6_:QECXC@8-_BE-3LTA8<_E'$/P%02P,$% @ /(2I3B?9#KQW M! U"8 \ !X;"]W;W)K8F]O:RYX;6S%FDMOVS@0@/\*H-UD_L6U4J.XGVSM57PZ$M]J+B]@]="^6/[+2IN/.;YG%H:R/XUNZ%<%4Y M3$:C\;#B4D7OWYW:NC=#N*&=*)S4RN\,.SY+\6Q_' ^;C/L3OHHUWTRB4<3X MP>D/LG3"S+D3'XT^U%(]3J(X8CMIK%N%>S=G5E+)2KZ(;;-E]_KY3VWDBU:. MEZO"Z+)LK@H'FHO\'>Q_>SX+XV31.M'QS0/WK)-H//(-?I56;F0IW?=)U*R7 M(O)/,02/T?3#:7GLQ"OS*]VH=SM9B+DN#I50[MB/1I3A[LKN96TCIG@E)M'I M%,;5EBV4\S3L1AV;\N>&9_&WOMD>G\OY'OL!R\R5] ?,S38.X'20L[OE?+%< M+>;,KZWN;F_FT[7?N)[>3I>S!0.0"0*9] CY)0&0*0*9]@*Y6OO%I\420&8( M9-8C9*LG>E# M!^O,X55783*)B6URS4L/)U@3HK&9KFJM?N;#/!)3BT17E71-ES5!V,S'ESX@ M%;Y#10L2\TA,+)+5GANQU^56&/L;6_Q]\'$B9,/T$1/[8^5T\33PLXG8-L,K ME'T5NV+FB(G5<:,*70FVYM_:XXF)(B8VQ=*W>ZNM9;4PK!E<&$1C@DCZ%$0K M^$LP023$@L Q8?B7H#D)=5+2X3%VX9/5LC7HF$"2/@3R+Z/]'5)B)DEZ,LF9 MSL2$DO0I%'8!,3&E)-1*Z9BVS_0F9I>$V"ZO9\JSOTM,, FQ8/"Y"&9Y">:< MA-@Y.";,\U),0&FO H*97HH)*.U50)<0$Q-0VI> !BP\ <1$RV+4=;%NS-F> MPU RQ0R44E?&NC$??.,0$S-02FZ@3LRIUSO$Q R44E?'NC$_"5- 3,Q *75] MK!LSO&2 F)B%4NH*63?F6E828F(62HDM=*ROJ+: MBIU48KOTM[!^?\'+XMZPL#B^S\WR\$YF=RC+F=]WIVXU;[Y["FVIR#+Y2H,TQG5X\-TYN)YNZZ&YVVL%K_J M89_*N@IOQ_"G&UYSDU+)X?P6;\8%XT_>^_0_Z[O=[K!)3]WF]RFUY8N*?PNJ M\'60S <)/4CG@Y0>9/-!1@_R^2"G!ZWF@U;TH-OYH%MZT-U\T!T]Z'X^Z)X> M%)= QB4_"6'-USH"KB/?ZPC CGRQ(R [\LV. .W(5SL"MB/?[0C@CGRY(Z [ M\NV. ._(UUN WL+76X#>PM=;@-["UUN MWL+76X#>PM=;@-["UUN!WLK76X'>RM=;@=YZA;,2=%C"UUN!WLK76X'>RM=; M@=[*UUN!WLK76X'>RM=;@=[*U]N WL;7VX#>QM?;@-[&U]N WG:%LVYTV,W7 MVX#>QM?;@-[&U]N WL;7VX#>QM?;@-[&U]N!WL[7VX'>SM?;@=[.U]N!WL[7 MVX'>?H6[2G19R=?;@=[.U]N!WL[7VX'>SM?;)WKGIA[2]J4,AW:?+UWR:?BW ME]X3N'-Y/Z;+9YRG?KM_HG09MZ1P?KVXS>>I'Q'ATW]D'O\"4$L#!!0 ( M #R$J4Z;Z.7DWP$ - B 3 6T-O;G1E;G1?5'EP97-=+GAM;,W:74_" M,!0&X+]"=FM8Z1=^!+A1;]5$_T#=#FQA6YNV(/Y[NZ$F&DPT0O+>,+;3G?-N M-,\5LZ=71V&T:YLNS+,J1G?%6"@J:DW(K:,N59;6MR:F4[]BSA1KLR(F)I,I M*VP7J8OCV/?(%K,;6II-$T?7^^M]ZWEFG&OJPL3:=FS;E=^:CM\;YIZ:84VH M:A?.TH)L=+M+74*Z-L]2-63L%Q.^W]B?I_ONM^1]7=*?HMGELBZHM,6F3;?D MP7DR9:B(8MODH3*>RL?HZV[UGO?!^'AGVM28[1KV94%^NASQM:'# 8;*,2?' MM"WHT*BAL/_D_QKXL1L*ZVGL?*KZ6!]XO!3I(54#ZQ<>\Q&IWSHEE;\:GEJ? M[H=]L7X]?#_TPC^+@0V'_[WUX^40(#DD2 X%DD.#Y)B"Y#@'R7$!DN,2) >? MH 1!$96CD,I13.4HJ'(453D*JQS%58X"*T>15:#(*E!D%2BR"A19!8JL D56 M@2*K0)%5H,@J4&25*+)*%%DEBJP215:)(JM$D56BR"I19)4HLDH4616*K I% M5H4BJT*15:'(JE!D52BR*A19%8JL"D56C2*K1I%5H\BJ4635*+)J%%DUBJP: M159]0EF'8]Z:NOLIR;.UZX_Y;/@CR^(-4$L! A0#% @ /(2I3A\CSP/ M $P( L ( ! %]R96QS+RYR96QS4$L! A0#% M @ /(2I3B?HAPZ" L0 ! ( !Z0 &1O8U!R;W!S M+V%P<"YX;6Q02P$"% ,4 " \A*E.V6:W9.\ K @ $0 M @ &9 0 9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 " \A*E.F5R< M(Q & "<)P $P @ &W @ >&PO=&AE;64O=&AE;64Q+GAM M;%!+ 0(4 Q0 ( #R$J4[U$X;;< ( -D( 8 " ?@( M !X;"]W;W)K"P >&PO=V]R:W-H965T&UL4$L! A0#% @ /(2I3CS.12E! @ P < !@ M ( !)Q 'AL+W=O , )@. 8 " 9X2 !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% M @ /(2I3CFQCX+9 0 7P0 !@ ( !QQ@ 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ /(2I3H&-V.JQ! MA!8 !@ ( !5R$ 'AL+W=O&UL4$L! A0#% @ /(2I3C2L M$1&U 0 T@, !D ( !)2@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /(2I3E S8F2T 0 T@, !D M ( !YBT 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ /(2I3O2S 0 T@, !D ( ! MI3, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ /(2I3HK^F3*S 0 T@, !D ( !9SD 'AL+W=O&UL4$L! A0#% @ /(2I3OT^76K& M 0 -P0 !D ( !CC\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /(2I3EEY M2X 0 T@, !D M ( !B$4 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ /(2I3F&.%RZW @ Z D !D ( !CTL M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M/(2I3O9!P0Y @ W08 !D ( !#%< 'AL+W=O&UL4$L! A0#% @ /(2I3EHQ'KW?! MBA\ !D ( !2E\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /(2I3IY#I25G P 4P\ !D M ( !8&\ 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ /(2I3NK>._V>!0 ,2( !D ( !<'H 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /(2I M3A9YV2#] 0 =P4 !D ( !U80 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /(2I3CB#R;%@ @ YP< M !D ( !T(P 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /(2I3@1?3L#J @ "@P !D M ( !M9, 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ /(2I3ISF]7<\ @ $ < !D ( !P9T 'AL+W=O M&PO=V]R:W-H965T0( + ( 9 " <6C M !X;"]W;W)K&UL4$L! A0#% @ /(2I3G%& MI7EI @ N @ !D ( !=:8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /(2I3GD\(_[QE $I(" !0 M ( !6JX 'AL+W-H87)E9%-T&UL4$L! A0#% M @ /(2I3F)7:6M8 @ 7@P T ( !?4,! 'AL+W-T>6QE M&PO=V]R:V)O;VLN>&UL4$L! A0#% @ /(2I3C4#30$) @ M,R, !H ( !I$H! 'AL+U]R96QS+W=O3? 0 T"( !, ( ! MY4P! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& $, 0P!'$@ ]4X! end XML 84 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 85 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 86 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 279 264 1 false 97 0 false 12 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.modernatx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 1003001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) Sheet http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLossParenthetical CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) Statements 6 false false R7.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) Sheet http://www.modernatx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityDeficit CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) Statements 7 false false R8.htm 1004001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical) Sheet http://www.modernatx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityDeficitParenthetical CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical) Statements 8 false false R9.htm 1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 9 false false R10.htm 2101100 - Disclosure - Description of the Business Sheet http://www.modernatx.com/role/DescriptionOfBusiness Description of the Business Notes 10 false false R11.htm 2102100 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards Sheet http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandards Summary of Basis of Presentation and Recent Accounting Standards Notes 11 false false R12.htm 2103100 - Disclosure - Collaboration Agreements Sheet http://www.modernatx.com/role/CollaborationAgreements Collaboration Agreements Notes 12 false false R13.htm 2104100 - Disclosure - Grants Sheet http://www.modernatx.com/role/Grants Grants Notes 13 false false R14.htm 2105100 - Disclosure - Financial Instruments Sheet http://www.modernatx.com/role/FinancialInstruments Financial Instruments Notes 14 false false R15.htm 2106100 - Disclosure - Balance Sheet Components Sheet http://www.modernatx.com/role/BalanceSheetComponents Balance Sheet Components Notes 15 false false R16.htm 2107100 - Disclosure - Commitments and Contingencies Sheet http://www.modernatx.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 2108100 - Disclosure - Shareholders' Equity Sheet http://www.modernatx.com/role/ShareholdersEquity Shareholders' Equity Notes 17 false false R18.htm 2128100 - Disclosure - Stock-Based Compensation Sheet http://www.modernatx.com/role/StockBasedCompensation Stock-Based Compensation Notes 18 false false R19.htm 2134100 - Disclosure - Income Taxes Sheet http://www.modernatx.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 2137100 - Disclosure - Net Loss per Share Sheet http://www.modernatx.com/role/NetLossPerShare Net Loss per Share Notes 20 false false R21.htm 2202201 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Policies) Sheet http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies Summary of Basis of Presentation and Recent Accounting Standards (Policies) Policies http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandards 21 false false R22.htm 2302302 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Tables) Sheet http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables Summary of Basis of Presentation and Recent Accounting Standards (Tables) Tables http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandards 22 false false R23.htm 2303301 - Disclosure - Collaboration Agreements (Tables) Sheet http://www.modernatx.com/role/CollaborationAgreementsTables Collaboration Agreements (Tables) Tables http://www.modernatx.com/role/CollaborationAgreements 23 false false R24.htm 2305301 - Disclosure - Financial Instruments (Tables) Sheet http://www.modernatx.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.modernatx.com/role/FinancialInstruments 24 false false R25.htm 2306301 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.modernatx.com/role/BalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.modernatx.com/role/BalanceSheetComponents 25 false false R26.htm 2307301 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.modernatx.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.modernatx.com/role/CommitmentsAndContingencies 26 false false R27.htm 2328301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.modernatx.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.modernatx.com/role/StockBasedCompensation 27 false false R28.htm 2337301 - Disclosure - Net Loss per Share (Tables) Sheet http://www.modernatx.com/role/NetLossPerShareTables Net Loss per Share (Tables) Tables http://www.modernatx.com/role/NetLossPerShare 28 false false R29.htm 2402403 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive Loss (Details) Sheet http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveLossDetails Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive Loss (Details) Details 29 false false R30.htm 2402404 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Narrative (Details) Sheet http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsNarrativeDetails Summary of Basis of Presentation and Recent Accounting Standards - Narrative (Details) Details http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables 30 false false R31.htm 2402405 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Effect of Adoption of ASC 606 on Condensed Consolidated Financial Statements (Details) Sheet http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails Summary of Basis of Presentation and Recent Accounting Standards - Effect of Adoption of ASC 606 on Condensed Consolidated Financial Statements (Details) Details 31 false false R32.htm 2402406 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Details 32 false false R33.htm 2403402 - Disclosure - Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details) Sheet http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details) Details 33 false false R34.htm 2403403 - Disclosure - Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details) Sheet http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details) Details 34 false false R35.htm 2403404 - Disclosure - Collaboration Agreements - Remaining Performance Obligation (Details) Sheet http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails Collaboration Agreements - Remaining Performance Obligation (Details) Details 35 false false R36.htm 2403405 - Disclosure - Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details) Sheet http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details) Details 36 false false R37.htm 2403406 - Disclosure - Collaboration Agreements - Merck – Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details) Sheet http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails Collaboration Agreements - Merck – Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details) Details 37 false false R38.htm 2403407 - Disclosure - Collaboration Agreements - Vertex – 2016 Strategic Alliance in Cystic Fibrosis (Details) Sheet http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails Collaboration Agreements - Vertex – 2016 Strategic Alliance in Cystic Fibrosis (Details) Details 38 false false R39.htm 2403408 - Disclosure - Collaboration Agreements - Timing of Satisfaction (Details) Sheet http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails Collaboration Agreements - Timing of Satisfaction (Details) Details 39 false false R40.htm 2404401 - Disclosure - Grants (Details) Sheet http://www.modernatx.com/role/GrantsDetails Grants (Details) Details http://www.modernatx.com/role/Grants 40 false false R41.htm 2405402 - Disclosure - Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details) Sheet http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details) Details 41 false false R42.htm 2405403 - Disclosure - Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details) Sheet http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details) Details 42 false false R43.htm 2405404 - Disclosure - Financial Instruments - Narrative (Details) Sheet http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments - Narrative (Details) Details 43 false false R44.htm 2406402 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) Sheet http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) Details 44 false false R45.htm 2406403 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details) Sheet http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails Balance Sheet Components - Property and Equipment, Net (Details) Details 45 false false R46.htm 2406404 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details) Sheet http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails Balance Sheet Components - Accrued Liabilities (Details) Details 46 false false R47.htm 2407402 - Disclosure - Commitments and Contingencies - Lease Obligations (Details) Sheet http://www.modernatx.com/role/CommitmentsAndContingenciesLeaseObligationsDetails Commitments and Contingencies - Lease Obligations (Details) Details 47 false false R48.htm 2407403 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments Under Non-Cancelable Operating Lease Agreements (Details) Sheet http://www.modernatx.com/role/CommitmentsAndContingenciesFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeaseAgreementsDetails Commitments and Contingencies - Future Minimum Lease Payments Under Non-Cancelable Operating Lease Agreements (Details) Details 48 false false R49.htm 2407404 - Disclosure - Commitments and Contingencies - Strategic Collaborations (Details) Sheet http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails Commitments and Contingencies - Strategic Collaborations (Details) Details 49 false false R50.htm 2408401 - Disclosure - Shareholders' Equity (Details) Sheet http://www.modernatx.com/role/ShareholdersEquityDetails Shareholders' Equity (Details) Details http://www.modernatx.com/role/ShareholdersEquity 50 false false R51.htm 2428402 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 51 false false R52.htm 2428403 - Disclosure - Stock-Based Compensation - Options Activity (Details) Sheet http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails Stock-Based Compensation - Options Activity (Details) Details 52 false false R53.htm 2428404 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details) Sheet http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details) Details 53 false false R54.htm 2428405 - Disclosure - Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details) Sheet http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details) Details 54 false false R55.htm 2428406 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details) Sheet http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails Stock-Based Compensation - Stock-Based Compensation Expense (Details) Details 55 false false R56.htm 2434401 - Disclosure - Income Taxes (Details) Sheet http://www.modernatx.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.modernatx.com/role/IncomeTaxes 56 false false R57.htm 2437402 - Disclosure - Net Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) Sheet http://www.modernatx.com/role/NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails Net Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) Details 57 false false R58.htm 2437403 - Disclosure - Net Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) Sheet http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails Net Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) Details 58 false false All Reports Book All Reports mrna-20190331.xml mrna-20190331.xsd mrna-20190331_cal.xml mrna-20190331_def.xml mrna-20190331_lab.xml mrna-20190331_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 88 0001682852-19-000023-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001682852-19-000023-xbrl.zip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�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end
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~~LCG']:VO#_ ,-_%'C"&,Z=H%Q?ANDGE[(<_P#71\*/ MSKV.'QW\+_ .5\,>$_[5NEY%W>+@$^H:3~~
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�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end XML 25 R1.htm IDEA: XBRL DOCUMENT v3.19.1

Document and Entity Information - shares
3 Months Ended

Mar. 31, 2019

Apr. 29, 2019

Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Mar. 31, 2019

Document Fiscal Year Focus 2019

Document Fiscal Period Focus Q1

Entity Registrant Name Moderna, Inc.

Entity Central Index Key 0001682852

Current Fiscal Year End Date --12-31

Entity Filer Category Non-accelerated Filer

Entity Emerging Growth Company true

Entity Ex Transition Period false

Entity Small Business false

Entity Common Stock, Shares Outstanding 329,003,270

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Document And Entity Information [Abstract]
+ References
No definition available.
+ Details

Name: mrna_DocumentAndEntityInformationAbstract

Namespace Prefix: mrna_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R2.htm IDEA: XBRL DOCUMENT v3.19.1

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Mar. 31, 2019

Dec. 31, 2018

Current assets:

Cash and cash equivalents $ 502,934 $ 658,364

Investments 605,990 863,063

Accounts receivable 5,646 11,686

Accounts receivable from related party 965 899

Prepaid expenses and other current assets 25,292 28,399

Restricted cash 0 595

Total current assets 1,140,827 1,563,006

Investments, non-current 437,659 172,990

Property and equipment, net 213,460 211,977

Restricted cash, non-current 11,823 11,532

Other non-current assets 2,438 2,644

Total assets 1,806,207 1,962,149

Current liabilities:

Accounts payable 38,509 31,210

Accrued liabilities 42,183 79,073

Deferred revenue 73,958 109,056

Other current liabilities 4,509 3,464

Total current liabilities 159,159 222,803

Deferred revenue, non-current 156,862 165,352

Deferred lease obligation, non-current 10,556 10,006

Lease financing obligation 33,384 33,489

Other non-current liabilities 213 258

Total liabilities 360,174 431,908

Commitments and contingencies (Note 7)

Stockholders’ equity:

Preferred stock, par value $0.0001; 162,000,000 shares authorized as of March 31, 2019 and December 31, 2018; no shares issued or outstanding at March 31, 2019 and December 31, 2018 0 0

Common stock, par value $0.0001; 1,600,000,000 shares authorized as of March 31, 2019 and December 31, 2018; 328,853,340 and 328,798,904 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively 33 33

Additional paid-in capital 2,556,709 2,538,155

Accumulated other comprehensive income (loss) 591 (1,320)

Accumulated deficit (1,111,300) (1,006,627)

Total stockholders’ equity 1,446,033 1,530,241

Total liabilities and stockholders’ equity $ 1,806,207 $ 1,962,149

X

- Definition
Lease Financing Obligation
+ References
No definition available.
+ Details

Name: mrna_LeaseFinancingObligation

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864
+ Details

Name: us-gaap_AccountsReceivableRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044
+ Details

Name: us-gaap_ContractWithCustomerLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.26(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 25
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707
+ Details

Name: us-gaap_DeferredRentCreditNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_RestrictedCashCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 305
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84242212&loc=d3e2352-115587
+ Details

Name: us-gaap_RestrictedCashNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R3.htm IDEA: XBRL DOCUMENT v3.19.1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares

Mar. 31, 2019

Dec. 31, 2018

Statement of Financial Position [Abstract]

Preferred stock, par value (usd per share) $ 0.0001 $ 0.0001

Preferred stock, shares authorized 162,000,000 162,000,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par value (usd per share) $ 0.0001 $ 0.0001

Common stock, shares authorized 1,600,000,000 1,600,000,000

Common stock, shares issued 328,853,340 328,798,904

Common stock, shares outstanding 328,853,340 328,798,904

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R4.htm IDEA: XBRL DOCUMENT v3.19.1

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Revenue:

Total revenue $ 16,025 $ 29,039

Operating expenses:

Research and development 130,575 90,124

General and administrative 27,283 16,317

Total operating expenses 157,858 106,441

Loss from operations (141,833) (77,402)

Interest income 10,972 5,209

Other expense, net (1,820) (183)

Loss before benefit from income taxes (132,681) (72,376)

Benefit from income taxes (24) 0

Net loss (132,657) (72,376)

Net loss attributable to common stockholders (Note 11) $ (132,657) $ (75,857)

Net loss per share attributable to common stockholders, basic and diluted (usd per share) $ (0.40) $ (1.16)

Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted 328,809,986 65,430,835

Collaboration revenue

Revenue:

Total revenue $ 13,301 $ 20,110

Collaboration revenue from related party

Revenue:

Total revenue 814 7,350

Grant revenue

Revenue:

Total revenue $ 1,910 $ 1,579

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599
+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=mrna_CollaborativeArrangementWithAffiliateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_GrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R5.htm IDEA: XBRL DOCUMENT v3.19.1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Statement of Comprehensive Income [Abstract]

Net loss $ (132,657) $ (72,376)

Other comprehensive income (loss):

Unrealized gain (loss) on available-for-sale debt securities, net of tax, $540 and $0 1,908 (1,999)

Less: Amounts recognized for net realized loss included in net loss 3 6

Total other comprehensive income (loss) 1,911 (1,993)

Comprehensive loss $ (130,746) $ (74,369)

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e689-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17A
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL34724391-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R6.htm IDEA: XBRL DOCUMENT v3.19.1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Statement of Comprehensive Income [Abstract]

Unrealized gain (loss) on available-for-sale debt securities, tax $ 540 $ 0

X

- Definition
Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e640-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R7.htm IDEA: XBRL DOCUMENT v3.19.1

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands

Total

Redeemable Convertible Preferred Stock

Common Stock

Additional Paid-In Capital

Accumulated Other Comprehensive (Loss) Income

Accumulated Deficit

Balance at beginning of period (in shares) at Dec. 31, 2017 448,686,791 65,206,999

Balance at beginning of period at Dec. 31, 2017 $ (551,365) $ 1,176,661 $ 6 $ 71,679 $ (1,157) $ (621,893)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Vesting of restricted common stock (in shares) 335,053

Vesting of restricted common stock 0

Issuance of Series G redeemable convertible preferred stock, net of issuance costs of $10,517 (in shares) 55,666,004

Issuance of Series G redeemable convertible preferred stock, net of issuance costs of $10,517 152 $ 549,413 152

Exercise of options to purchase common stock, net (in shares) 1,789

Exercise of options to purchase common stock, net 22 22

Stock-based compensation 11,851 11,851

Unrealized gain (loss) on marketable securities (1,993) (1,993)

Net loss (72,376) (72,376)

Balance at end of period (in shares) at Mar. 31, 2018 504,352,795 65,543,841

Balance at end of period at Mar. 31, 2018 (613,709) $ 1,726,074 $ 6 83,704 (3,150) (694,269)

Balance at beginning of period (in shares) at Dec. 31, 2018 0 328,798,904

Balance at beginning of period at Dec. 31, 2018 1,530,241 $ 0 $ 33 2,538,155 (1,320) (1,006,627)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Vesting of restricted common stock (in shares) 48,911

Vesting of restricted common stock $ 0

Exercise of options to purchase common stock, net (in shares) 5,525 5,525

Exercise of options to purchase common stock, net $ 57 57

Stock-based compensation 18,497 18,497

Unrealized gain (loss) on marketable securities 1,911 1,911

Net loss (132,657) (132,657)

Balance at end of period (in shares) at Mar. 31, 2019 0 328,853,340

Balance at end of period at Mar. 31, 2019 $ 1,446,033 $ 0 $ 33 $ 2,556,709 $ 591 $ (1,111,300)

X

- Definition
Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate value of stock related to Restricted Stock Awards issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 32 R8.htm IDEA: XBRL DOCUMENT v3.19.1

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical)
$ in Thousands
3 Months Ended

Mar. 31, 2018

USD ($)

Statement of Stockholders' Equity [Abstract]

Issuance costs $ 10,517

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 33 R9.htm IDEA: XBRL DOCUMENT v3.19.1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Operating activities

Net loss $ (132,657) $ (72,376)

Adjustments to reconcile net loss to net cash (used in) operating activities:

Stock-based compensation 18,497 11,851

Depreciation and amortization 7,328 5,153

Amortization of investment premiums (1,005) (83)

Loss on disposal of property and equipment 19 0

Changes in assets and liabilities:

Accounts receivable 6,040 3,876

Accounts receivable from related party (66) (28,529)

Prepaid expenses and other assets 3,313 (2,241)

Accounts payable 1,731 1,467

Accrued liabilities (32,557) (37,031)

Deferred revenue (15,604) 6,193

Deferred lease obligation 550 152

Other liabilities 484 183

Net cash used in operating activities (143,927) (111,385)

Investing activities

Purchases of marketable securities (429,517) (660,239)

Proceeds from maturities of marketable securities 403,940 189,814

Proceeds from sales of marketable securities 21,413 18,630

Purchases of property and equipment (7,595) (31,909)

Net cash used in investing activities (11,759) (483,704)

Financing activities

Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs 0 549,531

Proceeds from issuance of common stock through equity plans 57 22

Reimbursement of assets under lease financing obligation 0 1,727

Payments on financing lease obligation (105) (1,285)

Net cash (used in) provided by financing activities (48) 549,995

Net decrease in cash, cash equivalents and restricted cash (155,734) (45,094)

Cash, cash equivalents and restricted cash, beginning of year 670,491 147,608

Cash, cash equivalents and restricted cash, end of period 514,757 102,514

Non-cash investing and financing activities

Issuance costs included in accounts payable and accrued liabilities 796 0

Purchases of property and equipment included in accounts payable and accrued liabilities 14,127 28,527

Leasehold improvements included in prepaid and other current assets 10,089 9,889

Lease financing obligation $ 10,089 $ 9,889

X

- Definition
Increase (Decrease) In Deferred Rent Credit
+ References
No definition available.
+ Details

Name: mrna_IncreaseDecreaseInDeferredRentCredit

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Lease Financing Obligations Incurred
+ References
No definition available.
+ Details

Name: mrna_LeaseFinancingObligationsIncurred

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Leasehold Improvements Incurred But Not Yet Reimbursed
+ References
No definition available.
+ Details

Name: mrna_LeaseholdImprovementsIncurredButNotYetReimbursed

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Payments For Lease Financing Obligation
+ References
No definition available.
+ Details

Name: mrna_PaymentsForLeaseFinancingObligation

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Reimbursement Of Assets From Lease Financing Obligation
+ References
No definition available.
+ Details

Name: mrna_ReimbursementOfAssetsFromLeaseFinancingObligation

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Stock Issuance Costs Incurred But Not Yet Paid
+ References
No definition available.
+ Details

Name: mrna_StockIssuanceCostsIncurredButNotYetPaid

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Future cash outflow to pay for purchases of fixed assets that have occurred.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in operating liabilities classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562
+ Details

Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from the stock plan during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromStockPlans

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 34 R10.htm IDEA: XBRL DOCUMENT v3.19.1

Description of the Business
3 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of the Business
Description of the Business

Moderna, Inc. is a Delaware Corporation, incorporated under the laws of the State of Delaware on July 22, 2016 (collectively, with its consolidated subsidiaries, any of Moderna, Company, we, us or our). In August 2018, we changed our name from Moderna Therapeutics, Inc. to Moderna, Inc. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. We are creating a new generation of potentially transformative medicines based on messenger RNA (mRNA), to improve the lives of patients. Since inception, we have incurred significant net losses. We expect to continue to incur significant expenses and operating losses for the foreseeable future. In addition, we anticipate that our expenses will increase significantly in connection with our ongoing activities to support our platform research, drug discovery and clinical development, infrastructure and Research Engine and Early Development engine, digital infrastructure, creation of a portfolio of intellectual property, and administrative support.

We do not expect to generate significant revenue from sales of potential mRNA medicines unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our investigational medicines. If we seek to obtain regulatory approval for any of our investigational medicines, we expect to incur significant commercialization expenses.

As a result, we will need substantial additional funding to support our continued operations and pursue our growth strategy. Until we can generate significant revenue from potential mRNA medicines, if ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings, government funding arrangements, strategic alliances and marketing, distribution and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our programs. We believe that our cash, cash equivalents, and investments as of March 31, 2019 will be sufficient to enable us to fund our projected operations through at least the next 12 months from the issuance of these financial statements.

Because of the numerous risks and uncertainties associated with pharmaceutical development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenues from the sale of our medicines, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R11.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Basis of Presentation and Recent Accounting Standards
3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Summary of Basis of Presentation and Recent Accounting Standards
Summary of Basis of Presentation and Recent Accounting Standards

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in conformity with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2018 (2018 Form 10-K), except for changes associated with recent accounting standards for revenue recognition as detailed in "Note 2 - Recent Accounting Standards and Accounting Policies." This report should be read in conjunction with the consolidated financial statements in our 2018 Form 10-K.

We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, income tax provisions, stock-based compensation, and useful lives of long-lived assets. We base our estimates on historical experience and on various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results that we experience may differ materially from our estimates. The condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, but are not necessarily indicative of the results of operations to be anticipated for the full year ending December 31, 2019.

Recent Accounting Standards and Accounting Policies

Revenue Recognition

On January 1, 2019, we adopted Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606), using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. We recognized the cumulative effect of the adoption as an adjustment to the opening balance of accumulated deficit in the current period condensed consolidated balance sheet. Results for reporting periods beginning after January 1, 2019 are presented under ASC 606, while prior period amounts have not been adjusted and continue to be reported in accordance with our historic accounting under ASC Topic 605, Revenue Recognition (ASC 605). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.

Our revenue is primarily generated through collaboration arrangements and grants from government-sponsored and private organizations. Our collaboration arrangements typically contain multiple promises, including licenses to our intellectual property, options to obtain development and commercialization rights, research and development services, and obligations to develop and manufacture preclinical and clinical material. Such arrangements provide for various types of payments to us, including upfront payments, funding of research and development activities, funding for the purchase of preclinical and clinical material, development, regulatory and commercial milestone payments, licensing fees, option exercise payments, and royalties based on product sales. We have received grants from various government-sponsored and private organizations for research and related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin.

We analyze our collaboration arrangements to assess whether they are within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and our collaboration partner are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606. If we conclude that some or all aspects of the arrangement are within the scope of ASC 808 and do not represent a transaction with a customer, we recognize our allocation of the shared costs incurred with respect to the jointly conducted activities as a component of the related expense in the period incurred. Pursuant to ASC 606, a customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. If we conclude a counter-party to a transaction is not a customer or otherwise not within the scope of ASC 606 or ASC 808, we consider the guidance in other accounting literature as applicable or by analogy to account for such transaction. We also consider the guidance in ASC 606 with respect to principal versus agent considerations, in determining the appropriate treatment for the transactions between us and the strategic collaborator and the transactions between us and other third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, are accounted for as gross revenue.

We receive payments from our customers based on billing schedules established in each contract. Upfront payments and fees are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period when we perform our obligations under the arrangement. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current liabilities on our condensed consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities on our condensed consolidated balance sheets. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. As of March 31, 2019, we had not capitalized any costs to obtain any of our contracts.

Collaboration Revenue

To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following steps: (i) identify the contract(s) with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) each performance obligation is satisfied.

We account for a contract with a customer that is within the scope of ASC 606 when all of the following criteria are met: (i) the arrangement has been approved by the parties and the parties are committed to perform their respective obligations; (ii) each party’s rights regarding the goods and/or services to be transferred can be identified; (iii) the payment terms for the goods and/or services to be transferred can be identified; (iv) the arrangement has commercial substance; and (v) collection of substantially all of the consideration to which we will be entitled in exchange for the goods and/or services that will be transferred to the customer is probable. We also determine the term of the contract based on the period in which we and our customer have present and enforceable rights and obligations for purposes of identifying the performance obligations and determining the transaction price.

We evaluate contracts that contain multiple promises to determine which promises are distinct. Promises are considered to be distinct and therefore, accounted for as separate performance obligations, provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. In assessing whether a promise is distinct, we consider factors such as whether: (i) we provide a significant service of integrating goods and/or services with other goods and/or services promised in the contract; (ii) one or more of the goods and/or services significantly modifies or customizes, or are significantly modified or customized by one or more of the other goods and/or services promised in the contract; and (iii) the goods and/or services are highly interdependent or highly interrelated. Individual goods or services (or bundles of goods and/or services) that meet both criteria for being distinct are accounted for as separate performance obligations. Promises that are not distinct at contract inception are combined and accounted for as a single performance obligation. Options to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer’s election.

The transaction price is generally comprised of an upfront payment due at contract inception and variable consideration in the form of payments for our services and materials and milestone payments due upon the achievement of specified events. Other payments the Company could be entitled to include tiered royalties earned when customers recognize net sales of licensed products. We consider the existence of any significant financing component within our arrangements and have determined that a significant financing component does not exist in our arrangements as substantive business purposes exist to support the payment structure other than to provide a significant benefit of financing. We measure the transaction price based on the amount of consideration we expect to be entitled in exchange for transferring the promised goods and/or services to the customer. We utilize either the expected value method or the most likely amount method to estimate the amount of variable consideration, depending on which method is expected to better predict the amount of consideration to which we will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. With respect to arrangements that include payments for a development or regulatory milestone payment, we evaluate whether the associated event is considered probable of achievement and estimate the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within our control or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, we re-evaluate the probability of achievement of each milestone and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, wherein the license is deemed to be the sole or predominant item to which the payments relate, we recognize revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.

We generally allocate the transaction price to each performance obligation based on a relative standalone selling price basis. We develop assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated research and development costs. However, in certain instances, we allocate variable consideration entirely to one or more performance obligation if the terms of the variable consideration relate to the satisfaction of the respective performance obligation and the amount allocated is consistent with the amount we would expect to receive for the satisfaction of the respective performance obligation.

We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. For performance obligations that are satisfied at a point in time, we recognize revenue when control of the goods and/or services is transferred to the customer. For performance obligations that are satisfied over time, we recognize revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. We generally use input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. With respect to arrangements containing a license to our intellectual property that is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from amounts allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which we are expected to complete our performance obligations under an arrangement. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.

Grant Revenue

We have contracts with the U.S. government’s Defense Advanced Research Projects Agency (DARPA), Biomedical Advanced Research (BARDA), and the Bill & Melinda Gates Foundation (Gates Foundation). We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Revenues and related expenses are presented gross in the condensed consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.

Comprehensive Loss

Comprehensive loss includes net loss and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments. Total comprehensive loss for all periods presented has been disclosed in the condensed consolidated statements of comprehensive loss.

The components of accumulated other comprehensive loss for the three months ended March 31, 2019 are as follows (in thousands):

Unrealized Gain on Available-for-Sale Debt Securities
Accumulated other comprehensive loss, balance at December 31, 2018
$
(1,320
)
Other comprehensive income
1,911

Accumulated other comprehensive loss, balance at March 31, 2019
$
591

Emerging Growth Company Status

We are an “emerging growth company,” (EGC) as defined in the Jumpstart Our Business Startups Act, (JOBS Act), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. We may take advantage of these exemptions until we are no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. We have elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, our condensed consolidated financial statements may not be comparable to companies that comply with public company FASB standards’ effective dates. We may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of our initial public offering (IPO) or such earlier time that we are no longer an EGC.

Recently Adopted Accounting Standards

ASU No. 2014-09, Revenue from Contracts with Customers

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements in ASC 605 and most industry specific guidance. ASC 606 provides a single comprehensive model for use in accounting for revenue arising from contracts with customers. We adopted the new revenue standard on January 1, 2019 using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. We recognized the cumulative effect of the adoption as an adjustment to the opening balance of accumulated deficit in the first quarter of 2019. We have elected to use the practical expedient to aggregate the impact of all contract modifications that occurred prior to the ASC 606 adoption with respect to (i) identification of the satisfied and unsatisfied performance obligations, (ii) determination of the transaction price and (iii) allocation of the transaction price to the satisfied and unsatisfied performance obligations.

ASC 606 requires significant judgment and estimates and results in changes to, but not limited to: (i) the determination of the transaction price, including estimates of variable consideration, (ii) the allocation of the transaction price, including the determination of estimated selling price, and (iii) the pattern of recognition, including the application of proportional performance as a measure of progress on service-related promises and application of point-in-time recognition for supply-related promises. We recorded the cumulative-effect adjustment of $28.0 million to the opening balance of accumulated deficit as of January 1, 2019 with a corresponding decrease to deferred revenue. The effect of the adoption of ASC 606 on our condensed consolidated balance sheet is as follows (in thousands):
Condensed Consolidated Balance Sheet

Balance at December 31, 2018

Adjustments

Balance at
January 1, 2019
Deferred revenue, current

$
109,056

$
(27,281
)

$
81,775

Deferred revenue, non-current

165,352

(3,441
)

161,911

Accounts receivable

11,686

(2,738
)

8,948

Accumulated deficit

(1,006,627
)

27,984

(978,643
)

The cumulative-effect adjustment is primarily due to the application of ASC 606 to our strategic collaboration agreements, particularly our Combined 2018 AZ Agreements, 2016 VEGF Exercise and Merck PCV/SAV Agreement (see Note 3). In addition, as a result of the cumulative decrease in deferred revenue, our corresponding deferred tax asset was decreased by $8.4 million, which was offset by a corresponding decrease to our valuation allowance.

A substantial portion of the $28.0 million cumulative-effect adjustment is the result of the application of ASC 606 regarding the allocation of the transaction price and the measurement of progress in satisfying performance obligations. In particular, for the Combined 2018 AZ Agreements, the adoption of ASC 606 resulted in the decrease of previously deferred revenue of $39.9 million. For the Merck PCV/SAV Agreement, the adoption of ASC 606 resulted in a reversal of previously recognized revenue and an increase in deferred revenue of $13.9 million. These adjustments are due to the change in the way we allocate the transaction price to each performance obligation and measure our performance under each agreement from a straight-line method to a proportional performance model. In addition, the adoption of ASC 606 resulted in the decrease of $4.3 million of previously deferred revenue relating to the 2016 VEGF Exercise. Under ASC 605, the product option fee and the clinical milestone payment we received pursuant to the VEGF Exercise were deferred until the consideration pertaining to the clinical supply of mRNA can be reasonably estimated. Under ASC 606, we are required to estimate the total variable consideration to determine the total consideration and recognize the revenue as clinical supply is shipped to the customer based on the proportionate amount of the transaction price. As a result, the balance of remaining deferred revenues at January 1, 2019 was $75.7 million, $37.1 million and $125.2 million related to the Combined 2018 AZ Agreements, 2016 VEGF Exercise and the Merck PCV/SAV Agreement, respectively.

The following tables summarize the effects of adopting ASC 606 on our condensed consolidated financial statements at March 31, 2019, and for the three months ended March 31, 2019 (in thousands, except per share data):

March 31, 2019
Condensed Consolidated Balance Sheet

As reported under ASC 606

Adjustments

Balance without adoption of ASC 606
Deferred revenue, current

$
73,958

$
36,452

$
110,410

Deferred revenue, non-current

156,862

(29,840
)

127,022

Accumulated deficit

(1,111,300
)

(6,077
)

(1,117,377
)

Three Months Ended March 31, 2019
Condensed Consolidated Statement of Operations

As reported under ASC 606

Adjustments

Amount without adoption of ASC 606
Revenue:

   Collaboration revenue

$
13,301

$
(1,786
)

$
11,515

   Collaboration revenue from related party

814

24,377

25,191

Total revenue

16,025

21,907

37,932

Loss from operations

(141,833
)

21,907

(119,926
)
Loss before benefit from income taxes

(132,681
)

21,907

(110,774
)
Net (loss) income

(132,657
)

21,907

(110,750
)
Net loss per share - basic and diluted

(0.40
)

0.06

(0.34
)

ASU No. 2016-18, Statement of Cash Flows: Restricted Cash

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires the statement of cash flows to explain the change during the period in the total of cash, cash equivalents and restricted cash. When cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new standard requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet. This reconciliation can be presented either on the face of the statement of cash flows or in the notes to the financial statements. The new standard became effective for us on January 1, 2019. As a result of adopting this new standard using a retrospective transition method for each period presented, we include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed statements of cash flows.

The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows (in thousands):

As of March 31,

2019

2018
Cash and cash equivalents

$
502,934

$
90,479

Restricted cash

—

237

Restricted cash, non-current

11,823

11,798

Total cash, cash equivalents and restricted cash shown in the condensed consolidated
    statements of cash flows

$
514,757

$
102,514

ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting

In June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance generally consistent with the accounting for employee share-based compensation. The new standard will be effective for us on January 1, 2020, with early adoption permitted. We early adopted this standard in the first quarter of 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and disclosure.

ASU No. 2018-18, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606

In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which clarifies the interaction between Topic 808 and Topic 606, Revenue from Contracts with Customers. Currently, Topic 808 does not provide comprehensive recognition or measurement guidance for collaborative arrangements, and the accounting for those arrangements is often based on an analogy to other accounting literature or an accounting policy election. Similarly, aspects of Topic 606 have resulted in diversity in practice on the effect of the revenue standard on the accounting for collaborative arrangements. The standard will become effective for us beginning on January 1, 2021, with early adoption permitted. We early adopted this standard in connection with the adoption of ASC 606 in the first quarter of 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and disclosure.

Recently Issued Accounting Standards

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our condensed consolidated financial statements and disclosures.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes all existing lease guidance. This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. The new standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments. Lessees are required to classify leases as either finance or operating leases. If the lease is effectively a financed-purchase by the lessee, it is classified as a financing lease, otherwise it is classified as an operating lease. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. ASC 842 provides accounting guidance for transactions that meet specific criteria for a leaseback transaction. If the criteria are not met, the transaction is considered a “failed sale” and the transaction must be accounted for as a financing arrangement. The new standard will be effective for us on January 1, 2020, assuming we continue to qualify as an EGC.. Upon adoption, the new standard, as amended, allows lessees to apply the transition requirements either (1) retrospectively to each prior reporting period presented in the financial statements with the cumulative effect of applying the new rules recognized at the beginning of the earliest comparative period presented, or (2) retrospectively at the beginning of the period of adoption with the cumulative effect of applying the new rules recognized then. We are currently evaluating the potential impact ASU 2016-02 may have on our financial position and results of operations. Our assessment will include, but is not limited to, evaluating the impact this standard has on the lease of our corporate headquarters at 200 Technology Square in Cambridge, MA, the lease of our office and laboratory space at 500 Technology Square, Cambridge, MA and our manufacturing and additional facilities in Norwood, MA, (see Note 7), and the identification of any embedded leases.

In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (ASU 2016-13). ASU 2016-13 will change how companies account for credit losses for most financial assets and certain other instruments. For trade receivables, loans and held-to-maturity debt securities, companies will be required to recognize an allowance for credit losses rather than reducing the carrying value of the asset. Assuming we continue to qualify as an EGC, ASU 2016-13 will be effective for us for fiscal years beginning after December 15, 2020, , including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 will have on the Company’s financial position and results of operations.

In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Topic 350): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This standard requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This standard should be applied either retrospectively or prospectively, and will be effective for us in January 2021, assuming we continue to qualify as an EGC, with early adoption permitted. We are currently evaluating the potential impact this standard may have on our condensed consolidated financial statements and results of operations upon adoption.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R12.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration Agreements
3 Months Ended

Mar. 31, 2019

Research and Development [Abstract]

Collaboration Agreements
Collaboration Agreements

The following table summarizes our total consolidated net revenues from our strategic collaborators for the periods presented (in thousands):

Three Months Ended
Collaboration Revenue by Strategic Collaborator:

March 31, 2019
as reported
(under ASU 606)

March 31, 2019
without adoption of 606
(under ASC 605)

March 31, 2018
as reported
(under ASC 605)
Merck

$
10,687

$
11,515

$
15,967

AstraZeneca

814

25,191

7,350

Vertex

2,614

—

4,143

Total collaborative revenue

$
14,115

$
36,706

$
27,460

The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the three months ended March 31, 2019 (in thousands):

January 1, 2019

Additions

Deductions

March 31, 2019
Contract Assets:

Accounts receivable

$
4,612

$
2,735

$
(3,747
)

$
3,600

Contract Liabilities:

Deferred revenue

$
240,924

$
1,137

$
(13,582
)

$
228,479

During the three months ended March 31, 2019, we recognized the following revenues as a result of the change in the contract liability balances related to our collaboration agreements (in thousands):
Revenue recognized in the period from:

Three Months Ended March 31, 2019
Amounts included in contract liabilities at the beginning of the period ⁽¹⁾

$
13,582

⁽¹⁾ We first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period first applies to the beginning contract liability.

As of March 31, 2019, the aggregated amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied was $279.5 million.

AstraZeneca – Strategic Alliances in Cardiovascular and Oncology

2013 Option Agreement and Services and Collaboration Agreement

In March 2013, we entered into an Option Agreement, the AZ Option Agreement, and a related Services and Collaboration Agreement, the AZ Services Agreement, with AstraZeneca, which were amended and restated in June 2018. We refer to these agreements in the forms that existed prior to the 2018 amendment and restatement as the 2013 AZ Agreements. Under the 2013 AZ Agreements, we granted AstraZeneca certain exclusive rights and licenses, and options to obtain exclusive rights to develop and commercialize potential therapeutic mRNA medicines directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services to AstraZeneca. Pursuant to the 2013 AZ Agreements, AstraZeneca was responsible for all research, development and commercialization activities, while we provided specified research and manufacturing services during a research and evaluation period, as described below, to further AstraZeneca’s activities pursuant to an agreed upon services plan. Under the 2013 AZ Agreements, AstraZeneca could have requested we provide additional services, at AstraZeneca’s expense. Subject to customary “back-up” supply rights granted to AstraZeneca, we exclusively manufactured (or had manufactured) mRNA for all research, development and commercialization purposes under the 2013 AZ Agreements until, on a product-by-product basis, the expiration of the time period for which we are entitled to receive earn-out payments with respect to such product pursuant to the 2013 AZ Agreements.

As of the effective date of the 2013 AZ Agreements, AstraZeneca acquired forty options that it may exercise to obtain exclusive rights to clinically develop and commercialize identified development candidates (and related back-up candidates) directed to specified targets that arise during the research and evaluation period. During the research and evaluation period for research candidates under the 2013 AZ Agreements, AstraZeneca could have elected to designate a limited number of research candidates as development candidates in order to continue preclinical development on such development candidates (and related back-up candidates). From such pool of development candidates designated by AstraZeneca, during a specified option exercise period, AstraZeneca could have then exercised one of its options to obtain exclusive rights to clinically develop and commercialize an identified development candidate (and related back-up candidates). If AstraZeneca did not exercise one of its options to acquire exclusive rights to clinically develop and commercialize a particular development candidate during the defined option exercise period for such development candidate, AstraZeneca’s rights to exercise an option and other rights granted under the 2013 AZ Agreements with respect to such development candidate (and related back-up candidates) would terminate, all rights to exploit such development candidate (and related back-up candidates) would be returned to us and all data and results generated by AstraZeneca with respect to such development candidate (and related back-up candidates) would be either assigned or licensed to us. Upon the earlier of termination of the 2013 AZ Agreements for any reason and a specified anniversary of the effective date of the 2013 AZ Agreements, all unexercised options, and the right to exercise any and all options if not previously exercised by AstraZeneca, would automatically terminate. On a target-by-target basis, we and AstraZeneca agreed to certain defined exclusivity obligations under the 2013 AZ Agreements with respect to the research, development and commercialization of mRNA medicines for such target.

As of the effective date of the 2013 AZ Agreements, AstraZeneca made upfront cash payments to us totaling $240.0 million. Under the 2013 AZ Agreements, we were entitled to receive payments that are not related to any specific program of up to $180.0 million in the aggregate for the achievement of three technical milestones relating to toxicity, delivery, and competition criteria. We achieved the toxicity and competition milestones in the year ended December 31, 2015. The delivery milestone has expired. Under the 2013 AZ Agreements, AstraZeneca was obligated to pay us a $10.0 million option exercise fee with respect to each development candidate (and related back-up candidates) for which it exercised an option. In addition, upon AstraZeneca’s exercise of each option, we were eligible to receive certain payments contingent upon the achievement of specified clinical, regulatory, and commercial events. For any product candidate optioned by AstraZeneca, we were eligible to receive, per product candidate, up to $100.0 million in payments for achievement of development milestones, up to $100.0 million payments for achievement of regulatory milestones, and up to $200.0 million payments for achievement of commercial milestones. Additionally, under the 2013 AZ Agreements, we were entitled to receive, on a product-by-product basis, earn-out payments on worldwide net sales of products ranging from a high-single digit percentage to 12%, subject to certain reductions, with an aggregate minimum floor.

We received from AstraZeneca under the 2013 AZ Agreements an option exercise payment of $10.0 million in the year ended December 31, 2016, and a clinical milestone payment of $30.0 million with respect to AstraZeneca’s VEGF-A product (AZD8601) during the year ended December 31, 2018, that is currently being developed in a Phase 2 clinical trial in certain fields.
Unless earlier terminated, the 2013 AZ Agreements would have continued until the expiration of AstraZeneca’s earn-out and contingent option exercise payment obligations for optioned product candidates. Either party had the right to terminate the 2013 AZ Agreements upon the other party’s material breach, either in its entirety or in certain circumstances, with respect to relevant candidates, subject to a defined materiality threshold and specified notice and cure provisions. If AstraZeneca had the right to terminate the 2013 AZ Agreements for our material breach, then AstraZeneca could have elected, in lieu of terminating the 2013 AZ Agreements, in their entirety or with respect to such candidates, to have the 2013 AZ Agreements remain in effect, subject to reductions in certain payments we were eligible to receive and certain adjustments to AstraZeneca’s obligations under the 2013 AZ Agreements. AstraZeneca had the right to terminate the 2013 AZ Agreements in full, without cause, upon 90-days’ prior notice to us.

2016 Strategic Alliance with AstraZeneca – IL12

In January 2016, we entered into a new Strategic Drug Development Collaboration and License Agreement, which we refer to as the 2016 AZ Agreement, with AstraZeneca to discover, develop and commercialize potential mRNA medicines for the treatment of a range of cancers.

Under the terms of the 2016 AZ Agreement, we and AstraZeneca have agreed to work together on an immuno-oncology program focused on the intratumoral delivery of a potential mRNA medicine to make the IL12 protein. The 2016 AZ Agreement initially included research activities with respect to a second discovery program. During a limited period of time, each party had an opportunity to propose additional discovery programs to be conducted under the 2016 AZ Agreement. We are responsible for conducting and funding all discovery and preclinical development activities under the 2016 AZ Agreement in accordance with an agreed upon discovery program plan for the IL12 program and any other discovery program the parties agree to conduct under the 2016 AZ Agreement. For the IL12 program and any other discovery program the parties agree to conduct under the 2016 AZ Agreement, during a defined election period that commenced as of the effective date of the 2016 AZ Agreement (for the IL12 program) and otherwise will commence on initiation of any such new discovery program, AstraZeneca may elect to participate in the clinical development of a development candidate arising under the 2016 AZ Agreement from such program. If AstraZeneca so elects (as it has for the IL12 program), AstraZeneca will lead clinical development activities worldwide and we will be responsible for certain activities, including being solely responsible for manufacturing activities, all in accordance with an agreed upon development plan. AstraZeneca will be responsible for funding all Phase 1 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan), and Phase 2 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan) up to a defined dollar threshold. We and AstraZeneca will equally share the costs of Phase 2 clinical development activities in excess of such dollar threshold, all Phase 3 clinical development activities and certain other costs of late-stage clinical development activities, unless we elect not to participate in further development and commercialization activities and instead receive tiered royalties, as described below.

We and AstraZeneca will co-commercialize products in the U.S. in accordance with an agreed upon commercialization plan and budget, and on a product-by-product basis will equally share the U.S. profits or losses arising from such commercialization. Notwithstanding, on a product-by-product basis, prior to a specified stage of development of a given product, we have the right to elect not to participate in the further development and commercialization activities for such product. If we make such election, instead of participating in the U.S. profits and losses share with respect to such product, we are obligated to discuss future financial terms with AstraZeneca. If we are unable to agree on future financial terms within a short, defined period of time, we are entitled to receive tiered royalties at default rates set forth in the 2016 AZ Agreement, ranging from percentages in the mid-single digits to 20% on worldwide net sales of products, subject to certain reductions with an aggregate minimum floor. AstraZeneca has sole and exclusive responsibility for all ex-U.S. commercialization efforts. Unless we have elected to not to participate in further development (in which case royalties on ex-U.S. net sales will be at the default rates as described above, unless otherwise agreed by the parties), we are entitled to tiered royalties at rates ranging from 10% to 30% on ex-U.S. net sales of the products, subject to certain reductions with an aggregate minimum floor. Subject to customary “back-up” supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) products for all development and commercialization purposes. We and AstraZeneca have agreed to certain defined exclusivity obligations with each other under the 2016 AZ Agreement with respect to the development and commercialization of mRNA medicines for IL12.

Unless earlier terminated, our strategic alliance under the 2016 AZ Agreement will continue on a product-by-product basis (i) until both parties cease developing and commercializing such product without the intention to resume, if we have not elected our right not to participate in further development and commercialization of such product or (ii) on a country-by-country basis, until the end of the applicable royalty term for such product in such country, if we have elected our right not to participate in further development and commercialization of such product.

Either party may terminate the 2016 AZ Agreement upon the other party’s material breach, subject to specified notice and cure provisions. Each party may also terminate the 2016 AZ Agreement in the event the other party challenges such party’s patent rights, subject to certain defined exceptions. AstraZeneca has the right to terminate the 2016 AZ Agreement in full or with respect to any program for scientific, technical, regulatory or commercial reasons at any time upon 90 days’ prior written notice to us. On a product-by-product basis, we have the right to terminate the 2016 AZ Agreement in certain cases if AstraZeneca has suspended or is no longer proceeding with the development or commercialization of such product for a period of twelve consecutive months, subject to specified exceptions, including tolling for events outside of AstraZeneca’s control. On a product-by-product basis, if the 2016 AZ Agreement is terminated with respect to a given product, AstraZeneca’s rights in such product will terminate and, to the extent we terminated for AstraZeneca’s breach, patent challenge or cessation of development or AstraZeneca terminated in its discretion, AstraZeneca will grant us reversion licenses and take certain other actions so as to enable us to continue developing and commercializing such product in the oncology field.

If we continue developing and commercializing a given product following termination of the 2016 AZ Agreement by AstraZeneca in its discretion with respect to such product, AstraZeneca is entitled to receive a mid-single digit royalty on our worldwide net sales of such product and a high-single digit percentage of the amounts received by us from a third party in consideration of a license to such third party to exploit such product, in each case, until AstraZeneca recovers an amount equal to specified development costs incurred by AstraZeneca under the 2016 AZ Agreement with respect to such product prior to such termination. Such percentages increase by a low to mid-single digit amount to the extent such termination occurs after such product achieves a specified stage of development.

2017 Strategic Alliance with AstraZeneca – Relaxin

In October 2017, we entered a new Collaboration and License Agreement, which we refer to as the 2017 AZ Agreement, under which AstraZeneca may clinically develop and commercialize a development candidate, now known as AZD7970, which is comprised of an mRNA construct for the relaxin protein designed by us and encapsulated in one of our proprietary lipid nanoparticles ("LNP"). We discovered and performed preclinical development activities for AZD7970 prior to the initiation of the strategic alliance with AstraZeneca under the 2017 AZ Agreement.

Under the terms of the 2017 AZ Agreement, we will fund and be responsible for conducting preclinical development activities for AZD7970 through completion of IND-enabling GLP toxicology studies and AstraZeneca will lead pharmacological studies, each in accordance with an agreed upon discovery program plan. During a defined election period that commences as of the effective date of the 2017 AZ Agreement, AstraZeneca may elect to participate in further development and commercialization of AZD7970. Upon such election, AstraZeneca will lead clinical development activities for AZD7970 worldwide and we will be responsible for manufacturing AZD7970, certain regulatory matters and any other development activities that we agree to perform and that are set forth in an agreed upon development plan. AstraZeneca will be responsible for funding Phase 1 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan, up to a cap above which such costs are shared), and Phase 2 clinical development activities (including costs associated with our manufacture of clinical materials in accordance with the development plan, up to a cap above which such costs are shared) up to a defined dollar threshold. Thereafter, we and AstraZeneca will equally share the costs of Phase 2 clinical development activities in excess of such defined dollar threshold, all Phase 3 clinical development activities and certain other costs of late-stage clinical development activities, unless we elect not to participate in further development and co-commercialization activities and instead receive tiered royalties as described below. If the development candidate is determined to be IND-ready, and AstraZeneca does not timely elect to participate in the clinical development of AZD7970, AstraZeneca is obligated to reimburse us for certain costs we incurred in the manufacture and development of AZD7970, since execution of the 2017 AZ Agreement.

We and AstraZeneca will co-commercialize AZD7970 in the United States in accordance with an agreed upon commercialization plan and budget, and will equally share U.S. profits or losses arising from such commercialization. Notwithstanding, prior to a specified stage of development of AZD7970, we have the right to elect not to participate in the further development and commercialization activities for AZD7970. If we make such election, instead of participating in the U.S. profits and losses share with respect to AZD7970, we are obligated to discuss future financial terms with AstraZeneca. If we are unable to agree on future financial terms within a short, defined period of time, we are entitled to receive tiered royalties at default rates set forth in the 2017 AZ Agreement, ranging from percentages in the mid-single digits to the low 20s on worldwide net sales by AstraZeneca of AZD7970, subject to certain reductions, with an aggregate minimum floor. AstraZeneca has sole and exclusive responsibility for all ex-U.S. commercialization efforts. Unless we have elected not to participate in further development (in which case royalties on ex-U.S. net sales will be at the default rates as described above, unless otherwise agreed by the parties), we are entitled to receive tiered royalties at rates ranging from 10% to 30% on annual ex-U.S. net sales of AZD7970, subject to certain reductions with an aggregate minimum floor. Subject to customary “back-up” supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) products for all development and commercialization purposes. Additionally, we and AstraZeneca have agreed to certain defined exclusivity obligations under the 2017 AZ Agreement with respect to the development and commercialization of mRNA medicines for Relaxin.

Unless earlier terminated, our strategic alliance under the 2017 AZ Agreement will continue (i) until the expiration of AstraZeneca’s election period, if it does not elect to participate in the clinical development of AZD7970, (ii) until both parties cease developing and commercializing AZD7970 without the intention to resume, if we have not elected our right not to participate in further development and commercialization of AZD7970, (iii) on a country-by-country basis, until the end of the applicable royalty term for AZD7970 in such country, if we have elected our right not to participate in further development and commercialization of AZD7970 or (iv) following completion of IND-enabling studies with respect to AZD7970, if we provide AstraZeneca with written notice that we do not reasonably believe that the product is IND-ready.

Either party may terminate the 2017 AZ Agreement upon the other party’s material breach, subject to specified notice and cure provisions. Each party may also terminate the 2017 AZ Agreement in the event the other party challenges the validity or enforceability of such party’s patent rights, subject to certain defined exceptions. AstraZeneca has the right to terminate the 2017 AZ Agreement in full for scientific, technical, regulatory or commercial reasons at any time upon 90 days’ prior written notice to us. We have the right to terminate the 2017 AZ Agreement in certain cases if AstraZeneca has suspended or is no longer proceeding with the development or commercialization of AZD7970 for a period of twelve consecutive months, subject to specified exceptions, including tolling for events outside of AstraZeneca’s control. If AstraZeneca does not timely elect to participate in clinical development of AZD7970, or the Agreement is terminated, AstraZeneca’s rights in AZD7970 will terminate and, to the extent we terminated for AstraZeneca’s breach, patent challenge or cessation of development or AstraZeneca terminated in its discretion, AstraZeneca will grant us reversion licenses and take certain other actions so as to enable us to continue developing and commercializing AZD7970 in the cardiovascular and cardiometabolic fields.

If we continue developing and commercializing AZD7970 following a termination of the 2017 AZ Agreement by AstraZeneca in its discretion, AstraZeneca is entitled to receive a mid-single digit royalty on our worldwide net sales of AZD7970 and a high-single digit percentage of the amounts received by us from a third party in consideration for a license to such third party to exploit AZD7970, in each case until AstraZeneca recovers an amount equal to specified development costs incurred by AstraZeneca under the 2017 AZ Agreement with respect to AZD7970 prior to such termination. Such percentages increase by a low to mid-single digit amount to the extent such termination occurs after such product achieves a specified stage of development.

2013 Agreements with AstraZeneca, amended and restated in 2018

In June 2018, we entered into an Amended and Restated Option Agreement and a related Amended and Restated Services and Collaboration Agreement with AstraZeneca, or the 2018 A&R Agreements, which amended and restated the 2013 AZ Agreements. Under the 2018 A&R Agreements, we granted AstraZeneca certain exclusive rights and licenses to research, develop and commercialize potential therapeutic mRNA medicines directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services to AstraZeneca. The activities to be performed by the parties under the 2018 A&R Agreements are limited to defined biological targets in the cardiovascular and cardiometabolic fields and one defined target in the cancer field.

Pursuant to the 2018 A&R Agreements, AstraZeneca is responsible for all research, development and commercialization activities and associated costs, while we provide specified research and manufacturing services during a research and evaluation period, as described below, to further AstraZeneca’s activities conducted pursuant to an agreed upon services plan. During this research and evaluation period, these research services, and manufacturing services in excess of a specified threshold, are provided at AstraZeneca’s expense, and manufacturing services below the specified threshold are provided at no additional expense to AstraZeneca. AstraZeneca may request we provide additional research and manufacturing services, at AstraZeneca’s expense, following the end of the research and evaluation period. Subject to customary “back-up” supply rights granted to AstraZeneca, we exclusively manufacture (or have manufactured) mRNA for all research, development and commercialization purposes under the 2018 A&R Agreements until, on a product-by-product basis, the expiration of the time period for which we are entitled to receive earn-out payments with respect to such product pursuant to the 2018 A&R Agreements.

As of the effective date of the 2013 AZ Agreements, and as further reflected in the 2018 A&R Agreements, AstraZeneca acquired forty options that it may exercise to obtain exclusive rights to clinically develop and commercialize identified development candidates (and related back-up candidates) directed to specified targets that arise during the research and evaluation period. During the research and evaluation period for research candidates, AstraZeneca may elect to designate a limited number of research candidates as development candidates in order to continue preclinical development on such development candidates (and related back-up candidates). From such pool of development candidates designated by AstraZeneca, during a specified option exercise period, AstraZeneca may then exercise one of its options to obtain exclusive rights to clinically develop and commercialize an identified development candidate (and related back-up candidates) in certain fields. If AstraZeneca does not exercise one of its options to acquire exclusive rights to clinically develop and commercialize a particular development candidate during the defined option exercise period for such development candidate, AstraZeneca’s rights to exercise an option and other rights granted under the 2018 A&R Agreements with respect to such development candidate (and related back-up candidates) will terminate, all rights to exploit such development candidate (and related back-up candidates) will be returned to us and all data and results generated by AstraZeneca with respect to such development candidate (and related back-up candidates) will be either assigned or licensed to us. Upon the earlier of termination of the 2018 A&R Agreements for any reason and a specified anniversary of the effective date of the 2013 AZ Agreements, all unexercised options, and the right to exercise any and all options if not previously exercised by AstraZeneca, will automatically terminate.

On a target-by-target basis, we and AstraZeneca have agreed to certain defined exclusivity obligations under the 2018 A&R Agreements with respect to the research, development and commercialization of mRNA medicines for such target in certain fields. In addition, we and AstraZeneca have agreed to certain defined exclusivity obligations with respect to the research, development and commercialization of mRNA medicines coding for the same polypeptide as any development candidate being developed under the 2018 A&R Agreements.

Unless earlier terminated, the 2018 A&R Agreements will continue until the expiration of AstraZeneca’s earn-out and contingent option exercise payment obligations for optioned product candidates. Either party may terminate the 2018 A&R Agreements upon the other party’s material breach, either in its entirety or in certain circumstances, with respect to relevant candidates, subject to a defined materiality threshold and specified notice and cure provisions. If AstraZeneca has the right to terminate the 2018 A&R Agreements for our material breach, then AstraZeneca may elect, in lieu of terminating the 2018 A&R Agreements, in their entirety or with respect to such candidates, to have the 2018 A&R Agreements remain in effect, subject to reductions in certain payments we are eligible to receive and certain adjustments to AstraZeneca’s obligations under the 2018 A&R Agreements. AstraZeneca may terminate the 2018 A&R Agreements in full, without cause, upon 90 days’ prior notice to us.

Accounting Treatment

For periods prior to January 1, 2019, we applied the provisions of ASC 605 in accounting for these arrangements, except for the 2017 AZ Agreement which was accounted for under ASC 808. In August 2016, AstraZeneca exercised a product option available pursuant to the 2013 AZ Agreements to obtain exclusive rights to clinically develop and commercialize the VEGF-A product (AZD8601). This option exercise is referred to as the 2016 VEGF Exercise. Consistent with our conclusions under ASC 605 and pursuant to ASC 606, we determined that the 2016 VEGF Exercise and the 2017 AZ Agreement should be accounted for as separate transactions as the agreements are not interrelated or interdependent. Conversely, the 2013 Agreements, as amended by the 2018 A&R Agreements, and the 2016 AZ Agreement, were combined for accounting purposes and treated as a single agreement, as these agreements were negotiated in contemplation of each other. As of the date of our initial application of ASC 606, we applied the practical expedient to include the aggregate effect of all modifications to the arrangement that occurred before January 1, 2019 with respect to (i) identification of the satisfied and unsatisfied performance obligations, (ii) determination of the transaction price and (iii) allocation of the transaction price to the satisfied and unsatisfied performance obligations. Therefore, we aggregated effects of all the modifications prior to January 1, 2019 to the 2013 Agreements, including the effects of the 2018 A&R Agreements, and the 2016 AZ Agreement were combined into one transaction for accounting purposes. We will refer to this combined transaction as the Combined 2018 AZ Agreements. We determined that all aspects of Combined 2018 AZ Agreements and the 2016 VEGF Exercise represent a transaction with a customer and therefore is accounted for in accordance with ASC 606 as of the date of the initial application.

Combined 2018 AZ Agreements

We identified the following performance obligations in the Combined 2018 AZ Agreements: (i) a combined performance obligation that includes a research license, research and development pool services, and manufacturing obligations related to the 2013 AZ Agreements, as amended by the 2018 A&R Agreements, collectively referred to as the Combined 2018 AZ Agreement Performance Obligation, (ii) preclinical development services for IL12, (iii) preclinical development services for an oncology development target, (iv) a combined performance obligation for a development and commercialization license and manufacturing obligations for IL12, and (v) a material right to receive development and commercialization rights and manufacturing services for an oncology development target.

We concluded that the research license is not distinct from the research and development pool services or the manufacturing obligations related to the 2018 A&R Agreements, as AstraZeneca cannot fully exploit the value of the research license without receipt of such services and supply. Our services and supply involve specialized expertise, particularly as it relates to mRNA technology that is not available in the marketplace. Any supply requested by AstraZeneca in excess of the minimum quantities specified in the agreement are considered customer options and treated as separate contracts for accounting purposes. Further, we concluded that AstraZeneca cannot exploit the value of the development and commercialization license for IL12 without receipt of supply as the development and commercialization license does not convey to AstraZeneca the right to manufacture and therefore combined the development and commercialization license and the manufacturing obligations for IL12 into one performance obligation.

As of January 1, 2019, the date of initial adoption of ASC 606, the total transaction price was determined to be $400.0 million comprised of the $240.0 million in upfront payments pertaining to the 2013 AZ Agreements and $160.0 million of variable consideration comprised of $40.0 million of estimated reimbursement for IL12 manufacturing obligations and $120.0 million of milestone payments ($60.0 million toxicity milestone and $60.0 million competition milestone), received prior to the adoption date of ASC 606. We utilize the most likely amount method to determine the amount of reimbursement for IL12 manufacturing obligations to be received. We determined that any sales-based royalties related to IL12 will be recognized when the related sales occur as they were determined to relate predominately to the license granted and therefore have been excluded from the transaction price. In addition, we are eligible to receive future milestones and royalties on future commercial sales for optioned product candidates under the 2018 A&R Agreements and future royalties under the 2016 Agreement; however, these amounts are not considered variable consideration under the Combined 2018 Agreements as we are only eligible to receive such amounts if AstraZeneca exercises its options (including certain options that are deemed to be material rights). We have concluded that the exercise of an optioned product candidate represents a separate transaction under ASC 606. We will re-evaluate the transaction price at the end of each reporting period. There was a $0.3 million increase to the transaction price resulting from a change in estimate of the variable consideration during the three months ended March 31, 2019.

The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation. We developed the estimated standalone selling price for the licenses included in the Combined 2018 AZ Agreement Performance Obligation and the combined performance obligation for a development and commercialization license and manufacturing obligations for IL12 primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success and the time needed to commercialize a product candidate pursuant to the associated license. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the performance obligation, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated costs, adjusted for a reasonable profit margin that would be expected to be realized under similar contracts. The estimated standalone selling price of the material right to receive development and commercialization rights and manufacturing services for an oncology development target was developed by estimating the amount of discount that AstraZeneca would receive when exercising the option and adjusting such amount by the likelihood that the option will be exercised.

The transaction price allocated to each performance obligation was as follows: (i) $292.4 million to the Combined 2018 AZ Agreement Performance Obligation, (ii) $8.1 million to the preclinical development services for IL12 performance obligation, (iii) $8.1 million to the preclinical development services for an oncology development target performance obligation, (iv) $89.8 million to the combined performance obligation for a development and commercialization license and manufacturing obligations for IL12, and (v) $1.6 million to the material right to receive development and commercialization rights and manufacturing services for an oncology development target. As part of the allocation of the transaction price to each of the performance obligations, we concluded that the $60.0 million toxicology milestone and the estimated reimbursement for IL12 manufacturing costs can be allocated entirely to specific performance obligations because the variable payment relates specifically to our effort to satisfy the performance obligation and such allocation is consistent with the allocation objectives of ASC 606.

We measure proportional performance over time using an input method based on cost incurred relative to the total estimated costs for the Combined 2018 AZ Agreement Performance Obligation and the preclinical development services for IL12 and the other oncology target performance obligations. We recognize revenue related to the amounts allocated to the combined performance obligation for a development and commercialization license and manufacturing obligations for IL12 based on the point in time upon which control of supply is transferred to AstraZeneca for each delivery of the associated supply.

We recognize revenue for the Combined 2018 AZ Agreement Performance Obligation, on a quarterly basis, by determining the proportion of effort incurred as a percentage of total effort we expect to expend. This ratio is applied to the transaction price allocated to this combined performance obligation. We also estimate the development plan, including expected demand from AstraZeneca, and the associated costs for this combined performance obligation, as we will satisfy this combined performance obligation as the manufacturing services are performed. Management has applied significant judgment in the process of developing our budget estimates. Any changes to these estimates will be recognized in the period in which they change as a cumulative catch up.

For the three months ended March 31, 2019 and 2018, we recognized collaboration revenue of $0.8 million and $7.4 million, respectively, from the Combined 2018 AZ Agreements. The revenue recognized for the three months ended March 31, 2019 includes the amortization of deferred revenue due to the satisfaction of our performance obligation during the period. As of March 31, 2019, the aggregate amount of the transaction price allocated to the remaining performance obligations that are unsatisfied is $112.5 million. $102.8 million is expected to be recognized as revenue through December 31, 2027 and $9.7 million is expected to be recognized as revenue at the earlier of expiration or modification of the Combined 2018 AZ Agreement. We had deferred revenue of $75.5 million and $115.6 million as of March 31, 2019 and December 31, 2018, respectively, from the Combined 2018 AZ Agreements, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the services are expected to be performed or control of the supply is expected to be transferred.

2016 VEGF Exercise

We concluded that the 2016 VEGF Exercise should be treated as a separate transaction for accounting purposes. We identified one performance obligation in this arrangement which is comprised of the exclusive license to develop and commercialize VEGF and the manufacturing of clinical supply. We concluded that the VEGF license is not distinct from the manufacturing obligations because AstraZeneca cannot fully exploit the value of the license without receipt of such supply. This is due to limitations inherent in the licenses conveyed wherein AstraZeneca does not have the contractual right to manufacture during the term of the agreement.

As of January 1, 2019, the date of initial adoption of ASC 606, the total transaction price was determined to be $55.1 million comprised of the $40.0 million in fixed payments pertaining to a $10.0 million option exercise fee and a $30.0 million milestone achieved prior to the adoption of ASC 606 and $15.1 million of variable consideration related to the estimated reimbursement for clinical supply. We are eligible to receive future milestones and royalties on future commercial sales under this arrangement. We utilize the most likely amount method to estimate any development and regulatory milestone payments to be received and the amount of estimated reimbursement for clinical supply. As of January 1, 2019, there were no milestones that had not been achieved included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or AstraZeneca’s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. We will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. When a milestone payment is included in the transaction price in the future, it will be recognized as revenue based on the relative completion of the underlying performance obligation. There were no changes to the transaction price during the three months ended March 31, 2019.

We recognize revenue related to the amount of the transaction price allocated to the VEGF Exercise performance obligation based on the point in time upon which control of supply is transferred to AstraZeneca for each delivery of the associated supply.

For the three months ended March 31, 2019 and 2018, we did not recognize any collaboration revenue from the 2016 VEGF Exercise. As of March 31, 2019, the aggregate amount of the transaction price allocated to the remaining performance obligation that is unsatisfied is $51.0 million, which is expected to be recognized as revenue through December 31, 2023. We had deferred revenue of $37.1 million and $41.2 million as of March 31, 2019 and December 31, 2018, respectively, from the 2016 VEGF Exercise, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the control of the supply is expected to be transferred.

2017 AZ Agreement

We concluded the 2017 AZ Agreement is under the scope of ASC 808 as we and AstraZeneca are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on commercial success of the activities of the arrangement. Additionally, we determined the development, manufacturing and commercialization activities are not deliverables under ASC 606. As a result, the activities conducted pursuant to the development, manufacturing and commercialization activities are accounted for as a component of the related expense in the period incurred. We considered the guidance in ASC 606 by analogy in determining the appropriate treatment for the transactions between us and AstraZeneca and concluded that reimbursement for transactions in which we are considered to be principal because we control a promised good or service before transferring that good or service to the customer, are accounted for as gross revenue.

We did not recognize any revenue from the 2017 AZ Agreement for the three months ended March 31, 2019 and 2018, respectively.

Merck – Strategic Alliances in Infectious Diseases and Cancer Vaccines

2015 Strategic Alliance with Merck – Infectious Disease

In January 2015, we entered into a Master Collaboration and License Agreement with Merck, which was amended in January 2016, June 2016, and May 2019, and which we refer to, as amended, as the 2015 Merck Agreement. Pursuant to the 2015 Merck Agreement, we and Merck have agreed to research, develop, and commercialize potential mRNA medicines for the prevention of infections by RSV. Pursuant to the 2015 Merck Agreement, Merck is primarily responsible for research, development, and commercialization activities and associated costs of such research and commercialization. We are responsible for designing and manufacturing all mRNA constructs for preclinical and Phase 1 and Phase 2 clinical development purposes, and Merck pays us for such manufacture, and we are responsible for certain costs associated with the conduct of a Phase 1 clinical trial for a RSV vaccine product candidate (mRNA-1172). Responsibility for manufacturing mRNA constructs for late stage clinical development and commercialization purposes is to be determined.

The 2015 Merck Agreement includes a three-year period, expected to end on January 12, 2022, during which Merck may continue to preclinically and clinically develop RSV vaccine product candidates that arose during an initial four-year research period which terminated in January 2019. Merck may, prior to the end of this three-year period, elect to exclusively develop and commercialize up to five RSV vaccine product candidates.

We and Merck have agreed to certain defined exclusivity obligations during the term of the 2015 Merck Agreement with respect to potential mRNA medicines against RSV infection. As part of the May 2019 amendment of the 2015 Merck Agreement, these exclusivity obligations do not restrict Moderna from researching, developing, and commercializing a potential mRNA medicine for the prevention of a specific set of respiratory infections, including RSV, for the pediatric population.

Under the terms of the 2015 Merck Agreement, we received a $50.0 million upfront payment. We are eligible to receive, on a product-by-product basis, up to $300.0 million in aggregate milestone payments upon the achievement of certain development, regulatory, and commercial milestone events. To date, we have received from Merck a clinical milestone payment of $5.0 million with respect to the initiation of a Phase 1 clinical trial for a Merck RSV vaccine product candidate. In addition, under the terms of the 2015 Merck Agreement, we are eligible to receive an additional milestone payment unless Merck elects not to continue with further clinical development of mRNA-1172. On a product-by-product basis, we are also entitled to receive royalties on Merck’s net sales of products at rates ranging from the mid-single digits to low teens, subject to certain reductions, with an aggregate minimum floor. Additionally, concurrent with entering into the 2015 Merck Agreement in 2015, Merck made a $50.0 million equity investment in us, and concurrent with amending the 2015 Merck Agreement in January 2016, we received an upfront payment of $10.0 million from Merck.

Unless earlier terminated, the 2015 Merck Agreement will continue on a product-by-product and country-by-country basis for so long as royalties are payable by Merck on a given product in a given country. Either party may terminate the 2015 Merck Agreement upon the other party’s material breach, either in its entirety or with respect to a particular program, product candidate, product or country, subject to specified notice and cure provisions. Merck may terminate the 2015 Merck Agreement in full or with respect to a particular product candidate or product upon certain advance notice to us for any reason, or earlier if Merck determines the alliance or product is no longer commercially practicable. If Merck has the right to terminate the 2015 Merck Agreement, in its entirety or with respect to a program, product candidate or product, for our material breach, then Merck may elect, in lieu of terminating the 2015 Merck Agreement, to have the 2015 Merck Agreement remain in effect, subject to reductions in certain payments we are eligible to receive with respect to the terminable rights. Upon a termination of the 2015 Merck Agreement with respect to a program, all licenses and other rights granted to Merck with respect to such program will terminate and the continued development and commercialization of product candidates and products will revert to us. If the 2015 Merck Agreement is terminated with respect to a given product candidate or product, all licenses and other rights granted to Merck with respect to such product candidate or product will terminate and, to the extent we terminated for Merck’s breach, Merck will grant us licenses under select Merck technology for our continued development and commercialization of such product candidate or product. As a part of the May 2019 amendment of the 2015 Merck Agreement, we and Merck agreed to and conclude the collaboration as it relates to development of potential mRNA medicines for other viruses, including mRNA-1278 for the prevention of VZV infection.

Accounting Treatment

For periods prior to January 1, 2019, we applied the provisions of ASC 605 in accounting for this arrangement. As of the date of our initial application of ASC 606, we applied the practical expedient to include the aggregate effect of all modifications to the arrangement that occurred before January 1, 2019 with respect to (i) identification of the satisfied and unsatisfied performance obligations, (ii) determination of the transaction price and (iii) allocation of the transaction price to the satisfied and unsatisfied performance obligations. Additionally, we determined that all aspects of amended 2015 Merck Agreement represent a transaction with a customer and therefore the amended 2015 Merck Agreement is accounted for in accordance with ASC 606 as of the date of the initial application. As of the date of initial adoption of ASC 606, the four-year research period was substantially complete and we concluded there were no unsatisfied performance obligations pertaining to the amended 2015 Merck Agreement. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) research services during the three-year period following the initial four-year research period during which Merck may continue to preclinically and clinically develop product candidates and (ii) clinical mRNA supply for Phase 1 and Phase 2 and/or non-cGMP mRNA supply beyond the initial four-year research period. Therefore, such options will be accounted for as a separate contract upon the customer’s election. After completion of the initial four-year research period and as a part of the May 2019 amendment of the 2015 Merck Agreement, Merck elected to establish a new RSV vaccine product candidate and to conduct a Phase 1 clinical trial. We and Merck agreed to focus the collaboration activities on RSV and discontinue the collaboration as it relates to the development of development candidates for other viruses.

As of the date of initial application of ASC 606, the total transaction price of $65.0 million comprised of the $60.0 million in aggregate upfront payments, including $50.0 million related to research and development funding plus a $10.0 million funding from the 2016 amendment of the 2015 Merck Agreement, and a $5.0 million payment pertaining to achievement of a development milestone during the year ended December 31, 2017, which had been allocated entirely to the satisfied performance obligation and recognized in full. We utilize the most likely amount method to estimate any development and regulatory milestone payments to be received. As of January 1, 2019, there were no milestones that had not been achieved included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or Merck’s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. We will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. When a milestone payment is included in the transaction price in the future, it will be recognized as revenue based on the relative completion of the underlying performance obligation. There were no changes to the transaction price during the three months ended March 31, 2019.

We had no deferred revenue as of March 31, 2019 or December 31, 2018 from the amended Merck 2015 Agreement as all performance obligations under the amended 2015 Merck Agreement were completed. For the three months ended March 31, 2018, we recognized collaboration revenue of $2.0 million from the amended 2015 Merck Agreement.

Additionally, we recognized collaboration revenue of $0.5 million for the three months ended March 31, 2019, pursuant to separate agreements with Merck related to the exercise of customer options to purchase clinical mRNA supply to further develop a product candidate after the initial four-year research period. Clinical mRNA supply is recognized as collaboration revenue at a point in time upon which control of supply is transferred to Merck for each delivery of the associated supply.

We are currently evaluating the accounting related to the May 2019 amendment of the 2015 Merck Agreement.

2016 Cancer Vaccine Strategic Alliance—Personalized mRNA Cancer Vaccines

In June 2016, we entered into a personalized mRNA cancer vaccines (PCV) Collaboration and License Agreement with Merck Sharp & Dohme Corp., or Merck, which we refer to as the PCV Agreement, to develop and commercialize PCVs for individual patients using our mRNA vaccine and formulation technology. Under the strategic alliance, we identify genetic mutations present in a particular patient’s tumor cells, synthesize mRNA for these mutations, encapsulate the mRNA in one of our proprietary LNPs and administer to each patient a unique mRNA cancer vaccine designed to specifically activate the patient’s immune system against her or his own cancer cells.

Pursuant to the PCV Agreement, we are responsible for designing and researching PCVs, providing manufacturing capacity and manufacturing PCVs, and conducting Phase 1 and Phase 2 clinical trials for PCVs, alone and in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget and under the oversight of a committee comprised of equal representatives of each party. The parties have entered into a clinical quality agreement with respect to Moderna’s manufacture and supply activities. We received an upfront payment of $200.0 million from Merck. In November 2017, we and Merck announced the achievement of a key milestone for the first-in-human dosing of a PCV (mRNA-4157) as a part of the alliance. The Phase 1 open-label, dose escalation, multicenter clinical trial in the United States (KEYNOTE-603) is designed to assess the safety, tolerability and immunogenicity of mRNA-4157 alone in subjects with resected solid tumors and in combination with KEYTRUDA, in subjects with unresectable solid tumors.

Until the expiration of a defined period of time following our completion of Phase 1 and Phase 2 clinical trials for PCVs under the PCV Agreement and delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of PCVs by making a $250.0 million participation payment to us. If Merck exercises its election and pays the participation payment, then the parties will equally co-fund subsequent clinical development of PCVs, with Merck primarily responsible for conducting clinical development activities under a jointly agreed development plan and budget. Each party may also conduct additional clinical trials for PCVs that are not included in the jointly agreed development plan and budget, in which case the non-conducting party will reimburse the conducting party for half of the total costs for such trials, plus interest, from its share of future profits resulting from sales of such PCVs, if any. Merck will lead worldwide commercialization of PCVs, subject to Moderna’s option to co-promote PCVs in the United States, and the parties will equally share the profits or losses arising from worldwide commercialization. Until a PCV becomes profitable, we may elect to defer payment of our share of the commercialization and related manufacturing costs and instead reimburse Merck for such costs, plus interest, from our share of future profits resulting from sales of such PCV, if any. Subject to customary “back-up” supply rights granted to Merck, we will manufacture (or have manufactured) PCVs for preclinical and clinical purposes. Manufacture of PCVs for commercial purposes will be determined by the parties in accordance with the terms of the PCV Agreement. Under the PCV Agreement, we grant certain licenses to Merck to perform its collaboration activities.

If Merck does not exercise its right to participate in future development and commercialization of PCVs, then Moderna will retain the exclusive right to develop and commercialize PCVs developed during the strategic alliance, subject to Merck’s rights to receive a percentage in the high teens to the low 20s, subject to reductions of our net profits on sales of such PCVs. During a limited period following such non-exercise, Merck has the right to perform clinical studies of such PCVs in combination with KEYTRUDA, for which we agree to use reasonable efforts to supply such PCVs. During such limited period, we also have the right to perform clinical studies of PCVs in combination with KEYTRUDA, for which Merck agrees to use reasonable efforts to supply KEYTRUDA. In addition, following its non-exercise, Merck is also entitled to receive a percentage in the high teens to the low 20s, subject to reductions, of our net profits on sales of certain PCVs first developed by us following such non-exercise and reaching a specified development stage within a defined period of time.

We and Merck have agreed to certain defined, limited exclusivity obligations with respect to the development and commercialization of PCVs.

2018 Expansion of the Cancer Vaccine Strategic Alliance—Shared Neoepitope Cancer Vaccines

In April 2018, we and Merck agreed to expand our cancer vaccine strategic alliance to include the development and commercialization of our KRAS vaccine development candidate, mRNA-5671, and potentially other shared neoantigen mRNA cancer vaccines (SAVs). We preclinically developed mRNA-5671 prior to its inclusion in the cancer vaccine strategic alliance and it is comprised of a novel mRNA construct designed by us and encapsulated in one of our proprietary LNPs. The PCV Agreement was amended and restated to include the new SAV strategic alliance (PCV/SAV Agreement).

We have granted Merck certain licenses and we and Merck have agreed to certain exclusivity obligations with respect to SAVs and particular SAV programs, which obligations are subject to termination or expiration upon certain triggering events.
Under the PCV/SAV Agreement, Merck will be responsible for conducting Phase 1 and Phase 2 clinical trials for mRNA-5671 and for all costs associated with such activities, in accordance with a jointly agreed development plan and budget, and we will be responsible for manufacturing and supplying all mRNA-5671 required to conduct such trials and for all costs and expenses associated with such manufacture and supply. Under the PCV/SAV Agreement, our budgeted commitment for PCVs increased to $243.0 million. Until the expiration of a defined period of time following the completion of Phase 1 and Phase 2 clinical trials for mRNA-5671 under the PCV/SAV Agreement and our delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of mRNA-5671 by making a participation payment to us. If Merck exercises its participation rights, then the parties will equally co-fund subsequent clinical development of mRNA-5671, with Merck primarily responsible for conducting clinical development activities under a jointly agreed development plan and budget. If Merck declines to participate in future development and commercialization activities following the initial Phase 1 and Phase 2 clinical trials for mRNA-5671, then we will retain the rights to develop and commercialize mRNA-5671. If Merck elects to participate in future development and commercialization of mRNA-5671, Merck may also conduct additional clinical trials for mRNA-5671 that are not included in the jointly agreed development plan and budget, in which case we will reimburse Merck for half of the total development costs for such clinical trials, plus interest, from our share of future profits resulting from sales of mRNA-5671, if any. If Merck does conduct additional clinical trials for mRNA-5671, we will be responsible for manufacturing and supplying all mRNA-5671 required to conduct such trials. Merck will lead worldwide commercialization of mRNA-5671, subject to our option to co-promote mRNA-5671 in the United States, and the parties will equally share the operating profits or losses arising from worldwide commercialization. Until mRNA-5671 becomes profitable, we may elect to defer payment of our share of the commercialization and related manufacturing costs and instead reimburse Merck for such costs, plus interest, from our share of future profits resulting from sales of mRNA-5671, if any. Subject to “back-up” supply rights granted to Merck, we will manufacture (or have manufactured) mRNA-5671 and other SAVs for preclinical and clinical purposes. After Merck exercises its right to participate in future development and commercialization of mRNA-5671 and other SAVs, we will grant the applicable development and commercialization licenses and the parties are obligated to discuss responsibility for future manufacturing, giving consideration to applicable criteria.

Pursuant to the PCV/SAV Agreement, for a defined period of time, either party may propose that the parties conduct additional programs for the research and development of SAVs directed to different shared neoantigens. If the parties agree to conduct any such programs, then we will be responsible for conducting and funding preclinical discovery and research activities for such SAVs, and otherwise the programs would be conducted on substantially the same terms as mRNA-5671 program. If we or Merck propose a new SAV program and the other party does not agree to conduct such program, then the PCV/SAV Agreement includes provisions allowing the proposing party to proceed with such development, at the proposing party’s expense. If Merck is the proposing party, we will be responsible for manufacturing and supplying material for such program at Merck’s expense. In such case, the non-proposing party will have the right to opt-in to such SAV program any time before the proposing party commits to performing Good Laboratory Practice (GLP)-toxicity studies. Until the expiration of a defined period of time following our completion of Phase 1 and Phase 2 clinical trials for any SAV program mutually agreed by the parties under the PCV/SAV Agreement and our delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of such SAV by making a participation payment to us.

Unless earlier terminated, the PCV/SAV Agreement will continue on a program-by-program basis until Merck terminates its participation in such program. Following any such termination, we will retain the exclusive right to develop and commercialize PCVs or SAVs developed as a part of such program, subject to restrictions and certain limited rights retained by Merck.

In connection with the amendment of the PCV Agreement to include the development and commercialization of mRNA-5671 and potentially other SAVs, Merck made a contemporaneous equity investment in our Series H redeemable convertible preferred stock, resulting in gross proceeds of $125.0 million, of which $13.0 million is determined to be a premium and recorded to deferred revenue.

Accounting Treatment

We determined that the PCV/SAV Agreement should be accounted for separately from the amended 2015 Merck Agreement, as the agreements were not negotiated in contemplation of one another and the elements within each of the agreements are not closely interrelated or interdependent on each other.

For periods prior to January 1, 2019, we applied the provisions of ASC 605 in accounting for this arrangement. As of the date of our initial application of ASC 606, we applied the practical expedient to include the aggregate effect of all modifications to the arrangement that occurred before January 1, 2019 with respect to: (i) identification of the satisfied and unsatisfied performance obligations, (ii) determination of the transaction price and (iii) allocation of the transaction price to the satisfied and unsatisfied performance obligations. Additionally, we determined that all aspects of the PCV/SAV Agreement represent a transaction with a customer and therefore the PCV/SAV Agreement is accounted for in accordance with ASC 606 as of the date of the initial application. Further, the equity investment in our Series H redeemable convertible preferred stock was considered together with the PCV/SAV Agreement as the transactions were executed contemporaneously in contemplation of one another. Further, the purchase price paid by Merck with respect to the investment in the Series H redeemable convertible preferred stock was not representative of fair value on the date of such purchase. As such, the incremental proceeds received in excess of the fair value of the underlying stock related to the equity investment were included in the transaction price related to the PCV/SAV Agreement and the shares of Series H redeemable convertible preferred stock purchased by Merck were recorded at their respective fair value on the date of issuance.

We identified the following performance obligations in the PCV/SAV Agreement: (i) a research license and research and development services, including manufacturing and supply of PCVs, during the proof of concept (POC) term for the PCV program, referred to as the PCV Performance Obligation, and (ii) research license and manufacturing and supply of mRNA-5671 during the POC term for the KRAS program, referred to as the KRAS Performance Obligation. We concluded that the research license is not distinct from the research and development services, including manufacturing and supply of PCVs, during the POC term for the PCV program, as Merck cannot fully exploit the value of the license without receipt of such services and supply. Our services and supply involve specialized expertise, particularly as it relates to mRNA technology that is not available in the marketplace. Therefore, the research license has been combined with the research and development services, including manufacturing and supply of PCVs, during the POC term for the PCV program, into a single performance obligation. Similarly, we concluded that the research license is not distinct from the manufacturing and supply of mRNA-5671 during the POC term for the KRAS program, as Merck cannot fully exploit the value of the license without receipt of such supply which must be provided by us. This is due to limitations inherent in the licenses conveyed wherein Merck does not have the contractual right to manufacture during the POC term. Therefore, the research license has been combined with the manufacturing and supply of mRNA-5671, during the POC term for the KRAS program, into a single performance obligation. Conversely, we concluded that the PCV Performance Obligation and the KRAS Performance Obligation are distinct from each other because Merck can fully exploit the value of each program for its intended purpose without the promises associated with the other program. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) Merck participation election license related to future joint development and commercialization on a program-by-program basis, (ii) manufacturing and supply in support of certain SAV programs and/or the PCV program upon Merck election to not participate in future development and commercialization of that program and (iii) research and development services associated with certain SAV programs. Therefore, such options will be accounted for as a separate contract upon the customer’s election.

As of January 1, 2019, the date of initial application of ASC 606, the total transaction price was determined to be $213.0 million comprised of the $200.0 million upfront payment pertaining to the PCV Agreement and the premium associated with the contemporaneous sale of Series H redeemable convertible preferred stock of $13.0 million. We determined there are no components of variable consideration that should be included in the transaction price as of the date of initial application, as additional consideration to which we could be entitled is subject to Merck’s election to exercise a customer option that was deemed to be a marketing offer. We will re-evaluate the transaction price at the end of each reporting period. There were no changes to the transaction price during the three months ended March 31, 2019.

The transaction price was allocated to the performance obligations based on the relative estimated standalone selling price of each performance obligation. We developed the estimated standalone selling price for the license included in each of the PCV Performance Obligation and the KRAS Performance Obligation primarily based on the probability-weighted present value of expected future cash flows associated with each license related to each specific program. In developing such estimate, we also considered applicable market conditions and relevant entity-specific factors, including those factors contemplated in negotiating the agreement, probability of success and the time needed to commercialize a product candidate pursuant to the associated license. We developed the estimated standalone selling price for the services and/or manufacturing and supply included in each of the PCV Performance Obligation and the KRAS Performance Obligation, as applicable, primarily based on the nature of the services to be performed and/or goods to be manufactured and estimates of the associated cost, adjusted for a reasonable profit margin that would be expected to be realized under similar contracts.

The transaction price allocated to each performance obligation was as follows: (i) $206.3 million to the PCV Performance Obligation and (ii) $6.7 million allocated to the KRAS Performance Obligation. We will recognize revenue related to amounts allocated to the PCV Performance Obligation over time as the underlying services are performed using a proportional performance model. We measure proportional performance using an input method based on the costs incurred relative to the total estimated costs of research and development efforts. We recognize revenue related to the amounts allocated to the KRAS Performance Obligation based on the point in time upon which control of supply is transferred to Merck for each delivery of the associated supply.

For the three months ended March 31, 2019 and 2018, we recognized collaboration revenue of $10.2 million and $14.0 million, respectively, in the condensed consolidated statements of operations, from the Merck PCV/SAV Agreement. The revenue recognized during the three months ended March 31, 2019 includes $10.2 million related to the amortization of deferred revenue due to the satisfaction of our performance during the period. As of March 31, 2019, the aggregate amount of the transaction price allocated to the remaining performance obligations that are unsatisfied is $115.0 million, which is expected to be recognized as revenue through December 31, 2021. We had deferred revenue of $115.0 million and $111.3 million, as of March 31, 2019 and December 31, 2018, respectively, from the Merck PCV/SAV Agreement, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the services are expected to be performed or control of the supply is expected to be transferred.

Vertex – 2016 Strategic Alliance in Cystic Fibrosis

In July 2016, we entered into a Strategic Collaboration and License Agreement, with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited, together, Vertex, which we refer to as the Vertex Agreement. The Vertex Agreement is aimed at the discovery and development of potential mRNA medicines for the treatment of cystic fibrosis (CF) by enabling cells in the lungs of people with CF to produce functional CFTR proteins.

Pursuant to the Vertex Agreement, we lead discovery efforts during a three-year research period, leveraging our Platform technology and mRNA delivery expertise along with Vertex’s scientific experience in CF biology and the functional understanding of CFTR. Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Subject to customary “back-up” supply rights granted to Vertex, we exclusively manufacture (or have manufactured) mRNA for preclinical, clinical and commercialization purposes. The parties established a joint steering committee to oversee and coordinate activities under the Vertex Agreement. We and Vertex have granted each other certain licenses under the Vertex Agreement.

Under the terms of the Vertex Agreement, we received a $20.0 million upfront payment from Vertex. Vertex has the right to extend the initial three-year research period by one additional year by making an additional payment to us. We are eligible to receive up to $55.0 million in payments for achievement of development milestones, up to $220.0 million in payments for achievement of regulatory milestones and potentially could receive an additional $3.0 million milestone payment for achievement of a regulatory milestone for second and each subsequent product under the Vertex Agreement. Vertex will also pay us tiered royalties at rates ranging from the low- to high-teens on worldwide net sales of products arising from the strategic alliance, subject to certain reductions, with an aggregate minimum floor. In connection with the strategic alliance, Vertex also made a $20.0 million equity investment in our Series F redeemable convertible preferred stock. During the term of the Vertex Agreement, we and Vertex have agreed to certain defined exclusivity obligations under the Vertex Agreement with respect to the development and commercialization of certain mRNA medicines.

Unless earlier terminated, the Vertex Agreement will continue until the expiration of all royalty terms. Vertex may terminate the Vertex Agreement for convenience upon 90 days’ prior written notice, except if termination relates to a product in a country where Vertex has received marketing approval, which, in such case, Vertex must provide 180 days’ prior written notice. Either party may terminate the Vertex Agreement upon the other party’s material breach, subject to specified notice and cure provisions. Each party may also terminate the Vertex Agreement in the event that the other party challenges the validity or enforceability of such party’s patent rights, subject to certain exceptions, or if the other party becomes insolvent.

Accounting Treatment

For periods prior to January 1, 2019, we applied the provisions of ASC 605 in accounting for this arrangement. As of the date of the initial application of ASC 606, we determined that all aspects of the arrangement with Vertex represent a transaction with a customer and therefore should be accounted for in accordance with ASC 606. We identified one performance obligation comprised of: (i) a research, development and commercialization license and (ii) research and development services, including manufacturing and supply of non-cGMP mRNA, during the initial three-year research period. We concluded that the license is not distinct from the research and development services, including manufacturing and supply of non-cGMP mRNA, during the initial three-year research period, as Vertex cannot fully exploit the value of the license without receipt of such services and supply. Our services and supply involve specialized expertise, particularly as it relates to mRNA technology that is not available in the marketplace. Therefore, the license has been combined with the research and development services, including manufacturing and supply of non-cGMP supply, into a single performance obligation. Additionally, we concluded the following customer options are marketing offers as such options did not provide any discounts or other rights that would be considered a material right in the arrangement: (i) Vertex’s right to extend the research period for an additional year and (ii) clinical mRNA supply and/or non-cGMP mRNA supply beyond the initial three-year research period. Therefore, such options will be accounted for as a separate contract upon the customer’s election.

As of January 1, 2019, the date of initial application of ASC 606, the total transaction price was determined to be $24.4 million, comprised of the $20.0 million upfront payment and $4.4 million in research and development funding related to the research and development services and supply of non-cGMP mRNA. We utilize the most likely amount method to determine the amount of research and development funding to be received. We also utilize the most likely amount method to estimate any development and regulatory milestone payments to be received. As of January 1, 2019, there were no milestones included in the transaction price. We considered the stage of development and the risks associated with the remaining development required to achieve each milestone, as well as whether the achievement of the milestone is outside of our or Vertex’s control. The outstanding milestone payments were fully constrained, as a result of the uncertainty whether any of the milestones would be achieved. We determined that any sales-based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price. We will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. There were no changes to the transaction price during the three months ended March 31, 2019.

The transaction price was allocated entirely to the single performance obligation. We recognize revenue related to amounts allocated to the single performance obligation over time as the underlying services are performed using a proportional performance model. We measure proportional performance using an input method based on the costs incurred relative to the total estimated costs of the research and development efforts.

For the three months ended March 31, 2019 and 2018, we recognized collaboration revenue of $2.6 million and $4.1 million, respectively, in the condensed consolidated statements of operations, from Vertex. The revenue recognized during the three months ended March 31, 2019 includes $2.6 million related to the amortization of the deferred revenue due to the satisfaction of our performance during the period. As of March 31, 2019, the aggregate amount of the transaction price allocated to the remaining performance obligation that is unsatisfied is $1.1 million, which is expected to be recognized as revenue through June 30, 2019. We had deferred revenue of $0.8 million and $3.3 million, as of March 31, 2019 and December 31, 2018, respectively, from Vertex, which is classified as current in the condensed consolidated balance sheets based on the period the services are expected to be performed.

X

- References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 730
-URI http://asc.fasb.org/subtopic&trid=2197926
+ Details

Name: us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R13.htm IDEA: XBRL DOCUMENT v3.19.1

Grants
3 Months Ended

Mar. 31, 2019

Revenue from Contract with Customer [Abstract]

Grants
Grants

Biomedical Advanced Research and Development Authority (BARDA)

In September 2016, we received an award of up to $125.8 million under Agreement No. HHSO100201600029C from BARDA, a component of the Office of the Assistant Secretary for Preparedness and Response, or ASPR within the U.S. Department of Health and Human Services, or HHS, to help fund our Zika vaccine program. Under the terms of the agreement with BARDA, an initial base award of $8.2 million supported toxicology studies, a Phase 1 clinical trial, and associated manufacturing activities. Contract options were available, for $117.6 million to support an additional Phase 1 study of an improved Zika vaccine candidate, Phase 2 and Phase 3 clinical studies, as well as large-scale manufacturing for the Zika vaccine.

As of March 31, 2019, three of the four contract options had been exercised resulting in $117.3 million of available funding with an additional $8.5 million available if the final contract option is exercised. For the three months ended March 31, 2019 and 2018, we recognized revenue of $1.5 million and $1.0 million, respectively, relating to the BARDA Agreement.

The Bill & Melinda Gates Foundation (Gates Foundation)

In January 2016, we entered a global health project framework agreement with the Gates Foundation to advance mRNA-based development projects for various infectious diseases. The Gates Foundation has committed up to $20.0 million in grant funding to support our initial project related to the evaluation of antibody combinations in a preclinical setting as well as the conduct of a first-in-human Phase 1 clinical trial of a potential mRNA medicine to help prevent human immunodeficiency virus, or HIV, infections. Follow-on projects which could bring total potential funding under the framework agreement up to $100.0 million (including the HIV antibody project) to support the development of additional mRNA-based projects for various infectious diseases can be proposed and approved until the sixth anniversary of the framework agreement, subject to the terms of the framework agreement, including our obligation to grant to the Gates Foundation certain non-exclusive licenses. In March 2019, the Gates Foundation provided an
additional funding commitment up to $1.1 million to support a follow-on project.
As of March 31, 2019, up to $21.1 million has been committed for funding with up to an additional $80 million available, if additional follow-on projects are approved. For the three months ended March 31, 2019 and 2018, we recognized $0.3 million for each period, relating to the Gates Foundation agreement. Deferred revenue of $0.6 million and $0.8 million was recorded for both March 31, 2019, and December 31, 2018, respectively, related to the Gates Foundation agreement.

Defense Advanced Research Projects Agency (DARPA)

In October 2013, DARPA awarded us up to $24.6 million under Agreement No. W911NF-13-1-0417, which was subsequently adjusted to $19.7 million, to research and develop potential mRNA medicines as a part of DARPA’s Autonomous Diagnostics to Enable Prevention and Therapeutics, or ADEPT, program, which is focused on assisting with the development of technologies to rapidly identify and respond to threats posed by natural and engineered diseases and toxins. The DARPA awards have been deployed primarily in support of our vaccine and antibody programs to protect against chikungunya infection.
As of March 31, 2019 and December 31, 2018, $19.7 million has been committed by DARPA. There was no revenue recognized for the three months ended March 31, 2019, related to the DARPA agreement. We recognized revenue of $0.2 million for the three months ended March 31, 2018, related to the DARPA agreement.

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueFromContractWithCustomerAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_RevenueFromContractWithCustomerTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R14.htm IDEA: XBRL DOCUMENT v3.19.1

Financial Instruments
3 Months Ended

Mar. 31, 2019

Investments, Debt and Equity Securities [Abstract]

Financial Instruments
Financial Instruments

Cash and Cash Equivalents and Investments

The following tables summarize our cash and available-for-sale securities by significant investment category at March 31, 2019 and December 31, 2018 (in thousands):

March 31, 2019

Amortized
Cost

Unrealized
Gains

Unrealized
Losses

Fair Value

Cash and
Cash
Equivalents

Current
Marketable
Securities

Non-
Current
Marketable
Securities
Cash and cash equivalents

$
502,935

$
—

$
(1
)

$
502,934

$
502,934

$
—

$
—

Available-for-sale:

Level 2:

Certificates of deposit

84,114

72

(1
)

84,185

—

80,483

3,702

U.S. treasury securities

119,347

155

(4
)

119,498

—

79,475

40,023

Debt securities of U.S. government agencies and corporate entities

839,055

1,129

(218
)

839,966

—

446,032

393,934

$
1,545,451

$
1,356

$
(224
)

$
1,546,583

$
502,934

$
605,990

$
437,659

December 31, 2018

Amortized
Cost

Unrealized
Gains

Unrealized
Losses

Fair Value

Cash and
Cash
Equivalents

Current
Marketable
Securities

Non-
Current
Marketable
Securities
Cash and cash equivalents

$
658,365

$
20

$
(21
)

$
658,364

$
658,364

$
—

$
—

Available-for-sale:

Level 2:

Certificates of deposit

173,102

42

(36
)

173,108

—

157,920

15,188

U.S. treasury securities

152,205

18

(48
)

152,175

—

152,175

—

Debt securities of U.S. government agencies and corporate entities

712,065

40

(1,335
)

710,770

—

552,968

157,802

$
1,695,737

$
120

$
(1,440
)

$
1,694,417

$
658,364

$
863,063

$
172,990

The amortized cost and estimated fair value of marketable securities, by contractual maturity at March 31, 2019 and December 31, 2018 are as follows (in thousands):

March 31, 2019

Amortized
Cost

Estimated
Fair Value
Due in one year or less

$
605,687

$
605,990

Due after one year through five years

436,829

437,659

Total

$
1,042,516

$
1,043,649

December 31, 2018

Amortized
Cost

Estimated
Fair Value
Due in one year or less

$
864,003

$
863,063

Due after one year through five years

173,369

172,990

Total

$
1,037,372

$
1,036,053

At March 31, 2019, we held 32 available-for-sale securities, or an estimated fair value of $135.8 million, out of our total investment portfolio that were in a continuous unrealized loss position for more than 12 months with a gross unrealized loss of $0.2 million. At December 31, 2018, we held 25 available-for-sale securities, or an estimated fair value of $82.8 million, out of our total investment portfolio that were in a continuous unrealized loss position for more than 12 months with a gross unrealized loss of $0.4 million. We concluded that the net declines in market value of our available-for-sale securities investment portfolio were temporary in nature and did not consider any of our investments to be other-than-temporarily impaired. In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for other-than-temporary impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. Furthermore, the aggregate of individual unrealized losses that had been outstanding for 12 months or less was not significant as of March 31, 2019 and December 31, 2018. We neither intend to sell these investments nor conclude that we are more-likely-than-not that we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for investments in certain debt and equity securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2209399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2324412

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-URI http://asc.fasb.org/topic&trid=2196928

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2176304
+ Details

Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R15.htm IDEA: XBRL DOCUMENT v3.19.1

Balance Sheet Components
3 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Balance Sheet Components
Balance Sheet Components

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets, as of March 31, 2019 and December 31, 2018 consists of the following (in thousands):

March 31,

December 31,

2019

2018
Prepaid expenses

$
7,895

$
10,401

Tenant incentives receivables

11,336

10,089

Interest receivable on marketable securities

6,061

7,909

Prepaid expenses and other current assets

$
25,292

$
28,399

Property and Equipment, Net

Property and equipment, net as of March 31, 2019 and December 31, 2018 consists of the following (in thousands):

March 31,

December 31,

2019

2018
Building

$
140,442

$
140,442

Laboratory equipment

98,891

96,907

Leasehold improvements

15,861

13,741

Furniture, fixtures and other

2,122

2,122

Computer equipment and software

9,456

11,513

Internally developed software

7,020

7,020

Construction in progress

11,403

4,688

285,195

276,433

Less: Accumulated depreciation

(71,735
)

(64,456
)
Property and equipment, net

$
213,460

$
211,977

Depreciation and amortization expense for the three months ended March 31, 2019 and 2018 was $7.3 million and $5.2 million, respectively.

Accrued Liabilities

Accrued liabilities, as of March 31, 2019 and December 31, 2018 consists of the following (in thousands):

March 31,

December 31,

2019

2018
In-licenses

$
—

$
22,000

Property and equipment

7,756

12,089

Compensation-related

11,577

23,406

External goods and services

22,850

21,578

Accrued liabilities

$
42,183

$
79,073

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-URI http://asc.fasb.org/topic&trid=2122208
+ Details

Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R16.htm IDEA: XBRL DOCUMENT v3.19.1

Commitments and Contingencies
3 Months Ended

Mar. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
Commitments and Contingencies

Lease Obligations

We have entered into various long-term non-cancelable operating lease arrangements for our facilities and equipment expiring at various times through 2032. Certain of these arrangements have free rent periods or escalating rent payment provisions, which we recognize rent expense under such arrangements on a straight-line basis over the life of the leases. We have two campuses in Massachusetts. We occupy a multi-building campus in Technology Square in Cambridge, MA with a mix of offices and research laboratory space totaling approximately 200,000 square feet. Our Cambridge facility leases have expiry ranges from 2020 to 2027. We have approximately 200,000 square feet of a manufacturing facility in Norwood, MA. This facility is leased through 2032.

In February 2019, we entered into a new lease agreement for office and laboratory space of approximately 200,000 square feet, located in Norwood, MA. The lease will commence in the second quarter of 2019, and expires in early 2031. We have the option to extend the lease for up to four additional five-year terms.

Total rent expense, for the three months ended March 31, 2019 and 2018 was $4.8 million and $5.2 million, respectively. Future minimum lease payments under non-cancelable operating lease agreements at March 31, 2019, are as follows (in thousands):
Fiscal Year
Minimum Lease Payments
2019
(remainder of the year)
$
15,190

2020

22,874

2021

24,105

2022

23,455

2023

20,498

Thereafter
140,384

Total
$
246,506

Strategic Collaborations

Under our strategic collaboration agreements, we are committed to perform certain research, development, and manufacturing activities. As part of our PCV Agreement and PCV/SAV Agreement with Merck, we are committed to perform certain research, development and manufacturing activities related to PCV products through an initial Phase 2 clinical trial up to a budgeted amount of $243.0 million for both periods as of March 31, 2019 and December 31, 2018 (see Note 3).

Legal Proceedings

We are not currently a party to any material legal proceedings.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R17.htm IDEA: XBRL DOCUMENT v3.19.1

Shareholders' Equity
3 Months Ended

Mar. 31, 2019

Equity [Abstract]

Shareholders' Equity
Shareholders' Equity

On February 28, 2018 and May 7, 2018, the Board of Directors approved an amendment to our Certificate of Incorporation resulting in a total of 775,000,000 shares of common stock and a total of 509,352,795 shares of redeemable convertible preferred stock being authorized, respectively. Upon completion of our IPO, our authorized capital stock consists of 1,600,000,000 shares of common stock, par value $0.0001 per share, and 162,000,000 shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock are undesignated.

On December 11, 2018, we completed our IPO, whereby we sold 26,275,993 shares of common stock at a price of $23.00 per share. The aggregate net proceeds received by us from the IPO were $563.0 million, net of underwriting discounts and commissions of $33.2 million and offering expenses of $8.1 million payable by us. Upon the closing of the IPO, all of the outstanding shares of our redeemable convertible preferred stock were converted into 236,012,913 shares of the common stock.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R18.htm IDEA: XBRL DOCUMENT v3.19.1

Stock-Based Compensation
3 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation
Stock-Based Compensation

Equity Plans

In connection with the IPO, we adopted the 2018 Stock Option and Incentive Plan (the 2018 Equity Plan) in November 2018. The 2018 Equity Plan became effective on the date immediately prior to the effective date of the IPO and replaced our 2016 Stock Option and Grant Plan (the 2016 Equity Plan). The number of shares of common stock available for issuance under the 2018 Equity Plan was increased by 13.2 million shares as a result of the automatic increase provision of the 2018 Equity Plan. As of March 31, 2019, we had a total of 72.4 million shares reserved for future issuance under our Equity Plans, of which 17.9 million shares were available for future grants.

Options

We have granted options generally through the 2018 Equity Plan and 2016 Equity Plan. The following table summarizes our option activity as of March 31, 2019:

Number of
Options

Weighted-
Average
Exercise
Price per
Share

Weighted-
Average
Grant
Date Fair
Value per
Share

Weighted-
Average
Remaining
Contractual
Term

Aggregate
Intrinsic
Value⁽¹⁾
(in thousands)
Outstanding at December 31, 2018

50,821,132

12.16

6.59

7.1 years

220,434

Granted

5,443,286

20.59

12.16

Exercised

(5,525
)

9.62

5.62

Canceled/forfeited

(2,987,612
)

14.29

8.48

Outstanding at March 31, 2019

53,271,281

12.92

6.99

7.5 years

412,480

Exercisable at March 31, 2019

24,769,502

8.54

4.05

5.7 years

292,602

Vested and expected to vest at March 31, 2019

28,501,493

16.73

9.55

9.0 years

119,876

_______
⁽¹⁾Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of March 31, 2019.

For the three months ended March 31, 2019, 5,525 stock options were exercised. The total intrinsic value of options exercised was $0.1 million. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The total consideration recorded as a result of stock option exercises was approximately $0.1 million for the three months ended March 31, 2019.

Stock-based compensation for options granted is determined using the Black-Scholes option pricing model. The weighted-average assumptions used to estimate the fair value of the options granted for the three months ended March 31, 2019 and 2018 are as follows:

Weighted Average

Three Months Ended March 31,

2019

2018
Risk-free interest rate

2.48
%

2.71
%
Expected term

6.12 years

6.06 years

Expected volatility

62
%

63
%
Expected dividends

—
%

—
%
Weighted average fair value per share

$
12.16

$
8.48

Restricted Common Stock

We have granted restricted stock awards generally through the 2016 Equity Plan. The following table summarizes our restricted stock activity during the three months ended March 31, 2019:

Number of
Shares

Weighted
Average
Grant Date
per Share
Outstanding, non-vested at December 31, 2018
198,597

$
12.15

Issued
—

—

Vested
(48,911
)

12.15

Canceled, forfeited and adjustments, net
711

12.15

Outstanding, non-vested at March 31, 2019
150,397

12.15

Restricted Common Stock Units

We have granted restricted stock awards generally through the 2018 Equity Plan and 2016 Equity Plan. The following table summarizes our restricted stock unit activity during the three months ended March 31, 2019:

Units

Weighted-Average
Grant Date
per Unit
Outstanding, non-vested at December 31, 2018
458,715

$
11.93

Issued
558,208

20.77

Vested ⁽¹⁾
14,334

11.93

Canceled/forfeited
(5,440
)

20.93

Pending settlement ⁽¹⁾
(14,334
)

11.93

Outstanding, non-vested at March 31, 2019
1,011,483

16.76

_________
⁽¹⁾The vested restricted stock units will be settled for common stock on the date which is 360 days after the consummation of the IPO.

Stock-Based Compensation Expense

The following table presents the components and classification of stock-based compensation expense for the three months ended March 31, 2019 and 2018 as follows (in thousands):

Three Months Ended
March 31,

2019

2018
Options
$
17,487

$
10,048

Restricted common stock and units
1,010

1,803

Total
$
18,497

$
11,851

Research and development
$
10,783

$
7,356

General and administrative
7,714

4,495

Total
$
18,497

$
11,851

As of March 31, 2019, there were $253.1 million of total unrecognized compensation cost related to unvested stock-based compensation with respect to options and restricted stock granted. That cost is expected to be recognized over a weighted-average period of 3.5 years at March 31, 2019.

2018 Employee Stock Purchase Plan

In November 2018, we adopted the 2018 Employee Stock Purchase Plan (the ESPP), which became effective on December 5, 2018. The ESPP initially reserves and authorizes the issuance of up to a total of 810,000 shares of common stock to participating employees. We had not made any offerings as of March 31, 2019.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-URI http://asc.fasb.org/subtopic&trid=2208855
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R19.htm IDEA: XBRL DOCUMENT v3.19.1

Income Taxes
3 Months Ended

Mar. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes
Income Taxes

We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates that are expected to be in effect for the years in which differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a “more likely than not” criterion. Realization of our deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. We continued to maintain a full valuation allowance against all of our deferred tax assets based on management’s evaluation of all available evidence.

There were no significant income tax provisions or benefits for the three months ended March 31, 2019 and 2018.

Upon adoption of ASC 606 (see Note 2), we recorded a cumulative-effect adjustment of $28.0 million to the opening balance of accumulated deficit as of January 1, 2019 with a decrease in deferred revenue of $30.7 million and a decrease in accounts receivable of $2.7 million. As a result of the cumulative decrease in deferred revenue, our corresponding deferred tax asset decreased by $8.4 million, which was offset by a corresponding decrease to our valuation allowance.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R20.htm IDEA: XBRL DOCUMENT v3.19.1

Net Loss per Share
3 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

Net Loss per Share
Net Loss per Share

Net Loss per Share Attributable to Common Stockholders

Basic and diluted net loss per share attributable to common stockholders for the three months ended March 31, 2019 and 2018 are calculated as follows (in thousands, except share and per share data):

Three Months Ended March 31,

2019

2018
Numerator:

Net loss
$
(132,657
)

$
(72,376
)
Cumulative dividends on redeemable convertible preferred stock
—

(3,481
)
Net loss attributable to common stockholders
$
(132,657
)

$
(75,857
)
Denominator:

Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted
328,809,986

65,430,835

Net loss per share attributable to common stockholders, basic and diluted
$
(0.40
)

$
(1.16
)

The following common stock equivalents, presented based on amounts outstanding as of March 31, 2019 and 2018 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive:

March 31,

2019

2018
Redeemable convertible preferred stock
—

260,817,303

Stock options
53,271,281

43,135,998

Restricted common stock
150,397

729,877

Restricted common stock units
1,011,483

458,715

54,433,161

305,141,893

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R21.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Basis of Presentation and Recent Accounting Standards (Policies)
3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Basis of Presentation and Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in conformity with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2018 (2018 Form 10-K), except for changes associated with recent accounting standards for revenue recognition as detailed in "Note 2 - Recent Accounting Standards and Accounting Policies." This report should be read in conjunction with the consolidated financial statements in our 2018 Form 10-K.

We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, income tax provisions, stock-based compensation, and useful lives of long-lived assets. We base our estimates on historical experience and on various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results that we experience may differ materially from our estimates. The condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, but are not necessarily indicative of the results of operations to be anticipated for the full year ending December 31, 2019.

Revenue Recognition
On January 1, 2019, we adopted Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606), using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. We recognized the cumulative effect of the adoption as an adjustment to the opening balance of accumulated deficit in the current period condensed consolidated balance sheet. Results for reporting periods beginning after January 1, 2019 are presented under ASC 606, while prior period amounts have not been adjusted and continue to be reported in accordance with our historic accounting under ASC Topic 605, Revenue Recognition (ASC 605). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.

Our revenue is primarily generated through collaboration arrangements and grants from government-sponsored and private organizations. Our collaboration arrangements typically contain multiple promises, including licenses to our intellectual property, options to obtain development and commercialization rights, research and development services, and obligations to develop and manufacture preclinical and clinical material. Such arrangements provide for various types of payments to us, including upfront payments, funding of research and development activities, funding for the purchase of preclinical and clinical material, development, regulatory and commercial milestone payments, licensing fees, option exercise payments, and royalties based on product sales. We have received grants from various government-sponsored and private organizations for research and related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin.

We analyze our collaboration arrangements to assess whether they are within the scope of ASC Topic 808, Collaborative Arrangements (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and our collaboration partner are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC 606. If we conclude that some or all aspects of the arrangement are within the scope of ASC 808 and do not represent a transaction with a customer, we recognize our allocation of the shared costs incurred with respect to the jointly conducted activities as a component of the related expense in the period incurred. Pursuant to ASC 606, a customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. If we conclude a counter-party to a transaction is not a customer or otherwise not within the scope of ASC 606 or ASC 808, we consider the guidance in other accounting literature as applicable or by analogy to account for such transaction. We also consider the guidance in ASC 606 with respect to principal versus agent considerations, in determining the appropriate treatment for the transactions between us and the strategic collaborator and the transactions between us and other third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, are accounted for as gross revenue.

We receive payments from our customers based on billing schedules established in each contract. Upfront payments and fees are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period when we perform our obligations under the arrangement. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current liabilities on our condensed consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities on our condensed consolidated balance sheets. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. As of March 31, 2019, we had not capitalized any costs to obtain any of our contracts.

Collaboration Revenue

To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following steps: (i) identify the contract(s) with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) each performance obligation is satisfied.

We account for a contract with a customer that is within the scope of ASC 606 when all of the following criteria are met: (i) the arrangement has been approved by the parties and the parties are committed to perform their respective obligations; (ii) each party’s rights regarding the goods and/or services to be transferred can be identified; (iii) the payment terms for the goods and/or services to be transferred can be identified; (iv) the arrangement has commercial substance; and (v) collection of substantially all of the consideration to which we will be entitled in exchange for the goods and/or services that will be transferred to the customer is probable. We also determine the term of the contract based on the period in which we and our customer have present and enforceable rights and obligations for purposes of identifying the performance obligations and determining the transaction price.

We evaluate contracts that contain multiple promises to determine which promises are distinct. Promises are considered to be distinct and therefore, accounted for as separate performance obligations, provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. In assessing whether a promise is distinct, we consider factors such as whether: (i) we provide a significant service of integrating goods and/or services with other goods and/or services promised in the contract; (ii) one or more of the goods and/or services significantly modifies or customizes, or are significantly modified or customized by one or more of the other goods and/or services promised in the contract; and (iii) the goods and/or services are highly interdependent or highly interrelated. Individual goods or services (or bundles of goods and/or services) that meet both criteria for being distinct are accounted for as separate performance obligations. Promises that are not distinct at contract inception are combined and accounted for as a single performance obligation. Options to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer’s election.

The transaction price is generally comprised of an upfront payment due at contract inception and variable consideration in the form of payments for our services and materials and milestone payments due upon the achievement of specified events. Other payments the Company could be entitled to include tiered royalties earned when customers recognize net sales of licensed products. We consider the existence of any significant financing component within our arrangements and have determined that a significant financing component does not exist in our arrangements as substantive business purposes exist to support the payment structure other than to provide a significant benefit of financing. We measure the transaction price based on the amount of consideration we expect to be entitled in exchange for transferring the promised goods and/or services to the customer. We utilize either the expected value method or the most likely amount method to estimate the amount of variable consideration, depending on which method is expected to better predict the amount of consideration to which we will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. With respect to arrangements that include payments for a development or regulatory milestone payment, we evaluate whether the associated event is considered probable of achievement and estimate the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within our control or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, we re-evaluate the probability of achievement of each milestone and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, wherein the license is deemed to be the sole or predominant item to which the payments relate, we recognize revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.

We generally allocate the transaction price to each performance obligation based on a relative standalone selling price basis. We develop assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated research and development costs. However, in certain instances, we allocate variable consideration entirely to one or more performance obligation if the terms of the variable consideration relate to the satisfaction of the respective performance obligation and the amount allocated is consistent with the amount we would expect to receive for the satisfaction of the respective performance obligation.

We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. For performance obligations that are satisfied at a point in time, we recognize revenue when control of the goods and/or services is transferred to the customer. For performance obligations that are satisfied over time, we recognize revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. We generally use input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. With respect to arrangements containing a license to our intellectual property that is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from amounts allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which we are expected to complete our performance obligations under an arrangement. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.

Grant Revenue

We have contracts with the U.S. government’s Defense Advanced Research Projects Agency (DARPA), Biomedical Advanced Research (BARDA), and the Bill & Melinda Gates Foundation (Gates Foundation). We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Revenues and related expenses are presented gross in the condensed consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.

Collaboration Revenue
To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following steps: (i) identify the contract(s) with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) each performance obligation is satisfied.

We account for a contract with a customer that is within the scope of ASC 606 when all of the following criteria are met: (i) the arrangement has been approved by the parties and the parties are committed to perform their respective obligations; (ii) each party’s rights regarding the goods and/or services to be transferred can be identified; (iii) the payment terms for the goods and/or services to be transferred can be identified; (iv) the arrangement has commercial substance; and (v) collection of substantially all of the consideration to which we will be entitled in exchange for the goods and/or services that will be transferred to the customer is probable. We also determine the term of the contract based on the period in which we and our customer have present and enforceable rights and obligations for purposes of identifying the performance obligations and determining the transaction price.

We evaluate contracts that contain multiple promises to determine which promises are distinct. Promises are considered to be distinct and therefore, accounted for as separate performance obligations, provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. In assessing whether a promise is distinct, we consider factors such as whether: (i) we provide a significant service of integrating goods and/or services with other goods and/or services promised in the contract; (ii) one or more of the goods and/or services significantly modifies or customizes, or are significantly modified or customized by one or more of the other goods and/or services promised in the contract; and (iii) the goods and/or services are highly interdependent or highly interrelated. Individual goods or services (or bundles of goods and/or services) that meet both criteria for being distinct are accounted for as separate performance obligations. Promises that are not distinct at contract inception are combined and accounted for as a single performance obligation. Options to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer’s election.

The transaction price is generally comprised of an upfront payment due at contract inception and variable consideration in the form of payments for our services and materials and milestone payments due upon the achievement of specified events. Other payments the Company could be entitled to include tiered royalties earned when customers recognize net sales of licensed products. We consider the existence of any significant financing component within our arrangements and have determined that a significant financing component does not exist in our arrangements as substantive business purposes exist to support the payment structure other than to provide a significant benefit of financing. We measure the transaction price based on the amount of consideration we expect to be entitled in exchange for transferring the promised goods and/or services to the customer. We utilize either the expected value method or the most likely amount method to estimate the amount of variable consideration, depending on which method is expected to better predict the amount of consideration to which we will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. With respect to arrangements that include payments for a development or regulatory milestone payment, we evaluate whether the associated event is considered probable of achievement and estimate the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within our control or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, we re-evaluate the probability of achievement of each milestone and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, wherein the license is deemed to be the sole or predominant item to which the payments relate, we recognize revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.

We generally allocate the transaction price to each performance obligation based on a relative standalone selling price basis. We develop assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated research and development costs. However, in certain instances, we allocate variable consideration entirely to one or more performance obligation if the terms of the variable consideration relate to the satisfaction of the respective performance obligation and the amount allocated is consistent with the amount we would expect to receive for the satisfaction of the respective performance obligation.

We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. For performance obligations that are satisfied at a point in time, we recognize revenue when control of the goods and/or services is transferred to the customer. For performance obligations that are satisfied over time, we recognize revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. We generally use input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. With respect to arrangements containing a license to our intellectual property that is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from amounts allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which we are expected to complete our performance obligations under an arrangement. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.

Comprehensive Loss
Comprehensive loss includes net loss and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments. Total comprehensive loss for all periods presented has been disclosed in the condensed consolidated statements of comprehensive loss.

Recently Adopted Accounting Standards and Recently Issued Accounting Standards
ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting

In June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance generally consistent with the accounting for employee share-based compensation. The new standard will be effective for us on January 1, 2020, with early adoption permitted. We early adopted this standard in the first quarter of 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and disclosure.

ASU No. 2018-18, Collaborative Arrangements: Clarifying the Interaction between Topic 808 and Topic 606

In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which clarifies the interaction between Topic 808 and Topic 606, Revenue from Contracts with Customers. Currently, Topic 808 does not provide comprehensive recognition or measurement guidance for collaborative arrangements, and the accounting for those arrangements is often based on an analogy to other accounting literature or an accounting policy election. Similarly, aspects of Topic 606 have resulted in diversity in practice on the effect of the revenue standard on the accounting for collaborative arrangements. The standard will become effective for us beginning on January 1, 2021, with early adoption permitted. We early adopted this standard in connection with the adoption of ASC 606 in the first quarter of 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and disclosure.

Recently Issued Accounting Standards

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our condensed consolidated financial statements and disclosures.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes all existing lease guidance. This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. The new standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments. Lessees are required to classify leases as either finance or operating leases. If the lease is effectively a financed-purchase by the lessee, it is classified as a financing lease, otherwise it is classified as an operating lease. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. ASC 842 provides accounting guidance for transactions that meet specific criteria for a leaseback transaction. If the criteria are not met, the transaction is considered a “failed sale” and the transaction must be accounted for as a financing arrangement. The new standard will be effective for us on January 1, 2020, assuming we continue to qualify as an EGC.. Upon adoption, the new standard, as amended, allows lessees to apply the transition requirements either (1) retrospectively to each prior reporting period presented in the financial statements with the cumulative effect of applying the new rules recognized at the beginning of the earliest comparative period presented, or (2) retrospectively at the beginning of the period of adoption with the cumulative effect of applying the new rules recognized then. We are currently evaluating the potential impact ASU 2016-02 may have on our financial position and results of operations. Our assessment will include, but is not limited to, evaluating the impact this standard has on the lease of our corporate headquarters at 200 Technology Square in Cambridge, MA, the lease of our office and laboratory space at 500 Technology Square, Cambridge, MA and our manufacturing and additional facilities in Norwood, MA, (see Note 7), and the identification of any embedded leases.

In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (ASU 2016-13). ASU 2016-13 will change how companies account for credit losses for most financial assets and certain other instruments. For trade receivables, loans and held-to-maturity debt securities, companies will be required to recognize an allowance for credit losses rather than reducing the carrying value of the asset. Assuming we continue to qualify as an EGC, ASU 2016-13 will be effective for us for fiscal years beginning after December 15, 2020, , including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2016-13 will have on the Company’s financial position and results of operations.

In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Topic 350): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This standard requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This standard should be applied either retrospectively or prospectively, and will be effective for us in January 2021, assuming we continue to qualify as an EGC, with early adoption permitted. We are currently evaluating the potential impact this standard may have on our condensed consolidated financial statements and results of operations upon adoption.

ASU No. 2016-18, Statement of Cash Flows: Restricted Cash

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires the statement of cash flows to explain the change during the period in the total of cash, cash equivalents and restricted cash. When cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new standard requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet. This reconciliation can be presented either on the face of the statement of cash flows or in the notes to the financial statements. The new standard became effective for us on January 1, 2019. As a result of adopting this new standard using a retrospective transition method for each period presented, we include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed statements of cash flows.
ASU No. 2014-09, Revenue from Contracts with Customers

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements in ASC 605 and most industry specific guidance. ASC 606 provides a single comprehensive model for use in accounting for revenue arising from contracts with customers. We adopted the new revenue standard on January 1, 2019 using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. We recognized the cumulative effect of the adoption as an adjustment to the opening balance of accumulated deficit in the first quarter of 2019. We have elected to use the practical expedient to aggregate the impact of all contract modifications that occurred prior to the ASC 606 adoption with respect to (i) identification of the satisfied and unsatisfied performance obligations, (ii) determination of the transaction price and (iii) allocation of the transaction price to the satisfied and unsatisfied performance obligations.

ASC 606 requires significant judgment and estimates and results in changes to, but not limited to: (i) the determination of the transaction price, including estimates of variable consideration, (ii) the allocation of the transaction price, including the determination of estimated selling price, and (iii) the pattern of recognition, including the application of proportional performance as a measure of progress on service-related promises and application of point-in-time recognition for supply-related promises. We recorded the cumulative-effect adjustment of $28.0 million to the opening balance of accumulated deficit as of January 1, 2019 with a corresponding decrease to deferred revenue.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for collaborative arrangements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790
+ Details

Name: us-gaap_CollaborativeArrangementAccountingPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for comprehensive income.
+ References
No definition available.
+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue from contract with customer.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388
+ Details

Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R22.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Basis of Presentation and Recent Accounting Standards (Tables)
3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Components of Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive loss for the three months ended March 31, 2019 are as follows (in thousands):

Unrealized Gain on Available-for-Sale Debt Securities
Accumulated other comprehensive loss, balance at December 31, 2018
$
(1,320
)
Other comprehensive income
1,911

Accumulated other comprehensive loss, balance at March 31, 2019
$
591

Effect of Adoption of ASC 606 on Condensed Financial Statements
The effect of the adoption of ASC 606 on our condensed consolidated balance sheet is as follows (in thousands):
Condensed Consolidated Balance Sheet

Balance at December 31, 2018

Adjustments

Balance at
January 1, 2019
Deferred revenue, current

$
109,056

$
(27,281
)

$
81,775

Deferred revenue, non-current

165,352

(3,441
)

161,911

Accounts receivable

11,686

(2,738
)

8,948

Accumulated deficit

(1,006,627
)

27,984

(978,643
)
The following tables summarize the effects of adopting ASC 606 on our condensed consolidated financial statements at March 31, 2019, and for the three months ended March 31, 2019 (in thousands, except per share data):

March 31, 2019
Condensed Consolidated Balance Sheet

As reported under ASC 606

Adjustments

Balance without adoption of ASC 606
Deferred revenue, current

$
73,958

$
36,452

$
110,410

Deferred revenue, non-current

156,862

(29,840
)

127,022

Accumulated deficit

(1,111,300
)

(6,077
)

(1,117,377
)

Three Months Ended March 31, 2019
Condensed Consolidated Statement of Operations

As reported under ASC 606

Adjustments

Amount without adoption of ASC 606
Revenue:

   Collaboration revenue

$
13,301

$
(1,786
)

$
11,515

   Collaboration revenue from related party

814

24,377

25,191

Total revenue

16,025

21,907

37,932

Loss from operations

(141,833
)

21,907

(119,926
)
Loss before benefit from income taxes

(132,681
)

21,907

(110,774
)
Net (loss) income

(132,657
)

21,907

(110,750
)
Net loss per share - basic and diluted

(0.40
)

0.06

(0.34
)
The following table summarizes our total consolidated net revenues from our strategic collaborators for the periods presented (in thousands):

Three Months Ended
Collaboration Revenue by Strategic Collaborator:

March 31, 2019
as reported
(under ASU 606)

March 31, 2019
without adoption of 606
(under ASC 605)

March 31, 2018
as reported
(under ASC 605)
Merck

$
10,687

$
11,515

$
15,967

AstraZeneca

814

25,191

7,350

Vertex

2,614

—

4,143

Total collaborative revenue

$
14,115

$
36,706

$
27,460

Reconciliation of Cash and Cash Equivalents
The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows (in thousands):

As of March 31,

2019

2018
Cash and cash equivalents

$
502,934

$
90,479

Restricted cash

—

237

Restricted cash, non-current

11,823

11,798

Total cash, cash equivalents and restricted cash shown in the condensed consolidated
    statements of cash flows

$
514,757

$
102,514

Reconciliation of Restricted Cash
The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows (in thousands):

As of March 31,

2019

2018
Cash and cash equivalents

$
502,934

$
90,479

Restricted cash

—

237

Restricted cash, non-current

11,823

11,798

Total cash, cash equivalents and restricted cash shown in the condensed consolidated
    statements of cash flows

$
514,757

$
102,514

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accumulated other comprehensive income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580
+ Details

Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of cash and cash equivalents.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e765-108305

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e725-108305

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794
+ Details

Name: us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(1)(a))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(2))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R23.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration Agreements (Tables)
3 Months Ended

Mar. 31, 2019

Research and Development [Abstract]

Summary of Total Consolidated Net Revenues from Strategic Collaborators
The effect of the adoption of ASC 606 on our condensed consolidated balance sheet is as follows (in thousands):
Condensed Consolidated Balance Sheet

Balance at December 31, 2018

Adjustments

Balance at
January 1, 2019
Deferred revenue, current

$
109,056

$
(27,281
)

$
81,775

Deferred revenue, non-current

165,352

(3,441
)

161,911

Accounts receivable

11,686

(2,738
)

8,948

Accumulated deficit

(1,006,627
)

27,984

(978,643
)
The following tables summarize the effects of adopting ASC 606 on our condensed consolidated financial statements at March 31, 2019, and for the three months ended March 31, 2019 (in thousands, except per share data):

March 31, 2019
Condensed Consolidated Balance Sheet

As reported under ASC 606

Adjustments

Balance without adoption of ASC 606
Deferred revenue, current

$
73,958

$
36,452

$
110,410

Deferred revenue, non-current

156,862

(29,840
)

127,022

Accumulated deficit

(1,111,300
)

(6,077
)

(1,117,377
)

Three Months Ended March 31, 2019
Condensed Consolidated Statement of Operations

As reported under ASC 606

Adjustments

Amount without adoption of ASC 606
Revenue:

   Collaboration revenue

$
13,301

$
(1,786
)

$
11,515

   Collaboration revenue from related party

814

24,377

25,191

Total revenue

16,025

21,907

37,932

Loss from operations

(141,833
)

21,907

(119,926
)
Loss before benefit from income taxes

(132,681
)

21,907

(110,774
)
Net (loss) income

(132,657
)

21,907

(110,750
)
Net loss per share - basic and diluted

(0.40
)

0.06

(0.34
)
The following table summarizes our total consolidated net revenues from our strategic collaborators for the periods presented (in thousands):

Three Months Ended
Collaboration Revenue by Strategic Collaborator:

March 31, 2019
as reported
(under ASU 606)

March 31, 2019
without adoption of 606
(under ASC 605)

March 31, 2018
as reported
(under ASC 605)
Merck

$
10,687

$
11,515

$
15,967

AstraZeneca

814

25,191

7,350

Vertex

2,614

—

4,143

Total collaborative revenue

$
14,115

$
36,706

$
27,460

Changes in Balances of Receivables and Contract Liabilities
The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the three months ended March 31, 2019 (in thousands):

January 1, 2019

Additions

Deductions

March 31, 2019
Contract Assets:

Accounts receivable

$
4,612

$
2,735

$
(3,747
)

$
3,600

Contract Liabilities:

Deferred revenue

$
240,924

$
1,137

$
(13,582
)

$
228,479

During the three months ended March 31, 2019, we recognized the following revenues as a result of the change in the contract liability balances related to our collaboration agreements (in thousands):
Revenue recognized in the period from:

Three Months Ended March 31, 2019
Amounts included in contract liabilities at the beginning of the period ⁽¹⁾

$
13,582

⁽¹⁾ We first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period first applies to the beginning contract liability.

X

- Definition
Tabular disclosure of contract balances and changes in contract balances.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045
+ Details

Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e765-108305

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e725-108305

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794
+ Details

Name: us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R24.htm IDEA: XBRL DOCUMENT v3.19.1

Financial Instruments (Tables)
3 Months Ended

Mar. 31, 2019

Investments, Debt and Equity Securities [Abstract]

Summary of Cash and Available-for-Sale Securities by Significant Investment Category
The following tables summarize our cash and available-for-sale securities by significant investment category at March 31, 2019 and December 31, 2018 (in thousands):

March 31, 2019

Amortized
Cost

Unrealized
Gains

Unrealized
Losses

Fair Value

Cash and
Cash
Equivalents

Current
Marketable
Securities

Non-
Current
Marketable
Securities
Cash and cash equivalents

$
502,935

$
—

$
(1
)

$
502,934

$
502,934

$
—

$
—

Available-for-sale:

Level 2:

Certificates of deposit

84,114

72

(1
)

84,185

—

80,483

3,702

U.S. treasury securities

119,347

155

(4
)

119,498

—

79,475

40,023

Debt securities of U.S. government agencies and corporate entities

839,055

1,129

(218
)

839,966

—

446,032

393,934

$
1,545,451

$
1,356

$
(224
)

$
1,546,583

$
502,934

$
605,990

$
437,659

December 31, 2018

Amortized
Cost

Unrealized
Gains

Unrealized
Losses

Fair Value

Cash and
Cash
Equivalents

Current
Marketable
Securities

Non-
Current
Marketable
Securities
Cash and cash equivalents

$
658,365

$
20

$
(21
)

$
658,364

$
658,364

$
—

$
—

Available-for-sale:

Level 2:

Certificates of deposit

173,102

42

(36
)

173,108

—

157,920

15,188

U.S. treasury securities

152,205

18

(48
)

152,175

—

152,175

—

Debt securities of U.S. government agencies and corporate entities

712,065

40

(1,335
)

710,770

—

552,968

157,802

$
1,695,737

$
120

$
(1,440
)

$
1,694,417

$
658,364

$
863,063

$
172,990

Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity
The amortized cost and estimated fair value of marketable securities, by contractual maturity at March 31, 2019 and December 31, 2018 are as follows (in thousands):

March 31, 2019

Amortized
Cost

Estimated
Fair Value
Due in one year or less

$
605,687

$
605,990

Due after one year through five years

436,829

437,659

Total

$
1,042,516

$
1,043,649

December 31, 2018

Amortized
Cost

Estimated
Fair Value
Due in one year or less

$
864,003

$
863,063

Due after one year through five years

173,369

172,990

Total

$
1,037,372

$
1,036,053

X

- Definition
Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.
+ References
No definition available.
+ Details

Name: us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of cash, cash equivalents, and investments.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R25.htm IDEA: XBRL DOCUMENT v3.19.1

Balance Sheet Components (Tables)
3 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets, as of March 31, 2019 and December 31, 2018 consists of the following (in thousands):

March 31,

December 31,

2019

2018
Prepaid expenses

$
7,895

$
10,401

Tenant incentives receivables

11,336

10,089

Interest receivable on marketable securities

6,061

7,909

Prepaid expenses and other current assets

$
25,292

$
28,399

Schedule of Property and Equipment, Net
Property and equipment, net as of March 31, 2019 and December 31, 2018 consists of the following (in thousands):

March 31,

December 31,

2019

2018
Building

$
140,442

$
140,442

Laboratory equipment

98,891

96,907

Leasehold improvements

15,861

13,741

Furniture, fixtures and other

2,122

2,122

Computer equipment and software

9,456

11,513

Internally developed software

7,020

7,020

Construction in progress

11,403

4,688

285,195

276,433

Less: Accumulated depreciation

(71,735
)

(64,456
)
Property and equipment, net

$
213,460

$
211,977

Schedule of Accrued Liabilities
Accrued liabilities, as of March 31, 2019 and December 31, 2018 consists of the following (in thousands):

March 31,

December 31,

2019

2018
In-licenses

$
—

$
22,000

Property and equipment

7,756

12,089

Compensation-related

11,577

23,406

External goods and services

22,850

21,578

Accrued liabilities

$
42,183

$
79,073

X

- Definition
Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R26.htm IDEA: XBRL DOCUMENT v3.19.1

Commitments and Contingencies (Tables)
3 Months Ended

Mar. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Future Minimum Lease Payments Under Non-Cancelable Operating Lease Agreements
Future minimum lease payments under non-cancelable operating lease agreements at March 31, 2019, are as follows (in thousands):
Fiscal Year
Minimum Lease Payments
2019
(remainder of the year)
$
15,190

2020

22,874

2021

24,105

2022

23,455

2023

20,498

Thereafter
140,384

Total
$
246,506

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R27.htm IDEA: XBRL DOCUMENT v3.19.1

Stock-Based Compensation (Tables)
3 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Options Activity
The following table summarizes our option activity as of March 31, 2019:

Number of
Options

Weighted-
Average
Exercise
Price per
Share

Weighted-
Average
Grant
Date Fair
Value per
Share

Weighted-
Average
Remaining
Contractual
Term

Aggregate
Intrinsic
Value⁽¹⁾
(in thousands)
Outstanding at December 31, 2018

50,821,132

12.16

6.59

7.1 years

220,434

Granted

5,443,286

20.59

12.16

Exercised

(5,525
)

9.62

5.62

Canceled/forfeited

(2,987,612
)

14.29

8.48

Outstanding at March 31, 2019

53,271,281

12.92

6.99

7.5 years

412,480

Exercisable at March 31, 2019

24,769,502

8.54

4.05

5.7 years

292,602

Vested and expected to vest at March 31, 2019

28,501,493

16.73

9.55

9.0 years

119,876

_______
⁽¹⁾Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of March 31, 2019.

Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted
The weighted-average assumptions used to estimate the fair value of the options granted for the three months ended March 31, 2019 and 2018 are as follows:

Weighted Average

Three Months Ended March 31,

2019

2018
Risk-free interest rate

2.48
%

2.71
%
Expected term

6.12 years

6.06 years

Expected volatility

62
%

63
%
Expected dividends

—
%

—
%
Weighted average fair value per share

$
12.16

$
8.48

Restricted Common Stock Activity
The following table summarizes our restricted stock activity during the three months ended March 31, 2019:

Number of
Shares

Weighted
Average
Grant Date
per Share
Outstanding, non-vested at December 31, 2018
198,597

$
12.15

Issued
—

—

Vested
(48,911
)

12.15

Canceled, forfeited and adjustments, net
711

12.15

Outstanding, non-vested at March 31, 2019
150,397

12.15

Restricted Common Stock Units Activity
The following table summarizes our restricted stock unit activity during the three months ended March 31, 2019:

Units

Weighted-Average
Grant Date
per Unit
Outstanding, non-vested at December 31, 2018
458,715

$
11.93

Issued
558,208

20.77

Vested ⁽¹⁾
14,334

11.93

Canceled/forfeited
(5,440
)

20.93

Pending settlement ⁽¹⁾
(14,334
)

11.93

Outstanding, non-vested at March 31, 2019
1,011,483

16.76

_________
⁽¹⁾The vested restricted stock units will be settled for common stock on the date which is 360 days after the consummation of the IPO.

Stock-Based Compensation Expense
The following table presents the components and classification of stock-based compensation expense for the three months ended March 31, 2019 and 2018 as follows (in thousands):

Three Months Ended
March 31,

2019

2018
Options
$
17,487

$
10,048

Restricted common stock and units
1,010

1,803

Total
$
18,497

$
11,851

Research and development
$
10,783

$
7,356

General and administrative
7,714

4,495

Total
$
18,497

$
11,851

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the changes in outstanding nonvested restricted stock shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the changes in outstanding nonvested restricted stock units.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R28.htm IDEA: XBRL DOCUMENT v3.19.1

Net Loss per Share (Tables)
3 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

Basic and Diluted Net Loss per Share Attributable to Common Stockholders
Basic and diluted net loss per share attributable to common stockholders for the three months ended March 31, 2019 and 2018 are calculated as follows (in thousands, except share and per share data):

Three Months Ended March 31,

2019

2018
Numerator:

Net loss
$
(132,657
)

$
(72,376
)
Cumulative dividends on redeemable convertible preferred stock
—

(3,481
)
Net loss attributable to common stockholders
$
(132,657
)

$
(75,857
)
Denominator:

Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted
328,809,986

65,430,835

Net loss per share attributable to common stockholders, basic and diluted
$
(0.40
)

$
(1.16
)

Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share
The following common stock equivalents, presented based on amounts outstanding as of March 31, 2019 and 2018 were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive:

March 31,

2019

2018
Redeemable convertible preferred stock
—

260,817,303

Stock options
53,271,281

43,135,998

Restricted common stock
150,397

729,877

Restricted common stock units
1,011,483

458,715

54,433,161

305,141,893

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R29.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Dec. 31, 2018

Dec. 31, 2017

AOCI Attributable to Parent, Net of Tax [Roll Forward]

Balance at beginning of period $ 1,446,033 $ (613,709) $ 1,530,241 $ (551,365)

Other comprehensive income 1,911 (1,993)

Balance at end of period 1,446,033 (613,709)

Accumulated Other Comprehensive (Loss) Income

AOCI Attributable to Parent, Net of Tax [Roll Forward]

Balance at beginning of period 591 (3,150) $ (1,320) $ (1,157)

Other comprehensive income 1,911 (1,993)

Balance at end of period 591 $ (3,150)

Unrealized Gain on Available-for-Sale Debt Securities

AOCI Attributable to Parent, Net of Tax [Roll Forward]

Other comprehensive income $ 1,911

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_AOCIAttributableToParentNetOfTaxRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R30.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Basis of Presentation and Recent Accounting Standards - Narrative (Details) - USD ($)
$ in Thousands

Mar. 31, 2019

Jan. 01, 2019

Dec. 31, 2018

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Cumulative-effect adjustment $ 27,984

Remaining deferred revenues $ 228,479 $ 240,924

Combined 2018 AZ Agreements

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Remaining deferred revenues 75,500 75,700 115,600

PCV/SAV Agreement

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Remaining deferred revenues 115,000 125,200 111,300

2016 VEGF Exercise

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Remaining deferred revenues $ 37,100 37,100 $ 41,200

Accumulated Deficit

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Cumulative-effect adjustment 27,984

Accounting Standards Update 2014-09

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Increase (decrease) in deferred revenue (30,700)

Decrease in deferred tax asset 8,400

Decrease in valuation allowance 8,400

Accounting Standards Update 2014-09 | Combined 2018 AZ Agreements

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Increase (decrease) in deferred revenue (39,900)

Accounting Standards Update 2014-09 | PCV/SAV Agreement

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Increase (decrease) in deferred revenue 13,900

Accounting Standards Update 2014-09 | 2016 VEGF Exercise

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Increase (decrease) in deferred revenue (4,300)

Accounting Standards Update 2014-09 | Accumulated Deficit

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Cumulative-effect adjustment $ 28,000

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.
+ References
No definition available.
+ Details

Name: us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R31.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Basis of Presentation and Recent Accounting Standards - Effect of Adoption of ASC 606 on Condensed Consolidated Financial Statements (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Jan. 01, 2019

Dec. 31, 2018

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Deferred revenue, current $ 73,958 $ 81,775 $ 109,056

Deferred revenue, non-current 156,862 161,911 165,352

Accounts receivable 5,646 8,948 11,686

Accumulated deficit (1,111,300) (978,643) (1,006,627)

Total revenue 16,025

Loss from operations (141,833) $ (77,402)

Loss before benefit from income taxes (132,681) (72,376)

Net (loss) income $ (132,657) $ (72,376)

Net loss per share - basic and diluted (usd per share) $ (0.40) $ (1.16)

Collaboration revenue

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total revenue $ 13,301

Collaboration revenue from related party

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total revenue 814

Accounting Standards Update 2014-09

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Accounts receivable (2,700)

Balance without adoption of ASC 606

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Deferred revenue, current 110,410 109,056

Deferred revenue, non-current 127,022 165,352

Accounts receivable 11,686

Accumulated deficit (1,117,377) $ (1,006,627)

Total revenue 37,932

Loss from operations (119,926)

Loss before benefit from income taxes (110,774)

Net (loss) income $ (110,750)

Net loss per share - basic and diluted (usd per share) $ (0.34)

Balance without adoption of ASC 606 | Collaboration revenue

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total revenue $ 11,515

Balance without adoption of ASC 606 | Collaboration revenue from related party

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total revenue 25,191

Adjustments | Accounting Standards Update 2014-09

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Deferred revenue, current 36,452 (27,281)

Deferred revenue, non-current (29,840) (3,441)

Accounts receivable (2,738)

Accumulated deficit (6,077) $ 27,984

Total revenue 21,907

Loss from operations 21,907

Loss before benefit from income taxes 21,907

Net (loss) income $ 21,907

Net loss per share - basic and diluted (usd per share) $ 0.06

Adjustments | Accounting Standards Update 2014-09 | Collaboration revenue

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total revenue $ (1,786)

Adjustments | Accounting Standards Update 2014-09 | Collaboration revenue from related party

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total revenue $ 24,377

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044
+ Details

Name: us-gaap_ContractWithCustomerLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=mrna_CollaborativeArrangementWithAffiliateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R32.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands

Mar. 31, 2019

Dec. 31, 2018

Mar. 31, 2018

Dec. 31, 2017

Accounting Policies [Abstract]

Cash and cash equivalents $ 502,934 $ 658,364 $ 90,479

Restricted cash 0 595 237

Restricted cash, non-current 11,823 11,532 11,798

Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows $ 514,757 $ 670,491 $ 102,514 $ 147,608

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_RestrictedCashCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 305
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84242212&loc=d3e2352-115587
+ Details

Name: us-gaap_RestrictedCashNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 57 R33.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue $ 16,025

Balance without adoption of ASC 606

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue 37,932

Collaboration Revenue by Strategic Collaborator

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue 14,115

Collaboration Revenue by Strategic Collaborator | Merck

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue 10,687

Collaboration Revenue by Strategic Collaborator | AstraZeneca

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue 814

Collaboration Revenue by Strategic Collaborator | Vertex

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue 2,614

Collaboration Revenue by Strategic Collaborator | Balance without adoption of ASC 606

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue 36,706 $ 27,460

Collaboration Revenue by Strategic Collaborator | Balance without adoption of ASC 606 | Merck

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue 11,515 15,967

Collaboration Revenue by Strategic Collaborator | Balance without adoption of ASC 606 | AstraZeneca

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue 25,191 7,350

Collaboration Revenue by Strategic Collaborator | Balance without adoption of ASC 606 | Vertex

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Total collaborative revenue $ 0 $ 4,143

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMemberMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=mrna_MerckMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=mrna_AstraZenecaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=mrna_VertexMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R34.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details)
$ in Thousands
3 Months Ended

Mar. 31, 2019

USD ($)

Contract Assets:

Beginning balance $ 4,612

Additions 2,735

Deductions (3,747)

Ending balance 3,600

Contract Liabilities:

Beginning balance 240,924

Additions 1,137

Deductions (13,582)

Ending balance 228,479

Amounts included in contract liabiliies at the beginning of the period $ 13,582

X

- Definition
Change In Contract with Customer, Asset [Roll Forward]
+ References
No definition available.
+ Details

Name: mrna_ChangeInContractwithCustomerAssetRollForward

Namespace Prefix: mrna_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Change In Contract with Customer, Liability [Roll Forward]
+ References
No definition available.
+ Details

Name: mrna_ChangeInContractwithCustomerLiabilityRollForward

Namespace Prefix: mrna_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Contract With Customer, Asset, Decrease During Period
+ References
No definition available.
+ Details

Name: mrna_ContractWithCustomerAssetDecreaseDuringPeriod

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Contract With Customer, Asset, Increase During Period
+ References
No definition available.
+ Details

Name: mrna_ContractWithCustomerAssetIncreaseDuringPeriod

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Contract With Customer, Liability, Decrease During Period
+ References
No definition available.
+ Details

Name: mrna_ContractWithCustomerLiabilityDecreaseDuringPeriod

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Contract With Customer, Liability, Increase During Period
+ References
No definition available.
+ Details

Name: mrna_ContractWithCustomerLiabilityIncreaseDuringPeriod

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044
+ Details

Name: us-gaap_ContractWithCustomerAssetNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 59 R35.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration Agreements - Remaining Performance Obligation (Details) - USD ($)
$ in Millions

Mar. 31, 2019

Jan. 01, 2019

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price $ 279.5

PCV/SAV Agreement

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price $ 213.0

PCV/SAV Agreement | Upfront Payment

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 200.0

PCV/SAV Agreement | Upfront Payment, Premium Associated With Contemporaneous Sale Of Preferred Stock

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 13.0

PCV/SAV Agreement | PCV Performance Obligation

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 206.3

PCV/SAV Agreement | KRAS Performance Obligation

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 6.7

2015 Merck Agreement

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 65.0

2015 Merck Agreement | Milestone Payments

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 5.0

2015 Merck Agreement | Upfront Payment

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 60.0

2015 Merck Agreement | Upfront Payment, Research And Development

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 50.0

2015 Merck Agreement | Upfront Payment, Funding From 2016 Amendment

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 10.0

2016 VEGF Exercise

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 55.1

2016 VEGF Exercise | Fixed Payments

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 40.0

2016 VEGF Exercise | Option Exercise Fee

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 10.0

2016 VEGF Exercise | Variable Consideration

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 15.1

2016 VEGF Exercise | Milestone Payments

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 30.0

2013 AZ Agreements

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 240.0

Combined 2018 AZ Agreements

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 400.0

Combined 2018 AZ Agreements | Variable Consideration

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 160.0

Combined 2018 AZ Agreements | Estimated Reimbursement

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 40.0

Combined 2018 AZ Agreements | Milestone Payments

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 120.0

Combined 2018 AZ Agreements | Milestone Payments | Toxicity Milestone

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 60.0

Combined 2018 AZ Agreements | Milestone Payments | Competition Milestone

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 60.0

Combined 2018 AZ Agreements | Combined 2018 AZ Agreement Performance Obligation

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 292.4

Combined 2018 AZ Agreements | IL12 Performance Obligation

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 8.1

Combined 2018 AZ Agreements | Oncology Development Target Performance Obligation

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 8.1

Combined 2018 AZ Agreements | Development And Commercialization License And Manufacturing Obligations For IL12

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 89.8

Combined 2018 AZ Agreements | Development And Commercialization Rights And Manufacturing Services For An Oncology Development Target

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 1.6

Vertex Agreement

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 24.4

Vertex Agreement | Upfront Payment

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 20.0

Vertex Agreement | Research And Development Funding

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price $ 4.4

X

- Definition
Amount of transaction price allocated to performance obligation that has not been recognized as revenue.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045
+ Details

Name: us-gaap_RevenueRemainingPerformanceObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentPremiumAssociatedWithContemporaneousSaleOfPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_PerformanceObligationAxis=mrna_PCVPerformanceObligationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_PerformanceObligationAxis=mrna_KRASPerformanceObligationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_MerckAgreement2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_MilestonePaymentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentResearchAndDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentFundingFrom2016AmendmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_FixedPaymentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_OptionExerciseFeeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_VariableConsiderationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_EstimatedReimbursementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_ToxicityMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_CompetitionMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_PerformanceObligationAxis=mrna_Combined2018AZAgreementPerformanceObligationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_PerformanceObligationAxis=mrna_IL12PerformanceObligationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_PerformanceObligationAxis=mrna_OncologyDevelopmentTargetPerformanceObligationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_PerformanceObligationAxis=mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_PerformanceObligationAxis=mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_ResearchAndDevelopmentFundingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 60 R36.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details)
1 Months Ended 3 Months Ended 12 Months Ended

Jun. 30, 2018

option

Oct. 31, 2017

Jan. 31, 2016

Mar. 31, 2013

USD ($)

milestone

option

Mar. 31, 2019

USD ($)

Mar. 31, 2018

USD ($)

Dec. 31, 2018

USD ($)

Dec. 31, 2016

USD ($)

Jan. 01, 2019

USD ($)

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Transaction price $ 279,500,000

Total collaborative revenue 16,025,000

Deferred revenue 228,479,000 $ 240,924,000

Revenue 16,025,000 $ 29,039,000

Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue 13,301,000

Revenue 13,301,000 20,110,000

2013 AZ Agreements

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Number of options | option 40

Upfront cash payments $ 240,000,000 $ 10,000,000

Estimated arrangement consideration $ 180,000,000.0

Number of milestones | milestone 3

Option exercise fee $ 10,000,000

Termination period 90 days

Transaction price $ 240,000,000

2013 AZ Agreements | VEGF-A product (AZD8601)

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Upfront cash payments 30,000,000

2013 AZ Agreements | Development Milestones

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Estimated arrangement consideration $ 100,000,000.0

2013 AZ Agreements | Regulatory Milestones

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Estimated arrangement consideration 100,000,000.0

2013 AZ Agreements | Commercial Milestones

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Estimated arrangement consideration $ 200,000,000.0

2013 AZ Agreements | Maximum

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Earn-out payments 12.00%

2016 AZ Agreement

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Termination period 90 days

Suspension period 12 months

2016 AZ Agreement | Maximum

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Tiered royalties at default rate 20.00%

Tiered royalties 30.00%

2016 AZ Agreement | Minimum

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Tiered royalties 10.00%

2017 AZ Agreement

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Termination period 90 days

Suspension period 12 months

2017 AZ Agreement | Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue 0 0

2017 AZ Agreement | Maximum

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Tiered royalties 30.00%

2017 AZ Agreement | Minimum

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Tiered royalties 10.00%

2018 A&R Agreements

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Number of options | option 40

Termination period 90 days

Combined 2018 AZ Agreements

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Increase to the transaction price 300,000

Transaction price 400,000,000

Deferred revenue 75,500,000 115,600,000 75,700,000

Combined 2018 AZ Agreements | Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue 800,000 7,400,000

2016 VEGF Exercise

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Increase to the transaction price 0

Transaction price 55,100,000

Deferred revenue 37,100,000 $ 41,200,000 37,100,000

2016 VEGF Exercise | Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue $ 0 $ 0

IL12 Performance Obligation | Combined 2018 AZ Agreements

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Transaction price $ 8,100,000

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Earnout Payment, Percent
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent

Namespace Prefix: mrna_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Maximum Amount
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Number Of Milestones
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones

Namespace Prefix: mrna_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Number Of Options
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions

Namespace Prefix: mrna_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Option Exercise Fee
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Product Suspension Period
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod

Namespace Prefix: mrna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Default Percent
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent

Namespace Prefix: mrna_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Percent
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent

Namespace Prefix: mrna_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Termination Period
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod

Namespace Prefix: mrna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredRevenueAdditions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of transaction price allocated to performance obligation that has not been recognized as revenue.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045
+ Details

Name: us-gaap_RevenueRemainingPerformanceObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_VEGFAProductAZD8601Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_DevelopmentMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_RegulatoryMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_CommercialMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2016StrategicAllianceWithAstraZenecaIL12Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2017StrategicAllianceWithAstraZenecaRelaxinMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_PerformanceObligationAxis=mrna_IL12PerformanceObligationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 R37.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration Agreements - Merck – Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details)
1 Months Ended 3 Months Ended 52 Months Ended

Apr. 30, 2018

USD ($)

Jun. 30, 2016

USD ($)

Jan. 31, 2016

USD ($)

Jan. 31, 2015

USD ($)

Mar. 31, 2019

USD ($)

Mar. 31, 2018

USD ($)

May 09, 2019

USD ($)

candidate

Jan. 01, 2019

USD ($)

Dec. 31, 2018

USD ($)

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Upfront payment $ (15,604,000) $ 6,193,000

Total collaborative revenue 16,025,000

Deferred revenue 228,479,000 $ 240,924,000

Amortization of deferred revenue due to the satisfaction of our performance obligation during the period 13,582,000

Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue 13,301,000

2015 Merck Agreement

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Proceeds from equity investment $ 50,000,000

Upfront cash payments $ 10,000,000

Increase to the transaction price 0

Deferred revenue 0 0

2015 Merck Agreement | Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue 2,000,000

2015 Merck Agreement | Subsequent Event

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Performance period 3 years

Research period 4 years

Number of product candidates | candidate 5

Upfront payment $ 50,000,000

Estimated arrangement consideration 300,000,000.0

2015 Merck Agreement | Subsequent Event | Milestone Payments

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue $ 5,000,000

Separate Agreements With Merck | Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue 500,000

PCV Agreement

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Estimated arrangement consideration $ 250,000,000

Upfront cash payments $ 200,000,000

PCV Agreement | Series H Redeemable Convertible Preferred Stock

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Aggregate net proceeds from the offering $ 125,000,000

Premium recorded to deferred revenue 13,000,000

PCV Agreement | PCV products

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Estimated arrangement consideration 243,000,000 243,000,000

PCV/SAV Agreement

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Increase to the transaction price 0

Deferred revenue 115,000,000 $ 125,200,000 $ 111,300,000

Amortization of deferred revenue due to the satisfaction of our performance obligation during the period 10,200,000

PCV/SAV Agreement | PCV products

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Estimated arrangement consideration $ 243,000,000

PCV/SAV Agreement | Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue $ 10,200,000 $ 14,000,000

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Maximum Amount
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Number Of Product Candidates
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfProductCandidates

Namespace Prefix: mrna_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Performance Period
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformancePeriod

Namespace Prefix: mrna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Research Period
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod

Namespace Prefix: mrna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredRevenueAdditions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share.
+ References
No definition available.
+ Details

Name: us-gaap_RedemptionPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Cash received on stock transaction after deduction of issuance costs.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_MerckAgreement2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_MilestonePaymentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_SeparateAgreementsWithMerckMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_PersonalizedMRNACancerVaccinesProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 62 R38.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration Agreements - Vertex – 2016 Strategic Alliance in Cystic Fibrosis (Details) - USD ($)
1 Months Ended 3 Months Ended

Jul. 31, 2016

Mar. 31, 2019

Mar. 31, 2018

Dec. 31, 2018

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue $ 16,025,000

Amortization of deferred revenue due to the satisfaction of our performance obligation during the period 13,582,000

Deferred revenue 228,479,000 $ 240,924,000

Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue 13,301,000

Vertex Agreement

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research period 3 years

Upfront cash payments $ 20,000,000

Research extension period 1 year

Proceeds from equity investment $ 20,000,000

Termination period 90 days

Written notice period 180 days

Increase to the transaction price 0

Amortization of deferred revenue due to the satisfaction of our performance obligation during the period 2,600,000

Deferred revenue 800,000 $ 3,300,000

Vertex Agreement | Collaboration revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total collaborative revenue $ 2,600,000 $ 4,100,000

Vertex Agreement | Development Milestones

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Estimated arrangement consideration $ 55,000,000.0

Vertex Agreement | Regulatory Milestones

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Estimated arrangement consideration 220,000,000.0

Vertex Agreement | Regulatory Milestones, Subsequent Products

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Estimated arrangement consideration $ 3,000,000.0

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Marketing Approval, Termination Period
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod

Namespace Prefix: mrna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Maximum Amount
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Research Extension Period
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod

Namespace Prefix: mrna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Research Period
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod

Namespace Prefix: mrna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Termination Period
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod

Namespace Prefix: mrna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredRevenueAdditions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_DevelopmentMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_RegulatoryMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_RegulatoryMilestonesSubsequentProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 R39.htm IDEA: XBRL DOCUMENT v3.19.1

Collaboration Agreements - Timing of Satisfaction (Details) - USD ($)
$ in Millions

Mar. 31, 2019

Jan. 01, 2019

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price $ 279.5

Combined 2018 AZ Agreements

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price $ 400.0

Combined 2018 AZ Agreements | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 9.7

Combined 2018 AZ Agreements | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil)

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 112.5

2016 VEGF Exercise

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 55.1

2016 VEGF Exercise | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 51.0

PCV/SAV Agreement

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 213.0

PCV/SAV Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price 115.0

Vertex Agreement

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price $ 24.4

Vertex Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Transaction price $ 1.1

X

- Definition
Amount of transaction price allocated to performance obligation that has not been recognized as revenue.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045
+ Details

Name: us-gaap_RevenueRemainingPerformanceObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-04-01

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=None

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PCVSAVAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 64 R40.htm IDEA: XBRL DOCUMENT v3.19.1

Grants (Details)
1 Months Ended 3 Months Ended

Mar. 31, 2019

USD ($)

contract_option

Sep. 30, 2016

USD ($)

Jan. 31, 2016

USD ($)

Oct. 31, 2013

USD ($)

Mar. 31, 2019

USD ($)

contract_option

Mar. 31, 2018

USD ($)

Dec. 31, 2018

USD ($)

Disaggregation of Revenue [Line Items]

Total revenue $ 16,025,000

Deferred revenue $ 228,479,000 228,479,000 $ 240,924,000

BARDA

Disaggregation of Revenue [Line Items]

Award amount $ 125,800,000

Amount committed for funding 117,300,000 117,300,000

Available funding $ 8,500,000 $ 8,500,000

BARDA | Initial base award

Disaggregation of Revenue [Line Items]

Award amount 8,200,000

BARDA | Contract options

Disaggregation of Revenue [Line Items]

Award amount $ 117,600,000

Number of contract options exercised | contract_option 3 3

Number of contract options | contract_option 4 4

BARDA | Grant revenue

Disaggregation of Revenue [Line Items]

Total revenue $ 1,500,000 $ 1,000,000

The Bill & Melinda Gates Foundation

Disaggregation of Revenue [Line Items]

Award amount $ 100,000,000.0

Available funding $ 80,000,000 80,000,000

Deferred revenue 600,000 600,000 $ 800,000

The Bill & Melinda Gates Foundation | Initial project

Disaggregation of Revenue [Line Items]

Award amount $ 20,000,000.0

Amount committed for funding 21,100,000 21,100,000

The Bill & Melinda Gates Foundation | Follow-on project

Disaggregation of Revenue [Line Items]

Award amount 1,100,000.0

The Bill & Melinda Gates Foundation | Grant revenue

Disaggregation of Revenue [Line Items]

Total revenue 300,000 300,000

DARPA

Disaggregation of Revenue [Line Items]

Award amount $ 24,600,000 19,700,000

Amount committed for funding $ 19,700,000 19,700,000 19,700,000

DARPA | Grant revenue

Disaggregation of Revenue [Line Items]

Total revenue $ 0 $ 200,000

X

- Definition
Revenue From Grants, Current Funding Capacity
+ References
No definition available.
+ Details

Name: mrna_RevenueFromGrantsCurrentFundingCapacity

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Revenue From Grants, Maximum Award
+ References
No definition available.
+ Details

Name: mrna_RevenueFromGrantsMaximumAward

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revenue From Grants, Number Of Contract Options
+ References
No definition available.
+ Details

Name: mrna_RevenueFromGrantsNumberOfContractOptions

Namespace Prefix: mrna_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Revenue From Grants, Number Of Contract Options Exercised
+ References
No definition available.
+ Details

Name: mrna_RevenueFromGrantsNumberOfContractOptionsExercised

Namespace Prefix: mrna_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Revenue From Grants, Remaining Funding Capacity
+ References
No definition available.
+ Details

Name: mrna_RevenueFromGrantsRemainingFundingCapacity

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DisaggregationOfRevenueLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_InitialBaseAwardMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_ContractOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_GrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_InitialProjectMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_FollowOnProjectMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 65 R41.htm IDEA: XBRL DOCUMENT v3.19.1

Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details) - USD ($)
$ in Thousands

Mar. 31, 2019

Dec. 31, 2018

Mar. 31, 2018

Debt Securities, Available-for-sale [Line Items]

Amortized Cost $ 1,042,516 $ 1,037,372

Level 2

Debt Securities, Available-for-sale [Line Items]

Amortized Cost 1,545,451 $ 1,695,737

Unrealized Gains 1,356 120

Unrealized Losses (224) (1,440)

Fair Value 1,546,583 1,694,417

Level 2 | Cash and Cash Equivalents

Debt Securities, Available-for-sale [Line Items]

Fair Value 502,934 658,364

Level 2 | Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value 605,990 863,063

Level 2 | Non- Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value 437,659 172,990

Cash and Cash Equivalents

Debt Securities, Available-for-sale [Line Items]

Amortized Cost 502,935 658,365

Unrealized Gains 0 20

Unrealized Losses (1) (21)

Fair Value 502,934 658,364

Cash and Cash Equivalents | Cash and Cash Equivalents

Debt Securities, Available-for-sale [Line Items]

Fair Value 502,934 658,364

Cash and Cash Equivalents | Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value 0 0

Cash and Cash Equivalents | Non- Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value 0 0

Certificates of deposit | Level 2

Debt Securities, Available-for-sale [Line Items]

Amortized Cost 84,114 173,102

Unrealized Gains 72 42

Unrealized Losses (1) (36)

Fair Value 84,185 173,108

Certificates of deposit | Level 2 | Cash and Cash Equivalents

Debt Securities, Available-for-sale [Line Items]

Fair Value 0 0

Certificates of deposit | Level 2 | Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value 80,483 157,920

Certificates of deposit | Level 2 | Non- Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value 3,702 15,188

U.S. treasury securities | Level 2

Debt Securities, Available-for-sale [Line Items]

Amortized Cost 119,347 152,205

Unrealized Gains 155 18

Unrealized Losses (4) (48)

Fair Value 119,498 152,175

U.S. treasury securities | Level 2 | Cash and Cash Equivalents

Debt Securities, Available-for-sale [Line Items]

Fair Value 0 0

U.S. treasury securities | Level 2 | Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value 79,475 152,175

U.S. treasury securities | Level 2 | Non- Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value 40,023 0

Debt securities of U.S. government agencies and corporate entities | Level 2

Debt Securities, Available-for-sale [Line Items]

Amortized Cost 839,055 712,065

Unrealized Gains 1,129 40

Unrealized Losses (218) (1,335)

Fair Value 839,966 710,770

Debt securities of U.S. government agencies and corporate entities | Level 2 | Cash and Cash Equivalents

Debt Securities, Available-for-sale [Line Items]

Fair Value 0 0

Debt securities of U.S. government agencies and corporate entities | Level 2 | Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value 446,032 552,968

Debt securities of U.S. government agencies and corporate entities | Level 2 | Non- Current Marketable Securities

Debt Securities, Available-for-sale [Line Items]

Fair Value $ 393,934 $ 157,802

X

- Definition
Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=mrna_CurrentMarketableSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=mrna_NoncurrentMarketableSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=mrna_USGovernmentAgenciesAndCorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 66 R42.htm IDEA: XBRL DOCUMENT v3.19.1

Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details) - USD ($)
$ in Thousands

Mar. 31, 2019

Mar. 31, 2018

Amortized Cost

Due in one year or less $ 605,687 $ 864,003

Due after one year through five years 436,829 173,369

Amortized Cost 1,042,516 1,037,372

Estimated Fair Value

Due in one year or less 605,990 863,063

Due after one year through five years 437,659 172,990

Total $ 1,043,649 $ 1,036,053

X

- Definition
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 67 R43.htm IDEA: XBRL DOCUMENT v3.19.1

Financial Instruments - Narrative (Details)
$ in Millions

Mar. 31, 2019

USD ($)

security

Dec. 31, 2018

USD ($)

security

Investments, Debt and Equity Securities [Abstract]

Number of available-for-sale securitiesin a continuous unrealized loss position for more than 12 months | security 32 25

Estimated fair value of total investment portfolio in a continuous unrealized loss position for more than 12 months $ 135.8 $ 82.8

Gross unrealized loss of total investment portfolio in a continuous unrealized loss position for more than 12 months $ 0.2 $ 0.4

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer.
+ References
No definition available.
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 68 R44.htm IDEA: XBRL DOCUMENT v3.19.1

Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands

Mar. 31, 2019

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Prepaid expenses $ 7,895 $ 10,401

Tenant incentives receivables 11,336 10,089

Interest receivable on marketable securities 6,061 7,909

Prepaid expenses and other current assets $ 25,292 $ 28,399

X

- Definition
Tenant Incentives Receivables, Current
+ References
No definition available.
+ Details

Name: mrna_TenantIncentivesReceivablesCurrent

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 69 R45.htm IDEA: XBRL DOCUMENT v3.19.1

Balance Sheet Components - Property and Equipment, Net (Details) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Dec. 31, 2018

Property, Plant and Equipment [Line Items]

Property, plant and equipment, gross $ 285,195 $ 276,433

Less: Accumulated depreciation (71,735) (64,456)

Property and equipment, net 213,460 211,977

Depreciation and amortization 7,328 $ 5,153

Building

Property, Plant and Equipment [Line Items]

Property, plant and equipment, gross 140,442 140,442

Laboratory equipment

Property, Plant and Equipment [Line Items]

Property, plant and equipment, gross 98,891 96,907

Leasehold improvements

Property, Plant and Equipment [Line Items]

Property, plant and equipment, gross 15,861 13,741

Furniture, fixtures and other

Property, Plant and Equipment [Line Items]

Property, plant and equipment, gross 2,122 2,122

Computer equipment and software

Property, Plant and Equipment [Line Items]

Property, plant and equipment, gross 9,456 11,513

Internally developed software

Property, Plant and Equipment [Line Items]

Property, plant and equipment, gross 7,020 7,020

Construction in progress

Property, Plant and Equipment [Line Items]

Property, plant and equipment, gross $ 11,403 $ 4,688

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 70 R46.htm IDEA: XBRL DOCUMENT v3.19.1

Balance Sheet Components - Accrued Liabilities (Details) - USD ($)
$ in Thousands

Mar. 31, 2019

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

In-licenses $ 0 $ 22,000

Property and equipment 7,756 12,089

Compensation-related 11,577 23,406

External goods and services 22,850 21,578

Accrued liabilities $ 42,183 $ 79,073

X

- Definition
Accrued External Goods And Services, Current
+ References
No definition available.
+ Details

Name: mrna_AccruedExternalGoodsAndServicesCurrent

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued In-Licenses, Current
+ References
No definition available.
+ Details

Name: mrna_AccruedInLicensesCurrent

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued Property And Equipment, Current
+ References
No definition available.
+ Details

Name: mrna_AccruedPropertyAndEquipmentCurrent

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 71 R47.htm IDEA: XBRL DOCUMENT v3.19.1

Commitments and Contingencies - Lease Obligations (Details)
ft² in Millions, $ in Millions
3 Months Ended

Mar. 31, 2019

USD ($)

ft²

campus

Mar. 31, 2018

USD ($)

Feb. 28, 2019

ft²

extension_period

Operating Leased Assets [Line Items]

Number of campuses | campus 2

Rent expense | $ $ 4.8 $ 5.2

Cambridge, MA

Operating Leased Assets [Line Items]

Area of office space (in sqft) 0.2

Norwood, MA

Operating Leased Assets [Line Items]

Area of office space (in sqft) 0.2 0.2

Number of extension terms | extension_period 4

Extension period 5 years

X

- Definition
Lessee, Operating Lease, Number Of Extension Periods
+ References
No definition available.
+ Details

Name: mrna_LesseeOperatingLeaseNumberOfExtensionPeriods

Namespace Prefix: mrna_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Area of a real estate property.
+ References
No definition available.
+ Details

Name: us-gaap_AreaOfRealEstateProperty

Namespace Prefix: us-gaap_

Data Type: num:areaItemType

Balance Type: na

Period Type: instant

X

- Definition
Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseRenewalTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLeasedAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717
+ Details

Name: us-gaap_OperatingLeasesRentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of units (items of property) under operating lease arrangements.
+ References
No definition available.
+ Details

Name: us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits

Namespace Prefix: us-gaap_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Details

Name: srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 72 R48.htm IDEA: XBRL DOCUMENT v3.19.1

Commitments and Contingencies - Future Minimum Lease Payments Under Non-Cancelable Operating Lease Agreements (Details)
$ in Thousands

Mar. 31, 2019

USD ($)

Minimum Lease Payments

2019 (remainder of the year) $ 15,190

2020 22,874

2021 24,105

2022 23,455

2023 20,498

Thereafter 140,384

Total $ 246,506

X

- Definition
Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 73 R49.htm IDEA: XBRL DOCUMENT v3.19.1

Commitments and Contingencies - Strategic Collaborations (Details) - PCV Agreement - USD ($)
$ in Millions

Mar. 31, 2019

Dec. 31, 2018

Jun. 30, 2016

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Budgeted amount $ 250.0

PCV products

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Budgeted amount $ 243.0 $ 243.0

X

- Definition
Research And Development Arrangement, Contract To Perform For Others, Maximum Amount
+ References
No definition available.
+ Details

Name: mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_PersonalizedMRNACancerVaccinesProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 74 R50.htm IDEA: XBRL DOCUMENT v3.19.1

Shareholders' Equity (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended

Dec. 11, 2018

Mar. 31, 2018

Mar. 31, 2019

Dec. 31, 2018

May 07, 2018

Feb. 28, 2018

Subsidiary, Sale of Stock [Line Items]

Common stock, shares authorized 1,600,000,000 1,600,000,000 1,600,000,000 775,000,000

Redeemable convertible preferred stock, shares authorized 509,352,795

Common stock, par value (usd per share) $ 0.0001 $ 0.0001 $ 0.0001

Preferred stock, shares authorized 162,000,000 162,000,000 162,000,000

Preferred stock, par value (usd per share) $ 0.0001 $ 0.0001 $ 0.0001

Offering expenses $ 10,517

IPO

Subsidiary, Sale of Stock [Line Items]

Shares of common stock issued (in shares) 26,275,993

Price per share (usd per share) $ 23.00

Aggregate net proceeds from the offering $ 563,000

Underwriting discounts 33,200

Offering expenses $ 8,100

IPO | Common Stock

Subsidiary, Sale of Stock [Line Items]

Preferred stock converted into common stock (in shares) 236,012,913

X

- Definition
Payments Of Underwriting Discounts
+ References
No definition available.
+ Details

Name: mrna_PaymentsOfUnderwritingDiscounts

Namespace Prefix: mrna_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued for each share of convertible preferred stock that is converted.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644
+ Details

Name: us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Cash received on stock transaction after deduction of issuance costs.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SubsidiarySaleOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TemporaryEquitySharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 75 R51.htm IDEA: XBRL DOCUMENT v3.19.1

Stock-Based Compensation - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended

Nov. 30, 2018

Mar. 31, 2019

Mar. 31, 2018

Dec. 05, 2018

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Aggregate number of shares authorized for issuance (in shares) 72,400,000.0

Stock options exercised (in shares) 5,525

Total intrinsic value of options exercised (less than for the year ended December 31, 2017) $ 100

Exercise of options to purchase common stock, net 57 $ 22

Total unrecognized compensation cost related to non-vested stock-based compensation $ 253,100

Weighted-average period of cost expected to be recognized 3 years 6 months

2018 Equity Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of additional shares of common stock authorized for issuance (in shares) 13,200,000

Shares available for future grant (in shares) 17,900,000

ESPP | Employee stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Aggregate number of shares authorized for issuance (in shares) 810,000

X

- Definition
Unrecognized cost of unvested share-based compensation awards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of additional shares authorized for issuance under an established share-based compensation plan.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=mrna_StockOptionAndIncentivePlan2018Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=mrna_EmployeeStockPurchasePlan2018Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 76 R52.htm IDEA: XBRL DOCUMENT v3.19.1

Stock-Based Compensation - Options Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended

Mar. 31, 2019

Dec. 31, 2018

Number of Options

Outstanding at beginning of period (in shares) 50,821,132

Granted (in shares) 5,443,286

Exercised (in shares) (5,525)

Cancelled/forfeited (in shares) (2,987,612)

Outstanding at end of period (in shares) 53,271,281 50,821,132

Weighted- Average Exercise Price per Share

Outstanding at beginning of period (usd per share) $ 12.16

Granted (usd per share) 20.59

Exercised (usd per share) 9.62

Cancelled/forfeited (usd per share) 14.29

Outstanding at end of period (usd per share) 12.92 $ 12.16

Weighted- Average Grant Date Fair Value per Share

Outstanding at beginning of period (usd per share) 6.59

Granted (usd per share) 12.16

Exercised (usd per share) 5.62

Cancelled/forfeited (usd per share) 8.48

Outstanding at end of period (usd per share) $ 6.99 $ 6.59

Outstanding and Exercisable

Number of Options, Exercisable (in shares) 24,769,502

Weighted- Average Exercise Price per Share, Exercisable (usd per share) $ 8.54

Weighted- Average Grant Date Fair Value per Share, Exercisable (usd per share) $ 4.05

Weighted- Average Remaining Contractual Term, Outstanding 7 years 5 months 15 days 7 years 1 month

Weighted- Average Remaining Contractual Term, Exercisable 5 years 8 months

Aggregate Intrinsic Value, Outstanding $ 412,480 $ 220,434

Aggregate Intrinsic Value, Exercisable $ 292,602

Vested and expected to vest

Number of Options (in shares) 28,501,493

Weighted- Average Exercise Price per Share (usd per share) $ 16.73

Weighted- Average Grant Date Fair Value per Share $ 9.55

Weighted- Average Remaining Contractual Term 9 years

Aggregate Intrinsic Value $ 119,876

X

- Definition
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value
+ References
No definition available.
+ Details

Name: mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue

Namespace Prefix: mrna_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Grant Date Fair Value
+ References
No definition available.
+ Details

Name: mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: mrna_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Grant Date Fair Value
+ References
No definition available.
+ Details

Name: mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: mrna_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value
+ References
No definition available.
+ Details

Name: mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue

Namespace Prefix: mrna_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value
+ References
No definition available.
+ Details

Name: mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue

Namespace Prefix: mrna_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Share-Based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Weighted Average Grant Date Fair Value [Roll Forward]
+ References
No definition available.
+ Details

Name: mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: mrna_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 77 R53.htm IDEA: XBRL DOCUMENT v3.19.1

Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details) - Options - $ / shares
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Risk-free interest rate 2.48% 2.71%

Expected term 6 years 1 month 14 days 6 years 22 days

Expected volatility 62.00% 63.00%

Expected dividends 0.00% 0.00%

Weighted average

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted average fair value per share (usd per share) $ 12.16 $ 8.48

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_WeightedAverageMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 78 R54.htm IDEA: XBRL DOCUMENT v3.19.1

Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details) - $ / shares
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Restricted Common Stock

Number of Shares/Units

Outstanding, non-vested at beginning of period (in shares) 198,597

Issued (in shares) 0

Vested (in shares) 48,911

Canceled, forfeited and adjustments, net (in shares) 711

Outstanding, non-vested at end of period (in shares) 150,397

Weighted-Average Grant Date per Share/Unit

Outstanding, non-vested at beginning of period (usd per share) $ 12.15

Issued (usd per share) 0.00

Vested (usd per share) 12.15

Canceled, forfeited and adjustments, net (usd per share) 12.15

Outstanding, non-vested at end of period (usd per share) $ 12.15

Restricted Common Stock Units

Number of Shares/Units

Outstanding, non-vested at beginning of period (in shares) 458,715

Issued (in shares) 558,208

Vested (in shares) 14,334

Canceled, forfeited and adjustments, net (in shares) 5,440

Pending settlement (in shares) (14,334)

Outstanding, non-vested at end of period (in shares) 1,011,483

Weighted-Average Grant Date per Share/Unit

Outstanding, non-vested at beginning of period (usd per share) $ 11.93

Issued (usd per share) 20.77

Vested (usd per share) 11.93

Canceled, forfeited and adjustments, net (usd per share) 20.93

Pending settlement (usd per share) $ 11.93

Outstanding, non-vested at end of period (usd per share) $ 16.76

Settlement period after consummation of IPO 360 days

X

- Definition
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Settled In Period
+ References
No definition available.
+ Details

Name: mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInPeriod

Namespace Prefix: mrna_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Settled In Period, Weighted Average Grant Date Fair Value
+ References
No definition available.
+ Details

Name: mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: mrna_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-Based Compensation Arrangement By Share-Based Payment Award, Vested Awards, Settlement Period
+ References
No definition available.
+ Details

Name: mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAwardsSettlementPeriod

Namespace Prefix: mrna_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(3)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 79 R55.htm IDEA: XBRL DOCUMENT v3.19.1

Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock-based compensation expense $ 18,497 $ 11,851

Research and development

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock-based compensation expense 10,783 7,356

General and administrative

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock-based compensation expense 7,714 4,495

Options

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock-based compensation expense 17,487 10,048

Restricted common stock and units

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Stock-based compensation expense $ 1,010 $ 1,803

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=mrna_RestrictedStockAndRestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 80 R56.htm IDEA: XBRL DOCUMENT v3.19.1

Income Taxes (Details) - USD ($)
$ in Thousands

Mar. 31, 2019

Jan. 01, 2019

Dec. 31, 2018

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Cumulative-effect adjustment $ 27,984

Decrease in accounts receivable $ (5,646) (8,948) $ (11,686)

Accumulated Deficit

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Cumulative-effect adjustment 27,984

Accounting Standards Update 2014-09

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Deferred Tax Assets, Valuation Allowance 8,400

Decrease in deferred revenue 30,700

Decrease in accounts receivable 2,700

Decrease in deferred tax asset 8,400

Accounting Standards Update 2014-09 | Accumulated Deficit

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Cumulative-effect adjustment $ 28,000

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.
+ References
No definition available.
+ Details

Name: us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 81 R57.htm IDEA: XBRL DOCUMENT v3.19.1

Net Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Numerator:

Net loss $ (132,657) $ (72,376)

Cumulative dividends on redeemable convertible preferred stock 0 (3,481)

Net loss $ (132,657) $ (75,857)

Denominator:

Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted 328,809,986 65,430,835

Net loss per share attributable to common stockholders, basic and diluted (usd per share) $ (0.40) $ (1.16)

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1377-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RedeemablePreferredStockDividends

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 82 R58.htm IDEA: XBRL DOCUMENT v3.19.1

Net Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares
3 Months Ended 12 Months Ended

Mar. 31, 2019

Dec. 31, 2018

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Anti-dilutive securities (in shares) 54,433,161 305,141,893

Redeemable convertible preferred stock

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Anti-dilutive securities (in shares) 0 260,817,303

Stock options

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Anti-dilutive securities (in shares) 53,271,281 43,135,998

Restricted common stock

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Anti-dilutive securities (in shares) 150,397 729,877

Restricted common stock units

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Anti-dilutive securities (in shares) 1,011,483 458,715

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 83 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 84 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 85 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 86 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 279 264 1 false 97 0 false 12 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.modernatx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.modernatx.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.modernatx.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.modernatx.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 1003001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) Sheet http://www.modernatx.com/role/CondensedConsolidatedStatementsOfComprehensiveLossParenthetical CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) Statements 6 false false R7.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) Sheet http://www.modernatx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityDeficit CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) Statements 7 false false R8.htm 1004001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical) Sheet http://www.modernatx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityDeficitParenthetical CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical) Statements 8 false false R9.htm 1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.modernatx.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 9 false false R10.htm 2101100 - Disclosure - Description of the Business Sheet http://www.modernatx.com/role/DescriptionOfBusiness Description of the Business Notes 10 false false R11.htm 2102100 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards Sheet http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandards Summary of Basis of Presentation and Recent Accounting Standards Notes 11 false false R12.htm 2103100 - Disclosure - Collaboration Agreements Sheet http://www.modernatx.com/role/CollaborationAgreements Collaboration Agreements Notes 12 false false R13.htm 2104100 - Disclosure - Grants Sheet http://www.modernatx.com/role/Grants Grants Notes 13 false false R14.htm 2105100 - Disclosure - Financial Instruments Sheet http://www.modernatx.com/role/FinancialInstruments Financial Instruments Notes 14 false false R15.htm 2106100 - Disclosure - Balance Sheet Components Sheet http://www.modernatx.com/role/BalanceSheetComponents Balance Sheet Components Notes 15 false false R16.htm 2107100 - Disclosure - Commitments and Contingencies Sheet http://www.modernatx.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 2108100 - Disclosure - Shareholders' Equity Sheet http://www.modernatx.com/role/ShareholdersEquity Shareholders' Equity Notes 17 false false R18.htm 2128100 - Disclosure - Stock-Based Compensation Sheet http://www.modernatx.com/role/StockBasedCompensation Stock-Based Compensation Notes 18 false false R19.htm 2134100 - Disclosure - Income Taxes Sheet http://www.modernatx.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 2137100 - Disclosure - Net Loss per Share Sheet http://www.modernatx.com/role/NetLossPerShare Net Loss per Share Notes 20 false false R21.htm 2202201 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Policies) Sheet http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsPolicies Summary of Basis of Presentation and Recent Accounting Standards (Policies) Policies http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandards 21 false false R22.htm 2302302 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards (Tables) Sheet http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables Summary of Basis of Presentation and Recent Accounting Standards (Tables) Tables http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandards 22 false false R23.htm 2303301 - Disclosure - Collaboration Agreements (Tables) Sheet http://www.modernatx.com/role/CollaborationAgreementsTables Collaboration Agreements (Tables) Tables http://www.modernatx.com/role/CollaborationAgreements 23 false false R24.htm 2305301 - Disclosure - Financial Instruments (Tables) Sheet http://www.modernatx.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.modernatx.com/role/FinancialInstruments 24 false false R25.htm 2306301 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.modernatx.com/role/BalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.modernatx.com/role/BalanceSheetComponents 25 false false R26.htm 2307301 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.modernatx.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.modernatx.com/role/CommitmentsAndContingencies 26 false false R27.htm 2328301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.modernatx.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.modernatx.com/role/StockBasedCompensation 27 false false R28.htm 2337301 - Disclosure - Net Loss per Share (Tables) Sheet http://www.modernatx.com/role/NetLossPerShareTables Net Loss per Share (Tables) Tables http://www.modernatx.com/role/NetLossPerShare 28 false false R29.htm 2402403 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive Loss (Details) Sheet http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsComponentsOfAccumulatedOtherComprehensiveLossDetails Summary of Basis of Presentation and Recent Accounting Standards - Components of Accumulated Other Comprehensive Loss (Details) Details 29 false false R30.htm 2402404 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Narrative (Details) Sheet http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsNarrativeDetails Summary of Basis of Presentation and Recent Accounting Standards - Narrative (Details) Details http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsTables 30 false false R31.htm 2402405 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Effect of Adoption of ASC 606 on Condensed Consolidated Financial Statements (Details) Sheet http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsEffectOfAdoptionOfAsc606OnCondensedConsolidatedFinancialStatementsDetails Summary of Basis of Presentation and Recent Accounting Standards - Effect of Adoption of ASC 606 on Condensed Consolidated Financial Statements (Details) Details 31 false false R32.htm 2402406 - Disclosure - Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.modernatx.com/role/SummaryOfBasisOfPresentationAndRecentAccountingStandardsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Details 32 false false R33.htm 2403402 - Disclosure - Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details) Sheet http://www.modernatx.com/role/CollaborationAgreementsSummaryOfTotalConsolidatedNetRevenuesFromStrategicCollaboratorsDetails Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details) Details 33 false false R34.htm 2403403 - Disclosure - Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details) Sheet http://www.modernatx.com/role/CollaborationAgreementsChangesInBalancesOfReceivablesAndContractLiabilitiesDetails Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details) Details 34 false false R35.htm 2403404 - Disclosure - Collaboration Agreements - Remaining Performance Obligation (Details) Sheet http://www.modernatx.com/role/CollaborationAgreementsRemainingPerformanceObligationDetails Collaboration Agreements - Remaining Performance Obligation (Details) Details 35 false false R36.htm 2403405 - Disclosure - Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details) Sheet http://www.modernatx.com/role/CollaborationAgreementsAstrazenecaStrategicAlliancesInCardiovascularAndOncologyDetails Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details) Details 36 false false R37.htm 2403406 - Disclosure - Collaboration Agreements - Merck – Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details) Sheet http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesInInfectiousDiseasesAndCancerVaccinesDetails Collaboration Agreements - Merck – Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details) Details 37 false false R38.htm 2403407 - Disclosure - Collaboration Agreements - Vertex – 2016 Strategic Alliance in Cystic Fibrosis (Details) Sheet http://www.modernatx.com/role/CollaborationAgreementsVertex2016StrategicAllianceInCysticFibrosisDetails Collaboration Agreements - Vertex – 2016 Strategic Alliance in Cystic Fibrosis (Details) Details 38 false false R39.htm 2403408 - Disclosure - Collaboration Agreements - Timing of Satisfaction (Details) Sheet http://www.modernatx.com/role/CollaborationAgreementsTimingOfSatisfactionDetails Collaboration Agreements - Timing of Satisfaction (Details) Details 39 false false R40.htm 2404401 - Disclosure - Grants (Details) Sheet http://www.modernatx.com/role/GrantsDetails Grants (Details) Details http://www.modernatx.com/role/Grants 40 false false R41.htm 2405402 - Disclosure - Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details) Sheet http://www.modernatx.com/role/FinancialInstrumentsSummaryOfCashAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetails Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details) Details 41 false false R42.htm 2405403 - Disclosure - Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details) Sheet http://www.modernatx.com/role/FinancialInstrumentsAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesByContractualMaturityDetails Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details) Details 42 false false R43.htm 2405404 - Disclosure - Financial Instruments - Narrative (Details) Sheet http://www.modernatx.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments - Narrative (Details) Details 43 false false R44.htm 2406402 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) Sheet http://www.modernatx.com/role/BalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) Details 44 false false R45.htm 2406403 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details) Sheet http://www.modernatx.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails Balance Sheet Components - Property and Equipment, Net (Details) Details 45 false false R46.htm 2406404 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details) Sheet http://www.modernatx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails Balance Sheet Components - Accrued Liabilities (Details) Details 46 false false R47.htm 2407402 - Disclosure - Commitments and Contingencies - Lease Obligations (Details) Sheet http://www.modernatx.com/role/CommitmentsAndContingenciesLeaseObligationsDetails Commitments and Contingencies - Lease Obligations (Details) Details 47 false false R48.htm 2407403 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments Under Non-Cancelable Operating Lease Agreements (Details) Sheet http://www.modernatx.com/role/CommitmentsAndContingenciesFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeaseAgreementsDetails Commitments and Contingencies - Future Minimum Lease Payments Under Non-Cancelable Operating Lease Agreements (Details) Details 48 false false R49.htm 2407404 - Disclosure - Commitments and Contingencies - Strategic Collaborations (Details) Sheet http://www.modernatx.com/role/CommitmentsAndContingenciesStrategicCollaborationsDetails Commitments and Contingencies - Strategic Collaborations (Details) Details 49 false false R50.htm 2408401 - Disclosure - Shareholders' Equity (Details) Sheet http://www.modernatx.com/role/ShareholdersEquityDetails Shareholders' Equity (Details) Details http://www.modernatx.com/role/ShareholdersEquity 50 false false R51.htm 2428402 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 51 false false R52.htm 2428403 - Disclosure - Stock-Based Compensation - Options Activity (Details) Sheet http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails Stock-Based Compensation - Options Activity (Details) Details 52 false false R53.htm 2428404 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details) Sheet http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsGrantedDetails Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details) Details 53 false false R54.htm 2428405 - Disclosure - Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details) Sheet http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockAndCommonStockUnitsActivityDetails Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details) Details 54 false false R55.htm 2428406 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details) Sheet http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails Stock-Based Compensation - Stock-Based Compensation Expense (Details) Details 55 false false R56.htm 2434401 - Disclosure - Income Taxes (Details) Sheet http://www.modernatx.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.modernatx.com/role/IncomeTaxes 56 false false R57.htm 2437402 - Disclosure - Net Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) Sheet http://www.modernatx.com/role/NetLossPerShareBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails Net Loss per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) Details 57 false false R58.htm 2437403 - Disclosure - Net Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) Sheet http://www.modernatx.com/role/NetLossPerShareCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetails Net Loss per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) Details 58 false false All Reports Book All Reports mrna-20190331.xml mrna-20190331.xsd mrna-20190331_cal.xml mrna-20190331_def.xml mrna-20190331_lab.xml mrna-20190331_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 88 0001682852-19-000023-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001682852-19-000023-xbrl.zip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
'%YMG!EBL_SU6C-N<6O]GE-L9FXP/% MGOC!"^SZ!":$"HXGWMHTQVYN:VURRO5>;MTU:W[<_,I>O[_Q6V=WBDIS,$2S M +&:A*A20,#O+8_6!9I$WC"ZQ;(M=X_/:4F6A3FX!M'G#] MNCN8HDY/1ZCC\R=AMN?G/U%V=LO%J;&,*B8CGJQZK[#)>+E<+%-'&Q?7C'V" MV*KEU?JU]_'39+R^6'4:%5?*#=Z 6^T//WY=>M+[[NAC<7Y5"QGG?PKAE;>* M08B4,B'U?@/WUYR20K<1[6SG(/LJ8J,,07EK(45;U]E RF(7WS M!'#C4.G_WU_=NT>6_F'U(9YZBS/!E ++%9(GVN"U;A(3H=G$AM#5$^0%#A7Z M5H/S//:!%-9S&Q,E!GNFVDQ4[4:HU2PUVO@]AWT 2GG6VX!+%9,W0;BHG2+. M:N?+;1!,3K0YVX\1M>5*SJ-*_0'RFO<_7='7NV)2'JK,WUU/D&TZP#B#%JM' M;C4L_7" P@Q-,NJDHM3:)&&RY! X,9-R M\IKB!'2;\12D7'*E8FYBO"=?\F.6(8TGP/L$KU_W;C],1^/SK!)V)N;@ .F! M^359T<0M@;5(WH/KL\V,@WB.:Y%[OQ77I]\.^POA5O/%(@NE:*0^>@Q#D]8. MC*$E>+;M9>-4^UF*_ORMD=%X'I.L4,)K H!;$@,[P/$H- 1!S29:[+(..]?A MX(9RH._9XD#4X+.SQ)M(I17,82+'$MJX)/H4QR;/2/X'FJ&D$@7S3Z+-1E)O M=%"A,D/"&6<:Q]+\.:K_F[LJ95]))1?K]8)/)WY 0@GG<[A$H\D>$"\3M?BY MU+)Y=>HYBG^S>/-TL!@@_DV=1V[W^4KSI$+& V)&DPO.X%T@P%Q8%R :%X#% M$Q\F'+/8?[Z[&<'':T-7+S)6WN%NX!5=7Y8RD[[C5-%F(_7RPWI=]YT'Z5CFB)8^-7-NSC 8?2_J' MIMQLE"#Z0'' IZ,N$? ]/%BN">OBP&X^'5W@OY+I\!/[<+0IV4 RGXW?=?H$/:LY'?OHMZ2SG M2EA/(R5.0!@:$"#@O$78HLHU1K!L&L3\S)9LLZS/R$-Q;@&O"1F]UT03F;V+ M)3[@@L$Z-:MRGN,V^DMWU,-1Z_"=<>^Z&)WGP5Q4U$6 SJFLK,6;NQZ3-5%J M3"9O: _S+-'"(Z_%@1&K"S*R&+.TG@7/HP.W4>YJ/?3 MFP;AP$KCE#($-]E8G34#V:E D@^<-TS#3'3?E.P.]FT@(4H\5S0P0:VU@#VH ME2HR">+3K($WU+DD7Y\.H3D)0(QP9:3S5$H2HP6$YD.F@2O;K @]&XCV3<SI$+,+!&@,F4VF@6&9R;2ZO)=QNHG5\"#FG MZ7'(\8H0^'8*!D-*;HU+V@3J/;$AB=SP5$ .W2CWQ^/E5!A*SPV)Z_=[J#=E M5X?%?(A?BW[WM]Y@7T\9B75B#'E-!B-H@E89@%3B 4 $:717>#19'MW])25- MJ9&:4W X) ?/E(S854#JR*-LW/S9-DFX);YFZ[^ML_8RZ3+('*(7QM,D%6 Q M$;!5N=4AQ.QX8S&HU _9JGMFV0"J ?QL8Q0R2QRC[I1/"4(7*9(!S'CO638' MD7,BRZ%I8CA>5 $O1@IGP%R'K(F51)@F]MC:'?7Q>#EWR^$$J"7W+$.0D*27 MS(H,ED,[PB@VYFW-PR]6V=XRR;N23_FUN"I R-=O M!F4CD^KBW@I_E5UD[F[$R4GB#GAM.,![/(!N?_W%!=3BT5^Z5U<0_HXA*KD/ MN"XCOG> F^^0HN&GVR( KE[;>^\FH#8E%Q+8V5Y8,EZQ?B_-R7%M^)' MQ:E-V6D1,N"8Z+P%/0.G*[16/(8&)IO=;U]:L(,6I\U5%;&XH@L0_F[Z 9[1 MZXZ^+CUX14 _OWVS]R#3>TMD8DP9+&K...(W:B/ \1D:FPTE52,P;$,3XOKGQ]%&JN&-04'\$7JK&,B0B3,G(,X=,J&NIR6#>NX)!6[ M+C(MP5UO%,A>OK;( [.K!6RU\GN-:.PTO(.7%LJ29$(RAG$ ;2&@*L /1J_2 MVC7$&7$@ /YJBSJL<+'"*;[@N^/BNKP[ ,)H7M"^1WS%E&()E U9H# M$7 'MD+JDI7W7Q1S-DLR'K7N_LLR/Z%X(P8KAC =VE# MPY+V+0A.\6P9;YT M)$"(+KG@EE@='5T9,#_W41*PE7F,I5H5S'DLQBG\$WOF?E7=RP0@J,N"'Y*2BWK&<= *7Y83-L'([O)/6C[]> M9VG=SL)'.:9RU,XJ6$ I@C%X$R02+V!=@V5\VT*25_LCFV]V'7\9#CZ#D(OK M*CG0;$NF_Y\XC8_2/ 2N$DV4.)E-L)8SE70@65LKZ";X+J31CP,GUL1R)FMA M#EV+_8,D(&2B/& /7>D5YIM8S)D1"%@]=7+#&E!KI'T4NW>>:[#K3+L:!/KYEW['LZ(U2Q.'4ST2CU(%YI:GBTMO@0_/" MYU(P2A\IGW!_F9W_&K;@<]B*QXGHY4WF3DD7K(M$"05!$LX;<&HK2'NT1,*W MM'8M^"JV4B"8" $\'3F$12EDDU1$H*#Q4#QZ?5F[IUR[^]G.H*,CV2M"292 MY9R"32@5P<93 M.HE-<$1P+AYCG5;EBIB'J<8^ MSCG3TZ_!667R:N5I"%YR3JTG4AL/]D[3V"A$>P)<>*#LGLF"MI_)H]RK M#$@#_L=)S:(WEA (DY,+PE%*GAQH/,5"SI_FQN/I;47'K(-^['WN71>#ZU_A M5X_<<>GVKC_\6A3E\E1L[C.-@AF1,EY]HD&"D30V1.4RTZ5 I)DD](]^ZU/\RQ!%Z?=B@ MI];V%=^BE5)$0O@:HXPB&? MG.N857246+-)ZJ]4&U[E_K)X:^4TT5HF MZB36A3N,^"37269!5D:F+ M>M%&^\:B"GU4DN^OKLF-WMU]^;NRFDT_#$5;U M;RJU_F7XF9.?W[Z9"_AMOSOXI7N[MX4\U'.UBO13R>45F6_4^*;AK"NY2AX2B0%$$T0 M$!8[QSW*BBBM)$3-;%,59MUTX56;TGHZ&2V*X.4AAF#M@DE3AU<^_78ZNOH$ MY&W7X-5E ?>H3:3624")DE'CL\[,*FM,M'+E(M!L60QM68$?8TD^=WM];/22 MAZ,R[MJ=2&W;4'!!N!1*YDQ!W%;XP "$1ZH3H/$8-TF9EC0%EK]Q6"J>3(1!;9.*"EID)+*2V7&F1&1;>;DUHF5>RC1SP M89R=0)C%O%KJ_7#2[0/\&/4&X][5SD34]M%,EJ6<'!:V*"FMQJ/'$)/(+D8E M=/-2=5O[] "FVA3B4DGTOI3Y]HUKO'(F>("=A$FMG>?.Q."2%5);0^BFC6N- M5K3%?;N!D3;EM%J7]\?1<'RO*_*K2 &G,4S&E&]::* M:R$X,VT9NAIO;KW=9Z..4GII62"2>&)"U)R&% D/)JP@\JHY M"B."BU9-W59.GDA<:SYV15PQ,Q]TQD;)3%)AG$L!4(DVB3 -4FMT/:,0:+?K M&1Y;7#OJ2W52$E)%A[)[M^3M;.0YHZ0@6CPEM8G%I61B25OP)MF MR7CV7H B[I"F/R$,3/QXH/\:4E2MS'CZ/B(WCOA[@+8P*@$^Z) MLDJ"(70TV.@248!4?*8;YLDC'&[571S-Z>.*^R@;*J+5"O8^N XM2RAMX3]. MIY2E)WY3R1,SDE#12@7'@;P]KCQ;LQ&)$Q$5A"M2"ND,=8R'S)B(6G*KUEN] MK=8 /JJ46S,=XT-#\_O+>G]@XR0/44@JB58R4&\$$2I1%Z.$M]C6:A9[V"%F MJSRV*MT-\7N;\@U4:&P@*[RBD@;F!0U96)R!+E#+MZJS>,5LBP(^D,U61;PS M:GV0=!/7@!M2##D3&7WR 129<48CPVSNUIO_C+R2;4KW_APV!+L5D]*RZ=JO M2$)Y(H!_K3UY[92FI9(&FD3BF2COM)49E!=L EZZBYEJDOQ6DV!>-W7 M6BS"Q6BL<\K1&(ADD0#(B=Y+YH/1X*'M=__U5OV-O&8LKK%_$D:?2IP/K:!8 M%$TPYBU>H@R)2>ZP18DQRBF\S!>]3*4XZ6LJGH\XFP'A:Z>)(@LO:4 M9N7 E$=CHE3&)1D,P+[U)BZ8R&>*L&;H4-#Y:Y5*D91-9S;+@H&#R;^;U281U7S;:E.)V(+[MY]DF:RE6 MI1@TU2&"'V"@B]8!&O9,NL@I3=[3S$"*&K9I>U(\@HVSDV)#%UW*4<,^5A93 MC9H81CB7FF#S! -&L)2B?$UE&\;N/ 1Y<+CXD+W.LK(AX30>PR781X I7B=M MHW%"1JU!OA9\UYD]OJ @1R,AP@-E]QQO#R[7!PO\M3 M6AM./0DX(4$+2E3&HU&\[QM(TILRXDHRHJQ=#QV6F3@YA_MZ^*XQZ3'V3*!' MH!H6VSWQ7#)I&=@UL^GH5PBCC-)V/>__ "[-4IE3Z^MH,C@Z83G#P2 VH+N3 MR*)VT0=B-M4Y*2D%-^)).3QL'64J+XXQ9K&9)_R'65\RJ:B*$)EM/. 27#*( MX=KD\I3[D42LN?(D"NH#5@9&,&J]7 MK:_C=%0-W.D-KZOO_%)\*=_:/MWCE%Q[2RVAA&8:K( @T7F@&N=N$F*J(TE M1!)O):WLS7OQ=V^)K%W;+!'+E@JIHR1T@.H+(JRSB1B*5WN)$UHQ% _G">^% M;C+/ (F)Y/<4SE963R$L>V)AY1!PD ^X)T="TA!F93#C7$0*F):2^]Q:/ZVL MEC(Y\Y.)_=T56I>3]T(Z;K(F-"3%E,D2':(*WH7DW*:B%JJ-O:>8-C+9MHCV M5G!:3KG,V)#>RPS<$3"F MBDCGN2-V$W*9D\/Q9/"&\#YL.(),PGH62(1BC< M+1!:LR#I1N1W>A&5>;&]+FEKMD\()[SQ7@E/C+0B"T.!*0-&5!/.&\,TJ%Q+ M]=V'JM;8.'!Q%W>CWG9[US\/0O>N-^GV]TS'T30YG%BE9'9>!X#Y$1&^,5%8 MJTBC,O)9B63OX)F5"4<0B'.; 5BQ'!R$!+P,!(S!,RDP@HU)*\**<@KGB81Q M,,[8D>0.@7 B7;+9X[&P%@(X UMG-79QV3&-ZB@"3\#AGND=0H!SR@&@#]/ M%K6YC $<$RX"+-HU;^ND'![DTK>O'R(6DY-7V,N/2>VRI-'A73OB7'-0W_IMG?-C;V7QI 8R5I("/T5D8T9:ZY+Z-.Q?%Z-QQ=K&]/+V M$:2:44F9C#'$C"T3"<6850DG#4FZX69?2DFYDDT&5F@X@L)#5^KJ:GH[[>-D MZ;+U$7YL5'PJ!N/>YP+G3M_N&Z$8(]9T8XDA=4;EJX MQ^;[. UU(E%F &X$)FV,5!!=\LHE3U8V]K*F:FU!X+^37,7-A)&, CD7RQ)=G.$)G*GP3&+]4C!J[ M ?,_B$VSZR:6L=(9A9EZGJ,W3"J+%!H1$N>B45K_4E&N2=L[Z?!CIH=;RP! M0 KNHG9!5H"@3$,9XG+6S7GF+SF5&^#.8_-]E+5DG'@<G]K:1*8$:-RXDY9+,[(NO1\.GC"PGJ'Z_:M9?O'I*N0 M1N$4,&$5DSSF*!-SI:IJG6#?FF8.13-%]-,OX('6,JB@%,\&MJ0/5N&8WG(5 M#0O\VB+K&"J?5NT'5NJ0",EGD@EF9126,J$XD)) 6@SA0WY/4Z8:-MM M'7Z6^W!KZ2*$ IX$DXP%132):\1;3#GEDK>-2:LOZ^9,3\SW4=8R&R^MYK# MS&+W80D>N>:54+=^>02"?,D-E6U'$"T7):QR" Z!Y41]TB()8A,H:L6A-HZ) M1E4J;Q^2G!1>:D<3MHV45NC@L'+4(ZIAAC"E M^;D'QDW@ZTD\9S$DTF-F. M0"'&];5^HH]W3SPFHF'&TJ2M1&:&IF=T=ZS2,OT TM$.I]YPU=+V[9[.(+KH\RDA9A, M6D.SX. 1(@<-,@A MA'(XG?OD9K+]HI\5_F0&@)P23S&E#&@KFGH% ^%6T'Q2,WDX;X?"26]TD-D: M+YCWV6KEJYU(!:AB^I/!_?%-*>RN?[PL@=-0=?:W>JLZ>=[8L9*^[7_6. M>DCGJ:8>HQBC.] M*S>XCKW^='*_$R:R''\2$;(-%K&&A,C$ < W,5/""0;5F\JLL),E,7R)J^-( M/06SS7.&96:C"SE+0/T.0"$UT2KIB%/*05A&1=[4=P_K!8FURXVI'LXMOC5^ M]S9SSYVB_^\[L;>.3+F^YMK__UQ_>]VV+<^:7XTOEU>-L= M_%2^-P8U_)&2N\E/W_W'Q\E/:U_OPR9_^:GD_T?*R/_Y">E[V>WW/@Y^[!^T]%IPLBNKWK#KYBY>5TT)U>]^IUOP;/7_UK#&*[ M1ES0N>D-NH.K7KO#,[__HW-O?^B #G2Z=W>PH'AAJ3.:XGOXXJCXB"@&#UDZPQLDI_.NN)J" M$'KU)])O5Y_PGD0'W6%O/(:/=KY_E\(/'2 +")R Q&Z7> 72AR,DXT4IC=YX M GPC(T!NY[:+'R\_-<:K%..*)S X((62P(KIX734<8/!%#[Y:_F\#OQJ!C%T M*'GY?\M?1E*_%MU1IP#A7_]']_;NIW^CBOP4BZO2W"]>X?1%!RU/Y_ORO_/' M_/"B4_R&TBN?5W$)/(_'0V $15K2-BJP[>BR>,LMU1U=C\OOC8K/Q6!:X.>& M'P*ON9!>X7[Y M VZ(V>;Y ^S ^VS&-C= M8CSIH997Z_GWZ?7'2MS=FQO0=UQ87)[N+2[S;%$7.G^()<'G3]:-4FE)7G7> M@ ["$P6[4FM MBIWATI> ]C+\Z4R&F_9 ^4R(@CJ3[F]@D(:?>V@YX*?&")1>EE>M.E=+U[%> ME Q-Q\7-M-_I0Q15&J0^\/ 2_[K&C5E,@#<0-WY[E06T#[!+)@!]X;2D&H2 &WIQ.;@RRE_0^((!@I4$EJH--H98!PWF%):E M,CE7O1%$?F@"KE!P^!+8LFE_4I+[Y5/OZA.:A=ORG5+PI96X[?X#);FD#Q^& MTTGUQ.YH5*X=KDW%=<5J27J_U_V DPQ0_)7O&)7^HMS^/70 =^@J@*&;T?"V M,\1@M#,&V5RA'E1."Z^?S:F<\;HDHMONU\YU#Q1T-#?0\.#J>EWPW&M8$MR'P(OE1>KU.BJ.X9EZ ^_C.>^8N:I[LH2 _CX+[[ MH;9EG!>&_3ZHW:CD;>GVX_HC[H'T2,A&)8#FV*V7&R'P_HZ%_W@!T8>G)T=Z M=]UKE.S+R?#N1W[W6P/YS=['/WZD\(%6H> 0W7L!H&Q05";X#BPDN=5>9[\G%4U$QT9F#7\ ?&%^!XN$SW;O04425QAQ4 M<6YI;F!MAU\J=%+1?U^_,,23( -"$9Z]!-\ M?OT+]>/1T'6&'T"TM=[7),V>5WX5OKLJ$7@+['H%2NZP(PA^[/,/: B&5RBF MC1]"41WTT[C7OX?'SH4[%_J73X"COT=! []%%ZSRYH=VP$"C QK? /3-1IZTMWTUV*&-:J-,5_>2DV[ MXH'IAPHO+?;K%:Q*46U\6*?Z Y,*=RPM7AE 7M<>%PFJ\-47M(WP*: %*9G4 M858QBU3W\%4:V_K[R^S5QF>N;J!IH (?$ "6J+/;'Z\;?OSW$K&5VE;8=CB8 MF3+L[0[DS6DO$2F"_=D/E='##/3@NP6&_%=%%:M7RE!^:7P;XYF3XL2A?+AU#%>K KJF"G45T-(^,9D-7&CN[-$-SFU@)IOQ0;0TV MDK3!/,R$@5%#;13+WUL*Q>:KL89=7G5^'I1QWGB,VQ#<5OGQ[IP<>/QL44JT M-ULRB(JN(,R%'Y_"8L.*U%^M)/VEF,D?'C4&Q062KC#;T1#/X RU:@Y&Y!A6;6/XZ56DUI/-G\;"?L$%J0,'&$C7A=WF)#$"&"T\D:= M+FGFTPZP%7,;T[3/QUB#V0\0)CH;7X4*"&+2S+J#C*NRH!6X&R#W@*6"6_ MUW\8=\?@8W_;#[_JO+F;A_G=JW].>TC]_/A[AS+,;/CUJFWNW50;=GA7N]ER MDR(=BYPX.J*&F:E +R"6,N^+O)=P =/295H,]RJFDHHROP$"!VT;KIL:^/%A ME:RJ?Q^LRR:1[%Z-\D% P?J3EKP)LC/Z1U':EF&94:IASRQKO>M7YPLYO:O1 MTTP**_"XJ*'C\:GI9PU2'A64O-\8IL.:+TZ@,(D[*@TH9BX'L'C@_N"79K'& M-43C6W8I;$S,RY8^ 9LQU4_]4#DS5!)S#_ M%I(PURF(N3#)6]*&P0>$9Y4CP,'5YQ"QB1LFM))Y07J4YF1NJZ]K. M[GWD]1#H1G-4$M/9^/3Q(K3#H\TIF%S .XNXI?HJB' \O2M/MY9C5!SP?H4= MFVOO#70-JNSP)GPS0Y0@D#FU9=1V6W3'^)#-":>56&V1NEM5QCI;?C6IP?+V MH',63YDWWHE.!E])VS^+5^EF]\8**4@B320ENB^O>U62G M\'9%[:\ZKCX(VTI4Z5/K'3:':%L3AV :R_1&[3.7(OA-:HVYPA%LP-ECEUBH MBOMZGXOULZU_E2ZW/,Z 3UY=34?5_L;O3V%'CC!0FWQM'"/C^]ML7;5-BG]. MBQ+98DC3_WQ>4/&OU5'X>+8+FNGKF15<,=5=4*G/17]X=ULCXKK>8#CZVK33 MJR>4LXBH7)B%,$LCO08ZYFN,UG#)NI>IE T[H-K%^Y5J.I[MXZV;[%7G==/= MK"#5)=-;NL!A?[9S:XL/4?8LE*OJ(!8A1.FS2J1W5Y\HS*57I2>[_1?S'VK$ M]-O$@F<]_9KEWL>/%6JLY%HJ-+A 5^WI8E Z]3)-.:_KJ%-:Y6J-BI?S!:OM MW8?JO/+K^J_.GK-8]A*7#[[.#Y*1 5B$'FH"O@>0>7XL^*(^+5PYD)Q'=Y]+ M*+(IC^70.9;273ILK)($5\/1=67[N\O[_:H[N?KT!FJ H\H2=?JX M_TH(5<&*ZL>0+="4FN9:$IXK$2H M=SO#Q-*9UL9GG@%KFI^-H/D!J=E'/=5YTK"GC3.II1*[O6>6N\X7YPBS6^DW MVIBJ@JR/&WI<]/MUS=Y573!2PL#:;S;+5$9%E8R8E9*LIAG*+;OMZ:B:.X]" M!VO(!"W)HFJPBNS+^H_>XC!A7E!3@KJO+^MXZFJ6IURV8[/497W>/:JG8-S> M5?L>?G]0?!S"SEL42GT<%955:YQ9K[AWI&,,JH:6OCSA6*".*_#=(-/_'GY! MN/>BY+(VCKW!O) 'SV5FZ[P%IR&#(T0 (/'E'.,V:=[,CXCFM95;GEP9OAF( MK4Q.=WX\5I>@S(X1M_S<0E9WPR\OE%>51^G*(W%T- MD'>@/IE4M?%G6@ BD0V*#ILWAU[FKF+Z %J<]9 M<>'P_<8);_WA:IO4?RSMB^JHZ7KYZ'%V=%KR-DN++<.>ZOBT?/J@6V4*9Z48 M]='/]F!A^=1\D6C8]\7>1ITIK6##WJ 87B *6-KHD[5BP9W[;[W$8[:\^*%Z M@5]UWBWELX#<;EV",Q=3>7.@1(REVJR7?LS#P^+F!A.P\\]6%<_=P4IAS[SV MJ0YR/R_.=ZJ2Q>4:Y7PLH_OU2_\V'8OZX>M"2^9NMJS GPJ\&O)F86'.C9%G)?65ZTUE@4'I1<"X MSZ[3E/=SRBI(X.+E%9K3JN2JOB@!EKE?+LD*BIJ=X@)$F]UM*8-Y\#U5S Y^ MI%=%")/Y3TU*:S#Y-!I./W[J,,+9JTZH _G*[Z__3$GVS:A .XT'TM7-C^H6 MTU6W7Y%7O55G")I[0!4. M**'0S1RJE-*I4CXEN:V&2$O M""&M/&MQ@C^NN+\I"H W;T#UYT*8;8*OM2K4FPTWP-?.J+J36H)H1AA!7 7_ MJQ?Z\APE4)U0@$>?8HQ6H=ZY%$!!?AF.O@SQA.FU>U5=?EV\.Z[$=+UF",[2 M=QB[;_"[ U"\S;]AE@?!)&F!>?$./JDZVZJ%6/HUW,R5$05- MZ*-\.5ULX:5B.LR^80G#]<(WE *&0 +>:H7;&[SUW8K8ELHAVZ$,XI16'O2R MO'M9)MY?=2ZFH87[CI/RXNX"_+PHM;(=K(*)Z4\(TF[AW4_CNI]#*QK:RE-> M(P9I7MAM:0_!5F_)(%+3#DE?NN-V2/IW\O?Y2O6*FDOE@Y, M^E]?=?*TS$=BINUV>EM;\GF51!4Z[(N89BYVC%'0V:MR58C4'==[WN# MQ4]AC?H8EF_\PX]'F[AM)FWI.RO';?/#PUY9357^O?S0JB'!RGDCQ<_,'SRI MCFJ+?K_^3-F_"?]&:#/[^_#$U9?>]>03_!-X^H#IP]%+O _9O1L7/\[^T;#G M"Z)&\W_A$1"2,OC/[^1WG1$(O?PWG7_V#Y/KQ3]'&Y]04U^1)/[/3RO/63Q_ MXS/7OZ[UP[Y/'_CUQ_WY;1*=?XO-=0,"_[*I2KV@M[WKZWZQ>C;,0/&6-7'Y M[P_#R61XN_)2>5>D?&7CPB]MB=TGTFQMC[PL7UGHJSD..YBM*=+W;GLU?6:2Y3OD>F]7ZJ)4;O?NN4'4HZ_U:VZR./+_.K,H0ZI41?USZF2GW6 MX\MWYSWO;Q?6I%Q)Y:W"-EFLX^O'?KJZ*XN;F%.+=M MWJ'>; MN'>C;]RNI!>137[Z?E3<=GLEO*D3G!B+_="6%(\1UE;)GXO,_OW1=&R'E(X4 M1JF!K4J#RA?4-A,[;8OD7!;_J$3 0^WWMV5S,#'^E ;F89+!4R'L5/;C)T P MQ?9#[J.4:QY_'8.UMN+7!\CJ .34OFEA[(71HBU5.1?U?Q(+\CN!,V!:Z#>( M )^OS6E5B$]KC,0+2N0%YUQPS@'&B%UPS@7G[%<4_D+(UDS+N:C_!>>$<\D+8YM'T!><<9J5.ZJT>?JK4I@C?8VN"[LVD..J$Z)OSYE20 M%]Q$C^JE[R/:P<]F6BKH>K%0;CUWYW6^=Z^$4BR<>BWP\_U;FO;!]R[',*49XB5Z)>2*): Q%'2_19:%Z+EO4/90G4 MQL^?05WJ48R>\>6U=Q-L@_JQ=]59NKMYNJK9\ M,;O,O'&JPZQUS.QRTHOE7C,OZG:DRQ=;L O!Y_*.VZN.&Y>=I.>67RVO1[TN1E?_> !=.\E:'N2%%,WZC\YOV'2Q44X/^V%U MWG["&B,&JPZO8!W7I.Q<7%U/Z'8^3*\_%N4PPGG?D88Z'.5+F>"O2+NUQ&6' M:NQ9/;L6V!VW1N_)2\9G_?CWV!&BG'C(?SB^"]#%=-W?;_RI M^(A[]_3>%3G-6FV4+1C' MB^8;Y8R=LA?,UY\ M!']=#WDXG+FO>G[0@;FU_<8C1RB MT]Y+:FRPTE"B/?-1.\HTR;[H$A"\'U3N7"^ZDS7O\#T#+/5]*:Z'7TW:5?#_ MS"\KW79''WN#BLCN=#*IV+C29I[V1],"ODV=-_87Y"_// M@/EG4EEV=K4,%_GLEL_^.XL;CR-^%W<6_Z<[*!O-; -S%ZV[:%W[6N?JAC7W MOAQ[T;>+OCU WV*!!RD7A;LHW&.U BC;)6Y-D5P*HX_(&]=YLC(7.=Z=(;H4 M23_R#G_:"KZS$]S9".NB<1>-NVC<1>,N&G<^@KMHW#&":R$Y3)X[!JX'AHR7 M#I$O\>SYIM'/16U::VMU.I[;OZD@7BC:VB7]K/:/V?M 'LQ4@\#R7Y71H)_D)M&&/T M.X<*EQ/)>YQ(_FE1N7\YEKPD4,]7<&CF3O*08+BF&C:<1@KRP[-) \F('+G;@]VP'Z O* M6SN..)>5O%B!BQ6X6(%#3B4I?R%-ZX-$+L>2%RMQL1+?C)5@S+P0NK6+^>>R ME@]%"Y?6R"?)Y#SO+F)E8]Y1<37\..AA7[_)2I^V.CM5]I?M8GO>:7\RFXU< M-6U;ZLZWVI/MZZ*-VUIKMJT-V2X-S<_;:2U!\.T/:2BS@V M.&V;N)/[H&,(Z_RUZ-ST1N,)=OD?7D'T/TLE8!( 73$$UKW/O>MI.1]@6^J@ M,YQ.QI/N .W%/J<.R*#7+U^8_5+Q&XZTP%% \-7ZB:\Z/]]TT !A[J'Z[7$/ MMEN5B^C-V@0 MAB6N8CQ(K-1MJ4R^&S# Z>2[ \UF!6I!2&X\DX=._* M.2[ T%O@I-N[AH>4XR.J[F(;9GW<8\:!EBHSEHEC.LHDEFS MGMM1RPD4\0X'5ZS,Z*CFLJ#B%#BUZSG-;VKE2;,A4 U"6QKDM#RV9#6G^7UO ML/C1-M*-WTQR\0290WO)'/YXZ8=_YFG32U1\D4];N$>/YW),=!:GBV=S@*A?&-M: M9\6S7WO\WBDO-UTLS<727"S-EE(%\D(0>C$U)T.2OS_ ^+X8=.%;O0$& ;W/ MQ7)'_OA%)'; M0PY^G\6UHO:RN/<5X;._E<;D"V;;NY6V3V[/0HTN.9F+ ;L8L.=BP,P+;MM# MM!<#M@I[[W>]MGEW\*&7_U8N$L[??G,3AK<(,\L+E[]6C:'*GWCWJ3LJ?'<, MO]#]6O:#.N0>H6=.QY@RL9S+_Y^]+VUN&\D2_+S[*Q"UW1MV!,3F3XHPYOV=45VU\V(# IH0L$6#@DJW_]OOD>2P(2F2_? M?8X^#J]ZO<'D_4W__?2R/YI>3MM:1T@_5K+DOB0 E0L"EE6$YT;T.)L*ZD." MFAY_1[CNK@'^AS]3+%'^[#O!9HN( ;Z3NQJI.Q N%6 _>LD]E6M^^OR++*R> MAHLEV#^##H5E!_37CO6U MYCGK5KC.0EAB/L<-/0A9!2ZL&5:P>XN%F'GP+__)6D9>&.F2[?QQ>DY5G,(1 M:(/ +WW'Q8KRE+X]KI[AAPA#ZZ7]CTO[E]L-4MH_K!\CLZ3:5C=<+&"5F)9T M'AS/)Q__'';GQ7%*5?1I !+/J@.,]>A0.YU($"^Y?3)3W-L;=/H6/.77\:1] M%M0'KFE#B#WO%L#]W.P<<#GA@Q MH*WOY4[L=X9&KRK?G[HS^(^(L*,"XN0\34 +6$5-I(PB6[7QF0[5F>^0R.-.%>E.U3FD#3)B5Z$LF2G+XQ=O]G?D-P\*6U%H M2.#Z$ONHS"]NZ^7)RC-5J67%%YY P85A4X7"R>"C\=$_J&2ABA' M\<66-,3@KA&'Z!K1,]-P=C Z;>N#=C=NX-V?[O7^:P(>EW0WI,CCS."S/3ED M 3OU10OJ;(WW)_XY+7=@ +MR1T7FJ-O<1:UGHF"B,(-MO],OQ.RBD;1P!??D MW&V>%'NJO7WX)B+7BYNYN<^1YU*;T$;NCN)>S."8P3&#:S"#HPA-(W=V@R&G MCX[73.[V3\=/F?>^%M[;-'Z[>P8/\][F\MY?Q<+QL"-Z(W>G>ZRGCM_(_7T5 MT8)9'*N7QV B=W>1N -]I)&$\ GHU MBSVWD[DA1JNQL]Y4G:U?&=?8>$C)2 M0T)R6GG.R*I3 7--B_]=R;SM,]=.78+^2WEJB^[W:ZV=\,"5L4>NSSA8->PI M"PE&77O:[]F]P>%G=)U+G0!3&%/8<](G^YV>L09.3%Q,7 T 7&.(:]P9<5^' M1J((T]:IS9@#M%'I]*PG0#[N@756&-<8_.KWN_9P,&2&?DB?2\-<*T?HU?.# M+,LPA5;,F\S#IS$L:&0/AP.[/^66NTP53!698.X:M+.8(I@B6D\11KUZ3!%, M$0P?AL^IV_H_/U6F6? YZQR$(QC*NB+%F*G<(-@V"U-?IW_OS<@>]0\_S*^* M*(<#DG$=;.>$*Z8]IKUGP.FR,^84GT:B"--6VVEKQ+3%M'5>M,6 8\"=;EC0 MJW1$O#Y_PS6V,_7%#$ :S87',?H3#9LP4VC7&'7L3=^^G$[L<>] $U[6@^MU M>QR8Z,XYX#GL]#D%@"F"*4*_-^T,C55E,D$P03!\&#Z< < 9 WJ0K#K% !V MO#5L5J11R+9C).)H8/RJ]B7B)3=QOB$8VASUZ_8W#D,D=)F;A. M#[C&$->X8W :,-,6TU;; 7?@/@@C[H-P?AC7&/P:]OKV<-IEAGY(K\_K<^ZH M\@X::7AXYPZSKC..??6']F1\:8^ZQBRZ<^%%3!:OF"RFG9&Q[D5,$$P0K2>( M8:=KK-Z/"8()XN2*^R&*AR9FG0F,/V?,4/N7?7O,6K<1#T"#O&ZG=@W\4\2) MF%E.,+/$MZ5P\8NR\[H\#V.F+:8MMH"N -36Y=S,I3V=\ "O M/3PQ?TLPU:#V^<*_"^?:,%/UY0?[?_)_-IYCTUXVNFCZPU47#?W&],7L/9)V MHD;2;AM$N\_&L@G&EJ>G!5L/.)G7\F(+=NBFOD/.I=A*[H4U\^9S$8G %=:M M2!Z%".C70O4>M9:1!W\*Y_1;H!,1^4]8CA0N$R\,8O)1X9_FCA>I[\##;KA8 MA %L/73_L.9A!(^$L)A^R9,?@4?$$VX$WC!R]ET=8_NLW3&&JB?G#Z?:[$= M!"-W@"4"BYCRT!B%GM5K//TLU'1'N#KK#/>O5=8/>"G:1W3>6/P%A?OY0];ST"8S"RK;]T.ST+GO+A V98 1W%6$T8>D27'C"@Y4<6A4^A%5R)!<<^"E._61UP>Q+<8Z">$O.!\OEXHL+S$#$FCR19> #BW F?$GJCW0H,;MP0$-U[H#-Q'&Z M4!])8QE7%'%"Q%NCR.%O5O?$E&1DA\CPC:P$6ZIVOMEO2Q$B"%RP[X/U^VYO M\EE'+H5W2O9:=\5<2161NP ;9QF+=_H?%5Z1;ZJ8 M^I"Y$"YK6WCLGCPAMS09_G6[CZ+6$:*.=-K7NZW>?:L.WY)JG'8Y5QD^^78G M!VA\M*W-48'GNB P1%0XU^5^X,#7Z">I,L'N_9EE0UE74H?:P_?*E,>4 M=WS*.WA;X5-3YE4=A/(FYEJZOF[*>[Z^\?K4B@]9_:.(%FPS M')]SM8Y!C3N]OMD<]*8P%GR/6UTP6>Q)%MTQDP6;_8>2SP^A[R2>[R5/;'@T MB$^=C^%QA*'>K\/L8+ICNGL.W1V^-<'KH#LV]Y^A3L">//C&C/NPL7&S*SBF M_5[?N#%\WCR)J8:IAJGF\)*\03KUJ45\EDZK2Y(*%4=+$5GQO1-QVD ;,_@: MWTWC+T=#JU;T4NEW>MQ)A3D-Q'&$;*VF7/U+&\J\B3B*/7%O7LCD2]0%HVG%:!7ME3ECW8$EDW0FB'-"R M=XGSZ$2SV+H3 9@;OO^$+0?"].Z>>AOTN[VQ]>'/U$N>K,^^$\BN";( WL-> M"U18'J>+A1/!=V,K3*.:3[B)]X!+J(8K%4#M<[!7W1V!>P\.$*?:VP^H$.?H>+.M&.]4^T2?_Y?G^/PY^O("_O1+FL2)$^ W M;0M8^L6#FC656#?"%OEKF0-[@$RJQ-S M=K@9TVCKAK7N"^VE I!V*P_&;-PA13\'2TZS5& M&4==>V PRK@WB#D,R;8@VX)L"W+YRRLJP6C+9N6/^/A>M3K6;X&7;$Y[Y1LX M1L7.M%BQ0TX0,V4\*=POU_)P+0_7\G MSTZO9D(:[J2YZ)0-5.GM%+ABM7H>A4DFST,6G8S&W0SMZQWB.(0^/J0N.QC8M.2J[O7N?R\.W#FW+W+^4TG ;%12?/ ,4(!'F_ M:TS;.1D=;'6?K-T5FRRRSML.-">9FH+Z; >>4#)]%A2%M&*1)+[ >DNV M"5LJ3(]D%+*899.1348V&5^SR?BZ*U'/N.#4[O9Z]G!JCI2WEIQR92G;K&=M ML_;&G8FQ>8SG0A$[E8.^M)YHGX/]/_T_&T]RRH) $U:EM=&LW&=G6)BG)'1M M 5YL/7J^;]T*96G/L-\1(##587%9HSQP;@+RSY5 M*R+V6+!WL,Y_>[3YU\ZU5TW!7G:4$TJ?\3'-]?S4O7N MQ7LGE@6]2Q'$\B8^?,-_[UQFP)>PB:A7JVV70-[8E4P1P&()1\ ?L5[7]9TX M]N; DC1%$&5?W-(=N<4[$O*.B L8(R4FVAQ7Y;BA7NQ-8;#UE[ MF,:PS?@M%PX?HG!X:J9P^/*DI;?35M<-M^GL7'7\0CMU3'F)&-4:US:BV<_G.^29O'"-& MM$1;\J2-+AH?J^3*U9(S?F(/IX'AV]: MTI3+?RFKX9R8[3 N=# M1<[0^YL^L^77&0?<[6[/6%'%N9 7F[2OFB*F72Z; M8,O;8&0X3!S?F&YSD(3+5L^R,*=*OWBL2ON36J?VD(>H-$3/:! /;9P"PDR2 MF>3I"GCLZ+&O0U#> #HW9N)!^.$2RW-/:? V!?^,,;Z6^5,G MY@J3FG*5[-=I7R"F*;CS*MG Q!Z,N)R*?5GF@/^#'$BFQJXOO,"+D\A)O(?- M%22OON9_8D]ZW(.1'2,-BLR<#W$-[>$E#_-@@_I5A6S:X/LYGM/Q?'R+1P[ MM &-V.X_QW!*&S"/&5CC@R-M0".#*MOZ#C!'VQBW@]AALU, M$RL2OH,)OTD(3ZH..VN[:CQZR3WVWUD*-\$W0ED@1:ZM2EN>.QS(*F8=Z^N] MD\B/>3$UYG#5!V^%5=@;"GC+L1[UO%='SGNUEG#(<&8,-0:=D?4$Y&"J6X^A MAKZ'Q-C.WN3>%E[T[S1.O/F3J?W*'_'QS2V"L!+3^K!8^N&3$!8U#+(^IW"1 M0#K69]^ITO+ISW:8NS"YN4^!]3,P YS22X-Y;> )EC,#9H-LXUY86\%NO<'' M/GSY_/FMK7I]W0K760A+S.? ?KP'@>W ]"Q@:R0G ".KDJ]97N EGN/[3\C7 M1 2,4?KOT^0^C&"[LC^1%\RS\X09)/%7H-WW/@#TO__G__@OO=0')PH05)]%1&]D#V&7-Z3V7\7\[]]] MO,&S_I_>__UZ\YWES> 7CIMH/1=_^]0IY%>&QI%52GUQ^U$UN%J?XL$NO',(Y1\%L$*^YW=PQA5@/WJP14 MNMM4MJD"[G MN05QW'MX4=1H47PUS]PL\ [/E6EHGI^BC O@)GQ]$\2K0 MDWOCC4[;7J[;YNYV[3H\-R [5'>\!>S4%Z^Q.Y[%;?"X-]G)\9+;X#&J<1N\ M\\KL^CE=B,A) 8'P=PC KH-)-\88)TOKV2,.Z/4UB,,-.J=@T)2_G M51:%O>D-^O9X9"S'M$H.+<( 'J5^)&'/;*)M;&+2MP?FAO&]#BYQOJ;9$323 MZW2!,2',9X%=>?"568R9+9&8";&0$90P(!BJX5IS$44Z16\?Y?KUE,A)AC[M M]_J'-]^:0K7X'E>A"." M<.$%'/YNA*1I#EXV#G",U:M MV-;M:OW+07QFITT(-J]'#?I3>]J]M"^GQN)-VV#4%,7GT$YJ%B9G/*MJ/+*' M@ZX]'1CK?G@N9,%F@@G'\A&%WPF<,JT>J\'S7 RZ<;J=H;$AF"^'YROV[K#- MW"JW-G-0YJ JTM?I'Q$G^FWH/C8R,F M&Q,>8RQ$G%FRFR$\Y2R "I+8"M,D3D#QQ@5:TKZ*[ 1J?D:])\4WUT^Q\GL> MA0OJ1Z9[A&"O1CB0@7XRN*ILP!A;8#P!YR%@"M=)8VP2([P(?@_[B*D_9)CZ M,^O>>1#PB !8!XEW0;OP'D0U?,*]0_[^W=A,[Y!)J_I?.UZAM9]L=O?;N M'=RJHVE^[-?9/X%;=3"J<:N.,PI#_&JZ[NM$A2BG=,QPW1?7?37'"7V6)-8? M=^UI;V(/NL8&;I\]B;4^4^T(XD^. E!324ZIVS:&TD8#NS_IV7US59;G0D]L MTKQBLA@.[-Y@9%]>[FR6O!:R8//K1>97-@.K&%!A97#C],-1UQX8G-]Z[HH@ MVUIL:ST#3I/^I3V=,'FQG75P.6>E@9>PW45"S>[V>O9P:LR_<2[DQ6;7*Z:* MX6AJ3WI<>?,BD<-JW@LUF!?GRIZZC\D!W(1#>S@8V+WQ$:?0MSH3GHTXIN[6 M4/>@.[)[PYX]O307;F/RWE&BKR\IV#Q[>.W X.)4X4\!V%_BJ_,MGU3\G,'" M'\;]C]=7U\-^__+]:#!X?_6^.^R_'T\'UY/K?G#*,>2)6"S#R(F>K)F'0\7E'VY%\HAE!+C*W N
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�TE'B;=KC@]?M9X;DT7RO)T+K>%IRK?R %<51F>N?CE0,P()YX* M1B0VTA-$)8;6:IRBXGIX>Z=!?#7 [2XSLW95*?J1@?4DCP;@N U)A;4%E'$N MG4321H5A.?"TTAE\4ZIC_=W%?@US,[@;!\T=^S=LT@%V.H4FLC=>I, M"40(Y%XZ#ZA&P5DW)+CJ5(GP8URM&LG+L?];1MHSK=2JL#JWM*H ^/C@3 ?: ME%;.,8&#EX^EI-9[S)UPP2;PK=[?:"->VRU(:Q=(:X<$V]C1\TN2JPVT4NVB MRI-D$&'HH%$<(T"!%5)Y;Z &%FL3KW=>UF%ZMZ!L3"SM6'5[6O=V9M"]#Y0$ MRF,CH0<'-Q4LM<,#,T4Q=C3PW#M)C:::(*&,#\+&Q!!7Z=2_68H?KGI5FGYU M"KH]Q3K)]CI[SHP)*Q'7C"IF*#1( &8#_+41WC%@+^Q>:UV@*;IA?Z\U=3,YB-QL67P3RVF9E% W(Z+";%S>[F"A>@82BE&E./&*58 M$>N<"SN*109P%[,5NBR>N-VB]I PFPVF-RNIEFWX/A;O\EELK>B+V_ MB)/ZDHP$TXTJQS3# "#KF<.@Y"0%)B76]/)T4&58[;5+6I;'V3?M-R^/^N.^ MQ_J>RS:'!V0B&/U,*@ZI-,QB8!DK5PPQYQ=VV:L+41<-R*%>Y.R]/7-L2(8P MPP)QX:D43""C&?'EJH4 *1FB/4)/7:([BH2SN'HV%EZ]AFCG,O9F4E49EAGD MJ&:*Q;N0B%/LH9#EZIU1%Y*,4)\0B\9XVU;0)D&75KHG6LO\&8#AVPRL]P1C M3B0@V/$-[Q"1/.4F::^3L%K?Z;H4VPN ?*7[JK7,GTEA$%5&6BJUUXQ#XDN+ M&#FN4J*;/5+%'>&M/K2?+;&SMWX5?H37'?&V88H'A2]7(9A=H8S#ED':K!G7 M"D!JG+9(<*R-04*5M!OIR ^T)N"EZ$I.21AES^)E_Q@O/J_B:?^UBJ=%@^DX M*$^8)D/&6W@?SL?CJS@ O*#6<" V:9]P*:;NW4BXY.IG"]L:ALE?=/'DBLP1K9H0.!JF''F)DH-NLFS!X*8U!:3]Z)K.!/D'BU6A&I%(^D%&BG "1U)ZEC_(^ M56)%/7QK5.;CZ7&9/WPF4\Z'32Q8R%QYAZ'!TI1Q-B(PN9 &=[7(/(%O9YN* M"3O7F_$D>%3%=)]I4.O\F61!:4:X6VUCQC\ A);\0)I?F&/==8I/1V+K%,:' M$XCJ>T/&,1<>6,5<8$DP[;'PY:=-L;/R,K;!CG!4-XK/DMG9.'Y8O*IJ(Q*X^8*/7D0DK[]@(YM4GA;.1\++Z.A^-%98VS[_E,"T40LV'5 MQG'B%/'(ENO5+*D49H_L^UZ@IB89I&B;NWPQ7F4$5UQ66&58OOWSV4&J\BT7IBC-*T(75Z>D4 M#<\+HIPMAZ1D A7>/%J&U?^7%0S X_D$.P=D3D@6K%'BD'66^N#! %:NV'E[ M8;G19TKK:6I ':QL\DAHL[RKV2:OZD"BP*Y'LP!]!I $ACM-))5:T=+H9(:1 M%'72PSR3CG,&:I! "UB:/\CCWQN5/_A\YK #" DH=6"*4>$?4Q[ <1/T[66H MFG21/L=&,C,3_,*'V9CW'\(QU_#0J(P[I(UTG%NO&>+,.5OF6W#%_(58*S7) MKVB*KR_@1N/K"ET2ZI@^0\I" *WGPC#C&!,RYG"L.1?^FY+UU,,F'3UPZ#J0 M6A<'V6^7\<.\NE[GP3>1D?'D#9D#W%JFI" "41?+U:@RQLSMCYNY23"JZ1P[ M361MJ>VR'.W[0-UTF:O1:+P/P\>&9,1:X*VCD K&+$0$.[2A4'B25!F_1P>7 MG8*R9AETDO6S3K!4M\5R9\^06N?/J#>,*8Z51H0;1KD4Y;T/H;1*J;+8HR/1 M%ZTH4P36Y6Y_?P[3X(9__Y*,6DR0,!!8AXCG4!)2!IZ$"V[G99S3OF@H)TNM M"SRO#93R'I3/=]6>K/T=F=;:N2 3:(A%0D$1FR1O^&($3 D3]?!P[46B.55H M78#9#6;38KEX-_@6GPN_'>:-6!D[WY-AH(AFSGKLD6>QG# I;7QA65* H8<1 M]1<)ZCH$UP6P/^:SV_%TW84MGXV+40.@?O:.3!@;S"_CJ:"(8ZHYW,8O)?,D MQ7SN8<3L10(Z56A=@/E]\6TP67S;?(3!F1TL)PTJZT.ORRCWEA*ML;3&LM@^ MUF^Y!;1,T=GB!\3[)K_NT=X6S$O^:$X $=P")I6E-+93*&/WDM*D"(C\@>_> M"*X+8&_./3\LYW?Y=-ZD9;+G31D#E',L&'!4:*9A\+!+24EI;4J*)@0_T-TC MV;66MKRA(Y:B,LOYHKC-9V6CJ6]FW2QY_"4W@\7P\^]W:O3/\$RD_V.QB<6; MSY$EKZ9NOAC?#A;YU?7'P*1YF'+50'D\/-3;HX6W9U@JB 5ED"C'@G[A6)7Y M<%)@G50+XL?A8=_EV5X^R&K][_.8!S.>WNPL2W\PX:/"^(P3+ 675 -@@WB4 MY[P\[I(^Z)84+/>R+V2G:&Y")BWC,2:*[_HHUXGD@:;8>#7\,_HX^'H"U08EU N+Y%Q;(F.<*ZP4)Q1S M%+Y1@%P9RE>"P:3&33^.$YN31,OZ\G!.YOJ1S&(#?"R-Z"5D3#/B:'G&J;!) M.O: )Q_F?2^:[52VWP.G@Q:6:S-V_FJJ!Y-5V\J8E#K,QU]B>NFZ'O":80]Z M^EYJ^TK@%<(*PMCU"PDL+-5$2J6),@P172EWLVI>_\9[*+G[UP,%M.HP_SZ( M*T#SK\%L;]3FE#DR;8""3CICG0Y;::!&VPUM7!'P?364K"SHHAUV=VFPK);^ M-C_TV1P:E@$#A-%($$&5Q!QBJK:42N!:K:=TMXI??5@,9HOF"@XT@X,*ALF9 M+$^X>[1G#:^FPUD^F.=V.5O[F@="RR=-DB$4/%)-C20,,D ) EB4E 6']4(J M8S8/H\997S^H;%X#J'9-DA&'H,#0&\4H1\%NUV3+/(-,"JBJ>_=R#:II?A/[ M+7R\6&S5((&7O!M:'8\#+::8:*85I(;"#:5"!?N_S53@]6[HIJ,7"K0&&'Z^ MVCI Z#9@D&BS[YHGLPQ(*1 +_SCC';'.EFI96 TNK+EIVW9[#2Q_V<%&(ST2 M@A(M!*' 282U*VD5P1;XKJSW-#2<%%H\C>^U6EO;1:2:\0&E&?HM;YFE<[P7" MMFD9P^)F&LOEG0NY9Q-ES#'/,!),4D<4)X0!M>&&%$ZU6E&ZPX.] MZ<'>FWPV_/-9(]SYJ^FKZ74>D]261SV^.N6+OYS],1@.Q]/+/>!3 "JK M#4$(>&-< :P$UYH!43L1%+R M+FCU"RO9U 7HZBL^=K;87@#D[YOF-@/Y!TUY'7?&0*JU$U@*#^(17\D[1TQ* M0:@>0KYEO-6']K,E=G8L9V4U;HW(\'MZN-+HONQ[1EUJMZC!TC@[,%(?*>VJQ5 Q(X*1A MH*2 R:2\_!Z%D'N H;I%<3:8 F'S8KIN+?#F_5OUV"U]9_YX[.Q.1Z_'PWPZ MOU_X=MT?/@]F=Y&5Q>?;W!2SN\-@;/S%&4",@]CG5G@DM< &&N4=;F U2: %+-70:"DV#<": M!_/1(1%8Y!UGV^^#7DI/MW215FJT=!HS$Y+8&FBT!+B!E@!-&*3,$>1B^LIZ M[=2I[Z/14F7YG=!HZ32^MI8*].+[ZL;RC!XA;H+KZX"%+OR@Y*L-6_YEA0MZ MX,]U+\2V/H[S^NI208@"P=*4!D"(-,50E;3$)GZ7H4![@8:#?75/DT-3X?_- M'I,4R7\T1R8)HEHIR4GL%ZL]AIAM-Q+.+RRF<*9,3PBNIW"WMCG\\?S@ 0'#$!E;8($R^HV@9;F!,LY0)H#U54#=)]:F*ELK0UO93/PO[^ M?]Z5$EFM^'C<<_^H3)! IJ$F?%P($H6"2UZ>9#&BDOI2]1 Z*8)^JF-J8VJ7 MUU#T8#X.#(FU:&,YQ2/N9*4)LD"XD$BJ8$HZ8R% C)5& P.6IY0H[F$?G1YL M=XW(I3^H/+XC5IPBXT03BACPAB$*-)6,V2T')+XT95^Y-E);:X.K9M$V484KD)3OVD-=VRZ4ZNK_DBBT+L!<#FT, MR8]?D&'CO>8BGEQ:!IF,-SPW'!'#1:/MRI^]*P,64T2"E!0UQFKIH3 EGR#5^+)RGUXDLNL27EM6]K8*U:9" MT'W-F%,+\)PX4_CHB16(4^0,0= YPUUYU"0(3ZI"?7+FPHOIGAF^"(U;XK MVHMI=-TXBX8OV7@DJ'3::L848*6[("R5*<;QR:S#( :#W+^6ARV#XX,S3PA2U#-'N&+8Q*N::ONY"IB2D]'#0%JG MH*Q=&FUAT&Z$N/FJU&@TCJ(^%.3=-R33VD,.F6/,8$NK]"[I=LZEMJAO!+LG2J(7J&NPM*\2!DM/A2,> M>*V!\JS,,),,\B1<_C@Z:U$TK66.KLSM59)BH&<^#J)>"7[=R#,?74T?Z/E# MN:2GS),!:C35!G!%.1;8DF#;E[P S"?=G?AQ--:>9-H+5XWRV[NUJ9'?CI>W M!X-13Y[-J!(P6"82*(J)02[\N>23TOR"SU&$"'L+(>$Z>8M5L.&L.^CY*X)\-I M=XRZ75F\@!S2%JN90PT@U@YIQXBV##-$1)[ 7 MO<5*YI)X;BCP%'$5^"41SL;) ZJJ?0V+&,_S\%MV&"^[G\ZLH1IA;Z#F2FHGM*"R M7*LE.,7?N*QX1BI::N'_V5A1X4?XZNY1C.)!D;38>FUG'.,PIM)FS222UF*N M" 18*4.@4]OOA%'3:I?ZB\9>JW(Z&Z.FN/TTGN:CZ BH_WK80O!P[<-#HS+! M16 91MP[I+AG6'-:KCU^>#^27&O"6*UR.!M#VTZ35;HK_)'/%OG7=Y\'P5,? MYLO%>#B8S%]-A\7L+@[,1V'QW\^/#0D?8R72TH P@ZXG"T5BVQ M!L4CPY+C%.F4],,>ULCH$/DO1<3G^["[HEE[HHB'!V1*>TZ=8\@&BP=BZBQ4 M6S4 2\-QQX9D@%,<_"GJM5-((*8IV[KAQ";UD.E1 M%*0NT1U%PEEKQPBF^ L]VJ": 4N] MO#T;&5?!FIH4-]\>V($?![.;_!QU<\YC.8+J,%MYQ%BVZ[VGEP.>(W M1?,Z 7/KTDDY M4C]C)S\\*G.4:0&U1V&AB"KDQ;UM0E'2J6F/HF7-(*M6UIX-B__[7GTX Q=' MAF60QA05H;$F3" BL#/;U7.6=+.P1[>XFP%&O;SM\L)5$T6L'6(&V< !%CPA M3I3##);4 ^@NK.M?QRF2CO3N'[V'NG'7_-1M>+5.QX-JY1<15\%&,2#\E;D?BQ0J;0<- M]?#X_%3"P6P>*&TOUE@4NZ92WAY9-L\BH MC\]GHZ,LU#%ZGX]O/RT#/X^G!AX:DU'%43RNU)A)BI&GWF_7+7C266Z/8I+M MX*-&1I^?NUY/7PQ&M!$>.PLX, H"(397O?#ZL*:V#4+BWIX?#8B?K\+!$\7 MFYUPX6:F!P34#87.17\WDQ M'$>EM2(X_#Z_C>EOT[Q8SM=%)BKVGZO]'9D0PG&"!&2Q_PR684]E6Y5IDFR7 M'ODX->!B/\):E4!-R-R=/WH*[@[-D$'-,0&K3K=&0@["5[P]^L,07Z%'A9Z-347-XC@Q;$\PTYX$S&&@8\ ^VUX.811=R M/:M1W-3*X;.1LQN]F[4=!DR%H9FV@31*H546 ZZ]@6 ;)X"(7EC3KF;-I?KY M73-JJI6.+QV 0XGZ=D%E@-&5!&DQ[!0W@AKM[TU-?DO'?/H[J1O%9,CL;QQ^+KV%G67S; MOOY(D&O?\QFFDD*@M+"(!Y9QB1Z$])VZD(Z$G4FYJ%\&*==>[O+%JC1\5=@< M&)(!A#ABCEI&C K.#H)Z>X?64YP2'^V;$]DUM*#8;K>DD6 M3&=A!)(2*DBY\!;*[2<8/;#+"O9W7B"N([GU"OVIP,XD\Q9KJ01P3F%BE6?; M*)-"[1;G;*?15/NP.0>Y)PKF'I0=% ;^L+R]'$P-N"+\)L5T_#'X5J65[.RE\G#)\;3X?ANDA\K&)PT;X88(Q90ZX PGEGN M#?0EOY1E287(^[A]U@.>HCL1G+D3SF>+!U -?WL*T_"C;-.8]VJVN:ZS)^2W M[]',&>TH1D!1;K' 'B@,[RGAX++ U)+4BUJ9W@)\Y@]*@NV-N!U\/@N.%298 M&:HX?Z:W_X6#RCCMDSZ0!D$AF,N,!2QFM(5 9K,M9JPAI<2&"V)CP47?._ M+:_OU72\& \FZNYN,AZN* SNP;@8W7>A<]?7P3E9=:49'ZA:E39AYBV!A@AD MN":2RU@ID962(="CRPC,=;-_MBJ:_@+WZ 6OVB!569+A4WJ@=FC]+ON'.-DEC<) MG+>#V_SJ^M$2#[K%>Y_/J+;8(@&QXXA8J#$BJJ2)."TO0TVE"K2HGY7GWVB* MO1TJ-.#8]@A!1@372""K*262E MM(_<9'[P3$9PL%QL3#K'4!(C8IGZ?AG]''P]7@RS"FS9=A(SG P\R2PVD##'/-;?2YQJT>(;:3&M(BDW1DQ#4JG MT_R8U0=^>?DMF(*PK7HJYQ^#B'18WY\'.%3OBS(A.#=2>\4TL<9I;9 O.2J ;/5(L)UD MO'H 5O1(*JW%K7:H ^8S9,F<5#4J82Z> 4$$X M/M;X IX)YD!P6R[#=6P8J\TSOMNM;T<&[:7F>W(+-!'<$^,%\00PI*$4U"KG M.;:\TI%Y3R]2'$O\K.DN@$!< 0L)QYQ@CY'B6F\X**1F*1A1SK!M.=5^, M.$<6[7F%-;1I/_T3/[$-O(*.6*^I0EH(X#V,UP0VO"-47$CLO"O /<-[^R)[ M 7"_;P'9#-P?M)@42DO- 2.(2\BXU"HV25CQ3E(E[:7!O56\U8?VLR66GR>'\XZZ=3>;W'GSM;DD/ MB1+,,\XY1$(#IY5SY5J9 "D'$2_'56T#,[7P_VRLO#-_?%!_/.GUO@\J.Q_. M!(1681Q\>(,95XB1V+]CO=(86KZ,P](>(*4.]I\-E!\]U;<-M[G@P>26QFK' M&>-&!7.DY#C!.L5XZ^$9;8> ?RDB[E5]@T-NXX?%8+:P@1E'??HZ7Y0A%&_! M:0:M@]Y [4M_52%);BP'A&=._<=RN[%? FOVZUS0RB1/F@_@PPU&BAD>6GY M*X-(2KFO7MI(+_L+.%=NO4)_*K SH;&A0L7S6X^M48[%?\I-CX1\XYZWM)AH7S#BB O.<>.H0@AUM.(O9] M!,U/AM7>3)^6Y?$"#H!:/._TL78D4P)Z1V)1!4(\V?(.T NID=(EZ!HY\SQ- M;"\ \BV>>7)L8;!9@ 4&:"0@B1&6->]BEL:%E#SN"&^-G'F>)K$?H>7TN*-B MT'%BC6?",605,Z3C%-0PQ7!$G"@-$( M,$NBLUCR@Q!S(==I>V )=2FV3F'<6N,099DQ '&'5+SR0 6SJN2)4>Q"*CQT MA*.&&H><)K.SQ %,QJ]QW9O^(#&F$B6-8 @"D$UQ@9LLU4T$O)+&K%]"I30JU(N?# M\M,\_]B$&5+M)*-IM-:K1VESF&C<7!*@,"N M7+O"2:6?^@F$%/E5J3%^%E]?P,G)ZTH99.G39U988E3@&T?:8JB #@[SAG-2 MR)3RMCU,-W[91X7G2JV+^%@Y=%T^N('PV.,79,H8+JD-1J@PT JC"=YR1"&: MTKBR1YJU&Q#5%!Q+DEA;.MMN!+U)EE.CT:K*]2$]O&](YA!UFB@KI%#6*N<8 MW%(H?%+$MD?!D$XQ6;,,NM24+F8CSK<5UQM4F4_>E 4KC*)@E#DJ!=2K8LKE M&2<"AJ>4N>JAT_NB=6>:Z#HY*!M\'=\N;]5MK.C5Q#'9P_DSHA7T1G#)A8?* M,\?DUM4T1OVX/=<]E%,$UI85$+S789Z/5DU27\WGRU6._.S#('H.[E_+\>+; M 7O@^. ,219]!\'"YH2#MT"EVU(ME4EIK=G+SM0=6@:U2Z,+)?HQG]V.IP_Z ML32@2)^](PML#NXM,9"9\&VJ8"[I[0%DK(J2@%+V Z6]$%HW%L'LSSP6]U1W M=[/BRV#2!KJ/OS1CU%CJO0<,LFA/<>YIR3GB:(KMP'_ O9]2;,N@V%56=%M. M]+ZYEADLAI]_OU.C?X9G(BL^%AN/MJSW[>:+\>U@$3:O50NN]=W =[/Q\- U MJ1;>GD&GO# &@&"T2280%,Y*P1PF&C)+*E6?WO/UB!]?3\_%V=Z)2M=-"*S" M2!'':=AAH?1,>+X]:7("IMQ;EOV\M]PAT)L74"_T__9B]K"XF8[_G>^R?\Z; M*%/66X"84H$M !EI]7UF#L$ZJ?,J^*&6VQ--+X!Z+BXS[((CS; *_T<%M<1; MS+<9(-*F7,. /X[GFI/$H*7R#K>WXY6%LNH"4:PZ/^33X;C#)BT'UF3'\^&D MF"]G>87Z#2?-$]NB 8XL%L)0:H$403581I"P!G-?K5%VA_RHUMGBE(DR2J65 M"AB&G:;6& D--!9R+Z@Q'%]8Z>Z&T/),0S0H@LY5AE\NPO+?C*?QE.%U/ICG M[P;?5D^N.DR_+:8FQH G,8OGZBZ/*673F]5S]Y5ENBX7TXWV<5H8YZC6RB)# M8N<4P+G$G@O+M/*52"L(YY X,2& M)YS0=NM4]4W_5,9+T:8,VK*4JU"QKK45I'UU[0/_!I/_#'9A(CIWSIDY[ZR MC'+G-;V3S:&H#.06H<\^H39P+=7TX]_%9&,0VEO)\^56>) M8(A6!'LIE8A&Q58*WE_(Y< ^8C1%#OW#9GAK7A\ZM[-EVA/*A5+6>:@=)1YA M6_)%")AR -C#/+C^X?-<2?0.H;Y8SFH#Z':RC"EF**8>!SN+*@@\ :4$A"4H M)9^XA\EMO*P,TL(2OC@(YC$7OG (E3P2&*:TL>YC+ MUC-PGBV'GF$S'9&9(,H[@X7!R@/A# &ZM&P$HCAE#S\]R:Q8#";?$PY/Y'[G MH>P5-?>UV;_3L#14!A)/G>4N&%W.4V(VVYD#BK-*E^:;X+' !RM.H:? M4+U\__!,2(B51= *#8371GA04@^Q(Q=2]JUA9.PM4UX;X\_Y_/<&QQPC74P@"F"?,4;6GRX0^7!:9ZQ5S4S^!& M09/?/%WAP>HU>Y_/G&>$8$TTYP*9X%H0+4J:F$X*._0(-#7)M:B?HV??T3"# MVT^S\>@F?S.8SP?#S\N ^J/-?@^,R4BPS!2BSDD L76(4%=R 3F 4W*\^X:$ M=-D5S7#U;#2\+69_%<7H!"SL'Y$Q1SAE5C%GI#.:(()5N>9 0$JLIT='.0T@ MH3:>=N,:;[;.UQ7*$QT>F$G$J=82>&D$9S2&K'!)K0 ^I6%#CQ#4J"G2"*=; MO&(=EKWX]F'YZ9]YS(2]FJDOP;N-G(C9L(]H>KN,7\C5]>_3\>(0YLZ?-+,: M862Y9SBX%$A3">56"QM++SJ!XGS(/+]LW0[_VT*IFN6#6"QL,''S:!R6!![ MX+XAF8>*.Z4Q%4AJ&UA+M2LIA-RF6$\]U'@-(:PF[G846'X?&!>;/$X#^O,3 MTA0?C\L819X3*"S@! >S07%/MM^*%Q?6\+4A)-7)XK.-\M?QWEJ^6R\^J?6S MMUG**7-DP5M51DO+N";<0J8PBF78,#686LQ2(D"]SR%(AD[3[&Y+*^TB(> _ M_VM]H?Z 7CHR,F,D7D.0F&DAF A40\/7]#+,#4XI)=;['(#:-%.]3.[\%&MW M-ZSO]##+(&(-)LH1PZFP08*84ZB)@ I 2"K=)VCZ,.ME-.Q5"$AJN-<.^? G M'A2J*3F)M+R06MH-HZRY_KVGB:>] A(OH7^OP?%&N!8ZEC*@/K!1V))WG%Q: MH\8N0-=(_][3Q/8"(-]B_UX7[R,P9+TQD&+$41#@AG>0!F/ILB#?,MX:Z=][ MFL3.]I##"N;%=#")-3/>O'^K5I=W9W\,AL-@9\_?F3^J]%A]D\^&?W[X/)C= M19J+S[>Y*69WAT^_&G]QYA4BTL# 0(0)]TPJIDH.&D=2>B]<%N;/05W18U&V M5LQE<#=>K,DVQ7PQC['V6#QR)*Z+<+/_KWB@OY6AE:O M9N%/,9Q_Q/9IX&V9YI@[2[W 4@(C&3:$;?B*@ $7=F6P!Y90]T)L\0 RKG#O M)K#SN8SBX%9Q1)4 0'"NK4&^I$4K?R')4+U P_.SQ;/ET)3U4:G%Y2ES9%A" MY[C1V@M%@@./K2[W-Z0\2*J4U3]\G2G3$_;V%.Z^ _M=5M]P@S04$OF!2"$ M$H&1MJ5L,-8\1>_U\,BQ!QMQ!U([6TN^G/8@@C$ N2)>0$^)PMZ4WS\F7K5: MS>?%5&^M#*)F&H2<)++.#[M6'_WW=JC%@_L;+QDS07C0=;&]-$,(A%V;JK#3 M=E@X[%Z1/[H3&),]!I/R9N"SS+2U%*M4,ZQE_HP+9@&VPB.H*94QHD+=(L9Y%=E>'RY/D,$N8-]HY#'/Z-I'18E;19GE1NI8>H.5>P._&1QLKV MHO?S:#['_\1&95\&D]66N3"#V>Q;V+#^&$P.EJ2H-#[C1B$*@55.*F6HD4BQ M#>W.$7UA :=$^3\+EM?/X=:4T(-[&;$;WH=\N)R-8T#7YI\6]W_;\.J0>CIM MIHQ"(Z0FQGD+O=,26"Y*?@ A4F[:]/!,IU[$-8IFBKGIX8Z)I8-7!X_9.B/.[P7BT MN144-OI5?/(1APZ>&Q\=G1D- +%8<>JPE1)( 4HSUC,"R65=EZ@76_7SM\7S MOL5L/ R?0;0PSF#-NU8")_OFOKTMIL/:/+C[ MR3+' U.TYQ12@17"R-WOV,:)%'SUUHE+CSXUS>>VBW>\FPS"]S8=Q>C'ZH#W M\*WV0\,R(8B"$NO 52H@=IH;MZ8T*%_*4@)1O77@DA%5(T>[L7XJZ:=]0[+P M.6A@J1 .K"(;6 );4JB93#DX[:UOEHR9FKC96@F->[.^$EAV/I]AS!VB1'*G M-?&(\F#FE;11[%+N%_76TTI&2AVL;-=,/FH?9TPKHC$TVC'K!($6&U:NWH.D M;>9TMZDEP[BF8[,3>==:-8M-<]M@.(4=\,.B&/[YN9@$BH4 MF=4"$:@H\P(:;(1 ?,L!;CV[++.WT:/ZAGC> >JJG^3O'Q2^+:-9[,ALC MV M/0]N)M]0"36W%U9_KG[A[T=7&J?;/M!X-_@6/<3JYQ>/!V3(>&<\M PIRWGP M "PN=V?H5)*&ZC>.SA;SGC.+)+ZVB)K9,DCC&1L. V?WF(P2IQPE@'+O/ Z. MHRQ/BP/A E_8[M8,=FIA;6LI1ILD_'B_V2SGB^(VGY6+_W8<256&9XR'3X8S M!S72% LJO2,;RH-F!RF1PA[&=1H 50-<;M5W/TDY[1F1"8^)U\@Y!($+]J4! M6I7T:0 N[!2^ 135P]CNK.N3K.H,0D-B]--Z!R"3U&DA2ZJ !>W6(6S48688 Q#J4OZK=4I[8'[;1TUXZ$UP_:V8&FDIC(T#K$9>GWTS>G6I M;!,[F][V$UFAM7,[5QN@/;NII1G3E,HZ7'I X? M17 Q#81E\ )[(5.43P_/S-J,39_(VO:,ZKU7M \:TGM'92 (6%;YE9Z#P!AVV1=CT'X?IH!I@4"@@(?>!13"B'MHP_$"N\N*RP3P,P2>1H:T>I MH]$JL256AQF/7DTWM2\/':3N'I$!PRFGT&AD%87 46=+1A$"D[:F'L9Q&D!, M/8QM\0Q^>;M<76M<^8(![T%&GV,CJ"_YJ^FPN,U?%_/YVWQQ=?UQ\/7PR?PI M,V4H>)2246TXPDAA12@&)3^X!RD!PQX&A9H 6J,,;R^C?C$83_.1&\RFP0V8 M/Z#*YM?CX?AP;OVQP1DB3%$II E_ %CIV&B@I!JPI)YQ/0P8-0"SVGG,T^R;(!%4R M;(H SHPL\HI!UCT,)4UTDM"W)I:J8-YEH*O7L9\6L-7(J>[Q-6K^7QY,J;6@S)" M3=BD8[/I+"YWB:6KY6*^&$Q'P1D\$5 / M1F:!+(L$@TP 9ACVP".QHE<%+X.*E&X&O0S_M(RJ\UG=P;'&&;96A=$9QI1C MS()#H2%62!&X4L^1GXP:?G&AGP8A5C^[.X#9"2;6@5&99,J'C1XC2;FCBBC" M:$DG!$G5&'I8NZPM6"6RN3,X';6L]HS(F""8$@VL",8BPA)[5?*,*9!4 J^' M247MPN@L%G<&H6H&U:%A&6.(L MZ[!O4ZP_'9;[;E9\&0?^ZF^_!^&\FFZ;]:CA8OQE'<(^SH/3)\LL9-*8H.JX MX22@E'FK2\X@)B^L'7T]("E:YGI;FTT@Y#X5X##,[I_+7+#?O:;&!XU)M1B?"I:PE+SN*T++8>QL!;!' /I-5:_DBT_O1@95C=QCKM M^RX_'AZ0<0RI4T IISDP-.Q(N/S*/?+PPKJN=PN0IQDH=4BDO5O909;!E8E+ M#'^>Y"MA3T .H9LV5.<<2H!=Q:P>,U M0\]8R9<8X&GE#%*N<3O-;Z*'_?'[@F_S4FL+S;\-QM/(NZMI+&-_=?VH#/FV M!OD! %>;()/2(RX1A,Q Z2PQ(-:<65-O!&PGP?V[QFPC@FI/Z0YGL=:#S=?_ M?<"BS962"LY5]4EB+2V%B C6D"2<>W@\5;3X+>P9DR+*'WDEKDHQ\(J(3A\Y,& M!+9KCG3*19P>)HIV@L(Z!7 24I=(0BQ:37 MA&P^+(B93TED[V&J:(- :HKE'<8$HUFYY<^Y6^C>63*!*.':*"B)%4HR#O26 M#S&#ZK(22SO1874QO\64LHJ!T5K2&C-*L>!$*^6"#XEY5.JE61' M0:'=9+1F9- Q$M='E34EVAZ8+ M; Z-4,6TDL!1ZQQ$JN0*=N+CJ>NTEVM;' M]=9NR@Z^;4Z3U/!?R_$L/]PO_0 03YPI4Y@B@S&60&NO&=;8;'<)9-1E'HPT MB9NGUVL;E4=[-[F+89Z/YCZP\LU@L5GP*ESY;5N*>3"9S*^N]]-W"+5US)\9 M+;Q!&EIEN0.<. DV5A5$+DCMLC1JFR#N0#Q=0'N=Z'&^[CUQJLP:9ZED%!*E M@Q6&J'.E/(*@<(I_U,/B&!T!M@%)=&86/,I!"A]=E82SZI-DT>)'!".A,!%" M: 'X]@N%@3D7F736I3%0ERCZYS/5XBMEEC/)5/!//2#<&.:H B47 O-3@N ] M;&;8(A(;DT''2-SVMJK#>S\P60:Q4=9ZP;!DGE%B)"U/X1$RX,*V[C:]]_JX MWH4)&8M'Q,J<5]?O\U&>WZX:J1?ALYHMQN&/CZLM5;0E3YHS0UA;)1E&FE/( M=6 0+%4"YCJI@E\/;XPU":(#1F63(NG$\UD59PI62%4O_7Y 1I2SA"A&A0LV MBE<,,%U29[%.484OQ^UN&G!G\_OL@^GW^?CVTS*P:*, M(5D@08BGA)-B[Y8$!5AQ?6!N1%A#5BAS.1EKI%@77_%1L51B:B6":D+AZ M(8DV7FHL?$D%D_XRKU*U!:KZ!= _#Z(6SR$CP K%M0%*>J.BHP:W7 B_J%1R MZ,7[LDULDXW)H+6:;F'U\7\Q^O-E,,E75Q4"4\;#H"KB+]1T]/@'#YY\E\_& MQ>AY8LAPLHQ%Q]S7X>?!]"9_']2.N[[.#_K![2XDDT(*) D0U!-IN,5N>^V" M>(?:"3>VV".E 1^ZUQ)[$=]/4Y]#AIREVD,&G68P^'Z>ZC*"2Y"7K5Z)O5M) M.B!PMOC.,'ZB&+YOR&)@J;=&0(L8X" P*1CY&UY)3'6;.>=KR+KIZ'L#[&E" M:!.PD3MOB^DP_/'^H& ZVF%HQ7(>DV*^G.45HN^I4V?!H0C&HC7^B(U3 M]X4+*@[/G&&("(2LA@Q 9B$26VJX!2F*L( M+&/=\(I(/'6*C#L.PA=M(*$B4"UB6\P-!ZAE[,)Z,K6.QH;E<;:N6\738G_" M5[=WL^++NB#WLQ5MH[I[E=ZI\V0"*J@D!4IQX@B4@4I1TJWB)OT-8U2B% M>QQUVX3@87?RA\7(NVQ&L"[V%5.?G_=./ZT_0969,JRX]T"(V'.2RAC1$$H& M[Q-G:2(NYHU)+@X5SA"GN!"CI$9*SR[*Q&Y/VP1KQI_&X M+=MY=6=U!_%QR6']5]J@0:B+Q6S\:;F(^34?BW6CXPK?5DUOR(PP M#E,(G*742J"H5++DGR/ZPFZ4M(71;J33-;I_G\[RP21V)_L_P>P+N_.# J/; MRPAJ-IZ'7]GPU^G-^GRFY,@9<$]]9::HHYI"'LP#9)&AWD-3.RXG?1LAB[_E B9>_SX60PGX^OQ\,U<+855V/"DKHRKS;W>*ZN[UF0\*4D MOS/C88M5EG@B+1;<8* UVGV\SPZA1^[T^CO< U6^FY?A7;7K6,4O!$CI!9?60>LX XYY" )OG0FL MADY4XNW+\:D:0U[#OM/IDNJ)+ML4X"JFW<7(UYS?+JI:IY%=(S( (;?.28RU MTI!SH04,V'"2<\J)JE3WN6'=_/%(<>O'#V;"2*R\MP)0H*P.7Y2S&XK"S^R% M998DR_5I2[X49IYIQLYGBP>P"']["HGPHWA5;[0<+JYF'_+9E_$P5U_'NTY" M]CV:4*!,?*2:&UHEX#LEE[L%)L2H"QGT!(D5_1 M%%_KP,27_,$J8O%Q=7T]GHR#3JP,D&-39 8(33C"U FDK0=6N,T.*Z "23G1 M/3JY;!8M-3.YK3#:;V'-^U7-CJ>RX&0Q21V3S#KE&(*"N T=" *>LL?T*.&O M7K"D\[$M/&RMK>!JYJ_"'P_EZ#Q_.)/QM!!PK"GF&'/K?:!P0Q66*B51IT>J MI";;M#8^MH6.]_F7?+JL5";KZ:,9#?K/,TL1-]!B(1BEH*3( W2I*5QGB+2H ME9-M8Z,")K)8HY!+ YDAQCCOD39VJ_LXN;!4D?,%N <))_*OM0/GLIS_IA== M%36Q=TR&(43!OM9&.@,%!YZ8C:DM,(2='U1%TO;4QSS/+PK7G2U M >"38E74=+/X@]KDP+A,$H:5Y5;CL"L[@KB7Y3>&G?8IC=EZJ&)JD/DS75,? M=UMS9O)I8,,D+%F-;L?3<61!],R.8^G(R,Q;CQ%S\8.DEFOD / EO3AX=I>E MC.I'4[W\[6Q#.V4CRS# )&AO !T+RAM3R&'I\.- 9THIL1[FD]2/F52.MHZ2 M2O=:=CR=F4"+"D8AXLHCAPQQM P%8"+,I68>U6CJG,W,MD"ROM(7J5XO]=4T MJ/'PDX/GW+N'9"CH26^HX=X*SCS#T1G84$A94G&X'MZ-K!$N-7&TU03>M\6T M>(SRX];,X8'!>^1(8TNL=( R3+D38D,M(;^Z/RZF&U2H#X.ON;S-^-I,1LOOI7?1S#;'L\22Q MOKW) M%Y]C2;CRHSK2";2M5628Q415@214G""%(!)E=(1(#5+NCI_>#?DE;:?]%5*[ M'TN@;/--Z^"W7._LJ7QD1&8P\51 ;:7&P"LF(-%;^I2[L$[*M8,PE:%M >:\ MZ^R8028A!GVUACO!*4^.%;.,@FWWQGS,,62AST\Q:D1=ZTPO">W6%9$;?3SVMVP MP6([AYK!=WVA6\_>,SIS3"EBLO T8P]YTY, MI7$9)YX$J\Q1"RV1,%AI1I:T(@,N%48G"GH?7FI@:6L6[^.E[KTU<_#Y3"LJ M#(.&BT>3WW<]GEE$(9,: M*VX)\A9ZA$E)&6'LPM*+$J7[K%5A,D-;K#)2!@".XN39LQFGV!C'(4>6:<\@ M9WI+$P7DPBH"U@N25&ZVA1 U&HVC; :36.[[U713&/PH6@Z.RRPQAE(CH$;, M6J@ITFI#*X6!H:UFA+PPY-3)V=90-!PN;Y>3Z-GN*TYQ'%%5Y\@08AX!8F-C MSIC$:0#9\B!X_RGV<0\32&I&5T-<;B_;>A'(ST=E8/(HK'8/R"A#@G 0.R0J M3 53FHN2.@U@2C^^'B:1U(NA6ECZ4FX$(LI H =PSA@ER%#':4D5UCP%*#TT M@NIVQL_E8XL)$T\:0CX/9;TO)A-?S/X:S X=$9PX4P8P01)"+HFU5$+O"$/W M_" I*?D]],!2 /$\P:)!1K>FEF+0?_[@*..05GKZ; 8TET@CA;@1A!%HD2]] M"<8,;S7DTU:_S<;D_E1W)7*[O8WM*?4'-[:G#V="R\ (:CC7E'M(=?@.2ZJ0 M-2G9%B=O;!>'H51VMQ8@6CL#\2K3JNOQU?7;_*_@(Q3+F#QY\VXVG@['=Y/ MJ'6IP*MK-2KNHK@/19+.GC1S7!#JPT8 M A\HHP[6'))29QB;?4P<- 6'%L3 M2*NZ+_93S$'R&F: 8NZ_Y;#C>W7;X_,DR#0D..P!UD%A/#(=\NQ%P"5'*1>C3K]%<.B+K M$T0?U&)-Z-P_5X:$E$ (S@,''(RG?UIO>>)I2NYZ#R_C]$%=UB&']M)&R@9C M\X_%GHR%U1?W:;#*?+^-=R%7.'B?!V;.QXM\4Y-TS8#W^;"XF:YF6?'B8.9) MLZ_.*.,0QYX7"GA+HIQ%>3 1?L92G/H^WA9J"_H]DUNK53!ZV<8."@V\EH#J MU649C)@NXR5":9[4G.?D4Z0O^>Q3<2%(;U(4FOU-L-$6*E2#A/AR<YM[[IB M-G@1UR(KPW?NK33"$(XAE#8@ F#)'??5VGDW=-5I\*T45.DX#Z;#W!3S@]6Z M#@W+"'=888>U9!A9+9VB.%)+C)14TTN]+EA:J/T>TH!)O/A[/Q*L9R M=:V7\_$TGW?7//)J=C.8CO^](N1>0T5,34?O'A!Y=>W'T\#8OK(?_L>#Z<%//E+/\81*[#"O]L MBI4[7I7%W'M/PW<7JZ?8V$J:Z9*K%*9%F?JGAEI&XE.'O%OAM:3:BN%RU7AT M&JS,Q:JFX74QNQT\3-8[0UVZ"T'-%+EL9D/]B=T2$-.(!02@95Y&EDK MM,:J4G777=IF7JJ;>3[\VTWQY==1/EYKFO"'IPHF_&B[VH_A13LH>OI()H.] MC 1CL=$\,F&I5.+-PHT(;+R,#[H!01:U,+2:4WHR"E18SB@NR4\&NP(8SY[) M/ YVDX>>$XH"8Y5'7)7+-AJFM+?M4<"K61RD<+0A()2TOBO]>!LVB"-ZX=&S M&5:"4*N)U";L$UP (T!)!K1)UW^_:<78]FRDJ, M 76,,VU0,*,8D1LBK(5)ETQ[E&S;+$1J8&RCZ#"!Z-E@\BIX=%__;[[KB&3O MLQDB",*P>RIBD3<4.!%LJPT9WOL+R8EM Q]IG&T((&8YFSW:!P^;K?L>SV"P MLR%"4@5MZ*G2F* M,;SV[&TYO?9L5?B\\QN6DP M/0R1G2.R8&D[ A5CBACL#:*0^)(D!8!.@$J?DBO;P$H=#&X6,U\_!H-IODK1 M7)O6AP'S[/%,0"0=T$$M0F8%8,'!+XUPBR1.*I+RW015:^)NHU#Y<#N83)Z> MQ^Y$R:,G,VBLP0K@0 ?2P;>/]]LV)+CPXZ0*^]]-M#6=LE-*ND%%8; MF!FK <;.PO_?WKLVMXTKZ\+?WU^#^^7+J<)U3JHR<2J7M>J<+RC%IFVM94L^ MDIQ)]J]_ 4FT9=F2*)$$*3I[S\Q*;!($NI]N= -]$8)C!J1*G7O+!>I:&='' MQQ>>-W(:I'.>J]*G6]X/D[CXQQ?-_[('@6QTE;/%CR6/EL$Y7XO+QUE4UT65 M2(_J@P2LO+:I*X?#D!(@):+.$RHU(5PA5LGG;YT2'R;K9?P]FOVW6(;'OUK0 MY,H4LU2),&YL"6IJ/B^.#>MHZY/!TVBBBQ13*P6UWBJ(F);>6+;,@+JX?B;(,RGT M[]0),]'^<73W]VB1?OS;IA*>=^]'Z2D0G2&L,7'*4!SK:)-Q:4UK?J6EO&#_8>+4&C>+!3: W]V#!Z<4Q<@2 M&4E&B4O-K2%2W $.A&-B8$TN,B'L1%PWQJ:^@5M=1];&=7V[G4T?;V[]^.=R MB?.F<5[I.T%XZ1G /%HSAJ;ZVX *;SQBDB)#1)WCU1X=AYP'Y-O@6%?H3RO; MV TW5Y!Z,.Y+QCEVJ&B01T,<"JJ! Y02J:%0VBA#-*',VCJ!M,7;H? M&&Z8*7U3TD\N4H.&\ZLQ P7 VRC/6B)(/1-2&1S_BK"EQ"-8Q][HH?+MD=%< MEQ5]@^L+8^EI<4T;RT\#!RBI<5 C+Z2CADCE)8F$@LA:HHBJ4Y/QC WE&JAJ MPD@^E3U] _,N,ZA)7!_\1D!*6+@-2,+^"3%!KTK]4&ZAXW&2CZQ0W5-3A#>B6&[:% MP72/,YX\3A_GWR>S8G27/+14_^GS=!76 ]'?\8G;^<7LXW1R4\P^/::^;!?7 MY>_W>>DM?SDX(SS2Q%@?G4@&J2) ,1I%Q5E*G7V_]Z&5P3CM,\-R;C$JO(*J2X441I-K VU+7Q-.T-*W*!>FU-I?])F\7/*--QRG\7Z;Q@#TCW MO1:XDLP1:($"AG(J! %(2<@M,PQR.)!2:=V"9+L%;'/\R(:\8K98&NF+1!-; M/"2'Y3#P=K\5B.(HQ2(0KPR5RBC,%050&BP90W8@I=GZA;O&V)$+=M^_?DNE MTQ]G&V;Q0=3M?BEH*WBZR>202BJXT\@"":P5T0:*%,Q[4_<^0-<8-PYC;D>9 MU.]?_YK^+&:3I85Q4\3UK7*2IK.'Z2S*PDNC>2>\3AXK6(^C#0,M,A)3@Y@T M"FFK2&HE@S2J$]+3HSIRO4!=+B9EUB[<:MNU5T^_4R M#KK%1XT3C#*&\;V,%?TP#9A;\62)\=AA\F#X^+ M^9(HZ*#=M^>M8*.!@:$#@%M.@4D=W20T%C!$A,!L8"$/+6%@%])JTSL7KO3H M+K5$^7I;%(N/B<>)D_OWSUVOI%MJS TST(MHG&B6*K)$4?5<0NB=KV/4]="5 M:'/';(C$78+HX(:X^Z6@G(>. L^(I-$+DI)I2B4#S"+K/*A3][.'JJD^LRN@ MYR3*GOKPK+JYW!VM]'$^*#XOB?I_!?-0X 49Z,D,\PP900*+G 8QC6G(/F%.UPC-Z M>#3:IA7=)MW?0Z4#RH!5@- H[XQ:&G=\P F&EB-D") LJQG>>A)72VBI6]G@ M.";T!);/,;I_S:;SCO^(^HHOKZ2R*]J_3L5IM_$"M]IIX9RUUE+%DI%)O M,4::8:Q-I69]YV/A]0+ K7"F[ZA.@>AMHOK%^$%'*QIP";%EF&I+I(0&26\= M5 (+6BHGA0W:;[?WCFXZS"H'RGBSW\[ K^[A@C* N,% T@X1PV& M4=B1@2QN95(@)NO<+?30ANT&FPT1O[N,F*5Q_W[R6%(O: 8T[)[SJC.Y\"X-(A9223Q@CH4T\O9(75D!"&$'&P.P5@Q_/1S?3[ > .^7*UP+U70:^,@>W4[>9(?:(Y.I\M-@ 5 M_[8-IOBC\/?H/]-9N>CYCE"ZMQ\,%BC)4+1%D(S6-85>$UZN(OYW8"&9S3!T MVB!%V\1%ZLN=.N!L3'%GB-S>YP-0#&"!O>0<(JR9CD*T7A/6L%97[!ZAI"Y# MI\V3\N00%3V.W[P:7X[NU-7/%%UQ]262/P4<1__(IB#AZ<,R,^=Q$3WOZ+CL MCUHY<;B@L>+1Y''0Z:AT)8]ZMZ0=!L32X0"G 8Y/LQ/\9'A]NRWT^.XN=1PK MXM-7H[]2.JN?/L8_)C[M1U.UMP/"Q&.K)27&(F2I .B)<%$?U\D3[=$Q1@O@ M:86^)V/%1CI/YL4VCC_/IO\I+A?S96[@ ?5SQ!!!(ZZDUSI.Q#O"D3.&E:NB MT?,:1NQ<"ZAIC\AM&CEQ>E>/EXN+V2K+M=AC_K[U:! P.OO.(B-\_*,F#*(G MA>F%K .7'BF9U@S@!FB: 1W/6=#%[FI">Y\/:1_5ACMN/ %.6BD)*M?$-!J0 M)5./I:^Q49N8N:YRED=C!U- -IX* "/KF( .*$6$H9Y!O%X'P5(/Y+BE(5Y. MFZ)COARAA_%B%6V3@B/G%]??)P^SZ<_B*E+C(95Q*>;NU^7=XU5QEJM(01#J"WG^(FN5-6RH'MD"[6RN?6' M+;G@OI[A007XXKG@O(40&"&T%E0[(K0JQ3^N3F1->FL?8IVB8=H<'TYVYCY, MQHOQZ$Z/HJ/PSVAVM=]O>_OIH*+CZ92"T7V(C@EEB,%2%BETL-*=S/E@YD0^ M39NFX^D)D>N[E8N'92.$ TF0;ST<)/'&1-(QQZE U#MC53E3B=S FDTUP/$F MR%A7R ]M"#N?39FZ*E6G=B4HG=;SX<'.5<("8DMDPB8QA@NIPI,V!@"80-\+L),N:R"W>8U1\KI*$> M>C40C0F"3*>.(I2IE*#SI-"4JA:=<3[ :<5!:9C&)ZN1C6",58S1WZ-?X_O' M^Z7!LDN=['TI:(J1P0@IAZ)X680A*8^Q6;28!^9;-,?(:4L4;@X;97>M+3/' M_2IFE^-Y41TOAP8*U#+ L=%.6<*1B,J:F'*%"JN!]9G*A*&&J=XZKNK"*2 4 M=V"/6=3(WCH>_T'E?1=#KI;_TD.#MEL4'4GLYL"SKB_C'R=7X\F-&3V,+L>+ MWY6Q\_;K02KL,%3>[K17%D' 9.R#*#FT56M.VCX64G"M8GG]PA7F=ZW3^CF#6))'S)"5]F,0_ID(6 MG2;GK^<0^7)Y-TT5FRMEX^]\*P"K)#1$""D(I5%^M97*6A/M$V04J70JFFVM MU9*2=[\6C'<02N*0)3@"C$N#J-1,"0-PRK<=UF%-(WQ_E67<&'FSBVW7"87- M2Z]C44M*0>.>*P!$TG'OEGH2&^0T[S!Q\%/QC[J\G#ZF+L8WGV?32?SCY:J\ M_,7,W(XF-\6'R>83X\GE^.%P>]A:XP8$E?9, 9O"C0D3$"I>TDOKH?6/: 0Y MT^[HGZT$U-5_'M>5$_QTMF>%!Z+CCAHG4.@L4P2E0%7B -=T?0Z #5:*#:Q\ M2R;<;!>':I$CN="96E]=7*NKZI*5]CP<."(381K8AP2@!'EA?KDP@,9# M\):YOMU%MCZALRFXI_5_78PF5Z/9U?S[P]5H4<3G"9 ',57I_: QI])%9Q"J M2 5$E8SFY7KMW*F!1\6(K3JJ*1F=X_3"<5=LN][P4K MN=;1.Y%.&\T,AEQ$2EKN@/!*N(&5A^IF=VR2 [G0MC75@^UTWGP^.(.MP))8 M2"+1%(8D6;]I;1(Z80964:(A/D^;IVR^VXGH^4^**S>:I2N5PSUTWGXA2 B0 M(9!%BP$[H!ABC"]7!P&@8&BXJ:8FTO9(F77S/TV^I6N\!;SU)AQA8(4[IO2ZO<% MRQY^.QK!*X]IE&AMD:*"JCQ*,GHN*;1A\GG8C:>7CV[6_MN;T\>-%@=7;:H)I@!7$-@/ =B MM;-%[0%Q';5ZM,^1HS=>=YC-QJ3<6G5]/UY!@ZZ?#!1%N72:6F-25?KX_REQ M9DU"9^K$$_2W;47WVO(T\F<^L)M_*2Z+\<]DQWPJ%NMXPL/G=&^^%@B$3F)L MG?564:E]=/3*E:;:LEEB/%\";: 8:Y -G5F%RTXNQQB"RQ<"QM(1X)Q$2%!# M-10I0<@J*6TD8ZV>!-5#0=^?-JO%A3QQ&)]2W\SY/.[G7V\C53L+PBB/'\J) M5(C V/5*B$:(CQZE8C3N'M!SI1&C ".M?>F6FF=/*NL$CFU\YW@B4(,.1-7 MAJCP6'/G"$8"(B$Y)G4:QO7QV*LVN[=/2ALB;">"FMHM7J9ZGN.[QZA-MWZK M%HO9^,?CLGWMMZF9WM]/)U\7<6FWT[LXM\]W5717&?Z/"YY-:2$';\55IUGCABL-I#A+QE MFD!&M;!.E1N'%M&C&5: 5N-V7AZRYX+EOXOQS6VY!Y6D#!J0=\4A)R*#VDA@@3:D<-%2X3J'T'EJ.K6-HV@%3>J)) M3]>8T:X1QF(.$#,P;E/6<YU;U![$2D+E*=X\M1:\_-ZF?+,97 MB1/CGQM-Y%\P;7K_\+A8,^W5H>Z!Q,5F/Q2\5E@@KS6,*IMS!I599ZTHS308 M6B1J;6#M;/7= 3>R11'46YK^_?8 A[(@V_MJP$)PFYJ&>1=);A!T#I9TMLC6 M*7'60]1W!=+M<(;>,+1;P4FMK [FFQQZ-2AH'>8""*"HP9XZ3TLN&..'5E>^ M%]BIA.>3693_3-Q,)S]3&X=79ZL5TEHJCA&XQ)I*DZ*#)1=196B4XN*LL=(Q M[H:6,=P8)':>@C=+\&Q>\OW#W?1W42QG>E$M WWG.P$P*C607E/*.. 6 /U$ M10MIG>BP7@98MP:KIDB<3W=%>WU\N:BNI]YX/C -#220>N$DL1HYPM=18"4BTBGXE/_+%"?F=3GPA>(IC M@6 *$8:*244I54)I[YV!WE(3_\KJW/CUT!IL$M^T#W O=8;KH& M'CLQ6H\9V0#W/,MTA7!Q_6TVFLRCE$9V'XR..?QR !19*7UJ38 P=EPY5,JZ M4*!6%\M>0_!D[F_CJ6D2YP+6A\\7!Z_UGIX)<9K2:HZT)4H!;5&T"\LU,*WJ M7.'U$28-,G6[H<^)),VF;\KBQ>9N-)]7W.!VO1-2 @IV0$ !D*/60ZG=>HT2 M&CNPLN+]V. :8D:VJI0;TSRXH;U^." 1:1-7D*(GI'"4*8G+5:4K\(%IIOK< MW:X-69>DV8#RG.5S<.-Z]6Q 3 K,'8D+HT!1+1C1Y9JXX0/;P.HP]57GR'JD M[-0S^U@A?F3_BT$XK1B2F$GEA>>$6BK*U:I(N&%%P?5C"VN2(QVHI^6AXEP] M1L+-QO^S-[EUSUL!KKYH$S@6D;\7] MPW06Z; 2J2/ =.#-(%)XBL(8:Z*80MXH5)H(BCI5IQUKKZWQ1@'5+)$[T$Z? M1[.+V=*.O$JEZXOM$J'[M=2NMX,DW@%"&*,V+=Q;KTMEKY"2 TO#;U];-43H M7 ![F61SA-+:_V+P&@C!C7, >V81T4B7.EHI:_*4T3YW6#5*XVX0=8+6JC9 M@$QBC#SC%",K(/30ZB=YLM6J"M>NH3TLA#5$ZR[N6#:+[,P_S.>/1?1]-HY_ M*]ZV'!HF,"V,HE)(;Q&,?K1'X$F+"V3K&/?LW:"N18IW@+W/L_%E%;VVZY6 MJ&?8.&X @@!S286SZQ7JZ(+7V2OY>\14'>IV@!\SG42"%+,E[U;-,(JKB^.5 MU^%Q G>(&B*C1\,8UO%?9TU)"Z!1G3U3O$>D-4[RP_"[GTU&"502X#6DTD_" MY]'O52>-Z^^3.*%_4K3NY":%\RU[K+R!H"JO!6R\MQ821)B(-!$,$%_.WDE5 MYY9&#AXP+5 XFQ'_-.LE#=*^G#KDF>G\32Q5>2UPZJA-QW8M/,RAX[_AQU?W&] M.:$OQ5WRQ9>2O:3PCS3E4OXKQ)K7&S@H3%-Y H\(8C1N4XH3'+TO'$UI)P7O ML!YEY87IS85523RI.7*(6[CW4>DZ:1BU!@LGD7#0:.^!H7Y@M95S 6R[H5M6 M)G6IDSZ-9K-E!]BN\UOZJJ.$)=AH30#UTCC',6*(2^RY4)XR6BG?LR47_RF5 M\AF*FPM4D;.3FU4#1/W[%5S5/Z/95?5RN36_$9A61"!@D+4& AHE!*H5'36@ M3-<)^1R>WJH,NIW9M7G9EZ_D KP,$;+N/IQ,_-XP.QA6_?#!8ARQRFC&A(&..*JSYTVH('%@USM,8 MN0,-)U'PY-/*C8*,:G+U87(9EQMMG#29!(F=<<+57PY.6PZE$501+^*"+$:E M>$!C]<#L\%/9.&V9KBXQ*A1IW M6UOGJJR'".G>+*E#_6R7MB?3YGEUDZO*UDT;GPL6>@H\C%SQVCJK@ 5@35FD M :EU$-X_7)^(JFVWK7M&Y(+X"S5_7 WS]28 A22,.D4DM(1"H16GZW5A@N3 M#A*ZA<:^>N[?W:6]1[H96"DNKH:IU=&=T<$Y[?XU4 ]<)1%/X$S0!)3E3 EG3VH=Y/> M0]'(",RF9*)Q)IZ-L.04D5=5NJAU:$_8\&HR;IS M$X>RB[N?SOZ*[^Z[C&WKDT%9"C1"Z7*,$BV\! J6%&:(USF:[Z-!=?["49.# M^>H>K4,@BRO[.!M/;CX7L_'T:K6(C1/MN?M5S"['\_U[PM&#!:41$50[YHD0 M'!-A/5M3A5!+2 U<'YWGF"6FM4-DM\V=WNOUK?7-/TQ6)/@V78SN/DP6D2CS M\>4R=:\-'7_$YX-5!#!KE=(6.A+_ /03Y3&S=6H6]#$[\PSU?7O<[%CW+Z?< MD.K?/59@$&@M.8'2 *$U4\Y[+IE4%D=VN3IUQ_N8"=H[O=\8:[(?K1>SG^/+ MXFV*?IJN2C&MCH?G2V'<_'V*3/LT7?R?8O&EN)S>3 YXN:U],R@D"2,88FNI MUH# 5"!^K1(LPG7JAO0Q:;4[^/>%A6SI+]FTWDKD3J[OQ:D(*EAF:"6:&8 T]2P-5VE\;1.-:6CKV%[?2+? M3T&IS])W<_6DA-/6*6:DX!9C9Q$MJ2)HK0X*U:]4Y0KHD^(FV2K?^NLWMH3V MMMEV+GH_$O*Z&"\>9\\7"2WJ_3>^%J@4PBIG.-9>&($B#TL62B)=G;CCZC>Q M[UT<.N?KNRWLZN' HWN?HC*/E8>H9B M\N]B?'.;#F2C43VZ*+ *W6 B )&-3<4TLP+<\RM?6^3BS4T,_<.A?% MSF!P-N+X*D2R*XD\:B)!6 . L1 ZY3U(;465*+FA3*U6%4-*N3A#D6P3!V%MH_-L=Z19+:+A-[(YF#\ MR!0;[HQGVD8G @")HIIEAQ.3^.7L[21+>C M1>%'X]DR+V)_^%Z7TPG4D^BJVZCK"!#"X6B.E ?5AG-3)TV^AV9IYB/1,^)L MZW)TO%IXO;RZPM/$'(+52#'D/96 $^,4L=*7=+669&THWO9AYWD ^!1IZP * MYV(O[CUBJB24'U_ MATZ/\NV"Q\\D:(&P @2@"%[#L 4*/=%8"9,GZ+%UZ_&LQ.T\H-"9N!T^$LHG M<*?,)6 )A0-&:2$$EM'D8$P_J37"ZO1M[-%IY?L3N0Q@^./C537L$2> 1K)Z M[B(Y$5.(@S5=G4"BCB'9LX/(]R=H+0+A7#R\YU*DSP=B55*U6_UN5&8 $RDM MB?:",R2:[K \F'98XSH'*SW:V;@B?[91U.YFK9R@I'5TU5YQ!0(A!+ C01(FH M0[W13TFL#D TL%2 P4M5@[SN^B3PC>5D/P.L-(?@A4;.&<-MZFI(,*/8EG15 MHE95T1Z=_O53AOK.[:P[UH\V7-K^$W]NII,ECQY'=]^*V3TZM'OEG4T0 M0!$/+!'*+ML124G*@U>ON,]:\_J]2>'Y\/UR'%*M[5[+8_M\/Q>/;D,S92MIO_.;P1CDH2!*P6C! M6^F!1N6IEY> JAJR-:0JW[WVVIKB[AGN:"_7FVGCVOIHD!@3C(R5G '$)1<( MKKUA!(BMY;4-J53XN>Q/]=A[+MO0OU;5GR=7[M=#<9F*.4W3CS+<61WXOH5JS>Q *SF!JD(W04]M'4(>B96U[+ M.B;C "_+SE#A)7B@QJ;.:?\ M[]R:%L4SA<&Y')4<39DN[@2:FV3 C#N&(-+<"N89-1")DHO2XCKI,P.\NFMU M7SU'0 S'+%8W-[-ED>YL=PPGSRDX1IV@RDAC!6"06TG* S8(E?+#.O#IM="> M ?^[["#W)2XHFN[+<[G[^^ED^51<\L;?OD_&BS\MY@Z<6A)"K);64".BSZ,U M!)9(J321&DO%*DE\2YKY\K:X>KR+RSHH#SMK97U+MPC[-&U3WPB1A(I+A&C\ M!PN)M;-T34=B%*E3:Z:'9WRY0+>M&#MB5RYC9#7!^$GU:[ROF=6+YX(VE$;[ M24D9R2DQ19@]K85Z.;0DBOP8F#9'_=Z8M3MI\[RZR=7GN]'DT^B^L--DU->Q M6$_X7'!2("28)LCPE$RI/?0E91FKE0W>0UR?B*K&RDHVQHA<$'^V )?6WM_% M@>N^-Y\/(B[#0(4$3$4#@1/.@?7:**4R:\/+7M03;Q4@T^99TA'"!,)1[JBQ&&'"E<$J8_7J9T;H]E9UGN@N__W.%[\_C") MLOVX)/S%XK:8?;L=3=;'8Y^FDY_+$[+]I6N[F4B@7C/ML<): 8FBTN&(/W&# M8C LJS'=^P< O" :\*QP\13Z8'SJN0!PT[4Z8;0N_*V M?8=Y?FD\"03G+X@O:XMV(HLY*BTM:ZSJD>P"97(C591EA=?7OODM5K M")S_[M;'@Q:O$9/4*,HA50H!)EEIX4??&]>Y!3BZED7/F]T-97>K!X$!B6'- MCGD]G6EPWG+(A(#4<(R4PD399W[J.LE9?;S8&_2]1(N,?T^"W'/I#90 K;P% MA!ACK>3@.V/0< R3*PV71/J2MD09) M*$L>*JG$84=(IJZZPVW@D/W9J'@M-: M_6?>YX7/F>N =O%S_CI@HV-=/Q7 ,1,,D7'80F0I9)IRZ+Q6Y5F,L-37*2W[ M/B^:SESZ6P1/_R^I\I=(:GR&P9-42 ,8*[!7-E7E9J;D"8Y,^5.GH4\"?=[H M.?_-?#@G>D0![Y@$CF("*,!*Z-(5$Y3;/_=JO9/]/JWC2/CDW\K7A6O2']=: M+?VJI=B2?1\+SG%&-3+<.B61U,HX_FSTF#JA64/RET^_[>H-[[HL8O3V3U/5 MILF\^%.QZ,V!@V2 ,FZ@ PHA)CDFCBQK5 '+$5*5L@?:KECD[A_NIK^+XFLQ M^SF^+';@_&XYN?BGB^LOQ>7T9C+^G[C>)8B71*A>O:C![P4K/1?(4&^D@AYZ MJK5=TU=@0^MD9_0P 3$7&'=6,NJ.=?VN:F0%TWL%R,SO?"80*R*%C&E,%J8.:DW*KDLKQ.CE?/01;MS"9 MML.4DSWRK4HW<67'EC,Z99B@%;-( ,"]ML0HX*@!Y>HH-75NG<\Q9C0'Y#+P M*9?Z^S")[G.4F6B')TI]7%L\!ZS(/6\%XB0D@"A./(Q;CG;6T_4ZE7&U3G7Z MB,=>V93-\:5C_!TT%?>^%RC"' !)@(%:(R.Q4:9<*Z.B3L6W'F[#C7"]&I). MHF_&ZH%%_-9M5,6V^%G<31_2U-=9@[\YP=2P&7A<$;)C.N?#U5S$I9J.[.'%U=3^>C-/QU&+\LZB*L$KO!XRT M)U82S@55"#.HF2O7C@4>V/[9#L;:H'1VA[26'?&Q0B7*AK\4&,+2, DD5E H M2Q 'K*2G K7JK/;Q/J]7EE^WO,QVRKU:0'2PWES?6KSW'7]7&B!(K#5Q-CIL MGCF?DFI->6*@+<99JZ+GR.?H##W;9^)ML*?+R^>E4/^Y7MZ^T>."(\U4W'Z] MIH9[H91'V,?=%T %2:5N&CT+D*O>%BK];MD7-6%C"9!O$1(ZKN>_;83&-3*Q MP!.3J&%1T @5#BIA@5$6D;A%"6OHL#R?7/#.WY.L.1YGNX-\H_SWYMHWSOOG M*0)O1;/Y_/%^];/J$M;HAP+WDEL@H7 *40KBWYSQQBL?71IGJH70G(\?UY7$ M=,FS7!+P7)SFY07#^C;=83F#)S)K[5W+>I%Y\@3E/0)XP8G!%5,:Z@THYYAB5WT1APS %F@:9T3 MBA[FZ'6ND]MG47XX-W38R9B^O-^AG%U9_X_+=!Z8CR M5$?G3'! (5.*QY]8AJUW'AM8J01K/G>MOQV%L742 B"P1X0"A;4WU%,:K7UA ML44#:W^9"W2M=10^CEW]CKV/AKHTQELF!8D6#]7<<8@8T!9*'3>684&O PSL MC;<_COI_XNVK!U-2[;W'2D?6,$JED8@ )(62/OFDM9H3]A#7)Z(J1[S]<8PX MSWA[S8U+T;H,6D0MCDN6'CHK(NV-@&1H"4R=PJ1RO/UQ3#D1>//98@-T\6_; M@(L_"E\287;LRB]^'Z"G %FDE(*2"LFE)1!&^>4(F_A_=>ZW>GA:W]UN7(?J MK2-EIR+:>B(0@N.J.30\+I=RI5%<*TFQMAXC:NPPU,Z)O-KF]$DT:Y/76Z<2 M>[G^YK,! J: I3"'M[!=>\Q9F=9[X'^=$Z[<9+[93S_KY\5 MQ8=)Q$0Q7WP9+5HI\57UVT%CX!3DS".-*7Z2P>'I*;5CX:(NN9Q,Y:@T54BS2EHS(FHG8T M5B)>IY];'WV?C@6F#SP\RXVF7/"_IG=QF+OQXG?.K>;MKP>*#;66$^>-IM$? MBHA0W&DCE'#&,3 PFVP@FTTCS#QK(;+CG^.K8G+5A0AM?CMH:RF! C.N+!4: M".L(ME9SY9!CMDXL2@]#LH8F0#58F55\/L_&EP=QOGPH.,DY4 )1+RW5$FEC M!8JV)O5:<" &%AS5-2!/H7FFB*;'^_O1[/?%=5SZ>'YQ_7F3IZG8RV4BQ>7E M]'&R&$]NOJ8,BU0JM;-8I>>Y?)[>C2_'194XI-TO!0PY%08H;^(6* 4R0C,N ML><*18M25(J-:4FDQS>3\?7X/R]BJ94'Q]+M9<1NU M[/AG\7$ZGW<=WMBTRK"<(81U9"1S5ACG 90K1D)'69 M,TRP@!@I"8T;(P08,,T1>**&0>]'?52&Q7;(5GO4SF9]EI5-5BT&GK7#@5C! MO>\%9#V**Z3*(*&CLL12X7*M.IIC@T-6"S#8WJH:)'BV6*J74ST8[_?F\T%Z MYB7F(,JG09[$#=X]22>T3L8J@'*9@M7/BQ.!R/R*H\1E"3:&P$M MQ8D8"ECFUS3P5H*!A$HTA(/C][^3J-P!TCX5B^^363&Z2UE-'Y9I@4D(_XKD M2;K[&,!5&BIXZS& 2!@&B6&".NF?*4)JX:Z'EUJMX:X-8O=(T:4U?*P0O7/L M4"$ZL(8HA8#53CHN@!?E1N*IHP.+)\UBH;7,@VRHO# ?U&(Q&_]X7"Q3GZ>? MES2.DG9Q_6WT:Z,1VCY 5A\E$,FIII QC0V-@HDU?Y).AM3 #+SV8+*-Q]98 MD,\YG5[^]W9Z%UDY7^T@>SW2[8<#0UI:PQC%QD%##)&2KL_M@%-\8-F3K?#[ ME1=:D\BYH+-/M$J"?)[.EEQ]@V9[<%9SY I L@ &CTY"^+_:,MQ22\M:KFS M?=QY,X R+T?.1?DIZ8FB@EH#-(-,,LA1N2IJ99TU( 1Y'Z'[? M#KGKZ^(R4DM=31]6M3[4_)(!=C$QT\E5*FYZ%?\PG]Z-KY(!X\>3T>1R/+I[ M.K4:W)41\!!A' VO"!1-#$84.BF @QQ;P*'K[LKH2_&SF#Q&73=>1 ZHAXBKWNH46_@(*G0G G$"::$6F"E,27%N!Q: MCZDFH/.J T%&^N?:SHY?S<$>/Z<,& ".+A.@QF-I@?,2&\;7U''$ZSH!L3U$ M9RXHO>K.DH$W_45NA>Y IPT9#+6$0&@ EDI&#B!I94DAY%REW>A\T-LVC&JC M]B2NY,*M&=U=KLZ9OD?;:[96!7\]1M-MSJ*I_#!.=M[!>X[3 M!PW$2VL1L98B0V$DDR>PI)+6>&"%5]H'T[0CSN3"KQW'&4=27Q:Z6/Q3%).] M2TJ]=*XC6RLCN8GA@Q)(,F8U4E!*3!VD&I64PQK7L2:./LS)T8@C.ZH[X%*V MBY:K_SRN;BOG?CK[5/RSX4K,II/XQ\N52WVH;-LQXP2*%4'CPP10$Q2 EIF59&>BM]N3)% MV- B3-OA^K1Q0F<,<-@^8/S^D X.X_,$R"I!-8??#\P;XR42D096D6CPZU3? M;K5VP-3 FJG68__KD(7&"=QF9:0H1E>/EXN+V;I4]9[2:6\]&IQ"V%* %?8. M$6624G]:"0!U[MYZF V=>?-KB.H9\#./=N)Z@O.=9S5[GP\^RH&.:S$0,D4X M50RHA M"F^%N'L3(:7'DCI@!1,,B7+N3 REPF=#_)NV1=+6W5]/;X; MQ]VP,D .#1$ T!PKYG%<"4;& \:>3EJB7YSUO.![$$]6,J'5MV\-"%QT=#&3G4[;+ANED>>F=Y-%$+WAZ M7\P^CD<_EL5KS./L0%!=E==#=&^X(9@+J11 ' EAG[:$5,DCYU:;X[ U)UBV M+Q.:YT,#K9"6P&./B<*J ME#+,U, JHG6(O<9YD=G5\9&8;ZEN]^OR[G'9[7L^+^:IT=[HUV'?YIC1 @>. M"*>YX9P( :P6Q)9TB:[GP(JD=8K1MIF3+6/HH4BG"Y.;Y^21?5E KY\.#D-B MN+91&A%!0!FF=;DNR5T=#YK] 5VCQ,\7.UI.L)20\>0Q3GR]@NEDO@I<63T7 MA:.8_SV>3&?1KBT+C:O)U+V^E&QOO^4.ELLP@*628MP@( M+4L XY3?&:251+ISOL M&;XGE.]B9F[37>2'R>83X\GE^.&N.)1H66O<0+#!AAM("792*V,!7%N\=%GG M:!B1!TT"Y]7VE(_\PPXJ]XA9:XBR"EL.8-2T")6TT'YH]3XSX:963/EQ'#FG MF'+*#'/0XW2\J240:5,O5T:B43DLK+7$]2HQY<<1>E@QY=QC$KU=;)74Q#$2 M[49>KMTCHX8%LGKL/RFF_#@"YZNYTT8U;,JA@T;9:)A8K:-'(PTKUPH4KW,9 MT<,X@6YVQR8YD.WHH9'RV!8#ZX210GL)4N=KJDKKUU@"T+!454-\KE0>^SC* M=G6]?W#'>_N% "W#G@%"@#*$*9J*H)6KH[)6"$D/<5.3PP=NYD\B:3[ S(OX MK=MT'E;\+.ZF#\LF6<\QU.7%[;?IYV)V/9W=1TMS65-OKG\GT^# YM?(^($[ MHJVQ2J6 ;8)1M &>6.$-&UAJ5C>;9!><.@.4IY4=W'P;&3]X9:G'6G(IO8R; M%)?6/CEH6@ZL!DIFO#6']I,Y5B,/Z?Y'VE$2NM7_53>S8J4-#J4>[7LK$ XL MMYXAC23'VAE.?#EWB?S >EMDYO>T+3ZOKX?.F\^'(2A($Z) M1-O%4,$T80(\S92BP54'Z0PQ39#_9*#\R_WEW:]B=CF>IU.9W;62]CP=) /" M,T$-5HY:JI5'3[X6M;6@TD.#K4.H-$+_?#$YIQFV'RLD.=8>.W#E//31E#"& M.>D YHP\TAZ-TY&;BYERRO;BE^YN-Y:Z7H='];Q+L\'ZGL@??J@ M@5/H$&>:&4((Q091L#Z?9Y!ID?6*(D=X449<;:>?Y6)2+BC;-6_7$5M[\+GU M9)"62:0!T(YI)R2,>Q MUP/PT*K'=0>Y>G3/C:-OHU\IOV,Q_VNV/Q+W[1>" M@()Q8;01!FJ-M 9=>TTA*@C7Q6LJUB=:$RX)B3LT1M8,[*:^"2A,,]"Y)\GTU=%VW$!!:X4D]Q0 M:!55"" %2V)[#P<6M=8"ZEJE=S[#Y^VZ>]NRM-<&JC9$$$L!3#G#%7TRC6YP*WHY3@U8SFM^F?U.$Z\_1W3(6.KT>:3R^7!17Z7=#2Q5. M.H1JB:!'&'/,;/Q78DNUD];Y:O>X+>UAD=J1_-L,69C1;/8[+B6=>.T[L*ST M?H"IKQV7$@@A&7#&NR0WJ_73".]WXQ%6!L*K9FG-DSECI.N&:!\N)/GF\P$R M2AD43B&/+7:<6P?+M0DOZUP?][)S60L@:H*PW8"F4AG<7:\$H(FFR KN+.3$ M2LX-*5=H,*V3[7U>?EHSP#F9LMG\LM<6QLL5O+(W-IX\L->=/&Z GBG%/>-6 M**4LQ3QZLBM:.8Q G3SPXSVXZ6)T=VXHS$G^?IO4RX"WX5C'0A "N$",0.B) MI]):O/9V<.HZUYUU_/7RMKAZO"N69_%E+=MEE.P;QPFI:-B2,U6<\)HC!TN< MUTP0 21 % @GT1/-%#,#RZ)M CS;"=A9&9"M(,#3JO:5WHB.Q/+R>O[F[?7\ M./PV\:& +7>&<"*Y$B(:H58YNJ8F<4Q5NC0=Q.5-?3AWP(_\Z'[;'SY!^U89 M*! (,!8DVBD0($^(@=*7U) &UL4$L! A0#% @ /(2I3JP^TOQ(%0 H^X !$ M ( !6+(! &UR;F$M,C Q.3 S,S$N>'-D4$L! A0#% @ /(2I M3NMPB_'#'0 N#4! !4 ( !S\;0[3 "*/ L %0 @ &;1 ( ;7)N82TR,#$Y,#,S,5]L M86(N>&UL4$L! A0#% @ /(2I3BJ#67-PC XS ' !4 M ( !W!<# &UR;F$M,C Q.3 S,S%?<')E+GAM;%!+!08 !@ & (H! !_ %I , ! end

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2019	Apr. 29, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Entity Registrant Name	Moderna, Inc.
Entity Central Index Key	0001682852
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		329,003,270

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 502,934	$ 658,364
Investments	605,990	863,063
Accounts receivable	5,646	11,686
Accounts receivable from related party	965	899
Prepaid expenses and other current assets	25,292	28,399
Restricted cash	0	595
Total current assets	1,140,827	1,563,006
Investments, non-current	437,659	172,990
Property and equipment, net	213,460	211,977
Restricted cash, non-current	11,823	11,532
Other non-current assets	2,438	2,644
Total assets	1,806,207	1,962,149
Current liabilities:
Accounts payable	38,509	31,210
Accrued liabilities	42,183	79,073
Deferred revenue	73,958	109,056
Other current liabilities	4,509	3,464
Total current liabilities	159,159	222,803
Deferred revenue, non-current	156,862	165,352
Deferred lease obligation, non-current	10,556	10,006
Lease financing obligation	33,384	33,489
Other non-current liabilities	213	258
Total liabilities	360,174	431,908
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, par value $0.0001; 162,000,000 shares authorized as of March 31, 2019 and December 31, 2018; no shares issued or outstanding at March 31, 2019 and December 31, 2018	0	0
Common stock, par value $0.0001; 1,600,000,000 shares authorized as of March 31, 2019 and December 31, 2018; 328,853,340 and 328,798,904 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively	33	33
Additional paid-in capital	2,556,709	2,538,155
Accumulated other comprehensive income (loss)	591	(1,320)
Accumulated deficit	(1,111,300)	(1,006,627)
Total stockholders’ equity	1,446,033	1,530,241
Total liabilities and stockholders’ equity	$ 1,806,207	$ 1,962,149

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value (usd per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	162,000,000	162,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (usd per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,600,000,000	1,600,000,000
Common stock, shares issued	328,853,340	328,798,904
Common stock, shares outstanding	328,853,340	328,798,904

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue:
Total revenue	$ 16,025	$ 29,039
Operating expenses:
Research and development	130,575	90,124
General and administrative	27,283	16,317
Total operating expenses	157,858	106,441
Loss from operations	(141,833)	(77,402)
Interest income	10,972	5,209
Other expense, net	(1,820)	(183)
Loss before benefit from income taxes	(132,681)	(72,376)
Benefit from income taxes	(24)	0
Net loss	(132,657)	(72,376)
Net loss attributable to common stockholders (Note 11)	$ (132,657)	$ (75,857)
Net loss per share attributable to common stockholders, basic and diluted (usd per share)	$ (0.40)	$ (1.16)
Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted	328,809,986	65,430,835
Collaboration revenue
Revenue:
Total revenue	$ 13,301	$ 20,110
Collaboration revenue from related party
Revenue:
Total revenue	814	7,350
Grant revenue
Revenue:
Total revenue	$ 1,910	$ 1,579

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Statement of Comprehensive Income [Abstract]
Net loss	$ (132,657)	$ (72,376)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale debt securities, net of tax, $540 and $0	1,908	(1,999)
Less: Amounts recognized for net realized loss included in net loss	3	6
Total other comprehensive income (loss)	1,911	(1,993)
Comprehensive loss	$ (130,746)	$ (74,369)

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Redeemable Convertible Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit
Balance at beginning of period (in shares) at Dec. 31, 2017		448,686,791	65,206,999
Balance at beginning of period at Dec. 31, 2017	$ (551,365)	$ 1,176,661	$ 6	$ 71,679	$ (1,157)	$ (621,893)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted common stock (in shares)			335,053
Vesting of restricted common stock	0
Issuance of Series G redeemable convertible preferred stock, net of issuance costs of $10,517 (in shares)		55,666,004
Issuance of Series G redeemable convertible preferred stock, net of issuance costs of $10,517	152	$ 549,413		152
Exercise of options to purchase common stock, net (in shares)			1,789
Exercise of options to purchase common stock, net	22			22
Stock-based compensation	11,851			11,851
Unrealized gain (loss) on marketable securities	(1,993)				(1,993)
Net loss	(72,376)					(72,376)
Balance at end of period (in shares) at Mar. 31, 2018		504,352,795	65,543,841
Balance at end of period at Mar. 31, 2018	(613,709)	$ 1,726,074	$ 6	83,704	(3,150)	(694,269)
Balance at beginning of period (in shares) at Dec. 31, 2018		0	328,798,904
Balance at beginning of period at Dec. 31, 2018	1,530,241	$ 0	$ 33	2,538,155	(1,320)	(1,006,627)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted common stock (in shares)			48,911
Vesting of restricted common stock	$ 0
Exercise of options to purchase common stock, net (in shares)	5,525		5,525
Exercise of options to purchase common stock, net	$ 57			57
Stock-based compensation	18,497			18,497
Unrealized gain (loss) on marketable securities	1,911				1,911
Net loss	(132,657)					(132,657)
Balance at end of period (in shares) at Mar. 31, 2019		0	328,853,340
Balance at end of period at Mar. 31, 2019	$ 1,446,033	$ 0	$ 33	$ 2,556,709	$ 591	$ (1,111,300)

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2018 USD ($)
Statement of Stockholders' Equity [Abstract]
Issuance costs	$ 10,517

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating activities
Net loss	$ (132,657)	$ (72,376)
Adjustments to reconcile net loss to net cash (used in) operating activities:
Stock-based compensation	18,497	11,851
Depreciation and amortization	7,328	5,153
Amortization of investment premiums	(1,005)	(83)
Loss on disposal of property and equipment	19	0
Changes in assets and liabilities:
Accounts receivable	6,040	3,876
Accounts receivable from related party	(66)	(28,529)
Prepaid expenses and other assets	3,313	(2,241)
Accounts payable	1,731	1,467
Accrued liabilities	(32,557)	(37,031)
Deferred revenue	(15,604)	6,193
Deferred lease obligation	550	152
Other liabilities	484	183
Net cash used in operating activities	(143,927)	(111,385)
Investing activities
Purchases of marketable securities	(429,517)	(660,239)
Proceeds from maturities of marketable securities	403,940	189,814
Proceeds from sales of marketable securities	21,413	18,630
Purchases of property and equipment	(7,595)	(31,909)
Net cash used in investing activities	(11,759)	(483,704)
Financing activities
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs	0	549,531
Proceeds from issuance of common stock through equity plans	57	22
Reimbursement of assets under lease financing obligation	0	1,727
Payments on financing lease obligation	(105)	(1,285)
Net cash (used in) provided by financing activities	(48)	549,995
Net decrease in cash, cash equivalents and restricted cash	(155,734)	(45,094)
Cash, cash equivalents and restricted cash, beginning of year	670,491	147,608
Cash, cash equivalents and restricted cash, end of period	514,757	102,514
Non-cash investing and financing activities
Issuance costs included in accounts payable and accrued liabilities	796	0
Purchases of property and equipment included in accounts payable and accrued liabilities	14,127	28,527
Leasehold improvements included in prepaid and other current assets	10,089	9,889
Lease financing obligation	$ 10,089	$ 9,889

Description of the Business	3 Months Ended
Description of the Business	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of the Business	Description of the Business Moderna, Inc. is a Delaware Corporation, incorporated under the laws of the State of Delaware on July 22, 2016 (collectively, with its consolidated subsidiaries, any of Moderna, Company, we, us or our). In August 2018, we changed our name from Moderna Therapeutics, Inc. to Moderna, Inc. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. We are creating a new generation of potentially transformative medicines based on messenger RNA (mRNA), to improve the lives of patients. Since inception, we have incurred significant net losses. We expect to continue to incur significant expenses and operating losses for the foreseeable future. In addition, we anticipate that our expenses will increase significantly in connection with our ongoing activities to support our platform research, drug discovery and clinical development, infrastructure and Research Engine and Early Development engine, digital infrastructure, creation of a portfolio of intellectual property, and administrative support. We do not expect to generate significant revenue from sales of potential mRNA medicines unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our investigational medicines. If we seek to obtain regulatory approval for any of our investigational medicines, we expect to incur significant commercialization expenses. As a result, we will need substantial additional funding to support our continued operations and pursue our growth strategy. Until we can generate significant revenue from potential mRNA medicines, if ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings, government funding arrangements, strategic alliances and marketing, distribution and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our programs. We believe that our cash, cash equivalents, and investments as of March 31, 2019 will be sufficient to enable us to fund our projected operations through at least the next 12 months from the issuance of these financial statements. Because of the numerous risks and uncertainties associated with pharmaceutical development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenues from the sale of our medicines, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.

Grants	3 Months Ended
Grants	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
Grants	Grants Biomedical Advanced Research and Development Authority (BARDA) In September 2016, we received an award of up to $125.8 million under Agreement No. HHSO100201600029C from BARDA, a component of the Office of the Assistant Secretary for Preparedness and Response, or ASPR within the U.S. Department of Health and Human Services, or HHS, to help fund our Zika vaccine program. Under the terms of the agreement with BARDA, an initial base award of $8.2 million supported toxicology studies, a Phase 1 clinical trial, and associated manufacturing activities. Contract options were available, for $117.6 million to support an additional Phase 1 study of an improved Zika vaccine candidate, Phase 2 and Phase 3 clinical studies, as well as large-scale manufacturing for the Zika vaccine. As of March 31, 2019, three of the four contract options had been exercised resulting in $117.3 million of available funding with an additional $8.5 million available if the final contract option is exercised. For the three months ended March 31, 2019 and 2018, we recognized revenue of $1.5 million and $1.0 million, respectively, relating to the BARDA Agreement. The Bill & Melinda Gates Foundation (Gates Foundation) In January 2016, we entered a global health project framework agreement with the Gates Foundation to advance mRNA-based development projects for various infectious diseases. The Gates Foundation has committed up to $20.0 million in grant funding to support our initial project related to the evaluation of antibody combinations in a preclinical setting as well as the conduct of a first-in-human Phase 1 clinical trial of a potential mRNA medicine to help prevent human immunodeficiency virus, or HIV, infections. Follow-on projects which could bring total potential funding under the framework agreement up to $100.0 million (including the HIV antibody project) to support the development of additional mRNA-based projects for various infectious diseases can be proposed and approved until the sixth anniversary of the framework agreement, subject to the terms of the framework agreement, including our obligation to grant to the Gates Foundation certain non-exclusive licenses. In March 2019, the Gates Foundation provided an additional funding commitment up to $1.1 million to support a follow-on project. As of March 31, 2019, up to $21.1 million has been committed for funding with up to an additional $80 million available, if additional follow-on projects are approved. For the three months ended March 31, 2019 and 2018, we recognized $0.3 million for each period, relating to the Gates Foundation agreement. Deferred revenue of $0.6 million and $0.8 million was recorded for both March 31, 2019, and December 31, 2018, respectively, related to the Gates Foundation agreement. Defense Advanced Research Projects Agency (DARPA) In October 2013, DARPA awarded us up to $24.6 million under Agreement No. W911NF-13-1-0417, which was subsequently adjusted to $19.7 million, to research and develop potential mRNA medicines as a part of DARPA’s Autonomous Diagnostics to Enable Prevention and Therapeutics, or ADEPT, program, which is focused on assisting with the development of technologies to rapidly identify and respond to threats posed by natural and engineered diseases and toxins. The DARPA awards have been deployed primarily in support of our vaccine and antibody programs to protect against chikungunya infection. As of March 31, 2019 and December 31, 2018, $19.7 million has been committed by DARPA. There was no revenue recognized for the three months ended March 31, 2019, related to the DARPA agreement. We recognized revenue of $0.2 million for the three months ended March 31, 2018, related to the DARPA agreement.

Shareholders' Equity	3 Months Ended
Shareholders' Equity	Mar. 31, 2019
Equity [Abstract]
Shareholders' Equity	Shareholders' Equity On February 28, 2018 and May 7, 2018, the Board of Directors approved an amendment to our Certificate of Incorporation resulting in a total of 775,000,000 shares of common stock and a total of 509,352,795 shares of redeemable convertible preferred stock being authorized, respectively. Upon completion of our IPO, our authorized capital stock consists of 1,600,000,000 shares of common stock, par value $0.0001 per share, and 162,000,000 shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock are undesignated. On December 11, 2018, we completed our IPO, whereby we sold 26,275,993 shares of common stock at a price of $23.00 per share. The aggregate net proceeds received by us from the IPO were $563.0 million, net of underwriting discounts and commissions of $33.2 million and offering expenses of $8.1 million payable by us. Upon the closing of the IPO, all of the outstanding shares of our redeemable convertible preferred stock were converted into 236,012,913 shares of the common stock.

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates that are expected to be in effect for the years in which differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a “more likely than not” criterion. Realization of our deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. We continued to maintain a full valuation allowance against all of our deferred tax assets based on management’s evaluation of all available evidence. There were no significant income tax provisions or benefits for the three months ended March 31, 2019 and 2018. Upon adoption of ASC 606 (see Note 2), we recorded a cumulative-effect adjustment of $28.0 million to the opening balance of accumulated deficit as of January 1, 2019 with a decrease in deferred revenue of $30.7 million and a decrease in accounts receivable of $2.7 million. As a result of the cumulative decrease in deferred revenue, our corresponding deferred tax asset decreased by $8.4 million, which was offset by a corresponding decrease to our valuation allowance.

Summary of Basis of Presentation and Recent Accounting Standards - Narrative (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative-effect adjustment		$ 27,984
Remaining deferred revenues	$ 228,479		$ 240,924
Combined 2018 AZ Agreements
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Remaining deferred revenues	75,500	75,700	115,600
PCV/SAV Agreement
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Remaining deferred revenues	115,000	125,200	111,300
2016 VEGF Exercise
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Remaining deferred revenues	$ 37,100	37,100	$ 41,200
Accumulated Deficit
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative-effect adjustment		27,984
Accounting Standards Update 2014-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase (decrease) in deferred revenue		(30,700)
Decrease in deferred tax asset		8,400
Decrease in valuation allowance		8,400
Accounting Standards Update 2014-09 \| Combined 2018 AZ Agreements
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase (decrease) in deferred revenue		(39,900)
Accounting Standards Update 2014-09 \| PCV/SAV Agreement
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase (decrease) in deferred revenue		13,900
Accounting Standards Update 2014-09 \| 2016 VEGF Exercise
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase (decrease) in deferred revenue		(4,300)
Accounting Standards Update 2014-09 \| Accumulated Deficit
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative-effect adjustment		$ 28,000

Summary of Basis of Presentation and Recent Accounting Standards - Effect of Adoption of ASC 606 on Condensed Consolidated Financial Statements (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Jan. 01, 2019	Dec. 31, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Deferred revenue, current	$ 73,958		$ 81,775	$ 109,056
Deferred revenue, non-current	156,862		161,911	165,352
Accounts receivable	5,646		8,948	11,686
Accumulated deficit	(1,111,300)		(978,643)	(1,006,627)
Total revenue	16,025
Loss from operations	(141,833)	$ (77,402)
Loss before benefit from income taxes	(132,681)	(72,376)
Net (loss) income	$ (132,657)	$ (72,376)
Net loss per share - basic and diluted (usd per share)	$ (0.40)	$ (1.16)
Collaboration revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	$ 13,301
Collaboration revenue from related party
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	814
Accounting Standards Update 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable			(2,700)
Balance without adoption of ASC 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Deferred revenue, current	110,410			109,056
Deferred revenue, non-current	127,022			165,352
Accounts receivable				11,686
Accumulated deficit	(1,117,377)			$ (1,006,627)
Total revenue	37,932
Loss from operations	(119,926)
Loss before benefit from income taxes	(110,774)
Net (loss) income	$ (110,750)
Net loss per share - basic and diluted (usd per share)	$ (0.34)
Balance without adoption of ASC 606 \| Collaboration revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	$ 11,515
Balance without adoption of ASC 606 \| Collaboration revenue from related party
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	25,191
Adjustments \| Accounting Standards Update 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Deferred revenue, current	36,452		(27,281)
Deferred revenue, non-current	(29,840)		(3,441)
Accounts receivable			(2,738)
Accumulated deficit	(6,077)		$ 27,984
Total revenue	21,907
Loss from operations	21,907
Loss before benefit from income taxes	21,907
Net (loss) income	$ 21,907
Net loss per share - basic and diluted (usd per share)	$ 0.06
Adjustments \| Accounting Standards Update 2014-09 \| Collaboration revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	$ (1,786)
Adjustments \| Accounting Standards Update 2014-09 \| Collaboration revenue from related party
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	$ 24,377

Summary of Basis of Presentation and Recent Accounting Standards - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Cash and cash equivalents	$ 502,934	$ 658,364	$ 90,479
Restricted cash	0	595	237
Restricted cash, non-current	11,823	11,532	11,798
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows	$ 514,757	$ 670,491	$ 102,514	$ 147,608

Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019 USD ($)
Contract Assets:
Beginning balance	$ 4,612
Additions	2,735
Deductions	(3,747)
Ending balance	3,600
Contract Liabilities:
Beginning balance	240,924
Additions	1,137
Deductions	(13,582)
Ending balance	228,479
Amounts included in contract liabiliies at the beginning of the period	$ 13,582

Collaboration Agreements - Remaining Performance Obligation (Details) - USD ($) $ in Millions	Mar. 31, 2019	Jan. 01, 2019
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price	$ 279.5
PCV/SAV Agreement
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		$ 213.0
PCV/SAV Agreement \| Upfront Payment
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		200.0
PCV/SAV Agreement \| Upfront Payment, Premium Associated With Contemporaneous Sale Of Preferred Stock
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		13.0
PCV/SAV Agreement \| PCV Performance Obligation
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		206.3
PCV/SAV Agreement \| KRAS Performance Obligation
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		6.7
2015 Merck Agreement
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		65.0
2015 Merck Agreement \| Milestone Payments
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		5.0
2015 Merck Agreement \| Upfront Payment
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		60.0
2015 Merck Agreement \| Upfront Payment, Research And Development
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		50.0
2015 Merck Agreement \| Upfront Payment, Funding From 2016 Amendment
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		10.0
2016 VEGF Exercise
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		55.1
2016 VEGF Exercise \| Fixed Payments
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		40.0
2016 VEGF Exercise \| Option Exercise Fee
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		10.0
2016 VEGF Exercise \| Variable Consideration
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		15.1
2016 VEGF Exercise \| Milestone Payments
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		30.0
2013 AZ Agreements
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		240.0
Combined 2018 AZ Agreements
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		400.0
Combined 2018 AZ Agreements \| Variable Consideration
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		160.0
Combined 2018 AZ Agreements \| Estimated Reimbursement
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		40.0
Combined 2018 AZ Agreements \| Milestone Payments
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		120.0
Combined 2018 AZ Agreements \| Milestone Payments \| Toxicity Milestone
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		60.0
Combined 2018 AZ Agreements \| Milestone Payments \| Competition Milestone
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		60.0
Combined 2018 AZ Agreements \| Combined 2018 AZ Agreement Performance Obligation
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		292.4
Combined 2018 AZ Agreements \| IL12 Performance Obligation
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		8.1
Combined 2018 AZ Agreements \| Oncology Development Target Performance Obligation
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		8.1
Combined 2018 AZ Agreements \| Development And Commercialization License And Manufacturing Obligations For IL12
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		89.8
Combined 2018 AZ Agreements \| Development And Commercialization Rights And Manufacturing Services For An Oncology Development Target
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		1.6
Vertex Agreement
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		24.4
Vertex Agreement \| Upfront Payment
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		20.0
Vertex Agreement \| Research And Development Funding
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Transaction price		$ 4.4

Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details)	1 Months Ended				3 Months Ended		12 Months Ended
	Jun. 30, 2018 option	Oct. 31, 2017	Jan. 31, 2016	Mar. 31, 2013 USD ($) milestone option	Mar. 31, 2019 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2016 USD ($)	Jan. 01, 2019 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Transaction price					$ 279,500,000
Total collaborative revenue					16,025,000
Deferred revenue					228,479,000		$ 240,924,000
Revenue					16,025,000	$ 29,039,000
Collaboration revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total collaborative revenue					13,301,000
Revenue					13,301,000	20,110,000
2013 AZ Agreements
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of options \| option				40
Upfront cash payments				$ 240,000,000				$ 10,000,000
Estimated arrangement consideration				$ 180,000,000.0
Number of milestones \| milestone				3
Option exercise fee				$ 10,000,000
Termination period				90 days
Transaction price									$ 240,000,000
2013 AZ Agreements \| VEGF-A product (AZD8601)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront cash payments							30,000,000
2013 AZ Agreements \| Development Milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Estimated arrangement consideration				$ 100,000,000.0
2013 AZ Agreements \| Regulatory Milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Estimated arrangement consideration				100,000,000.0
2013 AZ Agreements \| Commercial Milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Estimated arrangement consideration				$ 200,000,000.0
2013 AZ Agreements \| Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Earn-out payments				12.00%
2016 AZ Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Termination period			90 days
Suspension period			12 months
2016 AZ Agreement \| Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Tiered royalties at default rate			20.00%
Tiered royalties			30.00%
2016 AZ Agreement \| Minimum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Tiered royalties			10.00%
2017 AZ Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Termination period		90 days
Suspension period		12 months
2017 AZ Agreement \| Collaboration revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue					0	0
2017 AZ Agreement \| Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Tiered royalties		30.00%
2017 AZ Agreement \| Minimum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Tiered royalties		10.00%
2018 A&R Agreements
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of options \| option	40
Termination period	90 days
Combined 2018 AZ Agreements
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Increase to the transaction price					300,000
Transaction price									400,000,000
Deferred revenue					75,500,000		115,600,000		75,700,000
Combined 2018 AZ Agreements \| Collaboration revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total collaborative revenue					800,000	7,400,000
2016 VEGF Exercise
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Increase to the transaction price					0
Transaction price									55,100,000
Deferred revenue					37,100,000		$ 41,200,000		37,100,000
2016 VEGF Exercise \| Collaboration revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total collaborative revenue					$ 0	$ 0
IL12 Performance Obligation \| Combined 2018 AZ Agreements
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Transaction price									$ 8,100,000

Collaboration Agreements - Merck – Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details)	1 Months Ended				3 Months Ended		52 Months Ended
	Apr. 30, 2018 USD ($)	Jun. 30, 2016 USD ($)	Jan. 31, 2016 USD ($)	Jan. 31, 2015 USD ($)	Mar. 31, 2019 USD ($)	Mar. 31, 2018 USD ($)	May 09, 2019 USD ($) candidate	Jan. 01, 2019 USD ($)	Dec. 31, 2018 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront payment					$ (15,604,000)	$ 6,193,000
Total collaborative revenue					16,025,000
Deferred revenue					228,479,000				$ 240,924,000
Amortization of deferred revenue due to the satisfaction of our performance obligation during the period					13,582,000
Collaboration revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total collaborative revenue					13,301,000
2015 Merck Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Proceeds from equity investment				$ 50,000,000
Upfront cash payments			$ 10,000,000
Increase to the transaction price					0
Deferred revenue					0				0
2015 Merck Agreement \| Collaboration revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total collaborative revenue						2,000,000
2015 Merck Agreement \| Subsequent Event
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Performance period							3 years
Research period							4 years
Number of product candidates \| candidate							5
Upfront payment							$ 50,000,000
Estimated arrangement consideration							300,000,000.0
2015 Merck Agreement \| Subsequent Event \| Milestone Payments
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total collaborative revenue							$ 5,000,000
Separate Agreements With Merck \| Collaboration revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total collaborative revenue					500,000
PCV Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Estimated arrangement consideration		$ 250,000,000
Upfront cash payments		$ 200,000,000
PCV Agreement \| Series H Redeemable Convertible Preferred Stock
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Aggregate net proceeds from the offering	$ 125,000,000
Premium recorded to deferred revenue	13,000,000
PCV Agreement \| PCV products
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Estimated arrangement consideration					243,000,000				243,000,000
PCV/SAV Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Increase to the transaction price					0
Deferred revenue					115,000,000			$ 125,200,000	$ 111,300,000
Amortization of deferred revenue due to the satisfaction of our performance obligation during the period					10,200,000
PCV/SAV Agreement \| PCV products
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Estimated arrangement consideration	$ 243,000,000
PCV/SAV Agreement \| Collaboration revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total collaborative revenue					$ 10,200,000	$ 14,000,000

Collaboration Agreements - Vertex – 2016 Strategic Alliance in Cystic Fibrosis (Details) - USD ($)	1 Months Ended	3 Months Ended
	Jul. 31, 2016	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total collaborative revenue		$ 16,025,000
Amortization of deferred revenue due to the satisfaction of our performance obligation during the period		13,582,000
Deferred revenue		228,479,000		$ 240,924,000
Collaboration revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total collaborative revenue		13,301,000
Vertex Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research period	3 years
Upfront cash payments	$ 20,000,000
Research extension period	1 year
Proceeds from equity investment	$ 20,000,000
Termination period	90 days
Written notice period	180 days
Increase to the transaction price		0
Amortization of deferred revenue due to the satisfaction of our performance obligation during the period		2,600,000
Deferred revenue		800,000		$ 3,300,000
Vertex Agreement \| Collaboration revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total collaborative revenue		$ 2,600,000	$ 4,100,000
Vertex Agreement \| Development Milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Estimated arrangement consideration	$ 55,000,000.0
Vertex Agreement \| Regulatory Milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Estimated arrangement consideration	220,000,000.0
Vertex Agreement \| Regulatory Milestones, Subsequent Products
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Estimated arrangement consideration	$ 3,000,000.0

Grants (Details)	1 Months Ended				3 Months Ended
Grants (Details)	Mar. 31, 2019 USD ($) contract_option	Sep. 30, 2016 USD ($)	Jan. 31, 2016 USD ($)	Oct. 31, 2013 USD ($)	Mar. 31, 2019 USD ($) contract_option	Mar. 31, 2018 USD ($)	Dec. 31, 2018 USD ($)
Disaggregation of Revenue [Line Items]
Total revenue					$ 16,025,000
Deferred revenue	$ 228,479,000				228,479,000		$ 240,924,000
BARDA
Disaggregation of Revenue [Line Items]
Award amount		$ 125,800,000
Amount committed for funding	117,300,000				117,300,000
Available funding	$ 8,500,000				$ 8,500,000
BARDA \| Initial base award
Disaggregation of Revenue [Line Items]
Award amount		8,200,000
BARDA \| Contract options
Disaggregation of Revenue [Line Items]
Award amount		$ 117,600,000
Number of contract options exercised \| contract_option	3				3
Number of contract options \| contract_option	4				4
BARDA \| Grant revenue
Disaggregation of Revenue [Line Items]
Total revenue					$ 1,500,000	$ 1,000,000
The Bill & Melinda Gates Foundation
Disaggregation of Revenue [Line Items]
Award amount			$ 100,000,000.0
Available funding	$ 80,000,000				80,000,000
Deferred revenue	600,000				600,000		$ 800,000
The Bill & Melinda Gates Foundation \| Initial project
Disaggregation of Revenue [Line Items]
Award amount			$ 20,000,000.0
Amount committed for funding	21,100,000				21,100,000
The Bill & Melinda Gates Foundation \| Follow-on project
Disaggregation of Revenue [Line Items]
Award amount	1,100,000.0
The Bill & Melinda Gates Foundation \| Grant revenue
Disaggregation of Revenue [Line Items]
Total revenue					300,000	300,000
DARPA
Disaggregation of Revenue [Line Items]
Award amount				$ 24,600,000	19,700,000
Amount committed for funding	$ 19,700,000				19,700,000	19,700,000
DARPA \| Grant revenue
Disaggregation of Revenue [Line Items]
Total revenue					$ 0	$ 200,000

Financial Instruments - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 1,042,516		$ 1,037,372
Level 2
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	1,545,451	$ 1,695,737
Unrealized Gains	1,356	120
Unrealized Losses	(224)	(1,440)
Fair Value	1,546,583	1,694,417
Level 2 \| Cash and Cash Equivalents
Debt Securities, Available-for-sale [Line Items]
Fair Value	502,934	658,364
Level 2 \| Current Marketable Securities
Debt Securities, Available-for-sale [Line Items]
Fair Value	605,990	863,063
Level 2 \| Non- Current Marketable Securities
Debt Securities, Available-for-sale [Line Items]
Fair Value	437,659	172,990
Cash and Cash Equivalents
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	502,935	658,365
Unrealized Gains	0	20
Unrealized Losses	(1)	(21)
Fair Value	502,934	658,364
Cash and Cash Equivalents \| Cash and Cash Equivalents
Debt Securities, Available-for-sale [Line Items]
Fair Value	502,934	658,364
Cash and Cash Equivalents \| Current Marketable Securities
Debt Securities, Available-for-sale [Line Items]
Fair Value	0	0
Cash and Cash Equivalents \| Non- Current Marketable Securities
Debt Securities, Available-for-sale [Line Items]
Fair Value	0	0
Certificates of deposit \| Level 2
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	84,114	173,102
Unrealized Gains	72	42
Unrealized Losses	(1)	(36)
Fair Value	84,185	173,108
Certificates of deposit \| Level 2 \| Cash and Cash Equivalents
Debt Securities, Available-for-sale [Line Items]
Fair Value	0	0
Certificates of deposit \| Level 2 \| Current Marketable Securities
Debt Securities, Available-for-sale [Line Items]
Fair Value	80,483	157,920
Certificates of deposit \| Level 2 \| Non- Current Marketable Securities
Debt Securities, Available-for-sale [Line Items]
Fair Value	3,702	15,188
U.S. treasury securities \| Level 2
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	119,347	152,205
Unrealized Gains	155	18
Unrealized Losses	(4)	(48)
Fair Value	119,498	152,175
U.S. treasury securities \| Level 2 \| Cash and Cash Equivalents
Debt Securities, Available-for-sale [Line Items]
Fair Value	0	0
U.S. treasury securities \| Level 2 \| Current Marketable Securities
Debt Securities, Available-for-sale [Line Items]
Fair Value	79,475	152,175
U.S. treasury securities \| Level 2 \| Non- Current Marketable Securities
Debt Securities, Available-for-sale [Line Items]
Fair Value	40,023	0
Debt securities of U.S. government agencies and corporate entities \| Level 2
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	839,055	712,065
Unrealized Gains	1,129	40
Unrealized Losses	(218)	(1,335)
Fair Value	839,966	710,770
Debt securities of U.S. government agencies and corporate entities \| Level 2 \| Cash and Cash Equivalents
Debt Securities, Available-for-sale [Line Items]
Fair Value	0	0
Debt securities of U.S. government agencies and corporate entities \| Level 2 \| Current Marketable Securities
Debt Securities, Available-for-sale [Line Items]
Fair Value	446,032	552,968
Debt securities of U.S. government agencies and corporate entities \| Level 2 \| Non- Current Marketable Securities
Debt Securities, Available-for-sale [Line Items]
Fair Value	$ 393,934	$ 157,802

Financial Instruments - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Amortized Cost
Due in one year or less	$ 605,687	$ 864,003
Due after one year through five years	436,829	173,369
Amortized Cost	1,042,516	1,037,372
Estimated Fair Value
Due in one year or less	605,990	863,063
Due after one year through five years	437,659	172,990
Total	$ 1,043,649	$ 1,036,053

Financial Instruments - Narrative (Details) $ in Millions	Mar. 31, 2019 USD ($) security	Dec. 31, 2018 USD ($) security
Investments, Debt and Equity Securities [Abstract]
Number of available-for-sale securitiesin a continuous unrealized loss position for more than 12 months \| security	32	25
Estimated fair value of total investment portfolio in a continuous unrealized loss position for more than 12 months	$ 135.8	$ 82.8
Gross unrealized loss of total investment portfolio in a continuous unrealized loss position for more than 12 months	$ 0.2	$ 0.4

Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid expenses	$ 7,895	$ 10,401
Tenant incentives receivables	11,336	10,089
Interest receivable on marketable securities	6,061	7,909
Prepaid expenses and other current assets	$ 25,292	$ 28,399

Balance Sheet Components - Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
In-licenses	$ 0	$ 22,000
Property and equipment	7,756	12,089
Compensation-related	11,577	23,406
External goods and services	22,850	21,578
Accrued liabilities	$ 42,183	$ 79,073

Commitments and Contingencies - Lease Obligations (Details) ft² in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2019 USD ($) ft² campus	Mar. 31, 2018 USD ($)	Feb. 28, 2019 ft² extension_period
Operating Leased Assets [Line Items]
Number of campuses \| campus	2
Rent expense \| $	$ 4.8	$ 5.2
Cambridge, MA
Operating Leased Assets [Line Items]
Area of office space (in sqft)	0.2
Norwood, MA
Operating Leased Assets [Line Items]
Area of office space (in sqft)	0.2		0.2
Number of extension terms \| extension_period			4
Extension period			5 years

Commitments and Contingencies - Future Minimum Lease Payments Under Non-Cancelable Operating Lease Agreements (Details) $ in Thousands	Mar. 31, 2019 USD ($)
Minimum Lease Payments
2019 (remainder of the year)	$ 15,190
2020	22,874
2021	24,105
2022	23,455
2023	20,498
Thereafter	140,384
Total	$ 246,506

Commitments and Contingencies - Strategic Collaborations (Details) - PCV Agreement - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Budgeted amount			$ 250.0
PCV products
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Budgeted amount	$ 243.0	$ 243.0

Shareholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
	Dec. 11, 2018	Mar. 31, 2018	Mar. 31, 2019	Dec. 31, 2018	May 07, 2018	Feb. 28, 2018
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized	1,600,000,000		1,600,000,000	1,600,000,000		775,000,000
Redeemable convertible preferred stock, shares authorized					509,352,795
Common stock, par value (usd per share)	$ 0.0001		$ 0.0001	$ 0.0001
Preferred stock, shares authorized	162,000,000		162,000,000	162,000,000
Preferred stock, par value (usd per share)	$ 0.0001		$ 0.0001	$ 0.0001
Offering expenses		$ 10,517
IPO
Subsidiary, Sale of Stock [Line Items]
Shares of common stock issued (in shares)	26,275,993
Price per share (usd per share)	$ 23.00
Aggregate net proceeds from the offering	$ 563,000
Underwriting discounts	33,200
Offering expenses	$ 8,100
IPO \| Common Stock
Subsidiary, Sale of Stock [Line Items]
Preferred stock converted into common stock (in shares)	236,012,913